<SEC-DOCUMENT>0000721371-21-000041.txt : 20210506
<SEC-HEADER>0000721371-21-000041.hdr.sgml : 20210506
<ACCEPTANCE-DATETIME>20210506162459
ACCESSION NUMBER:		0000721371-21-000041
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		83
CONFORMED PERIOD OF REPORT:	20210331
FILED AS OF DATE:		20210506
DATE AS OF CHANGE:		20210506

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CARDINAL HEALTH INC
		CENTRAL INDEX KEY:			0000721371
		STANDARD INDUSTRIAL CLASSIFICATION:	WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122]
		IRS NUMBER:				310958666
		STATE OF INCORPORATION:			OH
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-11373
		FILM NUMBER:		21898203

	BUSINESS ADDRESS:	
		STREET 1:		7000 CARDINAL PLACE
		CITY:			DUBLIN
		STATE:			OH
		ZIP:			43017
		BUSINESS PHONE:		6147573033

	MAIL ADDRESS:	
		STREET 1:		7000 CARDINAL PLACE
		CITY:			DUBLIN
		STATE:			OH
		ZIP:			43017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CARDINAL DISTRIBUTION INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>cah-20210331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:9b2cc92e-6994-4968-bb0f-b1e44b26b0f5,g:c415e902-95ac-4ff9-bfda-46a36d4f42b5,d:b6bf45669ad94861b0c50dbc2f4371ce--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:cah="http://www.cardinal.com/20210331" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cah-20210331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV80L2ZyYWc6ZTExMTZiMDUwMWEzNDVlMDljNTcxYzZmMDA2Njk0MzgvdGFibGU6OTVjNjAwYTU5NTZjNDRkY2JhZWQwMDQ4ZmY0MTFjMjUvdGFibGVyYW5nZTo5NWM2MDBhNTk1NmM0NGRjYmFlZDAwNDhmZjQxMWMyNV8yLTEtMS0xLTA_0658527b-c543-47cd-8948-ba7b4e35c01b">0000721371</ix:nonNumeric><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV80L2ZyYWc6ZTExMTZiMDUwMWEzNDVlMDljNTcxYzZmMDA2Njk0MzgvdGFibGU6OTVjNjAwYTU5NTZjNDRkY2JhZWQwMDQ4ZmY0MTFjMjUvdGFibGVyYW5nZTo5NWM2MDBhNTk1NmM0NGRjYmFlZDAwNDhmZjQxMWMyNV8zLTEtMS0xLTA_6e646d91-b960-4afe-b1f5-283dd59ecc40">--06-30</ix:nonNumeric><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV80L2ZyYWc6ZTExMTZiMDUwMWEzNDVlMDljNTcxYzZmMDA2Njk0MzgvdGFibGU6OTVjNjAwYTU5NTZjNDRkY2JhZWQwMDQ4ZmY0MTFjMjUvdGFibGVyYW5nZTo5NWM2MDBhNTk1NmM0NGRjYmFlZDAwNDhmZjQxMWMyNV80LTEtMS0xLTA_6f12bef4-2060-48ea-ba67-e54594a646ee">2021</ix:nonNumeric><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV80L2ZyYWc6ZTExMTZiMDUwMWEzNDVlMDljNTcxYzZmMDA2Njk0MzgvdGFibGU6OTVjNjAwYTU5NTZjNDRkY2JhZWQwMDQ4ZmY0MTFjMjUvdGFibGVyYW5nZTo5NWM2MDBhNTk1NmM0NGRjYmFlZDAwNDhmZjQxMWMyNV81LTEtMS0xLTA_46e23ead-d5a2-445c-9eec-0cad12109146">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV80L2ZyYWc6ZTExMTZiMDUwMWEzNDVlMDljNTcxYzZmMDA2Njk0MzgvdGFibGU6OTVjNjAwYTU5NTZjNDRkY2JhZWQwMDQ4ZmY0MTFjMjUvdGFibGVyYW5nZTo5NWM2MDBhNTk1NmM0NGRjYmFlZDAwNDhmZjQxMWMyNV82LTEtMS0xLTA_1de50e9c-4064-4ccc-9c98-bf517e069494">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cah-20210331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i087768a01b964091a69bb564b8374aa2_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ia48bb06cca3d4969bdeb6e18237b4224_D20190701-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia19c49a9fdf94744a98048c92ed6d989_D20200701-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2d5ee4c8487424fb522d83601a9e4ed_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:NetOperatingLossCarrybackAxis">cah:NetOperatingLossCarrybackMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95e27bf6690f452f80d7e0a0bf7a1856_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:NetOperatingLossCarrybackAxis">cah:NetOperatingLossCarrybackMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ibe76498d80224b4f96b532177a01467f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib19c0c691fb5445d9011b91ede443228_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95b9c22031624339add2f629ea1f1aae_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e48fd2c42b44627b6da89b6438745df_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44fa84a0c3ec48fcb9c8521f508b477d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if86f35ae66d245c78bacd2478b7f05b7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29ae1a4981b842e1a0eab772d873665f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04980c8bb80847f688361a08698a8057_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08d5fdbf648840f09c9f0acc3309de18_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9dbcfd0b21e415c99ceac87f678613b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ca53978778d45b291d32f2884428093_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c4059f309d347d8b4ac8135e44ee042_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7c7911192d9467a8120c5a8745e0ab4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc405b4ba93d4f15a1821281ca6c82e7_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0233856860d24d818336b00e3025a695_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i354467a0724c4e4cb8b779d18d807a9f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4419c8027c549be9d1aa39851d2726a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6de9849e852143f7be17f87669ee8388_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60045d83318a4375a6adbff989fd1e0b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0384aad99f0b44cfb95e1fcfadf13ba7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42416177b60446508042e47a8082a323_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea8dfdedd1e94a78a4b76f76961b61a8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2cae46a03fd4761a321a79b8d0f6b0f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6824c1c4ebaf4b5cbe01e36215bb8c94_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87c6427dabe74d41be38b4708d40f760_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92429500105f487686a760c50a01dbd4_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i097b90d861534948b48b5e94e8d68dbc_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5d2c55efe634921802f5f63cff13133_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i227cc70eba254c68b508a19a38a4772e_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08c6b70579ab4b44b051a8e476cdc0bc_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i873b7175bb9c48f9a92364ddc30859a3_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4adeac1e746a4298af939e62c0d13228_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic22356641f7147aa93c0793fd724bac3_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie21bd48f8a9a4cb0a6e3c0240434f025_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea0558a3dad14a5aa6f2a5ea17404724_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibccb3acafd0d46549dd7845b502cc7d7_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5da09f4564644c32a41c69fe1bca282b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if50ad56426144e3086cf7b567a121bdc_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39fcecca1a1841798fed70b14788390b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4123e12a9da4e40840720f78bc466d9_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3a494cf37a0408c9c5282b7bacaf665_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81dedbde5d2a466c9175f53824dd0c39_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8b3edc49b1248e896c9ddae3b113611_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3fc7d942b0147c78cd1b3b94f6611b5_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c2d8220369a4176bd9a77e28f267fbd_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib49cffead70d458293f7ab1592b008ac_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1be2640350446e5a3a575482a87bbcc_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7133a081957418da4808a2430c8abf0_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5179121c7a146c08a655a8cfcdaa830_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77e8dc2fb46740f7886bcac833bb3946_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51326a843a1e4ac4879b831c1444fdeb_D20190701-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cad0474bd2f40d886d9d8a4cf2c72fe_D20190701-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19b4605df85247908370653224b13cab_D20190701-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e9b39d228bb4305a9f94d21ff2986b6_D20190701-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c0e121749714201bffca84925398633_D20190701-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cdd3ec3331046ec97e3ab5eeb7a43e0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:CordisDivestitureAxis">cah:CordisDivestitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i872f564c51c449338d43396b08fe7bbf_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:CordisDivestitureAxis">cah:CordisDivestitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98ac083d3c7d4cab941676ec328bb04b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i821455dffe794014b8f8a131073f0e3a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5e179139d574d23982bca2fd8e461fd_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if42abb6c898a48ab9033252b5dbfcbee_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb3bd6687f4e44aab8db611ebf43f7d0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib963f36549774070a638555f5486bde0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb77c6fda9c84c43ba66e9e82d862e1d_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b24380305684bfe8bdfbb78576d14d2_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88705ecfe8f9467188b5fdceaff0c86b_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6f5e23cdbdc462981ce1345c1d0a482_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81339315e2c14539bee8f1c43e550ae5_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:CordisDivestitureAxis">cah:CordisDivestitureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03c64db735f449b18a2b4bbcb90984f0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:CordisDivestitureAxis">cah:CordisDivestitureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice72f79525cf4aaa96a799b1808b8a8b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33dcb67f0d874581b55d12fa93285854_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib86a8f16995f4394b90a5c5d09547673_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">cah:IPRDTrademarksandOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if58ac855c7a34cfa8030c801c94150d0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb5b051f9d274a4db0185de02ba05dcb_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a9ff348b06a48ae9bb2eb719908affb_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice8a5553e38b49b6ad19d2aaa439d996_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1197b65c014b476eb038f49933bfc8b8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d099e35f5894d5e9a24b39c60d6719a_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id75e1c542b0d4277aef6f4524dc533d0_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">cah:IPRDTrademarksandOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4f1de5725004793a5eb735884c24d4e_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc713be36ac74ca6995d6707e0fd4741_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c1148a859034784a3e672c820ea0c9d_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdab92a7a6fd41b39bd57e54be7e769f_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:FloatingRateNotesdue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f3611b603314fb097f4abad927ac3d9_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A2.616Notesdue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i504e4cad981b4ed993b975460c7fc7ac_D20190701-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A2.4Notesdue2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia090211208aa441088c4d8069f02dbfb_D20190701-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A2.616Notesdue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49a27c7578bd41088dddfb606868d281_D20190701-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A3.2Notesdue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6234f8623c6430bb624a2926a712aa6_D20190701-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:FloatingRateNotesdue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1eda4e509ce43798df227d81709d323_D20190701-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A3.41Notesdue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6db532c36ac040349356f496d49a51e5_D20190701-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A4.6Notesdue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3cfcd32bbbd409a8721be1d572e5196_D20190701-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A4.9Notesdue2045Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47aa282752004df79e631b50e9d85ec0_D20190701-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A4.368Notesdue2047Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78b6ef34025b4452a5b896401fa40e7c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f24903888fe442faadd663a0aba2ff7_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i604f1c37ba004bdaa7f5e22b3f373f12_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:CommittedReceivablesSalesFacilityProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cah:ShortTermCreditFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33f590b1fd8b44a8a08a2e3ea0f1b1bd_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cah:CVSHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c69ca015f5c476994fba9d5d8aef33b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12b52de2a6014b01b5857d8d032e2d95_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ia2b0385b5ab44d27a7dc86dee405b359_I20210503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cc62b61cd8d43428ee9e8e27d88fc65_I20210503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsStateDomain</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="stateag"><xbrli:measure>cah:StateAG</xbrli:measure></xbrli:unit><xbrli:context id="ib9e03386e8bb45b9bfa0b58a7c283f07_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32ccdaa0f4af4c919f10cbbfa4cc9a79_D20190701-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f40d9e3a7db48b09daa5018d3017966_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="lawsuit"><xbrli:measure>cah:lawsuit</xbrli:measure></xbrli:unit><xbrli:context id="i7e4a5266c9ee4255be61beea0051e346_I20210503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i807f09109de94752a25bb7a0eae4766f_I20210503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ClassActionLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica111f2089a54b038384fbd2c3ed75c2_D20210503-20210503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-03</xbrli:startDate><xbrli:endDate>2021-05-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="plaintiff"><xbrli:measure>cah:plaintiff</xbrli:measure></xbrli:unit><xbrli:context id="i1bf34677339c4ce196bf82617b72b6c2_D20210503-20210503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cah:AlamedaCountyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-03</xbrli:startDate><xbrli:endDate>2021-05-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c6a6bb892f345c4b3edac4aec0d217d_D20210503-20210503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-03</xbrli:startDate><xbrli:endDate>2021-05-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22d9e3f7ffff422283088171ae8c7f53_D20210503-20210503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cah:OtherJurisdictionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-03</xbrli:startDate><xbrli:endDate>2021-05-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39e08dcc3f9f4795a07a40686f4f773d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i901bacdc1d384d90bd9435b24ae9e637_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i200d0dbf02ed453d87b6ed7ec2d17a53_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:DOJInvestigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6be08e009bc84db19fea6af132f4df1c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64ace7956a934516b089799b59bc6227_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i352533a8ebdc4e1ea369fbf8d0b0cb22_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a9345a4d82147cbb391e59d3476b6af_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ided1be8f67714ed8b59a2a7328872d54_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfa1be8946614c2b9007346f625163d2_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4bf28e522354f2395213116e925d1b9_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e66f2887db842aa8968fdf63602e73d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:CareFusionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d53fc1dcd044ba08aabb87d0bbbcb75_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:CareFusionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49fd517f759e4c02bee7665cf6f0fc34_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:PatientRecoveryBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68ba2e46a7674cc8991710f46cdcb0b6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:PatientRecoveryBusinessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31c9d1ab6ad74ad6be84ceec57e39a73_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1c063a9eef24440b68b23b7cc020697_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb9fc5025c56429290c144a9ab02add4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia215aea801f34ad985846f37619f80f0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f7d6a255b6d43b7a97b861817531138_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80081b312cf4449bb7fe8a2f4e5535d7_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9020f748109a4007908680bcbacb5e56_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bde8641630642bf8d5434c1fadce5ef_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5987d078d03f4fc38046fb86086b6b1e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i949ddfae3947416db45abfd64c94adeb_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87eabc19117047338578608b2ee7dcd4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i334e47c1f3ff45dcb6b4856094c8f1c0_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58ec7cecb23b4f45bed4e5c64a8bb562_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1af6bf6a64a4c77ba66fed4c716d945_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia42786050a004af0aedbbe0f8357c727_D20190701-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="jpy"><xbrli:measure>iso4217:JPY</xbrli:measure></xbrli:unit><xbrli:context id="ia8c1b38a8f8d4adf9f86653e53b0dd5c_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i532e1aadd9b146e7ae42838aec9fcb8c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic014c1b02128475ba87eda0763cfdcc4_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3205d5053724d48900805160556c3d0_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa27c7b19457466dabe317a3abbbb6df_D20190701-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6794b69d98f24573ba346bd46b22a10a_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06a14268e5cb46ffb7dbf7a3ce7660f6_D20190701-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie14f3bec98e9401e9d0262da4f2de10b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ef4ab475d104948a5835edf958fa41a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10d07f0a48104550b0a508675603448e_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie27ad5c522f44e8b90817308ed523e4d_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b25597e1abd4762a53125bd127a7fc6_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2cfce8a58cc495e9d881af0122e343d_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ecadae65dfb4b55ab6336e5e1372f5e_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b80eecd6d274b6099620f1435d44f65_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1282072a9944c75994cdaf150f6cae9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e2d2af534744410b83b2b8c23ceae67_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i678e5905c5c04646a1adad096e2142a5_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>cah:segment</xbrli:measure></xbrli:unit><xbrli:context id="icb95c38f699b498bae7eccc1951e60ef_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id77fcd8f97ce44d28130b582a93ca388_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98a550bd18584222b45f6e22795837d8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i497d93eb01e34fc299e07f6c11433ddc_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13210788c384499eb6bd49c7ac901881_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie15bd6a384d84a93aa0435432170a9e0_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i754a245950334f9994b76f93229c450a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie00acdc941434982aa3c874289a0f3fd_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i980f0fff0b9a4c3190c440190a0f45b0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66cd600a4fa943049ca88903270b5e37_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a6b387b92814c6dbccb36d4616b973b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b2f4f39f2f9421c9376d5aeb5d1ebba_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic430db4eef8d4096927747687050f4ab_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i133a2afe200e422e8417d692d3db7c24_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3be9b6146804373965da8f26eb058f6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb553ffd18cb495b81f622bdfcdbd4c4_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38499692778a4677a3d0205a54dabc5e_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a204b9287bf45b1a70bdb9303162867_D20190701-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd1495b463924bf7a6a21f64497f4f5f_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d2aa45f535e4ad78bb4d60e6ab599cf_D20190701-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idaf142075796467695d26aed7ffad5a6_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7633f1494ae14d6db19bb6de3dd5dc7d_D20190701-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia66d6c475fbc4a4f93c1eed3e22397fe_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee665c670791489a9810213babe512b3_D20190701-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1306a7b737e45e5b5d2f6b30e1ae7c8_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8294a10e67a64ee889ba04da6c8dda53_D20190701-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6b13c1180504c8e8b9bbe3e3b0affe6_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac89152bf6b649d09d16a732e7fe9fd7_D20190701-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifdac359205cd4b9894e9c5b6bc9a75f9_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7571f4a1493c40f1948e2aa7d8298511_D20190701-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if00aae22cda442e2907fd2752c87fb3d_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8024f13f805493da1022a38d9655ca3_D20190701-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i155df096ff374a49874a1b86694a8d78_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ba2131531c140b1887cc40420a68d24_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c2e770d82df4fb29415150ac2904bdd_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1dce9a8c75d4af4a876d4bf69e8bed9_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia08f0b8f481d48ddaf2634a007190de5_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i627973ec4999405b88953cf1981248fe_D20190701-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c43376b1a4b4c3fb49e50efec9c4eb9_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i437975c25f184124919229aca35a0a19_D20190701-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbb9380a5af84ba6ae989a20e860a444_D20190701-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cah:SterileSurgicalGownRecallAxis">cah:SterileSurgicalGownRecallMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb1b5bacb6bb401e8fe737bb56674184_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia56ac1f95221479a8866de7ff447bece_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22ff8eca14d54d0e88769fe944e5fac0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8ac06c44c654f11a21c85f88fe7ba70_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b9e31e1c7394a41915dce3992145e0c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie599ab9917894d65ad37cc3447647eae_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5489b32b324b43e7b31fefeae25b8dc6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadf80adca21245ef9ca13b43ebeba09d_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i675bcdf093c842b683f5f42b5d7c6dd5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56e3ff286a3f4cc79923baab49b0ed00_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida44dc7e8fef4822b90092a960bfd60d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5fccbaecaed42a78b6b4926ea168dc1_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a89c112cd7f42b3a5456dc100a7ede7_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic52a8031a6f841969982b87db2a42528_D20190701-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96b93fe596a142948ea01b57dd171ae6_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26baad0d41684101ab66f22954853d05_D20190701-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04a5e9e5e39042d4954e45ee16242fba_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifacfc13c40bb4c9bb653687d05e0441a_D20190701-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6304faf17b842ef9c340762418125fc_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77e9bd39dd824727aafae148f4111ead_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5226be778dfe441d9f2c92df26a11158_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic86b7d6cb21f44eaad860256ec1bfebc_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae78c99bef954f35b10d2bf1557917a0_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if622e969bb1c456795db4df9e45f0a4b_D20200701-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f362429a27e4da98d58d075d240086a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7e27cac65544c18a83f69a3c9f73b79_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000721371</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ib6bf45669ad94861b0c50dbc2f4371ce_1"></div><div style="min-height:40.5pt;width:100%"><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.461%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:100%">UNITED STATES</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Washington,&#160;D.C. 20549</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Form <ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xL2ZyYWc6Y2RkMTE2MzFmOGFhNGM5YzhhNTU5MDdmOWI3ZDA3OGIvdGV4dHJlZ2lvbjpjZGQxMTYzMWY4YWE0YzljOGE1NTkwN2Y5YjdkMDc4Yl84NQ_3638c5bb-20d8-41a1-9658-abde8813d28b">10-Q</ix:nonNumeric> </span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.923%"><tr><td style="width:1.0%"></td><td style="width:5.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xL2ZyYWc6Y2RkMTE2MzFmOGFhNGM5YzhhNTU5MDdmOWI3ZDA3OGIvdGFibGU6YzQ0YWI1M2NjODNhNDU4ZGE5NDk0ZGZmZjU4YTgxOTcvdGFibGVyYW5nZTpjNDRhYjUzY2M4M2E0NThkYTk0OTRkZmZmNThhODE5N18wLTAtMS0xLTA_94c75c1e-4f36-4474-9f8a-ae996db50ada">&#9745;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xL2ZyYWc6Y2RkMTE2MzFmOGFhNGM5YzhhNTU5MDdmOWI3ZDA3OGIvdGV4dHJlZ2lvbjpjZGQxMTYzMWY4YWE0YzljOGE1NTkwN2Y5YjdkMDc4Yl8xMjI_9f91a8e2-5c55-44b5-a674-11d2ad066847">March 31, 2021</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.923%"><tr><td style="width:1.0%"></td><td style="width:5.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xL2ZyYWc6Y2RkMTE2MzFmOGFhNGM5YzhhNTU5MDdmOWI3ZDA3OGIvdGFibGU6NmJlMTUxZDFkMmIxNDdhNmE2NzJiYzgxMDU3MDMwYzAvdGFibGVyYW5nZTo2YmUxNTFkMWQyYjE0N2E2YTY3MmJjODEwNTcwMzBjMF8wLTAtMS0xLTA_94b6e4c1-f3d7-47dd-b1c6-e4e46a4f617e">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the transition period from ________ to ________</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission File Number:&#160;<ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xL2ZyYWc6Y2RkMTE2MzFmOGFhNGM5YzhhNTU5MDdmOWI3ZDA3OGIvdGV4dHJlZ2lvbjpjZGQxMTYzMWY4YWE0YzljOGE1NTkwN2Y5YjdkMDc4Yl8xNTgw_74fdb068-88ad-4d96-b934-fa2946fb3664">1-11373</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xL2ZyYWc6Y2RkMTE2MzFmOGFhNGM5YzhhNTU5MDdmOWI3ZDA3OGIvdGV4dHJlZ2lvbjpjZGQxMTYzMWY4YWE0YzljOGE1NTkwN2Y5YjdkMDc4Yl8xNTgx_a46857ef-2268-4df8-b565-282872a6d70e">Cardinal Health, Inc.</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.282%"><tr><td style="width:1.0%"></td><td style="width:24.998%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.865%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.892%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.865%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.346%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xL2ZyYWc6Y2RkMTE2MzFmOGFhNGM5YzhhNTU5MDdmOWI3ZDA3OGIvdGFibGU6ZTRkYTk4NDlhZjk1NGRkYjg2ZGJlOTllMjY3YTFjYjAvdGFibGVyYW5nZTplNGRhOTg0OWFmOTU0ZGRiODZkYmU5OWUyNjdhMWNiMF8wLTAtMS0xLTA_e3764a9b-2557-4da4-8c43-24428ad05065">Ohio</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xL2ZyYWc6Y2RkMTE2MzFmOGFhNGM5YzhhNTU5MDdmOWI3ZDA3OGIvdGFibGU6ZTRkYTk4NDlhZjk1NGRkYjg2ZGJlOTllMjY3YTFjYjAvdGFibGVyYW5nZTplNGRhOTg0OWFmOTU0ZGRiODZkYmU5OWUyNjdhMWNiMF8wLTYtMS0xLTA_ffd308b9-1625-4631-98bf-d5d16e852bdd">31-0958666</ix:nonNumeric></span></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(IRS Employer<br/>Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xL2ZyYWc6Y2RkMTE2MzFmOGFhNGM5YzhhNTU5MDdmOWI3ZDA3OGIvdGFibGU6ZTRkYTk4NDlhZjk1NGRkYjg2ZGJlOTllMjY3YTFjYjAvdGFibGVyYW5nZTplNGRhOTg0OWFmOTU0ZGRiODZkYmU5OWUyNjdhMWNiMF8zLTAtMS0xLTA_6ae7c4f5-dd69-47ea-be8b-6cefa7b8f465">7000 Cardinal Place</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xL2ZyYWc6Y2RkMTE2MzFmOGFhNGM5YzhhNTU5MDdmOWI3ZDA3OGIvdGFibGU6ZTRkYTk4NDlhZjk1NGRkYjg2ZGJlOTllMjY3YTFjYjAvdGFibGVyYW5nZTplNGRhOTg0OWFmOTU0ZGRiODZkYmU5OWUyNjdhMWNiMF8zLTItMS0xLTA_16a7993d-5cc2-4af7-9489-5f67088b70b8">Dublin</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">,</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xL2ZyYWc6Y2RkMTE2MzFmOGFhNGM5YzhhNTU5MDdmOWI3ZDA3OGIvdGFibGU6ZTRkYTk4NDlhZjk1NGRkYjg2ZGJlOTllMjY3YTFjYjAvdGFibGVyYW5nZTplNGRhOTg0OWFmOTU0ZGRiODZkYmU5OWUyNjdhMWNiMF8zLTQtMS0xLTA_71bab862-7027-4623-b224-8e4132aedc43">Ohio</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xL2ZyYWc6Y2RkMTE2MzFmOGFhNGM5YzhhNTU5MDdmOWI3ZDA3OGIvdGFibGU6ZTRkYTk4NDlhZjk1NGRkYjg2ZGJlOTllMjY3YTFjYjAvdGFibGVyYW5nZTplNGRhOTg0OWFmOTU0ZGRiODZkYmU5OWUyNjdhMWNiMF8zLTYtMS0xLTA_205ba8c0-f555-4afe-a52b-a2439e23e5e7">43017</ix:nonNumeric></span></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(Zip Code)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xL2ZyYWc6Y2RkMTE2MzFmOGFhNGM5YzhhNTU5MDdmOWI3ZDA3OGIvdGFibGU6ZTRkYTk4NDlhZjk1NGRkYjg2ZGJlOTllMjY3YTFjYjAvdGFibGVyYW5nZTplNGRhOTg0OWFmOTU0ZGRiODZkYmU5OWUyNjdhMWNiMF82LTQtMS0xLTA_059cdcae-0727-49db-8fb3-3db566419dba">(614)</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xL2ZyYWc6Y2RkMTE2MzFmOGFhNGM5YzhhNTU5MDdmOWI3ZDA3OGIvdGFibGU6ZTRkYTk4NDlhZjk1NGRkYjg2ZGJlOTllMjY3YTFjYjAvdGFibGVyYW5nZTplNGRhOTg0OWFmOTU0ZGRiODZkYmU5OWUyNjdhMWNiMF82LTYtMS0xLTA_011403af-76e3-408f-a72f-3f4b1f9c63f3">757-5000</ix:nonNumeric></span></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">(Registrant&#8217;s telephone number, including area code)</span></td></tr></table></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.435%"><tr><td style="width:1.0%"></td><td style="width:35.931%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.836%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xL2ZyYWc6Y2RkMTE2MzFmOGFhNGM5YzhhNTU5MDdmOWI3ZDA3OGIvdGFibGU6MGZkOGE4MGNlMTYyNDBiMWI0Yjc0NjVlNDM4MDY3MWYvdGFibGVyYW5nZTowZmQ4YTgwY2UxNjI0MGIxYjRiNzQ2NWU0MzgwNjcxZl8yLTAtMS0xLTA_013490a8-225e-4002-b46e-49642fc6b78e">Common shares (without par value)</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xL2ZyYWc6Y2RkMTE2MzFmOGFhNGM5YzhhNTU5MDdmOWI3ZDA3OGIvdGFibGU6MGZkOGE4MGNlMTYyNDBiMWI0Yjc0NjVlNDM4MDY3MWYvdGFibGVyYW5nZTowZmQ4YTgwY2UxNjI0MGIxYjRiNzQ2NWU0MzgwNjcxZl8yLTEtMS0xLTA_09b4367e-e79e-4b42-9d91-2ee741b2c8c2">CAH</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xL2ZyYWc6Y2RkMTE2MzFmOGFhNGM5YzhhNTU5MDdmOWI3ZDA3OGIvdGFibGU6MGZkOGE4MGNlMTYyNDBiMWI0Yjc0NjVlNDM4MDY3MWYvdGFibGVyYW5nZTowZmQ4YTgwY2UxNjI0MGIxYjRiNzQ2NWU0MzgwNjcxZl8yLTItMS0xLTA_c040d187-72d7-47f7-b877-681b2d7f4fa5">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xL2ZyYWc6Y2RkMTE2MzFmOGFhNGM5YzhhNTU5MDdmOWI3ZDA3OGIvdGV4dHJlZ2lvbjpjZGQxMTYzMWY4YWE0YzljOGE1NTkwN2Y5YjdkMDc4Yl8xNTgy_0db3cc20-215c-4b0e-bd84-0bc282a3d7ca">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#254;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xL2ZyYWc6Y2RkMTE2MzFmOGFhNGM5YzhhNTU5MDdmOWI3ZDA3OGIvdGV4dHJlZ2lvbjpjZGQxMTYzMWY4YWE0YzljOGE1NTkwN2Y5YjdkMDc4Yl8xNTgz_7e54f21b-a976-4c5c-a516-d3c6724ca715">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#254;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.694%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.032%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xL2ZyYWc6Y2RkMTE2MzFmOGFhNGM5YzhhNTU5MDdmOWI3ZDA3OGIvdGFibGU6ZTg5ODdiODllNWRjNDEyY2E4ZTFiMDE3NjQyYmVmZjQvdGFibGVyYW5nZTplODk4N2I4OWU1ZGM0MTJjYThlMWIwMTc2NDJiZWZmNF8wLTAtMS0xLTA_c071050b-04ec-43c4-9589-2bc861b4e9a1">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9745;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xL2ZyYWc6Y2RkMTE2MzFmOGFhNGM5YzhhNTU5MDdmOWI3ZDA3OGIvdGFibGU6ZTg5ODdiODllNWRjNDEyY2E4ZTFiMDE3NjQyYmVmZjQvdGFibGVyYW5nZTplODk4N2I4OWU1ZGM0MTJjYThlMWIwMTc2NDJiZWZmNF8xLTQtMS0xLTA_f1e6be38-48e3-4142-955f-33416d2f60fe">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xL2ZyYWc6Y2RkMTE2MzFmOGFhNGM5YzhhNTU5MDdmOWI3ZDA3OGIvdGFibGU6ZTg5ODdiODllNWRjNDEyY2E4ZTFiMDE3NjQyYmVmZjQvdGFibGVyYW5nZTplODk4N2I4OWU1ZGM0MTJjYThlMWIwMTc2NDJiZWZmNF8yLTQtMS0xLTA_e4fb2b95-447d-4f68-90be-f11fccbbccee">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span></div></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). &#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xL2ZyYWc6Y2RkMTE2MzFmOGFhNGM5YzhhNTU5MDdmOWI3ZDA3OGIvdGV4dHJlZ2lvbjpjZGQxMTYzMWY4YWE0YzljOGE1NTkwN2Y5YjdkMDc4Yl8xNTg0_cf7c1637-328f-400e-bea8-695bc2e82017">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#254;</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of the registrant&#8217;s common shares, without par value, outstanding as of April&#160;30, 2021, was the following: <ix:nonFraction unitRef="shares" contextRef="i087768a01b964091a69bb564b8374aa2_I20210430" decimals="0" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xL2ZyYWc6Y2RkMTE2MzFmOGFhNGM5YzhhNTU5MDdmOWI3ZDA3OGIvdGV4dHJlZ2lvbjpjZGQxMTYzMWY4YWE0YzljOGE1NTkwN2Y5YjdkMDc4Yl8xNTc4_d0d16d70-0604-4b53-85af-0182ed9d3527">290,147,927</ix:nonFraction>.</span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="ib6bf45669ad94861b0c50dbc2f4371ce_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:22pt;font-weight:700;line-height:100%">Cardinal Health</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:100%"> </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:18pt;font-weight:700;line-height:100%"> </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Q3 Fiscal 2021 Form 10-Q                                                                                                                                   </span></div></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.660%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.222%"><tr><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:91.080%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_13">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_13">2</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_31">Explanation and Reconciliation of Non-GAAP Financial Measures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_31">21</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_40">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_40">25</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_43">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_43">25</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_46">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_46">26</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_49">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_49">27</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_1216">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_1216">28</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_61">Financial Statemen</a>ts</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_61">29</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_121">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_121">48</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_124">Form 10-Q Cross Reference Index</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_124">49</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_127">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_127">50</a></span></div></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">About Cardinal Health</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardinal Health, Inc. is an Ohio corporation formed in 1979 and is a globally integrated healthcare services and products company providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices. We provide medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency. We connect patients, providers, payers, pharmacists and manufacturers for integrated care coordination and better patient management. We manage our business and report our financial results in two segments: Pharmaceutical and Medical. As used in this report, &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; and similar pronouns refer to Cardinal Health, Inc. and its subsidiaries, unless the context requires otherwise. Our fiscal year ends on June 30. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to fiscal 2021 and fiscal 2020 and to FY21 and FY20 are to the fiscal years ending or ended June&#160;30, 2021 and June 30, 2020, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2021 (this "Form 10-Q") (including information incorporated by reference) includes "forward-looking statements" addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. Many forward-looking statements appear in Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations ("MD&amp;A"), but there are others in this Form 10-Q, which may be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "will," "should," "could," "would," "project," "continue," "likely," and similar expressions, and include statements reflecting future results, trends or guidance, statements of outlook and expense accruals. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those made, projected or implied. The most significant of these risks and uncertainties are described in this Form 10-Q, including Exhibit 99.1, and in "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended June 30, 2020 (our &#8220;2020 Form 10-K&#8221;). Forward-looking statements in this Form 10-Q speak only as of the date of this document. Except to the extent required by applicable law, we undertake no obligation to update or revise any forward-looking statement.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Non-GAAP Financial Measures</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the "Overview of Consolidated Results" section of MD&amp;A, we use financial measures that are derived from our consolidated financial data but are not presented in our condensed consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). These measures are considered "non-GAAP financial measures" under the United States Securities and Exchange Commission ("SEC") rules. The reasons we use these non-GAAP financial measures and the reconciliations to their most directly comparable GAAP financial measures are included in the &#8220;Explanation and Reconciliation of Non-GAAP Financial Measures&#8221; section following MD&amp;A in this Form 10-Q. </span></div><div style="height:58.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="ib6bf45669ad94861b0c50dbc2f4371ce_13"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.820%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></div></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Management's Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion and analysis presented below is concerned with material changes in financial condition and results of operations between the periods specified in our condensed consolidated balance sheets at March&#160;31, 2021 and June&#160;30, 2020, and in our condensed consolidated statements of earnings/(loss) for the three and nine months ended March&#160;31, 2021 and 2020. All comparisons presented are with respect to the prior-year period, unless stated otherwise. This discussion and analysis should be read in conjunction with the MD&amp;A included in our 2020 Form 10-K.</span></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="ib6bf45669ad94861b0c50dbc2f4371ce_16"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Overview of Consolidated Results</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><img src="cah-20210331_g1.jpg" alt="cah-20210331_g1.jpg" style="height:200px;margin-bottom:5pt;vertical-align:text-bottom;width:266px"/></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021, revenue was flat at $39.3 billion. Sales growth from pharmaceutical distribution and specialty solutions customers during the three months ended March&#160;31, 2021 approximated the prior-year temporary increase in March 2020 pharmaceutical sales related to accelerated purchasing by customers in connection with the beginning of the COVID-19 pandemic (&#8220;COVID-19&#8221;). During the nine months ended March&#160;31, 2021, revenue increased 3 percent to $119.9 billion, primarily due to sales growth from pharmaceutical distribution and specialty solutions customers, partially offset due to volume declines related to the impact of COVID-19.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">GAAP and Non-GAAP Operating Earnings/(Loss)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:48.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.664%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">GAAP operating earnings/(loss)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">473</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">562&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(16)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">310</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,368)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surgical gown recall costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State opioid assessment related to prior fiscal years</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">81</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">111</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">345</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">69</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">78</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">15</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,085</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,729&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-GAAP operating earnings</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">689</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">719&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,935</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,942&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The sum of the components and certain computations may reflect rounding adjustments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in GAAP operating earnings during the three months ended March&#160;31, 2021 was primarily due to the write-down of the net assets held for sale from the planned divestiture of the Cordis business and restructuring and employee severance related to the implementation of certain enterprise-wide cost-saving measures. See further description of the planned divestiture of the Cordis business in the Significant Developments in Fiscal 2021 and Trends section in this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_1194">Note 2</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements."</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had GAAP operating earnings of $310 million and a GAAP operating loss of $4.4 billion during the nine months ended March&#160;31, 2021 and 2020, respectively, due to $1.02 billion and $5.63&#160;billion of pre-tax charges, respectively, recognized for the estimated liability associated with lawsuits and claims brought against us by states and political subdivisions relating to the distribution of prescription opioid pain medications. See further description of opioid lawsuits in the Significant Developments in Fiscal 2021 and Trends section in this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_97">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements." </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-GAAP operating earnings during the three and nine months ended March&#160;31, 2021 were adversely impacted due to volume declines in our generics program, primarily due to COVID-19, partially offset by higher contribution from branded pharmaceutical sales mix. Overall, COVID-19 has had a negative impact on consolidated non-GAAP operating earnings during these periods. During the nine months ended March&#160;31, 2021, non-GAAP operating earnings were positively impacted by Medical segment cost-savings measures, including global manufacturing efficiencies. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">GAAP and Non-GAAP Diluted EPS</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:48.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.664%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">($ per share)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020 </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (2) (3)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">GAAP diluted EPS </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.40</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.19&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.68</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.84)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surgical gown recall costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State opioid assessment related to prior fiscal years</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.10</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.06</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.21</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.28</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.34&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.88</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.01&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.25</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.22</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.54</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.09&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.70</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.80&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transitional tax benefit, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-GAAP diluted EPS </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.53</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.62&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4.79</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.41&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The sum of the components and certain computations may reflect rounding adjustments. </span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Diluted earnings/(loss) per share attributable to Cardinal Health, Inc. ("diluted EPS" or "diluted loss per share")</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The reconciling items are presented within this table net of tax. See quantification of tax effect of each reconciling item in our GAAP to Non-GAAP Reconciliations in the "Explanation and Reconciliation of Non-GAAP Financial Measures." </span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">For the nine months ended March&#160;31, 2020, GAAP diluted loss per share attributable to Cardinal Health, Inc. ("GAAP diluted EPS") and the EPS impact from the GAAP to non-GAAP per share reconciling items are calculated using a weighted average of 293 million common shares, which excludes potentially dilutive securities from the denominator due to their anti-dilutive effects resulting from our GAAP net loss for the period. Year-to-date fiscal 2020 non-GAAP diluted EPS is calculated using a weighted average of 295 million common shares which includes potentially dilutive shares.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Litigation (recoveries)/charges, net, includes a tax benefit recorded during the nine months ended March&#160;31, 2021 related to a net operating loss carryback. Our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation. This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes. The net operating loss was carried back and adjusted our taxable income for fiscal 2015, 2016, 2017 and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security (&#8220;CARES&#8221;) Act. The total benefit from the net operating loss carryback was $419 million; however, for purposes of Non-GAAP financial measures, we allocated $385 million of the benefit to litigation (recoveries)/charges, net, which is excluded from non-GAAP measures, based on the relative amount of the self-insurance pre-tax loss related to opioid litigation claims versus separate tax adjustments. The tax benefit allocated to the separate tax adjustments of $34 million is included in non-GAAP measures.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The charges we recognized in fiscal 2021 and 2020 for the estimated liability associated with lawsuits and claims brought against us by states and political subdivisions relating to the distribution of prescription opioid pain medications had a $(2.85) and $(17.53) per share after-tax impact on GAAP diluted EPS for the nine months ended March&#160;31, 2021 and 2020, respectively. In addition, GAAP diluted EPS for the three months ended March 31, 2021 was impacted by $(0.47) per share due to the tax effect of the litigation charge, which was recorded during the three months ended September 30, 2020. See the Significant Developments in Fiscal 2021 and Trends section in this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_100">Note 7</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March&#160;31, 2021, GAAP and non-GAAP diluted EPS were positively impacted by $1.42 and $0.12 per share, respectively, due to a tax benefit from the net operating loss carryback primarily related to a self-insurance pre-tax loss, as further described in Significant Developments in Fiscal 2021 and Trends section in this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_100">Note 7</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements."</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse tax matters that impacted GAAP and non-GAAP EPS for the three and nine months ended March 31, 2021 included an adjustment to our tax provision for the resolution of all open matters with the Internal Revenue Service ("IRS") for fiscal years 2008 to 2010 as well as certain transfer pricing matters for fiscal years 2011 to 2014, which also impacted reserves for later years. In addition, the tax provision was adversely impacted by withholding taxes for planned distributions from foreign subsidiaries.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021, GAAP diluted EPS decreased primarily due to the tax effect of the litigation charge and the adverse tax matters discussed above. GAAP diluted EPS was also adversely impacted by factors impacting GAAP operating earnings, including the write-down of the net assets held for sale from the planned divestiture of our Cordis business, which had a $(0.22) per share after-tax impact.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March&#160;31, 2021 and 2020, GAAP diluted EPS was primarily impacted by the litigation charges discussed above. During the nine months ended March&#160;31, 2021, GAAP diluted EPS was positively impacted by the net operating loss carryback discussed above.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021, non-GAAP diluted EPS decreased 6 percent to $1.53 per share. This decrease was primarily due to the adverse tax matters discussed above and factors impacting non-GAAP operating earnings, partially offset by lower interest expense resulting from less debt outstanding.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March&#160;31, 2021, non-GAAP diluted EPS increased 9 percent to $4.79 per share. This increase was primarily due to lower interest expense resulting from less debt outstanding and a net tax benefit. This benefit was primarily due to changes in discrete tax items, including the net operating loss carryback discussed above, partially offset by the adverse tax matters discussed above.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Cash and Equivalents</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash and equivalents balance was $3.5 billion at March&#160;31, 2021 compared to $2.8 billion at June&#160;30, 2020. During the nine months ended March&#160;31, 2021, net cash provided by operating activities was $1.8 billion and we deployed $432 million for cash dividends, $274 million for capital expenditures and $200 million for share repurchase.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Significant Developments in Fiscal 2021 and Trends</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Cordis Divestiture</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 12, 2021, we announced that we signed a definitive agreement to sell our Cordis business to Hellman &amp; Friedman for proceeds of $927 million in cash, subject to customary purchase price adjustments, and we will retain certain working capital accounts and certain liabilities, including product liability for lawsuits related to inferior vena cava filters in the U.S. and Canada as described in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_97">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the &#8220;Notes to Condensed Consolidated Financial Statements.&#8221; The proposed transaction is expected to close in the first quarter of fiscal 2022, subject to customary closing conditions and regulatory clearances. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_1194">Note 2</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information. In connection with the sale, we expect to enter into a Transition Services Agreement ("TSA") with the buyer to provide certain support functions for a period of up to twenty-four months following the sale.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the definitive agreement, during the three and nine months ended March&#160;31, 2021, we recognized a $58 million pre-tax write-down of the net assets held for sale in impairment and (gain)/loss on disposal of assets in the condensed consolidated statement of earnings/(loss). We recorded a net tax expense of $7 million associated with the impact of the write-down and the required tax adjustments triggered by held for sale accounting. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the planned divestiture, we expect to record costs associated with exit or disposal activities of up to $125 million in restructuring and employee severance in our consolidated statement of earnings/(loss), primarily during fiscal years 2021 and 2022. We expect these charges to consist of approximately $83 million of professional, project management and other service fees to support the planned divestiture; $19 million of employee-related costs; and additional expenses from facility exits and other restructuring activities. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the planned divestiture of the Cordis business will decrease annual Medical segment revenue by approximately $800 million and adversely impact Medical segment profit on a run-rate basis. The planned divestiture of our Cordis business is subject to risks and uncertainties that may adversely impact Medical segment revenue and profit. For example, we may not be successful in completing the divestiture on a timely basis and the TSA period may get extended beyond our current expectations. It is also possible that the costs associated with the exit or disposal activities and stranded costs could be greater than anticipated.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Tax Effects of Self-Insurance Pre-Tax Loss</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March&#160;31, 2021, our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation. This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes. The net operating loss was carried back and applied to adjust our taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security ("CARES") Act enacted by the United States Congress in March 2020.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, our provision for income taxes during the nine months ended March&#160;31, 2021 included a $419 million benefit from the net operating loss carryback primarily to reflect the difference between the federal statutory income tax rate during the fiscal years from 2015 to 2018 (35 percent for fiscal 2015, 2016, and 2017 and 28 percent for fiscal 2018) and the current federal statutory income tax rate of 21 percent.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have filed for a federal income tax refund of $974 million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have recorded a current asset on our condensed consolidated balance sheet at March&#160;31, 2021. We also increased our non-current deferred tax liability by approximately $700 million during the nine months ended March&#160;31, 2021 related to this matter.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Opioid Lawsuits Development</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, in October 2019, we agreed in principle to a global settlement framework with a leadership group of state attorneys general that is designed to resolve all pending and future opioid lawsuits and claims by states and political subdivisions, but not private plaintiffs (the "Settlement Framework"). Definitive terms for a settlement continue to be negotiated, and there is no assurance that the necessary parties will agree to a definitive settlement agreement or that the contingencies to any agreement will be satisfied.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the opioid lawsuits and settlement negotiations, we recorded pre-tax charges of $1.02&#160;billion and $5.63 billion during the nine months ended March&#160;31, 2021 and 2020, respectively, in litigation (recoveries)/charges, net, in the condensed consolidated </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">statements of earnings/(loss). We accrue for contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_97">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Effect of Opioid Litigation Charges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net tax benefits associated with the opioid litigation charges are $37 million and $488 million for fiscal 2021 and 2020, respectively. Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized tax benefits of $35 million and $468 million, respectively. Due to our assessment of non-deductibility for certain components considered in the fiscal 2021 and 2020 charges, the tax benefit for fiscal 2021 compared to fiscal 2020 resulted in a relatively lower tax benefit. Our assumptions and estimates around this benefit and uncertain tax position require significant judgment and the actual amount of tax benefit related to uncertain tax positions may differ materially from these estimates. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings/(loss) before income taxes for the year-to-date period to compute our provision for/(benefit from) income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the initial opioid litigation accrual during the three months ended September 30, 2019, the tax effect of the charge was treated as a discrete item because it was considered unusual or infrequent. However, the tax effect of the charge during the nine months ended March&#160;31, 2021 was included in our estimated annual effective tax rate because it was no longer considered unusual or infrequent. The inclusion of the relatively lower tax benefit of the current fiscal year charge in our estimated annual effective tax rate significantly increased the estimated annual effective tax rate for fiscal 2021. As such, the amount of tax expense increased by approximately $140 million during the three months ended March&#160;31, 2021 while the amount of tax benefit increased by approximately $180 million during the nine months ended March&#160;31, 2021 compared to the tax impacts that would have been recognized without the opioid litigation charge. As stated above, the benefit as of the end of fiscal 2021 is expected to be $37 million. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_100">Note 7</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the &#8220;Notes to Condensed Consolidated Financial Statements&#8221; for additional information.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">COVID-19</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic ("COVID-19") continues to affect the U.S. and global economies, and as previously disclosed in our Fiscal 2020 Form 10-K, the pandemic began to materially affect our businesses during the three months ended March 31, 2020. The length and severity of the pandemic and of the related economic impacts to our businesses and operations are uncertain, including its ongoing impacts to our businesses and results of operations.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In comparison to the prior year, COVID-19 has had a negative impact on our consolidated operating earnings in the three and nine months ended March&#160;31, 2021; however, given the negative impact of COVID-19 on operating earnings at the end of fiscal 2020, it is uncertain whether the year-over-year impact on fiscal 2021 operating earnings will be positive or negative. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical segment profit has been negatively impacted by COVID-19 largely due to volume declines in our generics program and Nuclear and Precision Health Solutions. While we expect that volumes within our generics program for the remainder of fiscal year 2021 will continue to be lower than levels prior to COVID-19, we currently believe that the impact of COVID-19 on Pharmaceutical segment profit will improve on a year-over-year basis for the remainder of fiscal year 2021. In addition, while the impact of COVID-19 was negative on Nuclear and Precision Health Solutions during the first six months of fiscal 2021, it improved during the three months ended March 31, 2021 and is expected to further improve during the remainder of fiscal 2021.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the nine months ended March&#160;31, 2021, COVID-19 benefited Medical segment profit due to higher volumes in our laboratory business, cost savings and a net positive contribution from personal protective equipment ("PPE") partially offset by the adverse effects of lower demand for surgical products resulting from reduced elective procedures. However, in the three months ended March&#160;31, 2021, COVID-19 had a slight negative impact on the Medical segment due to the comparison to the modest positive impact of sales volume increases in the prior period. For fiscal year 2021, we expect COVID-19 to have a beneficial impact on the Medical segment compared to the prior year. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the three months ended March 31, 2020, our Medical segment has seen dramatically increased demand for certain PPE, such as masks, gowns and gloves. This increased demand has resulted in higher sales volume for certain products and increased costs to manufacture and source these products and higher inventory levels. As a result, we have sought out additional sources for these products. To mitigate the impact of these cost increases, we have raised our selling prices for the affected products. While we have been successful </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Overview</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in mitigating the impact of these increased costs to date, it is possible that demand or selling prices for these products may decline in the future, resulting in excess inventory or inventory cost above net realizable value, requiring inventory reserves that could adversely impact Medical segment profit.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="ib6bf45669ad94861b0c50dbc2f4371ce_19"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.852%"><tr><td style="width:1.0%"></td><td style="width:24.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.797%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><img src="cah-20210331_g2.jpg" alt="cah-20210331_g2.jpg" style="height:250px;margin-bottom:5pt;vertical-align:text-bottom;width:266px"/><img src="cah-20210331_g3.jpg" alt="cah-20210331_g3.jpg" style="height:250px;margin-bottom:5pt;vertical-align:text-bottom;width:266px"/></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">35,104</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,112&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">107,452</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104,254&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,174</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12,441</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39,278</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,163&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">119,893</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116,245&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39,275</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,157&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">119,881</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116,233&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pharmaceutical Segment </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021, revenue was flat at $35.1 billion. Sales growth from pharmaceutical distribution and specialty solutions customers in the three months ended March&#160;31, 2021 approximated the prior-year temporary increase in March 2020 pharmaceutical sales related to accelerated purchasing by customers in connection with the outbreak in the United States of COVID-19. During the nine months ended March&#160;31, 2021, revenue increased 3 percent to $107.5 billion, primarily due to sales growth from pharmaceutical distribution and specialty solutions customers, partially offset due to volume declines related to the impact of COVID-19, which increased revenue by $3.2 billion.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Medical Segment</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical segment revenue increased during the three and nine months ended March&#160;31, 2021 primarily within products and distribution, which increased revenue by $99&#160;million and $322&#160;million, respectively, due to a net benefit from COVID-19. The net benefit from COVID-19 is due to higher volumes in our laboratory business and the positive impact of personal protective equipment ("PPE"), partially offset by the adverse impact of lower demand for surgical products resulting from reduced elective procedures.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Cost of Products Sold</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products sold for the three and nine months ended March&#160;31, 2021 increased 1 percent to $37.5 billion and 3 percent to $114.6 billion, respectively, compared to the respective prior-year periods as a result of the factors affecting the changes in revenue and gross margin. </span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.852%"><tr><td style="width:1.0%"></td><td style="width:24.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.797%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Gross Margin</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><img src="cah-20210331_g4.jpg" alt="cah-20210331_g4.jpg" style="height:200px;margin-bottom:5pt;vertical-align:text-bottom;width:266px"/><img src="cah-20210331_g5.jpg" alt="cah-20210331_g5.jpg" style="height:200px;margin-bottom:5pt;vertical-align:text-bottom;width:266px"/></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross margin</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,812</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,885&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,303</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,278&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross margins during the three and nine months ended March&#160;31, 2021 were negatively impacted due to volume declines in our generics program, primarily due to COVID-19, partially offset by higher contribution from branded pharmaceutical sales mix.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin during the nine months ended March&#160;31, 2021 increased due to beneficial comparison with the prior-year $55&#160;million charge in connection with a voluntary recall for certain surgical gowns and a voluntary recall and field actions for surgical procedure packs containing affected gowns (together, the "Recalls").</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin rate declined 20 basis points and 12 basis points during the three and nine months ended&#160;March&#160;31, 2021, respectively, mainly due to changes in pharmaceutical distribution product and sales mix. While branded pharmaceutical sales contributed positively to gross margin dollars during the three and nine months ended March&#160;31, 2021, they had a dilutive impact on our overall gross margin rate. Gross margin rate year-over-year comparison also benefited from the $55&#160;million charge recognized during the nine months ended March&#160;31, 2020 in connection with the Recalls.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Distribution, Selling, General and Administrative ("SG&amp;A") Expenses</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:11pt;margin-top:11pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SG&amp;A expenses</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,120</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,165&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,404</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,435&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021, SG&amp;A expenses decreased primarily due to the beneficial impact of enterprise-wide cost-savings measures.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March&#160;31, 2021, SG&amp;A expenses decreased primarily due to the beneficial impact of enterprise-wide cost-savings measures. The year-over-year comparison was also favorably impacted by the $40&#160;million charge in connection with the Recalls recognized during the nine months ended March&#160;31, 2020. These factors were partially offset by the $41&#160;million assessment on prescription opioid medications that were sold or distributed in New York state in calendar year 2017 and 2018 and fluctuations in deferred compensation liabilities. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_97">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information on the New York Opioid Stewardship Act.</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.852%"><tr><td style="width:1.0%"></td><td style="width:24.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.797%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Segment Profit</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate segment performance based on segment profit, among other measures. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_115">Note 12</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information on segment profit.</span></div><div style="margin-bottom:6pt;text-align:center"><img src="cah-20210331_g6.jpg" alt="cah-20210331_g6.jpg" style="height:200px;margin-bottom:5pt;vertical-align:text-bottom;width:266px"/><img src="cah-20210331_g7.jpg" alt="cah-20210331_g7.jpg" style="height:200px;margin-bottom:5pt;vertical-align:text-bottom;width:266px"/></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.195%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.450%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">511</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,326</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,394&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">174</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">640</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">543&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">685</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">712&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,966</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,937&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(212)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,656)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,305)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total consolidated operating earnings/(loss)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">473</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">562&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(16)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">310</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,368)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pharmaceutical Segment Profit</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended March&#160;31, 2021, Pharmaceutical segment profit was adversely impacted due to volume declines in our generics program, primarily due to COVID-19, partially offset by higher contribution from branded pharmaceutical sales mix. In addition, during the nine months ended March&#160;31, 2021, Pharmaceutical segment profit was adversely impacted due to volume declines in Nuclear and Precision Health Solutions.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical segment financial results do not include the $1.02 billion and $5.63&#160;billion charges associated with the opioid litigation during the nine months ended&#160;March&#160;31, 2021 and 2020, respectively. See the Significant Developments in Fiscal 2021 and Trends section in this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_97">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information. In addition, Pharmaceutical segment financial results do not include the $41&#160;million assessment during the nine months ended&#160;March&#160;31, 2021 on prescription opioid medications that were sold or distributed in New York state in calendar year 2017 and 2018. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_97">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information on the New York Opioid Stewardship Act.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Medical Segment Profit</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical segment profit decreased during the three months ended March&#160;31, 2021 due to the performance of products and distribution, offset by the beneficial impact of enterprise-wide cost-savings measures. COVID-19 had a slight negative impact on Medical segment profit due to the comparison to the modest positive impact of sales volume increases in the prior period.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical segment profit increased during nine months ended&#160;March&#160;31, 2021 due to enterprise-wide cost-savings measures, including global manufacturing efficiencies, and COVID-19. The benefit from COVID-19 was a result of higher volumes in our laboratory business, cost savings, and a net positive contribution from PPE, partially offset by the adverse impact of lower demand for surgical products resulting from reduced elective procedures. The net positive impact of PPE included timing favorability related to our cost mitigation efforts.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Corporate</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in Corporate during the three and nine months ended&#160;March&#160;31, 2021&#160;were due to the factors discussed in the Other Components of Consolidated Operating Earnings/(Loss) section that follows. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.852%"><tr><td style="width:1.0%"></td><td style="width:24.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.797%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Other Components of Consolidated Operating Earnings/(Loss)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to revenue, gross margin and SG&amp;A expenses discussed previously, consolidated operating earnings/(loss) were impacted by the following:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:51.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">81</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">111</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">345</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">69</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">78</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net</span></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">15</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,085</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,729&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring and Employee Severance</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring and employee severance during both the three and nine months ended March&#160;31, 2021 and 2020 was primarily related to the implementation of certain enterprise-wide cost-saving measures. The income during the three months ended March&#160;31, 2020 was due to changes in estimates for severance previously accrued.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortization and Other Acquisition-Related Costs</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of acquisition-related intangible assets was $109 million and $129 million for the three months ended March 31, 2021 and 2020, respectively, and $337 million and $385 million for the nine months ended March&#160;31, 2021 and 2020, respectively.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairments and (Gain)/Loss on Disposal of Assets, Net</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended March&#160;31, 2021 we recognized a $58 million pre-tax write-down of the assets held for sale from the planned divestiture of our Cordis business. See the Significant Developments in Fiscal 2021 and Trends section in this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_1194">Note 2</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation (Recoveries)/Charges, Net</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March&#160;31, 2021 and 2020, we recognized pre-tax charges of $1.02 billion and $5.63&#160;billion, respectively, associated with certain opioid matters. See the Significant Developments in Fiscal 2021 and Trends section in this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_97">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The costs we recognized in connection with the Cordis OptEase and TrapEase inferior vena cava ("IVC") filter product liability claims during the three months ended March&#160;31, 2021 and 2020 were $12 million and $30 million, respectively, and $40 million and $92 million during the nine months ended March&#160;31, 2021 and 2020, respectively. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_97">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Earnings/(Loss) Before Income Taxes</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the items discussed above, earnings/(loss) before income taxes were impacted by the following:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income)/expense, net</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(12)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(31)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">136</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M</span></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other (Income)/Expense, Net</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended&#160;March&#160;31, 2021, other (income)/expense, net was favorable compared to the prior-year period primarily due to an increase in the value of our deferred compensation plan investments, which offsets fluctuations included within SG&amp;A expenses and discussed further in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_103">Note 8</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements," and gains on investments in non-marketable equity securities.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Expense, Net</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in interest expense during the three and nine months ended&#160;March&#160;31, 2021 was primarily due to less debt outstanding and lower short-term interest rates.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.852%"><tr><td style="width:1.0%"></td><td style="width:24.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.797%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Results of Operations</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Provision for/(Benefit from) Income Taxes</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021 and 2020, the effective tax rate was 72.8 percent and&#160;26.8 percent, respectively. The increase in the effective tax rate for the three months ended March&#160;31, 2021 compared to the prior period was primarily due to the adverse tax impacts from the fiscal 2021 opioid litigation charge, as described below, adjustments to our provision for the resolution of all open matters with the Internal Revenue Service (&#8220;IRS&#8221;) for fiscal years 2008 to 2010 as well as certain transfer pricing matters for fiscal years 2011 to 2014, which also impacted reserves for later years, and withholding taxes for planned distributions from foreign subsidiaries.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the nine months ended March&#160;31, 2021 and 2020, the effective tax rate was (143.3)&#160;percent and 5.2&#160;percent, respectively. Included in the effective tax rate for the nine months ended March&#160;31, 2021 was the $419 million benefit from the net operating loss carryback primarily related to a self-insurance pre-tax loss. Included in both the nine months ended March&#160;31, 2021 and 2020 were net tax benefits related to the treatment of the tax impacts of the fiscal 2021 and 2020 opioid litigation charges.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Effects of Self-Insurance Pre-tax Loss</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March&#160;31, 2021, our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation. This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes. The net operating loss was carried back and applied to adjust our taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the CARES Act enacted by the United States Congress in March 2020. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our provision for income taxes during the nine months ended March&#160;31, 2021 included a $419 million benefit from the net operating loss carryback primarily to reflect the difference between the federal statutory income tax rate during the fiscal years from 2015 to 2018 (35 percent for fiscal 2015, 2016, and 2017 and 28 percent for fiscal 2018) and the current federal statutory income tax rate of 21 percent.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have filed for a federal income tax refund of $974 million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have recorded a current asset on our condensed consolidated balance sheet at March&#160;31, 2021. We also increased our non-current deferred tax liability by approximately $700 million during the nine months ended March&#160;31, 2021 related to this matter.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Effect of Opioid Litigation Charges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the $1.02 billion and $5.63&#160;billion pre-tax charges for the opioid litigation during the nine months ended March&#160;31, 2021 and 2020, respectively, the net tax benefits are $37 million and $488 million for fiscal 2021 and 2020, respectively. Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized tax benefits of $35 million and $468 million, respectively. Due to our assessment of non-deductibility for certain components considered in the fiscal 2021 and 2020 charges, the tax benefit for fiscal 2021 compared to fiscal 2020 resulted in a relatively lower tax benefit. Our assumptions and estimates around this benefit and uncertain tax position require significant judgment and the actual amount of tax benefit related to uncertain tax positions may differ materially from these estimates. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings/(loss) before income taxes for the year-to-date period to compute our provision for/(benefit from) income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the initial opioid litigation accrual during the three months ended September 30, 2019, the tax effect of the charge was treated as a discrete item because it was considered unusual or infrequent. However, the tax effect of the charge during the nine months ended March&#160;31, 2021 was included in our estimated annual effective tax rate because it was no longer considered unusual or infrequent. The inclusion of the relatively lower tax benefit of the current fiscal year charge in our estimated annual effective tax rate significantly increased the estimated annual effective tax rate for fiscal 2021. As such, the amount of tax expense increased by approximately $140 million during the three months ended March&#160;31, 2021 while the amount of tax benefit increased by approximately $180 million during the nine months ended March&#160;31, 2021 compared to the tax impacts that would have been recognized without the opioid litigation charge. As stated above, the benefit as of the end of fiscal 2021 is expected to be $37 million. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_100">Note 7</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the &#8220;Notes to the Condensed Consolidated Financial Statements&#8221; for additional information.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ongoing Audits</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and various foreign jurisdictions. During the three and nine months ended March&#160;31, 2021, the Company and the IRS resolved all open issues with respect to the Company&#8217;s activity within fiscal years 2008 through 2010. During the three and nine months ended March&#160;31, 2021, we resolved certain transfer pricing matters with the IRS for fiscal years 2011 to 2014; however, these periods remain open for audit.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="ib6bf45669ad94861b0c50dbc2f4371ce_22"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.262%"><tr><td style="width:1.0%"></td><td style="width:24.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liquidity and Capital Resources</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently believe that, based on available capital resources (cash on hand and committed credit facilities) and projected operating cash flow, we have adequate capital resources to fund working capital needs; currently anticipated capital expenditures; currently anticipated business growth and expansion; contractual obligations; tax payments; and current and projected debt service requirements, early extinguishment of debt, dividends and share repurchases as well as potential opioid litigation settlement payments associated with the Settlement Framework. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Cash and Equivalents</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash and equivalents balance was $3.5 billion at March&#160;31, 2021 compared to $2.8 billion at June&#160;30, 2020. At March&#160;31, 2021, our cash and equivalents were held in cash depository accounts with major banks or invested in high quality, short-term liquid investments. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March&#160;31, 2021 cash from operating cash flow was $1.8 billion, with uses of $432 million paid in dividends, $274 million of capital expenditures and $200 million for share repurchases. </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in working capital, which impact operating cash flow, can vary significantly depending on factors such as the timing of customer payments, inventory purchases and payments to vendors in the regular course of business, as well as fluctuating working capital needs driven by customer and product mix. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash and equivalents balance at March&#160;31, 2021 includes $579 million of cash held by subsidiaries outside of the United States. </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Other Financing Arrangements and Financial Instruments</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Credit Facilities and Commercial Paper</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to cash and equivalents and operating cash flow, other sources of liquidity at March&#160;31, 2021 include a $2.0 billion commercial paper program, backed by a $2.0 billion revolving credit facility. We also have a&#160;$1.0 billion&#160;committed receivables sales facility. At&#160;March&#160;31, 2021, we had no amounts outstanding under our commercial paper program, revolving credit facility, or our committed receivables sales facility.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1 beginning March 2021. As of March&#160;31, 2021, we were in compliance with this financial covenant. </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Long-Term Debt and Other Short-Term Borrowings</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At&#160;March&#160;31, 2021, we had total long-term obligations, including the current portion and other short-term borrowings, of&#160;$6.7 billion. During the nine months ended March&#160;31, 2021, we early repurchased $40 million of the Floating Rate Notes due 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $2 million of the 2.616% Notes due 2022 with available cash. In connection with the early debt repurchases, we recorded a $1 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">loss on early extinguishment of debt.</span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.262%"><tr><td style="width:1.0%"></td><td style="width:24.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liquidity and Capital Resources</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Anticipated Capital Resources</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Tax Effects of Self-Insurance Pre-tax Loss</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with a tax benefit from the net operating loss carryback primarily related to a self-insurance pre-tax loss as described further in Significant Developments in Fiscal 2021 and Trends section in this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_100">Note 7</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> of the "Notes to Condensed Consolidated Financial Statements," we have filed for a refund of $974 million, which we expect to receive within 12 months. Accordingly, we have recorded a current asset for this amount on our condensed consolidated balance sheet at March&#160;31, 2021. We also increased our non-current deferred tax liability by approximately $700 million during the nine months ended March&#160;31, 2021 related to this matter.</span></div><div style="margin-bottom:3pt"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cordis Divestiture</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 12, 2021, we announced that we signed a definitive agreement to sell our Cordis business to Hellman &amp; Friedman for proceeds of $927&#160;million in cash, subject to customary purchase price adjustments, and we will retain certain working capital accounts and certain liabilities. The proposed transaction is expected to close in the first quarter of fiscal 2022, subject to customary closing conditions and regulatory clearances.</span></div></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Capital Deployment</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Opioid Settlement Framework</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $6.59&#160;billion accrued at March&#160;31, 2021 related to certain opioid litigation, as further described within the Significant Developments in Fiscal 2021 and Trends section in this MD&amp;A and </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_97">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements." Negotiations under the Settlement Framework continue. If a definitive agreement is reached, and subject to participation by states and political subdivisions, we expect the majority of payment amounts to be spread over 18 years. We cannot currently predict when those payments might begin, and it is possible that all or part may ultimately be made over a different time period, or not at all. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Capital Expenditures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital expenditures during the nine months ended March&#160;31, 2021 and 2020 were $274 million and $239 million, respectively. </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On each of May 11, 2020, August 6, 2020, November 5, 2020 and February 5, 2021 our Board of Directors approved a quarterly dividend of $0.4859 per share, or $1.94 per share on an annualized basis, which were paid on July 15, 2020, October 15, 2020, January 15, 2021 and April 15, 2021 to shareholders of record on July 1, 2020, October 1, 2020, January 4, 2021 and April 1, 2021 respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 5, 2021, our Board of Directors approved a quarterly dividend of $0.4908 per share, or $1.96 per share on an annualized basis, payable on July 15, 2021 to shareholders of record on July 1, 2021.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Share Repurchases</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March&#160;31, 2021, we repurchased $200 million of our common shares under an accelerated share repurchase ("ASR") program. We funded the ASR program with available cash. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_109">Note 10</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information. At March 31, 2021, we had $743 million authorized for share repurchases.</span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="ib6bf45669ad94861b0c50dbc2f4371ce_25"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:24.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Items</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Other Items</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MD&amp;A in our 2020 Form 10-K addresses our contractual obligations and off-balance sheet arrangements, as of and for the fiscal year ended June 30, 2020. There have been no subsequent material changes outside the ordinary course of business to those items.</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div id="ib6bf45669ad94861b0c50dbc2f4371ce_28"></div></div></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:17pt;font-weight:700;line-height:120%">Critical Accounting Policies and Sensitive Accounting Estimates</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion and analysis presented below is a supplemental disclosure to the critical accounting policies and sensitive accounting estimates specified in our consolidated balance sheet at June&#160;30, 2020. This discussion and analysis should be read in conjunction with the Critical Accounting Policies and Sensitive Accounting Estimates included in our 2020 Form 10-K and our Forms 10-Q for the quarters ended September 30, 2020 and December 31, 2020.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Critical accounting policies are those accounting policies that (i) can have a significant impact on our financial condition and results of operations and (ii) require the use of complex and subjective estimates based upon past experience and management&#8217;s judgment. Other people applying reasonable judgment to the same facts and circumstances could develop different estimates. Because estimates are inherently uncertain, actual results may differ. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Assets Held for Sale</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify assets and liabilities (the &#8220;disposal group&#8221;) as held for sale when management commits to a plan to sell the disposal group in its present condition and at a price that is reasonable in relation to its current fair value. We also consider whether an active program to locate a buyer has been initiated and if it is probable that the sale will occur within one year without significant changes to the plan to sell. Upon classification of the disposal group as held for sale, we assess the assets for impairment and cease related depreciation and amortization. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 12, 2021, we signed a definitive agreement with Hellman &amp; Friedman to sell our Cordis business for gross proceeds of $927&#160;million in cash, subject to customary purchase price adjustments, and we will retain certain working capital accounts and certain liabilities, including product liability for lawsuits related to inferior vena cava filters in the U.S. and Canada as described in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_97">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the &#8220;Notes to Condensed Consolidated Financial Statements.&#8221; The transaction is expected to close in the first quarter of fiscal 2022, subject to customary closing conditions and regulatory clearances.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021, we met the criteria for the related assets and liabilities of the Cordis business to be classified as held for sale. In connection with the planned divestiture, we allocated $388&#160;million of goodwill from the Medical Unit (within our Medical Segment) to the Cordis disposal group </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">based on the estimated relative fair values of the business to be disposed of and the portion of the reporting unit that will be retained. We determined that the sale of the Cordis business does not meet the criteria to be classified as discontinued operations. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2021, the book value of the disposal group exceeded its fair value less costs to sell. Accordingly, we recognized a $58 million pre-tax write-down on the disposal group in impairments and (gain)/loss on disposal of assets in our condensed consolidated statement of earnings/(loss). This write-down includes a $2 million gain related to currency translation adjustments in accumulated other comprehensive income. We recorded a net tax expense of $7 million associated with the impact of the write-down and the required tax adjustments triggered by held for sale accounting. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final measurement of the book value of the disposal group minus the fair value less costs to sell at closing may be impacted by a number of factors, including, but not limited to, the calculation of allocated goodwill, changes in foreign exchange rates, the final value of assets and liabilities of the disposal group transferred upon consummation of the transaction, and the evaluation of any income tax impacts. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_1194">Note 2</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the &#8220;Notes to Condensed Consolidated Financial Statements&#8221; for additional information regarding assets held for sale.</span></div></div></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchased goodwill is tested for impairment annually or when indicators of impairment exist. Goodwill impairment testing involves a comparison of the estimated fair value of reporting units to the respective carrying amount, which may be performed utilizing either a qualitative or quantitative assessment. Qualitative factors are first assessed to determine if it is more likely than not that the fair value of a reporting unit is less than its carrying amount. There is an option to bypass the qualitative assessment </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for any reporting unit in any period and proceed directly to performing the quantitative goodwill impairment test. The quantitative goodwill impairment test involves a comparison of the estimated fair value of the reporting unit to the respective carrying amount. A reporting unit is defined as an operating segment or one level below an operating segment (also known as a component). </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. These </span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.820%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Critical Accounting Policies and Sensitive Accounting Estimates</span></div></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operating segments are comprised of divisions (which are components), for which discrete financial information is available. Components are aggregated into reporting units for purposes of goodwill impairment testing to the extent that they share similar economic characteristics. Our reporting units are: Pharmaceutical operating segment (excluding our Nuclear and Precision Health Solutions division); Nuclear and Precision Health Solutions division; Medical operating segment (excluding our Cardinal Health at-Home Solutions division) (&#8220;Medical Unit&#8221;); and Cardinal Health at-Home Solutions division.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill impairment testing involves judgment, including the identification of reporting units, qualitative evaluation of events and circumstances to determine if it is more likely than not that an impairment exists, and, if necessary, the estimation of the fair value of the applicable reporting unit. Our qualitative evaluation considers the weight of evidence and significance of all identified events and circumstances and most relevant drivers of fair value, both positive and negative, in determining whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Medical Unit Goodwill</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the planned divestiture of our Cordis business, we allocated $388&#160;million of goodwill from the Medical Unit to the Cordis disposal group based on the estimated relative fair values of the business to be disposed of and the portion of the reporting unit that </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will be retained. During the three months ended March&#160;31, 2021, we performed goodwill impairment testing for the portion of the Medical Unit that will be retained. The carrying value of the Medical Unit that will be retained at March&#160;31, 2021 was $9.3 billion, of which $4.1 billion was goodwill. The fair value of the reporting unit was estimated to be approximately 5 percent in excess of its carrying value, using a combination of the income-based approach (using a discount rate of 8.5 percent and a terminal growth rate of 2.0 percent), and the market-based approach.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse changes in key assumptions, including our current assumptions about the impact of the Cordis planned divestiture and the COVID-19 pandemic; an increase in the discount rate; a decrease in the terminal growth rate; or increases in tax rates, among other things, could result in a goodwill impairment for the Medical Unit that will be retained. For example, if we were to increase the discount rate by 0.5 percent, the carrying value would have exceeded the fair value for the Medical Unit that will be retained by approximately 1.0 percent at March&#160;31, 2021. Additionally, the estimated tax rate used in goodwill impairment testing is a market-based assumption, which is impacted by the U.S. federal statutory tax rate. If the U.S. federal statutory tax rate were to increase to 28 percent and no other inputs were changed, the carrying value would have exceeded the fair value of the Medical Unit that will be retained at March&#160;31, 2021.</span></div></div></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories included in the consolidated balance sheets are net of reserves for lower of cost or net realizable value and excess and obsolete inventory which were $168 million and $155 million at March 31, 2021 and June 30, 2020, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A substantial portion of our inventories are valued at the lower of cost, using the last-in, first-out ("LIFO") method, or market. These are primarily merchandise inventories at the core pharmaceutical distribution facilities within our Pharmaceutical segment (&#8220;distribution facilities&#8221;).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our remaining inventory, including inventory in our Medical segment, that is not valued at the lower of LIFO cost or market is stated at the lower of cost, using the first-in, first-out method, or net realizable value. We reserve for the lower of cost or net realizable value using the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. Due to the unprecedented demand for certain PPE as a result of COVID-19, our Medical segment continues to manufacture and source inventory at higher costs than in periods prior to COVID-19. Accordingly, we have raised our selling prices for these products. If demand or selling prices for these products declines in the future, resulting in excess inventory or inventory cost above net realizable value, additional inventory reserves may be required.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We reserve for inventory excess and obsolescence using estimates based on historical experience, historical and projected </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales trends, specific categories of inventory, age and expiration dates of on-hand inventory and manufacturer return policies. Within our Medical segment, we continue to procure greater quantities of PPE based upon customer demand. If actual conditions are less favorable than our assumptions, such as projected sales of PPE, additional inventory reserves may be required.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.820%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Critical Accounting Policies and Sensitive Accounting Estimates</span></div></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Loss Contingencies and Self-Insurance</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly review contingencies and self-insurance accruals to determine whether our accruals and related disclosures are adequate. Any adjustments for changes in reserves are recorded in the period in which the change in estimate occurs.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss Contingencies</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or outcomes can occur, assessing contingencies is highly subjective and requires judgments about future events.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="background-color:#def3c0;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n connection with the opioid litigation as described further in the Significant Developments in Fiscal 2021 and Trends section in this MD&amp;A, we recorded pre-tax charges of $1.02&#160;billion and $5.63&#160;billion during the nine months ended March&#160;31, 2021 and 2020, respectively. Definitive terms for a settlement pursuant to the Settlement Framework continue to be negotiated, and there is no assurance that the necessary parties will agree to a definitive settlement agreement or that the contingencies to any agreement will be satisfied. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of ultimate loss may differ materially from this accrual. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_97">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information.</span></div><div style="text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Self-Insurance</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We self-insure </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">through a wholly-owned insurance subsidiary</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for employee healthcare, certain product liability matters, auto liability, property and workers' compensation and maintain insurance for losses exceeding certain limits.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Self-insurance accruals include an estimate for expected resolution of pending claims, defense costs, administrative fees, claims adjustment costs and an estimate for claims incurred but not reported. For certain types of exposures, we develop the estimate of expected costs to resolve each claim based on specific information related to each claim, if available. Other exposure estimates are based on an assessment of outstanding claims, historical analysis and current payment trends. For claims incurred but not reported, the liabilities are calculated and derived in accordance with generally accepted actuarial practices or using an estimated lag period.</span></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.820%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Critical Accounting Policies and Sensitive Accounting Estimates</span></div></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:14pt;font-weight:700;line-height:174%">Provision for Income Taxes</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax benefits from uncertain tax positions are recognized when it is more likely than not that the position will be sustained upon examination of the technical merits of the position, including resolutions of any related appeals or litigation. The amount recognized is measured as the largest amount of tax benefit that is greater than 50 percent likely of being realized upon settlement. For tax benefits that do not qualify for recognition, we recognize a liability for unrecognized tax benefits.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2011 through the current fiscal year. Tax laws are complex and subject to varying interpretations. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Effects of Self-Insurance Pre-tax Loss</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March&#160;31, 2021, our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation. This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes. The net operating loss was carried back and applied to adjust our taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the CARES Act enacted by the United States Congress in March 2020.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, our provision for income taxes during the nine months ended March&#160;31, 2021 included a $419 million benefit from the net operating loss carryback primarily to reflect the difference between the federal statutory income tax rate during the fiscal years from 2015 to 2018 (35 percent for fiscal 2015, 2016, and 2017 and 28 percent for fiscal 2018) and the current federal statutory income tax rate of 21 percent.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have filed for a federal income tax refund of $974 million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have recorded a current asset on our condensed consolidated balance sheet at March&#160;31, 2021. We also increased our non-current deferred tax liability by approximately $700 million during the nine months ended March&#160;31, 2021 related to this matter.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the tax law; however, it is possible that the tax authorities could challenge these tax benefits or that the tax law could change. The actual tax benefit may differ materially from these amounts.</span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Effects of Opioid Litigation Charges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the $1.02 billion and $5.63&#160;billion pre-tax charges for the opioid litigation during the nine months ended March&#160;31, 2021 and 2020, respectively, the net tax benefits are $37 million and $488 million for fiscal 2021 and 2020, respectively. Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized tax benefits of $35 million and $468 million, respectively. Due to our assessment of non-deductibility for certain components considered in the fiscal 2021 and 2020 charges, the tax benefit for fiscal 2021 compared to fiscal 2020 resulted in a relatively lower tax benefit. Our assumptions and estimates around this benefit and uncertain tax position require significant judgment and the actual amount of tax benefit related to uncertain tax positions may differ materially from these estimates.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings/(loss) before income taxes for the year-to-date period to compute our provision for/(benefit from) income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the initial opioid litigation accrual during the nine months ended March&#160;31, 2021, the tax effect of the charge was treated as a discrete item because it was considered unusual or infrequent. However, the tax effect of the charges during the three and nine months ended March&#160;31, 2021 were included in our estimated annual effective tax rate because it was no longer considered unusual or infrequent. The inclusion of the relatively lower tax benefit of the current fiscal year charge in our estimated annual effective tax rate significantly increased the estimated annual effective tax rate for fiscal 2021. As such, the amount of tax expense increased by approximately $140 million during the three months ended March&#160;31, 2021 while the amount of tax benefit increased by approximately $180 million during the nine months ended March&#160;31, 2021 compared to the tax impacts that would have been recognized without the opioid litigation charge. As stated above, the benefit as of the end of fiscal 2021 is expected to be $37 million. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_100">Note 7</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the &#8220;Notes to the Condensed Consolidated Financial Statements&#8221; for additional information.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the U.S. Tax Cuts and Jobs Act ("Tax Act"); however, these estimates require significant judgment since the definitive settlement terms and documentation, including provisions related to deductibility, under the Settlement Framework have not been </span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.820%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MD&amp;A</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Critical Accounting Policies and Sensitive Accounting Estimates</span></div></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">negotiated and the U.S. tax law governing deductibility was changed by the Tax Act. Further, it is possible that the tax authorities could challenge our interpretation of the Tax Act or the estimates and assumptions used to assess the future deductibility of these benefits or that the tax law could change. The actual amount of the tax benefit related to uncertain tax positions may differ materially from these estimates. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_100">Note 7</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the &#8220;Notes to the Condensed Consolidated Financial Statements&#8221; for additional information.</span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="ib6bf45669ad94861b0c50dbc2f4371ce_31"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Explanation and Reconciliation of Non-GAAP Financial Measures</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Explanation and Reconciliation of Non-GAAP Financial Measures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The "Overview of Consolidated Results" section within MD&amp;A in this Form 10-Q contains financial measures that are not calculated in accordance with GAAP. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to analyzing our business based on financial information prepared in accordance with GAAP, we use these non-GAAP financial measures internally to evaluate our performance, engage in financial and operational planning, and, in most cases, determine incentive compensation because we believe that these measures provide additional perspective on and, in some circumstances are more closely correlated to, the performance of our underlying, ongoing business. We provide these non-GAAP financial measures to investors as supplemental metrics to assist readers in assessing the effects of items and events on our financial and operating results on a year-over-year basis and in comparing our performance to that of our competitors. However, the non-GAAP financial measures that we use may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. The non-GAAP financial measures disclosed by us should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements set forth below should be carefully evaluated. </span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Exclusions from Non-GAAP Financial Measures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes it is useful to exclude the following items from the non-GAAP measures presented in this report for its own and for investors&#8217; assessment of the business for the reasons identified below:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">LIFO charges and credits</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are excluded because the factors relating to last-in first-out ("LIFO") inventory charges or credits, such as pharmaceutical manufacturer price appreciation or deflation and year-end inventory levels (which can be meaningfully influenced by customer buying behavior immediately preceding our fiscal year-end), are largely out of our control and cannot be accurately predicted. The exclusion of LIFO charges and credits from non-GAAP metrics facilitates comparison of our current financial results to our historical financial results and to our peer group companies&#8217; financial results. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Surgical gown recall costs</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> includes inventory write-offs and certain remediation and supply disruption costs arising from the January 2020 recall of select Association for the Advancement of Medical Instrumentation ("AAMI") Level 3 surgical gowns and voluntary field actions (a recall of some packs and a corrective action allowing overlabeling of other packs) for Presource Procedure Packs containing affected gowns. We have excluded these costs from our non-GAAP metrics to allow investors to better understand the underlying operating results of the business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies&#8217; financial results.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.13pt;text-decoration:underline">State opioid assessments related to prior fiscal years</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> is the portion of state assessments for prescription opioid medications that were sold or distributed in periods prior to the period in which the expense is incurred. This portion is excluded from non-GAAP financial measures because it is retrospectively applied to sales in prior fiscal years and inclusion would obscure analysis of the current fiscal year results of our underlying, ongoing business. Additionally, while states' laws may require us to make payments on an ongoing basis, the portion of the assessment related to sales in prior periods are contemplated to be one-time, nonrecurring items. Income from state opioid assessments related to prior fiscal years represents reversals of accruals when the underlying assessments were invalidated by a Court, updates to prior estimates or reimbursement of assessments from manufacturers.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Restructuring and employee severance costs</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are excluded because they are not part of the ongoing operations of our underlying business. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Amortization and other acquisition-related costs</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which include transaction costs, integration costs, and changes in the fair value of contingent consideration obligations, are excluded because they are not part of the ongoing operations of our underlying business and to facilitate comparison of our current financial results to our historical financial results and to our peer group companies' financial results. Additionally, costs for amortization of acquisition-related intangible assets are non-cash amounts, which are variable in amount and frequency and are significantly impacted by the timing and size of acquisitions, so their exclusion facilitates comparison of historical, current and forecasted financial results. We also exclude other acquisition-related costs, which are directly related to an acquisition but do not meet the criteria to be recognized on the acquired entity&#8217;s initial balance sheet as part of the purchase price allocation. These costs are also significantly impacted by the timing, complexity and size of acquisitions. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Explanation and Reconciliation of Non-GAAP Financial Measures</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Impairments and gain or loss on disposal of assets</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;are excluded because they do not occur in or reflect the ordinary course of our ongoing business operations and are inherently unpredictable in timing and amount, and in the case of impairments, are non-cash amounts, so their exclusion facilitates comparison of historical, current and forecasted financial results. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:15.13pt;text-decoration:underline">Litigation recoveries or charges, net</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> are excluded because they often relate to events that may have occurred in prior or multiple periods, do not occur in or reflect the ordinary course of our business and are inherently unpredictable in timing and amount. During fiscal 2021, we incurred a tax benefit related to a carryback of a net operating loss. Some pre-tax amounts, which contributed to this loss, relate to litigation charges. As a result, we allocated a portion of the tax benefit to litigation charges. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Loss on early extinguishment of debt</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is excluded because it does not typically occur in the normal course of business and may obscure analysis of trends and financial performance. Additionally, the amount and frequency of this type of charge is not consistent and is significantly impacted by the timing and size of debt extinguishment transactions. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt;text-decoration:underline">Transitional tax benefit, net</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to the Tax Cuts and Jobs Act is excluded because it results from the one-time impact of a very significant change in the U.S. federal corporate tax rate and, due to the significant size of the benefit, obscures analysis of trends and financial performance. The transitional tax benefit includes the initial estimate and subsequent adjustments for the re-measurement of deferred tax assets and liabilities due to the reduction of the U.S. federal corporate income tax rate and the repatriation tax on undistributed foreign earnings. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax effect for each of the items listed above, other than the transitional tax benefit item, is determined using the tax rate and other tax attributes applicable to the item and the jurisdiction(s) in which the item is recorded. The gross, tax and net impact of each item are presented with our GAAP to non-GAAP reconciliations. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%">Definitions</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Growth rate calculation:</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> growth rates in this report are determined by dividing the difference between current-period results and prior-period results by prior-period results. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP operating earnings</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: operating earnings/(loss) excluding (1) LIFO charges/(credits), (2) surgical gown recall costs, (3) state opioid assessment related to prior fiscal years, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, and (7) litigation (recoveries)/charges, net. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP earnings before income taxes</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: earnings/(loss) before income taxes excluding (1) LIFO charges/(credits), (2) surgical gown recall costs, (3) state opioid assessment related to prior fiscal years, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, (7) litigation (recoveries)/charges, net, and (8) loss on early extinguishment of debt. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP net earnings attributable to Cardinal Health, Inc.</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: net earnings/(loss) attributable to Cardinal Health, Inc. excluding (1) LIFO charges/(credits), (2) surgical gown recall costs, (3) state opioid assessment related to prior fiscal years, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, (7) litigation (recoveries)/charges, net, (8) loss on early extinguishment of debt, each net of tax, and (9) transitional tax benefit, net. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP effective tax rate: </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provision for/(benefit from) income taxes adjusted for (1) LIFO charges/(credits), (2) surgical gown recall costs, (3) state opioid assessment related to prior fiscal years, (4) restructuring and employee severance, (5) amortization and other acquisition-related costs, (6) impairments and (gain)/loss on disposal of assets, (7) litigation (recoveries)/charges, net, (8) loss on early extinguishment of debt, and (9) transitional tax benefit, (net) divided by (earnings/(loss) before income taxes adjusted for the first eight items)</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP diluted earnings per share attributable to Cardinal Health, Inc.</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: non-GAAP net earnings attributable to Cardinal Health, Inc. divided by diluted weighted-average shares outstanding. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="ib6bf45669ad94861b0c50dbc2f4371ce_34"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Explanation and Reconciliation of Non-GAAP Financial Measures</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">GAAP to Non-GAAP Reconciliation</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.300%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:6.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.821%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.121%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per common share amounts)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Earnings/(Loss)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating Earnings Growth Rate</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Earnings/(Loss) Before Income Taxes</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Provision for/(Benefit from) Income Taxes</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Earnings/(Loss)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Earnings/(Loss)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> Growth Rate</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diluted EPS</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1,2</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diluted EPS</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"> Growth Rate</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="24" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">GAAP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">473</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(16)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">440</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">320</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">119</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">0.40</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surgical gown recall costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State opioid assessment related to prior fiscal years</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.06&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.25&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">3</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(144)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-GAAP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">689</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(4)</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">657</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">205</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">451</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(5)</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.53</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6)</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="24" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GAAP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">562&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">350&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.19&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surgical gown recall costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transitional tax benefit, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-GAAP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">719&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">639&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">474&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.62&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="24" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">GAAP</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">310</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">204</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(293)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">495</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.68</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surgical gown recall costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State opioid assessment related to prior fiscal years</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.88&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">3</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,085&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,085&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">584&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.70&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-GAAP</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,935</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,830</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">417</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,411</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4.79</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#dddddd;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="24" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended March 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GAAP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,368)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N.M.</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,587)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(237)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,352)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N.M.</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.84)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">N.M.</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Surgical gown recall costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.24&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State opioid assessment related to prior fiscal years</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.01&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">3</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,729&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,729&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,220&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.80&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transitional tax benefit, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.04)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-GAAP</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,942&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,732&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.41&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.076%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Explanation and Reconciliation of Non-GAAP Financial Measures</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">1&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Attributable to Cardinal Health, Inc.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">2&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the nine months ended March&#160;31, 2020, GAAP diluted loss per share attributable to Cardinal Health, Inc. ("GAAP diluted EPS") and the EPS impact from the GAAP to non-GAAP per share reconciling items are calculated using a weighted average of 293 million common shares, which excludes potentially dilutive securities from the denominator due to their anti-dilutive effects resulting from our GAAP net loss for the period. For the nine months ended March&#160;31, 2020, non-GAAP diluted EPS is calculated using a weighted average of 295 million common shares, which includes potentially dilutive shares</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">3&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Litigation (recoveries)/charges, net includes pre-tax charges of $1.02 billion and $5.63 billion recorded in the first quarter of fiscal 2021 and 2020, respectively, related to the opioid litigation. For fiscal 2021, the amount of tax expense increased by approximately $140 million during the three months ended March 31, 2021 while the amount of tax benefit increased by approximately $180 million during the nine months ended March 31, 2021 compared to the tax impacts that would have been recognized without the opioid litigation charge. The net tax benefits associated with the opioid litigation charges are $37 million and $488 million for fiscal 2021 and 2020, respectively. </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Litigation(recoveries)/charges, net also includes a tax benefit recorded during the nine months ended March&#160;31, 2021 related to a net operating loss carryback. Our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation. This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes. The net operating loss was carried back and adjusted our taxable income for fiscal 2015, 2016, 2017 and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security (&#8220;CARES&#8221;) Act</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:115%">. </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The total net benefit was $419 million; however, for purposes of reconciling Non-GAAP financial measures, we allocated $385 million of the benefit to litigation (recoveries)/charges, net, which is excluded from non-GAAP measures, based on the relative amount of the self-insurance pre-tax loss related to opioid litigation claims versus separate tax adjustments. The tax benefit allocated to the separate tax adjustments of $34 million is included in non-GAAP measures. </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sum of the components and certain computations may reflect rounding adjustments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="ib6bf45669ad94861b0c50dbc2f4371ce_37"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.158%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="text-align:justify"><span><br/></span></div><div id="ib6bf45669ad94861b0c50dbc2f4371ce_40"></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in the quantitative and qualitative market risk disclosures included in our&#160;2020&#160;Form 10-K since the end of fiscal&#160;2020&#160;through&#160;March&#160;31, 2021.</span></div><div id="ib6bf45669ad94861b0c50dbc2f4371ce_43"></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Controls and Procedures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluated, with the participation of our principal executive officer and principal financial officer, the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934 (the "Exchange Act")) as of March&#160;31, 2021. Based on this evaluation, our principal executive officer and principal financial officer have concluded that as of March&#160;31, 2021, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms and that such information is accumulated and communicated to management as appropriate to allow timely decisions regarding required disclosure. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting during the quarter ended March&#160;31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Implementation of Business Improvement Initiatives</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have certain business improvement initiatives underway that we expect to affect internal control over financial reporting. As a part of an ongoing effort to optimize and simplify our operating model, we are in the process of transitioning portions of our finance operations to a global professional services firm. Additionally, the Pharmaceutical segment is in a multi-year project to implement a replacement of certain finance and operating information systems. If either of these initiatives are not effectively implemented, or fail to operate as intended, it could adversely affect our internal control over financial reporting.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="ib6bf45669ad94861b0c50dbc2f4371ce_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the proceeding described below, the legal proceedings described in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_97">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" are incorporated in this "Legal Proceedings" section by reference.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, Melissa Cohen, a purported shareholder, filed an action on behalf of Cardinal Health, Inc. in the U.S. District Court for the Southern District of Ohio against certain current and former members of our Board of Directors alleging that the defendants breached their fiduciary duties by failing to effectively monitor Cardinal Health's distribution of controlled substances and approving certain payments of executive compensation. In December 2019 and January 2020, similar complaints were filed in the U.S. District Court for the Southern District of Ohio by purported shareholders, Stanley M. Malone and Michael Splaine, respectively. In January, 2020, the court consolidated the derivative cases under the caption In re Cardinal Health, Inc. Derivative Litigation and in March 2020, plaintiffs filed an amended complaint. The amended consolidated derivative complaint seeks, among other things, unspecified money damages against the defendants and an award of attorneys' fees. In February 2021, the court granted in part and denied in part defendants' motion to dismiss. The court dismissed the claim with respect to executive compensation but declined to dismiss the failure to monitor claim.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="ib6bf45669ad94861b0c50dbc2f4371ce_49"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.158%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Risk Factors</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should carefully consider the information in this Form 10-Q, including the risk factor below, and the risk factors discussed in "Risk Factors" and other risks discussed in our 2020 Form 10-K and our filings with the SEC since June&#160;30, 2020. These risks could materially and adversely affect our results of operations, financial condition, liquidity, and cash flows. Our business also could be affected by risks that we are not presently aware of or that we currently consider immaterial to our operations.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We could be subject to adverse changes in the tax laws or </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">challenges to our tax positions. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a large multinational corporation with operations in the United States and many foreign countries. As a result, we are subject to the tax laws of many jurisdictions. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, proposals are made in the United States and other jurisdictions in which we operate that could adversely affect our tax positions, effective tax rate or tax payments. Specific initiatives that may impact us include possible increases in U.S. or foreign corporate income tax rates or other changes in tax law to raise revenue, the repeal of the LIFO (last-in, first-out) method of inventory accounting for income tax purposes, the establishment or increase in taxation at the U.S. state level on the basis of gross revenues, recommendations of the recently completed base erosion and profit shifting project undertaken by the Organization for Economic Cooperation and Development and the European Commission&#8217;s investigation into illegal state aid. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in connection with the $5.63&#160;billion pre-tax charge for the opioid litigation taken in the fiscal year ended June 30, 2020, and the additional $1.02 billion pre-tax charge recorded in the nine months ended March 31, 2021, we recorded net tax benefits of $<ix:nonFraction unitRef="usd" contextRef="ia48bb06cca3d4969bdeb6e18237b4224_D20190701-20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV80OS9mcmFnOmY4NTcyZGI5ZDg3MjRmMmI5MzRkOTExZGE4NjNhZjE5L3RleHRyZWdpb246Zjg1NzJkYjlkODcyNGYyYjkzNGQ5MTFkYTg2M2FmMTlfMTA0NDUzNjA0ODEyNTk_d75a112c-e833-40ea-a866-b2fa89033254">488</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia19c49a9fdf94744a98048c92ed6d989_D20200701-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV80OS9mcmFnOmY4NTcyZGI5ZDg3MjRmMmI5MzRkOTExZGE4NjNhZjE5L3RleHRyZWdpb246Zjg1NzJkYjlkODcyNGYyYjkzNGQ5MTFkYTg2M2FmMTlfMTA0NDUzNjA0ODEyNzM_7fe79880-c57f-41a9-a126-ca85bd2f30e0">37</ix:nonFraction> million, respectively, reflecting our current assessment of the estimated future deductibility of the amount that may be paid. We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the Tax Act; however, these estimates require significant judgment since the definitive settlement terms and documentation, including provisions related to deductibility, under the Settlement Framework have not been negotiated. </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. tax law governing deductibility was changed by the </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tax Act and </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the tax authorities could challenge our interpretation of the Tax Act or the estimates and assumptions used to assess the future deductibility of these benefits, or tax law could change again. The actual amount of tax benefit related to uncertain tax positions may differ materially from these estimates. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_100">Note 7</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for more information regarding these matters. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the nine months ended March 31, 2021, our provision for income taxes reflects a $<ix:nonFraction unitRef="usd" contextRef="if2d5ee4c8487424fb522d83601a9e4ed_D20200701-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV80OS9mcmFnOmY4NTcyZGI5ZDg3MjRmMmI5MzRkOTExZGE4NjNhZjE5L3RleHRyZWdpb246Zjg1NzJkYjlkODcyNGYyYjkzNGQ5MTFkYTg2M2FmMTlfMTA0NDUzNjA0ODEyMTA_4b03f236-d976-4408-9244-d82e018f0810">419</ix:nonFraction> million benefit from the tax benefits of a net operating loss carryback under the CARES Act. Also as a result of this net operating loss carryback, we have filed for a federal income tax refund of $<ix:nonFraction unitRef="usd" contextRef="i95e27bf6690f452f80d7e0a0bf7a1856_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV80OS9mcmFnOmY4NTcyZGI5ZDg3MjRmMmI5MzRkOTExZGE4NjNhZjE5L3RleHRyZWdpb246Zjg1NzJkYjlkODcyNGYyYjkzNGQ5MTFkYTg2M2FmMTlfMTA0NDUzNjA0ODExOTU_dbf99d17-fde6-43c9-9fe8-21d9f61fb298">974</ix:nonFraction> million. In connection with this net operating loss carryback, certain industry participants, including us, received a letter from the U.S. House of Representatives&#8217; Committee on Oversight and Reform questioning, among other things, our plans to take tax deductions for opioid-related losses, including our use of the net operating loss carryback provisions under the CARES Act and deductibility under the Tax Act. We have responded to the letter. Additionally, legislation has been proposed that would retroactively repeal the net operating loss carryback provision of the CARES Act.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2011 through the current fiscal year. Tax laws are complex and subject to varying interpretations. Tax authorities have challenged some of our tax positions for the periods from 2011 to 2014. During the three and nine months ended March 31, 2021, we have resolved all open matters with the IRS for fiscal years 2008 to 2010 as well as certain transfer pricing matters for fiscal years 2011 to 2014, which also impacted reserves for later years. This resolution has resulted in an adjustment to our provision for income taxes. New challenges related to future audits may adversely affect our effective tax rate or tax payments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="ib6bf45669ad94861b0c50dbc2f4371ce_1216"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.158%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:14.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.138%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.754%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number<br/>of Shares<br/>Purchased&#160;(1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average Price Paid&#160;per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares<br/>Purchased<br/>as Part of Publicly Announced Programs&#160;(2,3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate<br/>Dollar Value of<br/>Shares That May<br/>Yet be Purchased<br/>Under the Program&#160;(3)<br/>(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 2021</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.59&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">943&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">February 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,021,903&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,021,719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">783&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 2021</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">654,899&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.10&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">654,681&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,677,048</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">54.40</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,676,400</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">743</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Reflects common shares purchased through a rabbi trust as investments of participants in our Deferred Compensation Plan.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8pt">In the third quarter of fiscal 2021, we purchased $<ix:nonFraction unitRef="usd" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMjE2L2ZyYWc6YWI0NjBiMmJmNzE5NDUwNzkxMGQyNDM1M2U2MDIwN2IvdGV4dHJlZ2lvbjphYjQ2MGIyYmY3MTk0NTA3OTEwZDI0MzUzZTYwMjA3Yl8yNzY_407d73a9-d30d-49fc-ab54-bf8d1bd62eec"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMjE2L2ZyYWc6YWI0NjBiMmJmNzE5NDUwNzkxMGQyNDM1M2U2MDIwN2IvdGV4dHJlZ2lvbjphYjQ2MGIyYmY3MTk0NTA3OTEwZDI0MzUzZTYwMjA3Yl8yNzY_ba84e18a-409e-4c7f-a903-b9ad007a600d">200</ix:nonFraction></ix:nonFraction> million of our common shares under an accelerated share repurchase ("ASR") program, which began on February 9, 2021 and was completed on March 31, 2021. We repurchased 3.7 million shares under the ASR at an average price paid per share of $54.40. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_109">Note 10</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> of the "Notes to Condensed Consolidated Financial Statements" for additional information. </span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">On November 7, 2018, our Board of Directors approved a $1.0 billion share repurchase program that expires on December 31, 2021 and as of March&#160;31, 2021, we have $743 million authorized for share repurchases remaining under this program.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="ib6bf45669ad94861b0c50dbc2f4371ce_58"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span><br/></span></div><div id="ib6bf45669ad94861b0c50dbc2f4371ce_61"></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Earnings/(Loss)</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:51.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.228%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per common share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMi0xLTEtMS0w_56cc19c2-517c-4429-b2ed-25cd5e12a068">39,275</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMi0zLTEtMS0w_671d8b9f-780d-48c4-b489-dfe2e4fb46e7">39,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMi01LTEtMS0w_c589282b-2ddc-4700-bddb-6be3df7174a6">119,881</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMi03LTEtMS0w_e7dbf0c4-9b32-4270-a175-1abd725f0a29">116,233</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMy0xLTEtMS0w_3a7a5369-d1eb-474a-aebe-5587a9700a02">37,463</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMy0zLTEtMS0w_41b77d9b-1f31-47d3-b633-aea440f820a2">37,272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMy01LTEtMS0w_48310487-16f2-4d50-af9a-4da00405290a">114,578</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMy03LTEtMS0w_2fa62bce-56ff-44f7-aa16-4b5c0e36c723">110,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfNC0xLTEtMS0w_4b4536c4-af84-4f92-bbb4-9c4cb8408160">1,812</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfNC0zLTEtMS0w_7debb2ed-97f2-4287-a8da-c1998f3a0bf0">1,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfNC01LTEtMS0w_ec96066f-ffb0-49c3-b8d7-2cecabd4ab34">5,303</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfNC03LTEtMS0w_3f62acb0-8701-4e72-a2f7-ae9a496b58fa">5,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distribution, selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfNy0xLTEtMS0w_74e4e4b0-ce7c-4661-b1f7-1de57fcdfea6">1,120</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfNy0zLTEtMS0w_7d58764f-8900-4182-8440-d9259bb958f4">1,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfNy01LTEtMS0w_299fb40a-3958-414d-be13-a4166886d42b">3,404</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfNy03LTEtMS0w_c0de216e-58cf-42ec-9df9-b63e015748ca">3,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring and employee severance</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfOC0xLTEtMS0w_8228f454-1050-4a20-956b-080bb6c15188">24</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfOC0zLTEtMS0w_3b03fcbb-18cc-469b-8808-0fadf5c2af8c">6</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfOC01LTEtMS0w_41c8ea20-4491-4e18-be1b-e9f68a3ad83c">81</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfOC03LTEtMS0w_2889d211-1b49-48e8-a325-ee5e6574a2d7">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and other acquisition-related costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="-6" name="cah:Amortizationandotheracquisitionrelatedcosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfOS0xLTEtMS0w_cbedbbdb-0ae9-404c-9724-980ef29a8107">111</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" decimals="-6" name="cah:Amortizationandotheracquisitionrelatedcosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfOS0zLTEtMS0w_9f8bdad6-605c-4ccb-a15f-8f1ef9e1b351">130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="cah:Amortizationandotheracquisitionrelatedcosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfOS01LTEtMS0w_4256fca7-31da-46c5-a20c-73ff77b137ef">345</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" name="cah:Amortizationandotheracquisitionrelatedcosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfOS03LTEtMS0w_ba3e90aa-809a-4472-9ae0-67696563800c">395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTAtMS0xLTEtMA_1950949d-e394-4001-ba28-fa8e076c6cf9">69</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" decimals="-6" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTAtMy0xLTEtMA_346dbdca-cac2-4a4d-8a53-668a05a48ae3">1</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTAtNS0xLTEtMA_222026dc-eca7-47ca-9478-592369c092b2">78</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTAtNy0xLTEtMA_c3c6c1a3-4e34-4a77-93eb-0a6124433f6e">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation (recoveries)/charges, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTEtMS0xLTEtMA_ca15c65f-8e1f-461a-ab71-96bd3f9991f2">15</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTEtMy0xLTEtMA_f2c014e9-0ce0-44c8-a7ae-7837f968874b">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTEtNS0xLTEtMA_b49bbf1b-f1e4-4f9f-b463-36b23c311434">1,085</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTEtNy0xLTEtMA_6b838bdb-7947-4bfd-8226-f5e8c0c8cbca">5,729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating earnings/(loss)</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTItMS0xLTEtMA_b6a49899-fc0a-4be2-8ad9-0dc25b0131b5">473</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTItMy0xLTEtMA_f018e686-e3ed-4199-80bf-231d10b330cd">562</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTItNS0xLTEtMA_18622733-3e2f-46a6-8f5f-99b2d9027c09">310</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTItNy0xLTEtMA_c9914652-5894-4c2e-96be-b85d68d71e05">4,368</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income)/expense, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTQtMS0xLTEtMA_bd7b0dff-b677-4b29-b9eb-620eba11aaa1">12</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTQtMy0xLTEtMA_8cafc47b-a0a5-4313-90f0-21094d24fe53">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTQtNS0xLTEtMA_a36a574f-5daf-4063-9fc2-87e7550aaff1">31</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTQtNy0xLTEtMA_c4c62ac4-c12d-48c7-afbe-cd5dfb300cab">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTUtMS0xLTEtMA_a74d1990-22d8-46a8-9eac-339a45f12afe">45</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTUtMy0xLTEtMA_ce7819a2-746f-41e7-a895-9228908f46b5">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTUtNS0xLTEtMA_366c4577-cfaf-4ac4-b335-3beccb4b1a99">136</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTUtNy0xLTEtMA_e2f7624d-3395-4ffb-8775-5d26e3281fb1">189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTYtMS0xLTEtMA_626ba75a-31f5-407c-8e77-e5bdac5d154e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTYtMy0xLTEtMA_4a0c4870-f0bc-4ae2-aab2-08242e02603a">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTYtNS0xLTEtMA_f9c789fa-182d-4ece-8f7b-99ddda8d1470">1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTYtNy0xLTEtMA_28401bbc-51b3-4b63-8256-4c0e3d11ddf1">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Earnings/(loss) before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTctMS0xLTEtMA_71d250bb-2c2d-48d2-bf2d-49c86164bc2e">440</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTctMy0xLTEtMA_b0e61b96-7371-4f9e-81ef-dabf3abc3c99">478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTctNS0xLTEtMA_d5865c49-2c0f-4aa7-ae39-c504626b8e04">204</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTctNy0xLTEtMA_ad2a0c85-8368-4991-b74c-1185b2dd0051">4,587</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for/(benefit from) income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTktMS0xLTEtMA_15b110d6-2546-491e-acf6-a066607b76dc">320</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTktMy0xLTEtMA_cea00296-4a00-4d84-b178-69e674be7670">127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTktNS0xLTEtMA_347409ec-e8bb-460f-b651-8d3b12407f53">293</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTktNy0xLTEtMA_17a2f871-1b0c-4916-a3e8-e005db5438ef">237</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings/(loss)</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMjAtMS0xLTEtMA_4ad53a3e-63ba-4087-8af5-9263f80b86aa">120</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMjAtMy0xLTEtMA_9a6b93cf-28ab-47de-bd34-2e02358c3eab">351</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMjAtNS0xLTEtMA_42135be7-6365-42b2-9fe0-272f72233492">497</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMjAtNy0xLTEtMA_791f8c03-2f0d-41ff-83f0-39b87e441852">4,350</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net earnings attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMjUtMS0xLTEtMA_8764ebd7-5694-44fe-9c7e-24c3f0b796dd">1</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMjUtMy0xLTEtMA_248eea37-cf71-46bf-b056-c8d64c620ef4">1</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMjUtNS0xLTEtMA_5fbf0ca7-5912-418f-9d5f-d588c8c7917b">2</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMjUtNy0xLTEtMA_8efe09b9-7aa5-4ceb-ab69-64c53e61a2a6">2</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net earnings/(loss) attributable to Cardinal Health, Inc. </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMjYtMS0xLTEtMA_6f31cafe-fbf4-42e9-a34c-33d2e94fcd58">119</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMjYtMy0xLTEtMA_01a51326-51e8-4267-b586-a2cc9ba3111e">350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMjYtNS0xLTEtMA_9379545d-c00b-411f-89d7-a995131f50d4">495</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMjYtNy0xLTEtMA_d5bd07bd-6b51-4db8-bd5e-b7c8b6b0f839">4,352</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Earnings/(loss) per common share attributable to Cardinal Health, Inc.:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMjktMS0xLTEtMA_affc9b23-cc0a-4ec9-8339-34f08da4a244">0.41</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMjktMy0xLTEtMA_4ebd4fc2-9afc-426f-ba87-d20afe664346">1.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMjktNS0xLTEtMA_0a801354-594b-43ca-8c22-dcf5c5765e61">1.69</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMjktNy0xLTEtMA_21c99149-20ee-4beb-b20f-6968730bfb90">14.84</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMzAtMS0xLTEtMA_c2ac6d02-e82e-4015-be6a-6c61c1d51c3c">0.40</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMzAtMy0xLTEtMA_352b551a-f2b7-4417-aafb-d73ca0acf2b1">1.19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMzAtNS0xLTEtMA_375660f4-70f0-444b-a0b9-9d06fd36b76f">1.68</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMzAtNy0xLTEtMA_1c0e151b-f152-495b-9108-b0e6beea1164">14.84</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average number of common shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMzMtMS0xLTEtMA_425390a2-1142-4bd3-8071-64a686d42b1b">292</ix:nonFraction></span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMzMtMy0xLTEtMA_8c7dccbc-06a4-4ec3-8ac8-9d34f149a9ac">292</ix:nonFraction></span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMzMtNS0xLTEtMA_4e218e0f-994f-4c23-9df2-bcffb61899ef">293</ix:nonFraction></span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMzMtNy0xLTEtMA_449a7c39-4e68-49a9-87b7-dd665afc06f7">293</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMzQtMS0xLTEtMA_3071e4db-fce6-4fe2-ac31-493deae66d91">294</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMzQtMy0xLTEtMA_1370e119-3d6d-49a9-babc-27c65a2c9a0a">294</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMzQtNS0xLTEtMA_ce2e7602-8da7-4c33-abda-a15ea4666612">294</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMzQtNy0xLTEtMA_17498a88-24e5-4f4e-8f1c-022e30d42dfd">293</ix:nonFraction></span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared per common share</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMzYtMS0xLTEtMA_2497126d-41f1-4bf3-a116-ce30c86e7183">0.4859</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMzYtMy0xLTEtMA_5881196f-3299-4ac1-b8b8-ad1a7f468b9f">0.4811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="4" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMzYtNS0xLTEtMA_c62835a7-25f0-49d1-b57f-ad9de0d4d0ab">1.4577</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="4" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMzYtNy0xLTEtMA_54fbd032-2d35-4e58-b8ad-913f67e7c4fa">1.4433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="ib6bf45669ad94861b0c50dbc2f4371ce_64"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Comprehensive Income/(Loss)</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:51.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.228%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings/(loss)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfMi0xLTEtMS0w_e3cea534-3385-42f9-a242-a1d5df28b031">120</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfMi0zLTEtMS0w_d57143cd-df99-4f49-a7ae-faae066a02fe">351</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfMi01LTEtMS0w_147e9f60-62b5-4edc-a39a-5438299180b0">497</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfMi03LTEtMS0w_8bb81636-98e6-4c5c-9d61-3e3c675b93dd">4,350</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other comprehensive income/(loss):</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfNS0xLTEtMS0w_7583fcf8-2d73-426a-9ee9-06f295da4bac">9</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfNS0zLTEtMS0w_e1835c03-1848-4488-834a-2a3f298b70a5">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfNS01LTEtMS0w_6f9e5db3-9584-4a8a-9334-878aeab3e65c">42</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfNS03LTEtMS0w_100f868b-0da1-47a5-87e3-d162287f33f8">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized gain/(loss) on derivative instruments, net of tax</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfNy0xLTEtMS0w_e23df289-d996-46c1-bdf7-59f4f169f1a0">4</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfNy0zLTEtMS0w_69ae2534-b434-4158-a187-7b5b1caad4b0">21</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfNy01LTEtMS0w_fa0e5bfc-6c87-4102-8841-ec3df54f8950">14</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfNy03LTEtMS0w_0fdaa1e7-3683-48b5-b478-635b510a900c">27</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive income/(loss), net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfOC0xLTEtMS0w_78f7d6e7-d388-4f67-9231-a1c0393b18c1">5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfOC0zLTEtMS0w_caf10055-62d7-4a4d-9f95-f5226a96b848">38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfOC01LTEtMS0w_46a8ac9d-2b1a-4b51-8780-97d327f16755">56</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfOC03LTEtMS0w_dd018013-5498-4e75-a66a-42307c300449">62</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total comprehensive income/(loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfMTAtMS0xLTEtMA_057c5062-59b7-4d85-8a6c-bbcc090f6e4b">125</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfMTAtMy0xLTEtMA_55a67ba0-3309-4a0f-bf7a-ec9535260fe7">313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfMTAtNS0xLTEtMA_cc5f9712-ddfe-4820-bcb2-54020c570c90">553</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfMTAtNy0xLTEtMA_0f2f2c17-1e53-4878-99d8-a61af923f2a0">4,412</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: comprehensive income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfMTItMS0xLTEtMA_3c34e1ed-cfbd-4e78-8216-85beb76f1386">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfMTItMy0xLTEtMA_4c152b76-c719-48fe-a590-71b2febfdea8">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfMTItNS0xLTEtMA_61948d2a-b441-4fc9-8f7f-7cfbd62a28fb">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfMTItNy0xLTEtMA_19911738-11ea-4ea7-8369-192e0b3ea34d">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total comprehensive income/(loss) attributable to Cardinal Health, Inc. </span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfMTQtMS0xLTEtMA_e0985496-e0f9-4d72-9094-785261ca707e">124</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfMTQtMy0xLTEtMA_47ceefdd-838e-4d21-a6ad-ea54448a7b90">312</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfMTQtNS0xLTEtMA_da633c4c-11da-4c40-8d34-b9c42d996964">551</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfMTQtNy0xLTEtMA_609e0525-fd65-496e-82ea-49ba60a872a7">4,414</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="ib6bf45669ad94861b0c50dbc2f4371ce_67"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.114%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and equivalents</span></td><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfNC0xLTEtMS0w_8d6464cc-f4e1-40a4-8de4-646e56ff829a">3,499</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfNC0zLTEtMS0w_8dfc8a0c-1964-4837-b4ca-ee85d32b1ca3">2,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfNS0xLTEtMS0w_58d8b8ac-e263-4800-9ee7-b1de539e3beb">8,727</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfNS0zLTEtMS0w_93ee814c-f840-4f1a-ae10-6ba5004ff1de">8,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfNi0xLTEtMS0w_55b8ab84-508c-42bb-86ae-ceb3f068857f">14,329</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfNi0zLTEtMS0w_55813dd6-e617-4955-a168-29149b72dd81">13,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfOC0xLTEtMS0w_63a55b27-810a-442b-a5ba-4d8fbefc384d">2,715</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfOC0zLTEtMS0w_ae6c053d-b591-4562-9aa0-879ed0e6117f">1,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets held for sale</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfOS0xLTEtMS0xNDgy_0095f4a7-2ccc-4cde-8ca0-8728f41d9c76">1,092</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="-6" format="ixt:zerodash" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfOS0zLTEtMS0xNDgy_0153826b-4546-4ae5-8e7b-8e2effd0991a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfOS0xLTEtMS0w_d9191bf3-7539-42b9-870e-b9b85390f984">30,362</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfOS0zLTEtMS0w_6c7c8cdb-6aa8-4483-99e6-ad9f632de89a">25,940</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMTEtMS0xLTEtMA_a9789d2a-232b-422c-9914-2350c416b560">2,315</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMTEtMy0xLTEtMA_5c320732-ec79-4ae1-ac1d-998dc38d4a9b">2,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill and other intangibles, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMTItMS0xLTEtMA_5455334d-8d21-4aa1-ac63-6802b690340c">10,179</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMTItMy0xLTEtMA_525756da-fd56-4646-a13a-5d835ef7c26f">11,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMTQtMS0xLTEtMA_04c1b15f-25f1-4ab7-8f2a-83fdd9b5f36c">1,018</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMTQtMy0xLTEtMA_397f0f12-d4ba-42d7-8b49-c0ce20fdfb90">1,185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMTUtMS0xLTEtMA_ebda2034-dcec-43b6-842b-275ecf9c7f19">43,874</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMTUtMy0xLTEtMA_2ab0a664-19fd-4a33-9c05-9c29a7c24b42">40,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities and Shareholders&#8217; Equity</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMTktMS0xLTEtMA_c886399b-d81a-423c-8f01-317d0d475a55">22,641</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMTktMy0xLTEtMA_509ba256-28a4-49cf-9d25-00a918448529">21,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of long-term obligations and other short-term borrowings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMjAtMS0xLTEtMA_2768e2b1-c8e8-41d2-affe-34c35e4ed448">16</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMjAtMy0xLTEtMA_9f62d65f-38d8-414b-bc4d-3f6d01d0fc71">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMjEtMS0xLTEtMA_edf54153-f92f-4fe9-9591-b9068ed142f6">2,573</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMjEtMy0xLTEtMA_79cc0093-e5b5-481a-9fe9-78cdfec23057">2,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liabilities related to assets held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMjItMS0xLTEtMjI1OA_7ac23b53-c840-40f2-919e-f3ce782662c9">93</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="-6" format="ixt:zerodash" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMjItMy0xLTEtMjI2MQ_2423880b-2b76-490e-995b-c9d584099303">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMjItMS0xLTEtMA_5f285416-1082-4fa9-b50f-fb9fff30170c">25,323</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMjItMy0xLTEtMA_ff55d3bf-b94e-4913-b589-87de654f4c7d">23,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term obligations, less current portion</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMjQtMS0xLTEtMA_a9755a4d-8ee8-41ab-adf3-9821b6938c37">6,715</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMjQtMy0xLTEtMA_da5f7f11-975d-48da-85fd-d81001c6c244">6,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMjUtMS0xLTEtMA_43ac5cee-1854-4edf-b84e-242de148bb05">10,042</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMjUtMy0xLTEtMA_1fbcc555-8812-4e73-bf71-48fbf8009f76">8,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shareholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred shares, without par value:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Authorized&#8212;<ix:nonFraction unitRef="shares" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjVhMDUzZDA5NjkxOTRjNWNiMTM5NzA1NDc3YTJiZmU0XzE1_733722a4-56e4-4549-a8c3-762725b5d7a1"><ix:nonFraction unitRef="shares" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjVhMDUzZDA5NjkxOTRjNWNiMTM5NzA1NDc3YTJiZmU0XzE1_94ce358b-fba3-480b-9dfd-d000f6be23f4">500</ix:nonFraction></ix:nonFraction> thousand shares, Issued&#8212;<ix:nonFraction unitRef="shares" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjVhMDUzZDA5NjkxOTRjNWNiMTM5NzA1NDc3YTJiZmU0XzMz_01eaecab-dae4-4dd4-af6d-4ca00acb8716"><ix:nonFraction unitRef="shares" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjVhMDUzZDA5NjkxOTRjNWNiMTM5NzA1NDc3YTJiZmU0XzMz_4226bbb7-ea6e-4a6f-91dd-059acb50877e">none</ix:nonFraction></ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMjktMS0xLTEtMA_723e89b6-82f0-4b06-bc4b-eaef23db4fcf">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="-6" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMjktMy0xLTEtMA_007f50da-5a8e-4423-b9d1-f8b3b70cff53">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common shares, without par value:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Authorized&#8212;<ix:nonFraction unitRef="shares" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjU1ODE1ZjRjMzRlZjQ4OTM4ZjQ4ZTMzZGFjMzEzMmMxXzE1_8ecfaeed-4511-4533-8afd-d331db279afc"><ix:nonFraction unitRef="shares" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjU1ODE1ZjRjMzRlZjQ4OTM4ZjQ4ZTMzZGFjMzEzMmMxXzE1_fc6b8855-547e-4ef6-8320-c582f88ca65d">755</ix:nonFraction></ix:nonFraction> million shares, Issued&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjU1ODE1ZjRjMzRlZjQ4OTM4ZjQ4ZTMzZGFjMzEzMmMxXzMz_4e27243f-65f6-40ff-9162-4db55517d9cb"><ix:nonFraction unitRef="shares" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjU1ODE1ZjRjMzRlZjQ4OTM4ZjQ4ZTMzZGFjMzEzMmMxXzMz_efdc2d5c-08d3-4931-ab56-88ac7d24e05c">327</ix:nonFraction></ix:nonFraction> million</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> shares at </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March&#160;31, 2021</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and June 30, 2020, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMzEtMS0xLTEtMA_6eb3201f-c011-4757-880b-2cb172d1490e">2,807</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMzEtMy0xLTEtMA_7748e048-ee08-4325-83ec-d9fbe3e74119">2,789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMzItMS0xLTEtMA_20ca4cd0-519b-40d5-9440-756031da53e3">1,233</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMzItMy0xLTEtMA_f603ecdc-94cd-426a-a658-9f80f4ac6347">1,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Common shares in treasury, at cost: </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmM0ODY2ZmZmZDFlNDQ3ODQ5ZTJmZTVlNTIwNzk3MTVhXzQw_2785de67-32e1-45c1-b8f3-4895d8013f2c">36</ix:nonFraction> million  </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">shares and <ix:nonFraction unitRef="shares" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmM0ODY2ZmZmZDFlNDQ3ODQ5ZTJmZTVlNTIwNzk3MTVhXzU1_d59b0fe0-cf53-4ac0-96f1-681a06c9804c">34</ix:nonFraction> million shares at</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> March&#160;31, 2021</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> and June 30, 2020, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMzMtMS0xLTEtMA_c6c5172c-7183-4922-af6c-7a2bbcf60662">2,202</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMzMtMy0xLTEtMA_4c81516f-83e3-4928-9e22-4973c093d362">2,066</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMzQtMS0xLTEtMA_127084ca-1588-411b-a3fe-b2aaabf80ee0">48</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMzQtMy0xLTEtMA_d6a56bc0-9633-4987-9519-255dc2da4903">104</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Cardinal Health, Inc. shareholders' equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMzUtMS0xLTEtMA_4ea90574-f9d5-4154-95a9-00cc4dd40eae">1,790</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMzUtMy0xLTEtMA_afedd7a0-02f4-4cec-8c2d-71e920fe52b6">1,789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMzYtMS0xLTEtMA_93050808-f424-4200-a98e-3e48778a18cd">4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMzYtMy0xLTEtMA_7f6ace14-cfab-464f-be14-bc5e374b958f">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total shareholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMzctMS0xLTEtMA_775d3f76-0bd5-427b-9f76-73043ad1352b">1,794</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMzctMy0xLTEtMA_0333594f-4d56-47e8-ba66-32def5a41811">1,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total liabilities and shareholders&#8217; equity</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMzgtMS0xLTEtMA_71e1052b-057f-4fbd-8cc7-efcc43d82705">43,874</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMzgtMy0xLTEtMA_de78042b-8237-42f6-9c25-fecf2fd4ecba">40,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="ib6bf45669ad94861b0c50dbc2f4371ce_70"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Shareholders' Equity</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:33.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.476%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.070%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling Interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Shareholders&#8217;<br/>Equity</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares Issued</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i95b9c22031624339add2f629ea1f1aae_I20201231" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfMy0xLTEtMS0w_b7a53eef-942d-4dae-8ab3-810d4f24746f">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95b9c22031624339add2f629ea1f1aae_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfMy0zLTEtMS0w_18b3b0f7-434b-4d27-9f71-0820f8d39be2">2,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e48fd2c42b44627b6da89b6438745df_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfMy01LTEtMS0w_e410f163-1c1f-48da-b8eb-b9ace336f227">1,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i44fa84a0c3ec48fcb9c8521f508b477d_I20201231" decimals="-6" sign="-" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfMy03LTEtMS0w_87b3ca18-1ddd-4b2b-b9f6-2f5705b08091">33</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i44fa84a0c3ec48fcb9c8521f508b477d_I20201231" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfMy05LTEtMS0w_1630c1a4-e8fa-40aa-9369-332e4c55844b">2,009</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if86f35ae66d245c78bacd2478b7f05b7_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfMy0xMS0xLTEtMA_72671d8b-475c-45c6-84f0-8408781407be">53</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29ae1a4981b842e1a0eab772d873665f_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfMy0xMy0xLTEtMA_f9e27980-7d2e-4342-afa4-33d1b7ce842f">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04980c8bb80847f688361a08698a8057_I20201231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfMy0xNS0xLTEtMA_4fc5e509-7ad9-4378-acb3-a6faaf79dd8f">1,975</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfNC01LTEtMS0w_6f31cafe-fbf4-42e9-a34c-33d2e94fcd58">119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08d5fdbf648840f09c9f0acc3309de18_D20210101-20210331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfNC0xMy0xLTEtMA_72a8ccf7-2c49-40c1-a613-e6d12be905e2">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfNC0xNS0xLTEtMA_5a421752-5fe6-4076-bcd7-827e667b33ff">120</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfNS0xMS0xLTEtMA_78f7d6e7-d388-4f67-9231-a1c0393b18c1">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfNS0xNS0xLTEtMA_74e952ed-1729-4f19-b293-a279da8900c8">5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock plans activity, net of shares withheld for employee taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib9dbcfd0b21e415c99ceac87f678613b_D20210101-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfNy0xLTEtMS0w_f1aa2ed2-e6ba-4e83-85ac-41516afd6b84">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9dbcfd0b21e415c99ceac87f678613b_D20210101-20210331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfNy0zLTEtMS0w_55334912-e126-4080-b4cd-df2da4aef989">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3ca53978778d45b291d32f2884428093_D20210101-20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfNy03LTEtMS0w_d96c30c5-51e9-4f4a-ac09-ce4be86e586a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ca53978778d45b291d32f2884428093_D20210101-20210331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfNy05LTEtMS0w_6cf4b25a-1539-43e9-b026-a850ac416c8a">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfNy0xNS0xLTEtMA_0b9e9fa4-6bf6-445b-ba96-48aadf485a4d">36</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share repurchase program activity</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3ca53978778d45b291d32f2884428093_D20210101-20210331" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfOC03LTEtMS0w_c830fd20-f38d-4c1e-bd9a-78fd1ee54eed">4</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3ca53978778d45b291d32f2884428093_D20210101-20210331" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfOC05LTEtMS0w_4779da49-e8f8-4c55-802f-63cdde872ce3">200</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfOC0xNS0xLTEtMA_ef472fca-52ff-45e2-a63d-677d168e8246">200</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c4059f309d347d8b4ac8135e44ee042_D20210101-20210331" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfOS01LTEtMS0w_15757b08-8f31-4c38-81dd-48619cf8ce16">143</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfOS0xNS0xLTEtMA_9d972fe0-6bd8-4e1d-9456-0fc85b4be92e">143</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ib9dbcfd0b21e415c99ceac87f678613b_D20210101-20210331" sign="-" xsi:nil="true" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfMTAtMy0xLTEtMA_c54c84c0-80db-427d-9064-8521f6846089"></ix:nonFraction></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c4059f309d347d8b4ac8135e44ee042_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfMTAtNS0xLTEtMA_e8dd15d4-0c59-49ee-925b-00758cf270b6">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3ca53978778d45b291d32f2884428093_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOtherShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfMTAtNy0xLTEtMjkwMA_bd444973-db82-4039-8f35-b2a77aaa202d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08d5fdbf648840f09c9f0acc3309de18_D20210101-20210331" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfMTAtMTMtMS0xLTA_152b2a74-a789-4cb9-b01d-e5b1008f49fb">1</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfMTAtMTUtMS0xLTA_a285a63d-3778-4ce4-a7d5-9c6b9ff3500c">1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7c7911192d9467a8120c5a8745e0ab4_I20210331" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfMTItMS0xLTEtMA_9b818f8c-4bf7-47f1-8be5-d17779386816">327</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7c7911192d9467a8120c5a8745e0ab4_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfMTItMy0xLTEtMA_9a3de837-e88c-48c3-8aec-3c0ac964c12a">2,807</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc405b4ba93d4f15a1821281ca6c82e7_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfMTItNS0xLTEtMA_d6657acc-7df1-4b77-8fbb-8fde9a6a530f">1,233</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0233856860d24d818336b00e3025a695_I20210331" decimals="-6" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfMTItNy0xLTEtMA_3b1eced2-d7a4-45ef-ad54-503d989045c3">36</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0233856860d24d818336b00e3025a695_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfMTItOS0xLTEtMA_5c73f073-fb23-4f3a-8452-516610dc0744">2,202</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i354467a0724c4e4cb8b779d18d807a9f_I20210331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfMTItMTEtMS0xLTA_66bc2c81-8c4a-46d7-bdee-840635b4d61e">48</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4419c8027c549be9d1aa39851d2726a_I20210331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfMTItMTMtMS0xLTA_b087d8fb-10cd-436e-ada6-08795e4bafc4">4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfMTItMTUtMS0xLTA_4b213184-7da8-4e05-805b-a9b939f3d2fc">1,794</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:33.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.476%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.070%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6de9849e852143f7be17f87669ee8388_I20191231" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfMS0xLTEtMS0w_106e61bd-1449-49e9-97be-bdabd6b045fc">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de9849e852143f7be17f87669ee8388_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfMS0zLTEtMS0w_578632f4-c9ea-416b-aa6b-f76086d77ae7">2,752</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60045d83318a4375a6adbff989fd1e0b_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfMS01LTEtMS0w_8d660774-5665-4a70-acd6-434176bb80e7">449</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0384aad99f0b44cfb95e1fcfadf13ba7_I20191231" decimals="-6" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfMS03LTEtMS0w_47c8122b-6ca6-4bb6-88ec-26fb7c485ec2">35</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0384aad99f0b44cfb95e1fcfadf13ba7_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfMS05LTEtMS0w_91743e20-854b-4df0-b97f-d47cc197a6f6">2,099</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i42416177b60446508042e47a8082a323_I20191231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfMS0xMS0xLTEtMA_2479c3f8-2fee-433c-94f8-441652d03e6a">103</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8dfdedd1e94a78a4b76f76961b61a8_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfMS0xMy0xLTEtMA_96b7246f-4567-4657-82c0-5a08d5773fd9">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2cae46a03fd4761a321a79b8d0f6b0f_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfMS0xNS0xLTEtMA_a41cf648-2071-48d6-8496-6f24428fb68d">1,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfMi01LTEtMS0w_fe5a3cf1-1d04-4373-8469-2a8c0703df2e">350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6824c1c4ebaf4b5cbe01e36215bb8c94_D20200101-20200331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfMi0xMy0xLTEtMA_c7567f67-2110-4362-b60b-b00bd6b68597">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfMi0xNS0xLTEtMA_c8f540e6-8c12-47db-9995-67a5a92944eb">351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87c6427dabe74d41be38b4708d40f760_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfMy0xMS0xLTEtMA_47e42bab-d22e-4374-876a-d682f23b18a5">38</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfMy0xNS0xLTEtMA_4c17ee17-47e7-457c-81dd-8ea2a362d6ac">38</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock plans activity, net of shares withheld for employee taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i92429500105f487686a760c50a01dbd4_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfNS0xLTEtMS0w_a928a9ee-8e1c-4957-b18f-ac3e94a4f167">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92429500105f487686a760c50a01dbd4_D20200101-20200331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfNS0zLTEtMS0w_17e78bd9-1e68-4887-bfe7-6840f16e98ab">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i097b90d861534948b48b5e94e8d68dbc_D20200101-20200331" decimals="-6" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfNS03LTEtMS0w_59d9644c-7667-4e11-8586-828b686eed43">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i097b90d861534948b48b5e94e8d68dbc_D20200101-20200331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfNS05LTEtMS0w_3f9bee6d-1bb4-402d-89f9-70a47017205c">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfNS0xNS0xLTEtMA_da1a4f2e-89eb-4179-809c-d7fc22f4c2ab">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5d2c55efe634921802f5f63cff13133_D20200101-20200331" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfNy01LTEtMS0w_ab5e5fcd-aca1-4591-a1b3-dafc03c26517">142</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfNy0xNS0xLTEtMA_6e555643-3f73-4192-ba0f-520185874aa7">142</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5d2c55efe634921802f5f63cff13133_D20200101-20200331" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfOC01LTEtMS0w_68c1fd46-5886-4185-a869-ff758d0eaf8f">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6824c1c4ebaf4b5cbe01e36215bb8c94_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfOC0xMy0xLTEtMA_3c29961f-5822-4be6-8aa0-8bb560862dd8">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfOC0xNS0xLTEtMA_f2d222a6-ee21-4bf2-ae5f-66ebe7b37956">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i227cc70eba254c68b508a19a38a4772e_I20200331" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfMTAtMS0xLTEtMA_b7bbe8d2-4acb-4f31-83d1-c1aa7b0bfe89">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227cc70eba254c68b508a19a38a4772e_I20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfMTAtMy0xLTEtMA_6685d888-1e92-41e8-85c2-3d778795668c">2,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c6b70579ab4b44b051a8e476cdc0bc_I20200331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfMTAtNS0xLTEtMA_01b753d5-dd31-45a5-ab7b-d76df7337297">656</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i873b7175bb9c48f9a92364ddc30859a3_I20200331" decimals="-6" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfMTAtNy0xLTEtMA_049eddc3-14c9-41de-8ee7-5f2601b3fc19">35</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i873b7175bb9c48f9a92364ddc30859a3_I20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfMTAtOS0xLTEtMA_77a7b543-98a9-4fcf-81e7-31fd17bf179f">2,086</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4adeac1e746a4298af939e62c0d13228_I20200331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfMTAtMTEtMS0xLTA_8b1b2256-a5ba-4593-a361-03a404ffc42c">141</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic22356641f7147aa93c0793fd724bac3_I20200331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfMTAtMTMtMS0xLTA_a9ac4358-de7a-4eaf-ad5b-6c25968d350e">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie21bd48f8a9a4cb0a6e3c0240434f025_I20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfMTAtMTUtMS0xLTA_1870a408-98bc-48f1-9eb0-1be3b23be463">1,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:33.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.476%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.070%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iea0558a3dad14a5aa6f2a5ea17404724_I20200630" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfMy0xLTEtMS0w_8f034cbc-21c1-471c-9030-db50b103f37c">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea0558a3dad14a5aa6f2a5ea17404724_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfMy0zLTEtMS0w_a621f27b-50fd-4154-8080-4665ddb44ee9">2,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibccb3acafd0d46549dd7845b502cc7d7_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfMy01LTEtMS0w_c72a4f04-724d-4b9f-a0b1-eb81d5f04928">1,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5da09f4564644c32a41c69fe1bca282b_I20200630" decimals="-6" sign="-" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfMy03LTEtMS0w_635e020a-079d-422d-b567-10a4dc110469">35</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5da09f4564644c32a41c69fe1bca282b_I20200630" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfMy05LTEtMS0w_b21d7425-3820-45a8-8506-a1e76c8a09da">2,066</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if50ad56426144e3086cf7b567a121bdc_I20200630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfMy0xMS0xLTEtMA_3208aeba-1be0-4a6b-a04c-8d7a7de00441">104</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39fcecca1a1841798fed70b14788390b_I20200630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfMy0xMy0xLTEtMA_59c3ba05-72c8-451e-8d66-d1d0d076c1fa">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfMy0xNS0xLTEtMA_7d8892f7-21f4-4ee8-91b4-8b8cadf75d11">1,792</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfNC01LTEtMS0w_8646542c-72f5-4486-8478-eb4c974578af">495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4123e12a9da4e40840720f78bc466d9_D20200701-20210331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfNC0xMy0xLTEtMA_44eb3b17-4662-444b-8fbb-6414719b3852">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfNC0xNS0xLTEtMA_daa3d69b-4303-48fa-ba0b-75b11958a9a4">497</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3a494cf37a0408c9c5282b7bacaf665_D20200701-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfNS0xMS0xLTEtMA_ae690a74-8eb4-49d5-b340-ef836e1f49bb">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfNS0xNS0xLTEtMA_84a4fa20-a6d0-4e3c-9784-e692645f2115">56</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock plans activity, net of shares withheld for employee taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i81dedbde5d2a466c9175f53824dd0c39_D20200701-20210331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfNy0xLTEtMS0w_66d836fa-3b26-454f-aa0b-17ea78b6d163">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81dedbde5d2a466c9175f53824dd0c39_D20200701-20210331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfNy0zLTEtMS0w_2d4746ae-8dde-47eb-85d2-229513e3d479">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfNy03LTEtMS0w_a4940cba-0d88-4365-9330-a60bcd08a431">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8b3edc49b1248e896c9ddae3b113611_D20200701-20210331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfNy05LTEtMS0w_2aa17525-326c-4a5d-8bb4-e0d7444dfbc7">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfNy0xNS0xLTEtMA_26d1d99e-9d48-436c-b98a-a4e9f1157855">82</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share repurchase program activity</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81dedbde5d2a466c9175f53824dd0c39_D20200701-20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfOC0zLTEtMS0w_9c4bbae2-98e5-4607-8bb4-b9a8c1a4afce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if8b3edc49b1248e896c9ddae3b113611_D20200701-20210331" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfOC03LTEtMS0w_8cfd733e-9b77-402b-9bf1-110ccfa9d0fb">4</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if8b3edc49b1248e896c9ddae3b113611_D20200701-20210331" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfOC05LTEtMS0w_7f911b16-9417-475e-bd00-4d78bd23dfce">200</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfOC0xNS0xLTEtMA_2a33d0ff-ecf6-48c1-98cf-9dba15ec1072">200</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia3fc7d942b0147c78cd1b3b94f6611b5_D20200701-20210331" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfOS01LTEtMS0w_dece6f23-fb65-4bfa-abae-55cad3803c3c">432</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfOS0xNS0xLTEtMA_06130a71-fd61-4f5a-bb8c-f4bc73cf61dd">432</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ia3fc7d942b0147c78cd1b3b94f6611b5_D20200701-20210331" xsi:nil="true" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfMTAtNS0xLTEtMA_c3ad66a6-e9e4-4a71-b455-8adac988286d"></ix:nonFraction></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if8b3edc49b1248e896c9ddae3b113611_D20200701-20210331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOtherShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfMTAtNy0xLTEtMA_737bd99b-8e41-4d85-8fa8-1149d335a78b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4123e12a9da4e40840720f78bc466d9_D20200701-20210331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfMTAtMTMtMS0xLTA_444ca20c-00ee-42d2-a4b5-b16c5a78b525">1</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfMTAtMTUtMS0xLTA_622a3f76-d1a9-419e-92a1-c80c37b14bee">1</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7c7911192d9467a8120c5a8745e0ab4_I20210331" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfMTItMS0xLTEtMA_450c6f8e-5bbd-44ff-9214-0311c8ef433b">327</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7c7911192d9467a8120c5a8745e0ab4_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfMTItMy0xLTEtMA_2f252bab-5a3a-492f-94f1-e3fb6437f3e8">2,807</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc405b4ba93d4f15a1821281ca6c82e7_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfMTItNS0xLTEtMA_62b16732-2318-44e1-b62b-2410f7545236">1,233</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0233856860d24d818336b00e3025a695_I20210331" decimals="-6" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfMTItNy0xLTEtMA_8f248521-859f-4b00-bbab-2ea91d1c248f">36</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0233856860d24d818336b00e3025a695_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfMTItOS0xLTEtMA_1d273fa9-5672-4138-aae4-f77d01abcfbd">2,202</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i354467a0724c4e4cb8b779d18d807a9f_I20210331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfMTItMTEtMS0xLTA_0e0f422f-edf9-49af-9100-84569ba72036">48</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4419c8027c549be9d1aa39851d2726a_I20210331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfMTItMTMtMS0xLTA_2778dede-25d6-49df-b66d-669eb5a72bea">4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfMTItMTUtMS0xLTA_c2a08aaf-79ba-4887-be79-7b8c0582bdeb">1,794</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:33.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.476%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.213%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.070%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended March 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2019</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1c2d8220369a4176bd9a77e28f267fbd_I20190630" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfMS0xLTEtMS0w_796fdd52-644d-4821-b26f-d4d1af7be44d">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c2d8220369a4176bd9a77e28f267fbd_I20190630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfMS0zLTEtMS0w_e2173227-bc37-4271-a4c6-abcdc4fda1d1">2,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib49cffead70d458293f7ab1592b008ac_I20190630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfMS01LTEtMS0w_ed931475-654d-4db1-a225-b4c88a446259">5,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia1be2640350446e5a3a575482a87bbcc_I20190630" decimals="-6" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfMS03LTEtMS0w_2178df6c-87b5-4445-9f35-29f4b691cb7a">28</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia1be2640350446e5a3a575482a87bbcc_I20190630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfMS05LTEtMS0w_4db58e53-fc42-41e1-97d3-c2ac81536007">1,790</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib7133a081957418da4808a2430c8abf0_I20190630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfMS0xMS0xLTEtMA_0bf3dfb9-9df0-412c-933a-ea71acc23240">79</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5179121c7a146c08a655a8cfcdaa830_I20190630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfMS0xMy0xLTEtMA_dbf5a2f1-4813-42a1-a58a-24e99198d65e">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77e8dc2fb46740f7886bcac833bb3946_I20190630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfMS0xNS0xLTEtMA_cfe424ca-8975-4262-b0cc-dbe34cb026d0">6,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings/(loss)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfMi01LTEtMS0w_05c6d16f-2379-42b9-8977-2c097521111f">4,352</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51326a843a1e4ac4879b831c1444fdeb_D20190701-20200331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfMi0xMy0xLTEtMA_1e8f29c2-5177-4db7-bcdb-668c1819306d">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfMi0xNS0xLTEtMA_a772f2ba-bc6f-4d42-8d47-5c8528db5718">4,350</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1cad0474bd2f40d886d9d8a4cf2c72fe_D20190701-20200331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfMy0xMS0xLTEtMA_c4a04796-2f9f-4c7d-9132-3b0a2b4c9824">62</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfMy0xNS0xLTEtMA_c4d27c8c-751d-45ea-9f32-4df97d43fe6e">62</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock plans activity, net of shares withheld for employee taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i19b4605df85247908370653224b13cab_D20190701-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfNS0xLTEtMS0w_9170f564-e17e-4948-874c-d55152951b5c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19b4605df85247908370653224b13cab_D20190701-20200331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfNS0zLTEtMS0w_7f7947b8-e86a-4575-b3ff-10b426900a73">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8e9b39d228bb4305a9f94d21ff2986b6_D20190701-20200331" decimals="-6" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfNS03LTEtMS0w_ea33bb89-759a-4b7e-979b-58938ea0e896">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e9b39d228bb4305a9f94d21ff2986b6_D20190701-20200331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfNS05LTEtMS0w_ac0d506c-0dc4-4bcb-a2aa-0fb9e823ebf9">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfNS0xNS0xLTEtMA_e15d0de0-6b19-4861-a00a-70566a2bdfe4">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share repurchase program activity</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8e9b39d228bb4305a9f94d21ff2986b6_D20190701-20200331" decimals="-6" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfNi03LTEtMS0w_a08e5657-6015-427e-977f-0f8d3f874d92">7</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e9b39d228bb4305a9f94d21ff2986b6_D20190701-20200331" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfNi05LTEtMS0w_e25a25c3-e224-4318-a517-4a8e1e6fec22">350</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfNi0xNS0xLTEtMA_14b31c96-4364-41e5-8f30-0a8b5bdb0972">350</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0c0e121749714201bffca84925398633_D20190701-20200331" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfNy01LTEtMS0w_caa1ddbe-23df-42a9-a32e-064bfca76b1c">426</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfNy0xNS0xLTEtMA_95a02721-2da1-48ac-a37f-7b220534edbd">426</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c0e121749714201bffca84925398633_D20190701-20200331" decimals="-6" format="ixt:zerodash" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfOC01LTEtMS0w_4b9904dd-f95d-435e-8914-e1d9726884cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i51326a843a1e4ac4879b831c1444fdeb_D20190701-20200331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfOC0xMy0xLTEtMA_7cadc154-33b4-4961-9e8a-f55f91ad8e4f">1</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfOC0xNS0xLTEtMA_ca7f303c-7ebf-494a-af91-fe981651d85f">1</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i227cc70eba254c68b508a19a38a4772e_I20200331" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfOS0xLTEtMS0w_c7de0338-9607-47e1-bcb9-9015b9aa57be">327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i227cc70eba254c68b508a19a38a4772e_I20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfOS0zLTEtMS0w_db4a8621-1be3-4cc1-9a41-a84be3061c64">2,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08c6b70579ab4b44b051a8e476cdc0bc_I20200331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfOS01LTEtMS0w_cb6896f4-af5a-4696-953c-93bbb3259315">656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i873b7175bb9c48f9a92364ddc30859a3_I20200331" decimals="-6" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfOS03LTEtMS0w_c9bf95f2-58c9-4d46-8ff4-a1f4ec693bc9">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i873b7175bb9c48f9a92364ddc30859a3_I20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfOS05LTEtMS0w_d95b8daf-aadc-4cca-937b-2765b01ab62c">2,086</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4adeac1e746a4298af939e62c0d13228_I20200331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfOS0xMS0xLTEtMA_40d3f9c6-30cf-41fd-847f-2270eb5ddd98">141</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic22356641f7147aa93c0793fd724bac3_I20200331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfOS0xMy0xLTEtMA_557bc588-09e6-45d0-82e6-47fd79cfac99">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie21bd48f8a9a4cb0a6e3c0240434f025_I20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfOS0xNS0xLTEtMA_bcc99c2a-44b5-480b-b32a-07a90a65a54d">1,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="ib6bf45669ad94861b0c50dbc2f4371ce_73"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.775%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.591%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings/(loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMy0xLTEtMS0w_8d59979a-d102-4298-b0bd-66f6f5f8f632">497</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMy0zLTEtMS0w_97a6034c-25da-4642-a3b0-ee60dbee74c0">4,350</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net earnings/(loss) to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfNi0xLTEtMS0w_528c784d-84c0-4e46-90fd-abe6152360cc">603</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfNi0zLTEtMS0w_e665f607-34c5-4c87-993c-3f821e47731e">688</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairments and (gain)/loss on disposal of assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfOC0xLTEtMS0w_03a9b502-684d-48e1-a28c-fde7865f77e8">78</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" sign="-" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfOC0zLTEtMS0w_7d37ec29-660b-4070-a891-c5a5c378c20f">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss on early extinguishment of debt</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfOS0xLTEtMS0w_7c9fce04-0999-49de-ab1b-428c472b229a">1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfOS0zLTEtMS0w_4c6e0c45-99dd-4bc8-b8d0-a11c8ace23e7">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMTAtMS0xLTEtMA_dc584b65-4312-4e0d-b21f-446d0fd60bfd">84</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMTAtMy0xLTEtMA_daa1d8fd-9946-406a-a848-6aeb56b3ae51">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Provision for bad debts</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMTItMS0xLTEtMA_d0bcab1b-cbb1-4805-9c3b-b8b6ec0e7238">49</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMTItMy0xLTEtMA_6f83922f-f40d-4e8e-8b01-192db549323c">86</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in operating assets and liabilities, net of effects from acquisitions and divestitures:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increase in trade receivables</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="us-gaap:IncreaseDecreaseInReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMTQtMS0xLTEtMA_7d5835ca-1cf2-46e8-bb26-d92fbe544911">511</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" name="us-gaap:IncreaseDecreaseInReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMTQtMy0xLTEtMA_d76960a4-d491-4c85-9da3-757cd03dd43f">653</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increase in inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMTUtMS0xLTEtMA_baf3dfce-946b-43de-84c5-bfd3fc29f5d0">1,323</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMTUtMy0xLTEtMA_305b8f76-be15-431a-a049-b6dfbbfef745">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Increase in accounts payable</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMTYtMS0xLTEtMA_5e88361c-7662-4815-96ca-bd49875b95d8">1,267</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMTYtMy0xLTEtMA_a0badb99-3233-4c46-823c-db7fbff46efc">448</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other accrued liabilities and operating items, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMTctMS0xLTEtMA_08140757-2269-406a-9e8d-e7be0e0eca3d">1,019</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMTctMy0xLTEtMA_709d79c1-4964-414a-b865-0d209a5d32dd">5,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMTgtMS0xLTEtMA_485960b0-818e-4640-a45a-e695273521ba">1,764</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMTgtMy0xLTEtMA_0f833f66-abed-451d-9bfe-bf6bbe5b7764">1,720</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition of subsidiaries, net of cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMjEtMS0xLTEtMA_6fc5f9f4-02e7-4fa5-bfd8-18a650e39c5b">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMjEtMy0xLTEtMA_daab24d1-9821-4221-9557-8e2320f672dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions to property and equipment</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMjItMS0xLTEtMA_fba75219-89aa-49da-aef2-e737d1b22fbf">274</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMjItMy0xLTEtMA_19aff834-1f3e-47fb-a5d2-4fec46f74c5e">239</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="cah:Purchaseofavailableforsalesecuritiesandotherinvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMjMtMS0xLTEtMA_6d8905df-b883-40ba-aba5-aaccbaa26e26">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" name="cah:Purchaseofavailableforsalesecuritiesandotherinvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMjMtMy0xLTEtMA_2ce04a0d-c0e0-4f29-8203-46dd39c85b26">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from investments</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMjQtMS0xLTEtMA_bf4390bf-be70-4015-a0ae-a80451842448">5</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" name="cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMjQtMy0xLTEtMA_fb94cd46-3ab4-4dfd-8b18-c2a4b32fdd66">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from disposal of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" format="ixt:zerodash" name="cah:Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMjYtMS0xLTEtMA_67151cb8-bf18-4be9-9534-93ceb6609bc4">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" name="cah:Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMjYtMy0xLTEtMA_0b9cccf9-d51e-448a-9d36-910b0772032b">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMjctMS0xLTEtMA_dcebcd3e-c04a-45b9-a0d0-0650f7ba6ccc">290</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMjctMy0xLTEtMA_44676097-2262-423d-96ea-aa9e0b1566ce">249</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net change in short-term borrowings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMzAtMS0xLTEtMA_93ee4577-14da-428f-95b7-8862fc567abb">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" sign="-" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMzAtMy0xLTEtMA_94669e68-7a27-43e3-b3c2-5d88a8811406">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from interest rate swap terminations</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromHedgeFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMzEtMS0xLTEtMjcyOQ_2a443e33-a5d4-45b9-ba3b-5577858380ad">18</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" format="ixt:zerodash" name="us-gaap:PaymentsForProceedsFromHedgeFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMzEtMy0xLTEtMjczMg_b0303bcf-0cf9-447b-af62-426addaee672">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reduction of long-term obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMzEtMS0xLTEtMA_abd93ab2-d8dc-45e7-a880-25eb3ee2e0ca">53</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMzEtMy0xLTEtMA_704c9bad-6bab-40ec-91f8-e06b9d7772b1">888</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net tax withholdings from share-based compensation</span></div></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" sign="-" name="cah:Netproceedstaxwithholdingsfromsharebasedcompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMzItMS0xLTEtMA_42466281-b2fc-43ef-895e-946c4ed53787">1</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" sign="-" name="cah:Netproceedstaxwithholdingsfromsharebasedcompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMzItMy0xLTEtMA_a19452a1-9f25-4e30-8534-2a4c35bfa90e">4</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends on common shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMzQtMS0xLTEtMA_8a0bcc00-1e75-40b5-8594-d252cb0c1a31">432</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMzQtMy0xLTEtMA_d6cff701-59c4-4676-b7d7-aa768be6e45c">428</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of treasury shares</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMzUtMS0xLTEtMA_ff7cddd8-6edf-431b-b617-adbc00e00764">200</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMzUtMy0xLTEtMA_e9f22f82-de0f-48e6-a0d7-cc10aaa2ec1b">350</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMzYtMS0xLTEtMA_0a3cf9a5-b1ad-4f03-ad24-d578367fa37f">668</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMzYtMy0xLTEtMA_8953b3d8-f609-48b1-a5ad-641526464803">1,672</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of exchange rates changes on cash and equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMzgtMS0xLTEtMA_837e606c-5433-43b9-838a-581ee4cbeebc">8</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMzgtMy0xLTEtMA_8a51f671-baf2-4eb1-b40f-471ade4894ed">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and equivalents reclassified to assets held for sale</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" sign="-" name="cah:CashReclassifiedToAssetHeldForSale" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMzktMS0xLTEtMjcxMQ_14476c86-467f-43ff-8d89-3bd232e748c6">86</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" format="ixt:zerodash" name="cah:CashReclassifiedToAssetHeldForSale" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMzktMy0xLTEtMjcxNg_02a32748-5dbe-4990-83f9-d81c2996447a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net increase/(decrease) in cash and equivalents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfNDAtMS0xLTEtMA_c8b8b80e-d9ca-462d-8097-663169b343bd">728</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfNDAtMy0xLTEtMA_cfadfcb2-6039-4953-a4cf-cb4550073560">202</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and equivalents at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfNDEtMS0xLTEtMA_8dfc8a0c-1964-4837-b4ca-ee85d32b1ca3">2,771</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77e8dc2fb46740f7886bcac833bb3946_I20190630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfNDEtMy0xLTEtMA_330614b0-4433-499f-afdd-e4dfdd8e50d3">2,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and equivalents at end of period</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfNDItMS0xLTEtMA_a8bd8869-00ba-4611-ab15-75132775c4cd">3,499</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie21bd48f8a9a4cb0a6e3c0240434f025_I20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfNDItMy0xLTEtMA_cae6d4b3-3e66-4263-a0d1-7895602980f8">2,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See notes to condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="ib6bf45669ad94861b0c50dbc2f4371ce_76"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div id="ib6bf45669ad94861b0c50dbc2f4371ce_79"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83OS9mcmFnOmE1MWE2ODU2YTQ4ZDQ2Mzg4OTI1ZjBiNWU0YTZkYzFhL3RleHRyZWdpb246YTUxYTY4NTZhNDhkNDYzODg5MjVmMGI1ZTRhNmRjMWFfMzc5MQ_6dfb594a-d562-4e03-a812-3b3cd6fa623e" continuedAt="i101c9d616004459ca4b683decb1d3ec7" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">1. Basis of Presentation and Summary of Significant Accounting Policies </span></div><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83OS9mcmFnOmE1MWE2ODU2YTQ4ZDQ2Mzg4OTI1ZjBiNWU0YTZkYzFhL3RleHRyZWdpb246YTUxYTY4NTZhNDhkNDYzODg5MjVmMGI1ZTRhNmRjMWFfMzc5NA_4768fe4c-f31c-46aa-a7b7-ff68451bca24" escape="true"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to "we," "our," and similar pronouns is in this Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2021 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context requires otherwise.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fiscal year ends on June 30. References to fiscal 2021 and 2020 in these condensed consolidated financial statements are to the fiscal years ending or ended June&#160;30, 2021 and June&#160;30, 2020, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic ("COVID-19") continues to affect the U.S. and global economies, and as previously disclosed in our Fiscal 2020 Form 10-K, the pandemic began to materially affect our businesses during the three months ended March 31, 2020. The length and severity of the pandemic and of the related economic impacts to our businesses and operations are uncertain, including its ongoing impacts to our businesses and results of operations.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.&#160;In addition, financial results presented for this fiscal 2021 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June&#160;30, 2021. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2020 (the "2020 Form 10-K").</span></div></ix:nonNumeric></ix:nonNumeric></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:continuation id="i101c9d616004459ca4b683decb1d3ec7"><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83OS9mcmFnOmE1MWE2ODU2YTQ4ZDQ2Mzg4OTI1ZjBiNWU0YTZkYzFhL3RleHRyZWdpb246YTUxYTY4NTZhNDhkNDYzODg5MjVmMGI1ZTRhNmRjMWFfMzc5NQ_b6e3828b-e814-4a5d-9dbd-9e6b2b93410b" escape="true"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Adopted Financial Accounting Standards</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued amended accounting guidance that will require entities to measure credit losses on trade and other receivables, held-to-maturity debt securities, loans and other instruments using an "expected credit loss" model that considers historical experience, current conditions and reasonable supportable forecasts. This guidance also requires that credit losses on available-for-sale debt securities with unrealized losses be recognized as allowances rather than as deductions in the amortized cost of the securities. We consider historical experience, the current economic environment, customer credit ratings or bankruptcies, and reasonable and supportable forecasts to develop our allowance for credit losses. We review these factors quarterly to determine if any adjustments are needed to the allowance. This guidance was effective beginning the first quarter of fiscal 2021 and did not have a material impact on our condensed consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div id="ib6bf45669ad94861b0c50dbc2f4371ce_1194"></div><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTk0L2ZyYWc6OTJhMzMyZjgzOTNlNDMwNDkwZDFhNTk3MmYyYWQzOWQvdGV4dHJlZ2lvbjo5MmEzMzJmODM5M2U0MzA0OTBkMWE1OTcyZjJhZDM5ZF80Mzk4MDQ2NTI3MzUy_b98a5da9-8b3f-4178-a728-2db6b13eee05" continuedAt="idd2b110220234f8bb908b1ff44dcfa33" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">2. Assets Held for Sale</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify assets and liabilities (the &#8220;disposal group&#8221;) as held for sale when management commits to a plan to sell the disposal group in its present condition and at a price that is reasonable in relation to its current fair value. We also consider whether an active program to locate a buyer has been initiated and if it is probable that the sale will occur within one year without significant changes to the plan to sell. Upon classification of the disposal group as held for sale, we assess the assets for impairment and cease related depreciation and amortization.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 12, 2021, we signed a definitive agreement with Hellman &amp; Friedman to sell our Cordis business for gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i7cdd3ec3331046ec97e3ab5eeb7a43e0_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTk0L2ZyYWc6OTJhMzMyZjgzOTNlNDMwNDkwZDFhNTk3MmYyYWQzOWQvdGV4dHJlZ2lvbjo5MmEzMzJmODM5M2U0MzA0OTBkMWE1OTcyZjJhZDM5ZF8zMjk4NTM0ODk5NTMz_6a25bcea-30d1-46d7-8eb3-0db495670100">927</ix:nonFraction>&#160;million in cash, subject to customary purchase price adjustments, and we will retain certain working capital accounts and certain liabilities. The transaction is expected to close in the first quarter of fiscal 2022, subject to customary closing conditions and regulatory clearances. Cardinal Health will retain liability associated with lawsuits related to inferior vena cava ("IVC") filters in the U.S. and Canada, as well as authority for these matters discussed in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_97">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021, we met the criteria for the related assets and liabilities of the Cordis business to be classified as held for sale. In connection with the planned divestiture, we allocated $<ix:nonFraction unitRef="usd" contextRef="i7cdd3ec3331046ec97e3ab5eeb7a43e0_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTk0L2ZyYWc6OTJhMzMyZjgzOTNlNDMwNDkwZDFhNTk3MmYyYWQzOWQvdGV4dHJlZ2lvbjo5MmEzMzJmODM5M2U0MzA0OTBkMWE1OTcyZjJhZDM5ZF8zMjk4NTM0ODk5NTQ4_954a771a-4b93-4caa-a4ed-9a2764360175">388</ix:nonFraction>&#160;million of goodwill from the Medical Unit (within our Medical Segment) to the Cordis disposal group based on the estimated relative fair values of the business to be disposed of and the portion of the reporting unit that will be retained. We determined that the sale of the Cordis business does not meet the criteria to be classified as discontinued operations. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2021, the book value of the disposal group exceeded its fair value less costs to sell. Accordingly, we recognized a $<ix:nonFraction unitRef="usd" contextRef="i7cdd3ec3331046ec97e3ab5eeb7a43e0_I20210331" decimals="-6" sign="-" format="ixt:numdotdecimal" name="cah:WriteDownOfAssetsHeldForSale" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTk0L2ZyYWc6OTJhMzMyZjgzOTNlNDMwNDkwZDFhNTk3MmYyYWQzOWQvdGV4dHJlZ2lvbjo5MmEzMzJmODM5M2U0MzA0OTBkMWE1OTcyZjJhZDM5ZF8zMjk4NTM0ODk5NTEy_a8cc8edb-131c-4e11-9dd0-0427ccbeafff">58</ix:nonFraction> </span></div></ix:nonNumeric></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.857%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="idd2b110220234f8bb908b1ff44dcfa33"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million pre-tax write-down on the disposal group in impairments and (gain)/loss on disposal of assets in our condensed consolidated statement of earnings/(loss). This write-down includes a $<ix:nonFraction unitRef="usd" contextRef="i872f564c51c449338d43396b08fe7bbf_D20200701-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTk0L2ZyYWc6OTJhMzMyZjgzOTNlNDMwNDkwZDFhNTk3MmYyYWQzOWQvdGV4dHJlZ2lvbjo5MmEzMzJmODM5M2U0MzA0OTBkMWE1OTcyZjJhZDM5ZF8zMjk4NTM0ODk5NDkz_7a7c5ebd-654a-4489-bf02-95a6a3a127ca">2</ix:nonFraction> million gain related to currency translation adjustments in accumulated other comprehensive income. We recorded a net tax expense of $<ix:nonFraction unitRef="usd" contextRef="i872f564c51c449338d43396b08fe7bbf_D20200701-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTk0L2ZyYWc6OTJhMzMyZjgzOTNlNDMwNDkwZDFhNTk3MmYyYWQzOWQvdGV4dHJlZ2lvbjo5MmEzMzJmODM5M2U0MzA0OTBkMWE1OTcyZjJhZDM5ZF8xNTk0MjkxODYyMDI2NA_9fa34553-5ef2-447f-b60d-11e2438691e3">7</ix:nonFraction> million associated with the impact of the write-down and the required tax adjustments triggered by held for sale accounting.</span></div><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTk0L2ZyYWc6OTJhMzMyZjgzOTNlNDMwNDkwZDFhNTk3MmYyYWQzOWQvdGV4dHJlZ2lvbjo5MmEzMzJmODM5M2U0MzA0OTBkMWE1OTcyZjJhZDM5ZF80Mzk4MDQ2NTI3MzUz_b8f431a0-1375-48c8-8494-87223c479882" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information related to the assets and liabilities that were classified as held for sale at March&#160;31, 2021 related to the Cordis planned divestiture in the condensed consolidated balance sheets:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.246%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and equivalents</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cdd3ec3331046ec97e3ab5eeb7a43e0_I20210331" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTk0L2ZyYWc6OTJhMzMyZjgzOTNlNDMwNDkwZDFhNTk3MmYyYWQzOWQvdGFibGU6MjY4NzJkODJmZjA3NDY2ZmJjNTJlY2I0YjkwNTE5NzMvdGFibGVyYW5nZToyNjg3MmQ4MmZmMDc0NjZmYmM1MmVjYjRiOTA1MTk3M18xLTEtMS0xLTI0MzQ_c9c89c76-f394-48ce-92d8-78c635e87ad5">86</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cdd3ec3331046ec97e3ab5eeb7a43e0_I20210331" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTk0L2ZyYWc6OTJhMzMyZjgzOTNlNDMwNDkwZDFhNTk3MmYyYWQzOWQvdGFibGU6MjY4NzJkODJmZjA3NDY2ZmJjNTJlY2I0YjkwNTE5NzMvdGFibGVyYW5nZToyNjg3MmQ4MmZmMDc0NjZmYmM1MmVjYjRiOTA1MTk3M18yLTEtMS0xLTI0MzQ_a2d6a614-bcf3-486f-a163-153930b0acf4">175</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cdd3ec3331046ec97e3ab5eeb7a43e0_I20210331" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTk0L2ZyYWc6OTJhMzMyZjgzOTNlNDMwNDkwZDFhNTk3MmYyYWQzOWQvdGFibGU6MjY4NzJkODJmZjA3NDY2ZmJjNTJlY2I0YjkwNTE5NzMvdGFibGVyYW5nZToyNjg3MmQ4MmZmMDc0NjZmYmM1MmVjYjRiOTA1MTk3M180LTEtMS0xLTI0MzQ_48a396ba-9437-41fe-a4eb-f7726c6197b8">88</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill and other intangibles, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cdd3ec3331046ec97e3ab5eeb7a43e0_I20210331" decimals="-6" name="cah:DisposalGroupIncludingDiscontinuedOperationGoodwillAndOtherIntangiblesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTk0L2ZyYWc6OTJhMzMyZjgzOTNlNDMwNDkwZDFhNTk3MmYyYWQzOWQvdGFibGU6MjY4NzJkODJmZjA3NDY2ZmJjNTJlY2I0YjkwNTE5NzMvdGFibGVyYW5nZToyNjg3MmQ4MmZmMDc0NjZmYmM1MmVjYjRiOTA1MTk3M181LTEtMS0xLTI0MzQ_21518460-d533-4219-87eb-44276f808df1">779</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cdd3ec3331046ec97e3ab5eeb7a43e0_I20210331" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTk0L2ZyYWc6OTJhMzMyZjgzOTNlNDMwNDkwZDFhNTk3MmYyYWQzOWQvdGFibGU6MjY4NzJkODJmZjA3NDY2ZmJjNTJlY2I0YjkwNTE5NzMvdGFibGVyYW5nZToyNjg3MmQ4MmZmMDc0NjZmYmM1MmVjYjRiOTA1MTk3M182LTEtMS0xLTI0MzQ_bf2e83b1-01bf-4f77-9e96-4efa0fdd08b4">12</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Write-down of assets held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7cdd3ec3331046ec97e3ab5eeb7a43e0_I20210331" decimals="-6" sign="-" name="cah:WriteDownOfAssetsHeldForSale" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTk0L2ZyYWc6OTJhMzMyZjgzOTNlNDMwNDkwZDFhNTk3MmYyYWQzOWQvdGFibGU6MjY4NzJkODJmZjA3NDY2ZmJjNTJlY2I0YjkwNTE5NzMvdGFibGVyYW5nZToyNjg3MmQ4MmZmMDc0NjZmYmM1MmVjYjRiOTA1MTk3M183LTEtMS0xLTIzOTY_3812ddd6-f740-420e-ad76-6f9b1b70318c">58</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets held for sale</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cdd3ec3331046ec97e3ab5eeb7a43e0_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTk0L2ZyYWc6OTJhMzMyZjgzOTNlNDMwNDkwZDFhNTk3MmYyYWQzOWQvdGFibGU6MjY4NzJkODJmZjA3NDY2ZmJjNTJlY2I0YjkwNTE5NzMvdGFibGVyYW5nZToyNjg3MmQ4MmZmMDc0NjZmYmM1MmVjYjRiOTA1MTk3M184LTEtMS0xLTIwODA_429a835b-4e1c-4e8a-a55c-65912a0c7388"><ix:nonFraction unitRef="usd" contextRef="i7cdd3ec3331046ec97e3ab5eeb7a43e0_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTk0L2ZyYWc6OTJhMzMyZjgzOTNlNDMwNDkwZDFhNTk3MmYyYWQzOWQvdGFibGU6MjY4NzJkODJmZjA3NDY2ZmJjNTJlY2I0YjkwNTE5NzMvdGFibGVyYW5nZToyNjg3MmQ4MmZmMDc0NjZmYmM1MmVjYjRiOTA1MTk3M184LTEtMS0xLTIwODA_4923bed0-9e1d-45ee-be8f-47a1c08a1a35">1,082</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cdd3ec3331046ec97e3ab5eeb7a43e0_I20210331" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTk0L2ZyYWc6OTJhMzMyZjgzOTNlNDMwNDkwZDFhNTk3MmYyYWQzOWQvdGFibGU6MjY4NzJkODJmZjA3NDY2ZmJjNTJlY2I0YjkwNTE5NzMvdGFibGVyYW5nZToyNjg3MmQ4MmZmMDc0NjZmYmM1MmVjYjRiOTA1MTk3M18xMC0xLTEtMS0yNDM4_b7926305-c78f-4c2b-8027-08d60c091c0d">59</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cdd3ec3331046ec97e3ab5eeb7a43e0_I20210331" decimals="-6" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTk0L2ZyYWc6OTJhMzMyZjgzOTNlNDMwNDkwZDFhNTk3MmYyYWQzOWQvdGFibGU6MjY4NzJkODJmZjA3NDY2ZmJjNTJlY2I0YjkwNTE5NzMvdGFibGVyYW5nZToyNjg3MmQ4MmZmMDc0NjZmYmM1MmVjYjRiOTA1MTk3M18xMS0xLTEtMS0yNDM4_694b429e-c988-4708-87cc-fb150feca207">34</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total liabilities related to assets held for sale</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cdd3ec3331046ec97e3ab5eeb7a43e0_I20210331" decimals="-6" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTk0L2ZyYWc6OTJhMzMyZjgzOTNlNDMwNDkwZDFhNTk3MmYyYWQzOWQvdGFibGU6MjY4NzJkODJmZjA3NDY2ZmJjNTJlY2I0YjkwNTE5NzMvdGFibGVyYW5nZToyNjg3MmQ4MmZmMDc0NjZmYmM1MmVjYjRiOTA1MTk3M18xMi0xLTEtMS0yMDkx_d16d7826-eba6-45c5-87a9-48032385ac23">93</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="ib6bf45669ad94861b0c50dbc2f4371ce_82"></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RleHRyZWdpb246YzcyNmFkYTIwMDlkNDJlMGJlOGQyYmZlM2Q3ZDk4NTFfOTE5_ef9a6cb4-6e34-452e-92e8-74ba6c1c8fcc" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">3. Restructuring and Employee Severance</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RleHRyZWdpb246YzcyNmFkYTIwMDlkNDJlMGJlOGQyYmZlM2Q3ZDk4NTFfOTI2_de71d468-3c1b-4e6c-9bbd-0d3632fa2413" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restructuring and employee severance:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RhYmxlOjBkMDRhMGJhZmY0NjRkZTg4YWUwMWNiZWZlYjIyNGEyL3RhYmxlcmFuZ2U6MGQwNGEwYmFmZjQ2NGRlODhhZTAxY2JlZmViMjI0YTJfMi0xLTEtMS0w_26a64b5c-aea6-4073-9b76-6d88348e2a7b">13</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RhYmxlOjBkMDRhMGJhZmY0NjRkZTg4YWUwMWNiZWZlYjIyNGEyL3RhYmxlcmFuZ2U6MGQwNGEwYmFmZjQ2NGRlODhhZTAxY2JlZmViMjI0YTJfMi0zLTEtMS0w_e8a94eef-e375-4571-b72a-9becfc606429">15</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="-6" name="cah:FacilityExitAndOtherCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RhYmxlOjBkMDRhMGJhZmY0NjRkZTg4YWUwMWNiZWZlYjIyNGEyL3RhYmxlcmFuZ2U6MGQwNGEwYmFmZjQ2NGRlODhhZTAxY2JlZmViMjI0YTJfMy0xLTEtMS0w_6cdf5379-b021-4c70-bef7-a96fd3f81ca4">11</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" decimals="-6" name="cah:FacilityExitAndOtherCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RhYmxlOjBkMDRhMGJhZmY0NjRkZTg4YWUwMWNiZWZlYjIyNGEyL3RhYmxlcmFuZ2U6MGQwNGEwYmFmZjQ2NGRlODhhZTAxY2JlZmViMjI0YTJfMy0zLTEtMS0w_9fefa071-0790-4bde-af46-cf8e853278ac">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RhYmxlOjBkMDRhMGJhZmY0NjRkZTg4YWUwMWNiZWZlYjIyNGEyL3RhYmxlcmFuZ2U6MGQwNGEwYmFmZjQ2NGRlODhhZTAxY2JlZmViMjI0YTJfNC0xLTEtMS0w_3de30764-1a40-490e-aa52-31674299c598">24</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RhYmxlOjBkMDRhMGJhZmY0NjRkZTg4YWUwMWNiZWZlYjIyNGEyL3RhYmxlcmFuZ2U6MGQwNGEwYmFmZjQ2NGRlODhhZTAxY2JlZmViMjI0YTJfNC0zLTEtMS0w_d784e584-16a9-4e75-abf3-97fb1e6330f6">6</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RhYmxlOjJmNmQ0M2I5MmEyODQ4YjA4ZWRlNzQ5NTNkODhmYjRkL3RhYmxlcmFuZ2U6MmY2ZDQzYjkyYTI4NDhiMDhlZGU3NDk1M2Q4OGZiNGRfMi0xLTEtMS0w_74157cc8-292e-45e5-bc4f-7515beeed972">45</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RhYmxlOjJmNmQ0M2I5MmEyODQ4YjA4ZWRlNzQ5NTNkODhmYjRkL3RhYmxlcmFuZ2U6MmY2ZDQzYjkyYTI4NDhiMDhlZGU3NDk1M2Q4OGZiNGRfMi0zLTEtMS0w_5bfb01ef-daa5-4321-878d-12988091e5d2">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="cah:FacilityExitAndOtherCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RhYmxlOjJmNmQ0M2I5MmEyODQ4YjA4ZWRlNzQ5NTNkODhmYjRkL3RhYmxlcmFuZ2U6MmY2ZDQzYjkyYTI4NDhiMDhlZGU3NDk1M2Q4OGZiNGRfMy0xLTEtMS0w_74217a14-13f1-4c98-94b2-5aa0c8b190f5">36</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" name="cah:FacilityExitAndOtherCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RhYmxlOjJmNmQ0M2I5MmEyODQ4YjA4ZWRlNzQ5NTNkODhmYjRkL3RhYmxlcmFuZ2U6MmY2ZDQzYjkyYTI4NDhiMDhlZGU3NDk1M2Q4OGZiNGRfMy0zLTEtMS0w_3294b3b3-63f6-484f-85c2-4caf7b106bd4">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RhYmxlOjJmNmQ0M2I5MmEyODQ4YjA4ZWRlNzQ5NTNkODhmYjRkL3RhYmxlcmFuZ2U6MmY2ZDQzYjkyYTI4NDhiMDhlZGU3NDk1M2Q4OGZiNGRfNC0xLTEtMS0w_ef6e9751-136d-4319-86cf-6fe770aebb8d">81</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RhYmxlOjJmNmQ0M2I5MmEyODQ4YjA4ZWRlNzQ5NTNkODhmYjRkL3RhYmxlcmFuZ2U6MmY2ZDQzYjkyYTI4NDhiMDhlZGU3NDk1M2Q4OGZiNGRfNC0zLTEtMS0w_4ab4a7b3-71a8-4642-ad1a-4ce25905f344">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of vendor transition fees, professional, project management and other service fees to support divestitures, accelerated depreciation, lease costs associated with vacant facilities, equipment relocation costs, project consulting fees, costs associated with restructuring our delivery of information technology infrastructure services and certain other divestiture-related costs.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring costs during both the three and nine months ended March&#160;31, 2021 and 2020 were primarily related to the implementation of certain enterprise-wide cost-savings measures. The income during the three months ended March&#160;31, 2020 was due to changes in estimates for severance previously accrued.</span></div><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RleHRyZWdpb246YzcyNmFkYTIwMDlkNDJlMGJlOGQyYmZlM2Q3ZDk4NTFfOTEz_f6da560f-21af-45b5-b6ec-19799aac3c04" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity related to liabilities associated with restructuring and employee severance:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:43.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.237%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.237%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.241%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-<br/>Related Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility Exit<br/>and Other Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98ac083d3c7d4cab941676ec328bb04b_I20200630" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RhYmxlOmVjMmIxOGE1MjdkNjRiMWFhNTJhNjcyMzA4YTg0MDJkL3RhYmxlcmFuZ2U6ZWMyYjE4YTUyN2Q2NGIxYWE1MmE2NzIzMDhhODQwMmRfMS0xLTEtMS0w_c9296721-c6e9-47bd-94b2-3251ed074f82">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i821455dffe794014b8f8a131073f0e3a_I20200630" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RhYmxlOmVjMmIxOGE1MjdkNjRiMWFhNTJhNjcyMzA4YTg0MDJkL3RhYmxlcmFuZ2U6ZWMyYjE4YTUyN2Q2NGIxYWE1MmE2NzIzMDhhODQwMmRfMS0zLTEtMS0w_357707f9-fa79-4488-a5cc-c8520c1cbc0a">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RhYmxlOmVjMmIxOGE1MjdkNjRiMWFhNTJhNjcyMzA4YTg0MDJkL3RhYmxlcmFuZ2U6ZWMyYjE4YTUyN2Q2NGIxYWE1MmE2NzIzMDhhODQwMmRfMS01LTEtMS0w_e837a217-2001-47c0-a031-b444ec69d7ad">96</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5e179139d574d23982bca2fd8e461fd_D20200701-20210331" decimals="-6" name="us-gaap:RestructuringCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RhYmxlOmVjMmIxOGE1MjdkNjRiMWFhNTJhNjcyMzA4YTg0MDJkL3RhYmxlcmFuZ2U6ZWMyYjE4YTUyN2Q2NGIxYWE1MmE2NzIzMDhhODQwMmRfMi0xLTEtMS0w_e8476476-2474-4383-9174-f08845f2a2e9">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if42abb6c898a48ab9033252b5dbfcbee_D20200701-20210331" decimals="-6" name="us-gaap:RestructuringCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RhYmxlOmVjMmIxOGE1MjdkNjRiMWFhNTJhNjcyMzA4YTg0MDJkL3RhYmxlcmFuZ2U6ZWMyYjE4YTUyN2Q2NGIxYWE1MmE2NzIzMDhhODQwMmRfMi0zLTEtMS0w_c379c210-6832-4a31-a2f8-f80c41246f74">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="us-gaap:RestructuringCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RhYmxlOmVjMmIxOGE1MjdkNjRiMWFhNTJhNjcyMzA4YTg0MDJkL3RhYmxlcmFuZ2U6ZWMyYjE4YTUyN2Q2NGIxYWE1MmE2NzIzMDhhODQwMmRfMi01LTEtMS0w_1fdf5c36-1bac-4f2e-b255-384ca0818b69">59</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5e179139d574d23982bca2fd8e461fd_D20200701-20210331" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RhYmxlOmVjMmIxOGE1MjdkNjRiMWFhNTJhNjcyMzA4YTg0MDJkL3RhYmxlcmFuZ2U6ZWMyYjE4YTUyN2Q2NGIxYWE1MmE2NzIzMDhhODQwMmRfMy0xLTEtMS0w_e77e2075-e851-4114-99a3-2f36943a48f8">49</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if42abb6c898a48ab9033252b5dbfcbee_D20200701-20210331" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RhYmxlOmVjMmIxOGE1MjdkNjRiMWFhNTJhNjcyMzA4YTg0MDJkL3RhYmxlcmFuZ2U6ZWMyYjE4YTUyN2Q2NGIxYWE1MmE2NzIzMDhhODQwMmRfMy0zLTEtMS0w_77e73c2b-101e-454c-aeac-476f9ac05b29">25</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RhYmxlOmVjMmIxOGE1MjdkNjRiMWFhNTJhNjcyMzA4YTg0MDJkL3RhYmxlcmFuZ2U6ZWMyYjE4YTUyN2Q2NGIxYWE1MmE2NzIzMDhhODQwMmRfMy01LTEtMS0w_16ee61d2-c838-49d6-bf72-dc9b0c45c558">74</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2021</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb3bd6687f4e44aab8db611ebf43f7d0_I20210331" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RhYmxlOmVjMmIxOGE1MjdkNjRiMWFhNTJhNjcyMzA4YTg0MDJkL3RhYmxlcmFuZ2U6ZWMyYjE4YTUyN2Q2NGIxYWE1MmE2NzIzMDhhODQwMmRfNC0xLTEtMS0w_6b7b1d4e-3420-4e6f-9fc0-a5017eee1b32">56</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib963f36549774070a638555f5486bde0_I20210331" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RhYmxlOmVjMmIxOGE1MjdkNjRiMWFhNTJhNjcyMzA4YTg0MDJkL3RhYmxlcmFuZ2U6ZWMyYjE4YTUyN2Q2NGIxYWE1MmE2NzIzMDhhODQwMmRfNC0zLTEtMS0w_6498c44c-08c2-400f-9856-bfb45b2f113e">25</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RhYmxlOmVjMmIxOGE1MjdkNjRiMWFhNTJhNjcyMzA4YTg0MDJkL3RhYmxlcmFuZ2U6ZWMyYjE4YTUyN2Q2NGIxYWE1MmE2NzIzMDhhODQwMmRfNC01LTEtMS0w_fd5f4f36-1de3-4259-840c-445a8246ea9d">81</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">35</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="ib6bf45669ad94861b0c50dbc2f4371ce_85"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RleHRyZWdpb246MzU5NWE5MGE0YmIwNGI2NzhkY2RkNzcwZjZjMzUwMGRfNTMw_7e01ec7e-7d65-4e11-a61b-0d5d0aa53882" continuedAt="i61d88a99e3f24e9c84e3c931cfe3ab91" escape="true"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">4. Goodwill and Other Intangible Assets</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Goodwill</span></div><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RleHRyZWdpb246MzU5NWE5MGE0YmIwNGI2NzhkY2RkNzcwZjZjMzUwMGRfNTIz_4e665d8c-06a4-4618-b0b9-e88650ccf9ec" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill by segment and in total:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.739%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.171%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.482%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb77c6fda9c84c43ba66e9e82d862e1d_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOmQ0ZjU1MGI2MDUwODQxZTg4MmUyNGViZGRhODU5MTE5L3RhYmxlcmFuZ2U6ZDRmNTUwYjYwNTA4NDFlODgyZTI0ZWJkZGE4NTkxMTlfMS0xLTEtMS0w_0fe40f28-63a5-42fa-9f6d-76941a428cfc">2,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b24380305684bfe8bdfbb78576d14d2_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOmQ0ZjU1MGI2MDUwODQxZTg4MmUyNGViZGRhODU5MTE5L3RhYmxlcmFuZ2U6ZDRmNTUwYjYwNTA4NDFlODgyZTI0ZWJkZGE4NTkxMTlfMS0zLTEtMS0w_c8365f5a-19e3-4b98-9957-9f1e2069edc1">5,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOmQ0ZjU1MGI2MDUwODQxZTg4MmUyNGViZGRhODU5MTE5L3RhYmxlcmFuZ2U6ZDRmNTUwYjYwNTA4NDFlODgyZTI0ZWJkZGE4NTkxMTlfMS01LTEtMS0w_436af2bb-5217-42c0-93d2-2350e0082c55">8,357</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill acquired, net of purchase price adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88705ecfe8f9467188b5fdceaff0c86b_D20200701-20210331" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOmQ0ZjU1MGI2MDUwODQxZTg4MmUyNGViZGRhODU5MTE5L3RhYmxlcmFuZ2U6ZDRmNTUwYjYwNTA4NDFlODgyZTI0ZWJkZGE4NTkxMTlfMi0xLTEtMS0w_bdcfcedf-54e9-47a5-a3ac-18afed32b77d">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6f5e23cdbdc462981ce1345c1d0a482_D20200701-20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOmQ0ZjU1MGI2MDUwODQxZTg4MmUyNGViZGRhODU5MTE5L3RhYmxlcmFuZ2U6ZDRmNTUwYjYwNTA4NDFlODgyZTI0ZWJkZGE4NTkxMTlfMi0zLTEtMS0w_7b4e6b92-8b44-41c3-936b-1e1dcc5def25">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOmQ0ZjU1MGI2MDUwODQxZTg4MmUyNGViZGRhODU5MTE5L3RhYmxlcmFuZ2U6ZDRmNTUwYjYwNTA4NDFlODgyZTI0ZWJkZGE4NTkxMTlfMi01LTEtMS0w_3d7bd649-fd4a-43ea-b94e-7f47d4a0e738">2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments and other</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88705ecfe8f9467188b5fdceaff0c86b_D20200701-20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOmQ0ZjU1MGI2MDUwODQxZTg4MmUyNGViZGRhODU5MTE5L3RhYmxlcmFuZ2U6ZDRmNTUwYjYwNTA4NDFlODgyZTI0ZWJkZGE4NTkxMTlfMy0xLTEtMS0w_1ea6d8cf-05f0-4e4e-8172-4b5e3d410d81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6f5e23cdbdc462981ce1345c1d0a482_D20200701-20210331" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOmQ0ZjU1MGI2MDUwODQxZTg4MmUyNGViZGRhODU5MTE5L3RhYmxlcmFuZ2U6ZDRmNTUwYjYwNTA4NDFlODgyZTI0ZWJkZGE4NTkxMTlfMy0zLTEtMS0w_bb19b1a1-cf4f-40be-8897-cf99ae0507fe">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOmQ0ZjU1MGI2MDUwODQxZTg4MmUyNGViZGRhODU5MTE5L3RhYmxlcmFuZ2U6ZDRmNTUwYjYwNTA4NDFlODgyZTI0ZWJkZGE4NTkxMTlfMy01LTEtMS0w_3c6e8803-7378-4bc2-9032-00c910a90c6e">15</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassified to assets held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81339315e2c14539bee8f1c43e550ae5_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOmQ0ZjU1MGI2MDUwODQxZTg4MmUyNGViZGRhODU5MTE5L3RhYmxlcmFuZ2U6ZDRmNTUwYjYwNTA4NDFlODgyZTI0ZWJkZGE4NTkxMTlfNC0xLTEtMS0yNjU5_78a30237-3f4e-4fe7-a111-9bde19248840">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03c64db735f449b18a2b4bbcb90984f0_I20210331" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOmQ0ZjU1MGI2MDUwODQxZTg4MmUyNGViZGRhODU5MTE5L3RhYmxlcmFuZ2U6ZDRmNTUwYjYwNTA4NDFlODgyZTI0ZWJkZGE4NTkxMTlfNC0zLTEtMS0yNjY5_1ef59bd6-7d00-495f-92ba-8bcd24d2426e">388</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7cdd3ec3331046ec97e3ab5eeb7a43e0_I20210331" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOmQ0ZjU1MGI2MDUwODQxZTg4MmUyNGViZGRhODU5MTE5L3RhYmxlcmFuZ2U6ZDRmNTUwYjYwNTA4NDFlODgyZTI0ZWJkZGE4NTkxMTlfNC01LTEtMS0yNjcz_6ffd43f5-05b0-4e00-bdd9-da47e6058ed9">388</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2021</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice72f79525cf4aaa96a799b1808b8a8b_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOmQ0ZjU1MGI2MDUwODQxZTg4MmUyNGViZGRhODU5MTE5L3RhYmxlcmFuZ2U6ZDRmNTUwYjYwNTA4NDFlODgyZTI0ZWJkZGE4NTkxMTlfNC0xLTEtMS0w_31a693d2-9e23-4be7-a5d9-6ff0aceb8202">2,659</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33dcb67f0d874581b55d12fa93285854_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOmQ0ZjU1MGI2MDUwODQxZTg4MmUyNGViZGRhODU5MTE5L3RhYmxlcmFuZ2U6ZDRmNTUwYjYwNTA4NDFlODgyZTI0ZWJkZGE4NTkxMTlfNC0zLTEtMS0w_9ec8ea4e-42c5-49bf-840f-cc1536e0c8af">5,327</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOmQ0ZjU1MGI2MDUwODQxZTg4MmUyNGViZGRhODU5MTE5L3RhYmxlcmFuZ2U6ZDRmNTUwYjYwNTA4NDFlODgyZTI0ZWJkZGE4NTkxMTlfNC01LTEtMS0w_21f20969-a829-4128-8356-0db4344e3f7d">7,986</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the planned divestiture of our Cordis business, during the three months ended March 31, 2021, we allocated and reclassified $<ix:nonFraction unitRef="usd" contextRef="i7cdd3ec3331046ec97e3ab5eeb7a43e0_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RleHRyZWdpb246MzU5NWE5MGE0YmIwNGI2NzhkY2RkNzcwZjZjMzUwMGRfMzI5ODUzNDg4ODMwMg_954a771a-4b93-4caa-a4ed-9a2764360175">388</ix:nonFraction>&#160;million of goodwill from the Medical Unit (within our Medical Segment) to the Cordis disposal group based on the estimated relative fair values of the business to be disposed of and the portion of the reporting unit that will be retained, discussed further in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_1194">Note 2</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Intangible Assets</span></div><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RleHRyZWdpb246MzU5NWE5MGE0YmIwNGI2NzhkY2RkNzcwZjZjMzUwMGRfNTE1_f787796a-055c-4251-a4ad-f29598805116" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize other intangible assets by class at:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:24.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.070%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.409%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted- Average Remaining Amortization Period (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IPR&amp;D, trademarks and other</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib86a8f16995f4394b90a5c5d09547673_I20210331" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjQ5ZjUzYWUzZmM1MjQ3M2NhYmRmY2IyYzJkNDgyYTk3L3RhYmxlcmFuZ2U6NDlmNTNhZTNmYzUyNDczY2FiZGZjYjJjMmQ0ODJhOTdfMy0xLTEtMS0w_7baac895-289f-4893-8fc4-2b8cbe967701">12</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib86a8f16995f4394b90a5c5d09547673_I20210331" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjQ5ZjUzYWUzZmM1MjQ3M2NhYmRmY2IyYzJkNDgyYTk3L3RhYmxlcmFuZ2U6NDlmNTNhZTNmYzUyNDczY2FiZGZjYjJjMmQ0ODJhOTdfMy01LTEtMS0w_4179a66d-2a80-4640-94ba-478a6a424ac9">12</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjQ5ZjUzYWUzZmM1MjQ3M2NhYmRmY2IyYzJkNDgyYTk3L3RhYmxlcmFuZ2U6NDlmNTNhZTNmYzUyNDczY2FiZGZjYjJjMmQ0ODJhOTdfNC0xLTEtMS0w_0d288a12-088e-4535-93a1-737f97419b68">12</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjQ5ZjUzYWUzZmM1MjQ3M2NhYmRmY2IyYzJkNDgyYTk3L3RhYmxlcmFuZ2U6NDlmNTNhZTNmYzUyNDczY2FiZGZjYjJjMmQ0ODJhOTdfNC01LTEtMS0w_e35eb47b-b5cf-46f1-a85d-efa421b1acf9">12</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if58ac855c7a34cfa8030c801c94150d0_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjQ5ZjUzYWUzZmM1MjQ3M2NhYmRmY2IyYzJkNDgyYTk3L3RhYmxlcmFuZ2U6NDlmNTNhZTNmYzUyNDczY2FiZGZjYjJjMmQ0ODJhOTdfNy0xLTEtMS0w_8a10e0cb-22da-4157-bad6-e2ba32600d03">3,331</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if58ac855c7a34cfa8030c801c94150d0_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjQ5ZjUzYWUzZmM1MjQ3M2NhYmRmY2IyYzJkNDgyYTk3L3RhYmxlcmFuZ2U6NDlmNTNhZTNmYzUyNDczY2FiZGZjYjJjMmQ0ODJhOTdfNy0zLTEtMS0w_e7a76886-7a43-4af9-9a6c-ccbd70a501c4">1,925</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if58ac855c7a34cfa8030c801c94150d0_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjQ5ZjUzYWUzZmM1MjQ3M2NhYmRmY2IyYzJkNDgyYTk3L3RhYmxlcmFuZ2U6NDlmNTNhZTNmYzUyNDczY2FiZGZjYjJjMmQ0ODJhOTdfNy01LTEtMS0w_21a38ecb-4a36-42b0-a5bd-34895e2baf63">1,406</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ifb5b051f9d274a4db0185de02ba05dcb_D20200701-20210331" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjQ5ZjUzYWUzZmM1MjQ3M2NhYmRmY2IyYzJkNDgyYTk3L3RhYmxlcmFuZ2U6NDlmNTNhZTNmYzUyNDczY2FiZGZjYjJjMmQ0ODJhOTdfNy03LTEtMS0w_f20b6f5c-ff3b-4b51-8da8-1de710de5e50">11</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a9ff348b06a48ae9bb2eb719908affb_I20210331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjQ5ZjUzYWUzZmM1MjQ3M2NhYmRmY2IyYzJkNDgyYTk3L3RhYmxlcmFuZ2U6NDlmNTNhZTNmYzUyNDczY2FiZGZjYjJjMmQ0ODJhOTdfOC0xLTEtMS0w_e38f88d0-6feb-4227-9577-1936dc61540a">551</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a9ff348b06a48ae9bb2eb719908affb_I20210331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjQ5ZjUzYWUzZmM1MjQ3M2NhYmRmY2IyYzJkNDgyYTk3L3RhYmxlcmFuZ2U6NDlmNTNhZTNmYzUyNDczY2FiZGZjYjJjMmQ0ODJhOTdfOC0zLTEtMS0w_81da435f-61af-4151-bfa1-b3642f0c857e">319</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a9ff348b06a48ae9bb2eb719908affb_I20210331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjQ5ZjUzYWUzZmM1MjQ3M2NhYmRmY2IyYzJkNDgyYTk3L3RhYmxlcmFuZ2U6NDlmNTNhZTNmYzUyNDczY2FiZGZjYjJjMmQ0ODJhOTdfOC01LTEtMS0w_43add388-bec0-490e-a0a7-a5db86c5a28b">232</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ice8a5553e38b49b6ad19d2aaa439d996_D20200701-20210331" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjQ5ZjUzYWUzZmM1MjQ3M2NhYmRmY2IyYzJkNDgyYTk3L3RhYmxlcmFuZ2U6NDlmNTNhZTNmYzUyNDczY2FiZGZjYjJjMmQ0ODJhOTdfOC03LTEtMS0w_94ba132f-3627-408e-af6a-df63f98c8c61">9</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1197b65c014b476eb038f49933bfc8b8_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjQ5ZjUzYWUzZmM1MjQ3M2NhYmRmY2IyYzJkNDgyYTk3L3RhYmxlcmFuZ2U6NDlmNTNhZTNmYzUyNDczY2FiZGZjYjJjMmQ0ODJhOTdfOS0xLTEtMS0w_96a7eeae-a5c2-414c-b093-1227073d77c5">1,031</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1197b65c014b476eb038f49933bfc8b8_I20210331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjQ5ZjUzYWUzZmM1MjQ3M2NhYmRmY2IyYzJkNDgyYTk3L3RhYmxlcmFuZ2U6NDlmNTNhZTNmYzUyNDczY2FiZGZjYjJjMmQ0ODJhOTdfOS0zLTEtMS0w_c63925e7-abef-4188-ad3b-462afb925b1d">488</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1197b65c014b476eb038f49933bfc8b8_I20210331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjQ5ZjUzYWUzZmM1MjQ3M2NhYmRmY2IyYzJkNDgyYTk3L3RhYmxlcmFuZ2U6NDlmNTNhZTNmYzUyNDczY2FiZGZjYjJjMmQ0ODJhOTdfOS01LTEtMS0w_90c78239-9c01-40ef-994f-c3bf1b797014">543</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i3d099e35f5894d5e9a24b39c60d6719a_D20200701-20210331" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjQ5ZjUzYWUzZmM1MjQ3M2NhYmRmY2IyYzJkNDgyYTk3L3RhYmxlcmFuZ2U6NDlmNTNhZTNmYzUyNDczY2FiZGZjYjJjMmQ0ODJhOTdfOS03LTEtMS0w_f2c400ab-eefe-43d0-b57c-176984540b2f">10</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjQ5ZjUzYWUzZmM1MjQ3M2NhYmRmY2IyYzJkNDgyYTk3L3RhYmxlcmFuZ2U6NDlmNTNhZTNmYzUyNDczY2FiZGZjYjJjMmQ0ODJhOTdfMTAtMS0xLTEtMA_57f05783-4e7f-4f2f-9612-01c7586c2a2d">4,913</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjQ5ZjUzYWUzZmM1MjQ3M2NhYmRmY2IyYzJkNDgyYTk3L3RhYmxlcmFuZ2U6NDlmNTNhZTNmYzUyNDczY2FiZGZjYjJjMmQ0ODJhOTdfMTAtMy0xLTEtMA_7226e932-7c4a-41b2-a7a1-3766ca5b279a">2,732</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjQ5ZjUzYWUzZmM1MjQ3M2NhYmRmY2IyYzJkNDgyYTk3L3RhYmxlcmFuZ2U6NDlmNTNhZTNmYzUyNDczY2FiZGZjYjJjMmQ0ODJhOTdfMTAtNS0xLTEtMA_7c257c2b-2e01-4256-8d57-dc726a054162">2,181</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjQ5ZjUzYWUzZmM1MjQ3M2NhYmRmY2IyYzJkNDgyYTk3L3RhYmxlcmFuZ2U6NDlmNTNhZTNmYzUyNDczY2FiZGZjYjJjMmQ0ODJhOTdfMTAtNy0xLTEtMA_8c96e4f8-681f-4022-9633-ed8def836e1b">11</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjQ5ZjUzYWUzZmM1MjQ3M2NhYmRmY2IyYzJkNDgyYTk3L3RhYmxlcmFuZ2U6NDlmNTNhZTNmYzUyNDczY2FiZGZjYjJjMmQ0ODJhOTdfMTEtMS0xLTEtMA_deab5c41-c100-40f7-9ce6-7800335351c6">4,925</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjQ5ZjUzYWUzZmM1MjQ3M2NhYmRmY2IyYzJkNDgyYTk3L3RhYmxlcmFuZ2U6NDlmNTNhZTNmYzUyNDczY2FiZGZjYjJjMmQ0ODJhOTdfMTEtMy0xLTEtMA_15a86b0b-5ff0-4ee0-94df-9e48b5365558">2,732</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjQ5ZjUzYWUzZmM1MjQ3M2NhYmRmY2IyYzJkNDgyYTk3L3RhYmxlcmFuZ2U6NDlmNTNhZTNmYzUyNDczY2FiZGZjYjJjMmQ0ODJhOTdfMTEtNS0xLTEtMA_a824d4bc-a9ab-4f5e-abfb-fa8af2e6bacb">2,193</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:42.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.308%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.643%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.312%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IPR&amp;D, trademarks and other</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id75e1c542b0d4277aef6f4524dc533d0_I20200630" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjA4OWIwZWU4NWZlYjQ4Mzg5Yzc0NTVjZjcwMTk4MGU1L3RhYmxlcmFuZ2U6MDg5YjBlZTg1ZmViNDgzODljNzQ1NWNmNzAxOTgwZTVfMy0xLTEtMS0w_2f726d34-ed0b-4e47-a7aa-e91bdd03ed52">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id75e1c542b0d4277aef6f4524dc533d0_I20200630" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjA4OWIwZWU4NWZlYjQ4Mzg5Yzc0NTVjZjcwMTk4MGU1L3RhYmxlcmFuZ2U6MDg5YjBlZTg1ZmViNDgzODljNzQ1NWNmNzAxOTgwZTVfMy01LTEtMS0w_ade80b03-2d82-4ab1-a8d8-b93f77ce9b18">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjA4OWIwZWU4NWZlYjQ4Mzg5Yzc0NTVjZjcwMTk4MGU1L3RhYmxlcmFuZ2U6MDg5YjBlZTg1ZmViNDgzODljNzQ1NWNmNzAxOTgwZTVfNC0xLTEtMS0w_13b289d0-8ea6-46bf-a3a7-12c836e94775">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjA4OWIwZWU4NWZlYjQ4Mzg5Yzc0NTVjZjcwMTk4MGU1L3RhYmxlcmFuZ2U6MDg5YjBlZTg1ZmViNDgzODljNzQ1NWNmNzAxOTgwZTVfNC01LTEtMS0w_2601f059-09f8-4eb8-8b07-8bdf22597991">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4f1de5725004793a5eb735884c24d4e_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjA4OWIwZWU4NWZlYjQ4Mzg5Yzc0NTVjZjcwMTk4MGU1L3RhYmxlcmFuZ2U6MDg5YjBlZTg1ZmViNDgzODljNzQ1NWNmNzAxOTgwZTVfNy0xLTEtMS0w_eac396dd-5efd-4f26-b06c-d8f79c37ee1a">3,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4f1de5725004793a5eb735884c24d4e_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjA4OWIwZWU4NWZlYjQ4Mzg5Yzc0NTVjZjcwMTk4MGU1L3RhYmxlcmFuZ2U6MDg5YjBlZTg1ZmViNDgzODljNzQ1NWNmNzAxOTgwZTVfNy0zLTEtMS0w_cc51216a-4a1e-4eaa-9791-a9fab82f1fb6">1,828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4f1de5725004793a5eb735884c24d4e_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjA4OWIwZWU4NWZlYjQ4Mzg5Yzc0NTVjZjcwMTk4MGU1L3RhYmxlcmFuZ2U6MDg5YjBlZTg1ZmViNDgzODljNzQ1NWNmNzAxOTgwZTVfNy01LTEtMS0w_0ae6f645-f069-46d0-9f98-c768d4e39090">1,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc713be36ac74ca6995d6707e0fd4741_I20200630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjA4OWIwZWU4NWZlYjQ4Mzg5Yzc0NTVjZjcwMTk4MGU1L3RhYmxlcmFuZ2U6MDg5YjBlZTg1ZmViNDgzODljNzQ1NWNmNzAxOTgwZTVfOC0xLTEtMS0w_b3d9120c-c18e-4e70-b94b-5a200066c5c1">673</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc713be36ac74ca6995d6707e0fd4741_I20200630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjA4OWIwZWU4NWZlYjQ4Mzg5Yzc0NTVjZjcwMTk4MGU1L3RhYmxlcmFuZ2U6MDg5YjBlZTg1ZmViNDgzODljNzQ1NWNmNzAxOTgwZTVfOC0zLTEtMS0w_c0cedcf0-ce98-47c9-9bfd-fd5a06e152f3">341</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc713be36ac74ca6995d6707e0fd4741_I20200630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjA4OWIwZWU4NWZlYjQ4Mzg5Yzc0NTVjZjcwMTk4MGU1L3RhYmxlcmFuZ2U6MDg5YjBlZTg1ZmViNDgzODljNzQ1NWNmNzAxOTgwZTVfOC01LTEtMS0w_a9d00f61-b0cf-4d59-8aba-548d232c4a4c">332</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c1148a859034784a3e672c820ea0c9d_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjA4OWIwZWU4NWZlYjQ4Mzg5Yzc0NTVjZjcwMTk4MGU1L3RhYmxlcmFuZ2U6MDg5YjBlZTg1ZmViNDgzODljNzQ1NWNmNzAxOTgwZTVfOS0xLTEtMS0w_dd014c19-2827-4b0f-a6e3-64776ae90491">1,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c1148a859034784a3e672c820ea0c9d_I20200630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjA4OWIwZWU4NWZlYjQ4Mzg5Yzc0NTVjZjcwMTk4MGU1L3RhYmxlcmFuZ2U6MDg5YjBlZTg1ZmViNDgzODljNzQ1NWNmNzAxOTgwZTVfOS0zLTEtMS0w_ed8c6848-2a28-4d36-baaf-c06ab5a2dcb0">767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c1148a859034784a3e672c820ea0c9d_I20200630" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjA4OWIwZWU4NWZlYjQ4Mzg5Yzc0NTVjZjcwMTk4MGU1L3RhYmxlcmFuZ2U6MDg5YjBlZTg1ZmViNDgzODljNzQ1NWNmNzAxOTgwZTVfOS01LTEtMS0w_ef9f914c-6db8-4ef4-9512-58237c105261">837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjA4OWIwZWU4NWZlYjQ4Mzg5Yzc0NTVjZjcwMTk4MGU1L3RhYmxlcmFuZ2U6MDg5YjBlZTg1ZmViNDgzODljNzQ1NWNmNzAxOTgwZTVfMTAtMS0xLTEtMA_6b1babbe-98db-4ce2-b6cd-e18405590ed1">5,831</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjA4OWIwZWU4NWZlYjQ4Mzg5Yzc0NTVjZjcwMTk4MGU1L3RhYmxlcmFuZ2U6MDg5YjBlZTg1ZmViNDgzODljNzQ1NWNmNzAxOTgwZTVfMTAtMy0xLTEtMA_df2b0408-811f-46a6-9d97-eaae61a5f611">2,936</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjA4OWIwZWU4NWZlYjQ4Mzg5Yzc0NTVjZjcwMTk4MGU1L3RhYmxlcmFuZ2U6MDg5YjBlZTg1ZmViNDgzODljNzQ1NWNmNzAxOTgwZTVfMTAtNS0xLTEtMA_964eb98e-629e-4b58-85c9-715e338fc25e">2,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjA4OWIwZWU4NWZlYjQ4Mzg5Yzc0NTVjZjcwMTk4MGU1L3RhYmxlcmFuZ2U6MDg5YjBlZTg1ZmViNDgzODljNzQ1NWNmNzAxOTgwZTVfMTEtMS0xLTEtMA_cea658fc-047a-4801-ad42-715eb6fcc49f">5,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjA4OWIwZWU4NWZlYjQ4Mzg5Yzc0NTVjZjcwMTk4MGU1L3RhYmxlcmFuZ2U6MDg5YjBlZTg1ZmViNDgzODljNzQ1NWNmNzAxOTgwZTVfMTEtMy0xLTEtMA_36a09b00-3f2d-408b-b28b-9917c6f42238">2,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjA4OWIwZWU4NWZlYjQ4Mzg5Yzc0NTVjZjcwMTk4MGU1L3RhYmxlcmFuZ2U6MDg5YjBlZTg1ZmViNDgzODljNzQ1NWNmNzAxOTgwZTVfMTEtNS0xLTEtMA_c5fe8704-d1af-4ce9-bee9-e028a1fd7f09">2,918</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total amortization of intangible assets was $<ix:nonFraction unitRef="usd" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RleHRyZWdpb246MzU5NWE5MGE0YmIwNGI2NzhkY2RkNzcwZjZjMzUwMGRfMjY1_959727a6-b112-473e-b0c3-02c60c2c947b">109</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RleHRyZWdpb246MzU5NWE5MGE0YmIwNGI2NzhkY2RkNzcwZjZjMzUwMGRfMjcy_92165799-f39a-4885-9640-e071a144e731">129</ix:nonFraction> million for the three months ended March 31, 2021 and 2020, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RleHRyZWdpb246MzU5NWE5MGE0YmIwNGI2NzhkY2RkNzcwZjZjMzUwMGRfMzMx_0c43305d-f2d9-4d45-8aa9-ef5b38397781">337</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RleHRyZWdpb246MzU5NWE5MGE0YmIwNGI2NzhkY2RkNzcwZjZjMzUwMGRfMzM4_f8bc277d-d945-426d-a6f0-6fb10b6a2f55">385</ix:nonFraction> million for the nine months ended March&#160;31, 2021 and 2020, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2021 through 2025 is as follows: $<ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RleHRyZWdpb246MzU5NWE5MGE0YmIwNGI2NzhkY2RkNzcwZjZjMzUwMGRfNDg1_697753d1-6c5b-41a4-8104-7472aa6acf45">91</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RleHRyZWdpb246MzU5NWE5MGE0YmIwNGI2NzhkY2RkNzcwZjZjMzUwMGRfNDg5_2bf69b09-e59c-4007-a71c-f947f1349cb5">314</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RleHRyZWdpb246MzU5NWE5MGE0YmIwNGI2NzhkY2RkNzcwZjZjMzUwMGRfNDkz_07b5319a-ace8-479d-8ec8-2a9791f4cf3a">287</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RleHRyZWdpb246MzU5NWE5MGE0YmIwNGI2NzhkY2RkNzcwZjZjMzUwMGRfNDk3_07afe53a-ce5f-4d42-a671-7964ebc4eb72">263</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RleHRyZWdpb246MzU5NWE5MGE0YmIwNGI2NzhkY2RkNzcwZjZjMzUwMGRfNTA0_624480c3-f64c-4a9e-a5be-0245832ae7a1">238</ix:nonFraction> million.</span></div></div></ix:nonNumeric></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">36</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:6pt;text-align:justify"><ix:continuation id="i61d88a99e3f24e9c84e3c931cfe3ab91"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, other intangible assets of $<ix:nonFraction unitRef="usd" contextRef="i7cdd3ec3331046ec97e3ab5eeb7a43e0_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RleHRyZWdpb246MzU5NWE5MGE0YmIwNGI2NzhkY2RkNzcwZjZjMzUwMGRfNTQ5NzU1ODE0NTY0Mw_b0ff5ac5-a916-43c7-8360-9326e173bbd6">391</ix:nonFraction> million was reclassified to assets held for sale in connection with the planned divestiture of our Cordis business, discussed further in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_1194">Note 2</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></ix:continuation></div><div id="ib6bf45669ad94861b0c50dbc2f4371ce_94"></div><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85NC9mcmFnOjQxMWM1N2FkMjg3ZjRlYjJhMDIyMDllODY4NDg3YWU4L3RleHRyZWdpb246NDExYzU3YWQyODdmNGViMmEwMjIwOWU4Njg0ODdhZThfMjM3MQ_abaaa361-5426-4bd2-99eb-7fe100137ece" continuedAt="i026d9be25624498a858fb4545d74ef9b" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">5. Long-Term Obligations and Other Short-Term Borrowings</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Long-Term Debt and Other Short-Term Borrowings</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2021 and June&#160;30, 2020, we had total long-term obligations, including the current portion and other short-term borrowings, of $<ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-8" format="ixt:numdotdecimal" name="cah:TotalLongTermandShortTermObligations" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85NC9mcmFnOjQxMWM1N2FkMjg3ZjRlYjJhMDIyMDllODY4NDg3YWU4L3RleHRyZWdpb246NDExYzU3YWQyODdmNGViMmEwMjIwOWU4Njg0ODdhZThfMTcx_d124ec3e-6d5b-4675-b747-edef4094bd21">6.7</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="-8" format="ixt:numdotdecimal" name="cah:TotalLongTermandShortTermObligations" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85NC9mcmFnOjQxMWM1N2FkMjg3ZjRlYjJhMDIyMDllODY4NDg3YWU4L3RleHRyZWdpb246NDExYzU3YWQyODdmNGViMmEwMjIwOWU4Njg0ODdhZThfMTc4_f4528731-9a98-4afc-9cd4-9448feca7de0">6.8</ix:nonFraction> billion, respectively. All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These obligations are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $<ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrentAndNoncurrent" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85NC9mcmFnOjQxMWM1N2FkMjg3ZjRlYjJhMDIyMDllODY4NDg3YWU4L3RleHRyZWdpb246NDExYzU3YWQyODdmNGViMmEwMjIwOWU4Njg0ODdhZThfNTU3_61747931-bd91-44d9-8589-bd1a1e322b17">22.6</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="-8" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrentAndNoncurrent" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85NC9mcmFnOjQxMWM1N2FkMjg3ZjRlYjJhMDIyMDllODY4NDg3YWU4L3RleHRyZWdpb246NDExYzU3YWQyODdmNGViMmEwMjIwOWU4Njg0ODdhZThfNTY0_dd65287c-3a67-4494-ae32-2cb824d0c34d">21.4</ix:nonFraction> billion at March&#160;31, 2021 and June&#160;30, 2020, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March&#160;31, 2021, we early repurchased $<ix:nonFraction unitRef="usd" contextRef="icdab92a7a6fd41b39bd57e54be7e769f_D20200701-20210331" decimals="-6" format="ixt:numdotdecimal" name="cah:NotesPayableRepurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85NC9mcmFnOjQxMWM1N2FkMjg3ZjRlYjJhMDIyMDllODY4NDg3YWU4L3RleHRyZWdpb246NDExYzU3YWQyODdmNGViMmEwMjIwOWU4Njg0ODdhZThfNjM0_2237b9cb-23fe-4765-b1c4-10a5461daa72">40</ix:nonFraction> million of the Floating Rate Notes due 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $<ix:nonFraction unitRef="usd" contextRef="i9f3611b603314fb097f4abad927ac3d9_D20200701-20210331" decimals="-6" format="ixt:numdotdecimal" name="cah:NotesPayableRepurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85NC9mcmFnOjQxMWM1N2FkMjg3ZjRlYjJhMDIyMDllODY4NDg3YWU4L3RleHRyZWdpb246NDExYzU3YWQyODdmNGViMmEwMjIwOWU4Njg0ODdhZThfNjUx_a33973dd-18cd-413a-ac92-3bda1d8c16eb">2</ix:nonFraction> million of the 2.616% Notes due 2022. The repurchases were paid for with available cash. In connection with the early debt repurchases, we recorded a $<ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85NC9mcmFnOjQxMWM1N2FkMjg3ZjRlYjJhMDIyMDllODY4NDg3YWU4L3RleHRyZWdpb246NDExYzU3YWQyODdmNGViMmEwMjIwOWU4Njg0ODdhZThfNzc3_f9c789fa-182d-4ece-8f7b-99ddda8d1470">1</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">loss on early extinguishment of debt during the nine months ended March&#160;31, 2021. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we repaid the full principal of the 2.4% Notes due 2019 at maturity for $<ix:nonFraction unitRef="usd" contextRef="i504e4cad981b4ed993b975460c7fc7ac_D20190701-20200331" decimals="-6" format="ixt:numdotdecimal" name="cah:NotesPayableRepurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85NC9mcmFnOjQxMWM1N2FkMjg3ZjRlYjJhMDIyMDllODY4NDg3YWU4L3RleHRyZWdpb246NDExYzU3YWQyODdmNGViMmEwMjIwOWU4Njg0ODdhZThfOTQw_3a55296e-fd39-47f3-90c9-b7632d45eda2">450</ix:nonFraction>&#160;million. During the nine months ended March 31, 2020, we early repurchased $<ix:nonFraction unitRef="usd" contextRef="ia090211208aa441088c4d8069f02dbfb_D20190701-20200331" decimals="-6" format="ixt:numdotdecimal" name="cah:NotesPayableRepurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85NC9mcmFnOjQxMWM1N2FkMjg3ZjRlYjJhMDIyMDllODY4NDg3YWU4L3RleHRyZWdpb246NDExYzU3YWQyODdmNGViMmEwMjIwOWU4Njg0ODdhZThfOTk4_74aa96b9-34ca-4bf1-9f70-9c4c624821eb">247</ix:nonFraction>&#160;million of the 2.616% Notes due 2022, $<ix:nonFraction unitRef="usd" contextRef="i49a27c7578bd41088dddfb606868d281_D20190701-20200331" decimals="-6" format="ixt:numdotdecimal" name="cah:NotesPayableRepurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85NC9mcmFnOjQxMWM1N2FkMjg3ZjRlYjJhMDIyMDllODY4NDg3YWU4L3RleHRyZWdpb246NDExYzU3YWQyODdmNGViMmEwMjIwOWU4Njg0ODdhZThfMTAxMg_bc6c83b1-2c02-4381-909d-c61e26cac6fd">11</ix:nonFraction>&#160;million of the 3.2% Notes due 2022, $<ix:nonFraction unitRef="usd" contextRef="ia6234f8623c6430bb624a2926a712aa6_D20190701-20200331" decimals="-6" format="ixt:numdotdecimal" name="cah:NotesPayableRepurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85NC9mcmFnOjQxMWM1N2FkMjg3ZjRlYjJhMDIyMDllODY4NDg3YWU4L3RleHRyZWdpb246NDExYzU3YWQyODdmNGViMmEwMjIwOWU4Njg0ODdhZThfMTAyNg_f0c8820c-8fd1-4253-a53d-29d691666916">20</ix:nonFraction>&#160;million of the Floating Rate Notes due 2022, $<ix:nonFraction unitRef="usd" contextRef="if1eda4e509ce43798df227d81709d323_D20190701-20200331" decimals="-6" format="ixt:numdotdecimal" name="cah:NotesPayableRepurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85NC9mcmFnOjQxMWM1N2FkMjg3ZjRlYjJhMDIyMDllODY4NDg3YWU4L3RleHRyZWdpb246NDExYzU3YWQyODdmNGViMmEwMjIwOWU4Njg0ODdhZThfMTA0MA_cc687cf5-e02d-448b-a959-64f0344803b0">104</ix:nonFraction>&#160;million of the 3.41% Notes due 2027, $<ix:nonFraction unitRef="usd" contextRef="i6db532c36ac040349356f496d49a51e5_D20190701-20200331" decimals="-6" format="ixt:numdotdecimal" name="cah:NotesPayableRepurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85NC9mcmFnOjQxMWM1N2FkMjg3ZjRlYjJhMDIyMDllODY4NDg3YWU4L3RleHRyZWdpb246NDExYzU3YWQyODdmNGViMmEwMjIwOWU4Njg0ODdhZThfMTA1NA_0a42897d-73db-403b-9a36-47ac6555ef0d">6</ix:nonFraction>&#160;million of the 4.6% Notes due 2043, $<ix:nonFraction unitRef="usd" contextRef="ia3cfcd32bbbd409a8721be1d572e5196_D20190701-20200331" decimals="-6" format="ixt:numdotdecimal" name="cah:NotesPayableRepurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85NC9mcmFnOjQxMWM1N2FkMjg3ZjRlYjJhMDIyMDllODY4NDg3YWU4L3RleHRyZWdpb246NDExYzU3YWQyODdmNGViMmEwMjIwOWU4Njg0ODdhZThfMTA2Nw_d913183f-caa8-4cab-a6d7-90525243f592">5</ix:nonFraction>&#160;million of the 4.9% Notes due 2045, and $<ix:nonFraction unitRef="usd" contextRef="i47aa282752004df79e631b50e9d85ec0_D20190701-20200331" decimals="-6" format="ixt:numdotdecimal" name="cah:NotesPayableRepurchased" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85NC9mcmFnOjQxMWM1N2FkMjg3ZjRlYjJhMDIyMDllODY4NDg3YWU4L3RleHRyZWdpb246NDExYzU3YWQyODdmNGViMmEwMjIwOWU4Njg0ODdhZThfMTA4NQ_9b2a0aab-3e69-42ef-8237-ab7029cf93d7">35</ix:nonFraction>&#160;million of the 4.368% Notes due 2047. The repurchases were paid for with available cash and other short-term borrowings. In connection with the early debt repurchases, we recorded a $<ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85NC9mcmFnOjQxMWM1N2FkMjg3ZjRlYjJhMDIyMDllODY4NDg3YWU4L3RleHRyZWdpb246NDExYzU3YWQyODdmNGViMmEwMjIwOWU4Njg0ODdhZThfMzI5ODUzNDg4NTg0Nw_28401bbc-51b3-4b63-8256-4c0e3d11ddf1">9</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">loss on early extinguishment of debt during the nine months ended March 31, 2020. </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Financing Arrangements</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to cash and equivalents and operating cash flow, other sources of liquidity include a&#160;$<ix:nonFraction unitRef="usd" contextRef="i78b6ef34025b4452a5b896401fa40e7c_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85NC9mcmFnOjQxMWM1N2FkMjg3ZjRlYjJhMDIyMDllODY4NDg3YWU4L3RleHRyZWdpb246NDExYzU3YWQyODdmNGViMmEwMjIwOWU4Njg0ODdhZThfMTQ2OA_c4ebdbea-730b-449c-85f8-b8e728ec344e">2.0</ix:nonFraction> billion&#160;commercial paper program backed by a $<ix:nonFraction unitRef="usd" contextRef="i5f24903888fe442faadd663a0aba2ff7_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85NC9mcmFnOjQxMWM1N2FkMjg3ZjRlYjJhMDIyMDllODY4NDg3YWU4L3RleHRyZWdpb246NDExYzU3YWQyODdmNGViMmEwMjIwOWU4Njg0ODdhZThfMTUwOA_d4a77e0d-490b-4430-b1b0-0b92d682fd23">2.0</ix:nonFraction> billion&#160;revolving credit facility. We also have a&#160;$<ix:nonFraction unitRef="usd" contextRef="i604f1c37ba004bdaa7f5e22b3f373f12_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85NC9mcmFnOjQxMWM1N2FkMjg3ZjRlYjJhMDIyMDllODY4NDg3YWU4L3RleHRyZWdpb246NDExYzU3YWQyODdmNGViMmEwMjIwOWU4Njg0ODdhZThfMTU1Mw_5b3f4ef8-6709-454f-821d-7c1fe6a680c9">1.0</ix:nonFraction> billion&#160;committed receivables sales facility. At&#160;March&#160;31, 2021, we had no amounts outstanding under our commercial paper program, revolving credit facility, or our committed receivables sales facility.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (&#8220;CHF&#8221;) through September 30, 2022. CHF was organized for</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health, Inc. in accordance with GAAP, CHF is a separate legal entity from Cardinal Health, Inc. and from our </span></div></ix:nonNumeric></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i026d9be25624498a858fb4545d74ef9b" continuedAt="i1d9a8312ed304961a4f372d637b7163c">subsidiary that sells receivables to CHF. CHF is designed to be a special purpose, bankruptcy-remote entity whose assets are available solely to satisfy the claims of its creditors. </ix:continuation></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1d9a8312ed304961a4f372d637b7163c">Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1 beginning March 2021. As of March&#160;31, 2021, we were in compliance with this financial covenant.</ix:continuation> </span></div><div id="ib6bf45669ad94861b0c50dbc2f4371ce_97"></div><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85Ny9mcmFnOjQyNjdmNTQxNzNkZjQzM2JiOWMyNjI4YzE2MzY3OWIzL3RleHRyZWdpb246NDI2N2Y1NDE3M2RmNDMzYmI5YzI2MjhjMTYzNjc5YjNfMTU0MTM_caa3bc9b-093f-4b61-b64e-81167e390c95" continuedAt="ie7a18dd8253d4613879835aa9a5dc871" escape="true"><div style="margin-bottom:6pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">6. Commitments, Contingent Liabilities and Litigation</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commitments</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Generic Sourcing Venture with CVS Health Corporation ("CVS Health")</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of <ix:nonNumeric contextRef="i33f590b1fd8b44a8a08a2e3ea0f1b1bd_D20200701-20210331" format="ixt-sec:duryear" name="us-gaap:LongtermPurchaseCommitmentPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85Ny9mcmFnOjQyNjdmNTQxNzNkZjQzM2JiOWMyNjI4YzE2MzY3OWIzL3RleHRyZWdpb246NDI2N2Y1NDE3M2RmNDMzYmI5YzI2MjhjMTYzNjc5YjNfMjU0_65f1704c-ba10-4862-9bd2-540e751fa150">10</ix:nonNumeric> years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. Due to the achievement of predetermined milestones, we are required to make quarterly payments of $<ix:nonFraction unitRef="usd" contextRef="i33f590b1fd8b44a8a08a2e3ea0f1b1bd_D20200701-20210331" decimals="-5" format="ixt:numdotdecimal" name="cah:MaximumQuarterlyPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85Ny9mcmFnOjQyNjdmNTQxNzNkZjQzM2JiOWMyNjI4YzE2MzY3OWIzL3RleHRyZWdpb246NDI2N2Y1NDE3M2RmNDMzYmI5YzI2MjhjMTYzNjc5YjNfNDU1_1fc3792b-6506-42a1-830d-24451d5e1563">45.6</ix:nonFraction> million to CVS Health for the remainder of the initial term.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New York Opioid Stewardship Act</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the State of New York passed a budget which included the Opioid Stewardship Act (the "OSA"). The OSA created an aggregate $<ix:nonFraction unitRef="usd" contextRef="i6c69ca015f5c476994fba9d5d8aef33b_I20210331" decimals="-6" format="ixt:numdotdecimal" name="cah:AggregateAnnualAssessment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85Ny9mcmFnOjQyNjdmNTQxNzNkZjQzM2JiOWMyNjI4YzE2MzY3OWIzL3RleHRyZWdpb246NDI2N2Y1NDE3M2RmNDMzYmI5YzI2MjhjMTYzNjc5YjNfNjk0_7f1c844b-5f9f-4e21-b880-38f7c3333b3b">100</ix:nonFraction>&#160;million annual assessment on all manufacturers and distributors licensed to sell or distribute opioids in New York. Under the OSA, each licensed manufacturer and distributor would be required to pay a portion of the assessment based on its share of the total morphine milligram equivalents sold or distributed in New York during the applicable calendar year, beginning in 2017.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The constitutionality of portions of the OSA has been challenged in court. In December 2018, the OSA was ruled unconstitutional by the U.S. district court for the Southern District of New York. Subsequently, New York passed a new statute that modified the assessment going forward and limited the OSA to two years (2017 and 2018). The U.S. Court of Appeals for the Second Circuit reversed the district court's decision on procedural grounds. In February 2021, the Second Circuit stayed the effect of the ruling pending a petition to the U.S. Supreme Court to review the Second Circuit's opinion. If the U.S. Supreme Court declines to take the case, or if it ultimately upholds the Second Circuit's ruling, New York State would likely seek to collect amounts allegedly owed under the OSA. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue contingencies if it is probable that a liability has been incurred and the amount can be estimated. Because of the Second Circuit ruling, we recorded an aggregate accrual of $<ix:nonFraction unitRef="usd" contextRef="i12b52de2a6014b01b5857d8d032e2d95_D20200701-20210331" decimals="-6" format="ixt:numdotdecimal" name="cah:EstimatedLiabilityForNewYorkOpioidStewardshipAct" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85Ny9mcmFnOjQyNjdmNTQxNzNkZjQzM2JiOWMyNjI4YzE2MzY3OWIzL3RleHRyZWdpb246NDI2N2Y1NDE3M2RmNDMzYmI5YzI2MjhjMTYzNjc5YjNfMTgwNQ_4d568cce-2a74-47b4-ae93-bff4145093b7">41</ix:nonFraction>&#160;million for calendar year 2017 and 2018 in the nine months ended March 31, 2021 based on the estimated payment amount, which is our best estimate of the OSA payments probable at March 31, 2021.</span></div></ix:nonNumeric></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><ix:continuation id="ie7a18dd8253d4613879835aa9a5dc871" continuedAt="i2a68189fcea3420eb438b29845ef3c24"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We become involved from time to time in disputes, litigation and regulatory matters.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we determine that products we source, manufacture or market do not meet our specifications, regulatory requirements, or published standards. When we or a regulatory agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions have led to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, product liability claims and lawsuits and can lead to action by regulators. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we become aware through employees, internal audits or other parties of possible compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.</span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges in our condensed consolidated statements of earnings/(loss).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opioid Lawsuits and Investigations</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical wholesale distributors, including us, have been named as defendants in approximately <ix:nonFraction unitRef="number" contextRef="ia2b0385b5ab44d27a7dc86dee405b359_I20210503" decimals="0" format="ixt:numdotdecimal" name="cah:LossContingencyLawsuitsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85Ny9mcmFnOjQyNjdmNTQxNzNkZjQzM2JiOWMyNjI4YzE2MzY3OWIzL3RleHRyZWdpb246NDI2N2Y1NDE3M2RmNDMzYmI5YzI2MjhjMTYzNjc5YjNfNTQwNQ_56f44e5f-53aa-49e1-8c19-753a566e8e59">3,300</ix:nonFraction> lawsuits relating to the distribution of prescription opioid pain medications. The lawsuits seek equitable relief and monetary damages based on a variety of legal theories including various common law claims, such as public nuisance, negligence and unjust enrichment as well as violations of controlled substance laws, the Racketeer Influenced and Corrupt Organizations Act and various other statutes. These lawsuits also name pharmaceutical manufacturers, retail pharmacy chains and other entities as defendants.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">States &amp; Political Subdivisions</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately <ix:nonFraction unitRef="number" contextRef="i3cc62b61cd8d43428ee9e8e27d88fc65_I20210503" decimals="0" format="ixt:numdotdecimal" name="cah:LossContingencyLawsuitsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85Ny9mcmFnOjQyNjdmNTQxNzNkZjQzM2JiOWMyNjI4YzE2MzY3OWIzL3RleHRyZWdpb246NDI2N2Y1NDE3M2RmNDMzYmI5YzI2MjhjMTYzNjc5YjNfNTk2OA_0d39cca5-0b22-4291-9657-8e1f5b614c49">2,800</ix:nonFraction> of these lawsuits have been filed by counties, municipalities, cities and political subdivisions in various federal, state, and other courts. The vast majority of these lawsuits were filed in U.S. federal court and have been transferred for consolidated pre-trial proceedings in a Multi-District Litigation proceeding in the U.S. District Court for the Northern District of Ohio (the &#8220;MDL&#8221;).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, <ix:nonFraction unitRef="stateag" contextRef="ia2b0385b5ab44d27a7dc86dee405b359_I20210503" decimals="0" name="cah:NumberofStateAttorneysGeneralfilinglawsuits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85Ny9mcmFnOjQyNjdmNTQxNzNkZjQzM2JiOWMyNjI4YzE2MzY3OWIzL3RleHRyZWdpb246NDI2N2Y1NDE3M2RmNDMzYmI5YzI2MjhjMTYzNjc5YjNfNjM3Ng_94158410-37b3-42b4-abdd-ec901f4c34d1">25</ix:nonFraction> state attorneys general have filed lawsuits against distributors, including us, in various state courts. We have also received requests, civil investigative demands, subpoenas or requests for information from additional state attorneys general offices and governmental authorities. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, we agreed in principle to a global settlement framework with a leadership group of state attorneys general; the framework is designed to resolve pending and future opioid lawsuits and claims by states and political subdivisions, but not private plaintiffs (the "Settlement Framework"). This Settlement Framework is the basis for the continued negotiation of definitive terms and documentation. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these discussions, we have recorded total pre-tax charges of $<ix:nonFraction unitRef="usd" contextRef="ib9e03386e8bb45b9bfa0b58a7c283f07_D20200701-20210331" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85Ny9mcmFnOjQyNjdmNTQxNzNkZjQzM2JiOWMyNjI4YzE2MzY3OWIzL3RleHRyZWdpb246NDI2N2Y1NDE3M2RmNDMzYmI5YzI2MjhjMTYzNjc5YjNfNzUwMw_089202f4-34a0-4f24-b2a6-730e01801ccc">1.02</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="i32ccdaa0f4af4c919f10cbbfa4cc9a79_D20190701-20200331" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85Ny9mcmFnOjQyNjdmNTQxNzNkZjQzM2JiOWMyNjI4YzE2MzY3OWIzL3RleHRyZWdpb246NDI2N2Y1NDE3M2RmNDMzYmI5YzI2MjhjMTYzNjc5YjNfNzUxMA_8ef151f9-98cc-4148-a8a2-1e0e26e2206b">5.63</ix:nonFraction>&#160;billion in litigation charges/(recoveries), net in the nine months ended March&#160;31, 2021 and 2020, respectively. In total, we have $<ix:nonFraction unitRef="usd" contextRef="i9f40d9e3a7db48b09daa5018d3017966_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LitigationReserve" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85Ny9mcmFnOjQyNjdmNTQxNzNkZjQzM2JiOWMyNjI4YzE2MzY3OWIzL3RleHRyZWdpb246NDI2N2Y1NDE3M2RmNDMzYmI5YzI2MjhjMTYzNjc5YjNfNzYzNw_274c7e5a-d354-4268-8041-230dd1e234ae">6.59</ix:nonFraction>&#160;billion accrued at March&#160;31, 2021, included in deferred income taxes and other liabilities in the condensed consolidated balance sheets, which represents the cash component. We are unable to estimate the range of possible loss associated with these matters. Definitive terms for a settlement pursuant to the Settlement Framework continue to be negotiated, and there is no assurance that the necessary parties will agree to a definitive settlement agreement or that the contingencies to any agreement will be satisfied. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of </span></div></div></ix:continuation></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><ix:continuation id="i2a68189fcea3420eb438b29845ef3c24" continuedAt="ib2ce1b316a4049298535cd01733c1f02"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ultimate loss may differ materially from this accrual, whether as a result of settlement discussions, a judicial decision or verdict or otherwise, but we are not able to estimate a range of reasonably possible additional losses for these matters. We continue to strongly dispute the allegations made in these lawsuits and reaching an agreement in principle on a global settlement framework is not an admission of liability or wrongdoing.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although COVID-19 continues to cause some uncertainty with respect to trial dates, trials are resuming in certain jurisdictions. A trial in West Virginia in the Cabell County and City of Huntington cases began on May 3, 2021. A liability-only trial in the cases brought by the New York Attorney General and Nassau and Suffolk Counties is currently scheduled for June 2021 and trials in the cases brought by the Ohio and Washington Attorneys General are scheduled to begin in September 2021. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Private Plaintiffs</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Settlement Framework does not address claims by private parties, which includes unions and other health and welfare funds, hospital systems and other healthcare providers, businesses and individuals. Private parties had brought approximately <ix:nonFraction unitRef="lawsuit" contextRef="i7e4a5266c9ee4255be61beea0051e346_I20210503" decimals="0" name="cah:LossContingencyLawsuitsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85Ny9mcmFnOjQyNjdmNTQxNzNkZjQzM2JiOWMyNjI4YzE2MzY3OWIzL3RleHRyZWdpb246NDI2N2Y1NDE3M2RmNDMzYmI5YzI2MjhjMTYzNjc5YjNfODk2OQ_fae07bd6-f069-4029-820a-ad67802908cd">430</ix:nonFraction> lawsuits as of May 3, 2021. Of these, <ix:nonFraction unitRef="lawsuit" contextRef="i807f09109de94752a25bb7a0eae4766f_I20210503" decimals="0" name="cah:LossContingencyLawsuitsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85Ny9mcmFnOjQyNjdmNTQxNzNkZjQzM2JiOWMyNjI4YzE2MzY3OWIzL3RleHRyZWdpb246NDI2N2Y1NDE3M2RmNDMzYmI5YzI2MjhjMTYzNjc5YjNfOTAxNQ_f770185c-24a0-4e22-a422-8cb22c2d6af7">127</ix:nonFraction> are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs. A trial in one case is currently scheduled to begin in October 2021; however trial dates remain uncertain due in part to circumstances arising from the COVID-19 pandemic. We are vigorously defending ourselves in these matters.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Insurance Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in legal proceedings with two insurers related to the availability of insurance coverage for the lawsuits described above. In October 2020, we filed a complaint for declaratory judgment against National Union Fire Insurance Company of Pittsburgh, PA (&#8220;National Union&#8221;) seeking a declaration that National Union is obligated to reimburse us for defense costs incurred in connection with the lawsuits described above. In January, 2021, Swiss Re International SE commenced an arbitration in London seeking a determination that it does not have an obligation to reimburse us for defense and indemnity expenses incurred in connection with the lawsuits described above. We have not recorded a receivable for any recoveries related to these insurance litigation matters as of March 31, 2021.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Department of Justice Investigations</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received federal grand jury subpoenas issued in connection with investigations being conducted by the U.S. Attorney's Office for the Eastern District of New York and the Fraud Section of the U.S. Department of Justice ("DOJ"). We have also received civil requests for information from other DOJ offices. We believe that these investigations concern operation of our anti-diversion program, our anti-diversion policies and procedures, and distribution of certain controlled substances. We are cooperating with these requests. We are unable to predict the outcome of any of these investigations. </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cordis Product Liability Lawsuits</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of May 3, 2021, we are named as a defendant in <ix:nonFraction unitRef="lawsuit" contextRef="ica111f2089a54b038384fbd2c3ed75c2_D20210503-20210503" decimals="0" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85Ny9mcmFnOjQyNjdmNTQxNzNkZjQzM2JiOWMyNjI4YzE2MzY3OWIzL3RleHRyZWdpb246NDI2N2Y1NDE3M2RmNDMzYmI5YzI2MjhjMTYzNjc5YjNfMTAzOTA_8b6d0ddd-e364-4866-89f7-bf2f31a4a903">396</ix:nonFraction> product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by approximately <ix:nonFraction unitRef="plaintiff" contextRef="i1bf34677339c4ce196bf82617b72b6c2_D20210503-20210503" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85Ny9mcmFnOjQyNjdmNTQxNzNkZjQzM2JiOWMyNjI4YzE2MzY3OWIzL3RleHRyZWdpb246NDI2N2Y1NDE3M2RmNDMzYmI5YzI2MjhjMTYzNjc5YjNfMTA1MTM_ffd82853-505b-4066-9796-98cbde942224">5,046</ix:nonFraction> plaintiffs that allege personal injuries associated with the use of Cordis OptEase and TrapEase inferior vena cava ("IVC") filter products. Another <ix:nonFraction unitRef="lawsuit" contextRef="i0c6a6bb892f345c4b3edac4aec0d217d_D20210503-20210503" decimals="0" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85Ny9mcmFnOjQyNjdmNTQxNzNkZjQzM2JiOWMyNjI4YzE2MzY3OWIzL3RleHRyZWdpb246NDI2N2Y1NDE3M2RmNDMzYmI5YzI2MjhjMTYzNjc5YjNfMTA2NjQ_ffa86e44-38db-43c7-a322-76c2862d9624">31</ix:nonFraction> lawsuits involving similar claims by approximately <ix:nonFraction unitRef="plaintiff" contextRef="i22d9e3f7ffff422283088171ae8c7f53_D20210503-20210503" decimals="0" name="us-gaap:LossContingencyNumberOfPlaintiffs" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85Ny9mcmFnOjQyNjdmNTQxNzNkZjQzM2JiOWMyNjI4YzE2MzY3OWIzL3RleHRyZWdpb246NDI2N2Y1NDE3M2RmNDMzYmI5YzI2MjhjMTYzNjc5YjNfMTA3MTg_088346ad-306a-4b39-997b-529b5ddae36c">36</ix:nonFraction> plaintiffs are pending in other jurisdictions. These lawsuits seek a variety of remedies, including unspecified monetary damages. We continue to vigorously defend ourselves in these lawsuits and are engaged in resolution discussions with certain plaintiffs. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2021, we had a total of $<ix:nonFraction unitRef="usd" contextRef="i39e08dcc3f9f4795a07a40686f4f773d_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85Ny9mcmFnOjQyNjdmNTQxNzNkZjQzM2JiOWMyNjI4YzE2MzY3OWIzL3RleHRyZWdpb246NDI2N2Y1NDE3M2RmNDMzYmI5YzI2MjhjMTYzNjc5YjNfMTEwMDU_afdc15dc-f21c-4dcd-a475-e5da99a11ee9">514</ix:nonFraction> million net of estimated insurance recoveries, accrued for losses and legal defense costs related to the Cordis IVC filter lawsuits which are presented on a gross basis in the condensed consolidated balance sheets. We believe there is a range of estimated losses with respect to these matters. Because no amount within the range is a better estimate than any other amount within the range, we have accrued the minimum amount in the range. We estimate the high end of the range to be approximately $<ix:nonFraction unitRef="usd" contextRef="i901bacdc1d384d90bd9435b24ae9e637_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85Ny9mcmFnOjQyNjdmNTQxNzNkZjQzM2JiOWMyNjI4YzE2MzY3OWIzL3RleHRyZWdpb246NDI2N2Y1NDE3M2RmNDMzYmI5YzI2MjhjMTYzNjc5YjNfMTE0OTc_98d9a4d5-6a2d-40f0-ba65-69226c4cbeed">1.01</ix:nonFraction> billion, net of estimated insurance recoveries. The sale of the Cordis disposal group does not include product liability related to the IVC filters in the U.S. and Canada, which we will retain. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SEC Investigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, we received a subpoena from the U.S. Securities and Exchange Commission requesting the production of documents from 2015 through 2019 relating to inventory in the Cordis business, analysis of goodwill of the Medical segment and other matters. We are cooperating with this inquiry and cannot predict its outcome or duration. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholder Securities Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Louisiana Sheriffs' Pension &amp; Relief Fund filed a purported class action complaint against Cardinal Health and certain current and former officers and employees in the United States District Court for the Southern District of Ohio purportedly on behalf of all purchasers of our common shares between March 2015 and May 2018. In June 2020, the court appointed 1199 SEIU Health Care Employees Pension Fund as lead plaintiff and a consolidated amended complaint was filed in September 2020. The amended complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities and Exchange Act of 1934 by making misrepresentations and omissions related to the acquisition integration of the Cordis business and inventory and supply chain problems within the Cordis business, and seeks to recover unspecified damages and equitable relief for the alleged misstatements and omissions. The complaint also alleges that one of the individual defendants violated Section 20A of the Exchange Act because he sold shares of Cardinal Health stock during the time period. In November 2020, we filed a motion to dismiss the amended complaint. We believe that the claims asserted in this complaint are without merit and intend to vigorously defend against them. </span></div></div></ix:continuation></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="ib2ce1b316a4049298535cd01733c1f02" continuedAt="i423c726cbe834dd0a1502d62697d8fb8"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Specialty Solutions DOJ Investigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the United States Attorney&#8217;s Office for the District of Massachusetts (the "USAO") commenced an investigation pertaining to the U.S. federal healthcare fraud and abuse laws. These requests sought, among other things, documents and information relating to discounts and rebates offered or provided to certain Specialty Solutions customers. We are cooperating with these requests and are engaged in resolution discussions with the USAO. In connection with these discussions, we recorded $<ix:nonFraction unitRef="usd" contextRef="i200d0dbf02ed453d87b6ed7ec2d17a53_D20200701-20210331" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85Ny9mcmFnOjQyNjdmNTQxNzNkZjQzM2JiOWMyNjI4YzE2MzY3OWIzL3RleHRyZWdpb246NDI2N2Y1NDE3M2RmNDMzYmI5YzI2MjhjMTYzNjc5YjNfMTM0MDk_3351def5-371a-4ae8-b26f-c48d2642626f">13</ix:nonFraction> million of expense within litigation charges/(recoveries) on our condensed consolidated statement of operations during the three months ended March&#160;31, 2021. We are not able to estimate a range of reasonably possible additional losses or other remedial measures for this matter.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Civil Litigation </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Pharmaceutical Pricing Antitrust Litigation </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, pharmaceutical distributors including us were added as defendants in a civil class action lawsuit filed by indirect purchasers of generic drugs, such as hospitals and retail pharmacies. The indirect purchaser case is part of a multidistrict litigation consisting of multiple individual class action matters consolidated in the Eastern District of Pennsylvania. The indirect purchaser plaintiffs allege that pharmaceutical distributors encouraged manufacturers to increase prices, provided anti-competitive pricing information to manufacturers and improperly engaged in customer allocation. We have filed a motion to dismiss the complaints and we intend to vigorously defend ourselves. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Active Pharmaceutical Ingredient Impurity Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many participants in the pharmaceutical supply chain, including active pharmaceutical ingredient ("API") manufacturers, finished dose manufacturers, repackagers, distributors, and retailers have been named as defendants in lawsuits arising out of recalls of certain medications due to alleged impurities in the active pharmaceutical ingredients or finished product. </span></div></ix:continuation><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i423c726cbe834dd0a1502d62697d8fb8">In February 2019, a Multidistrict Litigation was created in the U.S. District Court for the District of New Jersey (the &#8220;Sartan MDL&#8221;) alleging API impurities in certain generic blood pressure medications. We have been named as a defendant in the Sartan MDL. We are vigorously defending ourselves in this matter.</ix:continuation> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Antitrust Litigation Proceeds</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, we received cash proceeds resulting from settlements of lawsuits in which we were a class member of approximately $<ix:nonFraction unitRef="usd" contextRef="i6be08e009bc84db19fea6af132f4df1c_D20210401-20210630" decimals="-6" format="ixt:numdotdecimal" name="cah:ProceedsFromSettlementsOfClassActionLawsuits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85Ny9mcmFnOjQyNjdmNTQxNzNkZjQzM2JiOWMyNjI4YzE2MzY3OWIzL3RleHRyZWdpb246NDI2N2Y1NDE3M2RmNDMzYmI5YzI2MjhjMTYzNjc5YjNfNTQ5NzU1ODE3MjE4MA_efa5188a-633e-4207-9ba7-e07cacb616bc">100</ix:nonFraction> million, which will be recognized in litigation (recoveries)/charges, net, in the fourth quarter of fiscal year 2021.</span></div><div id="ib6bf45669ad94861b0c50dbc2f4371ce_100"></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzkwNzE_dc610499-1014-47ac-a22a-553f718146d4" continuedAt="i5b8a18a5e93f45809194101fbdcc8c61" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">7. Income Taxes</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in our provision for/(benefit from) income taxes as a percentage of pretax earnings (&#8220;effective tax rate&#8221;) are generally due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items. </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Effects of Self-Insurance Pre-tax Loss</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March&#160;31, 2021, our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation. This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes. The net operating loss was carried back and adjusted our taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security ("CARES") Act enacted by the United States Congress in March 2020.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, our provision for income taxes during the nine months ended March&#160;31, 2021 included a $<ix:nonFraction unitRef="usd" contextRef="if2d5ee4c8487424fb522d83601a9e4ed_D20200701-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzEwOTY_4b03f236-d976-4408-9244-d82e018f0810">419</ix:nonFraction> million benefit from the net operating loss carryback primarily to reflect the difference between the federal statutory income tax rate during the fiscal years from 2015 to 2018 (35 percent for fiscal 2015, 2016, and 2017 and 28 percent for fiscal 2018) and the current federal statutory income tax rate of 21 percent.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have filed for a federal income tax refund of $<ix:nonFraction unitRef="usd" contextRef="i95e27bf6690f452f80d7e0a0bf7a1856_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzE0NjM_dbf99d17-fde6-43c9-9fe8-21d9f61fb298">974</ix:nonFraction> million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have recorded a current asset on our condensed consolidated balance sheet at March&#160;31, 2021. We also increased our non-current deferred tax liability by approximately $<ix:nonFraction unitRef="usd" contextRef="i95e27bf6690f452f80d7e0a0bf7a1856_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzE3NTE_8e37e07f-b42b-4ed6-a690-e5ae10d58cf4">700</ix:nonFraction> million during the nine months ended March&#160;31, 2021 related to this matter.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of tax law; however, it is possible that the tax authorities could challenge these tax benefits or that the tax law could change. The actual amount of the tax benefit may differ materially from these estimates.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Effects of Opioid Litigation Charges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the $<ix:nonFraction unitRef="usd" contextRef="ib9e03386e8bb45b9bfa0b58a7c283f07_D20200701-20210331" decimals="-7" format="ixt:numdotdecimal" name="us-gaap:LitigationSettlementExpense" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzIxNjc_cf1785e7-fdb9-4ef0-a6ca-a22606c2c490">1.02</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i32ccdaa0f4af4c919f10cbbfa4cc9a79_D20190701-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LitigationSettlementExpense" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzIxNzQ_6b5d54da-be7d-49d2-93d0-bfc45ecdeb23">5.63</ix:nonFraction> billion pre-tax charges for the opioid litigation, during the nine months ended March&#160;31, 2021 and 2020, respectively, the net tax benefits are $<ix:nonFraction unitRef="usd" contextRef="ia19c49a9fdf94744a98048c92ed6d989_D20200701-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzIyODQ_7fe79880-c57f-41a9-a126-ca85bd2f30e0">37</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia48bb06cca3d4969bdeb6e18237b4224_D20190701-20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzIyOTE_d75a112c-e833-40ea-a866-b2fa89033254">488</ix:nonFraction> million for fiscal 2021 and 2020, respectively. Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized tax benefits of $<ix:nonFraction unitRef="usd" contextRef="i64ace7956a934516b089799b59bc6227_I20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzI1ODE_5d351a53-a799-4846-8a5c-16d4305f66f3">35</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i352533a8ebdc4e1ea369fbf8d0b0cb22_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzI1ODg_b4ca8382-ec39-43f5-9c80-bc1d9b687b6a">468</ix:nonFraction> million, respectively. Due to our assessment of non-deductibility for certain components considered in the fiscal 2021 and 2020 charges, the tax benefit for fiscal 2021 compared to fiscal 2020 resulted in a relatively lower tax benefit. Our assumptions and estimates around this benefit and uncertain tax </span></div></ix:nonNumeric></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><ix:continuation id="i5b8a18a5e93f45809194101fbdcc8c61" continuedAt="ibf9d9e37ff5f4410af6e359267e0fb15"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">position require significant judgment and the actual amount of tax benefit related to uncertain tax positions may differ materially from these estimates.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings/(loss) before income taxes for the year-to-date period to compute our provision for/(benefit from) income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the initial opioid litigation accrual during the nine months ended March 31, 2020, the tax effect of the charge was treated as a discrete item because it was considered unusual or infrequent. However, the tax effect of the charge during the three months ended September 30, 2020 was included in our estimated annual effective tax rate because it was no longer considered unusual or infrequent. The inclusion of the relatively lower tax benefit of the current fiscal year charge in our estimated annual effective tax rate significantly increased the estimated annual effective tax rate for fiscal 2021. As such, the amount of tax expense increased by approximately $<ix:nonFraction unitRef="usd" contextRef="i2a9345a4d82147cbb391e59d3476b6af_D20210101-20210331" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzU0OTc1NTgxNTEyNzY_203377f9-a47b-4a09-98c0-418df3e79391">140</ix:nonFraction> million during the three months ended March&#160;31, 2021 while the amount of tax benefit increased by approximately $<ix:nonFraction unitRef="usd" contextRef="ib9e03386e8bb45b9bfa0b58a7c283f07_D20200701-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzU0OTc1NTgxNTEyOTU_7313bd39-e6b8-4c4c-a337-44b51e52cf88">180</ix:nonFraction> million during the nine months ended March&#160;31, 2021 compared to the tax impacts that would have been recognized without the opioid litigation charge. As stated above, the benefit as of the end of fiscal 2021 is expected to be $<ix:nonFraction unitRef="usd" contextRef="ia19c49a9fdf94744a98048c92ed6d989_D20200701-20210630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzU0OTc1NTgxNTEzMDM_7fe79880-c57f-41a9-a126-ca85bd2f30e0">37</ix:nonFraction> million.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the U.S. Tax Cuts and Jobs Act ("Tax Act"); however, these estimates require significant judgment since the definitive settlement terms and documentation, including provisions related to deductibility, under the Settlement Framework have not been negotiated and the U.S. tax law governing deductibility was changed by the Tax Act. Further, it is possible that the tax authorities could challenge our interpretation of the Tax Act or the estimates and assumptions used to assess the future deductibility of these benefits or that the tax law could change. The actual amount of the tax benefit related to uncertain tax positions may differ materially from these estimates.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effective Tax Rate</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended&#160;March&#160;31, 2021&#160;and&#160;2020, the effective tax rate was&#160;<ix:nonFraction unitRef="number" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzU0NTg_17592b4e-429f-4abd-b571-abbd15ad45e4">72.8</ix:nonFraction> percent and&#160;<ix:nonFraction unitRef="number" contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzU0NzM_35dbd54c-1fcc-4402-965d-3eafa7538bb1">26.8</ix:nonFraction>&#160;percent, respectively. The change in the effective tax rate compared to the prior period was primarily due to the adverse tax impacts of the opioid litigation accrual, the resolution of certain transfer pricing matters with the IRS and withholding taxes for planned distributions from foreign subsidiaries.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended&#160;March&#160;31, 2021&#160;and&#160;2020, the effective tax rate was (<ix:nonFraction unitRef="number" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzU4MjE_29d1cc2c-e488-479c-934e-0cece025dbb8">143.3</ix:nonFraction>)&#160;percent and&#160;<ix:nonFraction unitRef="number" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzU4MzY_9897c642-d9e2-4895-b3e2-e02a095936c9">5.2</ix:nonFraction>&#160;percent, </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively. Included in the effective tax rate for the nine months ended March&#160;31, 2021 was the $<ix:nonFraction unitRef="usd" contextRef="if2d5ee4c8487424fb522d83601a9e4ed_D20200701-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzU5NDg_4b03f236-d976-4408-9244-d82e018f0810">419</ix:nonFraction> million benefit from a net operating loss carryback primarily related to a self-insurance pre-tax loss. Included in both the nine months ended March&#160;31, 2021 and 2020 were net tax benefits related to the treatment of the tax impacts of opioid litigation charges. </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrecognized Tax Benefits</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2021 and June&#160;30, 2020, we had $<ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzYyNTY_3ed02d9f-03ff-457b-888e-9a3e7ff0ef1d">785</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzYyNjM_6adbdbb3-4dfc-48cf-9d64-d21cf8813142">998</ix:nonFraction> million of unrecognized tax benefits, respectively. The March&#160;31, 2021 and June&#160;30, 2020 balances include $<ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzYzNDE_1ab86fcd-d81d-45af-89d4-e0e46e344b0f">703</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzYzNDg_2f4eab21-e26d-44b0-ab48-8078b16817e6">753</ix:nonFraction> million of unrecognized tax benefits, respectively, that if recognized, would have an impact on the effective tax rate. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2021 and June&#160;30, 2020, we had $<ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzY0ODU_49357af9-e9b9-46aa-b811-e2b197db0965">73</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzY0OTI_e88f33e0-2c32-4155-a20b-30990fab079f">146</ix:nonFraction> million, respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the provision for/(benefit from) income taxes in the condensed consolidated statements of earnings/(loss). These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of IRS and other audit issues, reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between <ix:nonFraction unitRef="usd" contextRef="ided1be8f67714ed8b59a2a7328872d54_I20210331" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzczNzU_6cd0ac14-472b-45bd-881a-0af0665e62ec">zero</ix:nonFraction> and a net decrease of up to $<ix:nonFraction unitRef="usd" contextRef="ibfa1be8946614c2b9007346f625163d2_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5Xzc0MDY_98c4154b-ce06-4363-a627-1c238eedb040">90</ix:nonFraction> million, exclusive of penalties and interest.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Tax Matters</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years <ix:nonNumeric contextRef="if4bf28e522354f2395213116e925d1b9_D20200701-20210331" name="us-gaap:OpenTaxYear" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzU0OTc1NTgxNTEyNDQ_f47a1064-dbd1-419b-9788-51e581495756">2011</ix:nonNumeric> through the current fiscal year. Tax laws are complex and subject to varying interpretations.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), a subsidiary of Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. The indemnification receivable was $<ix:nonFraction unitRef="usd" contextRef="i0e66f2887db842aa8968fdf63602e73d_I20210331" decimals="-6" format="ixt:numdotdecimal" name="cah:IndemnificationReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5Xzg0MDA_04c5cbff-fd4b-4153-b966-f1b3bc1653bb">119</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2d53fc1dcd044ba08aabb87d0bbbcb75_I20200630" decimals="-6" format="ixt:numdotdecimal" name="cah:IndemnificationReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5Xzg0MDc_910bb01a-1d0a-443e-bdae-5f3da7db158e">176</ix:nonFraction> million at March&#160;31, 2021 and June&#160;30, 2020, respectively, and is included in prepaid expenses and other assets and other assets in the condensed consolidated balance sheets. The indemnification receivable was reduced based on the ongoing negotiations with the IRS.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the acquisition of the Patient Recovery Business, Medtronic plc is obligated to indemnify us for certain tax exposures and transaction taxes related to periods prior to the acquisition under the purchase agreement. The indemnification receivable was $<ix:nonFraction unitRef="usd" contextRef="i49fd517f759e4c02bee7665cf6f0fc34_I20200630" decimals="-6" format="ixt:numdotdecimal" name="cah:IndemnificationReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5Xzg3ODE_22b846b9-7ec8-49ca-9f92-ffa97b641666"><ix:nonFraction unitRef="usd" contextRef="i68ba2e46a7674cc8991710f46cdcb0b6_I20210331" decimals="-6" format="ixt:numdotdecimal" name="cah:IndemnificationReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5Xzg3ODE_58f59b60-54c9-41c3-a7cc-3a8b8956fc44">19</ix:nonFraction></ix:nonFraction> million at both March&#160;31, 2021 and June&#160;30, 2020, </span></div></div></ix:continuation></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="ibf9d9e37ff5f4410af6e359267e0fb15"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively, and is included in other assets in the condensed consolidated balance sheet.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future adjustments to the financial statements may be necessary as final tax regulations related to U.S. Tax Reform are issued. We will assess any impact as additional guidance is issued.</span></div></ix:continuation><div id="ib6bf45669ad94861b0c50dbc2f4371ce_103"></div><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90ZXh0cmVnaW9uOjhlZTlkMTgxZGU4NzQ5NTA5ZGRlOGNjOTJiNmRiNThhXzEyMzM_f5a10dd5-9fde-40e1-8ee1-04bd46f59490" continuedAt="i1a5b15852d8743d48f8d0d550258a523" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">8. Fair Value Measurements</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Assets and (Liabilities) Measured on a Recurring Basis</span></div><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90ZXh0cmVnaW9uOjhlZTlkMTgxZGU4NzQ5NTA5ZGRlOGNjOTJiNmRiNThhXzEyMzY_a46dd327-ef9c-4bf9-b77c-d2d0e5aa04d8" continuedAt="ie7f210e9743c4b84ad3106b78c2bd400" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c9d1ab6ad74ad6be84ceec57e39a73_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90YWJsZTozNDk0ZWUyYWIyMmI0NzAyYjc2YTYzYWFiMDk3NDlkNS90YWJsZXJhbmdlOjM0OTRlZTJhYjIyYjQ3MDJiNzZhNjNhYWIwOTc0OWQ1XzMtMS0xLTEtMA_50d0818b-cae8-4bf3-99cd-c3a345c451c5">1,944</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1c063a9eef24440b68b23b7cc020697_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90YWJsZTozNDk0ZWUyYWIyMmI0NzAyYjc2YTYzYWFiMDk3NDlkNS90YWJsZXJhbmdlOjM0OTRlZTJhYjIyYjQ3MDJiNzZhNjNhYWIwOTc0OWQ1XzMtMy0xLTEtMA_3f8ce857-f9b2-4f2a-8e62-a3bed40a34d3">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb9fc5025c56429290c144a9ab02add4_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90YWJsZTozNDk0ZWUyYWIyMmI0NzAyYjc2YTYzYWFiMDk3NDlkNS90YWJsZXJhbmdlOjM0OTRlZTJhYjIyYjQ3MDJiNzZhNjNhYWIwOTc0OWQ1XzMtNS0xLTEtMA_a436fe26-e716-42fc-a1b6-3421116c32a7">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia215aea801f34ad985846f37619f80f0_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90YWJsZTozNDk0ZWUyYWIyMmI0NzAyYjc2YTYzYWFiMDk3NDlkNS90YWJsZXJhbmdlOjM0OTRlZTJhYjIyYjQ3MDJiNzZhNjNhYWIwOTc0OWQ1XzMtNy0xLTEtMA_51663c83-359a-47d4-b4e4-fc29279f5519">1,944</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c9d1ab6ad74ad6be84ceec57e39a73_I20210331" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90YWJsZTozNDk0ZWUyYWIyMmI0NzAyYjc2YTYzYWFiMDk3NDlkNS90YWJsZXJhbmdlOjM0OTRlZTJhYjIyYjQ3MDJiNzZhNjNhYWIwOTc0OWQ1XzUtMS0xLTEtMA_a148a4dc-1edb-4a89-8c99-c29ea9cce1b6">118</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1c063a9eef24440b68b23b7cc020697_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90YWJsZTozNDk0ZWUyYWIyMmI0NzAyYjc2YTYzYWFiMDk3NDlkNS90YWJsZXJhbmdlOjM0OTRlZTJhYjIyYjQ3MDJiNzZhNjNhYWIwOTc0OWQ1XzUtMy0xLTEtMA_341df822-4812-401f-b381-3cba09444905">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb9fc5025c56429290c144a9ab02add4_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90YWJsZTozNDk0ZWUyYWIyMmI0NzAyYjc2YTYzYWFiMDk3NDlkNS90YWJsZXJhbmdlOjM0OTRlZTJhYjIyYjQ3MDJiNzZhNjNhYWIwOTc0OWQ1XzUtNS0xLTEtMA_56cfb8ab-0480-4418-997c-2dd98788b42b">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia215aea801f34ad985846f37619f80f0_I20210331" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90YWJsZTozNDk0ZWUyYWIyMmI0NzAyYjc2YTYzYWFiMDk3NDlkNS90YWJsZXJhbmdlOjM0OTRlZTJhYjIyYjQ3MDJiNzZhNjNhYWIwOTc0OWQ1XzUtNy0xLTEtMA_f9e8d67d-965f-4450-983c-6479b24b97fa">118</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c9d1ab6ad74ad6be84ceec57e39a73_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90YWJsZTozNDk0ZWUyYWIyMmI0NzAyYjc2YTYzYWFiMDk3NDlkNS90YWJsZXJhbmdlOjM0OTRlZTJhYjIyYjQ3MDJiNzZhNjNhYWIwOTc0OWQ1XzYtMS0xLTEtMA_fc8242b2-2f07-4cae-ad7b-6dcf3622498f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1c063a9eef24440b68b23b7cc020697_I20210331" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90YWJsZTozNDk0ZWUyYWIyMmI0NzAyYjc2YTYzYWFiMDk3NDlkNS90YWJsZXJhbmdlOjM0OTRlZTJhYjIyYjQ3MDJiNzZhNjNhYWIwOTc0OWQ1XzYtMy0xLTEtMA_1d25dac7-b2a2-44fd-9626-77ea45fec9da">41</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb9fc5025c56429290c144a9ab02add4_I20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90YWJsZTozNDk0ZWUyYWIyMmI0NzAyYjc2YTYzYWFiMDk3NDlkNS90YWJsZXJhbmdlOjM0OTRlZTJhYjIyYjQ3MDJiNzZhNjNhYWIwOTc0OWQ1XzYtNS0xLTEtMA_afb15200-a8af-4fe4-a5f1-03d2d560e2f3">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia215aea801f34ad985846f37619f80f0_I20210331" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90YWJsZTozNDk0ZWUyYWIyMmI0NzAyYjc2YTYzYWFiMDk3NDlkNS90YWJsZXJhbmdlOjM0OTRlZTJhYjIyYjQ3MDJiNzZhNjNhYWIwOTc0OWQ1XzYtNy0xLTEtMA_c16ff2e7-c1cb-43af-a9d1-7beab1e065fa">41</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.937%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f7d6a255b6d43b7a97b861817531138_I20200630" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90YWJsZToyMzYwYTE2ZGRiZmM0MGJhOTFhNDZkMjM5MzcxMmUwYS90YWJsZXJhbmdlOjIzNjBhMTZkZGJmYzQwYmE5MWE0NmQyMzkzNzEyZTBhXzMtMS0xLTEtMA_5f99a255-b3fd-4974-ba38-0200bd826e9b">721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80081b312cf4449bb7fe8a2f4e5535d7_I20200630" decimals="-6" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90YWJsZToyMzYwYTE2ZGRiZmM0MGJhOTFhNDZkMjM5MzcxMmUwYS90YWJsZXJhbmdlOjIzNjBhMTZkZGJmYzQwYmE5MWE0NmQyMzkzNzEyZTBhXzMtMy0xLTEtMA_3c1c5c3d-adc9-4fd9-bca3-ef13df41056c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020f748109a4007908680bcbacb5e56_I20200630" decimals="-6" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90YWJsZToyMzYwYTE2ZGRiZmM0MGJhOTFhNDZkMjM5MzcxMmUwYS90YWJsZXJhbmdlOjIzNjBhMTZkZGJmYzQwYmE5MWE0NmQyMzkzNzEyZTBhXzMtNS0xLTEtMA_bd944a78-4246-4bad-8cbe-256d1fe88046">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bde8641630642bf8d5434c1fadce5ef_I20200630" decimals="-6" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90YWJsZToyMzYwYTE2ZGRiZmM0MGJhOTFhNDZkMjM5MzcxMmUwYS90YWJsZXJhbmdlOjIzNjBhMTZkZGJmYzQwYmE5MWE0NmQyMzkzNzEyZTBhXzMtNy0xLTEtMA_5593b75b-09aa-4f53-8ab5-915be9b27730">721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f7d6a255b6d43b7a97b861817531138_I20200630" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90YWJsZToyMzYwYTE2ZGRiZmM0MGJhOTFhNDZkMjM5MzcxMmUwYS90YWJsZXJhbmdlOjIzNjBhMTZkZGJmYzQwYmE5MWE0NmQyMzkzNzEyZTBhXzUtMS0xLTEtMA_5f9e516d-d036-4cb3-ae7a-47da965904ec">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80081b312cf4449bb7fe8a2f4e5535d7_I20200630" decimals="-6" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90YWJsZToyMzYwYTE2ZGRiZmM0MGJhOTFhNDZkMjM5MzcxMmUwYS90YWJsZXJhbmdlOjIzNjBhMTZkZGJmYzQwYmE5MWE0NmQyMzkzNzEyZTBhXzUtMy0xLTEtMA_80d59e42-0ca3-4941-b9a5-5752a2a7a2c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020f748109a4007908680bcbacb5e56_I20200630" decimals="-6" format="ixt:zerodash" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90YWJsZToyMzYwYTE2ZGRiZmM0MGJhOTFhNDZkMjM5MzcxMmUwYS90YWJsZXJhbmdlOjIzNjBhMTZkZGJmYzQwYmE5MWE0NmQyMzkzNzEyZTBhXzUtNS0xLTEtMA_fced72dc-2586-45ae-8128-4dfc9f31873a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bde8641630642bf8d5434c1fadce5ef_I20200630" decimals="-6" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90YWJsZToyMzYwYTE2ZGRiZmM0MGJhOTFhNDZkMjM5MzcxMmUwYS90YWJsZXJhbmdlOjIzNjBhMTZkZGJmYzQwYmE5MWE0NmQyMzkzNzEyZTBhXzUtNy0xLTEtMA_7a3431fa-dc7e-42b2-8184-da155a9e2551">114</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f7d6a255b6d43b7a97b861817531138_I20200630" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90YWJsZToyMzYwYTE2ZGRiZmM0MGJhOTFhNDZkMjM5MzcxMmUwYS90YWJsZXJhbmdlOjIzNjBhMTZkZGJmYzQwYmE5MWE0NmQyMzkzNzEyZTBhXzYtMS0xLTEtMA_54fe9620-6512-44a7-ac97-0f846618c261">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80081b312cf4449bb7fe8a2f4e5535d7_I20200630" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90YWJsZToyMzYwYTE2ZGRiZmM0MGJhOTFhNDZkMjM5MzcxMmUwYS90YWJsZXJhbmdlOjIzNjBhMTZkZGJmYzQwYmE5MWE0NmQyMzkzNzEyZTBhXzYtMy0xLTEtMA_d4fb827d-d4d0-4a15-911f-1f17b2683387">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9020f748109a4007908680bcbacb5e56_I20200630" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90YWJsZToyMzYwYTE2ZGRiZmM0MGJhOTFhNDZkMjM5MzcxMmUwYS90YWJsZXJhbmdlOjIzNjBhMTZkZGJmYzQwYmE5MWE0NmQyMzkzNzEyZTBhXzYtNS0xLTEtMA_5a6f1344-d66f-4994-9c24-29ec2aec0f6c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bde8641630642bf8d5434c1fadce5ef_I20200630" decimals="-6" name="us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90YWJsZToyMzYwYTE2ZGRiZmM0MGJhOTFhNDZkMjM5MzcxMmUwYS90YWJsZXJhbmdlOjIzNjBhMTZkZGJmYzQwYmE5MWE0NmQyMzkzNzEyZTBhXzYtNy0xLTEtMA_e23843f3-1ffe-484d-9271-53b36d19fe81">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The fair value of interest rate swaps, foreign currency contracts, commodity contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Assets and (Liabilities) Measured on a Nonrecurring Basis</span></div></ix:nonNumeric></ix:nonNumeric><div style="margin-bottom:6pt;text-align:justify"><ix:continuation id="i1a5b15852d8743d48f8d0d550258a523" continuedAt="ib03b6a15b3cc48ccbbb90d6079687477"><ix:continuation id="ie7f210e9743c4b84ad3106b78c2bd400" continuedAt="i62406363247e4a8299863ef72c1d29c2"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities held for sale of $<ix:nonFraction unitRef="usd" contextRef="i5987d078d03f4fc38046fb86086b6b1e_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90ZXh0cmVnaW9uOjhlZTlkMTgxZGU4NzQ5NTA5ZGRlOGNjOTJiNmRiNThhXzQzOTgwNDY1MTQzOTk_8cc18e40-254a-4deb-8004-7e6b7b19f4a0">1.1</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90ZXh0cmVnaW9uOjhlZTlkMTgxZGU4NzQ5NTA5ZGRlOGNjOTJiNmRiNThhXzMyOTg1MzQ4ODY1MTY_7ac23b53-c840-40f2-919e-f3ce782662c9">93</ix:nonFraction> million, respectively, at March&#160;31, 2021 are primarily related to the planned divestiture of our Cordis business. These estimated fair values utilized Level 3 unobservable inputs based on expected sales proceeds following a competitive bidding process. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_1194">Note 2</a></span></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib03b6a15b3cc48ccbbb90d6079687477"><ix:continuation id="i62406363247e4a8299863ef72c1d29c2"> for additional information regarding assets and liabilities held for sale.</ix:continuation></ix:continuation> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div id="ib6bf45669ad94861b0c50dbc2f4371ce_106"></div><ix:nonNumeric contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzgxMTc_04d878b6-268a-4c19-b1e3-31f92598a91d" continuedAt="i0df87968fe294d0ca948856cb29b1d89" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">9. Financial Instruments </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks </span></div></ix:nonNumeric></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:continuation id="i0df87968fe294d0ca948856cb29b1d89" continuedAt="i4ce6bd2abea64a348f4aeed4e7518cb2"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments. These derivative instruments are adjusted to current fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated investment grade or better. We do not have significant exposure to any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Interest Rate Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities along with both fixed-rate and variable-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Currency Exchange Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments and anticipated foreign currency revenue and expenses.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commodity Price Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fair Value Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the condensed consolidated statements of </span></div></ix:continuation></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><ix:continuation id="i4ce6bd2abea64a348f4aeed4e7518cb2" continuedAt="i0c80dc457b104b4e8fd46c1b1a054d27"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">earnings/(loss). For the three and nine months ended March&#160;31, 2021 and 2020, there was <ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzMyODA_1b58bee9-3a3a-4819-a584-5735c586516e"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzMyODA_2fad7b25-70b4-4ef7-821d-881863601977"><ix:nonFraction unitRef="usd" contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzMyODA_798173f9-9964-4d01-8f67-89644f5f1df4"><ix:nonFraction unitRef="usd" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzMyODA_ced2585f-12eb-4739-bd06-5ad6982c9dd8">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> gain or loss recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the three and nine months ended March&#160;31, 2021, we unwound certain interest rate swap contracts with the notional amount of $<ix:nonFraction unitRef="usd" contextRef="i949ddfae3947416db45abfd64c94adeb_I20200331" decimals="-6" format="ixt:numdotdecimal" name="cah:DerivativesHedgeDiscontinuancesHeadingInstrumentTerminatedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzQzOTgwNDY1NDEzODg_745ff314-a1b2-4f74-9430-53107ad115bf">550</ix:nonFraction>&#160;million. In connection with the unwind of these contracts, we received cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="i87eabc19117047338578608b2ee7dcd4_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredGainLossOnDiscontinuationOfInterestRateFairValueHedge" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzQzOTgwNDY1NDE0MDI_a24a270f-2184-4d77-ac39-aa22872d975c">18</ix:nonFraction>&#160;million. The related gain will be recognized in interest expense, net in our statements of earnings/(loss) over the remaining term of the debt agreement, which matures in March 2023.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the three and nine months ended March&#160;31, 2021, we entered into a pay-floating interest rate swap with total notional amounts of $<ix:nonFraction unitRef="usd" contextRef="i949ddfae3947416db45abfd64c94adeb_I20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzQzOTgwNDY1NDEzNzQ_fd0cc4aa-a759-4a1e-b9ba-5bebc8883379">200</ix:nonFraction>&#160;million. This swap has been designated as fair value hedges of our fixed rate debt and is included in deferred income taxes and other liabilities in the condensed consolidated balance sheets.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the debt repayment as described in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_94">Note 5</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, two pay-floating interest rate swaps with notional amounts of $<ix:nonFraction unitRef="usd" contextRef="i949ddfae3947416db45abfd64c94adeb_I20200331" decimals="-6" format="ixt:numdotdecimal" name="cah:DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzM1Njk_8f09cf9c-51d6-4fcb-a192-5354796ee381">200</ix:nonFraction> million matured in the second quarter of fiscal 2020. </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cash Flow Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the nine months ended March&#160;31, 2020, we entered into forward interest rate swaps with a total notional amount of $<ix:nonFraction unitRef="usd" contextRef="i334e47c1f3ff45dcb6b4856094c8f1c0_I20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzMyOTg1MzQ4OTQ4NDA_c85276ea-8c5a-45ca-8226-94fa48e2683d">200</ix:nonFraction>&#160;million to hedge probable, but not firmly committed, future transactions associated with our debt. During the three and nine months ended March&#160;31, 2021, we terminated these swaps </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and reclassified an immaterial deferred gain from accumulated other comprehensive loss into interest expense, net in our condensed consolidated statements of earnings/(loss) because the forecasted transactions were probable of not occurring</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. At March&#160;31, 2021, we had no outstanding forward interest rate swaps designated as cash-flow hedges.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pre-tax gain and loss recognized in other comprehensive loss was a $<ix:nonFraction unitRef="usd" contextRef="i58ec7cecb23b4f45bed4e5c64a8bb562_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzQ0NzI_5c9ae38c-d57f-4059-90dc-e628f38f5c49">13</ix:nonFraction>&#160;million gain and a $<ix:nonFraction unitRef="usd" contextRef="if1af6bf6a64a4c77ba66fed4c716d945_D20200701-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzMyOTg1MzQ4OTY4NjA_db69537a-b091-4c93-bbdc-2fcb25fa373f">20</ix:nonFraction>&#160;million loss during the three months ended March&#160;31, 2021 and 2020, respectively, and a $<ix:nonFraction unitRef="usd" contextRef="if1af6bf6a64a4c77ba66fed4c716d945_D20200701-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzQzOTgwNDY1MjQ4NTc_db69537a-b091-4c93-bbdc-2fcb25fa373f">20</ix:nonFraction>&#160;million gain and a $<ix:nonFraction unitRef="usd" contextRef="ia42786050a004af0aedbbe0f8357c727_D20190701-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzQzOTgwNDY1NDA5MzY_a5623e8e-4292-4cc9-987b-3bde2f3dff71">20</ix:nonFraction>&#160;million loss in the nine months ended March&#160;31, 2021 and 2020, respectively. Gains and losses recognized in accumulated other comprehensive loss and reclassified into earnings were immaterial for the three and nine months ended March&#160;31, 2021 and 2020. All gains and losses currently included within accumulated other comprehensive loss associated with our </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">cash flow hedges to be reclassified into net earnings within the next 12 months are immaterial.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Net Investment Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, we entered into a &#165;<ix:nonFraction unitRef="jpy" contextRef="ia8c1b38a8f8d4adf9f86653e53b0dd5c_I20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzUyMTI_fde73531-887b-4b24-8049-719d26a52a39">64.0</ix:nonFraction> billion ($<ix:nonFraction unitRef="usd" contextRef="ia8c1b38a8f8d4adf9f86653e53b0dd5c_I20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeLiabilityNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzUyMTY_8a72e78e-601a-47ec-8e11-ed0d94651566">600</ix:nonFraction> million) cross-currency swap maturing in 2022.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cross-currency swaps designated as net investment hedges are marked to market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive loss until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax gain and loss from net investment hedges recorded in the foreign currency translation component of accumulated other comprehensive loss was a $<ix:nonFraction unitRef="usd" contextRef="i532e1aadd9b146e7ae42838aec9fcb8c_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzU5NDA_a460193a-b43a-4cc4-80c1-c874cb7db0ee">49</ix:nonFraction>&#160;million gain and a $<ix:nonFraction unitRef="usd" contextRef="ic014c1b02128475ba87eda0763cfdcc4_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzU5NTQ_a4009024-b5dc-43cb-bbba-e26acd2e1889">18</ix:nonFraction>&#160;million gain during the three months ended March&#160;31, 2021 and 2020, respectively, and a $<ix:nonFraction unitRef="usd" contextRef="ib3205d5053724d48900805160556c3d0_D20200701-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzYwMjM_e00f10d2-1b32-46fa-816a-70aab41c44d7">3</ix:nonFraction>&#160;million loss and a $<ix:nonFraction unitRef="usd" contextRef="ifa27c7b19457466dabe317a3abbbb6df_D20190701-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzYwMzc_1435582e-c883-4523-8d99-4d3cee65fe3e">35</ix:nonFraction>&#160;million gain during the nine months ended March&#160;31, 2021 and 2020, respectively. Gains recognized in interest expense, net in the condensed consolidated statements of earnings/(loss) for the portion of the net investment hedges excluded from the assessment of hedge effectiveness were $<ix:nonFraction unitRef="usd" contextRef="ic014c1b02128475ba87eda0763cfdcc4_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzYzMDI_49559073-4396-42df-8721-a3b4d9a64e82"><ix:nonFraction unitRef="usd" contextRef="i532e1aadd9b146e7ae42838aec9fcb8c_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzYzMDI_b1add902-c5c0-4481-bf1d-df2dd8772eb4">5</ix:nonFraction></ix:nonFraction>&#160;million during the three months ended March&#160;31, 2021 and 2020, and $<ix:nonFraction unitRef="usd" contextRef="ib3205d5053724d48900805160556c3d0_D20200701-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzYzNTA_1d27525e-1658-4652-b949-a2d45b77913f">14</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ifa27c7b19457466dabe317a3abbbb6df_D20190701-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzYzNTc_bd9aac94-a747-44ff-9b66-5e51d35afb53">11</ix:nonFraction>&#160;million during the nine months ended March&#160;31, 2021 and 2020, respectively. </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Economic (Non-Designated) Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. We recorded a $<ix:nonFraction unitRef="usd" contextRef="i6794b69d98f24573ba346bd46b22a10a_D20200701-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzcyNzM_89b7a395-cdc2-413c-8452-7a6fa178f797">4</ix:nonFraction> million loss and $<ix:nonFraction unitRef="usd" contextRef="i06a14268e5cb46ffb7dbf7a3ce7660f6_D20190701-20200331" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzcyODU_0cb5fe03-8b08-478d-bb2c-9c937910be68">7</ix:nonFraction> million loss during the nine months ended March&#160;31, 2021 and 2020, respectively. The principal currencies managed through foreign currency contracts are Chinese renminbi, Canadian dollar, European euro and Japanese yen.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and equivalents, trade receivables, accounts payable and other accrued liabilities at March&#160;31, 2021 and June&#160;30, 2020 approximate fair value due to their short-term maturities.</span></div></div></ix:continuation></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">43</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="i0c80dc457b104b4e8fd46c1b1a054d27"><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzgxMjI_6e0f623a-becc-415e-b3ee-c771bf6502e9" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.109%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.986%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated fair value</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie14f3bec98e9401e9d0262da4f2de10b_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90YWJsZTo4NjJkNzBlOTkxYTI0ZDA1YTgyNzc3NDVjMjM3ODNhYi90YWJsZXJhbmdlOjg2MmQ3MGU5OTFhMjRkMDVhODI3Nzc0NWMyMzc4M2FiXzEtMS0xLTEtMA_8d98a938-87fe-4fe5-ba49-b5fda9b2e451">7,177</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ef4ab475d104948a5835edf958fa41a_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90YWJsZTo4NjJkNzBlOTkxYTI0ZDA1YTgyNzc3NDVjMjM3ODNhYi90YWJsZXJhbmdlOjg2MmQ3MGU5OTFhMjRkMDVhODI3Nzc0NWMyMzc4M2FiXzEtMy0xLTEtMA_a3411dbb-d2c4-4ef4-b82e-d0825c39d775">7,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying amount</span></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" format="ixt:numdotdecimal" name="cah:CarryingAmountofLongTermandotherShortTermBorrowings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90YWJsZTo4NjJkNzBlOTkxYTI0ZDA1YTgyNzc3NDVjMjM3ODNhYi90YWJsZXJhbmdlOjg2MmQ3MGU5OTFhMjRkMDVhODI3Nzc0NWMyMzc4M2FiXzItMS0xLTEtMA_aa8517fe-731c-4084-a251-91cc96b8c723">6,731</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="-6" format="ixt:numdotdecimal" name="cah:CarryingAmountofLongTermandotherShortTermBorrowings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90YWJsZTo4NjJkNzBlOTkxYTI0ZDA1YTgyNzc3NDVjMjM3ODNhYi90YWJsZXJhbmdlOjg2MmQ3MGU5OTFhMjRkMDVhODI3Nzc0NWMyMzc4M2FiXzItMy0xLTEtMA_bab0863f-bc5c-48dc-a0ea-c4e0e95947a9">6,775</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.</span></div></ix:continuation><div id="ib6bf45669ad94861b0c50dbc2f4371ce_109"></div><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90ZXh0cmVnaW9uOmFlMzIyYjFkYmM3ZjRiYTBiOWFhNzk1NjdhOWE4YTMzXzY0NQ_06e666b7-ec49-4562-94eb-cb207fba0fcf" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">10. Shareholders' Equity</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended March&#160;31, 2021, we repurchased <ix:nonFraction unitRef="shares" contextRef="if8b3edc49b1248e896c9ddae3b113611_D20200701-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90ZXh0cmVnaW9uOmFlMzIyYjFkYmM3ZjRiYTBiOWFhNzk1NjdhOWE4YTMzXzU0OTc1NTgxMzk2NDI_0ac54078-d43d-4e42-864a-3ce8c75e009b"><ix:nonFraction unitRef="shares" contextRef="i3ca53978778d45b291d32f2884428093_D20210101-20210331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90ZXh0cmVnaW9uOmFlMzIyYjFkYmM3ZjRiYTBiOWFhNzk1NjdhOWE4YTMzXzU0OTc1NTgxMzk2NDI_67c5031b-d3f1-44d4-909e-57f249f400d1">3.7</ix:nonFraction></ix:nonFraction> million common shares having an aggregate cost of $<ix:nonFraction unitRef="usd" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90ZXh0cmVnaW9uOmFlMzIyYjFkYmM3ZjRiYTBiOWFhNzk1NjdhOWE4YTMzXzU0OTc1NTgxMzk2MTM_407d73a9-d30d-49fc-ab54-bf8d1bd62eec"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90ZXh0cmVnaW9uOmFlMzIyYjFkYmM3ZjRiYTBiOWFhNzk1NjdhOWE4YTMzXzU0OTc1NTgxMzk2MTM_ba84e18a-409e-4c7f-a903-b9ad007a600d">200</ix:nonFraction></ix:nonFraction> million. The average price paid per common share was $<ix:nonFraction unitRef="usdPerShare" contextRef="if8b3edc49b1248e896c9ddae3b113611_D20200701-20210331" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90ZXh0cmVnaW9uOmFlMzIyYjFkYmM3ZjRiYTBiOWFhNzk1NjdhOWE4YTMzXzU0OTc1NTgxMzk2NTQ_3e279028-f05b-4eff-a835-da5e09916f9a"><ix:nonFraction unitRef="usdPerShare" contextRef="i3ca53978778d45b291d32f2884428093_D20210101-20210331" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90ZXh0cmVnaW9uOmFlMzIyYjFkYmM3ZjRiYTBiOWFhNzk1NjdhOWE4YTMzXzU0OTc1NTgxMzk2NTQ_4f7729f9-db1d-4e69-a12b-8a7e3069b913">54.40</ix:nonFraction></ix:nonFraction>. These repurchases were made under an accelerated share repurchase ("ASR") program, which began on February 9, 2021 and was completed on March 31, 2021.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March 31, 2020, we repurchased <ix:nonFraction unitRef="shares" contextRef="i8e9b39d228bb4305a9f94d21ff2986b6_D20190701-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90ZXh0cmVnaW9uOmFlMzIyYjFkYmM3ZjRiYTBiOWFhNzk1NjdhOWE4YTMzXzU0OTc1NTgxNDA0NTk_c0aef39e-b993-4f79-a007-4085b0b7b6e9">7.3</ix:nonFraction> million common shares having an aggregate cost of $<ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90ZXh0cmVnaW9uOmFlMzIyYjFkYmM3ZjRiYTBiOWFhNzk1NjdhOWE4YTMzXzU0OTc1NTgxNDA0NDE_23de761d-f6c5-4b41-8dba-ff274c12d2ef">350</ix:nonFraction> million. The average price paid per common share was $<ix:nonFraction unitRef="usdPerShare" contextRef="i8e9b39d228bb4305a9f94d21ff2986b6_D20190701-20200331" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90ZXh0cmVnaW9uOmFlMzIyYjFkYmM3ZjRiYTBiOWFhNzk1NjdhOWE4YTMzXzU0OTc1NTgxNDA0NzY_760ad2e4-5c1d-4b43-a252-e5e40ea04587">48.00</ix:nonFraction>. These repurchases were made under an ASR program, which began on August 20, 2019 and was completed on December 4, 2019.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We funded the repurchases with available cash and short-term borrowings. The common shares repurchased are held in treasury to be used for general corporate purposes.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss</span></div><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90ZXh0cmVnaW9uOmFlMzIyYjFkYmM3ZjRiYTBiOWFhNzk1NjdhOWE4YTMzXzY1Mw_8d5fa712-e214-48b0-bba8-7a1b57066646" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.097%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.492%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.875%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.050%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i10d07f0a48104550b0a508675603448e_I20200630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90YWJsZTo1MWZhZDUzMDdiYzQ0OTc5YWM2NjhjODlmM2NmZWIwNy90YWJsZXJhbmdlOjUxZmFkNTMwN2JjNDQ5NzlhYzY2OGM4OWYzY2ZlYjA3XzEtMS0xLTEtMA_d99c2db0-0db0-4203-ba68-4f9691152246">92</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie27ad5c522f44e8b90817308ed523e4d_I20200630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90YWJsZTo1MWZhZDUzMDdiYzQ0OTc5YWM2NjhjODlmM2NmZWIwNy90YWJsZXJhbmdlOjUxZmFkNTMwN2JjNDQ5NzlhYzY2OGM4OWYzY2ZlYjA3XzEtMy0xLTEtMA_643d4a75-46a9-4ff9-b3f3-371046deb5a2">12</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b25597e1abd4762a53125bd127a7fc6_I20200630" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90YWJsZTo1MWZhZDUzMDdiYzQ0OTc5YWM2NjhjODlmM2NmZWIwNy90YWJsZXJhbmdlOjUxZmFkNTMwN2JjNDQ5NzlhYzY2OGM4OWYzY2ZlYjA3XzEtNS0xLTEtMA_34e77afe-aba6-480e-97b8-4d1066d3d35a">104</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2cfce8a58cc495e9d881af0122e343d_D20200701-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90YWJsZTo1MWZhZDUzMDdiYzQ0OTc5YWM2NjhjODlmM2NmZWIwNy90YWJsZXJhbmdlOjUxZmFkNTMwN2JjNDQ5NzlhYzY2OGM4OWYzY2ZlYjA3XzItMS0xLTEtMA_22bd83c0-15b1-4fed-9582-04372191b391">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ecadae65dfb4b55ab6336e5e1372f5e_D20200701-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90YWJsZTo1MWZhZDUzMDdiYzQ0OTc5YWM2NjhjODlmM2NmZWIwNy90YWJsZXJhbmdlOjUxZmFkNTMwN2JjNDQ5NzlhYzY2OGM4OWYzY2ZlYjA3XzItMy0xLTEtMA_3b07f49c-fcab-4212-9a3c-37906d3244c9">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3a494cf37a0408c9c5282b7bacaf665_D20200701-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90YWJsZTo1MWZhZDUzMDdiYzQ0OTc5YWM2NjhjODlmM2NmZWIwNy90YWJsZXJhbmdlOjUxZmFkNTMwN2JjNDQ5NzlhYzY2OGM4OWYzY2ZlYjA3XzItNS0xLTEtMA_37f2c3e5-e821-4b03-bc53-3a1c8b718f0d">53</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2cfce8a58cc495e9d881af0122e343d_D20200701-20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90YWJsZTo1MWZhZDUzMDdiYzQ0OTc5YWM2NjhjODlmM2NmZWIwNy90YWJsZXJhbmdlOjUxZmFkNTMwN2JjNDQ5NzlhYzY2OGM4OWYzY2ZlYjA3XzMtMS0xLTEtMA_cf9ffed9-2208-4073-9799-f597d0e7488d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ecadae65dfb4b55ab6336e5e1372f5e_D20200701-20210331" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90YWJsZTo1MWZhZDUzMDdiYzQ0OTc5YWM2NjhjODlmM2NmZWIwNy90YWJsZXJhbmdlOjUxZmFkNTMwN2JjNDQ5NzlhYzY2OGM4OWYzY2ZlYjA3XzMtMy0xLTEtMA_a4bbbe8d-79a1-48f0-8c8e-3c0695688beb">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3a494cf37a0408c9c5282b7bacaf665_D20200701-20210331" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90YWJsZTo1MWZhZDUzMDdiYzQ0OTc5YWM2NjhjODlmM2NmZWIwNy90YWJsZXJhbmdlOjUxZmFkNTMwN2JjNDQ5NzlhYzY2OGM4OWYzY2ZlYjA3XzMtNS0xLTEtMA_d8c8fef3-feb9-46fa-bb45-855de7a6ea47">3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive income attributable to Cardinal Health, Inc. net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2cfce8a58cc495e9d881af0122e343d_D20200701-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90YWJsZTo1MWZhZDUzMDdiYzQ0OTc5YWM2NjhjODlmM2NmZWIwNy90YWJsZXJhbmdlOjUxZmFkNTMwN2JjNDQ5NzlhYzY2OGM4OWYzY2ZlYjA3XzQtMS0xLTEtMA_f5751945-18f0-47b8-b9fc-b7261202fcda">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ecadae65dfb4b55ab6336e5e1372f5e_D20200701-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90YWJsZTo1MWZhZDUzMDdiYzQ0OTc5YWM2NjhjODlmM2NmZWIwNy90YWJsZXJhbmdlOjUxZmFkNTMwN2JjNDQ5NzlhYzY2OGM4OWYzY2ZlYjA3XzQtMy0xLTEtMA_77fb82dc-3121-4958-b9af-6a1cfe4f124e">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b80eecd6d274b6099620f1435d44f65_D20200701-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90YWJsZTo1MWZhZDUzMDdiYzQ0OTc5YWM2NjhjODlmM2NmZWIwNy90YWJsZXJhbmdlOjUxZmFkNTMwN2JjNDQ5NzlhYzY2OGM4OWYzY2ZlYjA3XzQtNS0xLTEtMA_6c4ab9a4-6433-454c-9138-d35059cd8d15">56</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2021</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1282072a9944c75994cdaf150f6cae9_I20210331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90YWJsZTo1MWZhZDUzMDdiYzQ0OTc5YWM2NjhjODlmM2NmZWIwNy90YWJsZXJhbmdlOjUxZmFkNTMwN2JjNDQ5NzlhYzY2OGM4OWYzY2ZlYjA3XzUtMS0xLTEtMA_0e1335f5-154e-4e68-b646-cb26a3ab4e17">50</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e2d2af534744410b83b2b8c23ceae67_I20210331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90YWJsZTo1MWZhZDUzMDdiYzQ0OTc5YWM2NjhjODlmM2NmZWIwNy90YWJsZXJhbmdlOjUxZmFkNTMwN2JjNDQ5NzlhYzY2OGM4OWYzY2ZlYjA3XzUtMy0xLTEtMA_454bb963-0adf-45bd-9ea4-a8d0cbd5e0b5">2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i678e5905c5c04646a1adad096e2142a5_I20210331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90YWJsZTo1MWZhZDUzMDdiYzQ0OTc5YWM2NjhjODlmM2NmZWIwNy90YWJsZXJhbmdlOjUxZmFkNTMwN2JjNDQ5NzlhYzY2OGM4OWYzY2ZlYjA3XzUtNS0xLTEtMA_e3686501-aaab-4c96-83af-f34917e8b067">48</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div id="ib6bf45669ad94861b0c50dbc2f4371ce_112"></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTIvZnJhZzpjNDI3MTY1ODMzOWQ0N2Q1YmE5Njc4YmYxODdiNThkZS90ZXh0cmVnaW9uOmM0MjcxNjU4MzM5ZDQ3ZDViYTk2NzhiZjE4N2I1OGRlXzU5OQ_bdb27f7c-e9de-4571-838b-7487f0b109c7" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">11. Earnings/(Loss) Per Share Attributable to Cardinal Health, Inc.</span></div><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTIvZnJhZzpjNDI3MTY1ODMzOWQ0N2Q1YmE5Njc4YmYxODdiNThkZS90ZXh0cmVnaW9uOmM0MjcxNjU4MzM5ZDQ3ZDViYTk2NzhiZjE4N2I1OGRlXzU5OA_a57ca60b-43d8-415a-9505-34d0f8781575" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.407%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares&#8211;basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTIvZnJhZzpjNDI3MTY1ODMzOWQ0N2Q1YmE5Njc4YmYxODdiNThkZS90YWJsZToyOGZiZDk2YTMyYzc0NDI3YTg0ODQwY2RkMjUzYmJjMi90YWJsZXJhbmdlOjI4ZmJkOTZhMzJjNzQ0MjdhODQ4NDBjZGQyNTNiYmMyXzItMS0xLTEtMA_1a1df912-308b-4ac2-9f44-cd98bb7c1b5b">292</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTIvZnJhZzpjNDI3MTY1ODMzOWQ0N2Q1YmE5Njc4YmYxODdiNThkZS90YWJsZToyOGZiZDk2YTMyYzc0NDI3YTg0ODQwY2RkMjUzYmJjMi90YWJsZXJhbmdlOjI4ZmJkOTZhMzJjNzQ0MjdhODQ4NDBjZGQyNTNiYmMyXzItMy0xLTEtMA_cf8630cb-2c48-418f-a47c-befb0eddeba5">292</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTIvZnJhZzpjNDI3MTY1ODMzOWQ0N2Q1YmE5Njc4YmYxODdiNThkZS90YWJsZToyOGZiZDk2YTMyYzc0NDI3YTg0ODQwY2RkMjUzYmJjMi90YWJsZXJhbmdlOjI4ZmJkOTZhMzJjNzQ0MjdhODQ4NDBjZGQyNTNiYmMyXzQtMS0xLTEtMA_a1f52a86-ab34-4790-a849-c7ce973518ec">2</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTIvZnJhZzpjNDI3MTY1ODMzOWQ0N2Q1YmE5Njc4YmYxODdiNThkZS90YWJsZToyOGZiZDk2YTMyYzc0NDI3YTg0ODQwY2RkMjUzYmJjMi90YWJsZXJhbmdlOjI4ZmJkOTZhMzJjNzQ0MjdhODQ4NDBjZGQyNTNiYmMyXzQtMy0xLTEtMA_aa8cefb5-f6a9-42b5-a4b5-64f1b7fc611e">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares&#8211;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTIvZnJhZzpjNDI3MTY1ODMzOWQ0N2Q1YmE5Njc4YmYxODdiNThkZS90YWJsZToyOGZiZDk2YTMyYzc0NDI3YTg0ODQwY2RkMjUzYmJjMi90YWJsZXJhbmdlOjI4ZmJkOTZhMzJjNzQ0MjdhODQ4NDBjZGQyNTNiYmMyXzUtMS0xLTEtMA_356d7a37-b8e0-4380-aac5-f9803cb9d4e5">294</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTIvZnJhZzpjNDI3MTY1ODMzOWQ0N2Q1YmE5Njc4YmYxODdiNThkZS90YWJsZToyOGZiZDk2YTMyYzc0NDI3YTg0ODQwY2RkMjUzYmJjMi90YWJsZXJhbmdlOjI4ZmJkOTZhMzJjNzQ0MjdhODQ4NDBjZGQyNTNiYmMyXzUtMy0xLTEtMA_1b14bbee-bcdd-484a-b148-6d288d36c022">294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.407%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares&#8211;basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTIvZnJhZzpjNDI3MTY1ODMzOWQ0N2Q1YmE5Njc4YmYxODdiNThkZS90YWJsZTpjMTJmMjdkOGY5OGI0ZTEyYThhYTJkMDU0ZjY2OTRhMC90YWJsZXJhbmdlOmMxMmYyN2Q4Zjk4YjRlMTJhOGFhMmQwNTRmNjY5NGEwXzItMS0xLTEtMA_78b4b7e9-ae5d-4b57-82d7-482964882a4a">293</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTIvZnJhZzpjNDI3MTY1ODMzOWQ0N2Q1YmE5Njc4YmYxODdiNThkZS90YWJsZTpjMTJmMjdkOGY5OGI0ZTEyYThhYTJkMDU0ZjY2OTRhMC90YWJsZXJhbmdlOmMxMmYyN2Q4Zjk4YjRlMTJhOGFhMmQwNTRmNjY5NGEwXzItMy0xLTEtMA_822567d9-9657-4105-95ec-672ab3944d35">293</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTIvZnJhZzpjNDI3MTY1ODMzOWQ0N2Q1YmE5Njc4YmYxODdiNThkZS90YWJsZTpjMTJmMjdkOGY5OGI0ZTEyYThhYTJkMDU0ZjY2OTRhMC90YWJsZXJhbmdlOmMxMmYyN2Q4Zjk4YjRlMTJhOGFhMmQwNTRmNjY5NGEwXzQtMS0xLTEtMA_4a120701-7337-47bd-83ba-7311ded26fdb">1</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" format="ixt:zerodash" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTIvZnJhZzpjNDI3MTY1ODMzOWQ0N2Q1YmE5Njc4YmYxODdiNThkZS90YWJsZTpjMTJmMjdkOGY5OGI0ZTEyYThhYTJkMDU0ZjY2OTRhMC90YWJsZXJhbmdlOmMxMmYyN2Q4Zjk4YjRlMTJhOGFhMmQwNTRmNjY5NGEwXzQtMy0xLTEtMA_6cd3192d-3d19-4675-955f-2dedbcd53781">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares&#8211;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTIvZnJhZzpjNDI3MTY1ODMzOWQ0N2Q1YmE5Njc4YmYxODdiNThkZS90YWJsZTpjMTJmMjdkOGY5OGI0ZTEyYThhYTJkMDU0ZjY2OTRhMC90YWJsZXJhbmdlOmMxMmYyN2Q4Zjk4YjRlMTJhOGFhMmQwNTRmNjY5NGEwXzUtMS0xLTEtMA_620f0e08-dc48-4bb4-b405-8b5f530f7afb">294</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTIvZnJhZzpjNDI3MTY1ODMzOWQ0N2Q1YmE5Njc4YmYxODdiNThkZS90YWJsZTpjMTJmMjdkOGY5OGI0ZTEyYThhYTJkMDU0ZjY2OTRhMC90YWJsZXJhbmdlOmMxMmYyN2Q4Zjk4YjRlMTJhOGFhMmQwNTRmNjY5NGEwXzUtMy0xLTEtMA_615dcb45-4ca8-4259-9a97-01cd3527c331">293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potentially dilutive employee stock options, restricted share units and performance share units that were anti-dilutive were <ix:nonFraction unitRef="shares" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTIvZnJhZzpjNDI3MTY1ODMzOWQ0N2Q1YmE5Njc4YmYxODdiNThkZS90ZXh0cmVnaW9uOmM0MjcxNjU4MzM5ZDQ3ZDViYTk2NzhiZjE4N2I1OGRlXzI5Mw_82200c87-d780-40db-a74e-5c17089e47b1">3</ix:nonFraction> million for the three months ended March&#160;31, 2021 and <ix:nonFraction unitRef="shares" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTIvZnJhZzpjNDI3MTY1ODMzOWQ0N2Q1YmE5Njc4YmYxODdiNThkZS90ZXh0cmVnaW9uOmM0MjcxNjU4MzM5ZDQ3ZDViYTk2NzhiZjE4N2I1OGRlXzQzOTgwNDY1MTIwMTI_a9621d7f-9c88-4ba2-b1aa-68fcf643ed09">4</ix:nonFraction> million for the nine months ended March&#160;31, 2021.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potentially dilutive employee stock options, restricted share units and performance share units that were anti-dilutive were <ix:nonFraction unitRef="shares" contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTIvZnJhZzpjNDI3MTY1ODMzOWQ0N2Q1YmE5Njc4YmYxODdiNThkZS90ZXh0cmVnaW9uOmM0MjcxNjU4MzM5ZDQ3ZDViYTk2NzhiZjE4N2I1OGRlXzQ2NA_0df0bba0-4779-472a-86c7-82c34317f6ed">4</ix:nonFraction> million for the three months ended March&#160;31, 2020 and <ix:nonFraction unitRef="shares" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTIvZnJhZzpjNDI3MTY1ODMzOWQ0N2Q1YmE5Njc4YmYxODdiNThkZS90ZXh0cmVnaW9uOmM0MjcxNjU4MzM5ZDQ3ZDViYTk2NzhiZjE4N2I1OGRlXzQzOTgwNDY1MTIwMjI_9fad1ce8-20bd-4749-a299-8966c1325e0a">7</ix:nonFraction> million for the nine months ended March&#160;31, 2020 (<ix:nonFraction unitRef="shares" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" format="ixt:numdotdecimal" name="cah:Sharesthatwouldbeantidilutiveasaresultofnetloss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTIvZnJhZzpjNDI3MTY1ODMzOWQ0N2Q1YmE5Njc4YmYxODdiNThkZS90ZXh0cmVnaW9uOmM0MjcxNjU4MzM5ZDQ3ZDViYTk2NzhiZjE4N2I1OGRlXzUxOQ_2f01e0be-ef1e-4037-bd03-bde9cd12682e">2</ix:nonFraction> million of which were anti-dilutive as a result of the year-to-date net loss).</span></div></ix:nonNumeric><div id="ib6bf45669ad94861b0c50dbc2f4371ce_115"></div><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90ZXh0cmVnaW9uOmNhOGZiZWMxNWUyNDRiODE5MzFhMWE0MWMwMWIxZmVmXzUyODA_623b2a89-9ee7-4a9a-9e2d-6a1bf37023df" continuedAt="i376226caf7cd481e94ac422b4b410830" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">12. Segment Information</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are principally managed on a products and services basis and are comprised of <ix:nonFraction unitRef="segment" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90ZXh0cmVnaW9uOmNhOGZiZWMxNWUyNDRiODE5MzFhMWE0MWMwMWIxZmVmXzEwMQ_20c440b5-3ed0-4650-b6dd-b5d5253af641"><ix:nonFraction unitRef="segment" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90ZXh0cmVnaW9uOmNhOGZiZWMxNWUyNDRiODE5MzFhMWE0MWMwMWIxZmVmXzEwMQ_f06cd0a0-9d00-4d1f-983a-ba01b900bd5c">two</ix:nonFraction></ix:nonFraction> operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; provides pharmacy management services to hospitals as well as medication therapy management and patient outcomes services to hospitals, other healthcare providers and payers; and repackages generic pharmaceuticals and over-the-counter healthcare products. </span></div></ix:nonNumeric></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><ix:continuation id="i376226caf7cd481e94ac422b4b410830" continuedAt="i5408921a06b84686b743aa349bc97a22"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. This segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present revenue for each reportable segment and disaggregated revenue within our <ix:nonFraction unitRef="segment" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90ZXh0cmVnaW9uOmNhOGZiZWMxNWUyNDRiODE5MzFhMWE0MWMwMWIxZmVmXzE4NDc_20c440b5-3ed0-4650-b6dd-b5d5253af641"><ix:nonFraction unitRef="segment" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90ZXh0cmVnaW9uOmNhOGZiZWMxNWUyNDRiODE5MzFhMWE0MWMwMWIxZmVmXzE4NDc_f06cd0a0-9d00-4d1f-983a-ba01b900bd5c">two</ix:nonFraction></ix:nonFraction> reportable segments and Corporate:</span></div><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90ZXh0cmVnaW9uOmNhOGZiZWMxNWUyNDRiODE5MzFhMWE0MWMwMWIxZmVmXzUyOTI_11d0b71b-cb46-4c17-a956-3085fab1c9c2" escape="true"><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.593%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical Distribution and Specialty Solutions (1) (2)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb95c38f699b498bae7eccc1951e60ef_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo3NDk5NTZlZWViNDU0ZWNhYTk0YzM4MTkxMDVhZjdjZi90YWJsZXJhbmdlOjc0OTk1NmVlZWI0NTRlY2FhOTRjMzgxOTEwNWFmN2NmXzItMS0xLTEtMA_d6a725c4-1693-4470-9b54-b354acd556e1">34,903</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id77fcd8f97ce44d28130b582a93ca388_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo3NDk5NTZlZWViNDU0ZWNhYTk0YzM4MTkxMDVhZjdjZi90YWJsZXJhbmdlOjc0OTk1NmVlZWI0NTRlY2FhOTRjMzgxOTEwNWFmN2NmXzItMy0xLTEtMA_c8bc0056-0fa4-48d4-87ed-daeb4d9831d6">34,899</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98a550bd18584222b45f6e22795837d8_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo3NDk5NTZlZWViNDU0ZWNhYTk0YzM4MTkxMDVhZjdjZi90YWJsZXJhbmdlOjc0OTk1NmVlZWI0NTRlY2FhOTRjMzgxOTEwNWFmN2NmXzMtMS0xLTEtMA_b75d0443-d7e3-4c8a-851d-9afdacf8ea43">201</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i497d93eb01e34fc299e07f6c11433ddc_D20200101-20200331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo3NDk5NTZlZWViNDU0ZWNhYTk0YzM4MTkxMDVhZjdjZi90YWJsZXJhbmdlOjc0OTk1NmVlZWI0NTRlY2FhOTRjMzgxOTEwNWFmN2NmXzMtMy0xLTEtMA_faa91c85-495b-43c0-a129-8e53c30e4a52">213</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13210788c384499eb6bd49c7ac901881_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo3NDk5NTZlZWViNDU0ZWNhYTk0YzM4MTkxMDVhZjdjZi90YWJsZXJhbmdlOjc0OTk1NmVlZWI0NTRlY2FhOTRjMzgxOTEwNWFmN2NmXzQtMS0xLTEtMA_69c5501f-d972-45df-97b7-77a8d87b1947">35,104</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie15bd6a384d84a93aa0435432170a9e0_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo3NDk5NTZlZWViNDU0ZWNhYTk0YzM4MTkxMDVhZjdjZi90YWJsZXJhbmdlOjc0OTk1NmVlZWI0NTRlY2FhOTRjMzgxOTEwNWFmN2NmXzQtMy0xLTEtMA_a7c9d931-6b9b-42e3-9dfe-ce95f7847477">35,112</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical distribution and products (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i754a245950334f9994b76f93229c450a_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo3NDk5NTZlZWViNDU0ZWNhYTk0YzM4MTkxMDVhZjdjZi90YWJsZXJhbmdlOjc0OTk1NmVlZWI0NTRlY2FhOTRjMzgxOTEwNWFmN2NmXzUtMS0xLTEtMA_e39cbdc7-542e-4d93-90f9-fc640824a0d7">3,638</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie00acdc941434982aa3c874289a0f3fd_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo3NDk5NTZlZWViNDU0ZWNhYTk0YzM4MTkxMDVhZjdjZi90YWJsZXJhbmdlOjc0OTk1NmVlZWI0NTRlY2FhOTRjMzgxOTEwNWFmN2NmXzUtMy0xLTEtMA_e426cdd1-6dee-493d-9314-60490019d088">3,539</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health at-Home Solutions</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i980f0fff0b9a4c3190c440190a0f45b0_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo3NDk5NTZlZWViNDU0ZWNhYTk0YzM4MTkxMDVhZjdjZi90YWJsZXJhbmdlOjc0OTk1NmVlZWI0NTRlY2FhOTRjMzgxOTEwNWFmN2NmXzYtMS0xLTEtMA_8c9c0a62-c3ef-4fdc-a51b-b5238ba7bbcb">536</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66cd600a4fa943049ca88903270b5e37_D20200101-20200331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo3NDk5NTZlZWViNDU0ZWNhYTk0YzM4MTkxMDVhZjdjZi90YWJsZXJhbmdlOjc0OTk1NmVlZWI0NTRlY2FhOTRjMzgxOTEwNWFmN2NmXzYtMy0xLTEtMA_093b91c5-eef9-49ae-95e8-1f99fe57b47a">512</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical segment revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a6b387b92814c6dbccb36d4616b973b_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo3NDk5NTZlZWViNDU0ZWNhYTk0YzM4MTkxMDVhZjdjZi90YWJsZXJhbmdlOjc0OTk1NmVlZWI0NTRlY2FhOTRjMzgxOTEwNWFmN2NmXzctMS0xLTEtMA_e07ff9e5-8863-43ee-ad1c-ff5cfccd9c67">4,174</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b2f4f39f2f9421c9376d5aeb5d1ebba_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo3NDk5NTZlZWViNDU0ZWNhYTk0YzM4MTkxMDVhZjdjZi90YWJsZXJhbmdlOjc0OTk1NmVlZWI0NTRlY2FhOTRjMzgxOTEwNWFmN2NmXzctMy0xLTEtMA_27ec3a3d-74f7-4d67-85f3-c6178109ca1c">4,051</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic430db4eef8d4096927747687050f4ab_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo3NDk5NTZlZWViNDU0ZWNhYTk0YzM4MTkxMDVhZjdjZi90YWJsZXJhbmdlOjc0OTk1NmVlZWI0NTRlY2FhOTRjMzgxOTEwNWFmN2NmXzgtMS0xLTEtMA_62863918-78bf-4c7a-ba8b-73dd661e8020">39,278</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i133a2afe200e422e8417d692d3db7c24_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo3NDk5NTZlZWViNDU0ZWNhYTk0YzM4MTkxMDVhZjdjZi90YWJsZXJhbmdlOjc0OTk1NmVlZWI0NTRlY2FhOTRjMzgxOTEwNWFmN2NmXzgtMy0xLTEtMA_5ceea359-acf5-400b-9792-423f4e215da9">39,163</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3be9b6146804373965da8f26eb058f6_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo3NDk5NTZlZWViNDU0ZWNhYTk0YzM4MTkxMDVhZjdjZi90YWJsZXJhbmdlOjc0OTk1NmVlZWI0NTRlY2FhOTRjMzgxOTEwNWFmN2NmXzktMS0xLTEtMA_15d4e839-3799-4e83-985c-abc515ba10bf">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb553ffd18cb495b81f622bdfcdbd4c4_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo3NDk5NTZlZWViNDU0ZWNhYTk0YzM4MTkxMDVhZjdjZi90YWJsZXJhbmdlOjc0OTk1NmVlZWI0NTRlY2FhOTRjMzgxOTEwNWFmN2NmXzktMy0xLTEtMA_d5947291-4daa-48bb-b65d-6d4fec1f65bf">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo3NDk5NTZlZWViNDU0ZWNhYTk0YzM4MTkxMDVhZjdjZi90YWJsZXJhbmdlOjc0OTk1NmVlZWI0NTRlY2FhOTRjMzgxOTEwNWFmN2NmXzEwLTEtMS0xLTA_4eeeaf57-3665-48d2-b84d-a2d404e7ecd9">39,275</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo3NDk5NTZlZWViNDU0ZWNhYTk0YzM4MTkxMDVhZjdjZi90YWJsZXJhbmdlOjc0OTk1NmVlZWI0NTRlY2FhOTRjMzgxOTEwNWFmN2NmXzEwLTMtMS0xLTA_c80004a1-3cd8-43ac-90be-b29c320f5808">39,157</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.591%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.593%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical Distribution and Specialty Solutions (1) (2)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38499692778a4677a3d0205a54dabc5e_D20200701-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo0NTVjODlkYTU0NzY0NjgxYjczY2RjOGJjNDJjNzJiOC90YWJsZXJhbmdlOjQ1NWM4OWRhNTQ3NjQ2ODFiNzNjZGM4YmM0MmM3MmI4XzItMS0xLTEtMA_588a5ecc-f957-4a52-9165-55c4542e1e3a">106,859</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a204b9287bf45b1a70bdb9303162867_D20190701-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo0NTVjODlkYTU0NzY0NjgxYjczY2RjOGJjNDJjNzJiOC90YWJsZXJhbmdlOjQ1NWM4OWRhNTQ3NjQ2ODFiNzNjZGM4YmM0MmM3MmI4XzItMy0xLTEtMA_6bec33cf-4a60-4acd-8262-ea94c8540bb7">103,612</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd1495b463924bf7a6a21f64497f4f5f_D20200701-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo0NTVjODlkYTU0NzY0NjgxYjczY2RjOGJjNDJjNzJiOC90YWJsZXJhbmdlOjQ1NWM4OWRhNTQ3NjQ2ODFiNzNjZGM4YmM0MmM3MmI4XzMtMS0xLTEtMA_5e72ee8b-33fc-401b-bd40-bbfde7f7a7e3">593</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d2aa45f535e4ad78bb4d60e6ab599cf_D20190701-20200331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo0NTVjODlkYTU0NzY0NjgxYjczY2RjOGJjNDJjNzJiOC90YWJsZXJhbmdlOjQ1NWM4OWRhNTQ3NjQ2ODFiNzNjZGM4YmM0MmM3MmI4XzMtMy0xLTEtMA_00c79876-a717-447c-905b-6aaeb3882911">642</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaf142075796467695d26aed7ffad5a6_D20200701-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo0NTVjODlkYTU0NzY0NjgxYjczY2RjOGJjNDJjNzJiOC90YWJsZXJhbmdlOjQ1NWM4OWRhNTQ3NjQ2ODFiNzNjZGM4YmM0MmM3MmI4XzQtMS0xLTEtMA_3ce67dbf-b29d-4b2d-a10f-ec4e1b549d7c">107,452</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7633f1494ae14d6db19bb6de3dd5dc7d_D20190701-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo0NTVjODlkYTU0NzY0NjgxYjczY2RjOGJjNDJjNzJiOC90YWJsZXJhbmdlOjQ1NWM4OWRhNTQ3NjQ2ODFiNzNjZGM4YmM0MmM3MmI4XzQtMy0xLTEtMA_c2d7a065-5dba-4b3f-9db9-535ceef2c3a3">104,254</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical distribution and products (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia66d6c475fbc4a4f93c1eed3e22397fe_D20200701-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo0NTVjODlkYTU0NzY0NjgxYjczY2RjOGJjNDJjNzJiOC90YWJsZXJhbmdlOjQ1NWM4OWRhNTQ3NjQ2ODFiNzNjZGM4YmM0MmM3MmI4XzUtMS0xLTEtMA_433dc246-bf2a-4abf-a954-3afefed981c6">10,805</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee665c670791489a9810213babe512b3_D20190701-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo0NTVjODlkYTU0NzY0NjgxYjczY2RjOGJjNDJjNzJiOC90YWJsZXJhbmdlOjQ1NWM4OWRhNTQ3NjQ2ODFiNzNjZGM4YmM0MmM3MmI4XzUtMy0xLTEtMA_e719f29b-10e7-4550-a6e4-f0961417db2e">10,483</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health at-Home Solutions</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1306a7b737e45e5b5d2f6b30e1ae7c8_D20200701-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo0NTVjODlkYTU0NzY0NjgxYjczY2RjOGJjNDJjNzJiOC90YWJsZXJhbmdlOjQ1NWM4OWRhNTQ3NjQ2ODFiNzNjZGM4YmM0MmM3MmI4XzYtMS0xLTEtMA_30316a4d-8428-46f7-8693-7d847f75d663">1,636</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8294a10e67a64ee889ba04da6c8dda53_D20190701-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo0NTVjODlkYTU0NzY0NjgxYjczY2RjOGJjNDJjNzJiOC90YWJsZXJhbmdlOjQ1NWM4OWRhNTQ3NjQ2ODFiNzNjZGM4YmM0MmM3MmI4XzYtMy0xLTEtMA_62916ff3-8642-4e2b-8678-f98d02773463">1,508</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical segment revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6b13c1180504c8e8b9bbe3e3b0affe6_D20200701-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo0NTVjODlkYTU0NzY0NjgxYjczY2RjOGJjNDJjNzJiOC90YWJsZXJhbmdlOjQ1NWM4OWRhNTQ3NjQ2ODFiNzNjZGM4YmM0MmM3MmI4XzctMS0xLTEtMA_f613616b-a204-45f2-b0a1-97f2e7d8364c">12,441</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac89152bf6b649d09d16a732e7fe9fd7_D20190701-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo0NTVjODlkYTU0NzY0NjgxYjczY2RjOGJjNDJjNzJiOC90YWJsZXJhbmdlOjQ1NWM4OWRhNTQ3NjQ2ODFiNzNjZGM4YmM0MmM3MmI4XzctMy0xLTEtMA_dd28cc95-a1fc-4724-bb88-a3477e05c986">11,991</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdac359205cd4b9894e9c5b6bc9a75f9_D20200701-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo0NTVjODlkYTU0NzY0NjgxYjczY2RjOGJjNDJjNzJiOC90YWJsZXJhbmdlOjQ1NWM4OWRhNTQ3NjQ2ODFiNzNjZGM4YmM0MmM3MmI4XzgtMS0xLTEtMA_76852d10-2f39-403b-bbe4-d6e28c472947">119,893</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7571f4a1493c40f1948e2aa7d8298511_D20190701-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo0NTVjODlkYTU0NzY0NjgxYjczY2RjOGJjNDJjNzJiOC90YWJsZXJhbmdlOjQ1NWM4OWRhNTQ3NjQ2ODFiNzNjZGM4YmM0MmM3MmI4XzgtMy0xLTEtMA_fa933c18-b753-41f2-8b98-cd3fc27c0ed5">116,245</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if00aae22cda442e2907fd2752c87fb3d_D20200701-20210331" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo0NTVjODlkYTU0NzY0NjgxYjczY2RjOGJjNDJjNzJiOC90YWJsZXJhbmdlOjQ1NWM4OWRhNTQ3NjQ2ODFiNzNjZGM4YmM0MmM3MmI4XzktMS0xLTEtMA_94004ba1-6990-4f95-9763-562d3fc59a3c">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8024f13f805493da1022a38d9655ca3_D20190701-20200331" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo0NTVjODlkYTU0NzY0NjgxYjczY2RjOGJjNDJjNzJiOC90YWJsZXJhbmdlOjQ1NWM4OWRhNTQ3NjQ2ODFiNzNjZGM4YmM0MmM3MmI4XzktMy0xLTEtMA_eb701b2d-a679-4556-8b00-5c3d966ec8a5">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo0NTVjODlkYTU0NzY0NjgxYjczY2RjOGJjNDJjNzJiOC90YWJsZXJhbmdlOjQ1NWM4OWRhNTQ3NjQ2ODFiNzNjZGM4YmM0MmM3MmI4XzEwLTEtMS0xLTA_bb69f61f-954d-418a-8b77-aa4e695427f4">119,881</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo0NTVjODlkYTU0NzY0NjgxYjczY2RjOGJjNDJjNzJiOC90YWJsZXJhbmdlOjQ1NWM4OWRhNTQ3NjQ2ODFiNzNjZGM4YmM0MmM3MmI4XzEwLTMtMS0xLTA_e7dbf0c4-9b32-4270-a175-1abd725f0a29">116,233</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Products and services offered by our Specialty Solutions division are referred to as &#8220;specialty pharmaceutical products and services."</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div></ix:nonNumeric></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90ZXh0cmVnaW9uOmNhOGZiZWMxNWUyNDRiODE5MzFhMWE0MWMwMWIxZmVmXzUyNzU_378df650-4636-4920-a41e-b449f955a5c4" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present revenue by geographic area:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:43.482%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.215%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.217%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i155df096ff374a49874a1b86694a8d78_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo1ZDYyMzRhOTA4M2E0OGFiOTU5ODE3MWU3OTVmN2MxNy90YWJsZXJhbmdlOjVkNjIzNGE5MDgzYTQ4YWI5NTk4MTcxZTc5NWY3YzE3XzItMS0xLTEtMA_d3240e02-a638-495b-a472-a30e8acad610">38,089</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ba2131531c140b1887cc40420a68d24_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo1ZDYyMzRhOTA4M2E0OGFiOTU5ODE3MWU3OTVmN2MxNy90YWJsZXJhbmdlOjVkNjIzNGE5MDgzYTQ4YWI5NTk4MTcxZTc5NWY3YzE3XzItMy0xLTEtMA_6a8fb8a9-e60c-4b7c-b9c7-698718827754">38,073</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c2e770d82df4fb29415150ac2904bdd_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo1ZDYyMzRhOTA4M2E0OGFiOTU5ODE3MWU3OTVmN2MxNy90YWJsZXJhbmdlOjVkNjIzNGE5MDgzYTQ4YWI5NTk4MTcxZTc5NWY3YzE3XzMtMS0xLTEtMA_bde05350-7354-4671-95c8-86165c63f8c6">1,189</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1dce9a8c75d4af4a876d4bf69e8bed9_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo1ZDYyMzRhOTA4M2E0OGFiOTU5ODE3MWU3OTVmN2MxNy90YWJsZXJhbmdlOjVkNjIzNGE5MDgzYTQ4YWI5NTk4MTcxZTc5NWY3YzE3XzMtMy0xLTEtMA_e4cf9e12-0152-4c6a-8269-eaafdde4b82e">1,090</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic430db4eef8d4096927747687050f4ab_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo1ZDYyMzRhOTA4M2E0OGFiOTU5ODE3MWU3OTVmN2MxNy90YWJsZXJhbmdlOjVkNjIzNGE5MDgzYTQ4YWI5NTk4MTcxZTc5NWY3YzE3XzQtMS0xLTEtMA_9950a6bf-d349-4a28-96af-c241cc3d69d4">39,278</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i133a2afe200e422e8417d692d3db7c24_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo1ZDYyMzRhOTA4M2E0OGFiOTU5ODE3MWU3OTVmN2MxNy90YWJsZXJhbmdlOjVkNjIzNGE5MDgzYTQ4YWI5NTk4MTcxZTc5NWY3YzE3XzQtMy0xLTEtMA_b172961c-c069-4e1f-922e-085f64baaf4d">39,163</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3be9b6146804373965da8f26eb058f6_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo1ZDYyMzRhOTA4M2E0OGFiOTU5ODE3MWU3OTVmN2MxNy90YWJsZXJhbmdlOjVkNjIzNGE5MDgzYTQ4YWI5NTk4MTcxZTc5NWY3YzE3XzUtMS0xLTEtMA_adfc09be-870d-4e24-b1a6-c56b82aafeaf">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb553ffd18cb495b81f622bdfcdbd4c4_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo1ZDYyMzRhOTA4M2E0OGFiOTU5ODE3MWU3OTVmN2MxNy90YWJsZXJhbmdlOjVkNjIzNGE5MDgzYTQ4YWI5NTk4MTcxZTc5NWY3YzE3XzUtMy0xLTEtMA_6a1f5de9-226a-49bb-85fd-ce780d36ca7d">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo1ZDYyMzRhOTA4M2E0OGFiOTU5ODE3MWU3OTVmN2MxNy90YWJsZXJhbmdlOjVkNjIzNGE5MDgzYTQ4YWI5NTk4MTcxZTc5NWY3YzE3XzYtMS0xLTEtMA_b359e378-20a2-4763-b9e9-85a0cab38578">39,275</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo1ZDYyMzRhOTA4M2E0OGFiOTU5ODE3MWU3OTVmN2MxNy90YWJsZXJhbmdlOjVkNjIzNGE5MDgzYTQ4YWI5NTk4MTcxZTc5NWY3YzE3XzYtMy0xLTEtMA_9e5154cb-6529-4ea1-9983-d82d58fc8246">39,157</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:43.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.906%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.217%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia08f0b8f481d48ddaf2634a007190de5_D20200701-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTpjMzAxMGI2YWFiNzk0YWY1OTNjMWVmMzVjMjI5ZDdkMS90YWJsZXJhbmdlOmMzMDEwYjZhYWI3OTRhZjU5M2MxZWYzNWMyMjlkN2QxXzItMS0xLTEtMA_f85550e0-df54-42a4-b19b-b68ac282d910">116,425</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i627973ec4999405b88953cf1981248fe_D20190701-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTpjMzAxMGI2YWFiNzk0YWY1OTNjMWVmMzVjMjI5ZDdkMS90YWJsZXJhbmdlOmMzMDEwYjZhYWI3OTRhZjU5M2MxZWYzNWMyMjlkN2QxXzItMy0xLTEtMA_cbc9d1f2-f4a9-4772-98e9-31140b5bb022">113,053</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c43376b1a4b4c3fb49e50efec9c4eb9_D20200701-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTpjMzAxMGI2YWFiNzk0YWY1OTNjMWVmMzVjMjI5ZDdkMS90YWJsZXJhbmdlOmMzMDEwYjZhYWI3OTRhZjU5M2MxZWYzNWMyMjlkN2QxXzMtMS0xLTEtMA_8e6dad60-b917-412e-8d6e-6015e47abdc5">3,468</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i437975c25f184124919229aca35a0a19_D20190701-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTpjMzAxMGI2YWFiNzk0YWY1OTNjMWVmMzVjMjI5ZDdkMS90YWJsZXJhbmdlOmMzMDEwYjZhYWI3OTRhZjU5M2MxZWYzNWMyMjlkN2QxXzMtMy0xLTEtMA_2df40dea-adc4-4369-8a7b-0aa56900547e">3,192</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdac359205cd4b9894e9c5b6bc9a75f9_D20200701-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTpjMzAxMGI2YWFiNzk0YWY1OTNjMWVmMzVjMjI5ZDdkMS90YWJsZXJhbmdlOmMzMDEwYjZhYWI3OTRhZjU5M2MxZWYzNWMyMjlkN2QxXzQtMS0xLTEtMA_844872c1-e95e-40ae-bda8-c7c1e7bc3fc0">119,893</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7571f4a1493c40f1948e2aa7d8298511_D20190701-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTpjMzAxMGI2YWFiNzk0YWY1OTNjMWVmMzVjMjI5ZDdkMS90YWJsZXJhbmdlOmMzMDEwYjZhYWI3OTRhZjU5M2MxZWYzNWMyMjlkN2QxXzQtMy0xLTEtMA_c11f3f68-88b5-4ae1-a5a6-79ec4a2715b3">116,245</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if00aae22cda442e2907fd2752c87fb3d_D20200701-20210331" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTpjMzAxMGI2YWFiNzk0YWY1OTNjMWVmMzVjMjI5ZDdkMS90YWJsZXJhbmdlOmMzMDEwYjZhYWI3OTRhZjU5M2MxZWYzNWMyMjlkN2QxXzUtMS0xLTEtMA_b9622cfb-9503-41e4-b5ef-b2432a4689f3">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8024f13f805493da1022a38d9655ca3_D20190701-20200331" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTpjMzAxMGI2YWFiNzk0YWY1OTNjMWVmMzVjMjI5ZDdkMS90YWJsZXJhbmdlOmMzMDEwYjZhYWI3OTRhZjU5M2MxZWYzNWMyMjlkN2QxXzUtMy0xLTEtMA_de873f1d-b419-44f2-bbe4-af09841da98f">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTpjMzAxMGI2YWFiNzk0YWY1OTNjMWVmMzVjMjI5ZDdkMS90YWJsZXJhbmdlOmMzMDEwYjZhYWI3OTRhZjU5M2MxZWYzNWMyMjlkN2QxXzYtMS0xLTEtMA_7cd06e8d-7e1d-4045-8c62-13e7c9a22a18">119,881</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTpjMzAxMGI2YWFiNzk0YWY1OTNjMWVmMzVjMjI5ZDdkMS90YWJsZXJhbmdlOmMzMDEwYjZhYWI3OTRhZjU5M2MxZWYzNWMyMjlkN2QxXzYtMy0xLTEtMA_9683c241-fd44-43a5-a235-0bcb9c78a76f">116,233</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Profit</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&amp;A") expenses. Segment SG&amp;A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial, and customer care shared services, human resources, information technology, and legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation methodologies. The results attributable to noncontrolling interests are recorded within segment profit.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not allocate the following items to our segments: last-in first-out, or ("LIFO"), inventory charges/(credits); surgical gown recall costs; restructuring and employee severance; amortization and other acquisition-related costs; impairments and (gain)/loss on disposal of assets; litigation (recoveries)/charges, net; state opioid assessment related to prior fiscal years; other (income)/expense, net; interest expense, net; loss on early extinguishment of debt; and provision for income taxes. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $<ix:nonFraction unitRef="usd" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="cah:ProjectCostsOnInvestmentAndOtherSpending" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90ZXh0cmVnaW9uOmNhOGZiZWMxNWUyNDRiODE5MzFhMWE0MWMwMWIxZmVmXzQzMjA_0cc0da1f-a808-47f9-9b1a-56a0f950dfa5">4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="cah:ProjectCostsOnInvestmentAndOtherSpending" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90ZXh0cmVnaW9uOmNhOGZiZWMxNWUyNDRiODE5MzFhMWE0MWMwMWIxZmVmXzQzMjc_882ef099-7855-407c-8600-e0463a4fb730">17</ix:nonFraction> million for the three months ended March&#160;31, 2021 and 2020, and $<ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" format="ixt:numdotdecimal" name="cah:ProjectCostsOnInvestmentAndOtherSpending" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90ZXh0cmVnaW9uOmNhOGZiZWMxNWUyNDRiODE5MzFhMWE0MWMwMWIxZmVmXzQzNzI_34043b75-2ffd-494b-912c-a196d983960f">15</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" format="ixt:numdotdecimal" name="cah:ProjectCostsOnInvestmentAndOtherSpending" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90ZXh0cmVnaW9uOmNhOGZiZWMxNWUyNDRiODE5MzFhMWE0MWMwMWIxZmVmXzQzNzk_2efcc9c0-36fb-4b5d-b748-0f374797b52b">37</ix:nonFraction> million for the nine months ended March&#160;31, 2021 and 2020, respectively.</span></div></div></ix:continuation></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">45</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.682%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="i5408921a06b84686b743aa349bc97a22"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the planned divestiture of the Cordis business, we recognized a $<ix:nonFraction unitRef="usd" contextRef="i7cdd3ec3331046ec97e3ab5eeb7a43e0_I20210331" decimals="-6" sign="-" format="ixt:numdotdecimal" name="cah:WriteDownOfAssetsHeldForSale" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90ZXh0cmVnaW9uOmNhOGZiZWMxNWUyNDRiODE5MzFhMWE0MWMwMWIxZmVmXzMyOTg1MzQ4OTAxNDk_a8cc8edb-131c-4e11-9dd0-0427ccbeafff">58</ix:nonFraction>&#160;million pre-tax write-down of the net assets held for sale</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the three and nine months ended March&#160;31, 2021, which was retained at Corporate.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the opioid litigation as discussed further in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_97">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we recognized pre-tax charges of $<ix:nonFraction unitRef="usd" contextRef="ib9e03386e8bb45b9bfa0b58a7c283f07_D20200701-20210331" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90ZXh0cmVnaW9uOmNhOGZiZWMxNWUyNDRiODE5MzFhMWE0MWMwMWIxZmVmXzQ1MjQ_089202f4-34a0-4f24-b2a6-730e01801ccc">1.02</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i32ccdaa0f4af4c919f10cbbfa4cc9a79_D20190701-20200331" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90ZXh0cmVnaW9uOmNhOGZiZWMxNWUyNDRiODE5MzFhMWE0MWMwMWIxZmVmXzQ1MzE_8ef151f9-98cc-4148-a8a2-1e0e26e2206b">5.63</ix:nonFraction>&#160;billion</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the nine months ended March&#160;31, 2021 and 2020, respectively, which were retained at Corporate. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the New York Opioid Stewardship Act as discussed further in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_97">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we recognized a pre-tax charge of $<ix:nonFraction unitRef="usd" contextRef="i12b52de2a6014b01b5857d8d032e2d95_D20200701-20210331" decimals="-6" format="ixt:numdotdecimal" name="cah:EstimatedLiabilityForNewYorkOpioidStewardshipAct" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90ZXh0cmVnaW9uOmNhOGZiZWMxNWUyNDRiODE5MzFhMWE0MWMwMWIxZmVmXzQ3Mjk_674db16e-3cf6-492b-a085-130504a4ae5a">41</ix:nonFraction>&#160;million during the nine months ended March&#160;31, 2021, related to calendar year 2017 and 2018 assessments, which was retained at Corporate.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with a voluntary recall for certain surgical gowns and a voluntary recall and field actions for surgical procedure packs containing affected gowns, we recognized a pre-tax charge of $<ix:nonFraction unitRef="usd" contextRef="ibbb9380a5af84ba6ae989a20e860a444_D20190701-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InventoryRecallExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90ZXh0cmVnaW9uOmNhOGZiZWMxNWUyNDRiODE5MzFhMWE0MWMwMWIxZmVmXzQzOTgwNDY1MTc5NDQ_7a14e366-2a44-4a8d-85a9-eb0e348af52d">95</ix:nonFraction>&#160;million during the nine months ended March&#160;31, 2020 which was retained at Corporate.</span></div><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90ZXh0cmVnaW9uOmNhOGZiZWMxNWUyNDRiODE5MzFhMWE0MWMwMWIxZmVmXzUyODc_bf42d8da-8eb3-46a8-ae03-c5d18768a322" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present segment profit by reportable segment and Corporate:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13210788c384499eb6bd49c7ac901881_D20210101-20210331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo4NWNhYTdhYjlhNGU0YmFjODA4YWE2MzliMjI5YTAyNC90YWJsZXJhbmdlOjg1Y2FhN2FiOWE0ZTRiYWM4MDhhYTYzOWIyMjlhMDI0XzItMS0xLTEtMA_7c672516-7241-4975-a9ec-a0935184a3ad">511</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie15bd6a384d84a93aa0435432170a9e0_D20200101-20200331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo4NWNhYTdhYjlhNGU0YmFjODA4YWE2MzliMjI5YTAyNC90YWJsZXJhbmdlOjg1Y2FhN2FiOWE0ZTRiYWM4MDhhYTYzOWIyMjlhMDI0XzItMy0xLTEtMA_76ee3dbd-5ac7-41b4-bcd0-d1dfe3b878fc">534</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a6b387b92814c6dbccb36d4616b973b_D20210101-20210331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo4NWNhYTdhYjlhNGU0YmFjODA4YWE2MzliMjI5YTAyNC90YWJsZXJhbmdlOjg1Y2FhN2FiOWE0ZTRiYWM4MDhhYTYzOWIyMjlhMDI0XzMtMS0xLTEtMA_337a99e9-7e7e-40b2-ba47-8273b0368c3b">174</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b2f4f39f2f9421c9376d5aeb5d1ebba_D20200101-20200331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo4NWNhYTdhYjlhNGU0YmFjODA4YWE2MzliMjI5YTAyNC90YWJsZXJhbmdlOjg1Y2FhN2FiOWE0ZTRiYWM4MDhhYTYzOWIyMjlhMDI0XzMtMy0xLTEtMA_d78a603a-8a1f-4a37-a689-91d334e0f461">178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic430db4eef8d4096927747687050f4ab_D20210101-20210331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo4NWNhYTdhYjlhNGU0YmFjODA4YWE2MzliMjI5YTAyNC90YWJsZXJhbmdlOjg1Y2FhN2FiOWE0ZTRiYWM4MDhhYTYzOWIyMjlhMDI0XzQtMS0xLTEtMA_88f7a7ee-593d-41d9-9b7c-60a566bbde27">685</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i133a2afe200e422e8417d692d3db7c24_D20200101-20200331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo4NWNhYTdhYjlhNGU0YmFjODA4YWE2MzliMjI5YTAyNC90YWJsZXJhbmdlOjg1Y2FhN2FiOWE0ZTRiYWM4MDhhYTYzOWIyMjlhMDI0XzQtMy0xLTEtMA_cc01b2e9-99e2-4f18-956e-22540027be8d">712</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3be9b6146804373965da8f26eb058f6_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo4NWNhYTdhYjlhNGU0YmFjODA4YWE2MzliMjI5YTAyNC90YWJsZXJhbmdlOjg1Y2FhN2FiOWE0ZTRiYWM4MDhhYTYzOWIyMjlhMDI0XzUtMS0xLTEtMA_4f05a13b-5f76-4cf7-9fcf-dfc06ea64d41">212</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb553ffd18cb495b81f622bdfcdbd4c4_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo4NWNhYTdhYjlhNGU0YmFjODA4YWE2MzliMjI5YTAyNC90YWJsZXJhbmdlOjg1Y2FhN2FiOWE0ZTRiYWM4MDhhYTYzOWIyMjlhMDI0XzUtMy0xLTEtMA_cab1a206-a9df-4ca2-a611-8163c62aad33">150</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating earnings</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo4NWNhYTdhYjlhNGU0YmFjODA4YWE2MzliMjI5YTAyNC90YWJsZXJhbmdlOjg1Y2FhN2FiOWE0ZTRiYWM4MDhhYTYzOWIyMjlhMDI0XzYtMS0xLTEtMA_2756cd7f-af74-4070-a9f0-e7d07fcc121f">473</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo4NWNhYTdhYjlhNGU0YmFjODA4YWE2MzliMjI5YTAyNC90YWJsZXJhbmdlOjg1Y2FhN2FiOWE0ZTRiYWM4MDhhYTYzOWIyMjlhMDI0XzYtMy0xLTEtMA_8a71da24-90fa-41f9-91a7-aa1a4b9ccdc9">562</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaf142075796467695d26aed7ffad5a6_D20200701-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZToxYmVmM2EzYTFhMTE0ZjU2Yjg2NzA4ZjIxMWQyOTQxZS90YWJsZXJhbmdlOjFiZWYzYTNhMWExMTRmNTZiODY3MDhmMjExZDI5NDFlXzItMS0xLTEtMA_4a7d292f-2008-4501-a3ef-60a28c8ce690">1,326</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7633f1494ae14d6db19bb6de3dd5dc7d_D20190701-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZToxYmVmM2EzYTFhMTE0ZjU2Yjg2NzA4ZjIxMWQyOTQxZS90YWJsZXJhbmdlOjFiZWYzYTNhMWExMTRmNTZiODY3MDhmMjExZDI5NDFlXzItMy0xLTEtMA_dbda1495-471e-4913-9710-33b2d0e9817a">1,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6b13c1180504c8e8b9bbe3e3b0affe6_D20200701-20210331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZToxYmVmM2EzYTFhMTE0ZjU2Yjg2NzA4ZjIxMWQyOTQxZS90YWJsZXJhbmdlOjFiZWYzYTNhMWExMTRmNTZiODY3MDhmMjExZDI5NDFlXzMtMS0xLTEtMA_f82f088e-bd3c-4eb2-8a9b-fe441ac105c3">640</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac89152bf6b649d09d16a732e7fe9fd7_D20190701-20200331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZToxYmVmM2EzYTFhMTE0ZjU2Yjg2NzA4ZjIxMWQyOTQxZS90YWJsZXJhbmdlOjFiZWYzYTNhMWExMTRmNTZiODY3MDhmMjExZDI5NDFlXzMtMy0xLTEtMA_26904d0c-0993-46d6-91d5-7e19f0833a0a">543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdac359205cd4b9894e9c5b6bc9a75f9_D20200701-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZToxYmVmM2EzYTFhMTE0ZjU2Yjg2NzA4ZjIxMWQyOTQxZS90YWJsZXJhbmdlOjFiZWYzYTNhMWExMTRmNTZiODY3MDhmMjExZDI5NDFlXzQtMS0xLTEtMA_63501def-8505-442c-9024-c2fbb8244010">1,966</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7571f4a1493c40f1948e2aa7d8298511_D20190701-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZToxYmVmM2EzYTFhMTE0ZjU2Yjg2NzA4ZjIxMWQyOTQxZS90YWJsZXJhbmdlOjFiZWYzYTNhMWExMTRmNTZiODY3MDhmMjExZDI5NDFlXzQtMy0xLTEtMA_5a437a85-0662-403f-a1fa-27a06ea46da7">1,937</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if00aae22cda442e2907fd2752c87fb3d_D20200701-20210331" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZToxYmVmM2EzYTFhMTE0ZjU2Yjg2NzA4ZjIxMWQyOTQxZS90YWJsZXJhbmdlOjFiZWYzYTNhMWExMTRmNTZiODY3MDhmMjExZDI5NDFlXzUtMS0xLTEtMA_3c11891e-6339-44f5-ad43-3a49d667f66b">1,656</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic8024f13f805493da1022a38d9655ca3_D20190701-20200331" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZToxYmVmM2EzYTFhMTE0ZjU2Yjg2NzA4ZjIxMWQyOTQxZS90YWJsZXJhbmdlOjFiZWYzYTNhMWExMTRmNTZiODY3MDhmMjExZDI5NDFlXzUtMy0xLTEtMA_37d0120e-8586-4fd5-94d6-f854e52e405f">6,305</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating earnings/(loss)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZToxYmVmM2EzYTFhMTE0ZjU2Yjg2NzA4ZjIxMWQyOTQxZS90YWJsZXJhbmdlOjFiZWYzYTNhMWExMTRmNTZiODY3MDhmMjExZDI5NDFlXzYtMS0xLTEtMA_22f56b63-8b5d-40bc-aaef-aac102297ce7">310</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZToxYmVmM2EzYTFhMTE0ZjU2Yjg2NzA4ZjIxMWQyOTQxZS90YWJsZXJhbmdlOjFiZWYzYTNhMWExMTRmNTZiODY3MDhmMjExZDI5NDFlXzYtMy0xLTEtMA_d2213eb4-a0eb-46ea-8282-33a9b812ba22">4,368</ix:nonFraction>)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" name="us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90ZXh0cmVnaW9uOmNhOGZiZWMxNWUyNDRiODE5MzFhMWE0MWMwMWIxZmVmXzUyODk_27e7cf58-748f-4d04-9d2a-74d4e5a6d622" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total assets for each reportable segment and Corporate at: </span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:52.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.503%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb1b5bacb6bb401e8fe737bb56674184_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo2MmYyOWJkYTk2MDc0ZjRiOTA2YWI3MDllMThkZjBmYy90YWJsZXJhbmdlOjYyZjI5YmRhOTYwNzRmNGI5MDZhYjcwOWUxOGRmMGZjXzEtMS0xLTEtMA_7dafa78d-474f-454b-8dae-a94994f71466">23,078</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia56ac1f95221479a8866de7ff447bece_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo2MmYyOWJkYTk2MDc0ZjRiOTA2YWI3MDllMThkZjBmYy90YWJsZXJhbmdlOjYyZjI5YmRhOTYwNzRmNGI5MDZhYjcwOWUxOGRmMGZjXzEtMy0xLTEtMA_281279c2-4c6b-4de2-ba6e-0209ba089ea2">22,398</ix:nonFraction>&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22ff8eca14d54d0e88769fe944e5fac0_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo2MmYyOWJkYTk2MDc0ZjRiOTA2YWI3MDllMThkZjBmYy90YWJsZXJhbmdlOjYyZjI5YmRhOTYwNzRmNGI5MDZhYjcwOWUxOGRmMGZjXzItMS0xLTEtMA_c6bd227e-2363-4867-9c53-b8ee8402a21a">15,280</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8ac06c44c654f11a21c85f88fe7ba70_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo2MmYyOWJkYTk2MDc0ZjRiOTA2YWI3MDllMThkZjBmYy90YWJsZXJhbmdlOjYyZjI5YmRhOTYwNzRmNGI5MDZhYjcwOWUxOGRmMGZjXzItMy0xLTEtMA_24e56763-7d94-4459-aa4b-49e52fd74594">14,691</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b9e31e1c7394a41915dce3992145e0c_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo2MmYyOWJkYTk2MDc0ZjRiOTA2YWI3MDllMThkZjBmYy90YWJsZXJhbmdlOjYyZjI5YmRhOTYwNzRmNGI5MDZhYjcwOWUxOGRmMGZjXzMtMS0xLTEtMA_eb0afa1d-91c4-42ca-87d3-d920fce383b5">5,516</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"></td><td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie599ab9917894d65ad37cc3447647eae_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo2MmYyOWJkYTk2MDc0ZjRiOTA2YWI3MDllMThkZjBmYy90YWJsZXJhbmdlOjYyZjI5YmRhOTYwNzRmNGI5MDZhYjcwOWUxOGRmMGZjXzMtMy0xLTEtMA_1a776ca8-7fce-4593-8f43-0741f52623d7">3,677</ix:nonFraction>&#160;</span></td><td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo2MmYyOWJkYTk2MDc0ZjRiOTA2YWI3MDllMThkZjBmYy90YWJsZXJhbmdlOjYyZjI5YmRhOTYwNzRmNGI5MDZhYjcwOWUxOGRmMGZjXzQtMS0xLTEtMA_228aee25-cd21-46e9-97c3-1c8ed684369a">43,874</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo2MmYyOWJkYTk2MDc0ZjRiOTA2YWI3MDllMThkZjBmYy90YWJsZXJhbmdlOjYyZjI5YmRhOTYwNzRmNGI5MDZhYjcwOWUxOGRmMGZjXzQtMy0xLTEtMA_380d4cbe-65bc-4bd8-bd7d-d46f70d177c3">40,766</ix:nonFraction>&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Assets of $<ix:nonFraction unitRef="usd" contextRef="i03c64db735f449b18a2b4bbcb90984f0_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90ZXh0cmVnaW9uOmNhOGZiZWMxNWUyNDRiODE5MzFhMWE0MWMwMWIxZmVmXzc2OTY1ODE0MDQyOTM_8772644a-fe61-4ced-8652-b142557a5109">1.1</ix:nonFraction> billion classified as held for sale related to the Cordis planned divestiture were included within Medical at March&#160;31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:nonNumeric></ix:continuation><div id="ib6bf45669ad94861b0c50dbc2f4371ce_118"></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"><ix:nonNumeric contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90ZXh0cmVnaW9uOjE1ZjA5M2Q1ZDEyMjQ5NDE4NTc3NzNlMTk1YTZjMWQwXzIzNjE_01ba82a8-aa5a-42aa-9812-096625f19167" continuedAt="id52fb73b657b4c5f98ed93f994912784" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">13. Share-Based Compensation</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain stock incentive plans (collectively, the &#8220;Plans&#8221;) for the benefit of certain of our officers, directors and employees. </span></div><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90ZXh0cmVnaW9uOjE1ZjA5M2Q1ZDEyMjQ5NDE4NTc3NzNlMTk1YTZjMWQwXzIzODI_25e93a8a-0ab7-437c-9a0b-85b06526d60a" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides total share-based compensation expense by type of award:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5489b32b324b43e7b31fefeae25b8dc6_D20210101-20210331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpkZWE5YTIwZTI4OGM0NzRjYWU5ZTdjNzU3YzhhN2VmNS90YWJsZXJhbmdlOmRlYTlhMjBlMjg4YzQ3NGNhZTllN2M3NTdjOGE3ZWY1XzItMS0xLTEtMA_745b95ef-a8d2-4344-abc6-11520f2cafb6">20</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadf80adca21245ef9ca13b43ebeba09d_D20200101-20200331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpkZWE5YTIwZTI4OGM0NzRjYWU5ZTdjNzU3YzhhN2VmNS90YWJsZXJhbmdlOmRlYTlhMjBlMjg4YzQ3NGNhZTllN2M3NTdjOGE3ZWY1XzItMy0xLTEtMA_c860018e-9b77-4d68-b8a8-52e05e5f588d">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock option expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i675bcdf093c842b683f5f42b5d7c6dd5_D20210101-20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpkZWE5YTIwZTI4OGM0NzRjYWU5ZTdjNzU3YzhhN2VmNS90YWJsZXJhbmdlOmRlYTlhMjBlMjg4YzQ3NGNhZTllN2M3NTdjOGE3ZWY1XzMtMS0xLTEtMA_3f7fa365-1fc8-4b01-b9d9-7195a63654f0">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56e3ff286a3f4cc79923baab49b0ed00_D20200101-20200331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpkZWE5YTIwZTI4OGM0NzRjYWU5ZTdjNzU3YzhhN2VmNS90YWJsZXJhbmdlOmRlYTlhMjBlMjg4YzQ3NGNhZTllN2M3NTdjOGE3ZWY1XzMtMy0xLTEtMA_211289c4-91b5-4dd8-a610-dfeb847b2146">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida44dc7e8fef4822b90092a960bfd60d_D20210101-20210331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpkZWE5YTIwZTI4OGM0NzRjYWU5ZTdjNzU3YzhhN2VmNS90YWJsZXJhbmdlOmRlYTlhMjBlMjg4YzQ3NGNhZTllN2M3NTdjOGE3ZWY1XzQtMS0xLTEtMA_d54fecf8-3159-4241-83d1-db2fd3ab938b">13</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5fccbaecaed42a78b6b4926ea168dc1_D20200101-20200331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpkZWE5YTIwZTI4OGM0NzRjYWU5ZTdjNzU3YzhhN2VmNS90YWJsZXJhbmdlOmRlYTlhMjBlMjg4YzQ3NGNhZTllN2M3NTdjOGE3ZWY1XzQtMy0xLTEtMA_25894a44-f35b-431e-9c50-99cd75a2db41">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpkZWE5YTIwZTI4OGM0NzRjYWU5ZTdjNzU3YzhhN2VmNS90YWJsZXJhbmdlOmRlYTlhMjBlMjg4YzQ3NGNhZTllN2M3NTdjOGE3ZWY1XzUtMS0xLTEtMA_48bc164c-95d7-41c7-85e2-73066b1929fc">33</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpkZWE5YTIwZTI4OGM0NzRjYWU5ZTdjNzU3YzhhN2VmNS90YWJsZXJhbmdlOmRlYTlhMjBlMjg4YzQ3NGNhZTllN2M3NTdjOGE3ZWY1XzUtMy0xLTEtMA_b22b47c0-60ed-42eb-9564-185c84dd7c1e">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a89c112cd7f42b3a5456dc100a7ede7_D20200701-20210331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZToxOGM5MGUyMjNjNWM0M2I2Yjg4NDAwYjM1NzYwZjcxYy90YWJsZXJhbmdlOjE4YzkwZTIyM2M1YzQzYjZiODg0MDBiMzU3NjBmNzFjXzItMS0xLTEtMA_9a589eab-8ed8-4ed4-87ba-21db54173abf">56</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic52a8031a6f841969982b87db2a42528_D20190701-20200331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZToxOGM5MGUyMjNjNWM0M2I2Yjg4NDAwYjM1NzYwZjcxYy90YWJsZXJhbmdlOjE4YzkwZTIyM2M1YzQzYjZiODg0MDBiMzU3NjBmNzFjXzItMy0xLTEtMA_ecb8a8fc-0efc-41b7-a0bf-bd95066658b6">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock option expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96b93fe596a142948ea01b57dd171ae6_D20200701-20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZToxOGM5MGUyMjNjNWM0M2I2Yjg4NDAwYjM1NzYwZjcxYy90YWJsZXJhbmdlOjE4YzkwZTIyM2M1YzQzYjZiODg0MDBiMzU3NjBmNzFjXzMtMS0xLTEtMA_2130a233-ead2-4243-b7ee-eb92b238248f">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26baad0d41684101ab66f22954853d05_D20190701-20200331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZToxOGM5MGUyMjNjNWM0M2I2Yjg4NDAwYjM1NzYwZjcxYy90YWJsZXJhbmdlOjE4YzkwZTIyM2M1YzQzYjZiODg0MDBiMzU3NjBmNzFjXzMtMy0xLTEtMA_abcaf34d-eaf9-4761-816b-f974bf4a03b6">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04a5e9e5e39042d4954e45ee16242fba_D20200701-20210331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZToxOGM5MGUyMjNjNWM0M2I2Yjg4NDAwYjM1NzYwZjcxYy90YWJsZXJhbmdlOjE4YzkwZTIyM2M1YzQzYjZiODg0MDBiMzU3NjBmNzFjXzQtMS0xLTEtMA_031888ab-5db5-4cba-8492-eedf5467a25a">28</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifacfc13c40bb4c9bb653687d05e0441a_D20190701-20200331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZToxOGM5MGUyMjNjNWM0M2I2Yjg4NDAwYjM1NzYwZjcxYy90YWJsZXJhbmdlOjE4YzkwZTIyM2M1YzQzYjZiODg0MDBiMzU3NjBmNzFjXzQtMy0xLTEtMA_e8618710-9368-4bcb-82f7-4870297e0ba0">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZToxOGM5MGUyMjNjNWM0M2I2Yjg4NDAwYjM1NzYwZjcxYy90YWJsZXJhbmdlOjE4YzkwZTIyM2M1YzQzYjZiODg0MDBiMzU3NjBmNzFjXzUtMS0xLTEtMA_05f5cfbe-56b7-4554-8e19-55e5b30a1e1c">84</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZToxOGM5MGUyMjNjNWM0M2I2Yjg4NDAwYjM1NzYwZjcxYy90YWJsZXJhbmdlOjE4YzkwZTIyM2M1YzQzYjZiODg0MDBiMzU3NjBmNzFjXzUtMy0xLTEtMA_5ce0cafe-af67-44e5-920f-25424b2b6a6b">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total tax benefit related to share-based compensation was $<ix:nonFraction unitRef="usd" contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90ZXh0cmVnaW9uOjE1ZjA5M2Q1ZDEyMjQ5NDE4NTc3NzNlMTk1YTZjMWQwXzI5NA_ca64b13a-834f-43ad-aec8-1c77a85ddf2a"><ix:nonFraction unitRef="usd" contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90ZXh0cmVnaW9uOjE1ZjA5M2Q1ZDEyMjQ5NDE4NTc3NzNlMTk1YTZjMWQwXzI5NA_d3176ce9-776a-49c5-bc9c-81710adeb209">5</ix:nonFraction></ix:nonFraction> million for both the three months ended March&#160;31, 2021 and 2020, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90ZXh0cmVnaW9uOjE1ZjA5M2Q1ZDEyMjQ5NDE4NTc3NzNlMTk1YTZjMWQwXzM0NA_681ac546-96a1-47fe-8122-9f01623960dd"><ix:nonFraction unitRef="usd" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90ZXh0cmVnaW9uOjE1ZjA5M2Q1ZDEyMjQ5NDE4NTc3NzNlMTk1YTZjMWQwXzM0NA_ade8e185-4ef3-41b1-b3d8-f14d26d5f932">12</ix:nonFraction></ix:nonFraction> million for both the nine months ended March&#160;31, 2021 and 2020, respectively.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Restricted Share Units</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted share units granted under the Plans generally vest in equal annual installments over <ix:nonNumeric contextRef="i8a89c112cd7f42b3a5456dc100a7ede7_D20200701-20210331" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90ZXh0cmVnaW9uOjE1ZjA5M2Q1ZDEyMjQ5NDE4NTc3NzNlMTk1YTZjMWQwXzQ5Mw_3bd3776f-07f6-4ae3-a949-dc1e41091130">three years</ix:nonNumeric>. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards.</span></div><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90ZXh0cmVnaW9uOjE1ZjA5M2Q1ZDEyMjQ5NDE4NTc3NzNlMTk1YTZjMWQwXzIzMzc_b9d1cad0-681b-4f87-9991-6bb523c3af95" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to restricted share units under the Plans:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:51.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.218%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib6304faf17b842ef9c340762418125fc_I20200630" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpkMTZkZGFmMjlmOTI0MTAzYmRiNDc3OGQ1OThjZmQ2Ny90YWJsZXJhbmdlOmQxNmRkYWYyOWY5MjQxMDNiZGI0Nzc4ZDU5OGNmZDY3XzEtMS0xLTEtMA_d4bf324b-0b28-4d68-9b1e-822ccf5f73f9">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib6304faf17b842ef9c340762418125fc_I20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpkMTZkZGFmMjlmOTI0MTAzYmRiNDc3OGQ1OThjZmQ2Ny90YWJsZXJhbmdlOmQxNmRkYWYyOWY5MjQxMDNiZGI0Nzc4ZDU5OGNmZDY3XzEtMy0xLTEtMA_7106b549-65a8-4ee8-9b6c-5172c3ececd4">45.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8a89c112cd7f42b3a5456dc100a7ede7_D20200701-20210331" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpkMTZkZGFmMjlmOTI0MTAzYmRiNDc3OGQ1OThjZmQ2Ny90YWJsZXJhbmdlOmQxNmRkYWYyOWY5MjQxMDNiZGI0Nzc4ZDU5OGNmZDY3XzItMS0xLTEtMA_f96860df-b853-4f11-afb8-f9c930cefbde">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8a89c112cd7f42b3a5456dc100a7ede7_D20200701-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpkMTZkZGFmMjlmOTI0MTAzYmRiNDc3OGQ1OThjZmQ2Ny90YWJsZXJhbmdlOmQxNmRkYWYyOWY5MjQxMDNiZGI0Nzc4ZDU5OGNmZDY3XzItMy0xLTEtMA_158304d2-6790-4442-a70d-096ed09578d2">53.67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8a89c112cd7f42b3a5456dc100a7ede7_D20200701-20210331" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpkMTZkZGFmMjlmOTI0MTAzYmRiNDc3OGQ1OThjZmQ2Ny90YWJsZXJhbmdlOmQxNmRkYWYyOWY5MjQxMDNiZGI0Nzc4ZDU5OGNmZDY3XzMtMS0xLTEtMA_c553996b-81e0-408a-bc13-df32f1f8f696">1</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8a89c112cd7f42b3a5456dc100a7ede7_D20200701-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpkMTZkZGFmMjlmOTI0MTAzYmRiNDc3OGQ1OThjZmQ2Ny90YWJsZXJhbmdlOmQxNmRkYWYyOWY5MjQxMDNiZGI0Nzc4ZDU5OGNmZDY3XzMtMy0xLTEtMA_dc1f2106-4b33-42e3-a7ee-9b3ac7e01a79">49.45</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8a89c112cd7f42b3a5456dc100a7ede7_D20200701-20210331" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpkMTZkZGFmMjlmOTI0MTAzYmRiNDc3OGQ1OThjZmQ2Ny90YWJsZXJhbmdlOmQxNmRkYWYyOWY5MjQxMDNiZGI0Nzc4ZDU5OGNmZDY3XzQtMS0xLTEtMA_8d99e2a5-6c03-42fe-8fdd-9a54df96118d">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8a89c112cd7f42b3a5456dc100a7ede7_D20200701-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpkMTZkZGFmMjlmOTI0MTAzYmRiNDc3OGQ1OThjZmQ2Ny90YWJsZXJhbmdlOmQxNmRkYWYyOWY5MjQxMDNiZGI0Nzc4ZDU5OGNmZDY3XzQtMy0xLTEtMA_13e660a4-37f3-45b3-9d99-1e3c082afab5">48.52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at March 31, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i77e9bd39dd824727aafae148f4111ead_I20210331" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpkMTZkZGFmMjlmOTI0MTAzYmRiNDc3OGQ1OThjZmQ2Ny90YWJsZXJhbmdlOmQxNmRkYWYyOWY5MjQxMDNiZGI0Nzc4ZDU5OGNmZDY3XzUtMS0xLTEtMA_62366d2f-3745-4ee3-870a-2b4960572c15">3</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i77e9bd39dd824727aafae148f4111ead_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpkMTZkZGFmMjlmOTI0MTAzYmRiNDc3OGQ1OThjZmQ2Ny90YWJsZXJhbmdlOmQxNmRkYWYyOWY5MjQxMDNiZGI0Nzc4ZDU5OGNmZDY3XzUtMy0xLTEtMA_77fb4146-f655-4dfa-9374-7e44b6a5b631">48.96</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2021, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was $<ix:nonFraction unitRef="usd" contextRef="i77e9bd39dd824727aafae148f4111ead_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90ZXh0cmVnaW9uOjE1ZjA5M2Q1ZDEyMjQ5NDE4NTc3NzNlMTk1YTZjMWQwXzg0MA_d9bd0af0-4aa4-43de-9e61-f1af56f86671">90</ix:nonFraction> million, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i8a89c112cd7f42b3a5456dc100a7ede7_D20200701-20210331" format="ixt-sec:durwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90ZXh0cmVnaW9uOjE1ZjA5M2Q1ZDEyMjQ5NDE4NTc3NzNlMTk1YTZjMWQwXzkxMw_9d2a58ae-18f3-46a9-a69e-0cc4df7af50a">two years</ix:nonNumeric>.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee stock options granted under the Plans generally vest in equal annual installments over <ix:nonNumeric contextRef="i96b93fe596a142948ea01b57dd171ae6_D20200701-20210331" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90ZXh0cmVnaW9uOjE1ZjA5M2Q1ZDEyMjQ5NDE4NTc3NzNlMTk1YTZjMWQwXzEwMjc_b5f428f0-39ca-4695-9ef1-795001a6d3c4">three years</ix:nonNumeric> and are exercisable for <ix:nonNumeric contextRef="i96b93fe596a142948ea01b57dd171ae6_D20200701-20210331" format="ixt-sec:durwordsen" name="cah:ExercisablePeriodOfPlansInYears" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90ZXh0cmVnaW9uOjE1ZjA5M2Q1ZDEyMjQ5NDE4NTc3NzNlMTk1YTZjMWQwXzEwNTQ_87bf56a1-c44d-4550-b01e-3186b147b3f5">ten years</ix:nonNumeric> from the grant date. All stock options are exercisable at a price equal to the market value of the common shares underlying the option on the grant date.</span></div></ix:nonNumeric></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:24.720%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notes to Financial Statements</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:48.214%"><ix:continuation id="id52fb73b657b4c5f98ed93f994912784"><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90ZXh0cmVnaW9uOjE1ZjA5M2Q1ZDEyMjQ5NDE4NTc3NzNlMTk1YTZjMWQwXzIzNTc_5e797bdd-d70d-493c-bdd2-5b88fe15afda" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all stock option transactions under the Plans:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.616%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.480%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.061%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price per<br/>Common Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at June 30, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTo1Zjg0M2QwYjEzYWQ0MmM1YWYyODc4MTJjY2Y3MjZlOC90YWJsZXJhbmdlOjVmODQzZDBiMTNhZDQyYzVhZjI4NzgxMmNjZjcyNmU4XzEtMS0xLTEtMA_f4833571-1f97-4fd2-990c-7990eb631177">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTo1Zjg0M2QwYjEzYWQ0MmM1YWYyODc4MTJjY2Y3MjZlOC90YWJsZXJhbmdlOjVmODQzZDBiMTNhZDQyYzVhZjI4NzgxMmNjZjcyNmU4XzEtMy0xLTEtMA_e90a7ce9-3954-47f9-b0fa-3a013ec5ba16">65.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTo1Zjg0M2QwYjEzYWQ0MmM1YWYyODc4MTJjY2Y3MjZlOC90YWJsZXJhbmdlOjVmODQzZDBiMTNhZDQyYzVhZjI4NzgxMmNjZjcyNmU4XzItMS0xLTEtMA_d05ef15e-fa62-4035-9de1-a4cbd9f71347">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTo1Zjg0M2QwYjEzYWQ0MmM1YWYyODc4MTJjY2Y3MjZlOC90YWJsZXJhbmdlOjVmODQzZDBiMTNhZDQyYzVhZjI4NzgxMmNjZjcyNmU4XzItMy0xLTEtMA_127db55c-1ff9-4f1d-90ec-84aaf3db3b1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTo1Zjg0M2QwYjEzYWQ0MmM1YWYyODc4MTJjY2Y3MjZlOC90YWJsZXJhbmdlOjVmODQzZDBiMTNhZDQyYzVhZjI4NzgxMmNjZjcyNmU4XzMtMS0xLTEtMA_84ede452-bfd1-4f6d-b2be-e32dcad0e8c5">1</ix:nonFraction>)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTo1Zjg0M2QwYjEzYWQ0MmM1YWYyODc4MTJjY2Y3MjZlOC90YWJsZXJhbmdlOjVmODQzZDBiMTNhZDQyYzVhZjI4NzgxMmNjZjcyNmU4XzMtMy0xLTEtMA_c968618a-ab21-4b6b-9a15-ca08982965a2">40.94</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="-6" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTo1Zjg0M2QwYjEzYWQ0MmM1YWYyODc4MTJjY2Y3MjZlOC90YWJsZXJhbmdlOjVmODQzZDBiMTNhZDQyYzVhZjI4NzgxMmNjZjcyNmU4XzQtMS0xLTEtMA_a8c575b6-c8d0-49bd-bacb-0a55eed55a0c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTo1Zjg0M2QwYjEzYWQ0MmM1YWYyODc4MTJjY2Y3MjZlOC90YWJsZXJhbmdlOjVmODQzZDBiMTNhZDQyYzVhZjI4NzgxMmNjZjcyNmU4XzQtMy0xLTEtMA_0e2a3adc-45d8-4339-b49c-55800d8b804f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding at March 31, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTo1Zjg0M2QwYjEzYWQ0MmM1YWYyODc4MTJjY2Y3MjZlOC90YWJsZXJhbmdlOjVmODQzZDBiMTNhZDQyYzVhZjI4NzgxMmNjZjcyNmU4XzUtMS0xLTEtMA_dd8a3b99-bd7f-47cd-8ba7-e75096b7751d">4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTo1Zjg0M2QwYjEzYWQ0MmM1YWYyODc4MTJjY2Y3MjZlOC90YWJsZXJhbmdlOjVmODQzZDBiMTNhZDQyYzVhZjI4NzgxMmNjZjcyNmU4XzUtMy0xLTEtMA_f58f1d00-db7e-4031-b665-280ab903e845">67.60</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercisable at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTo1Zjg0M2QwYjEzYWQ0MmM1YWYyODc4MTJjY2Y3MjZlOC90YWJsZXJhbmdlOjVmODQzZDBiMTNhZDQyYzVhZjI4NzgxMmNjZjcyNmU4XzYtMS0xLTEtMA_8e0b804e-5ea1-4093-b1e9-7ad99044333a">4</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibe76498d80224b4f96b532177a01467f_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTo1Zjg0M2QwYjEzYWQ0MmM1YWYyODc4MTJjY2Y3MjZlOC90YWJsZXJhbmdlOjVmODQzZDBiMTNhZDQyYzVhZjI4NzgxMmNjZjcyNmU4XzYtMy0xLTEtMA_bc31219f-9c3d-4671-abc6-909e303fc90a">67.80</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2021, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested stock options not yet recognized was $<ix:nonFraction unitRef="usd" contextRef="i5226be778dfe441d9f2c92df26a11158_I20210331" decimals="5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90ZXh0cmVnaW9uOjE1ZjA5M2Q1ZDEyMjQ5NDE4NTc3NzNlMTk1YTZjMWQwXzE0MjM_ee0cb9a8-f664-4788-9db1-3562c1aa2556">0.2</ix:nonFraction> million, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i96b93fe596a142948ea01b57dd171ae6_D20200701-20210331" format="ixt-sec:durwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90ZXh0cmVnaW9uOjE1ZjA5M2Q1ZDEyMjQ5NDE4NTc3NzNlMTk1YTZjMWQwXzE0OTY_92c3b7a1-80cc-4691-adea-1f8ccd641189">two years</ix:nonNumeric>. </span></div><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" name="cah:AdditionalStockOptionPlanDataTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90ZXh0cmVnaW9uOjE1ZjA5M2Q1ZDEyMjQ5NDE4NTc3NzNlMTk1YTZjMWQwXzIzNDU_bfeb23b9-e3f2-4071-85da-81945d63f70f" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide additional detail related to stock options:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.850%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate intrinsic value of outstanding options at period end</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5226be778dfe441d9f2c92df26a11158_I20210331" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTo1MzMzMTI3ODhkZjM0MTQzYTFjYWQ5YTc3MjA3MDJiMi90YWJsZXJhbmdlOjUzMzMxMjc4OGRmMzQxNDNhMWNhZDlhNzcyMDcwMmIyXzEtMS0xLTEtMA_4e9c3a94-ff72-4223-a8bb-2bd59fa3664a">17</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic86b7d6cb21f44eaad860256ec1bfebc_I20200630" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTo1MzMzMTI3ODhkZjM0MTQzYTFjYWQ5YTc3MjA3MDJiMi90YWJsZXJhbmdlOjUzMzMxMjc4OGRmMzQxNDNhMWNhZDlhNzcyMDcwMmIyXzEtMy0xLTEtMA_f583331a-bf0d-4b9c-92d7-e7f71143a1ec">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate intrinsic value of exercisable options at period end</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5226be778dfe441d9f2c92df26a11158_I20210331" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTo1MzMzMTI3ODhkZjM0MTQzYTFjYWQ5YTc3MjA3MDJiMi90YWJsZXJhbmdlOjUzMzMxMjc4OGRmMzQxNDNhMWNhZDlhNzcyMDcwMmIyXzItMS0xLTEtMA_e90370a5-2d35-48c2-a88e-c74dee1bf8f9">17</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic86b7d6cb21f44eaad860256ec1bfebc_I20200630" decimals="-6" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTo1MzMzMTI3ODhkZjM0MTQzYTFjYWQ5YTc3MjA3MDJiMi90YWJsZXJhbmdlOjUzMzMxMjc4OGRmMzQxNDNhMWNhZDlhNzcyMDcwMmIyXzItMy0xLTEtMA_6bc2dd0c-6290-4863-9fc8-9a9dd4a41e4b">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.850%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.420%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining contractual life of outstanding options</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i96b93fe596a142948ea01b57dd171ae6_D20200701-20210331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTowODdjODY2MjU1NDY0NWI5ODI3YTNkNWVkODA4YjRlYS90YWJsZXJhbmdlOjA4N2M4NjYyNTU0NjQ1Yjk4MjdhM2Q1ZWQ4MDhiNGVhXzEtMS0xLTEtMA_9cfb0595-2511-428f-bd3f-56baf01f1e76">4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i26baad0d41684101ab66f22954853d05_D20190701-20200331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTowODdjODY2MjU1NDY0NWI5ODI3YTNkNWVkODA4YjRlYS90YWJsZXJhbmdlOjA4N2M4NjYyNTU0NjQ1Yjk4MjdhM2Q1ZWQ4MDhiNGVhXzEtMy0xLTEtMA_a2241eec-17be-4056-a739-638b0705c040">5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining contractual life of exercisable options</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i96b93fe596a142948ea01b57dd171ae6_D20200701-20210331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTowODdjODY2MjU1NDY0NWI5ODI3YTNkNWVkODA4YjRlYS90YWJsZXJhbmdlOjA4N2M4NjYyNTU0NjQ1Yjk4MjdhM2Q1ZWQ4MDhiNGVhXzItMS0xLTEtMA_878f6670-c5f1-4f65-a5fe-bc01b3cff3cc">4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i26baad0d41684101ab66f22954853d05_D20190701-20200331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTowODdjODY2MjU1NDY0NWI5ODI3YTNkNWVkODA4YjRlYS90YWJsZXJhbmdlOjA4N2M4NjYyNTU0NjQ1Yjk4MjdhM2Q1ZWQ4MDhiNGVhXzItMy0xLTEtMA_6cd2ae63-6a37-4970-ab40-88eee38a6cdd">5</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Performance Share Units</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance share units vest over a <ix:nonFraction unitRef="number" contextRef="i04a5e9e5e39042d4954e45ee16242fba_D20200701-20210331" decimals="INF" name="cah:VestingPeriodinyearsforShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90ZXh0cmVnaW9uOjE1ZjA5M2Q1ZDEyMjQ5NDE4NTc3NzNlMTk1YTZjMWQwXzE2Mzk_ae274305-37a7-4c80-b9ea-7a3fc6ddf579">3</ix:nonFraction>-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from <ix:nonFraction unitRef="number" contextRef="iae78c99bef954f35b10d2bf1557917a0_D20200701-20210331" decimals="2" format="ixt-sec:numwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90ZXh0cmVnaW9uOjE1ZjA5M2Q1ZDEyMjQ5NDE4NTc3NzNlMTk1YTZjMWQwXzE4MDI_798b7689-7166-4c4c-9f52-05ccd4b2b8b8">zero</ix:nonFraction> to <ix:nonFraction unitRef="number" contextRef="if622e969bb1c456795db4df9e45f0a4b_D20200701-20210331" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90ZXh0cmVnaW9uOjE1ZjA5M2Q1ZDEyMjQ5NDE4NTc3NzNlMTk1YTZjMWQwXzE4MDg_eee5259e-882a-4e0f-bc2a-7e0e7224bd4a">240</ix:nonFraction> percent of the target award amount. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards.</span></div><ix:nonNumeric contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331" name="us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90ZXh0cmVnaW9uOjE1ZjA5M2Q1ZDEyMjQ5NDE4NTc3NzNlMTk1YTZjMWQwXzIzNDE_c93f5b3c-1fbe-4f01-a6a1-3e544d7ad7ce" escape="true"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"></td><td style="width:49.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.023%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.347%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.147%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance<br/>Share Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9f362429a27e4da98d58d075d240086a_I20200630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpmZmU3OTJlNDQ5NTU0YTU5YjUxYzYyMTA3M2VkNjBlYS90YWJsZXJhbmdlOmZmZTc5MmU0NDk1NTRhNTliNTFjNjIxMDczZWQ2MGVhXzEtMS0xLTEtMA_dea9e879-cfa1-4852-8491-e0298380e6dd">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9f362429a27e4da98d58d075d240086a_I20200630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpmZmU3OTJlNDQ5NTU0YTU5YjUxYzYyMTA3M2VkNjBlYS90YWJsZXJhbmdlOmZmZTc5MmU0NDk1NTRhNTliNTFjNjIxMDczZWQ2MGVhXzEtMy0xLTEtMA_985ed9cc-719d-4473-8d41-11719e439e1d">54.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i04a5e9e5e39042d4954e45ee16242fba_D20200701-20210331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpmZmU3OTJlNDQ5NTU0YTU5YjUxYzYyMTA3M2VkNjBlYS90YWJsZXJhbmdlOmZmZTc5MmU0NDk1NTRhNTliNTFjNjIxMDczZWQ2MGVhXzItMS0xLTEtMA_48795e6e-7012-4352-8bb1-fc7eedf02f71">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i04a5e9e5e39042d4954e45ee16242fba_D20200701-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpmZmU3OTJlNDQ5NTU0YTU5YjUxYzYyMTA3M2VkNjBlYS90YWJsZXJhbmdlOmZmZTc5MmU0NDk1NTRhNTliNTFjNjIxMDczZWQ2MGVhXzItMy0xLTEtMA_f91b81b9-0f8c-4e16-8864-19026eccb837">55.45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i04a5e9e5e39042d4954e45ee16242fba_D20200701-20210331" decimals="-5" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpmZmU3OTJlNDQ5NTU0YTU5YjUxYzYyMTA3M2VkNjBlYS90YWJsZXJhbmdlOmZmZTc5MmU0NDk1NTRhNTliNTFjNjIxMDczZWQ2MGVhXzMtMS0xLTEtMA_b1074afb-5d65-46ce-9514-a339d32870c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i04a5e9e5e39042d4954e45ee16242fba_D20200701-20210331" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpmZmU3OTJlNDQ5NTU0YTU5YjUxYzYyMTA3M2VkNjBlYS90YWJsZXJhbmdlOmZmZTc5MmU0NDk1NTRhNTliNTFjNjIxMDczZWQ2MGVhXzMtMy0xLTEtMA_766d0034-eee2-4c44-89af-77c9e1770244">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i04a5e9e5e39042d4954e45ee16242fba_D20200701-20210331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpmZmU3OTJlNDQ5NTU0YTU5YjUxYzYyMTA3M2VkNjBlYS90YWJsZXJhbmdlOmZmZTc5MmU0NDk1NTRhNTliNTFjNjIxMDczZWQ2MGVhXzQtMS0xLTEtMA_e48292b6-0620-4568-9332-f065616dd4d5">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i04a5e9e5e39042d4954e45ee16242fba_D20200701-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpmZmU3OTJlNDQ5NTU0YTU5YjUxYzYyMTA3M2VkNjBlYS90YWJsZXJhbmdlOmZmZTc5MmU0NDk1NTRhNTliNTFjNjIxMDczZWQ2MGVhXzQtMy0xLTEtMA_eb3d82a6-a0f2-4cb7-ac84-1d36cac5278e">52.54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at March 31, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7e27cac65544c18a83f69a3c9f73b79_I20210331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpmZmU3OTJlNDQ5NTU0YTU5YjUxYzYyMTA3M2VkNjBlYS90YWJsZXJhbmdlOmZmZTc5MmU0NDk1NTRhNTliNTFjNjIxMDczZWQ2MGVhXzUtMS0xLTEtMA_1245d44a-7d4f-4182-8663-d311bdcaf0ca">1.6</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia7e27cac65544c18a83f69a3c9f73b79_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpmZmU3OTJlNDQ5NTU0YTU5YjUxYzYyMTA3M2VkNjBlYS90YWJsZXJhbmdlOmZmZTc5MmU0NDk1NTRhNTliNTFjNjIxMDczZWQ2MGVhXzUtMy0xLTEtMA_8a61f100-7071-4f10-a065-d934a983b775">60.32</ix:nonFraction></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2021, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $<ix:nonFraction unitRef="usd" contextRef="ia7e27cac65544c18a83f69a3c9f73b79_I20210331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90ZXh0cmVnaW9uOjE1ZjA5M2Q1ZDEyMjQ5NDE4NTc3NzNlMTk1YTZjMWQwXzIyMTc_26dc771c-6e2c-4cd6-bc11-ccfa60af31b8">41</ix:nonFraction> million, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i04a5e9e5e39042d4954e45ee16242fba_D20200701-20210331" format="ixt-sec:durwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90ZXh0cmVnaW9uOjE1ZjA5M2Q1ZDEyMjQ5NDE4NTc3NzNlMTk1YTZjMWQwXzIyOTA_5cefecd5-a93e-47ea-8012-74ff51b2a5a5">two years</ix:nonNumeric> if performance goals are achieved.</span></div></ix:continuation></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:48.215%"></div></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">47</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="ib6bf45669ad94861b0c50dbc2f4371ce_121"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="-sec-extract:summary;margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:50.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibits</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="-sec-extract:summary;margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Exhibits</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit<br/>Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Exhibit Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/721371/000119312508230011/dex31.htm">Amended and Restated Articles of Incorporation of Cardinal Health, Inc., as amended (incorporated by reference to Exhibit 3.1 to Cardinal Health&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2008, File No. 1-11373)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/721371/000072137120000133/restatedcodeofregulationsn.htm">Cardinal Health, Inc. Restated Code of Regulations (incorporated by reference to Exhibit 3.2 to Cardinal Health&#8217;s Current Report on Form 8-K filed on November 9, 2020, File No. 1-11373)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a21q3_10qx033121xexhibit311.htm">Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a21q3_10qx033121xexhibit312.htm">Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a21q3_10qx033121xexhibit321.htm">Certification of the Chief Executive Officer and the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="a21q3_10qx033121xexhibit991.htm">Statement Regarding Forward-Looking Information</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Instance Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cover Page Interactive Data File - formatted in Inline XBRL (included as Exhibit 101)</span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#ff0000;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Cardinal Health Website</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardinal Health&#160;uses its website as a channel of distribution for material company information. Important information, including news releases, financial information, earnings and analyst presentations and information about upcoming presentations and events is routinely posted and accessible at ir.cardinalhealth.com. In addition, the website allows investors and other interested persons to sign up automatically to receive e-mail alerts when the company posts news releases,&#160;SEC filings and certain other information on its website.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="-sec-extract:summary;margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">48</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="ib6bf45669ad94861b0c50dbc2f4371ce_124"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.115%"><tr><td style="width:1.0%"></td><td style="width:27.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.306%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Form 10-Q Cross Reference Index</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Form 10-Q Cross Reference Index</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part I. Financial Information</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_61">Financial Statements </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_61">29</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_13">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_13">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_40">Quantitative and Qualitative Disclosures about Market Risk </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_40">25</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_43">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_43">25</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part II. Other Information</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_46">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_46">26</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_49">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_49">27</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_1216">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_1216">28</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defaults Upon Senior Securities </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mine Safety Disclosures </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Information</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_121">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_121">48</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_127">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ib6bf45669ad94861b0c50dbc2f4371ce_127">50</a></span></div></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:3.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.739%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Not applicable</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">49</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div><div id="ib6bf45669ad94861b0c50dbc2f4371ce_127"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:24.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.075%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#e41f35;border-bottom:1pt solid #e41f35;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional Information</span></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #e41f35;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:20pt;font-weight:700;line-height:120%">Signatures</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.182%"><tr><td style="width:1.0%"></td><td style="width:4.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health, Inc.</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 6, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;MICHAEL C. KAUFMANN</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Michael C. Kaufmann</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;JASON M. HOLLAR</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jason M. Hollar</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ee2724;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">50</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardinal Health </span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">| </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q3</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiscal 2021 Form 10-Q</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>a21q3_10qx033121xexhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="iee63a65131344b4eb2f2ad21a1372ec1_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:31.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 31.1</font></td></tr></table></div><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michael C. Kaufmann, certify that&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">I have reviewed this Form 10-Q of Cardinal Health, Inc.&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.46pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;6, 2021 </font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:470.25pt"><tr><td style="width:1.0pt"></td><td style="width:147.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:319.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; MICHAEL C. KAUFMANN</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael C. Kaufmann</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>a21q3_10qx033121xexhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i2b8a5127531f4b86a89172f3a2249dc9_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:31.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 31.2</font></td></tr></table></div><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Jason M. Hollar, certify that&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">I have reviewed this Form 10-Q of Cardinal Health, Inc.&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.46pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.16pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;6, 2021 </font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:136.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:372.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> JASON M. HOLLAR</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jason M. Hollar</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>a21q3_10qx033121xexhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="if359d9742be04742be87fa5c2ad1787b_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:31.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 32.1</font></td></tr></table></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Certification of the Chief Executive Officer and the Chief Financial Officer Pursuant to 18 U.S.C. Section&#160;1350, as Adopted </font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Michael C. Kaufmann, Chief Executive Officer of Cardinal Health, Inc. (the &#8220;Company&#8221;) and Jason M. Hollar, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, that&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26pt">the Periodic Report on Form 10-Q for the quarter ended March 31, 2021 containing the financial statements of the Company (the &#8220;Periodic Report&#8221;), which this statement accompanies, fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d))&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26pt">the information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; May&#160;6, 2021 </font></div><div style="margin-bottom:11pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:69.031%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.769%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; MICHAEL C. KAUFMANN</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael C. Kaufmann</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer </font></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:69.031%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.769%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; JASON M. HOLLAR</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jason M. Hollar</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>a21q3_10qx033121xexhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ic779cece8c564d7ebd3527a88a151bf5_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:31.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 99.1</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Statement Regarding Forward-Looking Information </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As used in this exhibit, &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; and similar pronouns refer to Cardinal Health, Inc. and its subsidiaries, unless the context requires otherwise. Our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the fiscal year ended June&#160;30, 2020 (the &#8220;2020 Form 10-K&#8221;), our quarterly reports on Form 10-Q, including this one, and our current reports on Form 8-K (along with any exhibits and amendments to such reports), as well as our news releases or any other written or oral statements made by or on behalf of us, including materials posted on our website, may include, directly or by incorporation by reference, forward-looking statements that reflect our current view (as of the date the forward-looking statement is first made) about future events, prospects, projections or financial performance. The matters discussed in these forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied in or by such statements. These risks and uncertainties include&#58;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from the COVID-19 pandemic, including the possibility that our manufacturing or distribution facilities will be required to cease operations, whether from government regulation in the United States or internationally, or from reduction in available workforce due to illness&#59; the possibility that we could experience significant delays or disruptions in our supply of medical or pharmaceutical products resulting in an inability to fulfill customer demand, whether attributable to the use of the Defense Production Act or otherwise&#59; the risk that we will not be able to offset significant cost increases for certain personal protective equipment (PPE) products or that and price increases for these products could result in lost sales or customer losses or disputes&#59; the possibility that demand or selling prices for certain PPE products may decline in the future, resulting in excess inventory or inventory cost above net realizable value, requiring inventory reserves&#59; the possibility that reduced demand for elective medical procedures may result in a sustained reduction in demand for our products&#59; and the potential for us to receive negative publicity resulting from prolonged supply shortages or our participation in industry-wide collaboration to increase the supply of personal protective equipment in the United States&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">competitive pressures in the markets in which we operate, including pricing pressures&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties relating to the pricing of generic pharmaceuticals&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties relating to the timing, frequency and profitability of generic pharmaceutical launches or other components of our pharmaceutical generics program&#59;  </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">our ability to maintain the benefits of our generic pharmaceutical sourcing venture with CVS Health Corporation&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">with respect to our distribution services agreements with branded pharmaceutical manufacturers, changes in the amount of service fees we receive or, in cases where part of our compensation under these agreements is based on branded pharmaceutical price appreciation, changes in the frequency or magnitude of such price appreciation&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in manufacturer approaches to pricing branded pharmaceutical products and risks related to our compensation under contractual arrangements with manufacturers being set as a percentage of the wholesale acquisition cost of branded pharmaceuticals&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in the timing or frequency of the introduction of branded pharmaceuticals&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with the resolution and defense of the lawsuits and investigations in which we have been or will be named relating to the distribution of prescription opioid pain medication, including the risk that the outcome of these lawsuits and investigations could have a material adverse effect on our results of operations, financial condition, cash flows or liquidity&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">potential damage to our reputation, adverse operational impacts or other effects that may result from the national opioid epidemic, the allegations that have been made about our role in such epidemic and the ongoing unfavorable publicity surrounding the lawsuits and investigations against us&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with the ongoing discussions regarding a potential global settlement of certain opioid lawsuits and investigations against us, including the risk that we could fail to reach a final settlement, that any final settlement reached could require us to pay more than we currently anticipate or could have a negative effect on our liquidity or ability to return money to shareholders and the risk that any injunctive or non-monetary remedies we may agree to could have unintended consequences&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with the tax benefit from our self-insurance loss claims, including risks associated with the letter certain industry participants, including us, received from the U.S. House of Representatives' Committee on Oversight and Reform questioning, among other things, our plans to take tax deductions for opioid-related losses, including the net operating loss carryback provisions under the CARES Act and deductibility under the Tax Act&#59; the possibility that we may receive additional negative or unfavorable publicity or that the IRS may not agree with our underlying assumptions and judgments&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">potential adverse impact to our financial results from enacted and proposed state taxes or other assessments on the sale or distribution of opioid medications&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">our high sales concentration with certain key customers, including CVS Health Corporation and OptumRx&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">costs or claims resulting from a quality issue related to the manufacture of some of our sterile surgical gowns, or other potential errors or defects in our manufacturing of medical devices or other products or in our compounding, repackaging, information systems or pharmacy management services that may injure persons or damage property or operations, including costs from recalls, remediation efforts, and related product liability claims and lawsuits, including class action lawsuits&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">actions of regulatory bodies and other governmental authorities, including the U.S. Drug Enforcement Administration, certain agencies within the U.S. Department of Health and Human Services (including the U.S. Food and Drug Administration, Centers for Medicare and </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid Services, the Office of Inspector General and the Office for Civil Rights), the U.S. Nuclear Regulatory Commission, the U.S. Federal Trade Commission, the U.S. Customs and Border Protection, various state boards of pharmacy, state controlled substance authorities, state health departments, state insurance departments, state Medicaid departments or comparable regulatory bodies or governmental authorities or foreign equivalents that, in each case, could delay, limit or suspend product development, manufacturing, distribution, importation or sales or result in warning letters, recalls, seizures, injunctions or monetary sanctions&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">any compromise of our information systems or of those of a third-party service provider, including unauthorized access to or use or disclosure of company or customer information, disruption of access and ancillary risks associated with our ability to effectively manage any issues arising from any such compromise or disruption&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties related to our Medical segment's Cardinal Health Brand products, including our ability to manage cost, infrastructure and to retain margin or improve its performance&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with the realignment of our Medical segment's supply chain and other businesses, including our ability to achieve the expected benefits from such realignment&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties with respect to our cost-savings initiatives or IT infrastructure activities, including the ability to achieve the expected benefits from such initiatives, the risk that we could incur unexpected charges, and the risk that we may fail to retain key personnel&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">difficulties or delays in the development, production, manufacturing, sourcing and marketing of new or existing products and services, including difficulties or delays associated with obtaining or maintaining requisite regulatory consents, whether our own or third parties', or approvals associated with those activities&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">manufacturing disruptions, whether due to regulatory action, production quality deviations, safety issues or raw material shortages or defects, or because a key product is manufactured at a single manufacturing facility with limited alternate facilities&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from possible violations of healthcare fraud and abuse laws&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from possible violations of the U.S. Foreign Corrupt Practices Act and other similar anti-corruption laws in other jurisdictions and U.S. and foreign export control, trade embargo and customs laws&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from our collecting, handling and maintaining patient-identifiable health information and other sensitive personal and financial information, which are subject to federal, state and foreign laws that regulate the use and disclosure of such information&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from certain of our businesses being Medicare-certified suppliers or participating in other federal and state healthcare programs, such as state Medicaid programs and the federal 340B drug pricing program, which businesses are subject to accreditation and quality standards and other rules and regulations, including applicable reporting, billing, payment and record-keeping requirements&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from certain of our businesses manufacturing pharmaceutical and medical products or repackaging pharmaceuticals that are purchased or reimbursed through, or are otherwise governed by, federal or state healthcare programs, which businesses are subject to federal and state laws that establish eligibility for reimbursement by such programs and other applicable standards and regulations&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in laws or changes in the interpretation or application of laws or regulations, as well as possible failures to comply with applicable laws or regulations, including as a result of possible misinterpretations or misapplications&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">material reductions in purchases, pricing changes, non-renewal, early termination, or delinquencies or defaults under contracts with key customers&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">unfavorable changes to the terms or with our ability to meet contractual obligations of key customer or supplier relationships, or changes in customer mix&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks arising from changes in U.S. or foreign tax laws and unfavorable challenges to our tax positions and payments to settle these challenges, which may adversely affect our effective tax rate or tax payments&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties due to possible government healthcare reform, including proposals related to Medicare drug rebate arrangements, possible repeal or replacement of major parts of the Patient Protection and Affordable Care Act, proposals related to prescription drug pricing transparency and the possible adoption of Medicare-For-All&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">reductions or limitations on governmental funding at the state or federal level or efforts by healthcare insurance companies to limit payments for products and services&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in manufacturers' pricing, selling, inventory, distribution or supply policies or practices&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in legislation or regulations governing prescription drug pricing, healthcare services or mandated benefits&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in hospital buying groups or hospital buying practices&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes in distribution or sourcing models for pharmaceutical and medical and surgical products, including an increase in direct and limited distribution&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">changes to the prescription drug reimbursement formula and related reporting requirements for generic pharmaceuticals under Medicaid&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">continuing consolidation in the healthcare industry, which could give the resulting enterprises greater bargaining power and may increase pressure on prices for our products and services or result in the loss of customers&#59;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">disruption, damage or lack of access to, or failure of, our or our third-party service providers' information systems, our critical facilities, including our national logistics center, or our distribution networks&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks to our business and information and controls systems in the event that business process improvements, infrastructure modernizations or initiatives to use third-party service providers for key systems and processes are not effectively implemented&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">the results, costs, effects or timing of any commercial disputes, government contract compliance matters, patent infringement claims, </font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> actions, government investigations, shareholder lawsuits or other legal proceedings&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">possible losses relating to product liability lawsuits and claims regarding products for which we cannot obtain product liability insurance or for which such insurance may not be adequate to cover our losses, including the product liability lawsuits we are currently defending relating to alleged personal injuries associated with the use of Cordis inferior vena cava filter products&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">our ability to maintain adequate intellectual property protections&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">the costs, difficulties and uncertainties related to the integration of acquired businesses, including liabilities relating to the operations or activities of such businesses prior to their acquisition, and uncertainties relating to our ability to achieve the anticipated results from acquisitions&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">the ability to successfully complete the divestiture of the Cordis business on a timely basis, including receipt of required regulatory approvals and satisfaction of other conditions, the risk that the costs associated with exit or disposal activities could ultimately be greater than we currently expect or that we could incur greater stranded costs than expected, and the risk that the impairment of the transferred assets could ultimately be greater than we currently expect&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">our ability to manage and complete divestitures or other strategic business combination transactions, including our ability to find buyers or other strategic exit opportunities and risks associated with the possibility that we could experience greater dis-synergies than anticipated or otherwise fail to achieve our strategic objectives&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">increased costs for commodities and other materials used in the Medical segment manufacturing, including various components, compounds, raw materials or energy such as oil-based resins, pulp, cotton, latex and other commodities&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">shortages in commodities, components, compounds, raw materials or energy used by our businesses, including supply disruptions of radioisotopes&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">the loss of, or default by, one or more key suppliers for which alternative suppliers may not be readily available&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">bankruptcy, insolvency or other credit failure of a customer or supplier that owes us a substantial amount&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with global operations, including the effect of local economic environments, inflation, recession, currency volatility and global competition, in addition to risks associated with compliance with U.S. and international laws relating to global operations&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties with respect to U.S. or international trade policies, tariffs, excise or border taxes and their impact on our ability to source products or materials that we need to conduct our business&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">risks associated with our use of and reliance on the global capital and credit markets, including our ability to access credit and our cost of credit, which may adversely affect our ability to efficiently fund our operations or undertake certain expenditures&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">our ability to introduce and market new products and our ability to keep pace with advances in technology&#59;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">significant charges to earnings if goodwill or intangible assets become impaired&#59; </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">uncertainties relating to general political, business, industry, regulatory and market conditions&#59; and</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.13pt">other factors described in the &#8220;Risk Factors&#8221; section of the 2020 Form 10-K.</font></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The words &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;project,&#8221; &#8220;continue,&#8221; &#8220;likely,&#8221; and similar expressions generally identify &#8220;forward-looking statements,&#8221; which speak only as of the date the statements were made, and also include statements reflecting future results or guidance, statements of outlook and expense accruals. We undertake no obligation to update or revise any forward-looking statements, except to the extent required by applicable law.</font></div><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="margin-top:9pt;text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>cah-20210331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:9b2cc92e-6994-4968-bb0f-b1e44b26b0f5,g:c415e902-95ac-4ff9-bfda-46a36d4f42b5-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cah="http://www.cardinal.com/20210331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.cardinal.com/20210331">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cah-20210331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cah-20210331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cah-20210331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cah-20210331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.cardinal.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofEarnings" roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings">
        <link:definition>1001002 - Statement - Condensed Consolidated Statements of Earnings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncome" roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome">
        <link:definition>1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1003004 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1004005 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofShareholdersEquity" roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1006007 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPolicies" roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails" roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails">
        <link:definition>2403401 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Narrative, Recent Financial Accounting Standards) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Assetsheldforsale" roleURI="http://www.cardinal.com/role/Assetsheldforsale">
        <link:definition>2104102 - Disclosure - Assets held for sale</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsandDisposalGroupsTables" roleURI="http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsTables">
        <link:definition>2305301 - Disclosure - Discontinued Operations and Disposal Groups (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DiscontinuedOperationsandDisposalGroupsDetails" roleURI="http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails">
        <link:definition>2406402 - Disclosure - Discontinued Operations and Disposal Groups (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandEmployeeSeverance" roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeverance">
        <link:definition>2107103 - Disclosure - Restructuring and Employee Severance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandEmployeeSeveranceTables" roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables">
        <link:definition>2308302 - Disclosure - Restructuring and Employee Severance (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails">
        <link:definition>2409403 - Disclosure - Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails">
        <link:definition>2410404 - Disclosure - Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringandEmployeeSeveranceNarativeDetails" roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails">
        <link:definition>2411405 - Disclosure - Restructuring and Employee Severance Narative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssets" roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets">
        <link:definition>2112104 - Disclosure - Goodwill and Other Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsTables" roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables">
        <link:definition>2313303 - Disclosure - Goodwill and Other Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails">
        <link:definition>2414406 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails">
        <link:definition>2415407 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandOtherIntangibleAssetsNarrativeDetails" roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails">
        <link:definition>2416408 - Disclosure - Goodwill and Other Intangible Assets (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermObligationsandOtherShortTermBorrowings" roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings">
        <link:definition>2117105 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermObligationsandOtherShortTermBorrowingsTables" roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsTables">
        <link:definition>2318304 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermObligationsandOtherShortTermBorrowingsDetails" roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails">
        <link:definition>2419409 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails">
        <link:definition>2420410 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsContingentLiabilitiesandLitigation" roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation">
        <link:definition>2121106 - Disclosure - Commitments, Contingent Liabilities and Litigation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsContingentLiabilitiesandLitigationDetails" roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails">
        <link:definition>2422411 - Disclosure - Commitments, Contingent Liabilities and Litigation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.cardinal.com/role/IncomeTaxes">
        <link:definition>2123107 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>2424412 - Disclosure - Income Taxes (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.cardinal.com/role/FairValueMeasurements">
        <link:definition>2125108 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.cardinal.com/role/FairValueMeasurementsTables">
        <link:definition>2326305 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" roleURI="http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails">
        <link:definition>2427413 - Disclosure - Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.cardinal.com/role/FinancialInstruments">
        <link:definition>2128109 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.cardinal.com/role/FinancialInstrumentsTables">
        <link:definition>2329306 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsNarrativeDetails" roleURI="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails">
        <link:definition>2430414 - Disclosure - Financial Instruments (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" roleURI="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails">
        <link:definition>2431415 - Disclosure - Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquity" roleURI="http://www.cardinal.com/role/ShareholdersEquity">
        <link:definition>2132110 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityTables" roleURI="http://www.cardinal.com/role/ShareholdersEquityTables">
        <link:definition>2333307 - Disclosure - Shareholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityNarrativeDetails" roleURI="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails">
        <link:definition>2434416 - Disclosure - Shareholders' Equity (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>2435417 - Disclosure - Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareAttributabletoCardinalHealthInc" roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc">
        <link:definition>2136111 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc.</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareAttributabletoCardinalHealthIncTables" roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables">
        <link:definition>2337308 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails" roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails">
        <link:definition>2438418 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails">
        <link:definition>2439419 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://www.cardinal.com/role/SegmentInformation">
        <link:definition>2140112 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://www.cardinal.com/role/SegmentInformationTables">
        <link:definition>2341309 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationNarrativeDetails" roleURI="http://www.cardinal.com/role/SegmentInformationNarrativeDetails">
        <link:definition>2442420 - Disclosure - Segment Information (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationRevenuebyReportableSegmentDetails" roleURI="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails">
        <link:definition>2443421 - Disclosure - Segment Information (Revenue by Reportable Segment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationSegmentProfitbyReportableSegmentDetails" roleURI="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails">
        <link:definition>2444422 - Disclosure - Segment Information (Segment Profit by Reportable Segment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" roleURI="http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails">
        <link:definition>2445423 - Disclosure - Segment Information Revenue From External Customers By Geographic Areas (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationAssetsbyReportableSegmentDetails" roleURI="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails">
        <link:definition>2446424 - Disclosure - Segment Information (Assets by Reportable Segment) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://www.cardinal.com/role/ShareBasedCompensation">
        <link:definition>2147113 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://www.cardinal.com/role/ShareBasedCompensationTables">
        <link:definition>2348310 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationNarrativeDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails">
        <link:definition>2449425 - Disclosure - Share-Based Compensation (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails">
        <link:definition>2450426 - Disclosure - Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails">
        <link:definition>2451427 - Disclosure - Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails">
        <link:definition>2452428 - Disclosure - Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails">
        <link:definition>2453429 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails">
        <link:definition>2454430 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="cah_FloatingRateNotesdue2022Member" abstract="true" name="FloatingRateNotesdue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_OpioidLitigationDomain" abstract="true" name="OpioidLitigationDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_A3.41Notesdue2027Member" abstract="true" name="A3.41Notesdue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_NetOperatingLossCarrybackAxis" abstract="true" name="NetOperatingLossCarrybackAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_GownRecallAxis" abstract="true" name="GownRecallAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_DerivativesHedgeDiscontinuancesHeadingInstrumentTerminatedAmount" abstract="false" name="DerivativesHedgeDiscontinuancesHeadingInstrumentTerminatedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_LawsuitTypeDomain" abstract="true" name="LawsuitTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_TaxMattersAgreementAxis" abstract="true" name="TaxMattersAgreementAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount" abstract="false" name="DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_ClassActionLawsuitsMember" abstract="true" name="ClassActionLawsuitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_CareFusionMember" abstract="true" name="CareFusionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_A4.368Notesdue2047Member" abstract="true" name="A4.368Notesdue2047Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_PlaintiffTypeAxis" abstract="true" name="PlaintiffTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_CardinalHealthAtHomeMember" abstract="true" name="CardinalHealthAtHomeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_TaxMattersAgreementDomain" abstract="true" name="TaxMattersAgreementDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_Netproceedstaxwithholdingsfromsharebasedcompensation" abstract="false" name="Netproceedstaxwithholdingsfromsharebasedcompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_DisposalGroupIncludingDiscontinuedOperationGoodwillAndOtherIntangiblesNet" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationGoodwillAndOtherIntangiblesNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_IndemnificationReceivable" abstract="false" name="IndemnificationReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_NumberofStateAttorneysGeneralfilinglawsuits" abstract="false" name="NumberofStateAttorneysGeneralfilinglawsuits" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cah_SterileSurgicalGownRecallDomain" abstract="true" name="SterileSurgicalGownRecallDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_A2.4Notesdue2020Member" abstract="true" name="A2.4Notesdue2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_ProjectCostsOnInvestmentAndOtherSpending" abstract="false" name="ProjectCostsOnInvestmentAndOtherSpending" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_CordisDivestitureDomain" abstract="true" name="CordisDivestitureDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_AdditionalStockOptionPlanDataTableTextBlock" abstract="false" name="AdditionalStockOptionPlanDataTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="cah_A3.2Notesdue2022Member" abstract="true" name="A3.2Notesdue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_PlaintiffTypeDomain" abstract="true" name="PlaintiffTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_PharmaceuticalDistributionandSpecialtyMember" abstract="true" name="PharmaceuticalDistributionandSpecialtyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_SterileSurgicalGownRecallAxis" abstract="true" name="SterileSurgicalGownRecallAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_VestingPeriodinyearsforShares" abstract="false" name="VestingPeriodinyearsforShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cah_A4.6Notesdue2043Member" abstract="true" name="A4.6Notesdue2043Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_OtherJurisdictionsMember" abstract="true" name="OtherJurisdictionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_CashReclassifiedToAssetHeldForSale" abstract="false" name="CashReclassifiedToAssetHeldForSale" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_Purchaseofavailableforsalesecuritiesandotherinvestments" abstract="false" name="Purchaseofavailableforsalesecuritiesandotherinvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_TotalOpioidLitigationMember" abstract="true" name="TotalOpioidLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_A4.9Notesdue2045Member" abstract="true" name="A4.9Notesdue2045Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_SterileSurgicalGownRecallMember" abstract="true" name="SterileSurgicalGownRecallMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_IPRDTrademarksandOtherMember" abstract="true" name="IPRDTrademarksandOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_LongTermObligationsandOtherShortTermBorrowingsAbstract" abstract="true" name="LongTermObligationsandOtherShortTermBorrowingsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cah_Amortizationandotheracquisitionrelatedcosts" abstract="false" name="Amortizationandotheracquisitionrelatedcosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_GownRecallDomain" abstract="true" name="GownRecallDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_OpioidLawsuitsMember" abstract="true" name="OpioidLawsuitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_MedicalMember" abstract="true" name="MedicalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_NarativeAbstract" abstract="true" name="NarativeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cah_ShortTermCreditFacilitiesMember" abstract="true" name="ShortTermCreditFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_TrademarksAndPatentsMember" abstract="true" name="TrademarksAndPatentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_CordisDivestitureMember" abstract="true" name="CordisDivestitureMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_NuclearPrecisionHealthServicesMember" abstract="true" name="NuclearPrecisionHealthServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_TotalLongTermandShortTermObligations" abstract="false" name="TotalLongTermandShortTermObligations" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_DOJInvestigationMember" abstract="true" name="DOJInvestigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_PatientRecoveryBusinessMember" abstract="true" name="PatientRecoveryBusinessMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_FacilityExitAndOtherCosts" abstract="false" name="FacilityExitAndOtherCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems" abstract="true" name="SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="cah_OpioidLawsuitsStateDomain" abstract="true" name="OpioidLawsuitsStateDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_CARESActDomain" abstract="true" name="CARESActDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_ExercisablePeriodOfPlansInYears" abstract="false" name="ExercisablePeriodOfPlansInYears" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="cah_LawsuitTypeAxis" abstract="true" name="LawsuitTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_MedicaldistributionandproductsMember" abstract="true" name="MedicaldistributionandproductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" abstract="false" name="Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_TaxMatterDomain" abstract="true" name="TaxMatterDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_NewYorkOpioidStewardshipActMember" abstract="true" name="NewYorkOpioidStewardshipActMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_Sharesthatwouldbeantidilutiveasaresultofnetloss" abstract="false" name="Sharesthatwouldbeantidilutiveasaresultofnetloss" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable" abstract="true" name="SegmentRevenuefromExternalCustomersbyGeographicAreaTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_ProceedsFromSettlementsOfClassActionLawsuits" abstract="false" name="ProceedsFromSettlementsOfClassActionLawsuits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_CarryingAmountofLongTermandotherShortTermBorrowings" abstract="false" name="CarryingAmountofLongTermandotherShortTermBorrowings" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_AlamedaCountyMember" abstract="true" name="AlamedaCountyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_PrivatePartiesMember" abstract="true" name="PrivatePartiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_CordisDivestitureAxis" abstract="true" name="CordisDivestitureAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_NetOperatingLossCarrybackMember" abstract="true" name="NetOperatingLossCarrybackMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_OpioidLitigationAxis" abstract="true" name="OpioidLitigationAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="cah_ProductLiabilityLawsuitsMember" abstract="true" name="ProductLiabilityLawsuitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_A2.616Notesdue2022Member" abstract="true" name="A2.616Notesdue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_CommittedReceivablesSalesFacilityProgramMember" abstract="true" name="CommittedReceivablesSalesFacilityProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct" abstract="false" name="EstimatedLiabilityForNewYorkOpioidStewardshipAct" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_AggregateAnnualAssessment" abstract="false" name="AggregateAnnualAssessment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_LossContingencyLawsuitsNumber" abstract="false" name="LossContingencyLawsuitsNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="cah_NotesPayableRepurchased" abstract="false" name="NotesPayableRepurchased" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_CVSHealthMember" abstract="true" name="CVSHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_WriteDownOfAssetsHeldForSale" abstract="false" name="WriteDownOfAssetsHeldForSale" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_MaximumQuarterlyPayment" abstract="false" name="MaximumQuarterlyPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_PharmaceuticalMember" abstract="true" name="PharmaceuticalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets" abstract="false" name="Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="cah_TaxMatterAxis" abstract="true" name="TaxMatterAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>cah-20210331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:9b2cc92e-6994-4968-bb0f-b1e44b26b0f5,g:c415e902-95ac-4ff9-bfda-46a36d4f42b5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cardinal.com/role/CoverPage" xlink:type="simple" xlink:href="cah-20210331.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" xlink:type="simple" xlink:href="cah-20210331.xsd#CondensedConsolidatedStatementsofEarnings"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_c0b4a8ee-f9f9-4c3c-9a8d-c2f2c673595f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_abc2325b-2090-484c-975f-a82a533f448e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_c0b4a8ee-f9f9-4c3c-9a8d-c2f2c673595f" xlink:to="loc_us-gaap_Revenues_abc2325b-2090-484c-975f-a82a533f448e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_d1b86fef-1f20-4d77-aed5-173bf95f02ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_c0b4a8ee-f9f9-4c3c-9a8d-c2f2c673595f" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_d1b86fef-1f20-4d77-aed5-173bf95f02ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0833e7f1-e665-4c21-8e51-304c183f4e42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_87a9d791-0c4e-4329-90e5-00fbcefd1823" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0833e7f1-e665-4c21-8e51-304c183f4e42" xlink:to="loc_us-gaap_GrossProfit_87a9d791-0c4e-4329-90e5-00fbcefd1823" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b8fe0183-9097-4e50-9117-e300f4ad0aea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0833e7f1-e665-4c21-8e51-304c183f4e42" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b8fe0183-9097-4e50-9117-e300f4ad0aea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_9c3516a3-8354-4aca-bd4e-295dabbbb634" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0833e7f1-e665-4c21-8e51-304c183f4e42" xlink:to="loc_us-gaap_RestructuringCharges_9c3516a3-8354-4aca-bd4e-295dabbbb634" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Amortizationandotheracquisitionrelatedcosts_5c79f5ce-75cb-4173-a096-0ed88b8bcb7d" xlink:href="cah-20210331.xsd#cah_Amortizationandotheracquisitionrelatedcosts"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0833e7f1-e665-4c21-8e51-304c183f4e42" xlink:to="loc_cah_Amortizationandotheracquisitionrelatedcosts_5c79f5ce-75cb-4173-a096-0ed88b8bcb7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_0bca786c-ec77-4b7d-986e-2adfe764b87b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0833e7f1-e665-4c21-8e51-304c183f4e42" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_0bca786c-ec77-4b7d-986e-2adfe764b87b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_2325baa8-69c8-474e-864c-9ae5cb35c30f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_0833e7f1-e665-4c21-8e51-304c183f4e42" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_2325baa8-69c8-474e-864c-9ae5cb35c30f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2b8758f7-87d3-4992-8f40-c8a9442c0286" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_44830c07-4dd0-4451-8e7d-942bc5675a6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_2b8758f7-87d3-4992-8f40-c8a9442c0286" xlink:to="loc_us-gaap_ProfitLoss_44830c07-4dd0-4451-8e7d-942bc5675a6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e798fc87-3d93-4996-bbd8-66c6dc2d42db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_2b8758f7-87d3-4992-8f40-c8a9442c0286" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e798fc87-3d93-4996-bbd8-66c6dc2d42db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_4a5188db-5b39-4091-88b6-512c487779d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_01459b97-85de-4b59-9f56-534e9f412a0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_4a5188db-5b39-4091-88b6-512c487779d7" xlink:to="loc_us-gaap_OperatingIncomeLoss_01459b97-85de-4b59-9f56-534e9f412a0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_4d24958e-c4a8-4d95-aa1e-874b1f7123fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_4a5188db-5b39-4091-88b6-512c487779d7" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_4d24958e-c4a8-4d95-aa1e-874b1f7123fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_f57675df-88be-4c40-8191-4b0fa0202234" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_4a5188db-5b39-4091-88b6-512c487779d7" xlink:to="loc_us-gaap_InterestExpense_f57675df-88be-4c40-8191-4b0fa0202234" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_c398d39c-f3c0-4da5-8395-60dbf19f8f9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_4a5188db-5b39-4091-88b6-512c487779d7" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_c398d39c-f3c0-4da5-8395-60dbf19f8f9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a906f1b2-9b25-42f6-9e4c-38119409419f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_a9806af1-fabc-4889-99c9-fc15f797e118" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_a906f1b2-9b25-42f6-9e4c-38119409419f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_a9806af1-fabc-4889-99c9-fc15f797e118" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_009c5ced-9f96-41f0-8ce1-29bb04db1452" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_a906f1b2-9b25-42f6-9e4c-38119409419f" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_009c5ced-9f96-41f0-8ce1-29bb04db1452" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="cah-20210331.xsd#CondensedConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6711ed24-7dcd-4be6-8410-b63c9017587c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_db31e8ad-fd70-49f2-bff4-10ec87e95db3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6711ed24-7dcd-4be6-8410-b63c9017587c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_db31e8ad-fd70-49f2-bff4-10ec87e95db3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_bf8d15c4-0500-4166-a868-d65b6aa6958f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6711ed24-7dcd-4be6-8410-b63c9017587c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_bf8d15c4-0500-4166-a868-d65b6aa6958f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_b87befc0-2c31-41ec-9112-5969572cb2ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_08cf7ccb-890b-4527-8cd3-d4213462d0cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_b87befc0-2c31-41ec-9112-5969572cb2ad" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_08cf7ccb-890b-4527-8cd3-d4213462d0cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c62d0891-ca08-46a0-a88d-ec17034d61df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_b87befc0-2c31-41ec-9112-5969572cb2ad" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c62d0891-ca08-46a0-a88d-ec17034d61df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_ad188d29-eb0f-446a-b8ca-d1d0a35b0ca3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7c36550e-e139-4731-8f10-b088432f21f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_ad188d29-eb0f-446a-b8ca-d1d0a35b0ca3" xlink:to="loc_us-gaap_ProfitLoss_7c36550e-e139-4731-8f10-b088432f21f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c13852dd-70ef-4afc-88a1-d7f41505c39f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_ad188d29-eb0f-446a-b8ca-d1d0a35b0ca3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c13852dd-70ef-4afc-88a1-d7f41505c39f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cah-20210331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_10a5ea19-e1fd-48b7-be17-6f2416af62df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d654b953-2412-4ed9-955d-babeac727024" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_10a5ea19-e1fd-48b7-be17-6f2416af62df" xlink:to="loc_us-gaap_LiabilitiesCurrent_d654b953-2412-4ed9-955d-babeac727024" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_c38af383-73f7-4a4e-b8d9-15326bdcaff0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_10a5ea19-e1fd-48b7-be17-6f2416af62df" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_c38af383-73f7-4a4e-b8d9-15326bdcaff0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_acb907d5-9934-4238-83af-6ed9f85126fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_10a5ea19-e1fd-48b7-be17-6f2416af62df" xlink:to="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_acb907d5-9934-4238-83af-6ed9f85126fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d1a29c47-5fb7-400c-83aa-a29d17572c73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_10a5ea19-e1fd-48b7-be17-6f2416af62df" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d1a29c47-5fb7-400c-83aa-a29d17572c73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_568820e5-a9c0-4420-876c-850274100b20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_69c71293-ca2a-4a70-9117-6ba91e101065" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_568820e5-a9c0-4420-876c-850274100b20" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_69c71293-ca2a-4a70-9117-6ba91e101065" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_9f063920-89c3-434f-bb45-06b8a0630f90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_568820e5-a9c0-4420-876c-850274100b20" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_9f063920-89c3-434f-bb45-06b8a0630f90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_e09be465-581f-4f2d-bb7c-7b70d822a7af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_568820e5-a9c0-4420-876c-850274100b20" xlink:to="loc_us-gaap_AccountsPayableCurrent_e09be465-581f-4f2d-bb7c-7b70d822a7af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_292dccdd-bb14-42aa-9cf0-cbd95ed2c6d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_568820e5-a9c0-4420-876c-850274100b20" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_292dccdd-bb14-42aa-9cf0-cbd95ed2c6d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a9c26268-1737-47d4-890d-2a2d55069ac6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_63d9ade9-f156-4683-82e5-319ddf469abb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a9c26268-1737-47d4-890d-2a2d55069ac6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_63d9ade9-f156-4683-82e5-319ddf469abb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_f46b08e0-1157-42e5-849c-2c8343b09001" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a9c26268-1737-47d4-890d-2a2d55069ac6" xlink:to="loc_us-gaap_PreferredStockValue_f46b08e0-1157-42e5-849c-2c8343b09001" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_92623593-6912-47e4-bb0b-ff98bdcc0b17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a9c26268-1737-47d4-890d-2a2d55069ac6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_92623593-6912-47e4-bb0b-ff98bdcc0b17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_c90688c7-38e8-4f44-a242-51a4c3e9d93c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a9c26268-1737-47d4-890d-2a2d55069ac6" xlink:to="loc_us-gaap_CommonStockValue_c90688c7-38e8-4f44-a242-51a4c3e9d93c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_7b8db209-783e-41f1-a89d-0e88d07f6b0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a9c26268-1737-47d4-890d-2a2d55069ac6" xlink:to="loc_us-gaap_TreasuryStockValue_7b8db209-783e-41f1-a89d-0e88d07f6b0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b138e2c4-b648-4f4a-8308-0c7ab961de52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c4d75b93-44cb-4e36-bc75-25d7b5d761c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b138e2c4-b648-4f4a-8308-0c7ab961de52" xlink:to="loc_us-gaap_AssetsCurrent_c4d75b93-44cb-4e36-bc75-25d7b5d761c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c5e3dd97-60a5-456f-a1e7-a31e972da860" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b138e2c4-b648-4f4a-8308-0c7ab961de52" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c5e3dd97-60a5-456f-a1e7-a31e972da860" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_090f4d80-cb86-4197-8a0a-b0448249155a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b138e2c4-b648-4f4a-8308-0c7ab961de52" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_090f4d80-cb86-4197-8a0a-b0448249155a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_f54baabf-88fe-4194-b40e-1776248daf9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b138e2c4-b648-4f4a-8308-0c7ab961de52" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_f54baabf-88fe-4194-b40e-1776248daf9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d24c6969-1a64-4cfe-9a03-b09da55cdac9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d1732107-d441-47bf-ab93-d2654265ce20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d24c6969-1a64-4cfe-9a03-b09da55cdac9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d1732107-d441-47bf-ab93-d2654265ce20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_23ac5b7d-5304-4380-b740-059aab7afb4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d24c6969-1a64-4cfe-9a03-b09da55cdac9" xlink:to="loc_us-gaap_ReceivablesNetCurrent_23ac5b7d-5304-4380-b740-059aab7afb4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_41d81cf4-f708-4158-bed7-2c829d9304d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d24c6969-1a64-4cfe-9a03-b09da55cdac9" xlink:to="loc_us-gaap_InventoryNet_41d81cf4-f708-4158-bed7-2c829d9304d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_cfdc019c-2d63-450b-8fec-fd91ffc129f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d24c6969-1a64-4cfe-9a03-b09da55cdac9" xlink:to="loc_us-gaap_OtherAssetsCurrent_cfdc019c-2d63-450b-8fec-fd91ffc129f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_be9f1711-83c9-45d4-902e-39e3e6179a43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d24c6969-1a64-4cfe-9a03-b09da55cdac9" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_be9f1711-83c9-45d4-902e-39e3e6179a43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_72024641-6c1b-4ea9-9877-e0569157816d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_6fc14ab4-0905-4edd-932a-3eb831d2648d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_72024641-6c1b-4ea9-9877-e0569157816d" xlink:to="loc_us-gaap_CommonStockValue_6fc14ab4-0905-4edd-932a-3eb831d2648d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_72902a9e-23bd-4f28-be90-09889eb5ad12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_72024641-6c1b-4ea9-9877-e0569157816d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_72902a9e-23bd-4f28-be90-09889eb5ad12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_353e85b6-ca23-445f-94b1-e5929ea1fed0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_72024641-6c1b-4ea9-9877-e0569157816d" xlink:to="loc_us-gaap_TreasuryStockValue_353e85b6-ca23-445f-94b1-e5929ea1fed0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ea6d94b0-24c8-4182-a694-cf2201e3c8d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_72024641-6c1b-4ea9-9877-e0569157816d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ea6d94b0-24c8-4182-a694-cf2201e3c8d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_21674df1-3549-4146-8c3f-ef06538c0eeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_72024641-6c1b-4ea9-9877-e0569157816d" xlink:to="loc_us-gaap_MinorityInterest_21674df1-3549-4146-8c3f-ef06538c0eeb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cah-20210331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="cah-20210331.xsd#CondensedConsolidatedStatementsofShareholdersEquity"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cah-20210331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f007372e-b3e3-4870-aad4-688e9d89ff4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_40eeb105-fa09-40ea-9953-09db9257d1a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f007372e-b3e3-4870-aad4-688e9d89ff4a" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_40eeb105-fa09-40ea-9953-09db9257d1a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_f20f1b43-3027-4778-8fe0-ae50892b1685" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f007372e-b3e3-4870-aad4-688e9d89ff4a" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_f20f1b43-3027-4778-8fe0-ae50892b1685" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_9d59aa88-be55-43be-a7b8-e2d2aa893ced" xlink:href="cah-20210331.xsd#cah_Netproceedstaxwithholdingsfromsharebasedcompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f007372e-b3e3-4870-aad4-688e9d89ff4a" xlink:to="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_9d59aa88-be55-43be-a7b8-e2d2aa893ced" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_7a6e5958-4bb5-41ea-b784-5f41ba1c140e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f007372e-b3e3-4870-aad4-688e9d89ff4a" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_7a6e5958-4bb5-41ea-b784-5f41ba1c140e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_198a235d-7dbc-4d09-9540-97f9e95b2639" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f007372e-b3e3-4870-aad4-688e9d89ff4a" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_198a235d-7dbc-4d09-9540-97f9e95b2639" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromHedgeFinancingActivities_e7fd6087-2608-4c33-a30f-23f8d9d81ad0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromHedgeFinancingActivities"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f007372e-b3e3-4870-aad4-688e9d89ff4a" xlink:to="loc_us-gaap_PaymentsForProceedsFromHedgeFinancingActivities_e7fd6087-2608-4c33-a30f-23f8d9d81ad0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b4459de8-1bec-4663-b251-3034b7a8d860" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_19a61447-3045-48f2-bafc-d931d63b2fc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b4459de8-1bec-4663-b251-3034b7a8d860" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_19a61447-3045-48f2-bafc-d931d63b2fc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_eff7f03d-3f01-4a43-ae88-f79e1a5bc8ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b4459de8-1bec-4663-b251-3034b7a8d860" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_eff7f03d-3f01-4a43-ae88-f79e1a5bc8ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_2fa3d01c-e36b-4925-9db3-4ef972de981d" xlink:href="cah-20210331.xsd#cah_Purchaseofavailableforsalesecuritiesandotherinvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b4459de8-1bec-4663-b251-3034b7a8d860" xlink:to="loc_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_2fa3d01c-e36b-4925-9db3-4ef972de981d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_db5f1d99-aa17-41a1-b736-2a812b40df81" xlink:href="cah-20210331.xsd#cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b4459de8-1bec-4663-b251-3034b7a8d860" xlink:to="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_db5f1d99-aa17-41a1-b736-2a812b40df81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets_c0fba380-f395-4cda-b2ea-c1d2ef8506e9" xlink:href="cah-20210331.xsd#cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b4459de8-1bec-4663-b251-3034b7a8d860" xlink:to="loc_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets_c0fba380-f395-4cda-b2ea-c1d2ef8506e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9584f4dd-6fd8-41c5-bca4-2815347c4bb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_414d33c4-bc3d-4cd8-a98f-4b862dbcf757" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9584f4dd-6fd8-41c5-bca4-2815347c4bb0" xlink:to="loc_us-gaap_ProfitLoss_414d33c4-bc3d-4cd8-a98f-4b862dbcf757" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_4a362967-d888-434b-96a8-9d22b537e8e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9584f4dd-6fd8-41c5-bca4-2815347c4bb0" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_4a362967-d888-434b-96a8-9d22b537e8e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_e574485d-1886-43c0-ad27-f48125539c05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9584f4dd-6fd8-41c5-bca4-2815347c4bb0" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_e574485d-1886-43c0-ad27-f48125539c05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_db4b0a84-58c5-4826-929d-516b2a158500" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9584f4dd-6fd8-41c5-bca4-2815347c4bb0" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_db4b0a84-58c5-4826-929d-516b2a158500" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_6a56b8b8-37b6-476a-b68f-760d4754761f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9584f4dd-6fd8-41c5-bca4-2815347c4bb0" xlink:to="loc_us-gaap_ShareBasedCompensation_6a56b8b8-37b6-476a-b68f-760d4754761f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_23f69647-97c7-4229-9775-d8bd1b130750" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9584f4dd-6fd8-41c5-bca4-2815347c4bb0" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_23f69647-97c7-4229-9775-d8bd1b130750" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_eeeffdce-4cc3-41c4-abdf-eed8d04528e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9584f4dd-6fd8-41c5-bca4-2815347c4bb0" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_eeeffdce-4cc3-41c4-abdf-eed8d04528e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_cc8ee095-1b5d-4dd6-b4b1-97d6ba3f9a20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9584f4dd-6fd8-41c5-bca4-2815347c4bb0" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_cc8ee095-1b5d-4dd6-b4b1-97d6ba3f9a20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6df74dcc-f6d1-4c81-b923-cb7f01eb95da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9584f4dd-6fd8-41c5-bca4-2815347c4bb0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6df74dcc-f6d1-4c81-b923-cb7f01eb95da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_5b8cf0c9-a0a8-48f6-b666-1d8eac4fb539" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9584f4dd-6fd8-41c5-bca4-2815347c4bb0" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_5b8cf0c9-a0a8-48f6-b666-1d8eac4fb539" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_34733b09-9429-4683-9a80-d53b61be9580" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4de6157b-0438-4c28-9933-2b9247de5de6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_34733b09-9429-4683-9a80-d53b61be9580" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4de6157b-0438-4c28-9933-2b9247de5de6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f066a510-01e1-4063-8fc7-4afd3d55e5fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_34733b09-9429-4683-9a80-d53b61be9580" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f066a510-01e1-4063-8fc7-4afd3d55e5fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d1e96588-8386-4d8f-bc0e-a6e2f353f0b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_34733b09-9429-4683-9a80-d53b61be9580" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d1e96588-8386-4d8f-bc0e-a6e2f353f0b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_edb8e53c-483b-4878-90bc-538fb00f4353" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_34733b09-9429-4683-9a80-d53b61be9580" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_edb8e53c-483b-4878-90bc-538fb00f4353" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CashReclassifiedToAssetHeldForSale_562ef3b5-0fc5-467d-a216-d048facc1165" xlink:href="cah-20210331.xsd#cah_CashReclassifiedToAssetHeldForSale"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_34733b09-9429-4683-9a80-d53b61be9580" xlink:to="loc_cah_CashReclassifiedToAssetHeldForSale_562ef3b5-0fc5-467d-a216-d048facc1165" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="cah-20210331.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="cah-20210331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/Assetsheldforsale" xlink:type="simple" xlink:href="cah-20210331.xsd#Assetsheldforsale"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/Assetsheldforsale" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsTables" xlink:type="simple" xlink:href="cah-20210331.xsd#DiscontinuedOperationsandDisposalGroupsTables"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#DiscontinuedOperationsandDisposalGroupsDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_40054418-5e4a-4e08-ab4e-e4169da077c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_WriteDownOfAssetsHeldForSale_ea87500f-ad17-4abd-a9ea-b97782bf2ee3" xlink:href="cah-20210331.xsd#cah_WriteDownOfAssetsHeldForSale"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_40054418-5e4a-4e08-ab4e-e4169da077c8" xlink:to="loc_cah_WriteDownOfAssetsHeldForSale_ea87500f-ad17-4abd-a9ea-b97782bf2ee3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_8203b90d-d5b8-4319-9216-7eab1cfc0e02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_40054418-5e4a-4e08-ab4e-e4169da077c8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_8203b90d-d5b8-4319-9216-7eab1cfc0e02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DisposalGroupIncludingDiscontinuedOperationGoodwillAndOtherIntangiblesNet_0ae4d413-37d8-464a-a73a-3e12f7b1b340" xlink:href="cah-20210331.xsd#cah_DisposalGroupIncludingDiscontinuedOperationGoodwillAndOtherIntangiblesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_40054418-5e4a-4e08-ab4e-e4169da077c8" xlink:to="loc_cah_DisposalGroupIncludingDiscontinuedOperationGoodwillAndOtherIntangiblesNet_0ae4d413-37d8-464a-a73a-3e12f7b1b340" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_e32af55d-2b56-4a08-b2af-2df2948315be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_40054418-5e4a-4e08-ab4e-e4169da077c8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_e32af55d-2b56-4a08-b2af-2df2948315be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_a9b583a5-6c38-481a-bb32-d2eb85e574ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_40054418-5e4a-4e08-ab4e-e4169da077c8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_a9b583a5-6c38-481a-bb32-d2eb85e574ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_4678bb15-fc97-40b4-8c11-d0091374005e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_40054418-5e4a-4e08-ab4e-e4169da077c8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_4678bb15-fc97-40b4-8c11-d0091374005e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_b38a00fe-7c4d-4cd5-811c-67743ab3c022" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_8f8b4b01-b3f5-498f-ac93-6da738a0e46a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_b38a00fe-7c4d-4cd5-811c-67743ab3c022" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_8f8b4b01-b3f5-498f-ac93-6da738a0e46a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_5ecde7a5-84f8-43f8-a086-ced43d6a58da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_b38a00fe-7c4d-4cd5-811c-67743ab3c022" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_5ecde7a5-84f8-43f8-a086-ced43d6a58da" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeverance" xlink:type="simple" xlink:href="cah-20210331.xsd#RestructuringandEmployeeSeverance"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeverance" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables" xlink:type="simple" xlink:href="cah-20210331.xsd#RestructuringandEmployeeSeveranceTables"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_98ac9381-45bb-4009-ac6b-f1ca94c7632d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_c5969175-6d41-448e-93e8-afb03ea21ec2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCharges_98ac9381-45bb-4009-ac6b-f1ca94c7632d" xlink:to="loc_us-gaap_SeveranceCosts1_c5969175-6d41-448e-93e8-afb03ea21ec2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FacilityExitAndOtherCosts_d76f9fc9-1574-4eb4-97e6-c7e46f7d26ce" xlink:href="cah-20210331.xsd#cah_FacilityExitAndOtherCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCharges_98ac9381-45bb-4009-ac6b-f1ca94c7632d" xlink:to="loc_cah_FacilityExitAndOtherCosts_d76f9fc9-1574-4eb4-97e6-c7e46f7d26ce" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#RestructuringandEmployeeSeveranceNarativeDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets" xlink:type="simple" xlink:href="cah-20210331.xsd#GoodwillandOtherIntangibleAssets"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables" xlink:type="simple" xlink:href="cah-20210331.xsd#GoodwillandOtherIntangibleAssetsTables"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#GoodwillandOtherIntangibleAssetsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings" xlink:type="simple" xlink:href="cah-20210331.xsd#LongTermObligationsandOtherShortTermBorrowings"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsTables" xlink:type="simple" xlink:href="cah-20210331.xsd#LongTermObligationsandOtherShortTermBorrowingsTables"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#LongTermObligationsandOtherShortTermBorrowingsDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation" xlink:type="simple" xlink:href="cah-20210331.xsd#CommitmentsContingentLiabilitiesandLitigation"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#CommitmentsContingentLiabilitiesandLitigationDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cah-20210331.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#IncomeTaxesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="cah-20210331.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="cah-20210331.xsd#FairValueMeasurementsTables"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/FairValueMeasurementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstruments" xlink:type="simple" xlink:href="cah-20210331.xsd#FinancialInstruments"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/FinancialInstruments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="cah-20210331.xsd#FinancialInstrumentsTables"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="cah-20210331.xsd#ShareholdersEquity"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityTables" xlink:type="simple" xlink:href="cah-20210331.xsd#ShareholdersEquityTables"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#ShareholdersEquityNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_fc4587af-f0ea-4256-b3aa-f2d588af954c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_88c131a9-b080-4f08-8468-16b34ec120ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_fc4587af-f0ea-4256-b3aa-f2d588af954c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_88c131a9-b080-4f08-8468-16b34ec120ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_64e8e0bb-cf2c-41bb-8f3b-74ecd98e39ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_fc4587af-f0ea-4256-b3aa-f2d588af954c" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_64e8e0bb-cf2c-41bb-8f3b-74ecd98e39ca" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc" xlink:type="simple" xlink:href="cah-20210331.xsd#EarningsPerShareAttributabletoCardinalHealthInc"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables" xlink:type="simple" xlink:href="cah-20210331.xsd#EarningsPerShareAttributabletoCardinalHealthIncTables"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e13c6565-740b-4b14-a5e6-f1fca301d7a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_134905ca-64fc-4adf-9d2d-809f3a516f51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e13c6565-740b-4b14-a5e6-f1fca301d7a5" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_134905ca-64fc-4adf-9d2d-809f3a516f51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_99ab6329-139e-4144-904c-8c62096e2b00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e13c6565-740b-4b14-a5e6-f1fca301d7a5" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_99ab6329-139e-4144-904c-8c62096e2b00" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformation" xlink:type="simple" xlink:href="cah-20210331.xsd#SegmentInformation"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/SegmentInformation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="cah-20210331.xsd#SegmentInformationTables"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/SegmentInformationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationNarrativeDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#SegmentInformationNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/SegmentInformationNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#SegmentInformationRevenuebyReportableSegmentDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#SegmentInformationSegmentProfitbyReportableSegmentDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#SegmentInformationAssetsbyReportableSegmentDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="cah-20210331.xsd#ShareBasedCompensation"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="cah-20210331.xsd#ShareBasedCompensationTables"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#ShareBasedCompensationNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails"/>
  <link:calculationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>cah-20210331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:9b2cc92e-6994-4968-bb0f-b1e44b26b0f5,g:c415e902-95ac-4ff9-bfda-46a36d4f42b5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/CoverPage" xlink:type="simple" xlink:href="cah-20210331.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/CoverPage" xlink:type="extended" id="iac8d2bcb38c548138286ed1892565cd6_CoverPage"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" xlink:type="simple" xlink:href="cah-20210331.xsd#CondensedConsolidatedStatementsofEarnings"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" xlink:type="extended" id="i5e1871e664c24857b9b7bbc0c6f1b3c7_CondensedConsolidatedStatementsofEarnings"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="cah-20210331.xsd#CondensedConsolidatedStatementsofComprehensiveIncome"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="extended" id="ibcbe04af689541da8222d644d88fcbe9_CondensedConsolidatedStatementsofComprehensiveIncome"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cah-20210331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" id="iaf924392596a4ca3a38b4fffc2a648bb_CondensedConsolidatedBalanceSheets"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cah-20210331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="ibbd3d4f94c41433c81ef46171384268c_CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="cah-20210331.xsd#CondensedConsolidatedStatementsofShareholdersEquity"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="extended" id="ia17904245b3d415d8d6103aa8beec2d0_CondensedConsolidatedStatementsofShareholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_dbf8a4b6-3350-402b-b4c6-1028f6fef940" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_c167b80d-965d-4a99-b763-2a5b68275dc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dbf8a4b6-3350-402b-b4c6-1028f6fef940" xlink:to="loc_us-gaap_CommonStockSharesIssued_c167b80d-965d-4a99-b763-2a5b68275dc2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_beef5691-ce32-4ce3-9ed1-d92c29ca811f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dbf8a4b6-3350-402b-b4c6-1028f6fef940" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_beef5691-ce32-4ce3-9ed1-d92c29ca811f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_563158d3-82a7-42bb-8282-6b4ee4d23f92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dbf8a4b6-3350-402b-b4c6-1028f6fef940" xlink:to="loc_us-gaap_TreasuryStockShares_563158d3-82a7-42bb-8282-6b4ee4d23f92" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_62f76eed-e594-4c85-aa1f-71d54c1486a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dbf8a4b6-3350-402b-b4c6-1028f6fef940" xlink:to="loc_us-gaap_TreasuryStockValue_62f76eed-e594-4c85-aa1f-71d54c1486a2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f9686a27-bc71-46a3-b134-1d50e19e1f45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dbf8a4b6-3350-402b-b4c6-1028f6fef940" xlink:to="loc_us-gaap_ProfitLoss_f9686a27-bc71-46a3-b134-1d50e19e1f45" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4b0f101f-aed9-41b4-aea5-8358bd422412" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dbf8a4b6-3350-402b-b4c6-1028f6fef940" xlink:to="loc_us-gaap_NetIncomeLoss_4b0f101f-aed9-41b4-aea5-8358bd422412" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_30efd520-6fd1-48bb-92b4-98095de3636d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dbf8a4b6-3350-402b-b4c6-1028f6fef940" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_30efd520-6fd1-48bb-92b4-98095de3636d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6b12da8c-68c3-463a-a8d6-ba2890ecb110" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dbf8a4b6-3350-402b-b4c6-1028f6fef940" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6b12da8c-68c3-463a-a8d6-ba2890ecb110" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0c2865cf-b44e-4835-b064-c58e7141fd6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dbf8a4b6-3350-402b-b4c6-1028f6fef940" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0c2865cf-b44e-4835-b064-c58e7141fd6f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_a6ffce9e-c5b2-4142-aa5a-815f03a1b731" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dbf8a4b6-3350-402b-b4c6-1028f6fef940" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_a6ffce9e-c5b2-4142-aa5a-815f03a1b731" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_56d447fa-ba0e-43d6-af25-bab37bab556f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dbf8a4b6-3350-402b-b4c6-1028f6fef940" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_56d447fa-ba0e-43d6-af25-bab37bab556f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_5e07db3d-e1ff-4795-98bb-12c034917461" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dbf8a4b6-3350-402b-b4c6-1028f6fef940" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_5e07db3d-e1ff-4795-98bb-12c034917461" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_a7491a7c-d64c-48f7-9107-2ef74cebf597" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Dividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dbf8a4b6-3350-402b-b4c6-1028f6fef940" xlink:to="loc_us-gaap_Dividends_a7491a7c-d64c-48f7-9107-2ef74cebf597" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOtherShares_a4187946-0cea-48f7-b6cd-69acfbbfcb35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOtherShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dbf8a4b6-3350-402b-b4c6-1028f6fef940" xlink:to="loc_us-gaap_StockholdersEquityOtherShares_a4187946-0cea-48f7-b6cd-69acfbbfcb35" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_da3b3f79-36a2-4e1e-939b-6ac18ec61ad7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dbf8a4b6-3350-402b-b4c6-1028f6fef940" xlink:to="loc_us-gaap_StockholdersEquityOther_da3b3f79-36a2-4e1e-939b-6ac18ec61ad7" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_f255abd6-71fe-46ba-b6de-8b92cafbbf86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1e7d2649-3daa-4927-a233-e2a195a708c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_22d42cf8-18bb-4c7a-96c3-3e63d7f57f4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_a2cbec8c-bf03-4b8e-a919-b5c0ad642af5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_d8a8c4a7-f93a-4daf-b97b-6f406e836334" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dbf8a4b6-3350-402b-b4c6-1028f6fef940" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_d8a8c4a7-f93a-4daf-b97b-6f406e836334" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d1ae6588-091c-41d9-86f2-6b4bacc3e607" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_dbf8a4b6-3350-402b-b4c6-1028f6fef940" xlink:to="loc_us-gaap_StatementTable_d1ae6588-091c-41d9-86f2-6b4bacc3e607" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1dd759c9-479b-4415-b634-4572862c3645" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d1ae6588-091c-41d9-86f2-6b4bacc3e607" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1dd759c9-479b-4415-b634-4572862c3645" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1dd759c9-479b-4415-b634-4572862c3645_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1dd759c9-479b-4415-b634-4572862c3645" xlink:to="loc_us-gaap_EquityComponentDomain_1dd759c9-479b-4415-b634-4572862c3645_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_49e176b4-4b76-4b7b-a4d6-2e0729cf23f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1dd759c9-479b-4415-b634-4572862c3645" xlink:to="loc_us-gaap_EquityComponentDomain_49e176b4-4b76-4b7b-a4d6-2e0729cf23f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5acc2cce-3ddf-4286-bd01-a6dcc3a242e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_49e176b4-4b76-4b7b-a4d6-2e0729cf23f7" xlink:to="loc_us-gaap_CommonStockMember_5acc2cce-3ddf-4286-bd01-a6dcc3a242e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_b4aa59b0-b702-4d82-9112-0b1c34648260" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_49e176b4-4b76-4b7b-a4d6-2e0729cf23f7" xlink:to="loc_us-gaap_RetainedEarningsMember_b4aa59b0-b702-4d82-9112-0b1c34648260" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_0d778d73-0d07-45e2-9305-2cade3bed52f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_49e176b4-4b76-4b7b-a4d6-2e0729cf23f7" xlink:to="loc_us-gaap_TreasuryStockMember_0d778d73-0d07-45e2-9305-2cade3bed52f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_83f1f4a4-00c3-4a5c-959e-ebf5ccdd7cdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_49e176b4-4b76-4b7b-a4d6-2e0729cf23f7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_83f1f4a4-00c3-4a5c-959e-ebf5ccdd7cdc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_361c08a1-1d15-4f75-8873-4d1a41b43d4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_49e176b4-4b76-4b7b-a4d6-2e0729cf23f7" xlink:to="loc_us-gaap_NoncontrollingInterestMember_361c08a1-1d15-4f75-8873-4d1a41b43d4f" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cah-20210331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended" id="i5441aff590224beba963df97a09b4148_CondensedConsolidatedStatementsofCashFlows"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="cah-20210331.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended" id="i5f40eb05dd0b42bba306da2f2add733a_BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="cah-20210331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="ia022f24f272742758ce8019357d1e993_BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails" xlink:type="extended" id="i1f0e04ec00fe4fcd833f00b62e985d13_BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/Assetsheldforsale" xlink:type="simple" xlink:href="cah-20210331.xsd#Assetsheldforsale"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/Assetsheldforsale" xlink:type="extended" id="i97e8b1572fef45858108f493df330c95_Assetsheldforsale"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsTables" xlink:type="simple" xlink:href="cah-20210331.xsd#DiscontinuedOperationsandDisposalGroupsTables"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsTables" xlink:type="extended" id="i78901f895c29465eac14412db889fc20_DiscontinuedOperationsandDisposalGroupsTables"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#DiscontinuedOperationsandDisposalGroupsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails" xlink:type="extended" id="if62d10fa47ba41fab8551a18477394a1_DiscontinuedOperationsandDisposalGroupsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e4b3b01e-cf5a-4080-9666-736aa91c63fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_9da44bdd-9007-4a96-8af3-fbd02384d620" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e4b3b01e-cf5a-4080-9666-736aa91c63fc" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_9da44bdd-9007-4a96-8af3-fbd02384d620" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_b5d564e3-00b6-429f-9f84-cd8646f9cc07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e4b3b01e-cf5a-4080-9666-736aa91c63fc" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_b5d564e3-00b6-429f-9f84-cd8646f9cc07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_3b025337-5bd6-4cc9-83d6-88b1692e0a45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e4b3b01e-cf5a-4080-9666-736aa91c63fc" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_3b025337-5bd6-4cc9-83d6-88b1692e0a45" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DisposalGroupIncludingDiscontinuedOperationGoodwillAndOtherIntangiblesNet_035a7a6c-b7e2-45f6-bf25-08210dc48b76" xlink:href="cah-20210331.xsd#cah_DisposalGroupIncludingDiscontinuedOperationGoodwillAndOtherIntangiblesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e4b3b01e-cf5a-4080-9666-736aa91c63fc" xlink:to="loc_cah_DisposalGroupIncludingDiscontinuedOperationGoodwillAndOtherIntangiblesNet_035a7a6c-b7e2-45f6-bf25-08210dc48b76" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_82ebad87-8f33-45f1-9456-1fdde68b9758" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e4b3b01e-cf5a-4080-9666-736aa91c63fc" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_82ebad87-8f33-45f1-9456-1fdde68b9758" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_WriteDownOfAssetsHeldForSale_2d2ba27c-c0aa-424b-bb1c-2d24bee75572" xlink:href="cah-20210331.xsd#cah_WriteDownOfAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e4b3b01e-cf5a-4080-9666-736aa91c63fc" xlink:to="loc_cah_WriteDownOfAssetsHeldForSale_2d2ba27c-c0aa-424b-bb1c-2d24bee75572" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_b6009a8b-ab85-4e01-9c9d-8e61447d3718" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e4b3b01e-cf5a-4080-9666-736aa91c63fc" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_b6009a8b-ab85-4e01-9c9d-8e61447d3718" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_09cab8d6-ada0-448e-8ce2-9c6b0f8aa797" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e4b3b01e-cf5a-4080-9666-736aa91c63fc" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_09cab8d6-ada0-448e-8ce2-9c6b0f8aa797" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_e88d7d97-830b-48a3-82c0-a1338f2dd6a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e4b3b01e-cf5a-4080-9666-736aa91c63fc" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_e88d7d97-830b-48a3-82c0-a1338f2dd6a2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_096ee39a-5fd3-4a17-bba2-94385730bda9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e4b3b01e-cf5a-4080-9666-736aa91c63fc" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_096ee39a-5fd3-4a17-bba2-94385730bda9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses_4a4829ea-8912-4b71-8060-d6d1b04434ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e4b3b01e-cf5a-4080-9666-736aa91c63fc" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses_4a4829ea-8912-4b71-8060-d6d1b04434ab" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_1bf2135f-5e33-4d34-8eb7-78f23d058643" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e4b3b01e-cf5a-4080-9666-736aa91c63fc" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_1bf2135f-5e33-4d34-8eb7-78f23d058643" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_cc270032-912a-4af2-ac8a-ab47438b9b49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e4b3b01e-cf5a-4080-9666-736aa91c63fc" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_cc270032-912a-4af2-ac8a-ab47438b9b49" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_883eca56-9d0f-42c4-955b-faf3fc9aacc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e4b3b01e-cf5a-4080-9666-736aa91c63fc" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_883eca56-9d0f-42c4-955b-faf3fc9aacc4" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_efc8b54d-fa4f-4a22-80e8-e337d7f0408b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e4b3b01e-cf5a-4080-9666-736aa91c63fc" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_efc8b54d-fa4f-4a22-80e8-e337d7f0408b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4cb1215b-3190-49eb-aa71-4caf1fc5abf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_efc8b54d-fa4f-4a22-80e8-e337d7f0408b" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4cb1215b-3190-49eb-aa71-4caf1fc5abf2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4cb1215b-3190-49eb-aa71-4caf1fc5abf2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4cb1215b-3190-49eb-aa71-4caf1fc5abf2" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4cb1215b-3190-49eb-aa71-4caf1fc5abf2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_475346ca-736e-47ee-8a3d-07a193addb7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4cb1215b-3190-49eb-aa71-4caf1fc5abf2" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_475346ca-736e-47ee-8a3d-07a193addb7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_19326386-0eb3-4647-b90e-dd4d8e1e1055" xlink:href="cah-20210331.xsd#cah_CordisDivestitureAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_efc8b54d-fa4f-4a22-80e8-e337d7f0408b" xlink:to="loc_cah_CordisDivestitureAxis_19326386-0eb3-4647-b90e-dd4d8e1e1055" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_19326386-0eb3-4647-b90e-dd4d8e1e1055_default" xlink:href="cah-20210331.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_CordisDivestitureAxis_19326386-0eb3-4647-b90e-dd4d8e1e1055" xlink:to="loc_cah_CordisDivestitureDomain_19326386-0eb3-4647-b90e-dd4d8e1e1055_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_7933dd2c-c89e-432c-8967-231436da77ed" xlink:href="cah-20210331.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_CordisDivestitureAxis_19326386-0eb3-4647-b90e-dd4d8e1e1055" xlink:to="loc_cah_CordisDivestitureDomain_7933dd2c-c89e-432c-8967-231436da77ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_19295a9d-fc92-4990-96dd-f489a836f8c9" xlink:href="cah-20210331.xsd#cah_CordisDivestitureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_CordisDivestitureDomain_7933dd2c-c89e-432c-8967-231436da77ed" xlink:to="loc_cah_CordisDivestitureMember_19295a9d-fc92-4990-96dd-f489a836f8c9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeverance" xlink:type="simple" xlink:href="cah-20210331.xsd#RestructuringandEmployeeSeverance"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeverance" xlink:type="extended" id="i1af458291bde4eb28b68f759b80c7f1f_RestructuringandEmployeeSeverance"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables" xlink:type="simple" xlink:href="cah-20210331.xsd#RestructuringandEmployeeSeveranceTables"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables" xlink:type="extended" id="ifd1956e341f2408a9b7bf961f6403b5b_RestructuringandEmployeeSeveranceTables"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" xlink:type="extended" id="if2d7d4e11682465ea687e48e2f574622_RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" xlink:type="extended" id="i6e561cf925404f2887f27faa04524471_RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_dd26959f-9a9b-4eb8-91c0-695fc3b1d084" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_3498a397-ef6d-4844-b9cf-e62502b6f8ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_dd26959f-9a9b-4eb8-91c0-695fc3b1d084" xlink:to="loc_us-gaap_RestructuringReserveRollForward_3498a397-ef6d-4844-b9cf-e62502b6f8ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_90301ac0-e034-4489-82b6-4dc6164cc018" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_3498a397-ef6d-4844-b9cf-e62502b6f8ae" xlink:to="loc_us-gaap_RestructuringReserve_90301ac0-e034-4489-82b6-4dc6164cc018" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts_67f7915a-4e95-4c24-9350-3b5e2c41af93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_3498a397-ef6d-4844-b9cf-e62502b6f8ae" xlink:to="loc_us-gaap_RestructuringCosts_67f7915a-4e95-4c24-9350-3b5e2c41af93" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_59d08818-ad40-4876-9b01-b9bd28e6811d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_3498a397-ef6d-4844-b9cf-e62502b6f8ae" xlink:to="loc_us-gaap_PaymentsForRestructuring_59d08818-ad40-4876-9b01-b9bd28e6811d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_3c8b6e40-d872-4ed4-8dbf-eb88a3911e88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_aebfba1b-2257-41db-9bed-dcfb6fc7ca0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_dd26959f-9a9b-4eb8-91c0-695fc3b1d084" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_aebfba1b-2257-41db-9bed-dcfb6fc7ca0d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_93a8785c-4ce0-4e65-a68c-2bf254e23c4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_aebfba1b-2257-41db-9bed-dcfb6fc7ca0d" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_93a8785c-4ce0-4e65-a68c-2bf254e23c4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_93a8785c-4ce0-4e65-a68c-2bf254e23c4a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_93a8785c-4ce0-4e65-a68c-2bf254e23c4a" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_93a8785c-4ce0-4e65-a68c-2bf254e23c4a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_cc452652-b0e1-4b86-a83a-46c796fb7ad5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_93a8785c-4ce0-4e65-a68c-2bf254e23c4a" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_cc452652-b0e1-4b86-a83a-46c796fb7ad5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_851f9271-4685-4948-af7c-cbbc1dca5705" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_cc452652-b0e1-4b86-a83a-46c796fb7ad5" xlink:to="loc_us-gaap_EmployeeSeveranceMember_851f9271-4685-4948-af7c-cbbc1dca5705" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember_89bc9316-3970-41ca-8229-64bc8b2d9eaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FacilityClosingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_cc452652-b0e1-4b86-a83a-46c796fb7ad5" xlink:to="loc_us-gaap_FacilityClosingMember_89bc9316-3970-41ca-8229-64bc8b2d9eaf" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#RestructuringandEmployeeSeveranceNarativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails" xlink:type="extended" id="i287ff0c644f047e690aa2c291c336273_RestructuringandEmployeeSeveranceNarativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_1328f8bc-d7c9-4938-bb62-c871d93ae933" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts_e46e3b93-6b12-4846-bfbe-7b0db871b4aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1328f8bc-d7c9-4938-bb62-c871d93ae933" xlink:to="loc_us-gaap_RestructuringCosts_e46e3b93-6b12-4846-bfbe-7b0db871b4aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_6fc4dc6c-9e73-43bf-b8b3-66338b10fb55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1328f8bc-d7c9-4938-bb62-c871d93ae933" xlink:to="loc_us-gaap_SeveranceCosts1_6fc4dc6c-9e73-43bf-b8b3-66338b10fb55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FacilityExitAndOtherCosts_10f46ca9-4414-4383-a334-9718e2fec361" xlink:href="cah-20210331.xsd#cah_FacilityExitAndOtherCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1328f8bc-d7c9-4938-bb62-c871d93ae933" xlink:to="loc_cah_FacilityExitAndOtherCosts_10f46ca9-4414-4383-a334-9718e2fec361" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_37cbce92-f7d8-4ab5-8d89-6210a3fe6daa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1328f8bc-d7c9-4938-bb62-c871d93ae933" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_37cbce92-f7d8-4ab5-8d89-6210a3fe6daa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_3536a510-daa6-47cd-b89a-437089924315" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_37cbce92-f7d8-4ab5-8d89-6210a3fe6daa" xlink:to="loc_us-gaap_RestructuringPlanAxis_3536a510-daa6-47cd-b89a-437089924315" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_3536a510-daa6-47cd-b89a-437089924315_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_3536a510-daa6-47cd-b89a-437089924315" xlink:to="loc_us-gaap_RestructuringPlanDomain_3536a510-daa6-47cd-b89a-437089924315_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_7c7f9398-2c0b-4e79-b8d6-964bb9dc2f74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_3536a510-daa6-47cd-b89a-437089924315" xlink:to="loc_us-gaap_RestructuringPlanDomain_7c7f9398-2c0b-4e79-b8d6-964bb9dc2f74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLocationAxis_7ee71570-32b3-4554-8360-d976a5924c24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_37cbce92-f7d8-4ab5-8d89-6210a3fe6daa" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLocationAxis_7ee71570-32b3-4554-8360-d976a5924c24" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLocationDomain_7ee71570-32b3-4554-8360-d976a5924c24_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLocationAxis_7ee71570-32b3-4554-8360-d976a5924c24" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLocationDomain_7ee71570-32b3-4554-8360-d976a5924c24_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLocationDomain_45827447-dd2e-44f3-82e4-e35a1f81f6a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLocationAxis_7ee71570-32b3-4554-8360-d976a5924c24" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLocationDomain_45827447-dd2e-44f3-82e4-e35a1f81f6a5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets" xlink:type="simple" xlink:href="cah-20210331.xsd#GoodwillandOtherIntangibleAssets"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets" xlink:type="extended" id="iad7539b4568246748bd5e58f06651e79_GoodwillandOtherIntangibleAssets"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables" xlink:type="simple" xlink:href="cah-20210331.xsd#GoodwillandOtherIntangibleAssetsTables"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables" xlink:type="extended" id="ib830197500f441dfb75d744f7383b911_GoodwillandOtherIntangibleAssetsTables"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" xlink:type="extended" id="i4af89351806a4f9fa03962f4f45408d0_GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_2559f467-c75c-43bb-bd4f-1d902b8fbadc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_6e4b0f5c-c5f3-47ae-8628-ed7e5c0fa1ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_2559f467-c75c-43bb-bd4f-1d902b8fbadc" xlink:to="loc_us-gaap_GoodwillRollForward_6e4b0f5c-c5f3-47ae-8628-ed7e5c0fa1ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_38ea9843-9ee0-40e9-bb87-eee192e96bf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_6e4b0f5c-c5f3-47ae-8628-ed7e5c0fa1ea" xlink:to="loc_us-gaap_Goodwill_38ea9843-9ee0-40e9-bb87-eee192e96bf2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_3b83651e-d012-420e-9280-ddd3833a8766" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_6e4b0f5c-c5f3-47ae-8628-ed7e5c0fa1ea" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_3b83651e-d012-420e-9280-ddd3833a8766" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_6bb29733-8e15-4d53-83e0-292bd23c4c90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_6e4b0f5c-c5f3-47ae-8628-ed7e5c0fa1ea" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_6bb29733-8e15-4d53-83e0-292bd23c4c90" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_12a6264f-ce51-439d-9766-8d4333790c6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_6a9c5daf-9fd8-490b-8964-bb9a18615a74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_2559f467-c75c-43bb-bd4f-1d902b8fbadc" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_6a9c5daf-9fd8-490b-8964-bb9a18615a74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_8fef61c5-618f-4775-a97c-90ac4efe1156" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_2559f467-c75c-43bb-bd4f-1d902b8fbadc" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_8fef61c5-618f-4775-a97c-90ac4efe1156" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_b01c3768-018b-48fe-9536-6ede095b8593" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_8fef61c5-618f-4775-a97c-90ac4efe1156" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_b01c3768-018b-48fe-9536-6ede095b8593" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_b01c3768-018b-48fe-9536-6ede095b8593_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b01c3768-018b-48fe-9536-6ede095b8593" xlink:to="loc_us-gaap_SegmentDomain_b01c3768-018b-48fe-9536-6ede095b8593_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_fb5f7283-45ca-4af7-978f-5e38dd5cf726" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b01c3768-018b-48fe-9536-6ede095b8593" xlink:to="loc_us-gaap_SegmentDomain_fb5f7283-45ca-4af7-978f-5e38dd5cf726" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_fc64afb7-a849-4568-b5ae-e43d9e4c5436" xlink:href="cah-20210331.xsd#cah_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_fb5f7283-45ca-4af7-978f-5e38dd5cf726" xlink:to="loc_cah_PharmaceuticalMember_fc64afb7-a849-4568-b5ae-e43d9e4c5436" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_e9ea8308-58cb-4418-afdc-8de90b6b0996" xlink:href="cah-20210331.xsd#cah_MedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_fb5f7283-45ca-4af7-978f-5e38dd5cf726" xlink:to="loc_cah_MedicalMember_e9ea8308-58cb-4418-afdc-8de90b6b0996" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_3302a011-d98f-4619-85ae-0ae37718875b" xlink:href="cah-20210331.xsd#cah_CordisDivestitureAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_8fef61c5-618f-4775-a97c-90ac4efe1156" xlink:to="loc_cah_CordisDivestitureAxis_3302a011-d98f-4619-85ae-0ae37718875b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_3302a011-d98f-4619-85ae-0ae37718875b_default" xlink:href="cah-20210331.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_CordisDivestitureAxis_3302a011-d98f-4619-85ae-0ae37718875b" xlink:to="loc_cah_CordisDivestitureDomain_3302a011-d98f-4619-85ae-0ae37718875b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_0c548130-785e-4cc6-81b3-0078fa6d042b" xlink:href="cah-20210331.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_CordisDivestitureAxis_3302a011-d98f-4619-85ae-0ae37718875b" xlink:to="loc_cah_CordisDivestitureDomain_0c548130-785e-4cc6-81b3-0078fa6d042b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_3447f670-1441-400b-9caa-13f011cb7c7a" xlink:href="cah-20210331.xsd#cah_CordisDivestitureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_CordisDivestitureDomain_0c548130-785e-4cc6-81b3-0078fa6d042b" xlink:to="loc_cah_CordisDivestitureMember_3447f670-1441-400b-9caa-13f011cb7c7a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended" id="i3d37f19c67b244b1bac1f6f41b804286_GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_48a40ce0-7ed3-48c9-9d9d-364bbb0a0883" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_a609ee68-e392-4579-9202-d7ff045946bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_48a40ce0-7ed3-48c9-9d9d-364bbb0a0883" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_a609ee68-e392-4579-9202-d7ff045946bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_1d61cd53-a88a-4390-a5b6-728acd426257" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_48a40ce0-7ed3-48c9-9d9d-364bbb0a0883" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_1d61cd53-a88a-4390-a5b6-728acd426257" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_be2eef0e-8a89-4aed-baad-df1a0e0cd06d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_1d61cd53-a88a-4390-a5b6-728acd426257" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_be2eef0e-8a89-4aed-baad-df1a0e0cd06d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_be2eef0e-8a89-4aed-baad-df1a0e0cd06d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_be2eef0e-8a89-4aed-baad-df1a0e0cd06d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_be2eef0e-8a89-4aed-baad-df1a0e0cd06d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_576283c7-32c8-4220-9cdc-01a3c9223234" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_be2eef0e-8a89-4aed-baad-df1a0e0cd06d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_576283c7-32c8-4220-9cdc-01a3c9223234" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IPRDTrademarksandOtherMember_9559903c-476c-4762-9cd6-212dd0c1d22f" xlink:href="cah-20210331.xsd#cah_IPRDTrademarksandOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_576283c7-32c8-4220-9cdc-01a3c9223234" xlink:to="loc_cah_IPRDTrademarksandOtherMember_9559903c-476c-4762-9cd6-212dd0c1d22f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ec18f13c-bd95-4cf3-96d0-e6987d74a804" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b1849cf1-890f-43e6-a750-0bf0b4b5d2b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ec18f13c-bd95-4cf3-96d0-e6987d74a804" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b1849cf1-890f-43e6-a750-0bf0b4b5d2b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_774917a7-b1b0-4de1-8b4b-dc85aea1d6d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ec18f13c-bd95-4cf3-96d0-e6987d74a804" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_774917a7-b1b0-4de1-8b4b-dc85aea1d6d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4387a40b-72e6-4b8b-aa0f-39e253e0f2a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ec18f13c-bd95-4cf3-96d0-e6987d74a804" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4387a40b-72e6-4b8b-aa0f-39e253e0f2a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_09c3a637-e216-4206-853b-8338669afc99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ec18f13c-bd95-4cf3-96d0-e6987d74a804" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_09c3a637-e216-4206-853b-8338669afc99" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_63d3ba2a-23da-46fe-87d1-32dbff43e9d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ec18f13c-bd95-4cf3-96d0-e6987d74a804" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_63d3ba2a-23da-46fe-87d1-32dbff43e9d2" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ad2f1370-e02f-4d7a-b26e-8b26b354fe2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_63d3ba2a-23da-46fe-87d1-32dbff43e9d2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ad2f1370-e02f-4d7a-b26e-8b26b354fe2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ad2f1370-e02f-4d7a-b26e-8b26b354fe2d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ad2f1370-e02f-4d7a-b26e-8b26b354fe2d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ad2f1370-e02f-4d7a-b26e-8b26b354fe2d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8cf402c5-c97f-4501-b82b-cf1ad6ba940d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ad2f1370-e02f-4d7a-b26e-8b26b354fe2d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8cf402c5-c97f-4501-b82b-cf1ad6ba940d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_c099bc17-b2f0-4eae-88bd-f4373a499545" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8cf402c5-c97f-4501-b82b-cf1ad6ba940d" xlink:to="loc_us-gaap_CustomerRelationshipsMember_c099bc17-b2f0-4eae-88bd-f4373a499545" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TrademarksAndPatentsMember_f11f7618-f4e9-4c6c-a037-6223049c0dbe" xlink:href="cah-20210331.xsd#cah_TrademarksAndPatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8cf402c5-c97f-4501-b82b-cf1ad6ba940d" xlink:to="loc_cah_TrademarksAndPatentsMember_f11f7618-f4e9-4c6c-a037-6223049c0dbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_7517011b-a02a-4195-ba60-4c8a89834a81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8cf402c5-c97f-4501-b82b-cf1ad6ba940d" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_7517011b-a02a-4195-ba60-4c8a89834a81" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#GoodwillandOtherIntangibleAssetsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="extended" id="ia5d0be7e8bf342df89438c3e414e73ff_GoodwillandOtherIntangibleAssetsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_335965a3-39af-446b-b187-1f3ab4ea5f9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0a996425-f4d4-4c3c-b200-d7f19bb13881" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_335965a3-39af-446b-b187-1f3ab4ea5f9e" xlink:to="loc_us-gaap_Goodwill_0a996425-f4d4-4c3c-b200-d7f19bb13881" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_89bac0d7-4e1f-4d74-8bf4-74b3c100b1cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_335965a3-39af-446b-b187-1f3ab4ea5f9e" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_89bac0d7-4e1f-4d74-8bf4-74b3c100b1cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7fe35dfa-f164-4e04-872f-203327d6d299" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_335965a3-39af-446b-b187-1f3ab4ea5f9e" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7fe35dfa-f164-4e04-872f-203327d6d299" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9ada2c15-e031-4cd0-918f-b4000f27f847" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7fe35dfa-f164-4e04-872f-203327d6d299" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9ada2c15-e031-4cd0-918f-b4000f27f847" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9ada2c15-e031-4cd0-918f-b4000f27f847_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9ada2c15-e031-4cd0-918f-b4000f27f847" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9ada2c15-e031-4cd0-918f-b4000f27f847_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4db72a9b-eb14-43fb-904b-10fd5cd5d5ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9ada2c15-e031-4cd0-918f-b4000f27f847" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4db72a9b-eb14-43fb-904b-10fd5cd5d5ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_d5f64b2d-c23c-4d35-bce4-56f7b65377dc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7fe35dfa-f164-4e04-872f-203327d6d299" xlink:to="loc_srt_ConsolidationItemsAxis_d5f64b2d-c23c-4d35-bce4-56f7b65377dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_d5f64b2d-c23c-4d35-bce4-56f7b65377dc_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_d5f64b2d-c23c-4d35-bce4-56f7b65377dc" xlink:to="loc_srt_ConsolidationItemsDomain_d5f64b2d-c23c-4d35-bce4-56f7b65377dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_ce4bc601-8c3b-47ed-95b6-b0866f8ad34a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_d5f64b2d-c23c-4d35-bce4-56f7b65377dc" xlink:to="loc_srt_ConsolidationItemsDomain_ce4bc601-8c3b-47ed-95b6-b0866f8ad34a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2f3cb5ab-612c-4269-acdc-4a4be163c844" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7fe35dfa-f164-4e04-872f-203327d6d299" xlink:to="loc_srt_RangeAxis_2f3cb5ab-612c-4269-acdc-4a4be163c844" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2f3cb5ab-612c-4269-acdc-4a4be163c844_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2f3cb5ab-612c-4269-acdc-4a4be163c844" xlink:to="loc_srt_RangeMember_2f3cb5ab-612c-4269-acdc-4a4be163c844_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d3bdf1fa-e575-44e0-95e6-c7b9b4b8ce4a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2f3cb5ab-612c-4269-acdc-4a4be163c844" xlink:to="loc_srt_RangeMember_d3bdf1fa-e575-44e0-95e6-c7b9b4b8ce4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_0cb9de22-9436-4c27-8734-c1ccab2d8623" xlink:href="cah-20210331.xsd#cah_CordisDivestitureAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7fe35dfa-f164-4e04-872f-203327d6d299" xlink:to="loc_cah_CordisDivestitureAxis_0cb9de22-9436-4c27-8734-c1ccab2d8623" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_0cb9de22-9436-4c27-8734-c1ccab2d8623_default" xlink:href="cah-20210331.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_CordisDivestitureAxis_0cb9de22-9436-4c27-8734-c1ccab2d8623" xlink:to="loc_cah_CordisDivestitureDomain_0cb9de22-9436-4c27-8734-c1ccab2d8623_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_cd6120c6-cf39-4b08-b779-042f6cf8add4" xlink:href="cah-20210331.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_CordisDivestitureAxis_0cb9de22-9436-4c27-8734-c1ccab2d8623" xlink:to="loc_cah_CordisDivestitureDomain_cd6120c6-cf39-4b08-b779-042f6cf8add4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_8552629f-7037-42d6-8d91-5e9c401135fb" xlink:href="cah-20210331.xsd#cah_CordisDivestitureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_CordisDivestitureDomain_cd6120c6-cf39-4b08-b779-042f6cf8add4" xlink:to="loc_cah_CordisDivestitureMember_8552629f-7037-42d6-8d91-5e9c401135fb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings" xlink:type="simple" xlink:href="cah-20210331.xsd#LongTermObligationsandOtherShortTermBorrowings"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings" xlink:type="extended" id="i03f06ed16b6a4c56be59bea06a08eb4b_LongTermObligationsandOtherShortTermBorrowings"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsTables" xlink:type="simple" xlink:href="cah-20210331.xsd#LongTermObligationsandOtherShortTermBorrowingsTables"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsTables" xlink:type="extended" id="i439a702554a14c159b940f12cc6c1d8a_LongTermObligationsandOtherShortTermBorrowingsTables"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#LongTermObligationsandOtherShortTermBorrowingsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" xlink:type="extended" id="i7afb95b4d1ba4084b46bd2e63a6bd2e0_LongTermObligationsandOtherShortTermBorrowingsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_5f40ac11-46ef-4b8f-8786-15c8e69fbb30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalLongTermandShortTermObligations_270dd90a-11ae-44bf-abf3-7d84de2b525e" xlink:href="cah-20210331.xsd#cah_TotalLongTermandShortTermObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5f40ac11-46ef-4b8f-8786-15c8e69fbb30" xlink:to="loc_cah_TotalLongTermandShortTermObligations_270dd90a-11ae-44bf-abf3-7d84de2b525e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_c8057e38-8db8-447d-9cf2-ac34f715f9bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5f40ac11-46ef-4b8f-8786-15c8e69fbb30" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_c8057e38-8db8-447d-9cf2-ac34f715f9bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NotesPayableRepurchased_095cf3ff-0631-4955-adb7-b0c86c40afaa" xlink:href="cah-20210331.xsd#cah_NotesPayableRepurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5f40ac11-46ef-4b8f-8786-15c8e69fbb30" xlink:to="loc_cah_NotesPayableRepurchased_095cf3ff-0631-4955-adb7-b0c86c40afaa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_dee1d999-174f-4565-957c-2fc015aa2465" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5f40ac11-46ef-4b8f-8786-15c8e69fbb30" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_dee1d999-174f-4565-957c-2fc015aa2465" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_91c754af-28e4-403a-8504-9fa78e5a9fbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5f40ac11-46ef-4b8f-8786-15c8e69fbb30" xlink:to="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_91c754af-28e4-403a-8504-9fa78e5a9fbb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_730fca25-b422-48b8-ac8d-4f6b9bac54ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5f40ac11-46ef-4b8f-8786-15c8e69fbb30" xlink:to="loc_us-gaap_DebtInstrumentTable_730fca25-b422-48b8-ac8d-4f6b9bac54ff" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_eaee2051-fc29-44cd-a14b-bde971914933" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_730fca25-b422-48b8-ac8d-4f6b9bac54ff" xlink:to="loc_us-gaap_DebtInstrumentAxis_eaee2051-fc29-44cd-a14b-bde971914933" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_eaee2051-fc29-44cd-a14b-bde971914933_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_eaee2051-fc29-44cd-a14b-bde971914933" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_eaee2051-fc29-44cd-a14b-bde971914933_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3a42f6d9-7f71-4c4d-a0c1-61d86aaadc3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_eaee2051-fc29-44cd-a14b-bde971914933" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3a42f6d9-7f71-4c4d-a0c1-61d86aaadc3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A2.4Notesdue2020Member_7bbed007-8335-4caf-9bc8-b28b9a899ab8" xlink:href="cah-20210331.xsd#cah_A2.4Notesdue2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3a42f6d9-7f71-4c4d-a0c1-61d86aaadc3c" xlink:to="loc_cah_A2.4Notesdue2020Member_7bbed007-8335-4caf-9bc8-b28b9a899ab8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A2.616Notesdue2022Member_11f28d95-e8c6-42a5-91aa-1c3ae7a7ec24" xlink:href="cah-20210331.xsd#cah_A2.616Notesdue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3a42f6d9-7f71-4c4d-a0c1-61d86aaadc3c" xlink:to="loc_cah_A2.616Notesdue2022Member_11f28d95-e8c6-42a5-91aa-1c3ae7a7ec24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A3.41Notesdue2027Member_b4ee601e-0f61-47af-b3ce-f3b9811da55c" xlink:href="cah-20210331.xsd#cah_A3.41Notesdue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3a42f6d9-7f71-4c4d-a0c1-61d86aaadc3c" xlink:to="loc_cah_A3.41Notesdue2027Member_b4ee601e-0f61-47af-b3ce-f3b9811da55c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember_8977ae8f-bdca-43f5-b7b6-f55df46f6bc5" xlink:href="cah-20210331.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3a42f6d9-7f71-4c4d-a0c1-61d86aaadc3c" xlink:to="loc_cah_CommittedReceivablesSalesFacilityProgramMember_8977ae8f-bdca-43f5-b7b6-f55df46f6bc5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A4.6Notesdue2043Member_e8130a59-5979-4140-9919-b6605a90235d" xlink:href="cah-20210331.xsd#cah_A4.6Notesdue2043Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3a42f6d9-7f71-4c4d-a0c1-61d86aaadc3c" xlink:to="loc_cah_A4.6Notesdue2043Member_e8130a59-5979-4140-9919-b6605a90235d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A4.9Notesdue2045Member_25ec80a0-1b7d-4910-9763-dc2818432d26" xlink:href="cah-20210331.xsd#cah_A4.9Notesdue2045Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3a42f6d9-7f71-4c4d-a0c1-61d86aaadc3c" xlink:to="loc_cah_A4.9Notesdue2045Member_25ec80a0-1b7d-4910-9763-dc2818432d26" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A4.368Notesdue2047Member_85f6c3b6-5d29-497b-8e80-a56a83394e84" xlink:href="cah-20210331.xsd#cah_A4.368Notesdue2047Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3a42f6d9-7f71-4c4d-a0c1-61d86aaadc3c" xlink:to="loc_cah_A4.368Notesdue2047Member_85f6c3b6-5d29-497b-8e80-a56a83394e84" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FloatingRateNotesdue2022Member_91f6e297-85c7-44f7-8201-c9ab9077d01e" xlink:href="cah-20210331.xsd#cah_FloatingRateNotesdue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3a42f6d9-7f71-4c4d-a0c1-61d86aaadc3c" xlink:to="loc_cah_FloatingRateNotesdue2022Member_91f6e297-85c7-44f7-8201-c9ab9077d01e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A3.2Notesdue2022Member_9b8d657d-e2cb-4c84-8350-bd6c22e5c703" xlink:href="cah-20210331.xsd#cah_A3.2Notesdue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3a42f6d9-7f71-4c4d-a0c1-61d86aaadc3c" xlink:to="loc_cah_A3.2Notesdue2022Member_9b8d657d-e2cb-4c84-8350-bd6c22e5c703" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_543153c0-2a11-4a41-b9cd-c4aa43fa6111" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_730fca25-b422-48b8-ac8d-4f6b9bac54ff" xlink:to="loc_us-gaap_CreditFacilityAxis_543153c0-2a11-4a41-b9cd-c4aa43fa6111" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_543153c0-2a11-4a41-b9cd-c4aa43fa6111_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_543153c0-2a11-4a41-b9cd-c4aa43fa6111" xlink:to="loc_us-gaap_CreditFacilityDomain_543153c0-2a11-4a41-b9cd-c4aa43fa6111_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_c81b06a4-f742-4e1a-91e6-24bedd56adfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_543153c0-2a11-4a41-b9cd-c4aa43fa6111" xlink:to="loc_us-gaap_CreditFacilityDomain_c81b06a4-f742-4e1a-91e6-24bedd56adfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_cc0748aa-c7fc-4c6f-821e-630ddd67b8cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_c81b06a4-f742-4e1a-91e6-24bedd56adfb" xlink:to="loc_us-gaap_CommercialPaperMember_cc0748aa-c7fc-4c6f-821e-630ddd67b8cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_079e31b3-04b5-4943-99d9-966f3aa4732e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_c81b06a4-f742-4e1a-91e6-24bedd56adfb" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_079e31b3-04b5-4943-99d9-966f3aa4732e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShortTermCreditFacilitiesMember_9dd65a3c-7515-47ea-bf30-00b84f4e8d7a" xlink:href="cah-20210331.xsd#cah_ShortTermCreditFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_c81b06a4-f742-4e1a-91e6-24bedd56adfb" xlink:to="loc_cah_ShortTermCreditFacilitiesMember_9dd65a3c-7515-47ea-bf30-00b84f4e8d7a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember_29a756ee-78f9-4eef-8ae3-3694a677c658" xlink:href="cah-20210331.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_c81b06a4-f742-4e1a-91e6-24bedd56adfb" xlink:to="loc_cah_CommittedReceivablesSalesFacilityProgramMember_29a756ee-78f9-4eef-8ae3-3694a677c658" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" xlink:type="extended" id="if928d3f48c514db0af00b61e481c3eea_LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2c049a6c-d0e9-4761-9a9c-27537184bfea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalLongTermandShortTermObligations_e02bf44d-86e2-4139-8b78-eadc077080d0" xlink:href="cah-20210331.xsd#cah_TotalLongTermandShortTermObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2c049a6c-d0e9-4761-9a9c-27537184bfea" xlink:to="loc_cah_TotalLongTermandShortTermObligations_e02bf44d-86e2-4139-8b78-eadc077080d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_fbd81a94-0a20-42e9-9c52-bf31cd376a90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2c049a6c-d0e9-4761-9a9c-27537184bfea" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_fbd81a94-0a20-42e9-9c52-bf31cd376a90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_16eb91d8-84d2-4865-abad-ad87b8f848bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2c049a6c-d0e9-4761-9a9c-27537184bfea" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_16eb91d8-84d2-4865-abad-ad87b8f848bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_7aa136bc-85aa-4e5c-a800-2b92602c25e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2c049a6c-d0e9-4761-9a9c-27537184bfea" xlink:to="loc_us-gaap_DebtInstrumentTable_7aa136bc-85aa-4e5c-a800-2b92602c25e1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1a18eaa1-4890-4322-a5b6-963095cd9457" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7aa136bc-85aa-4e5c-a800-2b92602c25e1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1a18eaa1-4890-4322-a5b6-963095cd9457" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1a18eaa1-4890-4322-a5b6-963095cd9457_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1a18eaa1-4890-4322-a5b6-963095cd9457" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1a18eaa1-4890-4322-a5b6-963095cd9457_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_45b082c4-5460-44f3-9cc3-c6a452fccfcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1a18eaa1-4890-4322-a5b6-963095cd9457" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_45b082c4-5460-44f3-9cc3-c6a452fccfcf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_75ed1bde-7794-4af5-918c-ff06a429adf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7aa136bc-85aa-4e5c-a800-2b92602c25e1" xlink:to="loc_us-gaap_DebtInstrumentAxis_75ed1bde-7794-4af5-918c-ff06a429adf9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_75ed1bde-7794-4af5-918c-ff06a429adf9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_75ed1bde-7794-4af5-918c-ff06a429adf9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_75ed1bde-7794-4af5-918c-ff06a429adf9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_525a50db-ea85-4c29-a220-91ce5350769f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_75ed1bde-7794-4af5-918c-ff06a429adf9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_525a50db-ea85-4c29-a220-91ce5350769f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A2.4Notesdue2020Member_f7089326-0042-43f0-9b3e-45304993e707" xlink:href="cah-20210331.xsd#cah_A2.4Notesdue2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_525a50db-ea85-4c29-a220-91ce5350769f" xlink:to="loc_cah_A2.4Notesdue2020Member_f7089326-0042-43f0-9b3e-45304993e707" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A2.616Notesdue2022Member_b363fff7-93f7-492f-b98a-7aa9522b5c37" xlink:href="cah-20210331.xsd#cah_A2.616Notesdue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_525a50db-ea85-4c29-a220-91ce5350769f" xlink:to="loc_cah_A2.616Notesdue2022Member_b363fff7-93f7-492f-b98a-7aa9522b5c37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A3.2Notesdue2022Member_4092a062-eafb-495e-8a0a-514b4ebb3715" xlink:href="cah-20210331.xsd#cah_A3.2Notesdue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_525a50db-ea85-4c29-a220-91ce5350769f" xlink:to="loc_cah_A3.2Notesdue2022Member_4092a062-eafb-495e-8a0a-514b4ebb3715" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FloatingRateNotesdue2022Member_90860741-b6d5-43e2-9de5-8be3a97ccca6" xlink:href="cah-20210331.xsd#cah_FloatingRateNotesdue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_525a50db-ea85-4c29-a220-91ce5350769f" xlink:to="loc_cah_FloatingRateNotesdue2022Member_90860741-b6d5-43e2-9de5-8be3a97ccca6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A3.41Notesdue2027Member_ea9c7431-d3ba-484d-b9b2-8b4f7a8e6c8d" xlink:href="cah-20210331.xsd#cah_A3.41Notesdue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_525a50db-ea85-4c29-a220-91ce5350769f" xlink:to="loc_cah_A3.41Notesdue2027Member_ea9c7431-d3ba-484d-b9b2-8b4f7a8e6c8d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A4.6Notesdue2043Member_821adb29-07c6-4186-9156-bd0e23904af1" xlink:href="cah-20210331.xsd#cah_A4.6Notesdue2043Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_525a50db-ea85-4c29-a220-91ce5350769f" xlink:to="loc_cah_A4.6Notesdue2043Member_821adb29-07c6-4186-9156-bd0e23904af1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A4.9Notesdue2045Member_8a16c904-866d-45c0-a4ac-6edadc53be61" xlink:href="cah-20210331.xsd#cah_A4.9Notesdue2045Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_525a50db-ea85-4c29-a220-91ce5350769f" xlink:to="loc_cah_A4.9Notesdue2045Member_8a16c904-866d-45c0-a4ac-6edadc53be61" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A4.368Notesdue2047Member_d3d95e0f-26e0-4e0f-b0b2-a4c1bd04b01f" xlink:href="cah-20210331.xsd#cah_A4.368Notesdue2047Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_525a50db-ea85-4c29-a220-91ce5350769f" xlink:to="loc_cah_A4.368Notesdue2047Member_d3d95e0f-26e0-4e0f-b0b2-a4c1bd04b01f" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation" xlink:type="simple" xlink:href="cah-20210331.xsd#CommitmentsContingentLiabilitiesandLitigation"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation" xlink:type="extended" id="i5303f13624ed45e8b6867239ceeb6062_CommitmentsContingentLiabilitiesandLitigation"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#CommitmentsContingentLiabilitiesandLitigationDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" xlink:type="extended" id="ife0f8afda03e4c01bd670d6574fb01c8_CommitmentsContingentLiabilitiesandLitigationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_4abe5425-6968-4571-8eb8-ece987728529" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_e45b6f9e-869d-4a8f-8831-5ae2f05d4ad7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4abe5425-6968-4571-8eb8-ece987728529" xlink:to="loc_us-gaap_InventoryNet_e45b6f9e-869d-4a8f-8831-5ae2f05d4ad7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermPurchaseCommitmentPeriod_84ae2fba-f2a7-43de-85dd-c3970383d67b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermPurchaseCommitmentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4abe5425-6968-4571-8eb8-ece987728529" xlink:to="loc_us-gaap_LongtermPurchaseCommitmentPeriod_84ae2fba-f2a7-43de-85dd-c3970383d67b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MaximumQuarterlyPayment_71351497-b780-4733-9d3c-1942a567369d" xlink:href="cah-20210331.xsd#cah_MaximumQuarterlyPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4abe5425-6968-4571-8eb8-ece987728529" xlink:to="loc_cah_MaximumQuarterlyPayment_71351497-b780-4733-9d3c-1942a567369d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LossContingencyLawsuitsNumber_cb7c16a8-b67e-43da-bf54-b822d7c63b61" xlink:href="cah-20210331.xsd#cah_LossContingencyLawsuitsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4abe5425-6968-4571-8eb8-ece987728529" xlink:to="loc_cah_LossContingencyLawsuitsNumber_cb7c16a8-b67e-43da-bf54-b822d7c63b61" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NumberofStateAttorneysGeneralfilinglawsuits_add6b5f7-59ab-495b-946f-102bbed9288f" xlink:href="cah-20210331.xsd#cah_NumberofStateAttorneysGeneralfilinglawsuits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4abe5425-6968-4571-8eb8-ece987728529" xlink:to="loc_cah_NumberofStateAttorneysGeneralfilinglawsuits_add6b5f7-59ab-495b-946f-102bbed9288f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_d7b4c230-887c-4763-b379-3253350eb0f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4abe5425-6968-4571-8eb8-ece987728529" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_d7b4c230-887c-4763-b379-3253350eb0f9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_869346d6-d528-445c-8965-68afa8ab1640" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4abe5425-6968-4571-8eb8-ece987728529" xlink:to="loc_us-gaap_LitigationReserve_869346d6-d528-445c-8965-68afa8ab1640" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_1bcabac8-7c00-43ce-903e-a561f9ff2db0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4abe5425-6968-4571-8eb8-ece987728529" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_1bcabac8-7c00-43ce-903e-a561f9ff2db0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_b67b0fd8-9e47-4cdb-a761-17513ebeabfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4abe5425-6968-4571-8eb8-ece987728529" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_b67b0fd8-9e47-4cdb-a761-17513ebeabfb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_3a55a5a0-dabd-4d17-ad5c-ef32081ddd42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4abe5425-6968-4571-8eb8-ece987728529" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_3a55a5a0-dabd-4d17-ad5c-ef32081ddd42" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRecallExpense_b10d7dd6-2883-41a6-81ad-8c6b7856905a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRecallExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4abe5425-6968-4571-8eb8-ece987728529" xlink:to="loc_us-gaap_InventoryRecallExpense_b10d7dd6-2883-41a6-81ad-8c6b7856905a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_4a0dc763-146e-4dea-8291-5404db367519" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4abe5425-6968-4571-8eb8-ece987728529" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_4a0dc763-146e-4dea-8291-5404db367519" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3a193004-268a-46cb-9242-57f4f05de47d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4abe5425-6968-4571-8eb8-ece987728529" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3a193004-268a-46cb-9242-57f4f05de47d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e5caf2e3-536c-4695-beda-f99d40056740" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4abe5425-6968-4571-8eb8-ece987728529" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e5caf2e3-536c-4695-beda-f99d40056740" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_e5508ab8-88c7-4a24-a93d-cd4f8b7b4f1d" xlink:href="cah-20210331.xsd#cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4abe5425-6968-4571-8eb8-ece987728529" xlink:to="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_e5508ab8-88c7-4a24-a93d-cd4f8b7b4f1d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AggregateAnnualAssessment_92b859db-e7ee-49f5-9b42-c3a6e6706c5d" xlink:href="cah-20210331.xsd#cah_AggregateAnnualAssessment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4abe5425-6968-4571-8eb8-ece987728529" xlink:to="loc_cah_AggregateAnnualAssessment_92b859db-e7ee-49f5-9b42-c3a6e6706c5d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProceedsFromSettlementsOfClassActionLawsuits_27bfdf2b-e0a1-4f73-ac34-78f8443ca8f4" xlink:href="cah-20210331.xsd#cah_ProceedsFromSettlementsOfClassActionLawsuits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4abe5425-6968-4571-8eb8-ece987728529" xlink:to="loc_cah_ProceedsFromSettlementsOfClassActionLawsuits_27bfdf2b-e0a1-4f73-ac34-78f8443ca8f4" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_77d77986-218d-46eb-9c04-9d1f0f237ef8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_4abe5425-6968-4571-8eb8-ece987728529" xlink:to="loc_us-gaap_LossContingenciesTable_77d77986-218d-46eb-9c04-9d1f0f237ef8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GownRecallAxis_a41c34c3-4bb2-4fcb-acb4-b224cc0fbe27" xlink:href="cah-20210331.xsd#cah_GownRecallAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_77d77986-218d-46eb-9c04-9d1f0f237ef8" xlink:to="loc_cah_GownRecallAxis_a41c34c3-4bb2-4fcb-acb4-b224cc0fbe27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GownRecallDomain_a41c34c3-4bb2-4fcb-acb4-b224cc0fbe27_default" xlink:href="cah-20210331.xsd#cah_GownRecallDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_GownRecallAxis_a41c34c3-4bb2-4fcb-acb4-b224cc0fbe27" xlink:to="loc_cah_GownRecallDomain_a41c34c3-4bb2-4fcb-acb4-b224cc0fbe27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GownRecallDomain_1e63fcd2-4daa-4a27-9053-6d00c8c2e0aa" xlink:href="cah-20210331.xsd#cah_GownRecallDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_GownRecallAxis_a41c34c3-4bb2-4fcb-acb4-b224cc0fbe27" xlink:to="loc_cah_GownRecallDomain_1e63fcd2-4daa-4a27-9053-6d00c8c2e0aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_ddbb7c5c-fa83-422d-9446-4cd5980e5806" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_77d77986-218d-46eb-9c04-9d1f0f237ef8" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_ddbb7c5c-fa83-422d-9446-4cd5980e5806" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_ddbb7c5c-fa83-422d-9446-4cd5980e5806_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_ddbb7c5c-fa83-422d-9446-4cd5980e5806" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_ddbb7c5c-fa83-422d-9446-4cd5980e5806_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7dc01931-54c5-4de6-b739-0a12d1d55ed2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_ddbb7c5c-fa83-422d-9446-4cd5980e5806" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7dc01931-54c5-4de6-b739-0a12d1d55ed2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_870927a3-4e9f-4792-9a71-f4300bdad3ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_77d77986-218d-46eb-9c04-9d1f0f237ef8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_870927a3-4e9f-4792-9a71-f4300bdad3ee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_870927a3-4e9f-4792-9a71-f4300bdad3ee_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_870927a3-4e9f-4792-9a71-f4300bdad3ee" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_870927a3-4e9f-4792-9a71-f4300bdad3ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0877b631-78b1-4d54-ae76-d71dce6e682f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_870927a3-4e9f-4792-9a71-f4300bdad3ee" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0877b631-78b1-4d54-ae76-d71dce6e682f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_cb9cf933-004d-42b6-9ff8-eef670c3feb1" xlink:href="cah-20210331.xsd#cah_OpioidLitigationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_77d77986-218d-46eb-9c04-9d1f0f237ef8" xlink:to="loc_cah_OpioidLitigationAxis_cb9cf933-004d-42b6-9ff8-eef670c3feb1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_cb9cf933-004d-42b6-9ff8-eef670c3feb1_default" xlink:href="cah-20210331.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_OpioidLitigationAxis_cb9cf933-004d-42b6-9ff8-eef670c3feb1" xlink:to="loc_cah_OpioidLitigationDomain_cb9cf933-004d-42b6-9ff8-eef670c3feb1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_6341c95b-1df8-4d6a-8474-e030ba3136b8" xlink:href="cah-20210331.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_OpioidLitigationAxis_cb9cf933-004d-42b6-9ff8-eef670c3feb1" xlink:to="loc_cah_OpioidLitigationDomain_6341c95b-1df8-4d6a-8474-e030ba3136b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_64c7592b-cdc6-4d42-a9fc-cefd6920e0ea" xlink:href="cah-20210331.xsd#cah_TotalOpioidLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_OpioidLitigationDomain_6341c95b-1df8-4d6a-8474-e030ba3136b8" xlink:to="loc_cah_TotalOpioidLitigationMember_64c7592b-cdc6-4d42-a9fc-cefd6920e0ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeAxis_6a75f797-74dc-4eb2-a249-47919fd73e0d" xlink:href="cah-20210331.xsd#cah_LawsuitTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_77d77986-218d-46eb-9c04-9d1f0f237ef8" xlink:to="loc_cah_LawsuitTypeAxis_6a75f797-74dc-4eb2-a249-47919fd73e0d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeDomain_6a75f797-74dc-4eb2-a249-47919fd73e0d_default" xlink:href="cah-20210331.xsd#cah_LawsuitTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_LawsuitTypeAxis_6a75f797-74dc-4eb2-a249-47919fd73e0d" xlink:to="loc_cah_LawsuitTypeDomain_6a75f797-74dc-4eb2-a249-47919fd73e0d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeDomain_5e8e17c1-12c1-4356-8365-26512de26ec7" xlink:href="cah-20210331.xsd#cah_LawsuitTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_LawsuitTypeAxis_6a75f797-74dc-4eb2-a249-47919fd73e0d" xlink:to="loc_cah_LawsuitTypeDomain_5e8e17c1-12c1-4356-8365-26512de26ec7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ClassActionLawsuitsMember_5ff4cc43-5acc-48d3-85ec-6cffa44710bf" xlink:href="cah-20210331.xsd#cah_ClassActionLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_LawsuitTypeDomain_5e8e17c1-12c1-4356-8365-26512de26ec7" xlink:to="loc_cah_ClassActionLawsuitsMember_5ff4cc43-5acc-48d3-85ec-6cffa44710bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_9dbd1acb-cd74-43b5-b820-73b8cb2b322c" xlink:href="cah-20210331.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_LawsuitTypeDomain_5e8e17c1-12c1-4356-8365-26512de26ec7" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_9dbd1acb-cd74-43b5-b820-73b8cb2b322c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeAxis_bad5dcb7-f0a7-4117-9cd1-900612ccd943" xlink:href="cah-20210331.xsd#cah_PlaintiffTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_77d77986-218d-46eb-9c04-9d1f0f237ef8" xlink:to="loc_cah_PlaintiffTypeAxis_bad5dcb7-f0a7-4117-9cd1-900612ccd943" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeDomain_bad5dcb7-f0a7-4117-9cd1-900612ccd943_default" xlink:href="cah-20210331.xsd#cah_PlaintiffTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_PlaintiffTypeAxis_bad5dcb7-f0a7-4117-9cd1-900612ccd943" xlink:to="loc_cah_PlaintiffTypeDomain_bad5dcb7-f0a7-4117-9cd1-900612ccd943_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeDomain_c797710b-6199-459f-8cf2-9d804ce9e285" xlink:href="cah-20210331.xsd#cah_PlaintiffTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_PlaintiffTypeAxis_bad5dcb7-f0a7-4117-9cd1-900612ccd943" xlink:to="loc_cah_PlaintiffTypeDomain_c797710b-6199-459f-8cf2-9d804ce9e285" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PrivatePartiesMember_0c4ea8d4-f960-436d-84d8-10123afe9528" xlink:href="cah-20210331.xsd#cah_PrivatePartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_PlaintiffTypeDomain_c797710b-6199-459f-8cf2-9d804ce9e285" xlink:to="loc_cah_PrivatePartiesMember_0c4ea8d4-f960-436d-84d8-10123afe9528" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementAxis_f8a5f4f9-0f27-4e41-922f-55a20aea934b" xlink:href="cah-20210331.xsd#cah_TaxMattersAgreementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_77d77986-218d-46eb-9c04-9d1f0f237ef8" xlink:to="loc_cah_TaxMattersAgreementAxis_f8a5f4f9-0f27-4e41-922f-55a20aea934b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementDomain_f8a5f4f9-0f27-4e41-922f-55a20aea934b_default" xlink:href="cah-20210331.xsd#cah_TaxMattersAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_TaxMattersAgreementAxis_f8a5f4f9-0f27-4e41-922f-55a20aea934b" xlink:to="loc_cah_TaxMattersAgreementDomain_f8a5f4f9-0f27-4e41-922f-55a20aea934b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementDomain_561b708e-b90a-4de0-b8cf-a38c73c021e8" xlink:href="cah-20210331.xsd#cah_TaxMattersAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_TaxMattersAgreementAxis_f8a5f4f9-0f27-4e41-922f-55a20aea934b" xlink:to="loc_cah_TaxMattersAgreementDomain_561b708e-b90a-4de0-b8cf-a38c73c021e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_faf1dd2a-7d96-466d-915b-dcb28ff35abd" xlink:href="cah-20210331.xsd#cah_TotalOpioidLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_TaxMattersAgreementDomain_561b708e-b90a-4de0-b8cf-a38c73c021e8" xlink:to="loc_cah_TotalOpioidLitigationMember_faf1dd2a-7d96-466d-915b-dcb28ff35abd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_eaea1373-9f31-47a3-99b7-6b31be81f1c9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_77d77986-218d-46eb-9c04-9d1f0f237ef8" xlink:to="loc_srt_StatementGeographicalAxis_eaea1373-9f31-47a3-99b7-6b31be81f1c9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_eaea1373-9f31-47a3-99b7-6b31be81f1c9_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_eaea1373-9f31-47a3-99b7-6b31be81f1c9" xlink:to="loc_srt_SegmentGeographicalDomain_eaea1373-9f31-47a3-99b7-6b31be81f1c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e92ffcbd-ff9c-4394-b51c-48b937e3aa5f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_eaea1373-9f31-47a3-99b7-6b31be81f1c9" xlink:to="loc_srt_SegmentGeographicalDomain_e92ffcbd-ff9c-4394-b51c-48b937e3aa5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AlamedaCountyMember_f67688f1-140d-49e9-a719-d20fea1cb601" xlink:href="cah-20210331.xsd#cah_AlamedaCountyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e92ffcbd-ff9c-4394-b51c-48b937e3aa5f" xlink:to="loc_cah_AlamedaCountyMember_f67688f1-140d-49e9-a719-d20fea1cb601" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OtherJurisdictionsMember_769466c1-1f43-44ae-a2ec-8c0b4d2d015f" xlink:href="cah-20210331.xsd#cah_OtherJurisdictionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e92ffcbd-ff9c-4394-b51c-48b937e3aa5f" xlink:to="loc_cah_OtherJurisdictionsMember_769466c1-1f43-44ae-a2ec-8c0b4d2d015f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_41cb52be-5d66-40cb-ad89-d049a0db0a34" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_77d77986-218d-46eb-9c04-9d1f0f237ef8" xlink:to="loc_srt_RangeAxis_41cb52be-5d66-40cb-ad89-d049a0db0a34" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_41cb52be-5d66-40cb-ad89-d049a0db0a34_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_41cb52be-5d66-40cb-ad89-d049a0db0a34" xlink:to="loc_srt_RangeMember_41cb52be-5d66-40cb-ad89-d049a0db0a34_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f136467f-725c-4c9f-9b98-a8084d54c2d3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_41cb52be-5d66-40cb-ad89-d049a0db0a34" xlink:to="loc_srt_RangeMember_f136467f-725c-4c9f-9b98-a8084d54c2d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2d591bec-86fa-4347-bbc1-81855c5fec6e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f136467f-725c-4c9f-9b98-a8084d54c2d3" xlink:to="loc_srt_MinimumMember_2d591bec-86fa-4347-bbc1-81855c5fec6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2f7272c6-3c66-4972-8ca9-1e749680863b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f136467f-725c-4c9f-9b98-a8084d54c2d3" xlink:to="loc_srt_MaximumMember_2f7272c6-3c66-4972-8ca9-1e749680863b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_b55b7992-aa41-463f-907d-e2309f8bf319" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_77d77986-218d-46eb-9c04-9d1f0f237ef8" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_b55b7992-aa41-463f-907d-e2309f8bf319" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_b55b7992-aa41-463f-907d-e2309f8bf319_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_b55b7992-aa41-463f-907d-e2309f8bf319" xlink:to="loc_us-gaap_LossContingencyNatureDomain_b55b7992-aa41-463f-907d-e2309f8bf319_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_720947f9-a6b7-47f3-a3dd-2ee630d6f67e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_b55b7992-aa41-463f-907d-e2309f8bf319" xlink:to="loc_us-gaap_LossContingencyNatureDomain_720947f9-a6b7-47f3-a3dd-2ee630d6f67e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsMember_e1014869-bd79-433c-9ed4-f5281b72c611" xlink:href="cah-20210331.xsd#cah_OpioidLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_720947f9-a6b7-47f3-a3dd-2ee630d6f67e" xlink:to="loc_cah_OpioidLawsuitsMember_e1014869-bd79-433c-9ed4-f5281b72c611" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_135fdd69-2238-4b31-aa51-bc97bd776534" xlink:href="cah-20210331.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_720947f9-a6b7-47f3-a3dd-2ee630d6f67e" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_135fdd69-2238-4b31-aa51-bc97bd776534" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_b10232f5-1863-4e0d-934a-57a45a96590b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_77d77986-218d-46eb-9c04-9d1f0f237ef8" xlink:to="loc_srt_MajorCustomersAxis_b10232f5-1863-4e0d-934a-57a45a96590b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_b10232f5-1863-4e0d-934a-57a45a96590b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_b10232f5-1863-4e0d-934a-57a45a96590b" xlink:to="loc_srt_NameOfMajorCustomerDomain_b10232f5-1863-4e0d-934a-57a45a96590b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_69ed50d5-0aaf-49d0-82d6-a3dbbae6dac3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_b10232f5-1863-4e0d-934a-57a45a96590b" xlink:to="loc_srt_NameOfMajorCustomerDomain_69ed50d5-0aaf-49d0-82d6-a3dbbae6dac3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CVSHealthMember_ebbac0da-068a-4a10-9a76-786a79a6bcb6" xlink:href="cah-20210331.xsd#cah_CVSHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_69ed50d5-0aaf-49d0-82d6-a3dbbae6dac3" xlink:to="loc_cah_CVSHealthMember_ebbac0da-068a-4a10-9a76-786a79a6bcb6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_34b5284b-1dfa-45e7-97a8-5a0c2f4a4891" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_77d77986-218d-46eb-9c04-9d1f0f237ef8" xlink:to="loc_srt_LitigationCaseAxis_34b5284b-1dfa-45e7-97a8-5a0c2f4a4891" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_34b5284b-1dfa-45e7-97a8-5a0c2f4a4891_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_34b5284b-1dfa-45e7-97a8-5a0c2f4a4891" xlink:to="loc_srt_LitigationCaseTypeDomain_34b5284b-1dfa-45e7-97a8-5a0c2f4a4891_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_a49568b6-fd77-4dbe-9bc6-0b49fda6bc06" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_34b5284b-1dfa-45e7-97a8-5a0c2f4a4891" xlink:to="loc_srt_LitigationCaseTypeDomain_a49568b6-fd77-4dbe-9bc6-0b49fda6bc06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsStateDomain_e96154f3-ec50-4490-8bdb-3c480b8a2da5" xlink:href="cah-20210331.xsd#cah_OpioidLawsuitsStateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_a49568b6-fd77-4dbe-9bc6-0b49fda6bc06" xlink:to="loc_cah_OpioidLawsuitsStateDomain_e96154f3-ec50-4490-8bdb-3c480b8a2da5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsMember_7f444d01-f966-46eb-a08e-01c6ca742823" xlink:href="cah-20210331.xsd#cah_OpioidLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_a49568b6-fd77-4dbe-9bc6-0b49fda6bc06" xlink:to="loc_cah_OpioidLawsuitsMember_7f444d01-f966-46eb-a08e-01c6ca742823" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_9a269e39-b86d-429c-9106-913bbd1987c2" xlink:href="cah-20210331.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_a49568b6-fd77-4dbe-9bc6-0b49fda6bc06" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_9a269e39-b86d-429c-9106-913bbd1987c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NewYorkOpioidStewardshipActMember_dc438868-8f33-4b26-8169-36aa485d88bf" xlink:href="cah-20210331.xsd#cah_NewYorkOpioidStewardshipActMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_a49568b6-fd77-4dbe-9bc6-0b49fda6bc06" xlink:to="loc_cah_NewYorkOpioidStewardshipActMember_dc438868-8f33-4b26-8169-36aa485d88bf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DOJInvestigationMember_eb34df32-ec00-4852-86a6-748983d45626" xlink:href="cah-20210331.xsd#cah_DOJInvestigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_a49568b6-fd77-4dbe-9bc6-0b49fda6bc06" xlink:to="loc_cah_DOJInvestigationMember_eb34df32-ec00-4852-86a6-748983d45626" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b0f6192e-2624-4d87-8ddf-6d501fe09be8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_77d77986-218d-46eb-9c04-9d1f0f237ef8" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b0f6192e-2624-4d87-8ddf-6d501fe09be8" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_b0f6192e-2624-4d87-8ddf-6d501fe09be8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b0f6192e-2624-4d87-8ddf-6d501fe09be8" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_b0f6192e-2624-4d87-8ddf-6d501fe09be8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_cf48f691-099a-4922-b3d2-baab9f0f87be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b0f6192e-2624-4d87-8ddf-6d501fe09be8" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_cf48f691-099a-4922-b3d2-baab9f0f87be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_b6710810-9c88-4595-a5f9-75077db9ab4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_cf48f691-099a-4922-b3d2-baab9f0f87be" xlink:to="loc_us-gaap_SubsequentEventMember_b6710810-9c88-4595-a5f9-75077db9ab4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_bd0442df-5061-4186-b6c2-8b148c009b09" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_77d77986-218d-46eb-9c04-9d1f0f237ef8" xlink:to="loc_srt_StatementScenarioAxis_bd0442df-5061-4186-b6c2-8b148c009b09" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_bd0442df-5061-4186-b6c2-8b148c009b09_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_bd0442df-5061-4186-b6c2-8b148c009b09" xlink:to="loc_srt_ScenarioUnspecifiedDomain_bd0442df-5061-4186-b6c2-8b148c009b09_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_09add7d3-0d27-4ddb-bc37-db2b03380881" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_bd0442df-5061-4186-b6c2-8b148c009b09" xlink:to="loc_srt_ScenarioUnspecifiedDomain_09add7d3-0d27-4ddb-bc37-db2b03380881" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_f320bb6d-defc-4296-9860-4a03ad73ee74" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_09add7d3-0d27-4ddb-bc37-db2b03380881" xlink:to="loc_srt_ScenarioForecastMember_f320bb6d-defc-4296-9860-4a03ad73ee74" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cah-20210331.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/IncomeTaxes" xlink:type="extended" id="id42443c9828b49488542c60355f3be9e_IncomeTaxes"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="i257d606601f042598a06bccc84f24df6_IncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_84ebd8c4-bc39-4c2f-acae-a68c447378f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_379c312d-20b9-4992-bf62-8cf0e206d862" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_84ebd8c4-bc39-4c2f-acae-a68c447378f6" xlink:to="loc_us-gaap_LitigationReserve_379c312d-20b9-4992-bf62-8cf0e206d862" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_87b9e517-04e5-4515-b3db-48b305a0ac21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_84ebd8c4-bc39-4c2f-acae-a68c447378f6" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_87b9e517-04e5-4515-b3db-48b305a0ac21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_00415474-5791-4d77-bd8c-7fd63ac5ef01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_84ebd8c4-bc39-4c2f-acae-a68c447378f6" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_00415474-5791-4d77-bd8c-7fd63ac5ef01" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_b7ae3a1b-2586-4fa4-8184-58df0c425a41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_84ebd8c4-bc39-4c2f-acae-a68c447378f6" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_b7ae3a1b-2586-4fa4-8184-58df0c425a41" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_3bdba151-5dcb-4afd-bf53-df94e5e20e2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_84ebd8c4-bc39-4c2f-acae-a68c447378f6" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_3bdba151-5dcb-4afd-bf53-df94e5e20e2e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_08241f0d-3a34-451a-a335-2fc125092c3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_84ebd8c4-bc39-4c2f-acae-a68c447378f6" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_08241f0d-3a34-451a-a335-2fc125092c3d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OpenTaxYear_affc2716-d4c0-48f3-9233-d4ade6fac49d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OpenTaxYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_84ebd8c4-bc39-4c2f-acae-a68c447378f6" xlink:to="loc_us-gaap_OpenTaxYear_affc2716-d4c0-48f3-9233-d4ade6fac49d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IndemnificationReceivable_0362bf29-ee5b-4a34-97ed-49327e993a73" xlink:href="cah-20210331.xsd#cah_IndemnificationReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_84ebd8c4-bc39-4c2f-acae-a68c447378f6" xlink:to="loc_cah_IndemnificationReceivable_0362bf29-ee5b-4a34-97ed-49327e993a73" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_23cef2a7-b101-4082-a5b5-baa88c1ee332" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_84ebd8c4-bc39-4c2f-acae-a68c447378f6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_23cef2a7-b101-4082-a5b5-baa88c1ee332" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_cfb4cd45-bf83-4956-ac08-4aa4e9205c1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_84ebd8c4-bc39-4c2f-acae-a68c447378f6" xlink:to="loc_us-gaap_LitigationSettlementExpense_cfb4cd45-bf83-4956-ac08-4aa4e9205c1d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_8ca1f60a-9794-469f-ad26-c081379cdc78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_84ebd8c4-bc39-4c2f-acae-a68c447378f6" xlink:to="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_8ca1f60a-9794-469f-ad26-c081379cdc78" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReceivable_78a28168-0559-4444-87a4-7f91f6e04b99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_84ebd8c4-bc39-4c2f-acae-a68c447378f6" xlink:to="loc_us-gaap_IncomeTaxReceivable_78a28168-0559-4444-87a4-7f91f6e04b99" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_fa7e9997-1815-4242-98c5-73e74fa2f279" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_84ebd8c4-bc39-4c2f-acae-a68c447378f6" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_fa7e9997-1815-4242-98c5-73e74fa2f279" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_0919bde3-2e13-4eec-8839-8aaa64c23126" xlink:href="cah-20210331.xsd#cah_OpioidLitigationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_fa7e9997-1815-4242-98c5-73e74fa2f279" xlink:to="loc_cah_OpioidLitigationAxis_0919bde3-2e13-4eec-8839-8aaa64c23126" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_0919bde3-2e13-4eec-8839-8aaa64c23126_default" xlink:href="cah-20210331.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_OpioidLitigationAxis_0919bde3-2e13-4eec-8839-8aaa64c23126" xlink:to="loc_cah_OpioidLitigationDomain_0919bde3-2e13-4eec-8839-8aaa64c23126_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_3c644663-0f00-411e-a3e5-e21a9bd21038" xlink:href="cah-20210331.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_OpioidLitigationAxis_0919bde3-2e13-4eec-8839-8aaa64c23126" xlink:to="loc_cah_OpioidLitigationDomain_3c644663-0f00-411e-a3e5-e21a9bd21038" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_d6b25bf1-d4f4-4053-ad38-4b50b53764a3" xlink:href="cah-20210331.xsd#cah_TotalOpioidLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_OpioidLitigationDomain_3c644663-0f00-411e-a3e5-e21a9bd21038" xlink:to="loc_cah_TotalOpioidLitigationMember_d6b25bf1-d4f4-4053-ad38-4b50b53764a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterAxis_fb5e1025-49fe-4aa8-8d7f-5c9b804ec1f4" xlink:href="cah-20210331.xsd#cah_TaxMatterAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_fa7e9997-1815-4242-98c5-73e74fa2f279" xlink:to="loc_cah_TaxMatterAxis_fb5e1025-49fe-4aa8-8d7f-5c9b804ec1f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterDomain_fb5e1025-49fe-4aa8-8d7f-5c9b804ec1f4_default" xlink:href="cah-20210331.xsd#cah_TaxMatterDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_TaxMatterAxis_fb5e1025-49fe-4aa8-8d7f-5c9b804ec1f4" xlink:to="loc_cah_TaxMatterDomain_fb5e1025-49fe-4aa8-8d7f-5c9b804ec1f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterDomain_02ecccaf-c032-450b-96a6-72a064d5741c" xlink:href="cah-20210331.xsd#cah_TaxMatterDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_TaxMatterAxis_fb5e1025-49fe-4aa8-8d7f-5c9b804ec1f4" xlink:to="loc_cah_TaxMatterDomain_02ecccaf-c032-450b-96a6-72a064d5741c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PatientRecoveryBusinessMember_7605ddd6-b9e7-4fe5-858f-9499b6ccd05e" xlink:href="cah-20210331.xsd#cah_PatientRecoveryBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_TaxMatterDomain_02ecccaf-c032-450b-96a6-72a064d5741c" xlink:to="loc_cah_PatientRecoveryBusinessMember_7605ddd6-b9e7-4fe5-858f-9499b6ccd05e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CareFusionMember_e838b6d3-e520-4b35-8961-528c86a7ac99" xlink:href="cah-20210331.xsd#cah_CareFusionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_TaxMatterDomain_02ecccaf-c032-450b-96a6-72a064d5741c" xlink:to="loc_cah_CareFusionMember_e838b6d3-e520-4b35-8961-528c86a7ac99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a8536c55-09f3-4b3a-93a9-190e175f23ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_fa7e9997-1815-4242-98c5-73e74fa2f279" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a8536c55-09f3-4b3a-93a9-190e175f23ca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a8536c55-09f3-4b3a-93a9-190e175f23ca_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a8536c55-09f3-4b3a-93a9-190e175f23ca" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a8536c55-09f3-4b3a-93a9-190e175f23ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c0b9452b-fecb-4df4-a3a3-ea541f352991" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a8536c55-09f3-4b3a-93a9-190e175f23ca" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c0b9452b-fecb-4df4-a3a3-ea541f352991" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PatientRecoveryBusinessMember_c4c97058-57ba-403f-a5f2-9b772c887e8d" xlink:href="cah-20210331.xsd#cah_PatientRecoveryBusinessMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c0b9452b-fecb-4df4-a3a3-ea541f352991" xlink:to="loc_cah_PatientRecoveryBusinessMember_c4c97058-57ba-403f-a5f2-9b772c887e8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementAxis_18419650-a89a-4cb6-81b8-fe1a3a069f99" xlink:href="cah-20210331.xsd#cah_TaxMattersAgreementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_fa7e9997-1815-4242-98c5-73e74fa2f279" xlink:to="loc_cah_TaxMattersAgreementAxis_18419650-a89a-4cb6-81b8-fe1a3a069f99" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementDomain_18419650-a89a-4cb6-81b8-fe1a3a069f99_default" xlink:href="cah-20210331.xsd#cah_TaxMattersAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_TaxMattersAgreementAxis_18419650-a89a-4cb6-81b8-fe1a3a069f99" xlink:to="loc_cah_TaxMattersAgreementDomain_18419650-a89a-4cb6-81b8-fe1a3a069f99_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementDomain_3bc6b1ca-88c2-4180-9224-78530bff940e" xlink:href="cah-20210331.xsd#cah_TaxMattersAgreementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_TaxMattersAgreementAxis_18419650-a89a-4cb6-81b8-fe1a3a069f99" xlink:to="loc_cah_TaxMattersAgreementDomain_3bc6b1ca-88c2-4180-9224-78530bff940e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CareFusionMember_51da63d7-d23c-493b-adae-c7bb1b773739" xlink:href="cah-20210331.xsd#cah_CareFusionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_TaxMattersAgreementDomain_3bc6b1ca-88c2-4180-9224-78530bff940e" xlink:to="loc_cah_CareFusionMember_51da63d7-d23c-493b-adae-c7bb1b773739" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_2f8bb1b1-eebf-42e3-9dac-744eca2eddc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_fa7e9997-1815-4242-98c5-73e74fa2f279" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_2f8bb1b1-eebf-42e3-9dac-744eca2eddc0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_2f8bb1b1-eebf-42e3-9dac-744eca2eddc0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2f8bb1b1-eebf-42e3-9dac-744eca2eddc0" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_2f8bb1b1-eebf-42e3-9dac-744eca2eddc0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_d77207ed-dceb-481f-8035-90fa8d68181a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2f8bb1b1-eebf-42e3-9dac-744eca2eddc0" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_d77207ed-dceb-481f-8035-90fa8d68181a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_f4cd1258-6965-428e-9ce6-91164648bf93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d77207ed-dceb-481f-8035-90fa8d68181a" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_f4cd1258-6965-428e-9ce6-91164648bf93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_765172b8-7ffd-41f4-8878-59e2cdc7c808" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_fa7e9997-1815-4242-98c5-73e74fa2f279" xlink:to="loc_srt_RangeAxis_765172b8-7ffd-41f4-8878-59e2cdc7c808" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_765172b8-7ffd-41f4-8878-59e2cdc7c808_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_765172b8-7ffd-41f4-8878-59e2cdc7c808" xlink:to="loc_srt_RangeMember_765172b8-7ffd-41f4-8878-59e2cdc7c808_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_35586f79-109b-4cac-bc8d-6f2b9b1b30c1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_765172b8-7ffd-41f4-8878-59e2cdc7c808" xlink:to="loc_srt_RangeMember_35586f79-109b-4cac-bc8d-6f2b9b1b30c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_594ae1ec-777f-4621-9804-e9e3eb11361c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_35586f79-109b-4cac-bc8d-6f2b9b1b30c1" xlink:to="loc_srt_MinimumMember_594ae1ec-777f-4621-9804-e9e3eb11361c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f732605b-9b68-4eb9-b962-474be1c865e6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_35586f79-109b-4cac-bc8d-6f2b9b1b30c1" xlink:to="loc_srt_MaximumMember_f732605b-9b68-4eb9-b962-474be1c865e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NetOperatingLossCarrybackAxis_6c9d02e2-c3de-4dfe-ae55-c061d0eedf94" xlink:href="cah-20210331.xsd#cah_NetOperatingLossCarrybackAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_fa7e9997-1815-4242-98c5-73e74fa2f279" xlink:to="loc_cah_NetOperatingLossCarrybackAxis_6c9d02e2-c3de-4dfe-ae55-c061d0eedf94" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CARESActDomain_6c9d02e2-c3de-4dfe-ae55-c061d0eedf94_default" xlink:href="cah-20210331.xsd#cah_CARESActDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_NetOperatingLossCarrybackAxis_6c9d02e2-c3de-4dfe-ae55-c061d0eedf94" xlink:to="loc_cah_CARESActDomain_6c9d02e2-c3de-4dfe-ae55-c061d0eedf94_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CARESActDomain_733ff0d3-9a01-4678-8702-401c07b7c8dc" xlink:href="cah-20210331.xsd#cah_CARESActDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_NetOperatingLossCarrybackAxis_6c9d02e2-c3de-4dfe-ae55-c061d0eedf94" xlink:to="loc_cah_CARESActDomain_733ff0d3-9a01-4678-8702-401c07b7c8dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NetOperatingLossCarrybackMember_ed58fd56-0f92-457d-a13e-f9d9fb71e1ad" xlink:href="cah-20210331.xsd#cah_NetOperatingLossCarrybackMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_CARESActDomain_733ff0d3-9a01-4678-8702-401c07b7c8dc" xlink:to="loc_cah_NetOperatingLossCarrybackMember_ed58fd56-0f92-457d-a13e-f9d9fb71e1ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_e195e344-1a34-4b15-a599-02fd550baba2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_fa7e9997-1815-4242-98c5-73e74fa2f279" xlink:to="loc_srt_StatementScenarioAxis_e195e344-1a34-4b15-a599-02fd550baba2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_e195e344-1a34-4b15-a599-02fd550baba2_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_e195e344-1a34-4b15-a599-02fd550baba2" xlink:to="loc_srt_ScenarioUnspecifiedDomain_e195e344-1a34-4b15-a599-02fd550baba2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_0adfa7f7-c87b-4fa9-954c-491de6671f09" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_e195e344-1a34-4b15-a599-02fd550baba2" xlink:to="loc_srt_ScenarioUnspecifiedDomain_0adfa7f7-c87b-4fa9-954c-491de6671f09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_ef397ce8-6d92-4ca0-9ca7-840d88641c77" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_0adfa7f7-c87b-4fa9-954c-491de6671f09" xlink:to="loc_srt_ScenarioForecastMember_ef397ce8-6d92-4ca0-9ca7-840d88641c77" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="cah-20210331.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/FairValueMeasurements" xlink:type="extended" id="ia8019d884d954896a538ced9df3261cf_FairValueMeasurements"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="cah-20210331.xsd#FairValueMeasurementsTables"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/FairValueMeasurementsTables" xlink:type="extended" id="ie94c2769c7db455fbe6e1b0146da8850_FairValueMeasurementsTables"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="extended" id="i287e93b0d43a4a5dacb3e5da0e267cac_FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a5b89362-6f62-4134-868e-d9d46c36225d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_5ec05768-7ad3-492b-af97-f2c77ea3e1a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a5b89362-6f62-4134-868e-d9d46c36225d" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_5ec05768-7ad3-492b-af97-f2c77ea3e1a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a561a531-47a6-48a0-ac12-9f14049232d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5ec05768-7ad3-492b-af97-f2c77ea3e1a2" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a561a531-47a6-48a0-ac12-9f14049232d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_fe6e8f96-f979-4dcb-ba59-1bdb689d6742" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5ec05768-7ad3-492b-af97-f2c77ea3e1a2" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_fe6e8f96-f979-4dcb-ba59-1bdb689d6742" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_db43d31b-6e56-47a7-ae08-785debefd162" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5ec05768-7ad3-492b-af97-f2c77ea3e1a2" xlink:to="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_db43d31b-6e56-47a7-ae08-785debefd162" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_cf0a3365-c1df-499b-96b9-40bbbad46d28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a5b89362-6f62-4134-868e-d9d46c36225d" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_cf0a3365-c1df-499b-96b9-40bbbad46d28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_01be9cbd-1d42-42a0-8e25-343b8f34151a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a5b89362-6f62-4134-868e-d9d46c36225d" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_01be9cbd-1d42-42a0-8e25-343b8f34151a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_8746447c-2e40-4382-9be1-4dfe7593236c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a5b89362-6f62-4134-868e-d9d46c36225d" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_8746447c-2e40-4382-9be1-4dfe7593236c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4e29db3-4dd7-4b0c-b571-c1e05604db6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a5b89362-6f62-4134-868e-d9d46c36225d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4e29db3-4dd7-4b0c-b571-c1e05604db6c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_cd171f5f-402e-4465-a4a1-35f06e486b62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4e29db3-4dd7-4b0c-b571-c1e05604db6c" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_cd171f5f-402e-4465-a4a1-35f06e486b62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_cd171f5f-402e-4465-a4a1-35f06e486b62_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_cd171f5f-402e-4465-a4a1-35f06e486b62" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_cd171f5f-402e-4465-a4a1-35f06e486b62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_055f4327-dff6-4d6a-971d-6f50e4e646f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_cd171f5f-402e-4465-a4a1-35f06e486b62" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_055f4327-dff6-4d6a-971d-6f50e4e646f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_7569c7bf-2cad-4f1f-9053-23c616c4a1a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_055f4327-dff6-4d6a-971d-6f50e4e646f9" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_7569c7bf-2cad-4f1f-9053-23c616c4a1a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_d0cccadd-b01f-4e74-b5f5-768d47028869" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_055f4327-dff6-4d6a-971d-6f50e4e646f9" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_d0cccadd-b01f-4e74-b5f5-768d47028869" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_97f65cab-0e6f-4865-9a94-8b6da6d8f1c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4e29db3-4dd7-4b0c-b571-c1e05604db6c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_97f65cab-0e6f-4865-9a94-8b6da6d8f1c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_97f65cab-0e6f-4865-9a94-8b6da6d8f1c8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_97f65cab-0e6f-4865-9a94-8b6da6d8f1c8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_97f65cab-0e6f-4865-9a94-8b6da6d8f1c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0f444bad-9c7f-4b6e-b535-e3a113ef2cfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_97f65cab-0e6f-4865-9a94-8b6da6d8f1c8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0f444bad-9c7f-4b6e-b535-e3a113ef2cfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_c03fb0b3-7ccc-4bcf-87c8-03ae0efc5759" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0f444bad-9c7f-4b6e-b535-e3a113ef2cfb" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_c03fb0b3-7ccc-4bcf-87c8-03ae0efc5759" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e15c7e8a-af67-4f1e-a6f0-1b008a54300b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0f444bad-9c7f-4b6e-b535-e3a113ef2cfb" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e15c7e8a-af67-4f1e-a6f0-1b008a54300b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1920d1ee-58eb-4c03-8bfa-88ce3cd3d7b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0f444bad-9c7f-4b6e-b535-e3a113ef2cfb" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1920d1ee-58eb-4c03-8bfa-88ce3cd3d7b7" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstruments" xlink:type="simple" xlink:href="cah-20210331.xsd#FinancialInstruments"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/FinancialInstruments" xlink:type="extended" id="ied1cc8c542b649e889acd72907276fd4_FinancialInstruments"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="cah-20210331.xsd#FinancialInstrumentsTables"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsTables" xlink:type="extended" id="ifd139949f61341118355e73fd8674a76_FinancialInstrumentsTables"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended" id="ie26df7a1702e4e42ad75498d0b9e2e00_FinancialInstrumentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_c5d10dd3-ca8d-4097-ae46-13759e92b43e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_f6cf0d4b-3a46-4176-86c3-8914cb66c18b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_c5d10dd3-ca8d-4097-ae46-13759e92b43e" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_f6cf0d4b-3a46-4176-86c3-8914cb66c18b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount_a1b75f60-d04e-4733-8fa8-b9e00c39f313" xlink:href="cah-20210331.xsd#cah_DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_c5d10dd3-ca8d-4097-ae46-13759e92b43e" xlink:to="loc_cah_DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount_a1b75f60-d04e-4733-8fa8-b9e00c39f313" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_a62a8c56-aa10-4df8-8b94-7ffd1069fae4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_c5d10dd3-ca8d-4097-ae46-13759e92b43e" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_a62a8c56-aa10-4df8-8b94-7ffd1069fae4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_e3704719-81e5-4859-a781-32eec8dc6214" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_c5d10dd3-ca8d-4097-ae46-13759e92b43e" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_e3704719-81e5-4859-a781-32eec8dc6214" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_e81dc017-ab4e-4ca5-825a-896ed4b6da66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_c5d10dd3-ca8d-4097-ae46-13759e92b43e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_e81dc017-ab4e-4ca5-825a-896ed4b6da66" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_f1a2d26c-5d2d-461e-a8b8-ebf14bf98d06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_c5d10dd3-ca8d-4097-ae46-13759e92b43e" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_f1a2d26c-5d2d-461e-a8b8-ebf14bf98d06" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_ba8785a0-b80c-43c2-b703-9b039baa23c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_c5d10dd3-ca8d-4097-ae46-13759e92b43e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_ba8785a0-b80c-43c2-b703-9b039baa23c3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredGainLossOnDiscontinuationOfInterestRateFairValueHedge_4a562566-0a28-436a-9e29-171cfb7f9ffc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredGainLossOnDiscontinuationOfInterestRateFairValueHedge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_c5d10dd3-ca8d-4097-ae46-13759e92b43e" xlink:to="loc_us-gaap_DeferredGainLossOnDiscontinuationOfInterestRateFairValueHedge_4a562566-0a28-436a-9e29-171cfb7f9ffc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DerivativesHedgeDiscontinuancesHeadingInstrumentTerminatedAmount_5d71ba3f-825e-4322-aee9-328825296f27" xlink:href="cah-20210331.xsd#cah_DerivativesHedgeDiscontinuancesHeadingInstrumentTerminatedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_c5d10dd3-ca8d-4097-ae46-13759e92b43e" xlink:to="loc_cah_DerivativesHedgeDiscontinuancesHeadingInstrumentTerminatedAmount_5d71ba3f-825e-4322-aee9-328825296f27" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_b4e0fd6c-7af5-47dc-8a24-5ec3a6687a0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_c5d10dd3-ca8d-4097-ae46-13759e92b43e" xlink:to="loc_us-gaap_DerivativeTable_b4e0fd6c-7af5-47dc-8a24-5ec3a6687a0b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9cc5800d-fb68-4b93-9e6b-f6f79f005188" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_b4e0fd6c-7af5-47dc-8a24-5ec3a6687a0b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9cc5800d-fb68-4b93-9e6b-f6f79f005188" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9cc5800d-fb68-4b93-9e6b-f6f79f005188_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9cc5800d-fb68-4b93-9e6b-f6f79f005188" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9cc5800d-fb68-4b93-9e6b-f6f79f005188_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ebc54879-c083-4d21-8da7-8948d9106b83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9cc5800d-fb68-4b93-9e6b-f6f79f005188" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ebc54879-c083-4d21-8da7-8948d9106b83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_d5b15ab0-7554-4b53-accd-fcb64d4174a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ebc54879-c083-4d21-8da7-8948d9106b83" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_d5b15ab0-7554-4b53-accd-fcb64d4174a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ac151f90-e871-4bab-820e-7826a0bbc8cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_b4e0fd6c-7af5-47dc-8a24-5ec3a6687a0b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ac151f90-e871-4bab-820e-7826a0bbc8cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ac151f90-e871-4bab-820e-7826a0bbc8cf_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ac151f90-e871-4bab-820e-7826a0bbc8cf" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ac151f90-e871-4bab-820e-7826a0bbc8cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_89711d1c-85b9-4825-8c0b-ebf8507af399" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ac151f90-e871-4bab-820e-7826a0bbc8cf" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_89711d1c-85b9-4825-8c0b-ebf8507af399" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2dd24ef7-58bb-4bd4-8955-1e7c8000cb9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_89711d1c-85b9-4825-8c0b-ebf8507af399" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2dd24ef7-58bb-4bd4-8955-1e7c8000cb9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_2a3b5edf-42aa-4199-8c03-14b843202252" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_b4e0fd6c-7af5-47dc-8a24-5ec3a6687a0b" xlink:to="loc_us-gaap_HedgingDesignationAxis_2a3b5edf-42aa-4199-8c03-14b843202252" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_2a3b5edf-42aa-4199-8c03-14b843202252_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_2a3b5edf-42aa-4199-8c03-14b843202252" xlink:to="loc_us-gaap_HedgingDesignationDomain_2a3b5edf-42aa-4199-8c03-14b843202252_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_dcfd8767-0c00-4b81-8f02-ee8aa12822cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_2a3b5edf-42aa-4199-8c03-14b843202252" xlink:to="loc_us-gaap_HedgingDesignationDomain_dcfd8767-0c00-4b81-8f02-ee8aa12822cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_f924b5c0-172e-452b-8607-768c97b7282f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_dcfd8767-0c00-4b81-8f02-ee8aa12822cb" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_f924b5c0-172e-452b-8607-768c97b7282f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_de6d8eb8-3a0d-4768-b694-33ea779442a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_dcfd8767-0c00-4b81-8f02-ee8aa12822cb" xlink:to="loc_us-gaap_NondesignatedMember_de6d8eb8-3a0d-4768-b694-33ea779442a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7ed1a106-ef3d-415b-8333-2344dc00e2fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_b4e0fd6c-7af5-47dc-8a24-5ec3a6687a0b" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7ed1a106-ef3d-415b-8333-2344dc00e2fa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_7ed1a106-ef3d-415b-8333-2344dc00e2fa_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7ed1a106-ef3d-415b-8333-2344dc00e2fa" xlink:to="loc_us-gaap_HedgingRelationshipDomain_7ed1a106-ef3d-415b-8333-2344dc00e2fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_bcbe3499-13aa-4e0c-8ef6-6201ff90eca7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7ed1a106-ef3d-415b-8333-2344dc00e2fa" xlink:to="loc_us-gaap_HedgingRelationshipDomain_bcbe3499-13aa-4e0c-8ef6-6201ff90eca7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_154cd688-8f10-48db-bc4b-e8a892517033" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_bcbe3499-13aa-4e0c-8ef6-6201ff90eca7" xlink:to="loc_us-gaap_FairValueHedgingMember_154cd688-8f10-48db-bc4b-e8a892517033" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_083a17cb-cc65-4c43-bc43-b7e504feeb62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_b4e0fd6c-7af5-47dc-8a24-5ec3a6687a0b" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_083a17cb-cc65-4c43-bc43-b7e504feeb62" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_083a17cb-cc65-4c43-bc43-b7e504feeb62_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_083a17cb-cc65-4c43-bc43-b7e504feeb62" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_083a17cb-cc65-4c43-bc43-b7e504feeb62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c23bbce3-8f2b-46ee-b76d-b64a92484d47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_083a17cb-cc65-4c43-bc43-b7e504feeb62" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c23bbce3-8f2b-46ee-b76d-b64a92484d47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_a6a7ae15-1a79-480e-8655-93cb83fa2e43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c23bbce3-8f2b-46ee-b76d-b64a92484d47" xlink:to="loc_us-gaap_CashFlowHedgingMember_a6a7ae15-1a79-480e-8655-93cb83fa2e43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_2bc30f33-70bd-4e7d-a1ad-488b30e50e82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c23bbce3-8f2b-46ee-b76d-b64a92484d47" xlink:to="loc_us-gaap_InterestRateSwapMember_2bc30f33-70bd-4e7d-a1ad-488b30e50e82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_f565d8fb-0502-47a5-929e-8aa57a99c149" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c23bbce3-8f2b-46ee-b76d-b64a92484d47" xlink:to="loc_us-gaap_CurrencySwapMember_f565d8fb-0502-47a5-929e-8aa57a99c149" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_2b5ff947-3eab-4cf8-bc7f-be7f29ffef69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c23bbce3-8f2b-46ee-b76d-b64a92484d47" xlink:to="loc_us-gaap_ForeignExchangeContractMember_2b5ff947-3eab-4cf8-bc7f-be7f29ffef69" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" xlink:type="extended" id="i4d90ede38baf441db2a9390e7942ea7b_FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_08fd4039-2179-41c8-8e22-fe4fb7be5dda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_e57a2cb5-dc8a-4772-8099-9bb46a6c4084" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_08fd4039-2179-41c8-8e22-fe4fb7be5dda" xlink:to="loc_us-gaap_DebtInstrumentFairValue_e57a2cb5-dc8a-4772-8099-9bb46a6c4084" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings_36cd688b-de15-47b3-baa2-fa61bcab8d45" xlink:href="cah-20210331.xsd#cah_CarryingAmountofLongTermandotherShortTermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_08fd4039-2179-41c8-8e22-fe4fb7be5dda" xlink:to="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings_36cd688b-de15-47b3-baa2-fa61bcab8d45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9a17d5ac-6a74-4f7e-b0d2-7b6ce190f365" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_08fd4039-2179-41c8-8e22-fe4fb7be5dda" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9a17d5ac-6a74-4f7e-b0d2-7b6ce190f365" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cb38d5bc-ab5a-4aee-802d-fe7e57ed319a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9a17d5ac-6a74-4f7e-b0d2-7b6ce190f365" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cb38d5bc-ab5a-4aee-802d-fe7e57ed319a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cb38d5bc-ab5a-4aee-802d-fe7e57ed319a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cb38d5bc-ab5a-4aee-802d-fe7e57ed319a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cb38d5bc-ab5a-4aee-802d-fe7e57ed319a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_82abb655-0178-41e3-baf3-67c1972c9242" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cb38d5bc-ab5a-4aee-802d-fe7e57ed319a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_82abb655-0178-41e3-baf3-67c1972c9242" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_88f6fef2-7183-4053-b3dd-20f1539dbed5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_82abb655-0178-41e3-baf3-67c1972c9242" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_88f6fef2-7183-4053-b3dd-20f1539dbed5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="cah-20210331.xsd#ShareholdersEquity"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareholdersEquity" xlink:type="extended" id="ib7cbd5fa54004fc691c4593a112d3beb_ShareholdersEquity"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityTables" xlink:type="simple" xlink:href="cah-20210331.xsd#ShareholdersEquityTables"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityTables" xlink:type="extended" id="i45a03a8958fe4c53b966504c4b55ff98_ShareholdersEquityTables"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#ShareholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" xlink:type="extended" id="if9097ba88d204ccc9907753b2b667b43_ShareholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_94ed4260-0973-463d-934d-b3550e55e6e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_371ae0bc-78c7-4a13-9851-81870820b1ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_94ed4260-0973-463d-934d-b3550e55e6e3" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_371ae0bc-78c7-4a13-9851-81870820b1ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_ea650f3c-237b-461f-94f8-7f99a5a68a8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_94ed4260-0973-463d-934d-b3550e55e6e3" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_ea650f3c-237b-461f-94f8-7f99a5a68a8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_20bcae50-a0e8-4e98-afc4-5c24b059c1dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_94ed4260-0973-463d-934d-b3550e55e6e3" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_20bcae50-a0e8-4e98-afc4-5c24b059c1dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1b5f72f1-7be8-41e9-ad1b-e0a67b0c14d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_94ed4260-0973-463d-934d-b3550e55e6e3" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1b5f72f1-7be8-41e9-ad1b-e0a67b0c14d3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5cf26586-07f8-484d-83c6-6e8f09a3c001" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1b5f72f1-7be8-41e9-ad1b-e0a67b0c14d3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5cf26586-07f8-484d-83c6-6e8f09a3c001" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5cf26586-07f8-484d-83c6-6e8f09a3c001_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5cf26586-07f8-484d-83c6-6e8f09a3c001" xlink:to="loc_us-gaap_EquityComponentDomain_5cf26586-07f8-484d-83c6-6e8f09a3c001_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c7059d68-66fa-4fd7-83e4-c8947455ab52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5cf26586-07f8-484d-83c6-6e8f09a3c001" xlink:to="loc_us-gaap_EquityComponentDomain_c7059d68-66fa-4fd7-83e4-c8947455ab52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_81429178-3ef5-4200-b81a-24044c1f57b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c7059d68-66fa-4fd7-83e4-c8947455ab52" xlink:to="loc_us-gaap_TreasuryStockMember_81429178-3ef5-4200-b81a-24044c1f57b0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" id="i2f616892bc154af3837c628917dae0a5_ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_99eac9f5-c427-4333-95cd-ecf005525d45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_1ab0a059-fc38-42da-b964-bb909f40de76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_99eac9f5-c427-4333-95cd-ecf005525d45" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_1ab0a059-fc38-42da-b964-bb909f40de76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5b4a6763-4641-401f-9cbb-611c3c0f9316" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_1ab0a059-fc38-42da-b964-bb909f40de76" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5b4a6763-4641-401f-9cbb-611c3c0f9316" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_1949fa44-a1aa-4f8e-b5a4-b1e0b464e384" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_1ab0a059-fc38-42da-b964-bb909f40de76" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_1949fa44-a1aa-4f8e-b5a4-b1e0b464e384" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_3250b5b7-a50d-4514-9618-ddd6463acf32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_1ab0a059-fc38-42da-b964-bb909f40de76" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_3250b5b7-a50d-4514-9618-ddd6463acf32" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a6bd44c6-a083-44f6-9fa2-4913aa669544" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_1ab0a059-fc38-42da-b964-bb909f40de76" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a6bd44c6-a083-44f6-9fa2-4913aa669544" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c40219ec-4ad8-499e-b7fd-3888b0ad57d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_ac023935-7ad1-44bc-b62c-d2e9f6d55033" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_99eac9f5-c427-4333-95cd-ecf005525d45" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_ac023935-7ad1-44bc-b62c-d2e9f6d55033" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_38e230fb-baa1-4d8f-8be8-1814d0f9de06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_ac023935-7ad1-44bc-b62c-d2e9f6d55033" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_38e230fb-baa1-4d8f-8be8-1814d0f9de06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_38e230fb-baa1-4d8f-8be8-1814d0f9de06_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_38e230fb-baa1-4d8f-8be8-1814d0f9de06" xlink:to="loc_us-gaap_EquityComponentDomain_38e230fb-baa1-4d8f-8be8-1814d0f9de06_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_56884ca5-c796-4a45-9bc8-fc103d7ed309" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_38e230fb-baa1-4d8f-8be8-1814d0f9de06" xlink:to="loc_us-gaap_EquityComponentDomain_56884ca5-c796-4a45-9bc8-fc103d7ed309" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_26daa73c-3463-4564-9810-63ca9b1b9df9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_56884ca5-c796-4a45-9bc8-fc103d7ed309" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_26daa73c-3463-4564-9810-63ca9b1b9df9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_8e41f3a4-eaee-4df3-86e7-33a6a5a1d6b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_56884ca5-c796-4a45-9bc8-fc103d7ed309" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_8e41f3a4-eaee-4df3-86e7-33a6a5a1d6b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_386e7a93-7bc0-41d0-b180-a5545c8192e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_56884ca5-c796-4a45-9bc8-fc103d7ed309" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_386e7a93-7bc0-41d0-b180-a5545c8192e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ea6b4e14-c710-4f7b-a6f2-421671ecd181" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_56884ca5-c796-4a45-9bc8-fc103d7ed309" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ea6b4e14-c710-4f7b-a6f2-421671ecd181" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc" xlink:type="simple" xlink:href="cah-20210331.xsd#EarningsPerShareAttributabletoCardinalHealthInc"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc" xlink:type="extended" id="idca53db0f8fd4ca0b27806b08e88c95b_EarningsPerShareAttributabletoCardinalHealthInc"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables" xlink:type="simple" xlink:href="cah-20210331.xsd#EarningsPerShareAttributabletoCardinalHealthIncTables"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables" xlink:type="extended" id="i537dd7d3242446c8afe63aafff5ab2d7_EarningsPerShareAttributabletoCardinalHealthIncTables"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails" xlink:type="extended" id="i168f867cbbc8470eab339f1816adae78_EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" xlink:type="extended" id="iaa9d3f78a5374de784cd8be687b5666b_EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformation" xlink:type="simple" xlink:href="cah-20210331.xsd#SegmentInformation"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformation" xlink:type="extended" id="i0129dcdf43284b949056dbb60971ac87_SegmentInformation"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="cah-20210331.xsd#SegmentInformationTables"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationTables" xlink:type="extended" id="i04c3a853eed242ac96b0276f832d8339_SegmentInformationTables"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationNarrativeDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#SegmentInformationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationNarrativeDetails" xlink:type="extended" id="i8db5654df440469bb389e009d6e99987_SegmentInformationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_36662086-a714-4c83-a20f-736127126a25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_ecd7f25e-ca71-4ad7-bb66-5f2f0c645866" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36662086-a714-4c83-a20f-736127126a25" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_ecd7f25e-ca71-4ad7-bb66-5f2f0c645866" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRecallExpense_04208cd5-b7e0-405b-b72d-ac0aa6f28da2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRecallExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36662086-a714-4c83-a20f-736127126a25" xlink:to="loc_us-gaap_InventoryRecallExpense_04208cd5-b7e0-405b-b72d-ac0aa6f28da2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProjectCostsOnInvestmentAndOtherSpending_fd73c14d-e37c-49db-97ad-b2c743c4b4d4" xlink:href="cah-20210331.xsd#cah_ProjectCostsOnInvestmentAndOtherSpending"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36662086-a714-4c83-a20f-736127126a25" xlink:to="loc_cah_ProjectCostsOnInvestmentAndOtherSpending_fd73c14d-e37c-49db-97ad-b2c743c4b4d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_cea43f2c-3c2e-4292-901a-cc782a1e358e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36662086-a714-4c83-a20f-736127126a25" xlink:to="loc_us-gaap_NumberOfReportableSegments_cea43f2c-3c2e-4292-901a-cc782a1e358e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_6152fa21-63e5-414a-a77e-1e2293f60a99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36662086-a714-4c83-a20f-736127126a25" xlink:to="loc_us-gaap_NumberOfOperatingSegments_6152fa21-63e5-414a-a77e-1e2293f60a99" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_241f7ea5-a633-44c6-95c9-8571f8115445" xlink:href="cah-20210331.xsd#cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36662086-a714-4c83-a20f-736127126a25" xlink:to="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_241f7ea5-a633-44c6-95c9-8571f8115445" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_WriteDownOfAssetsHeldForSale_a853ae6d-f118-42b9-adfa-2a6bb9eb80da" xlink:href="cah-20210331.xsd#cah_WriteDownOfAssetsHeldForSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36662086-a714-4c83-a20f-736127126a25" xlink:to="loc_cah_WriteDownOfAssetsHeldForSale_a853ae6d-f118-42b9-adfa-2a6bb9eb80da" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9efaaf42-0f14-45d9-a933-0292f975a92a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36662086-a714-4c83-a20f-736127126a25" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9efaaf42-0f14-45d9-a933-0292f975a92a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SterileSurgicalGownRecallAxis_5aa9f09d-dae8-4cf1-960f-a652b73b6093" xlink:href="cah-20210331.xsd#cah_SterileSurgicalGownRecallAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9efaaf42-0f14-45d9-a933-0292f975a92a" xlink:to="loc_cah_SterileSurgicalGownRecallAxis_5aa9f09d-dae8-4cf1-960f-a652b73b6093" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SterileSurgicalGownRecallDomain_5aa9f09d-dae8-4cf1-960f-a652b73b6093_default" xlink:href="cah-20210331.xsd#cah_SterileSurgicalGownRecallDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_SterileSurgicalGownRecallAxis_5aa9f09d-dae8-4cf1-960f-a652b73b6093" xlink:to="loc_cah_SterileSurgicalGownRecallDomain_5aa9f09d-dae8-4cf1-960f-a652b73b6093_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SterileSurgicalGownRecallDomain_7bc74d22-999a-4942-a737-02c00ff59ece" xlink:href="cah-20210331.xsd#cah_SterileSurgicalGownRecallDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_SterileSurgicalGownRecallAxis_5aa9f09d-dae8-4cf1-960f-a652b73b6093" xlink:to="loc_cah_SterileSurgicalGownRecallDomain_7bc74d22-999a-4942-a737-02c00ff59ece" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SterileSurgicalGownRecallMember_5cc8ffe0-d814-4afb-b298-53694ebe058c" xlink:href="cah-20210331.xsd#cah_SterileSurgicalGownRecallMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_SterileSurgicalGownRecallDomain_7bc74d22-999a-4942-a737-02c00ff59ece" xlink:to="loc_cah_SterileSurgicalGownRecallMember_5cc8ffe0-d814-4afb-b298-53694ebe058c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_8f2246e0-d602-4346-a6e5-1ca5642dbaf2" xlink:href="cah-20210331.xsd#cah_OpioidLitigationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9efaaf42-0f14-45d9-a933-0292f975a92a" xlink:to="loc_cah_OpioidLitigationAxis_8f2246e0-d602-4346-a6e5-1ca5642dbaf2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_8f2246e0-d602-4346-a6e5-1ca5642dbaf2_default" xlink:href="cah-20210331.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_OpioidLitigationAxis_8f2246e0-d602-4346-a6e5-1ca5642dbaf2" xlink:to="loc_cah_OpioidLitigationDomain_8f2246e0-d602-4346-a6e5-1ca5642dbaf2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_91148723-2176-4631-bdb3-9540982c560e" xlink:href="cah-20210331.xsd#cah_OpioidLitigationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_OpioidLitigationAxis_8f2246e0-d602-4346-a6e5-1ca5642dbaf2" xlink:to="loc_cah_OpioidLitigationDomain_91148723-2176-4631-bdb3-9540982c560e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_6fa9e015-3e33-4c0d-b78f-e38a4bfd34ed" xlink:href="cah-20210331.xsd#cah_TotalOpioidLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_OpioidLitigationDomain_91148723-2176-4631-bdb3-9540982c560e" xlink:to="loc_cah_TotalOpioidLitigationMember_6fa9e015-3e33-4c0d-b78f-e38a4bfd34ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_9ec044be-25ea-489f-8339-52a65cafe1c1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9efaaf42-0f14-45d9-a933-0292f975a92a" xlink:to="loc_srt_LitigationCaseAxis_9ec044be-25ea-489f-8339-52a65cafe1c1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_9ec044be-25ea-489f-8339-52a65cafe1c1_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_9ec044be-25ea-489f-8339-52a65cafe1c1" xlink:to="loc_srt_LitigationCaseTypeDomain_9ec044be-25ea-489f-8339-52a65cafe1c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_0503bca2-6f7f-41dd-87c6-dcbe6dc33eb2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_9ec044be-25ea-489f-8339-52a65cafe1c1" xlink:to="loc_srt_LitigationCaseTypeDomain_0503bca2-6f7f-41dd-87c6-dcbe6dc33eb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NewYorkOpioidStewardshipActMember_988ed933-1038-409a-9048-091876ce63b7" xlink:href="cah-20210331.xsd#cah_NewYorkOpioidStewardshipActMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_0503bca2-6f7f-41dd-87c6-dcbe6dc33eb2" xlink:to="loc_cah_NewYorkOpioidStewardshipActMember_988ed933-1038-409a-9048-091876ce63b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_609a57bd-f26e-4a8b-8c7f-b56a2721fd57" xlink:href="cah-20210331.xsd#cah_CordisDivestitureAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9efaaf42-0f14-45d9-a933-0292f975a92a" xlink:to="loc_cah_CordisDivestitureAxis_609a57bd-f26e-4a8b-8c7f-b56a2721fd57" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_609a57bd-f26e-4a8b-8c7f-b56a2721fd57_default" xlink:href="cah-20210331.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_CordisDivestitureAxis_609a57bd-f26e-4a8b-8c7f-b56a2721fd57" xlink:to="loc_cah_CordisDivestitureDomain_609a57bd-f26e-4a8b-8c7f-b56a2721fd57_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_05d407b3-0788-476b-a437-49a8deb4cf20" xlink:href="cah-20210331.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_CordisDivestitureAxis_609a57bd-f26e-4a8b-8c7f-b56a2721fd57" xlink:to="loc_cah_CordisDivestitureDomain_05d407b3-0788-476b-a437-49a8deb4cf20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_a36fba51-9862-4140-8e4c-f15c9df6ea90" xlink:href="cah-20210331.xsd#cah_CordisDivestitureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_CordisDivestitureDomain_05d407b3-0788-476b-a437-49a8deb4cf20" xlink:to="loc_cah_CordisDivestitureMember_a36fba51-9862-4140-8e4c-f15c9df6ea90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_5140f9dc-eb23-43db-8449-6147a37c585a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9efaaf42-0f14-45d9-a933-0292f975a92a" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_5140f9dc-eb23-43db-8449-6147a37c585a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5140f9dc-eb23-43db-8449-6147a37c585a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5140f9dc-eb23-43db-8449-6147a37c585a" xlink:to="loc_us-gaap_SegmentDomain_5140f9dc-eb23-43db-8449-6147a37c585a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_73dbc06b-e7e8-4833-b02b-10ab7e675ad7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5140f9dc-eb23-43db-8449-6147a37c585a" xlink:to="loc_us-gaap_SegmentDomain_73dbc06b-e7e8-4833-b02b-10ab7e675ad7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#SegmentInformationRevenuebyReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" xlink:type="extended" id="ie334bd8ad9904aa5a3acc3eab345c76e_SegmentInformationRevenuebyReportableSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_654e1993-afcb-462c-960c-05076cf4e587" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_631a2ff8-72fd-47e1-b02a-fc1f635fdf73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_654e1993-afcb-462c-960c-05076cf4e587" xlink:to="loc_us-gaap_Revenues_631a2ff8-72fd-47e1-b02a-fc1f635fdf73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_73e57dab-5998-4598-9b19-bf69f9e97862" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_654e1993-afcb-462c-960c-05076cf4e587" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_73e57dab-5998-4598-9b19-bf69f9e97862" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_7718022b-e0ae-4d8e-9a90-58cad557d571" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_73e57dab-5998-4598-9b19-bf69f9e97862" xlink:to="loc_us-gaap_SubsegmentsAxis_7718022b-e0ae-4d8e-9a90-58cad557d571" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_7718022b-e0ae-4d8e-9a90-58cad557d571_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_7718022b-e0ae-4d8e-9a90-58cad557d571" xlink:to="loc_us-gaap_SubsegmentsDomain_7718022b-e0ae-4d8e-9a90-58cad557d571_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_f8e1f78e-1b61-4550-9d5b-9f5110bedb79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_7718022b-e0ae-4d8e-9a90-58cad557d571" xlink:to="loc_us-gaap_SubsegmentsDomain_f8e1f78e-1b61-4550-9d5b-9f5110bedb79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalDistributionandSpecialtyMember_bf50c32e-14ac-4c4d-bf5e-ab539e5c0b77" xlink:href="cah-20210331.xsd#cah_PharmaceuticalDistributionandSpecialtyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_f8e1f78e-1b61-4550-9d5b-9f5110bedb79" xlink:to="loc_cah_PharmaceuticalDistributionandSpecialtyMember_bf50c32e-14ac-4c4d-bf5e-ab539e5c0b77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NuclearPrecisionHealthServicesMember_28cc9233-9446-4176-ba79-fd4beb1154cf" xlink:href="cah-20210331.xsd#cah_NuclearPrecisionHealthServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_f8e1f78e-1b61-4550-9d5b-9f5110bedb79" xlink:to="loc_cah_NuclearPrecisionHealthServicesMember_28cc9233-9446-4176-ba79-fd4beb1154cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicaldistributionandproductsMember_1d610b5f-7b58-43b8-ae85-e3b54353fcad" xlink:href="cah-20210331.xsd#cah_MedicaldistributionandproductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_f8e1f78e-1b61-4550-9d5b-9f5110bedb79" xlink:to="loc_cah_MedicaldistributionandproductsMember_1d610b5f-7b58-43b8-ae85-e3b54353fcad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CardinalHealthAtHomeMember_33c098a5-8f3e-470d-b456-c44d376f08f5" xlink:href="cah-20210331.xsd#cah_CardinalHealthAtHomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_f8e1f78e-1b61-4550-9d5b-9f5110bedb79" xlink:to="loc_cah_CardinalHealthAtHomeMember_33c098a5-8f3e-470d-b456-c44d376f08f5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_f5f7d3f2-f7ed-4363-b646-eeebdacbc7cf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_73e57dab-5998-4598-9b19-bf69f9e97862" xlink:to="loc_srt_ConsolidationItemsAxis_f5f7d3f2-f7ed-4363-b646-eeebdacbc7cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_f5f7d3f2-f7ed-4363-b646-eeebdacbc7cf_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_f5f7d3f2-f7ed-4363-b646-eeebdacbc7cf" xlink:to="loc_srt_ConsolidationItemsDomain_f5f7d3f2-f7ed-4363-b646-eeebdacbc7cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_6bd2f737-1609-4da1-800c-64167d77da6d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_f5f7d3f2-f7ed-4363-b646-eeebdacbc7cf" xlink:to="loc_srt_ConsolidationItemsDomain_6bd2f737-1609-4da1-800c-64167d77da6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_5c57d2a0-539c-4f1f-b27a-fa55fb758a39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_6bd2f737-1609-4da1-800c-64167d77da6d" xlink:to="loc_us-gaap_OperatingSegmentsMember_5c57d2a0-539c-4f1f-b27a-fa55fb758a39" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_f5432687-42ba-485b-a71a-d039d93410e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_6bd2f737-1609-4da1-800c-64167d77da6d" xlink:to="loc_us-gaap_CorporateNonSegmentMember_f5432687-42ba-485b-a71a-d039d93410e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_28d2e0b2-edcf-4622-b0af-9a7d6f414193" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_73e57dab-5998-4598-9b19-bf69f9e97862" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_28d2e0b2-edcf-4622-b0af-9a7d6f414193" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_28d2e0b2-edcf-4622-b0af-9a7d6f414193_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_28d2e0b2-edcf-4622-b0af-9a7d6f414193" xlink:to="loc_us-gaap_SegmentDomain_28d2e0b2-edcf-4622-b0af-9a7d6f414193_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3317e79f-dee3-48e8-b559-07f91a96d2ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_28d2e0b2-edcf-4622-b0af-9a7d6f414193" xlink:to="loc_us-gaap_SegmentDomain_3317e79f-dee3-48e8-b559-07f91a96d2ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_b91e2801-6631-4743-8a3f-9c389183760d" xlink:href="cah-20210331.xsd#cah_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3317e79f-dee3-48e8-b559-07f91a96d2ae" xlink:to="loc_cah_PharmaceuticalMember_b91e2801-6631-4743-8a3f-9c389183760d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_a5b4e9a2-ebb6-4778-a3c5-22aa0726265b" xlink:href="cah-20210331.xsd#cah_MedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3317e79f-dee3-48e8-b559-07f91a96d2ae" xlink:to="loc_cah_MedicalMember_a5b4e9a2-ebb6-4778-a3c5-22aa0726265b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#SegmentInformationSegmentProfitbyReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" xlink:type="extended" id="ib359051660934cfdbb5356fc8609aa1c_SegmentInformationSegmentProfitbyReportableSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_fa2f1697-30c6-4a70-8091-6e1af92c3485" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_579cd751-8eef-40a2-80c6-eae8bd916b6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_fa2f1697-30c6-4a70-8091-6e1af92c3485" xlink:to="loc_us-gaap_OperatingIncomeLoss_579cd751-8eef-40a2-80c6-eae8bd916b6c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_ebbcf790-8a4e-4722-823a-cce794a477a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_fa2f1697-30c6-4a70-8091-6e1af92c3485" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_ebbcf790-8a4e-4722-823a-cce794a477a9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8b208f5a-ff2f-4d2a-b47b-66a84dbb7971" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_ebbcf790-8a4e-4722-823a-cce794a477a9" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8b208f5a-ff2f-4d2a-b47b-66a84dbb7971" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8b208f5a-ff2f-4d2a-b47b-66a84dbb7971_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8b208f5a-ff2f-4d2a-b47b-66a84dbb7971" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8b208f5a-ff2f-4d2a-b47b-66a84dbb7971_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f620a08b-ff3c-4437-9535-666df4b03822" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8b208f5a-ff2f-4d2a-b47b-66a84dbb7971" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f620a08b-ff3c-4437-9535-666df4b03822" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_656034f2-7b02-45fb-955b-c7918f7b8c24" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_ebbcf790-8a4e-4722-823a-cce794a477a9" xlink:to="loc_srt_ConsolidationItemsAxis_656034f2-7b02-45fb-955b-c7918f7b8c24" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_656034f2-7b02-45fb-955b-c7918f7b8c24_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_656034f2-7b02-45fb-955b-c7918f7b8c24" xlink:to="loc_srt_ConsolidationItemsDomain_656034f2-7b02-45fb-955b-c7918f7b8c24_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_ef7446ca-b814-45b0-a508-7b59ce1872ae" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_656034f2-7b02-45fb-955b-c7918f7b8c24" xlink:to="loc_srt_ConsolidationItemsDomain_ef7446ca-b814-45b0-a508-7b59ce1872ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_55ba15c1-7b84-4984-a405-acc84bdc1318" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_ef7446ca-b814-45b0-a508-7b59ce1872ae" xlink:to="loc_us-gaap_OperatingSegmentsMember_55ba15c1-7b84-4984-a405-acc84bdc1318" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_3cb48c2a-2837-4ccc-88a1-63cc6eb25daa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_ef7446ca-b814-45b0-a508-7b59ce1872ae" xlink:to="loc_us-gaap_CorporateNonSegmentMember_3cb48c2a-2837-4ccc-88a1-63cc6eb25daa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_483a8021-04f6-417f-bb98-4264d12fcf8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_ebbcf790-8a4e-4722-823a-cce794a477a9" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_483a8021-04f6-417f-bb98-4264d12fcf8c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_483a8021-04f6-417f-bb98-4264d12fcf8c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_483a8021-04f6-417f-bb98-4264d12fcf8c" xlink:to="loc_us-gaap_SegmentDomain_483a8021-04f6-417f-bb98-4264d12fcf8c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1036f40f-7131-406d-9f5b-c998cec87206" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_483a8021-04f6-417f-bb98-4264d12fcf8c" xlink:to="loc_us-gaap_SegmentDomain_1036f40f-7131-406d-9f5b-c998cec87206" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_18ea738d-3df2-4386-bb69-b7ea0119e66f" xlink:href="cah-20210331.xsd#cah_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1036f40f-7131-406d-9f5b-c998cec87206" xlink:to="loc_cah_PharmaceuticalMember_18ea738d-3df2-4386-bb69-b7ea0119e66f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_42340755-803c-4784-af14-98487af42c08" xlink:href="cah-20210331.xsd#cah_MedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_1036f40f-7131-406d-9f5b-c998cec87206" xlink:to="loc_cah_MedicalMember_42340755-803c-4784-af14-98487af42c08" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" xlink:type="extended" id="i0e341023658f46a5be224edf9b1289ee_SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails">
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_c2bc7360-2605-42ee-879b-4d8cb02b34ea" xlink:href="cah-20210331.xsd#cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_0b63fc45-3211-44d8-8f97-fe146fe478f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_c2bc7360-2605-42ee-879b-4d8cb02b34ea" xlink:to="loc_us-gaap_Revenues_0b63fc45-3211-44d8-8f97-fe146fe478f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_bee1ec1c-5b3a-4665-8b02-a4c15e3b49f9" xlink:href="cah-20210331.xsd#cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_c2bc7360-2605-42ee-879b-4d8cb02b34ea" xlink:to="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_bee1ec1c-5b3a-4665-8b02-a4c15e3b49f9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_97be6c76-cd22-47b0-a241-1a86a4a761b1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_bee1ec1c-5b3a-4665-8b02-a4c15e3b49f9" xlink:to="loc_srt_ConsolidationItemsAxis_97be6c76-cd22-47b0-a241-1a86a4a761b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_97be6c76-cd22-47b0-a241-1a86a4a761b1_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_97be6c76-cd22-47b0-a241-1a86a4a761b1" xlink:to="loc_srt_ConsolidationItemsDomain_97be6c76-cd22-47b0-a241-1a86a4a761b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_e172664d-4941-4a53-878e-656ec5b677c6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_97be6c76-cd22-47b0-a241-1a86a4a761b1" xlink:to="loc_srt_ConsolidationItemsDomain_e172664d-4941-4a53-878e-656ec5b677c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_941ae1c2-b0e8-4910-b8be-720a7bfd213f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_e172664d-4941-4a53-878e-656ec5b677c6" xlink:to="loc_us-gaap_OperatingSegmentsMember_941ae1c2-b0e8-4910-b8be-720a7bfd213f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_e058e81f-4b2c-4668-a753-e45a979b8de0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_e172664d-4941-4a53-878e-656ec5b677c6" xlink:to="loc_us-gaap_CorporateNonSegmentMember_e058e81f-4b2c-4668-a753-e45a979b8de0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_53f25bf5-7f79-4af1-88d3-3021c69d2888" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_bee1ec1c-5b3a-4665-8b02-a4c15e3b49f9" xlink:to="loc_srt_StatementGeographicalAxis_53f25bf5-7f79-4af1-88d3-3021c69d2888" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_53f25bf5-7f79-4af1-88d3-3021c69d2888_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_53f25bf5-7f79-4af1-88d3-3021c69d2888" xlink:to="loc_srt_SegmentGeographicalDomain_53f25bf5-7f79-4af1-88d3-3021c69d2888_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_16eccae0-11b4-4438-bbd9-6c49dc827416" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_53f25bf5-7f79-4af1-88d3-3021c69d2888" xlink:to="loc_srt_SegmentGeographicalDomain_16eccae0-11b4-4438-bbd9-6c49dc827416" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_ddb4c30d-9921-43b6-bc28-39481a89f32a" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_16eccae0-11b4-4438-bbd9-6c49dc827416" xlink:to="loc_country_US_ddb4c30d-9921-43b6-bc28-39481a89f32a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_5319a89b-95d5-4974-816e-dc116f52d236" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_16eccae0-11b4-4438-bbd9-6c49dc827416" xlink:to="loc_us-gaap_NonUsMember_5319a89b-95d5-4974-816e-dc116f52d236" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#SegmentInformationAssetsbyReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" xlink:type="extended" id="i3761a8416d91436da048b188361d33f0_SegmentInformationAssetsbyReportableSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_daf10bcc-cc5e-4383-8572-9324f89b0429" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_6a7ca0f3-9cf0-4c88-aa86-704562925916" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_daf10bcc-cc5e-4383-8572-9324f89b0429" xlink:to="loc_us-gaap_Assets_6a7ca0f3-9cf0-4c88-aa86-704562925916" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_16e5e7d8-887c-4b19-825d-0127d009d0d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_daf10bcc-cc5e-4383-8572-9324f89b0429" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_16e5e7d8-887c-4b19-825d-0127d009d0d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2374bedf-689d-4785-b802-91512bbc30e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_daf10bcc-cc5e-4383-8572-9324f89b0429" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2374bedf-689d-4785-b802-91512bbc30e4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_ef636eca-ee34-4bb2-bbd8-5f0f8c0392d2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2374bedf-689d-4785-b802-91512bbc30e4" xlink:to="loc_srt_ConsolidationItemsAxis_ef636eca-ee34-4bb2-bbd8-5f0f8c0392d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_ef636eca-ee34-4bb2-bbd8-5f0f8c0392d2_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_ef636eca-ee34-4bb2-bbd8-5f0f8c0392d2" xlink:to="loc_srt_ConsolidationItemsDomain_ef636eca-ee34-4bb2-bbd8-5f0f8c0392d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_47a2f88c-4257-4268-a505-70dadde061e2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_ef636eca-ee34-4bb2-bbd8-5f0f8c0392d2" xlink:to="loc_srt_ConsolidationItemsDomain_47a2f88c-4257-4268-a505-70dadde061e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_e78a3ab4-c67f-4910-98af-f84f2f30378b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_47a2f88c-4257-4268-a505-70dadde061e2" xlink:to="loc_us-gaap_OperatingSegmentsMember_e78a3ab4-c67f-4910-98af-f84f2f30378b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_0d3ac88c-522a-4fa8-8b20-527de722832b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_47a2f88c-4257-4268-a505-70dadde061e2" xlink:to="loc_us-gaap_CorporateNonSegmentMember_0d3ac88c-522a-4fa8-8b20-527de722832b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_e259e43a-aa3c-4582-8fd5-4525d569c0b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2374bedf-689d-4785-b802-91512bbc30e4" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_e259e43a-aa3c-4582-8fd5-4525d569c0b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e259e43a-aa3c-4582-8fd5-4525d569c0b4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e259e43a-aa3c-4582-8fd5-4525d569c0b4" xlink:to="loc_us-gaap_SegmentDomain_e259e43a-aa3c-4582-8fd5-4525d569c0b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_66fe2199-6b6e-4d14-8cd7-44003605ba86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e259e43a-aa3c-4582-8fd5-4525d569c0b4" xlink:to="loc_us-gaap_SegmentDomain_66fe2199-6b6e-4d14-8cd7-44003605ba86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_7bc338ec-fc11-4fd3-8b2b-ca958c3768a5" xlink:href="cah-20210331.xsd#cah_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_66fe2199-6b6e-4d14-8cd7-44003605ba86" xlink:to="loc_cah_PharmaceuticalMember_7bc338ec-fc11-4fd3-8b2b-ca958c3768a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_a3c3e9a3-4f49-4637-9a60-fbf5b4f9ab2a" xlink:href="cah-20210331.xsd#cah_MedicalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_66fe2199-6b6e-4d14-8cd7-44003605ba86" xlink:to="loc_cah_MedicalMember_a3c3e9a3-4f49-4637-9a60-fbf5b4f9ab2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_d85c2563-107b-438e-882b-a0a8a8a2d8f1" xlink:href="cah-20210331.xsd#cah_CordisDivestitureAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2374bedf-689d-4785-b802-91512bbc30e4" xlink:to="loc_cah_CordisDivestitureAxis_d85c2563-107b-438e-882b-a0a8a8a2d8f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_d85c2563-107b-438e-882b-a0a8a8a2d8f1_default" xlink:href="cah-20210331.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cah_CordisDivestitureAxis_d85c2563-107b-438e-882b-a0a8a8a2d8f1" xlink:to="loc_cah_CordisDivestitureDomain_d85c2563-107b-438e-882b-a0a8a8a2d8f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_f1c7a9a6-bb13-47e7-939a-bacde5acf2f4" xlink:href="cah-20210331.xsd#cah_CordisDivestitureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cah_CordisDivestitureAxis_d85c2563-107b-438e-882b-a0a8a8a2d8f1" xlink:to="loc_cah_CordisDivestitureDomain_f1c7a9a6-bb13-47e7-939a-bacde5acf2f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_49505474-2a7b-4796-afcd-575556e99be9" xlink:href="cah-20210331.xsd#cah_CordisDivestitureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cah_CordisDivestitureDomain_f1c7a9a6-bb13-47e7-939a-bacde5acf2f4" xlink:to="loc_cah_CordisDivestitureMember_49505474-2a7b-4796-afcd-575556e99be9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="cah-20210331.xsd#ShareBasedCompensation"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensation" xlink:type="extended" id="i69812418cc594453a3e9e0155c178a72_ShareBasedCompensation"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="cah-20210331.xsd#ShareBasedCompensationTables"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationTables" xlink:type="extended" id="ie3b716145d244f0aad81b40ed6266dc7_ShareBasedCompensationTables"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#ShareBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="extended" id="if5dcf7bfd61040aaad0ae94fc889ad2e_ShareBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7af49d7c-2e5c-4d4e-82bf-d45112fffd1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_VestingPeriodinyearsforShares_4ea24209-8b25-49ef-8a80-7a759c071574" xlink:href="cah-20210331.xsd#cah_VestingPeriodinyearsforShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7af49d7c-2e5c-4d4e-82bf-d45112fffd1b" xlink:to="loc_cah_VestingPeriodinyearsforShares_4ea24209-8b25-49ef-8a80-7a759c071574" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_d35412d5-8fa7-4b96-9cb8-8d22739ad9c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7af49d7c-2e5c-4d4e-82bf-d45112fffd1b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_d35412d5-8fa7-4b96-9cb8-8d22739ad9c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_982e73b6-cd04-4b92-a5c4-1a146e01fb59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7af49d7c-2e5c-4d4e-82bf-d45112fffd1b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_982e73b6-cd04-4b92-a5c4-1a146e01fb59" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_dba3e1ab-d6ca-459e-8fef-60209b6d897b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7af49d7c-2e5c-4d4e-82bf-d45112fffd1b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_dba3e1ab-d6ca-459e-8fef-60209b6d897b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7ecb1b28-a212-4ad9-abb0-4249a178bf22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7af49d7c-2e5c-4d4e-82bf-d45112fffd1b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7ecb1b28-a212-4ad9-abb0-4249a178bf22" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ExercisablePeriodOfPlansInYears_794cde8a-1c04-48fa-b9f4-1ae60595680a" xlink:href="cah-20210331.xsd#cah_ExercisablePeriodOfPlansInYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7af49d7c-2e5c-4d4e-82bf-d45112fffd1b" xlink:to="loc_cah_ExercisablePeriodOfPlansInYears_794cde8a-1c04-48fa-b9f4-1ae60595680a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_eb74a119-24a4-4170-a029-72b9aa329a15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7af49d7c-2e5c-4d4e-82bf-d45112fffd1b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_eb74a119-24a4-4170-a029-72b9aa329a15" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d203c6e-68f0-42a8-9dac-c8b1b5124d97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7af49d7c-2e5c-4d4e-82bf-d45112fffd1b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d203c6e-68f0-42a8-9dac-c8b1b5124d97" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6034abb0-6cc8-4b2a-bf27-5980423f0388" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d203c6e-68f0-42a8-9dac-c8b1b5124d97" xlink:to="loc_us-gaap_AwardTypeAxis_6034abb0-6cc8-4b2a-bf27-5980423f0388" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6034abb0-6cc8-4b2a-bf27-5980423f0388_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6034abb0-6cc8-4b2a-bf27-5980423f0388" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6034abb0-6cc8-4b2a-bf27-5980423f0388_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cfe8d313-566e-41a9-8576-a42305357c58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6034abb0-6cc8-4b2a-bf27-5980423f0388" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cfe8d313-566e-41a9-8576-a42305357c58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5bca0462-2f22-417e-88d0-ab04c05f15fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cfe8d313-566e-41a9-8576-a42305357c58" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5bca0462-2f22-417e-88d0-ab04c05f15fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_860b8b81-d158-4c7e-86b4-46e11f0864a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cfe8d313-566e-41a9-8576-a42305357c58" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_860b8b81-d158-4c7e-86b4-46e11f0864a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_b58f7cee-9311-46c9-97b2-899c57999145" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cfe8d313-566e-41a9-8576-a42305357c58" xlink:to="loc_us-gaap_PerformanceSharesMember_b58f7cee-9311-46c9-97b2-899c57999145" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a36af3a9-66d5-41e7-89a2-cd4a8f8c31c1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d203c6e-68f0-42a8-9dac-c8b1b5124d97" xlink:to="loc_srt_RangeAxis_a36af3a9-66d5-41e7-89a2-cd4a8f8c31c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a36af3a9-66d5-41e7-89a2-cd4a8f8c31c1_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a36af3a9-66d5-41e7-89a2-cd4a8f8c31c1" xlink:to="loc_srt_RangeMember_a36af3a9-66d5-41e7-89a2-cd4a8f8c31c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ab0831b0-c33a-48e8-89a7-116037f62c85" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a36af3a9-66d5-41e7-89a2-cd4a8f8c31c1" xlink:to="loc_srt_RangeMember_ab0831b0-c33a-48e8-89a7-116037f62c85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d67aa3f2-08da-435f-bca1-a4d74cb527ee" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ab0831b0-c33a-48e8-89a7-116037f62c85" xlink:to="loc_srt_MinimumMember_d67aa3f2-08da-435f-bca1-a4d74cb527ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e59b003a-03f9-4859-b55f-935babc488f5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ab0831b0-c33a-48e8-89a7-116037f62c85" xlink:to="loc_srt_MaximumMember_e59b003a-03f9-4859-b55f-935babc488f5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" xlink:type="extended" id="ie22a2aadee1c461d89f1b23bb1b9719f_ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1eca2c18-1060-4359-af75-61f209451479" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_e1a784cd-c2d3-4d27-a811-571a487fad67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1eca2c18-1060-4359-af75-61f209451479" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_e1a784cd-c2d3-4d27-a811-571a487fad67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9e2c147b-115a-441f-8930-c858535c99d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1eca2c18-1060-4359-af75-61f209451479" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9e2c147b-115a-441f-8930-c858535c99d0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_624623d0-4e1f-43ac-9744-f334081692c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9e2c147b-115a-441f-8930-c858535c99d0" xlink:to="loc_us-gaap_AwardTypeAxis_624623d0-4e1f-43ac-9744-f334081692c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_624623d0-4e1f-43ac-9744-f334081692c3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_624623d0-4e1f-43ac-9744-f334081692c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_624623d0-4e1f-43ac-9744-f334081692c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04613bee-d5df-498a-babd-1c14cf38329d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_624623d0-4e1f-43ac-9744-f334081692c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04613bee-d5df-498a-babd-1c14cf38329d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_38c1272d-4474-4d11-a057-58a74c6870c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04613bee-d5df-498a-babd-1c14cf38329d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_38c1272d-4474-4d11-a057-58a74c6870c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_bcd0df7a-53b1-4fdd-878f-b1d39caf2e70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04613bee-d5df-498a-babd-1c14cf38329d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_bcd0df7a-53b1-4fdd-878f-b1d39caf2e70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_f6502dc7-58b5-4a25-9e6a-894c9b41fa8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04613bee-d5df-498a-babd-1c14cf38329d" xlink:to="loc_us-gaap_PerformanceSharesMember_f6502dc7-58b5-4a25-9e6a-894c9b41fa8f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails" xlink:type="extended" id="i39db7a9bf1144d8594be25601aa15c53_ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"/>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" xlink:type="extended" id="i893322409c1c467eb4c0ba30809cc1d0_ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_259e2d62-5c7b-4704-bcf4-35843bb254e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_b8bb1456-3407-4881-9aaa-24b6b43a23eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_259e2d62-5c7b-4704-bcf4-35843bb254e9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_b8bb1456-3407-4881-9aaa-24b6b43a23eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_901191b3-35b2-447d-a39c-3a63426d727f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_259e2d62-5c7b-4704-bcf4-35843bb254e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_901191b3-35b2-447d-a39c-3a63426d727f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_552f0e0a-e294-4205-baa6-bf680ad36843" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_259e2d62-5c7b-4704-bcf4-35843bb254e9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_552f0e0a-e294-4205-baa6-bf680ad36843" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_9a65c720-6722-4626-8f2d-ed8fc19c378c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_259e2d62-5c7b-4704-bcf4-35843bb254e9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_9a65c720-6722-4626-8f2d-ed8fc19c378c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_504f5a60-6fca-4880-82cc-339e23341257" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_259e2d62-5c7b-4704-bcf4-35843bb254e9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_504f5a60-6fca-4880-82cc-339e23341257" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a8651bdd-1344-43bf-b820-710d479c2dcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_259e2d62-5c7b-4704-bcf4-35843bb254e9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a8651bdd-1344-43bf-b820-710d479c2dcc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_38bfb84b-1e7f-4a31-b08e-a8eaf21781d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a8651bdd-1344-43bf-b820-710d479c2dcc" xlink:to="loc_us-gaap_AwardTypeAxis_38bfb84b-1e7f-4a31-b08e-a8eaf21781d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_38bfb84b-1e7f-4a31-b08e-a8eaf21781d8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_38bfb84b-1e7f-4a31-b08e-a8eaf21781d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_38bfb84b-1e7f-4a31-b08e-a8eaf21781d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75a76bea-4e9d-473f-a6e3-9b2c59b58467" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_38bfb84b-1e7f-4a31-b08e-a8eaf21781d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75a76bea-4e9d-473f-a6e3-9b2c59b58467" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_20859eed-6e79-4235-9f28-8963e8a602ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75a76bea-4e9d-473f-a6e3-9b2c59b58467" xlink:to="loc_us-gaap_EmployeeStockOptionMember_20859eed-6e79-4235-9f28-8963e8a602ed" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" xlink:type="extended" id="i9b091777dbde4d63ba24ee65ffa75fe0_ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dcd9fea5-0349-44ff-b3d6-7ba136fccec0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e2262912-9516-4144-afe3-556e456c9997" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dcd9fea5-0349-44ff-b3d6-7ba136fccec0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e2262912-9516-4144-afe3-556e456c9997" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_cbde331f-74f8-4f9f-877e-4478121a069f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dcd9fea5-0349-44ff-b3d6-7ba136fccec0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_cbde331f-74f8-4f9f-877e-4478121a069f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bb32f4b4-08f5-4752-b659-72fb2664a3c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dcd9fea5-0349-44ff-b3d6-7ba136fccec0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bb32f4b4-08f5-4752-b659-72fb2664a3c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b5745935-4a71-485b-8592-3b379310300f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bb32f4b4-08f5-4752-b659-72fb2664a3c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b5745935-4a71-485b-8592-3b379310300f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5b0b7dc3-37f7-419f-8e3b-ae5aa96820f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bb32f4b4-08f5-4752-b659-72fb2664a3c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5b0b7dc3-37f7-419f-8e3b-ae5aa96820f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e2695733-3db2-4d71-8dc4-a9956064a2e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bb32f4b4-08f5-4752-b659-72fb2664a3c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e2695733-3db2-4d71-8dc4-a9956064a2e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_af3f6f7f-9472-4979-9036-d0722f8d5942" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bb32f4b4-08f5-4752-b659-72fb2664a3c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_af3f6f7f-9472-4979-9036-d0722f8d5942" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_065b8168-eb67-4810-9160-20e6815aff54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a7e74f25-7932-4e0f-8961-5ab8728c83a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dcd9fea5-0349-44ff-b3d6-7ba136fccec0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a7e74f25-7932-4e0f-8961-5ab8728c83a7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_61cb8a2f-5ba1-46b0-9660-f47342060f06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a7e74f25-7932-4e0f-8961-5ab8728c83a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_61cb8a2f-5ba1-46b0-9660-f47342060f06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_76ef8e39-6036-4e54-8470-ec0cf79c01c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a7e74f25-7932-4e0f-8961-5ab8728c83a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_76ef8e39-6036-4e54-8470-ec0cf79c01c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_be0b4bf6-c893-4859-9d56-691cfa524bc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a7e74f25-7932-4e0f-8961-5ab8728c83a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_be0b4bf6-c893-4859-9d56-691cfa524bc1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_bc930b0e-c624-40dc-a948-f38772a63c4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a7e74f25-7932-4e0f-8961-5ab8728c83a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_bc930b0e-c624-40dc-a948-f38772a63c4e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5e066563-d2f4-4d60-ba8b-d960d8fee30e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5ab87cb0-eb81-4477-aa3f-751f0d47f9df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dcd9fea5-0349-44ff-b3d6-7ba136fccec0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5ab87cb0-eb81-4477-aa3f-751f0d47f9df" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5cba3707-a894-43df-b7a6-68ab0cd20a5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5ab87cb0-eb81-4477-aa3f-751f0d47f9df" xlink:to="loc_us-gaap_AwardTypeAxis_5cba3707-a894-43df-b7a6-68ab0cd20a5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5cba3707-a894-43df-b7a6-68ab0cd20a5d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5cba3707-a894-43df-b7a6-68ab0cd20a5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5cba3707-a894-43df-b7a6-68ab0cd20a5d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56acf6e1-c731-4342-b6ce-8a0c27dc4da6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5cba3707-a894-43df-b7a6-68ab0cd20a5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56acf6e1-c731-4342-b6ce-8a0c27dc4da6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e7cba01b-cbc5-4cdf-989a-56f2d4290c94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56acf6e1-c731-4342-b6ce-8a0c27dc4da6" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e7cba01b-cbc5-4cdf-989a-56f2d4290c94" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2c379b97-c22a-423b-b2fa-149075cecbf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56acf6e1-c731-4342-b6ce-8a0c27dc4da6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2c379b97-c22a-423b-b2fa-149075cecbf6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails"/>
  <link:definitionLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" xlink:type="extended" id="i1d01de044d234a6da01f488afe83746d_ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66de9fbc-44f2-4263-8b8c-010250845647" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_e5b74250-fc9c-4470-b381-ced00f818a68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66de9fbc-44f2-4263-8b8c-010250845647" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_e5b74250-fc9c-4470-b381-ced00f818a68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_297adc2a-4884-42e1-b4f8-dd934544e359" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66de9fbc-44f2-4263-8b8c-010250845647" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_297adc2a-4884-42e1-b4f8-dd934544e359" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b7cf0f57-7100-4033-a152-5f852098d614" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_297adc2a-4884-42e1-b4f8-dd934544e359" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b7cf0f57-7100-4033-a152-5f852098d614" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4b31ef29-2201-4f05-8969-90cf2837dc98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_297adc2a-4884-42e1-b4f8-dd934544e359" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4b31ef29-2201-4f05-8969-90cf2837dc98" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_035dbed1-f6ae-4c65-b997-ba101f10b245" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_297adc2a-4884-42e1-b4f8-dd934544e359" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_035dbed1-f6ae-4c65-b997-ba101f10b245" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3234ee24-2270-4c99-a0f5-d853754633a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_297adc2a-4884-42e1-b4f8-dd934544e359" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3234ee24-2270-4c99-a0f5-d853754633a3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a6bcf269-9224-4f6b-9ce2-3bba38b2031d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_56292dcf-88bb-4af5-9197-df7a25b3e7cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66de9fbc-44f2-4263-8b8c-010250845647" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_56292dcf-88bb-4af5-9197-df7a25b3e7cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9b1e08da-3f5b-4d1a-ac7c-dd4958ed5ee9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_56292dcf-88bb-4af5-9197-df7a25b3e7cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9b1e08da-3f5b-4d1a-ac7c-dd4958ed5ee9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_52cb128d-cd9f-4b55-a97e-8f3e95666398" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_56292dcf-88bb-4af5-9197-df7a25b3e7cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_52cb128d-cd9f-4b55-a97e-8f3e95666398" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_96147130-70a1-4b1e-aeda-625e8f7d7fdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_56292dcf-88bb-4af5-9197-df7a25b3e7cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_96147130-70a1-4b1e-aeda-625e8f7d7fdd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_818c800e-18db-4a98-8a84-ba10ae9d2e54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_56292dcf-88bb-4af5-9197-df7a25b3e7cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_818c800e-18db-4a98-8a84-ba10ae9d2e54" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8c405f66-f944-4993-be8b-283149c6c805" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_407ab7dd-fd05-4b8c-8b0a-94a5b3a59567" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66de9fbc-44f2-4263-8b8c-010250845647" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_407ab7dd-fd05-4b8c-8b0a-94a5b3a59567" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f7fae39a-51a7-4e2e-a0c2-1a8387f68191" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66de9fbc-44f2-4263-8b8c-010250845647" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f7fae39a-51a7-4e2e-a0c2-1a8387f68191" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_847e990e-e37e-4394-b2b9-4b20b7203eb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66de9fbc-44f2-4263-8b8c-010250845647" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_847e990e-e37e-4394-b2b9-4b20b7203eb9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7cf36ce3-d974-41b7-b6d0-b732a19f50d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66de9fbc-44f2-4263-8b8c-010250845647" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7cf36ce3-d974-41b7-b6d0-b732a19f50d4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_72e773e9-a6e3-4607-b145-163e80c82aca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7cf36ce3-d974-41b7-b6d0-b732a19f50d4" xlink:to="loc_us-gaap_AwardTypeAxis_72e773e9-a6e3-4607-b145-163e80c82aca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72e773e9-a6e3-4607-b145-163e80c82aca_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_72e773e9-a6e3-4607-b145-163e80c82aca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72e773e9-a6e3-4607-b145-163e80c82aca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f466a809-2e40-476b-9db0-63d916c7c23a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_72e773e9-a6e3-4607-b145-163e80c82aca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f466a809-2e40-476b-9db0-63d916c7c23a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_033bcd04-3604-4912-b5a5-9169adf3aef4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f466a809-2e40-476b-9db0-63d916c7c23a" xlink:to="loc_us-gaap_PerformanceSharesMember_033bcd04-3604-4912-b5a5-9169adf3aef4" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>cah-20210331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:9b2cc92e-6994-4968-bb0f-b1e44b26b0f5,g:c415e902-95ac-4ff9-bfda-46a36d4f42b5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_cah_A2.4Notesdue2020Member_974d6ee5-feaa-45eb-b700-3edc133a39b3_terseLabel_en-US" xlink:label="lab_cah_A2.4Notesdue2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.4% Notes due 2020 [Member]</link:label>
    <link:label id="lab_cah_A2.4Notesdue2020Member_label_en-US" xlink:label="lab_cah_A2.4Notesdue2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.4% Notes due 2020 [Member]</link:label>
    <link:label id="lab_cah_A2.4Notesdue2020Member_documentation_en-US" xlink:label="lab_cah_A2.4Notesdue2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.4% Notes due 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A2.4Notesdue2020Member" xlink:href="cah-20210331.xsd#cah_A2.4Notesdue2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_A2.4Notesdue2020Member" xlink:to="lab_cah_A2.4Notesdue2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6ced1623-eee1-4e4b-abca-807a0f8e671b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_1f4c8f85-e537-40ea-8b0c-2553ef89f281_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c60089e5-93a0-4eae-86c4-452969649031_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of outstanding options at period end</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_31fa65e3-f94a-4e8e-b083-2637b2e99b19_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income)/expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_A4.9Notesdue2045Member_e20be22e-9459-4fb0-9817-4ce022bf2a13_terseLabel_en-US" xlink:label="lab_cah_A4.9Notesdue2045Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.9% Notes due 2045 [Member]</link:label>
    <link:label id="lab_cah_A4.9Notesdue2045Member_label_en-US" xlink:label="lab_cah_A4.9Notesdue2045Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.9% Notes due 2045 [Member]</link:label>
    <link:label id="lab_cah_A4.9Notesdue2045Member_documentation_en-US" xlink:label="lab_cah_A4.9Notesdue2045Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.9% Notes due 2045</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A4.9Notesdue2045Member" xlink:href="cah-20210331.xsd#cah_A4.9Notesdue2045Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_A4.9Notesdue2045Member" xlink:to="lab_cah_A4.9Notesdue2045Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_fb7460d0-d77a-4425-81aa-fccd09c2bd4d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, without par value:</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c0529e28-ae26-44a6-848f-e03845645c50_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8237d219-7a47-4acb-91f7-09cef4879ca0_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments, Contingent Liabilities and Litigation</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_8a5fcafd-c9a7-4561-b650-8996c2a28c7b_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_bfdaefd2-4f9a-44c1-9561-8ecf7dd11414_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_93474861-38e1-497c-9fe3-390f3974c0ba_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes and other liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax and Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_03129735-b855-4336-8f47-3928ae6d24d2_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating and Reportable Segment</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_02863cec-c822-4c1c-9c97-172d5089442e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss_7aa5d012-cd73-463b-8071-39b02ba9111c_terseLabel_en-US" xlink:label="lab_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">shares that would be antidilutive as a result of net loss</link:label>
    <link:label id="lab_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss_label_en-US" xlink:label="lab_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">shares that would be antidilutive as a result of net loss</link:label>
    <link:label id="lab_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss_documentation_en-US" xlink:label="lab_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">shares that would be antidilutive as a result of net loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss" xlink:href="cah-20210331.xsd#cah_Sharesthatwouldbeantidilutiveasaresultofnetloss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss" xlink:to="lab_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_fd8d361f-6e13-466c-8735-22b9b827fabe_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain/(loss) on derivative instruments, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_cd14ce67-4d4b-4677-93c1-0c7cbad58b4a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_4b39c50f-81c4-412c-b8c9-706677f766ce_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_c6608393-29fb-4a8c-852a-3ee7a048cc45_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_97bf7c2d-4eff-45b9-9b4b-50f9b39d17d3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PharmaceuticalMember_74cda5b3-f159-431d-a36e-b2b33722c098_terseLabel_en-US" xlink:label="lab_cah_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical</link:label>
    <link:label id="lab_cah_PharmaceuticalMember_label_en-US" xlink:label="lab_cah_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Member</link:label>
    <link:label id="lab_cah_PharmaceuticalMember_documentation_en-US" xlink:label="lab_cah_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember" xlink:href="cah-20210331.xsd#cah_PharmaceuticalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PharmaceuticalMember" xlink:to="lab_cah_PharmaceuticalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_e2c8de3f-1dc3-432f-90bd-4cd094e66893_terseLabel_en-US" xlink:label="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenue from External Customers by Geographic Area [Table]</link:label>
    <link:label id="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_label_en-US" xlink:label="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenue from External Customers by Geographic Area [Table]</link:label>
    <link:label id="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_documentation_en-US" xlink:label="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenue from External Customers by Geographic Area [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable" xlink:href="cah-20210331.xsd#cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable" xlink:to="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_8e8aced3-4b0b-4180-a35b-1626e569cf15_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4f7368ee-e350-47f9-a588-2b88e5fc6cd5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Shareholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a906e94e-784d-4b9f-8615-de5cd8a9bde6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_8b303867-39cc-433b-ac50-644e6a9a5c74_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_0f1f4818-c33b-45e6-bf23-94606501aded_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_bcafd53e-67dd-4f29-ad5e-9bdc1c0acfe7_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Intangible, Total other intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_VestingPeriodinyearsforShares_756e0c80-ce3a-4639-8948-02a3621c17c4_terseLabel_en-US" xlink:label="lab_cah_VestingPeriodinyearsforShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period in years for Shares</link:label>
    <link:label id="lab_cah_VestingPeriodinyearsforShares_label_en-US" xlink:label="lab_cah_VestingPeriodinyearsforShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period in years for Shares</link:label>
    <link:label id="lab_cah_VestingPeriodinyearsforShares_documentation_en-US" xlink:label="lab_cah_VestingPeriodinyearsforShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting Period in years for Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_VestingPeriodinyearsforShares" xlink:href="cah-20210331.xsd#cah_VestingPeriodinyearsforShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_VestingPeriodinyearsforShares" xlink:to="lab_cah_VestingPeriodinyearsforShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_65e4dd7f-fad8-4d90-97aa-b8aaa43cd7ff_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating earnings/(loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_f1797045-f167-473c-b00f-9e23edd63290_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating earnings</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ProductLiabilityLawsuitsMember_33168bbc-a729-4694-b602-87f8dcf36f34_terseLabel_en-US" xlink:label="lab_cah_ProductLiabilityLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Lawsuits</link:label>
    <link:label id="lab_cah_ProductLiabilityLawsuitsMember_label_en-US" xlink:label="lab_cah_ProductLiabilityLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Lawsuits [Member]</link:label>
    <link:label id="lab_cah_ProductLiabilityLawsuitsMember_documentation_en-US" xlink:label="lab_cah_ProductLiabilityLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Lawsuits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember" xlink:href="cah-20210331.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ProductLiabilityLawsuitsMember" xlink:to="lab_cah_ProductLiabilityLawsuitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_1795001a-7b00-4d70-a7a4-9664a0566676_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ClassActionLawsuitsMember_cda6261b-e987-47dc-9f8b-7aab0be6e6a0_terseLabel_en-US" xlink:label="lab_cah_ClassActionLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Action Lawsuits [Member]</link:label>
    <link:label id="lab_cah_ClassActionLawsuitsMember_label_en-US" xlink:label="lab_cah_ClassActionLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Action Lawsuits [Member]</link:label>
    <link:label id="lab_cah_ClassActionLawsuitsMember_documentation_en-US" xlink:label="lab_cah_ClassActionLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Action Lawsuits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ClassActionLawsuitsMember" xlink:href="cah-20210331.xsd#cah_ClassActionLawsuitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ClassActionLawsuitsMember" xlink:to="lab_cah_ClassActionLawsuitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_cec219b8-f9c0-4590-9320-3f16d468cdb0_verboseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related costs</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_6dfcda33-125c-466e-9208-7bbd149b169d_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_63a3437f-60f7-4e59-b38b-ee82e669f4eb_verboseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Unit</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6d49569b-a084-429b-84a2-95ea5950441c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested at beginning of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1e26c3cd-1f37-4d8e-8b25-0e2400f32369_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested at end of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_NumberofStateAttorneysGeneralfilinglawsuits_9e99cd7c-3feb-44cb-a4ee-8c74785332ce_terseLabel_en-US" xlink:label="lab_cah_NumberofStateAttorneysGeneralfilinglawsuits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of State Attorneys General filing lawsuits</link:label>
    <link:label id="lab_cah_NumberofStateAttorneysGeneralfilinglawsuits_label_en-US" xlink:label="lab_cah_NumberofStateAttorneysGeneralfilinglawsuits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of State Attorneys General filing lawsuits</link:label>
    <link:label id="lab_cah_NumberofStateAttorneysGeneralfilinglawsuits_documentation_en-US" xlink:label="lab_cah_NumberofStateAttorneysGeneralfilinglawsuits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of State Attorneys General filing lawsuits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NumberofStateAttorneysGeneralfilinglawsuits" xlink:href="cah-20210331.xsd#cah_NumberofStateAttorneysGeneralfilinglawsuits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_NumberofStateAttorneysGeneralfilinglawsuits" xlink:to="lab_cah_NumberofStateAttorneysGeneralfilinglawsuits" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CordisDivestitureDomain_2a0faa72-9a17-4b61-9fcb-e22b89b64ba4_terseLabel_en-US" xlink:label="lab_cah_CordisDivestitureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture [Domain]</link:label>
    <link:label id="lab_cah_CordisDivestitureDomain_label_en-US" xlink:label="lab_cah_CordisDivestitureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture [Domain]</link:label>
    <link:label id="lab_cah_CordisDivestitureDomain_documentation_en-US" xlink:label="lab_cah_CordisDivestitureDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain" xlink:href="cah-20210331.xsd#cah_CordisDivestitureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CordisDivestitureDomain" xlink:to="lab_cah_CordisDivestitureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_f6a29caa-45a6-486c-bc1e-18771bc3cd74_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_e6be7af8-d837-481d-adff-c4545a926a5c_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_f6255055-676a-4f2d-a713-dc603615afc6_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_bca320ff-d93c-4005-956a-76196a6d1389_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_6778d42f-b51f-444c-9fd8-0000a593a5fb_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_8919944d-7ed3-43f1-8f26-921260ffcba9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_ebb38105-fb95-4d90-a681-59e1fb548268_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_b960dced-cd6d-4e8a-b14f-597c7c892df8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_2bec41e2-fa5b-4700-9949-16f3c7c53089_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_NuclearPrecisionHealthServicesMember_9f16608e-1f41-414c-8853-dfba275668f0_terseLabel_en-US" xlink:label="lab_cah_NuclearPrecisionHealthServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nuclear Precision Health Services [Member]</link:label>
    <link:label id="lab_cah_NuclearPrecisionHealthServicesMember_label_en-US" xlink:label="lab_cah_NuclearPrecisionHealthServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nuclear Precision Health Services [Member]</link:label>
    <link:label id="lab_cah_NuclearPrecisionHealthServicesMember_documentation_en-US" xlink:label="lab_cah_NuclearPrecisionHealthServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nuclear Precision Health Services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NuclearPrecisionHealthServicesMember" xlink:href="cah-20210331.xsd#cah_NuclearPrecisionHealthServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_NuclearPrecisionHealthServicesMember" xlink:to="lab_cah_NuclearPrecisionHealthServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_9864d2ad-6a57-465a-9a68-2ef0618e731a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments and other</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_3b36bf9e-5f8a-41cd-85df-d2e5c07ac00e_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_WriteDownOfAssetsHeldForSale_23070685-ce20-4e39-a81f-d04988d59ff2_terseLabel_en-US" xlink:label="lab_cah_WriteDownOfAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-down of assets held for sale</link:label>
    <link:label id="lab_cah_WriteDownOfAssetsHeldForSale_940020c4-ae31-4163-85ab-06059b307c7d_negatedTerseLabel_en-US" xlink:label="lab_cah_WriteDownOfAssetsHeldForSale" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-down of assets held for sale</link:label>
    <link:label id="lab_cah_WriteDownOfAssetsHeldForSale_label_en-US" xlink:label="lab_cah_WriteDownOfAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-down of assets held for sale</link:label>
    <link:label id="lab_cah_WriteDownOfAssetsHeldForSale_documentation_en-US" xlink:label="lab_cah_WriteDownOfAssetsHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-down of assets held for sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_WriteDownOfAssetsHeldForSale" xlink:href="cah-20210331.xsd#cah_WriteDownOfAssetsHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_WriteDownOfAssetsHeldForSale" xlink:to="lab_cah_WriteDownOfAssetsHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_0e0a20c6-4406-48ee-945b-c7251cd731ed_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on Extinguishment of Debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_b934cfc3-5a7a-4b1b-a36e-22b82ed871c2_verboseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_87a7f168-509e-419a-ae61-166e53e51750_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares acquired (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_f9b4d6be-1d28-4f54-b54a-4ba7e335ef0b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_10a49c79-f7ba-438c-81d2-c04fe8217bd8_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3ac46334-f904-4f33-9f0e-175a30096002_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CashReclassifiedToAssetHeldForSale_b30697ca-742d-4e72-a487-06db65748f34_terseLabel_en-US" xlink:label="lab_cah_CashReclassifiedToAssetHeldForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Reclassified to Asset Held for Sale</link:label>
    <link:label id="lab_cah_CashReclassifiedToAssetHeldForSale_label_en-US" xlink:label="lab_cah_CashReclassifiedToAssetHeldForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Reclassified to Asset Held for Sale</link:label>
    <link:label id="lab_cah_CashReclassifiedToAssetHeldForSale_documentation_en-US" xlink:label="lab_cah_CashReclassifiedToAssetHeldForSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Reclassified to Asset Held for Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CashReclassifiedToAssetHeldForSale" xlink:href="cah-20210331.xsd#cah_CashReclassifiedToAssetHeldForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CashReclassifiedToAssetHeldForSale" xlink:to="lab_cah_CashReclassifiedToAssetHeldForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_931a61a3-3002-4add-adfc-039b56d4359d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_4b452648-40d3-44a9-9168-9dd99c80047d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_892bb375-076f-4f17-8fff-226149ff394f_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term obligations, less current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_8505d90a-d4a6-4801-b96d-b6a4a955ce09_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_5b79af3e-f2fe-452a-b9d3-def27695194d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Notional Amount</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:to="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_9ca6255a-c529-4569-98a0-72ab1842bee4_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_SterileSurgicalGownRecallAxis_7d1695bc-dcdf-49b1-b2c1-fbe574e4ffe8_terseLabel_en-US" xlink:label="lab_cah_SterileSurgicalGownRecallAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sterile Surgical Gown Recall [Axis]</link:label>
    <link:label id="lab_cah_SterileSurgicalGownRecallAxis_label_en-US" xlink:label="lab_cah_SterileSurgicalGownRecallAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sterile Surgical Gown Recall [Axis]</link:label>
    <link:label id="lab_cah_SterileSurgicalGownRecallAxis_documentation_en-US" xlink:label="lab_cah_SterileSurgicalGownRecallAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sterile Surgical Gown Recall [Axis] [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SterileSurgicalGownRecallAxis" xlink:href="cah-20210331.xsd#cah_SterileSurgicalGownRecallAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_SterileSurgicalGownRecallAxis" xlink:to="lab_cah_SterileSurgicalGownRecallAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_6ef1b55e-31d5-4ace-a4b1-f52d8ce532df_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_a1fc3057-616f-4b19-bc3d-d481b7d4d817_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized&#8212;500 thousand shares, Issued&#8212;none</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_6938005b-c5bf-4fff-abf8-e0f527af6e88_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_f4069f84-a4ff-4081-9ada-514dcccd58b0_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_a36f34b9-6943-46e2-8000-ca06273dd937_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income/(loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_cfb352f3-1d77-47ee-89f2-c49752c655c5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_GownRecallDomain_cc3d87e7-b580-43d0-9698-dd24ecd0f911_terseLabel_en-US" xlink:label="lab_cah_GownRecallDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gown Recall [Domain]</link:label>
    <link:label id="lab_cah_GownRecallDomain_label_en-US" xlink:label="lab_cah_GownRecallDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gown Recall [Domain]</link:label>
    <link:label id="lab_cah_GownRecallDomain_documentation_en-US" xlink:label="lab_cah_GownRecallDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Gown Recall [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GownRecallDomain" xlink:href="cah-20210331.xsd#cah_GownRecallDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_GownRecallDomain" xlink:to="lab_cah_GownRecallDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CommittedReceivablesSalesFacilityProgramMember_f16fa2ed-639b-49a7-82b4-a0bbf7bc2a86_terseLabel_en-US" xlink:label="lab_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Committed Receivables Sales Facility Program [Member]</link:label>
    <link:label id="lab_cah_CommittedReceivablesSalesFacilityProgramMember_label_en-US" xlink:label="lab_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Committed Receivables Sales Facility Program [Member]</link:label>
    <link:label id="lab_cah_CommittedReceivablesSalesFacilityProgramMember_documentation_en-US" xlink:label="lab_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Committed receivables sales facility program that exists largely to provide liquidity by selling interests in trade receivables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:href="cah-20210331.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:to="lab_cah_CommittedReceivablesSalesFacilityProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_f46fd975-e3a0-409f-8f6a-03ec43313d08_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled and forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_4926c674-05dd-4333-98bd-159dec702dc5_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ProjectCostsOnInvestmentAndOtherSpending_c23e5c10-f78c-4dab-811c-43dab879b205_terseLabel_en-US" xlink:label="lab_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project costs on investment and other spending</link:label>
    <link:label id="lab_cah_ProjectCostsOnInvestmentAndOtherSpending_label_en-US" xlink:label="lab_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project Costs On Investment And Other Spending</link:label>
    <link:label id="lab_cah_ProjectCostsOnInvestmentAndOtherSpending_documentation_en-US" xlink:label="lab_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment spending at the Corporate level. Investment spending generally includes the first year spend for certain projects that require incremental investments in the form of additional operating expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:href="cah-20210331.xsd#cah_ProjectCostsOnInvestmentAndOtherSpending"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:to="lab_cah_ProjectCostsOnInvestmentAndOtherSpending" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_MedicalMember_6d490730-00e3-4b27-aa77-c55b56b79ac8_terseLabel_en-US" xlink:label="lab_cah_MedicalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical</link:label>
    <link:label id="lab_cah_MedicalMember_label_en-US" xlink:label="lab_cah_MedicalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Member</link:label>
    <link:label id="lab_cah_MedicalMember_documentation_en-US" xlink:label="lab_cah_MedicalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember" xlink:href="cah-20210331.xsd#cah_MedicalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_MedicalMember" xlink:to="lab_cah_MedicalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2e9446ff-de58-477c-8f7c-63434076e442_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled and forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_7964d1f3-f920-4c8f-a4b8-73d518396609_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_bee5ba48-2d90-47a8-abd0-53a67650ce47_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_70bbce68-5cf7-4af4-9096-c8ce4fd19ecc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_DOJInvestigationMember_9e286d5c-086e-4223-8c5b-f2fe9674c043_terseLabel_en-US" xlink:label="lab_cah_DOJInvestigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DOJ Investigation [Member]</link:label>
    <link:label id="lab_cah_DOJInvestigationMember_label_en-US" xlink:label="lab_cah_DOJInvestigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DOJ Investigation [Member]</link:label>
    <link:label id="lab_cah_DOJInvestigationMember_documentation_en-US" xlink:label="lab_cah_DOJInvestigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DOJ Investigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DOJInvestigationMember" xlink:href="cah-20210331.xsd#cah_DOJInvestigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_DOJInvestigationMember" xlink:to="lab_cah_DOJInvestigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_IndemnificationReceivable_5ff32412-7b35-4658-b877-beaecef01b6d_terseLabel_en-US" xlink:label="lab_cah_IndemnificationReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification Receivable</link:label>
    <link:label id="lab_cah_IndemnificationReceivable_label_en-US" xlink:label="lab_cah_IndemnificationReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification Receivable</link:label>
    <link:label id="lab_cah_IndemnificationReceivable_documentation_en-US" xlink:label="lab_cah_IndemnificationReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indemnification receivable from Patient recovery related to certain pre-acquisition tax exposures and transaction taxes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IndemnificationReceivable" xlink:href="cah-20210331.xsd#cah_IndemnificationReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_IndemnificationReceivable" xlink:to="lab_cah_IndemnificationReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_370b48d5-0ea3-4398-876f-ce65548f2c2b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_9bfbab74-fdd0-4aac-83e5-ed37895a19b5_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_1bf215df-cbb7-4d4a-b0fe-bb353c6b45e1_terseLabel_en-US" xlink:label="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds/(tax withholdings) from share-based compensation</link:label>
    <link:label id="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_label_en-US" xlink:label="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds/(tax withholdings) from share-based compensation</link:label>
    <link:label id="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_documentation_en-US" xlink:label="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The net cash inflow/(outflow) associated with the amount received from holders exercising their stock options and paid by the company to satisfy an employee's income tax withholding obligation when shares are withheld from settlement of a share-based award to cover taxes. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:href="cah-20210331.xsd#cah_Netproceedstaxwithholdingsfromsharebasedcompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:to="lab_cah_Netproceedstaxwithholdingsfromsharebasedcompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_e666e6b7-e0cb-4333-b70b-4a8bec7720b5_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_47d3295a-e1c7-4d13-96cd-548dcaf7dabd_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PlaintiffTypeDomain_304c6ab8-00ae-4258-b2c0-760c818fc4d3_terseLabel_en-US" xlink:label="lab_cah_PlaintiffTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Type [Domain]</link:label>
    <link:label id="lab_cah_PlaintiffTypeDomain_label_en-US" xlink:label="lab_cah_PlaintiffTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Type [Domain]</link:label>
    <link:label id="lab_cah_PlaintiffTypeDomain_documentation_en-US" xlink:label="lab_cah_PlaintiffTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Plaintiff Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeDomain" xlink:href="cah-20210331.xsd#cah_PlaintiffTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PlaintiffTypeDomain" xlink:to="lab_cah_PlaintiffTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_742a14d6-8e71-4b66-b971-9fabdf37d9ed_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_efdf47d9-40ef-4db5-944c-204677a8296b_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_c3e84fc1-ae22-4378-a964-b7e31ed584b4_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_69c2c0e0-bb7b-43bf-9957-e8ab50d035fa_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_d73e64c0-fd92-4b8a-bbfc-31f55aedb19f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_5c359c86-f116-4472-bf66-f7fdde36a23b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares, issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_04636305-7e79-406c-93d4-dee119b7cafa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringMember_90f16629-8cb4-4920-abcc-f16e0ac955fb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Nonrecurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsNonrecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Nonrecurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsNonrecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_2bad6032-7bb5-483b-b287-032d020de789_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_db93f260-8db7-4f30-bbef-0d2c782394a7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_b2770c5c-6321-445f-8d83-756f8b5b89bc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Obligations and Other Short-Term Borrowings</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_8d776bc3-cbab-4509-83db-3217fc18f3f8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_A4.368Notesdue2047Member_bc269fc5-51b4-4536-8ada-719eb723778e_terseLabel_en-US" xlink:label="lab_cah_A4.368Notesdue2047Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.368% Notes due 2047 [Member]</link:label>
    <link:label id="lab_cah_A4.368Notesdue2047Member_label_en-US" xlink:label="lab_cah_A4.368Notesdue2047Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.368% Notes due 2047 [Member]</link:label>
    <link:label id="lab_cah_A4.368Notesdue2047Member_documentation_en-US" xlink:label="lab_cah_A4.368Notesdue2047Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.368% Notes due 2047</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A4.368Notesdue2047Member" xlink:href="cah-20210331.xsd#cah_A4.368Notesdue2047Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_A4.368Notesdue2047Member" xlink:to="lab_cah_A4.368Notesdue2047Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_627e95b7-79d3-4c2f-b5cd-e8b4b72f58f0_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_b796f288-534e-4a24-b52c-541cc0e3c5e0_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CordisDivestitureMember_1d4c63e7-d2b4-4806-a3be-ae36402ec35c_terseLabel_en-US" xlink:label="lab_cah_CordisDivestitureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture</link:label>
    <link:label id="lab_cah_CordisDivestitureMember_label_en-US" xlink:label="lab_cah_CordisDivestitureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture [Member]</link:label>
    <link:label id="lab_cah_CordisDivestitureMember_documentation_en-US" xlink:label="lab_cah_CordisDivestitureMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember" xlink:href="cah-20210331.xsd#cah_CordisDivestitureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CordisDivestitureMember" xlink:to="lab_cah_CordisDivestitureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_A2.616Notesdue2022Member_7f596d4a-a664-48ad-abde-f99e86422c97_terseLabel_en-US" xlink:label="lab_cah_A2.616Notesdue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.616% Notes due 2022 [Member]</link:label>
    <link:label id="lab_cah_A2.616Notesdue2022Member_label_en-US" xlink:label="lab_cah_A2.616Notesdue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.616% Notes due 2022 [Member]</link:label>
    <link:label id="lab_cah_A2.616Notesdue2022Member_documentation_en-US" xlink:label="lab_cah_A2.616Notesdue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.616% Notes due 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A2.616Notesdue2022Member" xlink:href="cah-20210331.xsd#cah_A2.616Notesdue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_A2.616Notesdue2022Member" xlink:to="lab_cah_A2.616Notesdue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_b7f05e03-8709-494c-b19e-383aacbe1673_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_00754ab6-ca0e-426b-8ce9-29aa15135ee8_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_83e3eabd-b0ad-4641-bce7-a15772ce7378_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_90c6a367-90fc-4fb6-ae85-fc6cdc61c09b_terseLabel_en-US" xlink:label="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from investments</link:label>
    <link:label id="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_label_en-US" xlink:label="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of available-for-sale securities and other investments</link:label>
    <link:label id="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_documentation_en-US" xlink:label="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash inflow from sales of available-for-sale securities and other investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:href="cah-20210331.xsd#cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:to="lab_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_ced25624-60b2-46ab-8759-d8b5988a8a3c_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, interest and penalties accrued</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_9893393d-166c-4fd2-ac64-09feb8121a58_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_91cf3ad2-93b4-4e89-be08-b9bf8b6bb29d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_8fd07c67-39b8-4b2d-9ec0-4b39e49fd4df_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7efdbfc-7a8f-445f-b9e1-3060ac63dca6_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_61979212-169b-4f58-af49-718247a0b23a_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_a68ef5ca-6211-40a4-a038-ca9bce2b00d9_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Employee Severance</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_e65f2e60-d54a-4953-9a14-6067ee280456_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_3cfd046c-c0c5-423f-8b69-fe0dfcdcfbd3_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_f141cd2b-e6a7-4237-a9e0-07ef4388adc3_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Deferred Tax Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_649fb9f1-8d2b-4484-acce-f0cb836e8eaa_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_92bd8988-adf1-487f-83b6-ea543a0ea537_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_58315aec-c0b9-432d-862a-4496022746f4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_FacilityExitAndOtherCosts_1eea6518-320d-445c-9f7d-8b309e1bad83_terseLabel_en-US" xlink:label="lab_cah_FacilityExitAndOtherCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Exit and Other Costs</link:label>
    <link:label id="lab_cah_FacilityExitAndOtherCosts_label_en-US" xlink:label="lab_cah_FacilityExitAndOtherCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Exit and Other Costs</link:label>
    <link:label id="lab_cah_FacilityExitAndOtherCosts_documentation_en-US" xlink:label="lab_cah_FacilityExitAndOtherCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FacilityExitAndOtherCosts" xlink:href="cah-20210331.xsd#cah_FacilityExitAndOtherCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_FacilityExitAndOtherCosts" xlink:to="lab_cah_FacilityExitAndOtherCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_dc2f5229-96fd-44bf-901b-2c217221e3bf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_a2fcb6b8-f73f-4111-8995-e75e9709c8af_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_cf146658-8bf7-4b49-ae8e-77c6a750b450_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities held for sale</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_31b91765-b3c1-404e-9d2e-5625e67b7865_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_a1ae7dfa-ab23-4fb8-94df-6f16df6ee2ad_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_7f7a093f-6397-48e7-8214-a6489adbf242_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_NetOperatingLossCarrybackMember_942c9efb-ce92-433f-88c5-e8d4010d33d6_terseLabel_en-US" xlink:label="lab_cah_NetOperatingLossCarrybackMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss Carryback [Member]</link:label>
    <link:label id="lab_cah_NetOperatingLossCarrybackMember_label_en-US" xlink:label="lab_cah_NetOperatingLossCarrybackMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss Carryback [Member]</link:label>
    <link:label id="lab_cah_NetOperatingLossCarrybackMember_documentation_en-US" xlink:label="lab_cah_NetOperatingLossCarrybackMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss Carryback</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NetOperatingLossCarrybackMember" xlink:href="cah-20210331.xsd#cah_NetOperatingLossCarrybackMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_NetOperatingLossCarrybackMember" xlink:to="lab_cah_NetOperatingLossCarrybackMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_0d8bcc77-b911-4e5b-8948-d10a14824e0c_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock options, restricted share units, and performance share units (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_03a01743-b552-48dd-ac85-d626a3e4b53f_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rates changes on cash and equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ProceedsFromSettlementsOfClassActionLawsuits_1a70cfc7-c9b2-47e1-9969-b91384ba2380_terseLabel_en-US" xlink:label="lab_cah_ProceedsFromSettlementsOfClassActionLawsuits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from Settlements of Class Action Lawsuits</link:label>
    <link:label id="lab_cah_ProceedsFromSettlementsOfClassActionLawsuits_label_en-US" xlink:label="lab_cah_ProceedsFromSettlementsOfClassActionLawsuits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Settlements of Class Action Lawsuits</link:label>
    <link:label id="lab_cah_ProceedsFromSettlementsOfClassActionLawsuits_documentation_en-US" xlink:label="lab_cah_ProceedsFromSettlementsOfClassActionLawsuits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Settlements of Class Action Lawsuits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProceedsFromSettlementsOfClassActionLawsuits" xlink:href="cah-20210331.xsd#cah_ProceedsFromSettlementsOfClassActionLawsuits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ProceedsFromSettlementsOfClassActionLawsuits" xlink:to="lab_cah_ProceedsFromSettlementsOfClassActionLawsuits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_13d70edd-6a67-44e8-bdb9-23f22f34cbcb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_3901bc97-c6cb-41f4-a1bd-76f48f33e97d_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Intangible Assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_38416b14-8461-4202-af01-704e834691d1_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_4b05d594-e7f2-47c5-991e-493dbda36f64_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_Amortizationandotheracquisitionrelatedcosts_c7b92223-9e74-4d9b-b55b-d5c19ef49643_terseLabel_en-US" xlink:label="lab_cah_Amortizationandotheracquisitionrelatedcosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and other acquisition-related costs</link:label>
    <link:label id="lab_cah_Amortizationandotheracquisitionrelatedcosts_label_en-US" xlink:label="lab_cah_Amortizationandotheracquisitionrelatedcosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and other acquisition-related costs</link:label>
    <link:label id="lab_cah_Amortizationandotheracquisitionrelatedcosts_documentation_en-US" xlink:label="lab_cah_Amortizationandotheracquisitionrelatedcosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The aggregate expense charged against earnings to allocate the cost of acquired intangible assets and changes in the fair value of contingent consideration obligations. This also represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Amortizationandotheracquisitionrelatedcosts" xlink:href="cah-20210331.xsd#cah_Amortizationandotheracquisitionrelatedcosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_Amortizationandotheracquisitionrelatedcosts" xlink:to="lab_cah_Amortizationandotheracquisitionrelatedcosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_682bfc62-711f-41db-9386-010c39448f52_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares acquired, average price per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_8a85518d-9a22-4bdd-96d4-a8c6f0a03b5f_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_76436e4a-63ec-4fcd-98e3-a6f7a197177a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_9ed28c82-5edc-413c-b309-6bc46a2a2821_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution, selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_42ba96fb-22a1-4fc2-a894-3d83480de581_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_bb32e10f-3344-43cd-988d-14e12f61d10e_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_af6a5403-e538-44ee-9e80-7184345ebddc_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_e9f76d63-3275-44c0-80a5-cd9719616497_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_ce1ae967-38de-45ac-879e-35157dc4e06f_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e75c7b2f-1a64-4e27-afb7-ec9cc25e3782_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_f766ced2-82f2-4f68-9ad6-2f709f10b5cc_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_860c16c4-e05f-4a79-98d7-2055e6611de8_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_b2683f4c-a313-4e77-b151-3751035e60d1_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_d001adb6-6305-4d96-8dfc-64523e9dc639_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_12df731b-f40b-4b66-8ee6-ea7fe4406316_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f405a589-7ac3-4b12-ad61-6b809eaa7af9_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_99f42526-535b-4ec9-a55f-f620ba769e99_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_b610d406-4ccd-42ea-8700-828fec3368d8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Intangible</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_de905178-014a-4f8b-b1ee-5d5e3bce3456_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_ed228925-04c1-440b-8f6b-361d6c3684f1_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_3aadc67d-fb53-4fa8-b8b4-00b3b9204893_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_60307d47-244d-4df3-b336-99df18314fd8_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_d69cf0b8-61fc-48af-a323-7161c9c94ed0_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_11ff7a44-d22f-447f-b1ea-b11a8cbb8dbf_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d3906cc1-84f9-4140-8669-8b16cbda1396_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_077a0ff6-c213-496d-addd-fe925cd2a2fa_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ShortTermCreditFacilitiesMember_f2310275-fd19-43fa-b24f-32ed2b9baba2_terseLabel_en-US" xlink:label="lab_cah_ShortTermCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Term Credit Facilities Member</link:label>
    <link:label id="lab_cah_ShortTermCreditFacilitiesMember_label_en-US" xlink:label="lab_cah_ShortTermCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Term Credit Facilities Member</link:label>
    <link:label id="lab_cah_ShortTermCreditFacilitiesMember_documentation_en-US" xlink:label="lab_cah_ShortTermCreditFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other short-term credit facilities and an unsecured line of credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShortTermCreditFacilitiesMember" xlink:href="cah-20210331.xsd#cah_ShortTermCreditFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ShortTermCreditFacilitiesMember" xlink:to="lab_cah_ShortTermCreditFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLocationDomain_d6c2a223-ecbe-4976-a7a0-6547b1e7e6cf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income Location [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLocationDomain_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLocationDomain" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount_47c93880-e1ed-497c-8a52-c810e4145a51_terseLabel_en-US" xlink:label="lab_cah_DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Hedge Discontinuances, Hedging Instrument Matured, Amount</link:label>
    <link:label id="lab_cah_DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount_label_en-US" xlink:label="lab_cah_DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Hedge Discontinuances, Hedging Instrument Matured, Amount</link:label>
    <link:label id="lab_cah_DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount_documentation_en-US" xlink:label="lab_cah_DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Hedge Discontinuances, Hedging Instrument Matured, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount" xlink:href="cah-20210331.xsd#cah_DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount" xlink:to="lab_cah_DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e0c6bdf7-1c35-4d18-a154-516c5882c452_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_c8f01cc4-efc5-45f5-bd77-b6e346d950e7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_1f14c9bb-d27c-48de-bd2d-a468cb00f76f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9d45b600-90fd-4134-af7d-ed83a81ce997_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a3a9314f-bb8a-49ae-a842-d6055e537429_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_8737a796-ef8b-4348-873e-c0ce959f2c3a_terseLabel_en-US" xlink:label="lab_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Liability for New York Opioid Stewardship Act</link:label>
    <link:label id="lab_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_label_en-US" xlink:label="lab_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Liability for New York Opioid Stewardship Act</link:label>
    <link:label id="lab_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_documentation_en-US" xlink:label="lab_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Liability for New York Opioid Stewardship Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct" xlink:href="cah-20210331.xsd#cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct" xlink:to="lab_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_40651072-0c3e-4995-bbec-e68f415dcf22_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_462a5090-d7e5-4752-b0c5-2ebd7b94e57a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_33600238-b750-4182-b92f-dcef43318fb2_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Share Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_e65905dd-f59f-4665-9b74-5d5594b571da_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities and operating items, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract_78945d7f-984a-4a03-836d-efbed1b352c8_terseLabel_en-US" xlink:label="lab_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Obligations and Other Short-Term Borrowings [Abstract]</link:label>
    <link:label id="lab_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract_label_en-US" xlink:label="lab_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Obligations and Other Short-Term Borrowings [Abstract]</link:label>
    <link:label id="lab_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract_documentation_en-US" xlink:label="lab_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Obligations and Other Short-Term Borrowings [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract" xlink:href="cah-20210331.xsd#cah_LongTermObligationsandOtherShortTermBorrowingsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract" xlink:to="lab_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_6ba8963e-03c8-4a35-9218-93ba365624d1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueHedgingMember_93c3abd6-2efe-4d1f-9432-33b332d2f127_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging</link:label>
    <link:label id="lab_us-gaap_FairValueHedgingMember_label_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueHedgingMember" xlink:to="lab_us-gaap_FairValueHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_f370cc84-0e1d-4dea-96bb-f2f05014b9f1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_65f54ce6-76ef-461f-af21-225f4f81b4a4_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_d87d30be-3220-4fee-9a9d-c287038bed11_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_35b3bba4-ce45-4158-8296-f2636a2ac913_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net earnings/(loss) to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_7b7e6daa-c665-456d-85d3-71ffd9ab1de8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_322a52e5-2294-4c1d-a101-6830c4484d24_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TrademarksAndPatentsMember_56a4cef5-0aac-495d-b00a-94f59304ddfb_terseLabel_en-US" xlink:label="lab_cah_TrademarksAndPatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks, trade names and patents</link:label>
    <link:label id="lab_cah_TrademarksAndPatentsMember_label_en-US" xlink:label="lab_cah_TrademarksAndPatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks And Patents Member</link:label>
    <link:label id="lab_cah_TrademarksAndPatentsMember_documentation_en-US" xlink:label="lab_cah_TrademarksAndPatentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, and the exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TrademarksAndPatentsMember" xlink:href="cah-20210331.xsd#cah_TrademarksAndPatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TrademarksAndPatentsMember" xlink:to="lab_cah_TrademarksAndPatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_A4.6Notesdue2043Member_9f6a7ba8-6ed0-44c5-96d6-51f0ca37c459_terseLabel_en-US" xlink:label="lab_cah_A4.6Notesdue2043Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.6% Notes due 2043 [Member]</link:label>
    <link:label id="lab_cah_A4.6Notesdue2043Member_label_en-US" xlink:label="lab_cah_A4.6Notesdue2043Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.6% Notes due 2043 [Member]</link:label>
    <link:label id="lab_cah_A4.6Notesdue2043Member_documentation_en-US" xlink:label="lab_cah_A4.6Notesdue2043Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.6% Notes due 2043</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A4.6Notesdue2043Member" xlink:href="cah-20210331.xsd#cah_A4.6Notesdue2043Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_A4.6Notesdue2043Member" xlink:to="lab_cah_A4.6Notesdue2043Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_610626c3-b742-4584-ad4d-40dda5c637ce_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TotalLongTermandShortTermObligations_62a9b23b-3f47-4487-8604-8ffac71f5628_terseLabel_en-US" xlink:label="lab_cah_TotalLongTermandShortTermObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Long-Term and Short-Term Obligations</link:label>
    <link:label id="lab_cah_TotalLongTermandShortTermObligations_label_en-US" xlink:label="lab_cah_TotalLongTermandShortTermObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Long-Term and Short-Term Obligations</link:label>
    <link:label id="lab_cah_TotalLongTermandShortTermObligations_documentation_en-US" xlink:label="lab_cah_TotalLongTermandShortTermObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Long-Term and Short-Term Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalLongTermandShortTermObligations" xlink:href="cah-20210331.xsd#cah_TotalLongTermandShortTermObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TotalLongTermandShortTermObligations" xlink:to="lab_cah_TotalLongTermandShortTermObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_877da06e-e384-4dd0-b0ac-f5a891dd1b69_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_50eaee57-f8c1-4f75-8205-25783fdd5b28_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReceivable_64a6f62e-45b0-42c6-9b97-485652e72c1c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Receivable</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReceivable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReceivable" xlink:to="lab_us-gaap_IncomeTaxReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CARESActDomain_a388d07b-4251-410b-8c5a-1df2deb27867_terseLabel_en-US" xlink:label="lab_cah_CARESActDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss Carryback [Domain]</link:label>
    <link:label id="lab_cah_CARESActDomain_label_en-US" xlink:label="lab_cah_CARESActDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act [Domain]</link:label>
    <link:label id="lab_cah_CARESActDomain_documentation_en-US" xlink:label="lab_cah_CARESActDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CARESActDomain" xlink:href="cah-20210331.xsd#cah_CARESActDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CARESActDomain" xlink:to="lab_cah_CARESActDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_3bf3e022-7404-4529-a5e6-ddfa273ef31f_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_0c0e826a-c53f-4fc2-8c2b-5e36d5f6a425_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0cfdf2a6-21a7-47cf-bed6-8548dfa2acf3_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ff6cc423-fc4f-4228-bd47-8bfb4361d9dd_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_2ca2be52-fff3-43ca-b5cf-668b5ac4ee2e_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of subsidiaries, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_075493bd-8b6c-4841-a822-b0d519129010_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_dc1cc81c-e988-4ba5-97f8-8c8b2267fc67_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Transactions Related to Restricted Share Units Under the Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_6d82edca-9bb0-4dcb-92c0-0ef2bc9528c6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_NotesPayableRepurchased_45fd65dc-ffb9-40b9-8d0f-acb6444765bf_terseLabel_en-US" xlink:label="lab_cah_NotesPayableRepurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable Repurchased</link:label>
    <link:label id="lab_cah_NotesPayableRepurchased_label_en-US" xlink:label="lab_cah_NotesPayableRepurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable Repurchased</link:label>
    <link:label id="lab_cah_NotesPayableRepurchased_documentation_en-US" xlink:label="lab_cah_NotesPayableRepurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal Amount of Notes Payable Repurchased during the year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NotesPayableRepurchased" xlink:href="cah-20210331.xsd#cah_NotesPayableRepurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_NotesPayableRepurchased" xlink:to="lab_cah_NotesPayableRepurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_5916889e-9cc1-4c1a-9492-b57e5f9c4bc4_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_82ba4ec4-8c54-483b-a7bb-a361b387390e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term obligations and other short-term borrowings</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_106f4898-67d3-4b30-9813-f1dc39ca6971_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation, Current</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_IPRDTrademarksandOtherMember_6acc06c1-8fae-4f68-af52-07eadfd5309a_terseLabel_en-US" xlink:label="lab_cah_IPRDTrademarksandOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D, trademarks and other</link:label>
    <link:label id="lab_cah_IPRDTrademarksandOtherMember_label_en-US" xlink:label="lab_cah_IPRDTrademarksandOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D,TrademarksandOther [Member]</link:label>
    <link:label id="lab_cah_IPRDTrademarksandOtherMember_documentation_en-US" xlink:label="lab_cah_IPRDTrademarksandOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Includes in process investigation of new knowledge useful in developing new product or service or new process or techniques or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for the improvements to existing product or process and rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IPRDTrademarksandOtherMember" xlink:href="cah-20210331.xsd#cah_IPRDTrademarksandOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_IPRDTrademarksandOtherMember" xlink:to="lab_cah_IPRDTrademarksandOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_bc9f1b19-8c9f-41dc-8e50-f22acc7eacb2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4eec3205-d680-498f-83ba-88f1af5478b4_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income/(Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_aa446664-eac9-48ce-90ae-af11edc14a83_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_66de6516-9e84-4346-a1ba-6870ac5b3fb2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated annual amortization of intangible assets - Year Four</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_438208a2-984b-451e-8245-59e08efc8889_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_a8b94ffb-05b6-4168-96d7-410749504a5f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_SterileSurgicalGownRecallMember_a44371b3-416f-46e4-a60e-15277d822483_terseLabel_en-US" xlink:label="lab_cah_SterileSurgicalGownRecallMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sterile Surgical Gown Recall [Member]</link:label>
    <link:label id="lab_cah_SterileSurgicalGownRecallMember_label_en-US" xlink:label="lab_cah_SterileSurgicalGownRecallMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sterile Surgical Gown Recall [Member]</link:label>
    <link:label id="lab_cah_SterileSurgicalGownRecallMember_documentation_en-US" xlink:label="lab_cah_SterileSurgicalGownRecallMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sterile Surgical Gown Recall [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SterileSurgicalGownRecallMember" xlink:href="cah-20210331.xsd#cah_SterileSurgicalGownRecallMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_SterileSurgicalGownRecallMember" xlink:to="lab_cah_SterileSurgicalGownRecallMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_999a1f40-cd81-444e-9d73-3153a32de353_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assets and Liabilities Held for Sale [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_22c72332-f31d-4ba9-96fb-3b573a8271e7_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:to="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_b1e3e270-4295-4c77-ad68-20a23d031d0c_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:to="lab_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_5a492c61-4017-4652-95d3-f38a30e58470_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_DerivativesHedgeDiscontinuancesHeadingInstrumentTerminatedAmount_ddcf36dd-af24-42f2-9939-e09fa39c1e95_terseLabel_en-US" xlink:label="lab_cah_DerivativesHedgeDiscontinuancesHeadingInstrumentTerminatedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Hedge Discontinuances, Heading Instrument Terminated, Amount</link:label>
    <link:label id="lab_cah_DerivativesHedgeDiscontinuancesHeadingInstrumentTerminatedAmount_label_en-US" xlink:label="lab_cah_DerivativesHedgeDiscontinuancesHeadingInstrumentTerminatedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Hedge Discontinuances, Heading Instrument Terminated, Amount</link:label>
    <link:label id="lab_cah_DerivativesHedgeDiscontinuancesHeadingInstrumentTerminatedAmount_documentation_en-US" xlink:label="lab_cah_DerivativesHedgeDiscontinuancesHeadingInstrumentTerminatedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Hedge Discontinuances, Heading Instrument Terminated, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DerivativesHedgeDiscontinuancesHeadingInstrumentTerminatedAmount" xlink:href="cah-20210331.xsd#cah_DerivativesHedgeDiscontinuancesHeadingInstrumentTerminatedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_DerivativesHedgeDiscontinuancesHeadingInstrumentTerminatedAmount" xlink:to="lab_cah_DerivativesHedgeDiscontinuancesHeadingInstrumentTerminatedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_6e11399f-eea4-4c62-aa9c-61466d608d83_terseLabel_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_MedicaldistributionandproductsMember_4c50aa54-6b94-4036-9dbc-2b401f365427_terseLabel_en-US" xlink:label="lab_cah_MedicaldistributionandproductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical distribution and products [Member]</link:label>
    <link:label id="lab_cah_MedicaldistributionandproductsMember_label_en-US" xlink:label="lab_cah_MedicaldistributionandproductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical distribution and products [Member]</link:label>
    <link:label id="lab_cah_MedicaldistributionandproductsMember_documentation_en-US" xlink:label="lab_cah_MedicaldistributionandproductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical distribution and products [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicaldistributionandproductsMember" xlink:href="cah-20210331.xsd#cah_MedicaldistributionandproductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_MedicaldistributionandproductsMember" xlink:to="lab_cah_MedicaldistributionandproductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_f16002d2-409b-4371-84b0-f6c85833dd7c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TaxMatterDomain_ac423c01-012e-4a38-ba82-eb06ccdf9059_terseLabel_en-US" xlink:label="lab_cah_TaxMatterDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matter [Domain]</link:label>
    <link:label id="lab_cah_TaxMatterDomain_label_en-US" xlink:label="lab_cah_TaxMatterDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matter [Domain]</link:label>
    <link:label id="lab_cah_TaxMatterDomain_documentation_en-US" xlink:label="lab_cah_TaxMatterDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Tax Matter [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterDomain" xlink:href="cah-20210331.xsd#cah_TaxMatterDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TaxMatterDomain" xlink:to="lab_cah_TaxMatterDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_1677842a-5aba-4e27-b0b5-898aa5d92672_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Dividends_28f19b54-65c3-4fac-87bc-2873e012db17_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:label id="lab_us-gaap_Dividends_label_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Dividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Dividends" xlink:to="lab_us-gaap_Dividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsDomain_4526a1b3-9c2d-4272-9805-55bf35868d95_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsDomain_label_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsDomain" xlink:to="lab_us-gaap_SubsegmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_1f992220-f90e-4f7a-8837-a9926251c8c1_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive income attributable to Cardinal Health, Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_079dc17c-36cc-4385-aae5-7e8ad7a28059_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_3490214f-37a9-4723-bdeb-fe1e3e4cec09_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Transactions Related to Performance Share Units Under the Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Performance-based Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_de39cf5d-4167-44e7-987a-fbf5d916effd_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4a240b6e-847d-489c-a766-d68dd9df0ac5_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_9ee97348-00b1-4fde-854c-ab79dc68059a_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_c8cf67e7-4520-4628-8b0e-203141773479_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_GownRecallAxis_985163c2-d10f-4edb-b454-1820120621bf_terseLabel_en-US" xlink:label="lab_cah_GownRecallAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gown Recall [Axis]</link:label>
    <link:label id="lab_cah_GownRecallAxis_label_en-US" xlink:label="lab_cah_GownRecallAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gown Recall [Axis]</link:label>
    <link:label id="lab_cah_GownRecallAxis_documentation_en-US" xlink:label="lab_cah_GownRecallAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gown Recall [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GownRecallAxis" xlink:href="cah-20210331.xsd#cah_GownRecallAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_GownRecallAxis" xlink:to="lab_cah_GownRecallAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_459c4b8f-3666-461d-aada-a544514b1d51_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_61de03b3-5204-4e43-bdaa-14e87a9c9b75_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_FloatingRateNotesdue2022Member_eb1b4b17-4c93-46bd-ac7d-baf0cbe624ec_terseLabel_en-US" xlink:label="lab_cah_FloatingRateNotesdue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating Rate Notes due 2022 [Member]</link:label>
    <link:label id="lab_cah_FloatingRateNotesdue2022Member_label_en-US" xlink:label="lab_cah_FloatingRateNotesdue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating Rate Notes due 2022 [Member]</link:label>
    <link:label id="lab_cah_FloatingRateNotesdue2022Member_documentation_en-US" xlink:label="lab_cah_FloatingRateNotesdue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating Rate Notes due 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FloatingRateNotesdue2022Member" xlink:href="cah-20210331.xsd#cah_FloatingRateNotesdue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_FloatingRateNotesdue2022Member" xlink:to="lab_cah_FloatingRateNotesdue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_7763faeb-e799-413f-a476-aec0975132fd_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Other Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_6bdb4c52-b0f4-4816-8051-25589a0b1171_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_OpioidLawsuitsStateDomain_2a3869df-74f3-4be1-8518-ce13abc14b1d_terseLabel_en-US" xlink:label="lab_cah_OpioidLawsuitsStateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Lawsuits State [Domain]</link:label>
    <link:label id="lab_cah_OpioidLawsuitsStateDomain_label_en-US" xlink:label="lab_cah_OpioidLawsuitsStateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Lawsuits State [Domain]</link:label>
    <link:label id="lab_cah_OpioidLawsuitsStateDomain_documentation_en-US" xlink:label="lab_cah_OpioidLawsuitsStateDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Lawsuits State and Political Subdivisions [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsStateDomain" xlink:href="cah-20210331.xsd#cah_OpioidLawsuitsStateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_OpioidLawsuitsStateDomain" xlink:to="lab_cah_OpioidLawsuitsStateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_3bfa6362-c98a-496a-8d24-86d8f55add56_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings/(loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_f0f08d39-8455-4b3a-8221-83567759aaa8_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings/(loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_52a3d6ea-6e1d-4779-b79d-5d2dba0fe04b_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_f5b01874-83c5-4bb9-856d-ac7859b916c6_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_MaximumQuarterlyPayment_f6a9b338-bd00-44dc-b618-0e98f37002f9_terseLabel_en-US" xlink:label="lab_cah_MaximumQuarterlyPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum quarterly payment</link:label>
    <link:label id="lab_cah_MaximumQuarterlyPayment_label_en-US" xlink:label="lab_cah_MaximumQuarterlyPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Quarterly Payment</link:label>
    <link:label id="lab_cah_MaximumQuarterlyPayment_documentation_en-US" xlink:label="lab_cah_MaximumQuarterlyPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Quarterly Payment for pharmaceutical sourcing venture if certain milestones are achieved.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MaximumQuarterlyPayment" xlink:href="cah-20210331.xsd#cah_MaximumQuarterlyPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_MaximumQuarterlyPayment" xlink:to="lab_cah_MaximumQuarterlyPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_a879bf46-ecd5-41ba-8470-0984037b76a6_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings/(loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_19c3509b-29b0-4584-87d8-759e8bd2b6b1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_3db59e7c-87c6-40a5-9af6-54b6e7648347_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_OtherJurisdictionsMember_4243721a-4a7c-4106-bcf8-d9ce278bcd76_terseLabel_en-US" xlink:label="lab_cah_OtherJurisdictionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Jurisdictions [Member]</link:label>
    <link:label id="lab_cah_OtherJurisdictionsMember_label_en-US" xlink:label="lab_cah_OtherJurisdictionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Jurisdictions [Member]</link:label>
    <link:label id="lab_cah_OtherJurisdictionsMember_documentation_en-US" xlink:label="lab_cah_OtherJurisdictionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Jurisdictions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OtherJurisdictionsMember" xlink:href="cah-20210331.xsd#cah_OtherJurisdictionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_OtherJurisdictionsMember" xlink:to="lab_cah_OtherJurisdictionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_685adc04-909a-4348-a210-112bdae6aed8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Total Share-based Compensation Expense by Type of Award</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRecallExpense_ded5c9f5-b2c5-44aa-b8c7-0e3a5031c13b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRecallExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Recall Expense</link:label>
    <link:label id="lab_us-gaap_InventoryRecallExpense_label_en-US" xlink:label="lab_us-gaap_InventoryRecallExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Recall Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRecallExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRecallExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRecallExpense" xlink:to="lab_us-gaap_InventoryRecallExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_61d5231b-0f0a-4334-93ce-2162d35eb0c1_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_305a8b66-29dd-4bef-9e19-684ef8b2a9a3_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings_a41f0779-76dc-4004-ba98-8409ac1a394d_terseLabel_en-US" xlink:label="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount of Long-Term and other Short-Term Borrowings</link:label>
    <link:label id="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings_label_en-US" xlink:label="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount of Long-Term and other Short-Term Borrowings</link:label>
    <link:label id="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings_documentation_en-US" xlink:label="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount of Long-Term and other Short-Term Borrowings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:href="cah-20210331.xsd#cah_CarryingAmountofLongTermandotherShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:to="lab_cah_CarryingAmountofLongTermandotherShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_8720c59f-cd02-40eb-bd50-b16c8e25500c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in short-term borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Repayments of) Short-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_LawsuitTypeDomain_d93dce4a-d61e-4ab4-a9d3-88d3647fffea_terseLabel_en-US" xlink:label="lab_cah_LawsuitTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lawsuit Type [Domain]</link:label>
    <link:label id="lab_cah_LawsuitTypeDomain_label_en-US" xlink:label="lab_cah_LawsuitTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lawsuit Type [Domain]</link:label>
    <link:label id="lab_cah_LawsuitTypeDomain_documentation_en-US" xlink:label="lab_cah_LawsuitTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Lawsuit Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeDomain" xlink:href="cah-20210331.xsd#cah_LawsuitTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_LawsuitTypeDomain" xlink:to="lab_cah_LawsuitTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_2badf079-5f66-4e62-80f3-2ea7f24f705f_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_OpioidLitigationDomain_7c33a04c-2a64-49f2-b01a-34918774558f_terseLabel_en-US" xlink:label="lab_cah_OpioidLitigationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Litigation [Domain]</link:label>
    <link:label id="lab_cah_OpioidLitigationDomain_label_en-US" xlink:label="lab_cah_OpioidLitigationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Litigation [Domain]</link:label>
    <link:label id="lab_cah_OpioidLitigationDomain_documentation_en-US" xlink:label="lab_cah_OpioidLitigationDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Litigation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain" xlink:href="cah-20210331.xsd#cah_OpioidLitigationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_OpioidLitigationDomain" xlink:to="lab_cah_OpioidLitigationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_82651150-8f06-476d-ac51-77e63695b2d4_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermPurchaseCommitmentPeriod_7fab7c90-6f59-4114-9808-007bca6977e1_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment, Period</link:label>
    <link:label id="lab_us-gaap_LongtermPurchaseCommitmentPeriod_label_en-US" xlink:label="lab_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Purchase Commitment, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermPurchaseCommitmentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:to="lab_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_64508a64-ba2c-453a-a04c-5c5d0e478bcf_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Transfers</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_a09ba63a-376b-49e7-b9a4-11325acf11da_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Restructuring and Employee Severance</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_f77278c9-dd69-44a2-9f68-653f4034b19a_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_0ee40b0d-7359-4836-95bd-c9d8f0fc9278_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CareFusionMember_99f7f77d-49da-44ed-8067-b18bf0b0bc99_terseLabel_en-US" xlink:label="lab_cah_CareFusionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CareFusion [Member]</link:label>
    <link:label id="lab_cah_CareFusionMember_label_en-US" xlink:label="lab_cah_CareFusionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CareFusion [Member]</link:label>
    <link:label id="lab_cah_CareFusionMember_documentation_en-US" xlink:label="lab_cah_CareFusionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CareFusion [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CareFusionMember" xlink:href="cah-20210331.xsd#cah_CareFusionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CareFusionMember" xlink:to="lab_cah_CareFusionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_ee38632d-a37b-4deb-b990-6863d2cd0ae3_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_6ce03ec5-8bf6-46ce-8ab5-90777f600e27_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses_1c9f2abb-6728-4335-8de6-9d3fc22a0bc6_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Foreign Currency Translation Gains (Losses)</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Foreign Currency Translation Gains (Losses)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_a9031fa0-69ae-44c5-8bcb-f36f830e75d6_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_923626cb-780e-4380-9a88-84b0275135c4_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_e49bdf8e-219f-4cdf-b64f-e3914ecbfa39_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_678aea09-879a-46c5-af78-6d0c500b7f37_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d72041d9-8c48-4d8e-91fc-fff7dbe7d358_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_ad6ead60-a822-4a27-890c-7d38dde92b5b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_908549d1-dead-4b99-9f89-fe9ac14e2481_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_4da5c6be-19ec-4c59-b166-8a49bc3d1202_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PatientRecoveryBusinessMember_1c04602e-da39-4550-af7a-dea5268c78a2_terseLabel_en-US" xlink:label="lab_cah_PatientRecoveryBusinessMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient Recovery Business</link:label>
    <link:label id="lab_cah_PatientRecoveryBusinessMember_label_en-US" xlink:label="lab_cah_PatientRecoveryBusinessMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient Recovery Business [Member]</link:label>
    <link:label id="lab_cah_PatientRecoveryBusinessMember_documentation_en-US" xlink:label="lab_cah_PatientRecoveryBusinessMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient Recovery Business [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PatientRecoveryBusinessMember" xlink:href="cah-20210331.xsd#cah_PatientRecoveryBusinessMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PatientRecoveryBusinessMember" xlink:to="lab_cah_PatientRecoveryBusinessMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_4822491f-8ac7-424e-8e08-1011b0c00a17_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net earnings attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ac8c22a5-31ba-4991-b0d9-60a814705074_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled and forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_b2fde74b-48e0-4edd-8558-a6e69f1b27f6_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_914fc4c0-3d2c-425c-b8ab-47e796e0ab74_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_6e78bb1d-ad60-48ef-a29a-50f22be6b6c9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PharmaceuticalDistributionandSpecialtyMember_bfdfab77-87e0-4014-b802-01051d639d39_terseLabel_en-US" xlink:label="lab_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Distribution and Specialty [Member]</link:label>
    <link:label id="lab_cah_PharmaceuticalDistributionandSpecialtyMember_label_en-US" xlink:label="lab_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Distribution and Specialty [Member]</link:label>
    <link:label id="lab_cah_PharmaceuticalDistributionandSpecialtyMember_documentation_en-US" xlink:label="lab_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical Distribution and Specialty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:href="cah-20210331.xsd#cah_PharmaceuticalDistributionandSpecialtyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:to="lab_cah_PharmaceuticalDistributionandSpecialtyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_8a8dce21-c135-4922-8253-6ff00b660670_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f42c2e38-5732-47cc-b705-a78e4e4f7799_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_53cbf5f7-d942-49ec-b876-09e85b49106c_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_dc3a8273-93e4-476d-97e0-ed31950215e2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Transactions Under the Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_43f4c6c9-d326-4acf-a18c-8c3e44097624_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_e6cd725f-42f6-4a18-bd30-6bca03144fba_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Amortization Period (Years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOtherShares_0f559144-65e4-4d45-b0a1-84f080c4a92d_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOtherShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other Shares</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOtherShares_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOtherShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOtherShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOtherShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOtherShares" xlink:to="lab_us-gaap_StockholdersEquityOtherShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_39bd3fa4-8ec5-4bd4-9162-365db2f7149f_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_fe9461a7-741a-4b12-8a77-f5e976abc5cd_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated annual amortization of intangible assets - Remainder of Fiscal Year</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_9d216f1e-3299-4491-9720-a83f7d75364a_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_63ab6454-3636-43c6-9e95-cf1b0ae39e0f_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_8ebe197c-4188-4e19-aef9-9de72c19f898_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_4eb8cfaf-8433-4019-b426-4a977d521b2b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrentAndNoncurrent_04875363-f4e5-4f40-9ec9-c4a3fab3bed5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_2cc68135-e8d2-472f-8f94-afc23560827e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_4bc8bc00-4a1b-4130-9f25-b8b975e0f8fe_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_2e829ea9-259e-45dc-a1f2-3dd2f874b0ea_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_380ac483-6dc4-42b9-84e5-8b9066402798_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Profit by Reportable Segment</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_82cf34f4-b469-4cbe-96e8-67d6a5ab6d3e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price per Common Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_6d485512-dfe6-4521-8356-68a17290b118_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Intangible, Total other intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_403b803a-b042-416d-8ce0-65d04dc951e9_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_e2b92eed-4356-4385-9ff8-e3e272dadec1_terseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated range of decrease in unrecognized tax benefits within the next 12 months</link:label>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_label_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CardinalHealthAtHomeMember_6e29132b-2a1b-4207-87bf-1bb77c7ba981_terseLabel_en-US" xlink:label="lab_cah_CardinalHealthAtHomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health At Home [Member]</link:label>
    <link:label id="lab_cah_CardinalHealthAtHomeMember_label_en-US" xlink:label="lab_cah_CardinalHealthAtHomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health At Home [Member]</link:label>
    <link:label id="lab_cah_CardinalHealthAtHomeMember_documentation_en-US" xlink:label="lab_cah_CardinalHealthAtHomeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health At Home [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CardinalHealthAtHomeMember" xlink:href="cah-20210331.xsd#cah_CardinalHealthAtHomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CardinalHealthAtHomeMember" xlink:to="lab_cah_CardinalHealthAtHomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OpenTaxYear_b35b0209-3d9b-432c-83bb-0a2e14f87636_terseLabel_en-US" xlink:label="lab_us-gaap_OpenTaxYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Tax Year</link:label>
    <link:label id="lab_us-gaap_OpenTaxYear_label_en-US" xlink:label="lab_us-gaap_OpenTaxYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Tax Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OpenTaxYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OpenTaxYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OpenTaxYear" xlink:to="lab_us-gaap_OpenTaxYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_356f8937-8342-4b23-9560-538f0632b729_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends on common shares</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:to="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_de79990d-63ba-4fe2-b2a2-fd1e21f8c7b9_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_32c40531-7267-426f-9757-25c013499dcb_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_999f0298-6f9f-4c92-8222-7bb9d6371414_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_e4682ca5-e229-4022-8e5b-23f53677a55f_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLocationAxis_4551bcd4-2181-41f8-8487-fae49f7c9188_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income Location [Axis]</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLocationAxis_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLocationAxis" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_0ba25a15-5670-4de0-bd98-7a8fa633d374_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_15701eef-b014-411a-b0e8-3785cc750dc2_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_e2d13416-512d-4929-99c4-fbc48cbfb64c_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable" xlink:to="lab_us-gaap_TaxCreditCarryforwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromHedgeFinancingActivities_ba05dc4f-6959-4852-8688-57b5e70126dc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromHedgeFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Hedge, Financing Activities</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromHedgeFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromHedgeFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Hedge, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromHedgeFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromHedgeFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromHedgeFinancingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromHedgeFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_96ce7254-288f-419c-bd74-23277fc67ca7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCosts_1120ebdc-8f6b-48a5-b10f-2723e2b03b02_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_RestructuringCosts_0f4de5e2-b160-4b6f-a773-a625f2e7d128_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Costs</link:label>
    <link:label id="lab_us-gaap_RestructuringCosts_label_en-US" xlink:label="lab_us-gaap_RestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCosts" xlink:to="lab_us-gaap_RestructuringCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_9cd9b957-63ab-474e-b6b6-daaba76ba1ca_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain/(Loss) on Derivatives, net of tax</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_1c8fad73-c084-4d5d-ae24-3d06a3fec436_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_6fa88632-53b2-40c6-ac7a-af375e82eb53_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments and other adjustments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_4441929d-0acb-469d-b7d3-a21ef2531e1a_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_c14aa813-10b2-47df-81ff-239bdc92c293_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_34bb5800-0332-4d98-956f-8820d2de9420_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_22dc8f21-f942-4056-89f0-82c1b4961d62_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_8b13dae4-574f-44c5-b115-b0e594ea6b45_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TotalOpioidLitigationMember_435726ac-a31a-478e-a766-1943d3ca1914_terseLabel_en-US" xlink:label="lab_cah_TotalOpioidLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Opioid Litigation [Member]</link:label>
    <link:label id="lab_cah_TotalOpioidLitigationMember_label_en-US" xlink:label="lab_cah_TotalOpioidLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Opioid Litigation [Member]</link:label>
    <link:label id="lab_cah_TotalOpioidLitigationMember_documentation_en-US" xlink:label="lab_cah_TotalOpioidLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Opioid Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember" xlink:href="cah-20210331.xsd#cah_TotalOpioidLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TotalOpioidLitigationMember" xlink:to="lab_cah_TotalOpioidLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_ab63f45d-327e-435a-8b61-20eddb6e93a2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends declared per common share</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_0cf7be8b-5eea-47ee-ae0f-7e174d48e16f_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_6afc86b0-fc18-464a-8194-eade51b0eb2c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_b471b06f-c9ee-4b9f-8e62-89e1b862b1a1_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_e2f136b4-1c36-479d-843c-965d3ed9c0b3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_fc5fc716-b304-45d0-abb0-fc8e2ad9873d_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_a320da37-2fbf-4b12-8759-52d4488a605f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill by Reportable Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_9342aaad-f6b9-4cf6-aea5-b834e53f3886_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_d9fb9b38-d57c-43f2-b95e-8dd425742033_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in trade receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_7b969914-921b-429c-9da4-f52c54ac7ce9_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_LawsuitTypeAxis_cde4becc-6cab-478a-a850-a2c454093e45_terseLabel_en-US" xlink:label="lab_cah_LawsuitTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lawsuit Type [Axis]</link:label>
    <link:label id="lab_cah_LawsuitTypeAxis_label_en-US" xlink:label="lab_cah_LawsuitTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lawsuit Type [Axis]</link:label>
    <link:label id="lab_cah_LawsuitTypeAxis_documentation_en-US" xlink:label="lab_cah_LawsuitTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lawsuit Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeAxis" xlink:href="cah-20210331.xsd#cah_LawsuitTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_LawsuitTypeAxis" xlink:to="lab_cah_LawsuitTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_741ab4df-bac4-4a86-90de-29f735a1099c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_059e7169-f5c8-4083-8e00-fa7cef2e2923_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_88e42429-2aaf-493e-a7fd-7b32363ae753_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_34ebc5e5-d85c-4d8c-b8ae-c070cb3baa1c_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d6edc9b5-2475-47c2-ae93-24af074478dd_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares&#8211;diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_a0a298c0-b756-4014-a0d2-f2e60dff0b16_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case Type</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_1cb9ca78-e0df-4a21-b31a-4b007b010f8b_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits that would impact effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_4e4e53ff-cac8-4edb-b1eb-4b101e9cdd08_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_6e778b17-d66c-4032-8d8e-33f80e0c47de_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_5f5fe293-be06-4dd5-9b37-69da76a7f3ec_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_44db0420-51c3-4c74-afff-f2775982b7e2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled and forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_46816ee3-7228-45a1-be8b-d924d5d553c4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_c3041baf-39ec-4367-9731-1188143d5986_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_64915130-3248-450c-86d7-4fc97f187923_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_9a6e6993-c2f9-42b4-8b77-edec03a220c9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_5f491262-5ef9-4eb6-ae70-6d36c6fbf310_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_82d6bc8e-7d90-4c68-afaf-2911832eee49_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction of long-term obligations</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_190c0d3c-c589-4455-9e5d-e6734cdca646_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Inventory</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_SterileSurgicalGownRecallDomain_febca364-f6f8-4303-8f22-ef5198462615_terseLabel_en-US" xlink:label="lab_cah_SterileSurgicalGownRecallDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sterile Surgical Gown Recall [Domain]</link:label>
    <link:label id="lab_cah_SterileSurgicalGownRecallDomain_label_en-US" xlink:label="lab_cah_SterileSurgicalGownRecallDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sterile Surgical Gown Recall [Domain]</link:label>
    <link:label id="lab_cah_SterileSurgicalGownRecallDomain_documentation_en-US" xlink:label="lab_cah_SterileSurgicalGownRecallDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Sterile Surgical Gown Recall [Axis] [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SterileSurgicalGownRecallDomain" xlink:href="cah-20210331.xsd#cah_SterileSurgicalGownRecallDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_SterileSurgicalGownRecallDomain" xlink:to="lab_cah_SterileSurgicalGownRecallDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_5012617f-589f-4e80-be5b-e11a667b6306_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total share-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_18d3ba1e-d4f0-4a18-9c1d-56af7b00a420_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Plaintiffs</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Plaintiffs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:to="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_1f576dc9-247b-44fb-bbd9-88ed8d33d7b8_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_6a13fdc6-4521-430a-a3af-8a8a2f514cd9_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_2fd52630-66ec-47c9-a2a4-d77d180ce444_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized&#8212;755 million shares, Issued&#8212;327 million shares at March&#160;31, 2021 and June 30, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bb4640b5-0af3-4bf3-b9dc-e3a1305e0a14_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_f5959d9f-9400-4a0f-81be-5e978873cb6f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_87f20b47-16f1-4b55-ab04-174b8541c42b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_f512d4dd-cb87-4189-a510-de03f659f884_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_5ab1c349-6f44-4957-845b-bf25c92d6339_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated annual amortization of intangible assets - Year Two</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_5ab5f10c-7a2c-4dc7-a140-498b52480a61_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Goodwill</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_11db4747-34fd-422a-81cf-eccf1660c29d_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_f09c68db-1945-4f4b-9b50-1055e371e969_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of exercisable options at period end</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_32bfb04a-dcb1-4c7e-a1e1-ed10dce06ecc_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefit related to share-based compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_8e913bb6-25bd-4a68-9b0c-8b689321b2eb_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets_df86e7a7-bfb8-4b0e-a9d8-99bd41b9425e_terseLabel_en-US" xlink:label="lab_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from divestitures and disposal of property and equipment and held for sale assets</link:label>
    <link:label id="lab_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets_label_en-US" xlink:label="lab_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from divestitures and disposal of property and equipment and held for sale assets</link:label>
    <link:label id="lab_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets_documentation_en-US" xlink:label="lab_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from divestitures and disposal of property and equipment and held for sale assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets" xlink:href="cah-20210331.xsd#cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets" xlink:to="lab_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrencySwapMember_97176559-e623-4500-ac42-71aae9095852_terseLabel_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency Swap [Member]</link:label>
    <link:label id="lab_us-gaap_CurrencySwapMember_label_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrencySwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrencySwapMember" xlink:to="lab_us-gaap_CurrencySwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CordisDivestitureAxis_7406cd3a-7b78-4762-9589-16f083d41de3_terseLabel_en-US" xlink:label="lab_cah_CordisDivestitureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture [Axis]</link:label>
    <link:label id="lab_cah_CordisDivestitureAxis_label_en-US" xlink:label="lab_cah_CordisDivestitureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture [Axis]</link:label>
    <link:label id="lab_cah_CordisDivestitureAxis_documentation_en-US" xlink:label="lab_cah_CordisDivestitureAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cordis Divestiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis" xlink:href="cah-20210331.xsd#cah_CordisDivestitureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CordisDivestitureAxis" xlink:to="lab_cah_CordisDivestitureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_8dc4ff1b-e60f-4653-8b96-1ecb9309ccd1_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and other intangibles, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Including Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_4314d0ff-8a07-4f1f-864a-38d696921855_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_d0845995-dc72-4ce9-b66f-9013693d5483_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive income/(loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_fe540f0e-3721-45bd-8937-fa958966d34d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_1b116f62-cf21-47bd-965a-e3e40bf16c0f_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_655db5c6-1015-45ad-b7cb-eaa62bde7887_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_0ccdb56e-8515-4c32-a99e-e0daa0e4be0c_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Target performance goal (as a percent)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_6c278a07-55ba-42b6-90a7-8a6f9559dd26_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a1b56cd1-09fb-4e73-bed7-ccceda490000_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_0d3c52d8-2303-4217-accc-282010a3c3c2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares, issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_616e6c0c-e964-4181-b697-93b1d3a17336_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_373da41b-7079-45e2-a8fe-6619b6e44ef2_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0a630869-5671-4f37-a732-ee89b1a10a70_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_a777e781-457b-4cf0-9832-13881c8b74c2_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_fb84fb9b-46f9-40da-a081-df0d8b5c5b4e_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserve_392ea213-c4e2-4554-91d7-3194ac8119b3_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability</link:label>
    <link:label id="lab_us-gaap_LitigationReserve_label_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserve" xlink:to="lab_us-gaap_LitigationReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_NetOperatingLossCarrybackAxis_7d0d1e0f-7aee-4449-9f50-db91b619de40_terseLabel_en-US" xlink:label="lab_cah_NetOperatingLossCarrybackAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss Carryback [Axis]</link:label>
    <link:label id="lab_cah_NetOperatingLossCarrybackAxis_label_en-US" xlink:label="lab_cah_NetOperatingLossCarrybackAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss Carryback [Axis]</link:label>
    <link:label id="lab_cah_NetOperatingLossCarrybackAxis_documentation_en-US" xlink:label="lab_cah_NetOperatingLossCarrybackAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Operating Loss Carryback</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NetOperatingLossCarrybackAxis" xlink:href="cah-20210331.xsd#cah_NetOperatingLossCarrybackAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_NetOperatingLossCarrybackAxis" xlink:to="lab_cah_NetOperatingLossCarrybackAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_4587dfb4-e9f2-4f17-904f-8d910109d171_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_e94165a1-8c9e-4417-81fb-3fdb3c2c93bd_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_5fbcc1f2-94e7-49b4-9c6e-f8fd10ef6c9f_verboseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_0525834a-1534-491c-84d5-5076dba310f2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_a8bcb6aa-4dc9-402a-bace-6ed507b87875_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Cardinal Health, Inc. shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0edb24cb-cd83-4043-9257-b0ed04381122_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_CVSHealthMember_bdb78acb-08ca-49ec-9282-4d36343efcb7_terseLabel_en-US" xlink:label="lab_cah_CVSHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CVS Health</link:label>
    <link:label id="lab_cah_CVSHealthMember_label_en-US" xlink:label="lab_cah_CVSHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CVS Health [Member]</link:label>
    <link:label id="lab_cah_CVSHealthMember_documentation_en-US" xlink:label="lab_cah_CVSHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CVS Health [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CVSHealthMember" xlink:href="cah-20210331.xsd#cah_CVSHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_CVSHealthMember" xlink:to="lab_cah_CVSHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_NewYorkOpioidStewardshipActMember_a8a4feaf-456c-4bb7-8ca3-d2013b48ce92_terseLabel_en-US" xlink:label="lab_cah_NewYorkOpioidStewardshipActMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York Opioid Stewardship Act [Member]</link:label>
    <link:label id="lab_cah_NewYorkOpioidStewardshipActMember_label_en-US" xlink:label="lab_cah_NewYorkOpioidStewardshipActMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York Opioid Stewardship Act [Member]</link:label>
    <link:label id="lab_cah_NewYorkOpioidStewardshipActMember_documentation_en-US" xlink:label="lab_cah_NewYorkOpioidStewardshipActMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York Opioid Stewardship Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NewYorkOpioidStewardshipActMember" xlink:href="cah-20210331.xsd#cah_NewYorkOpioidStewardshipActMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_NewYorkOpioidStewardshipActMember" xlink:to="lab_cah_NewYorkOpioidStewardshipActMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_9387b4af-c1e3-482f-9967-d504170eb2f9_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_b760c69b-9cfa-47b3-90c3-97cb30e53980_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_13ba5107-b5c6-4bc4-bae8-d4f4d2d908ea_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_dfe13788-4f60-4ff8-8b0e-8c83268c172a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Assets (Liabilities), at Fair Value, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:to="lab_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_c55a6aff-6460-45bf-81bd-45ae040a571a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_18750230-7332-4873-bff7-de957121bab3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_ExercisablePeriodOfPlansInYears_a79c04a8-2f1d-460a-84d7-bc23eac92d8f_terseLabel_en-US" xlink:label="lab_cah_ExercisablePeriodOfPlansInYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable period of plans (in years)</link:label>
    <link:label id="lab_cah_ExercisablePeriodOfPlansInYears_label_en-US" xlink:label="lab_cah_ExercisablePeriodOfPlansInYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable period of plans, in years</link:label>
    <link:label id="lab_cah_ExercisablePeriodOfPlansInYears_documentation_en-US" xlink:label="lab_cah_ExercisablePeriodOfPlansInYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The instrument's contractual term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ExercisablePeriodOfPlansInYears" xlink:href="cah-20210331.xsd#cah_ExercisablePeriodOfPlansInYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_ExercisablePeriodOfPlansInYears" xlink:to="lab_cah_ExercisablePeriodOfPlansInYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_64bb96c8-30b5-436b-ade8-20f9fdec8e3b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_1dbdeff4-93a9-4b1a-bd96-2416bdb12ad0_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_3cfa413d-1def-40fc-b52f-d0ae614e395e_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Unit</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_e3828208-5c00-4de7-b2a3-2209be8c2ba8_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_0b55d8cc-9abc-42fc-8cd0-a6fb6bddee04_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8308e3a2-c3dc-4606-983f-582606078485_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_e45c1526-3b50-45c2-b047-399079e59191_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_9b7d7259-ddb2-4e69-9d3c-9c6ae95457a4_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_ffbc7b32-00fd-42a0-892c-729a333f9194_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Loss [Rollforward]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_1ff4174c-8637-41d3-8364-7bda946a1b2d_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross margin</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_f29671da-0cf0-432a-86c8-9e0a3a73b588_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_370711e4-7983-48c6-b571-aa34043031cc_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated annual amortization of intangible assets - Year Three</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_daca7be6-79a0-49b2-b12e-75a728c5b90b_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_daa53afb-e328-4a34-bf3f-8fa1fe48f4c7_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_544197c1-ad5b-4eaf-b1c8-d6d8b90772e5_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_366b0cfb-65ec-4908-9619-8e12a693efa3_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_2bc94589-3b5d-4f07-8020-0ab5a9f1a5c4_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_e76a6d16-300e-40c9-b327-32311ab2302f_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_9d866c19-1b90-44f8-a980-d8314cf71e21_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings/(loss) attributable to Cardinal Health, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_ceb320d6-0792-4766-a201-527ec4557c59_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d293e0d6-acd9-4ffa-9883-b6eee4b94978_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in operating assets and liabilities, net of effects from acquisitions and divestitures:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7332fd2c-d06c-4180-92e4-19af42d06454_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other comprehensive income/(loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_cd62cd27-0157-4d75-a70f-3672f73edc46_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_38b8b000-47e3-4ff1-9d28-baaf425b972b_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_90f7ce58-3737-46eb-bb26-5aee5cf5d58d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_6782a56b-5dda-465f-9bfd-5b495641c456_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_6627f5e3-ad53-44b0-b192-266c2ed853b4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_daa6576b-57fc-487d-8ce5-0a7cbd120320_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_677de2a4-10f0-4866-8b6e-09f8dbe0de5b_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and employee severance</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_d5fa5cc9-cf5b-4f72-819b-e8cc19487afa_totalLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total restructuring and employee severance</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_81b4b658-de5f-4adc-8925-290e6c2b2584_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_81b58edb-3e7e-4acf-ba72-2f21bf96c14b_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_0607969a-2abf-4080-84d4-330bb5314967_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_df4a00cc-c4bc-4064-988c-9854ee81a48b_verboseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed technology and other</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f0e062ff-75fe-4427-bd02-2b157c1d4b73_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_75f1e518-6520-4ffc-90e2-42845d707c4f_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PlaintiffTypeAxis_9f06e00a-784e-4fbd-b6bc-0ca759f05b5a_terseLabel_en-US" xlink:label="lab_cah_PlaintiffTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Type [Axis]</link:label>
    <link:label id="lab_cah_PlaintiffTypeAxis_label_en-US" xlink:label="lab_cah_PlaintiffTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Type [Axis]</link:label>
    <link:label id="lab_cah_PlaintiffTypeAxis_documentation_en-US" xlink:label="lab_cah_PlaintiffTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plaintiff Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeAxis" xlink:href="cah-20210331.xsd#cah_PlaintiffTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PlaintiffTypeAxis" xlink:to="lab_cah_PlaintiffTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_4f832250-261d-4f61-97ff-c037984ddb51_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation (recoveries)/charges, net</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_f839ad49-9a5c-49fb-a804-29e1d06ecdb9_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_NarativeAbstract_53141463-1fca-4bd5-82b9-498a452d1e8f_terseLabel_en-US" xlink:label="lab_cah_NarativeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Narative [Abstract]</link:label>
    <link:label id="lab_cah_NarativeAbstract_label_en-US" xlink:label="lab_cah_NarativeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Narative [Abstract]</link:label>
    <link:label id="lab_cah_NarativeAbstract_documentation_en-US" xlink:label="lab_cah_NarativeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Narative [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NarativeAbstract" xlink:href="cah-20210331.xsd#cah_NarativeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_NarativeAbstract" xlink:to="lab_cah_NarativeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_A3.41Notesdue2027Member_fa1c8933-caf0-4751-91cf-ace9a1b27caf_terseLabel_en-US" xlink:label="lab_cah_A3.41Notesdue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.41% Notes due 2027 [Member]</link:label>
    <link:label id="lab_cah_A3.41Notesdue2027Member_label_en-US" xlink:label="lab_cah_A3.41Notesdue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.41% Notes due 2027 [Member]</link:label>
    <link:label id="lab_cah_A3.41Notesdue2027Member_documentation_en-US" xlink:label="lab_cah_A3.41Notesdue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.41% Notes due 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A3.41Notesdue2027Member" xlink:href="cah-20210331.xsd#cah_A3.41Notesdue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_A3.41Notesdue2027Member" xlink:to="lab_cah_A3.41Notesdue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_91f492cc-86cb-4669-a71b-9257e27ec6f3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_DisposalGroupIncludingDiscontinuedOperationGoodwillAndOtherIntangiblesNet_51767c71-cd6e-401f-81ae-73d66f7cedb6_terseLabel_en-US" xlink:label="lab_cah_DisposalGroupIncludingDiscontinuedOperationGoodwillAndOtherIntangiblesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Goodwill and other intangibles, net</link:label>
    <link:label id="lab_cah_DisposalGroupIncludingDiscontinuedOperationGoodwillAndOtherIntangiblesNet_label_en-US" xlink:label="lab_cah_DisposalGroupIncludingDiscontinuedOperationGoodwillAndOtherIntangiblesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Including Discontinued Operation Goodwill and other intangibles, net</link:label>
    <link:label id="lab_cah_DisposalGroupIncludingDiscontinuedOperationGoodwillAndOtherIntangiblesNet_documentation_en-US" xlink:label="lab_cah_DisposalGroupIncludingDiscontinuedOperationGoodwillAndOtherIntangiblesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Including Discontinued Operation Goodwill and other intangibles, net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DisposalGroupIncludingDiscontinuedOperationGoodwillAndOtherIntangiblesNet" xlink:href="cah-20210331.xsd#cah_DisposalGroupIncludingDiscontinuedOperationGoodwillAndOtherIntangiblesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_DisposalGroupIncludingDiscontinuedOperationGoodwillAndOtherIntangiblesNet" xlink:to="lab_cah_DisposalGroupIncludingDiscontinuedOperationGoodwillAndOtherIntangiblesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_42610c3b-aede-4c65-a425-b26735c5fc28_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredGainLossOnDiscontinuationOfInterestRateFairValueHedge_c17209fb-7a21-4df9-b574-e8bb1a402f48_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredGainLossOnDiscontinuationOfInterestRateFairValueHedge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Gain (Loss) on Discontinuation of Interest Rate Fair Value Hedge</link:label>
    <link:label id="lab_us-gaap_DeferredGainLossOnDiscontinuationOfInterestRateFairValueHedge_label_en-US" xlink:label="lab_us-gaap_DeferredGainLossOnDiscontinuationOfInterestRateFairValueHedge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Gain (Loss) on Discontinuation of Interest Rate Fair Value Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredGainLossOnDiscontinuationOfInterestRateFairValueHedge" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredGainLossOnDiscontinuationOfInterestRateFairValueHedge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredGainLossOnDiscontinuationOfInterestRateFairValueHedge" xlink:to="lab_us-gaap_DeferredGainLossOnDiscontinuationOfInterestRateFairValueHedge" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_4be1c3c1-050e-4e24-a71f-4392dca9879b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_f7cb4ea8-954d-4a63-ac13-13af0377897c_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TaxMatterAxis_dd74afe1-812c-403e-8ff2-3c4bd2edad0d_terseLabel_en-US" xlink:label="lab_cah_TaxMatterAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matter [Axis]</link:label>
    <link:label id="lab_cah_TaxMatterAxis_label_en-US" xlink:label="lab_cah_TaxMatterAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matter [Axis]</link:label>
    <link:label id="lab_cah_TaxMatterAxis_documentation_en-US" xlink:label="lab_cah_TaxMatterAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matter [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterAxis" xlink:href="cah-20210331.xsd#cah_TaxMatterAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TaxMatterAxis" xlink:to="lab_cah_TaxMatterAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_OpioidLawsuitsMember_f2eaae95-e615-4f91-af32-4e21f150caa6_terseLabel_en-US" xlink:label="lab_cah_OpioidLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Lawsuits [Member]</link:label>
    <link:label id="lab_cah_OpioidLawsuitsMember_label_en-US" xlink:label="lab_cah_OpioidLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Lawsuits [Member]</link:label>
    <link:label id="lab_cah_OpioidLawsuitsMember_documentation_en-US" xlink:label="lab_cah_OpioidLawsuitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Lawsuits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsMember" xlink:href="cah-20210331.xsd#cah_OpioidLawsuitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_OpioidLawsuitsMember" xlink:to="lab_cah_OpioidLawsuitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_AlamedaCountyMember_3fe22faa-6199-498a-bcda-fba32cfceaf4_terseLabel_en-US" xlink:label="lab_cah_AlamedaCountyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alameda County [Member]</link:label>
    <link:label id="lab_cah_AlamedaCountyMember_label_en-US" xlink:label="lab_cah_AlamedaCountyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alameda County [Member]</link:label>
    <link:label id="lab_cah_AlamedaCountyMember_documentation_en-US" xlink:label="lab_cah_AlamedaCountyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alameda County [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AlamedaCountyMember" xlink:href="cah-20210331.xsd#cah_AlamedaCountyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_AlamedaCountyMember" xlink:to="lab_cah_AlamedaCountyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_PrivatePartiesMember_be571656-2f02-4bae-a2a4-e3d96ca8b2de_terseLabel_en-US" xlink:label="lab_cah_PrivatePartiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Parties [Member]</link:label>
    <link:label id="lab_cah_PrivatePartiesMember_label_en-US" xlink:label="lab_cah_PrivatePartiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Parties [Member]</link:label>
    <link:label id="lab_cah_PrivatePartiesMember_documentation_en-US" xlink:label="lab_cah_PrivatePartiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Parties [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PrivatePartiesMember" xlink:href="cah-20210331.xsd#cah_PrivatePartiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_PrivatePartiesMember" xlink:to="lab_cah_PrivatePartiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_2a8deb7d-fbd7-442c-a645-a13313b4ea16_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Loss [Table]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringChargesAbstract_811b10ad-2f2a-401b-8f1c-105ef531cb46_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringChargesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringChargesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringChargesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringChargesAbstract" xlink:to="lab_us-gaap_RestructuringChargesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_6e8ab405-1a43-4456-a6a1-8b4ee603099d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Intangible</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_faaa3e23-7789-4683-87f0-396b0c9ab55e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_f39a9ba8-d844-4e57-8fe0-10925be49399_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for bad debts</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_472a50f8-1a1f-400b-8726-5b2f8c2c33a0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b23e304b-75f1-4dfd-b9d7-5ffa8cb7f609_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Total</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_de8b1d30-bf8d-4265-bf6d-ae4d4d9d4e12_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_6ec238a5-bcb1-4d34-b45d-106c5acba26b_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_194c4999-a01c-4fef-a0c3-e5d52e649dd2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_fb735985-630a-44cf-acd3-bb2da91d13e6_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_c3f9f3a2-3635-4cfc-a400-216aa0f07d3e_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_OpioidLitigationAxis_977ffe9e-ae42-466e-9834-d575d76c9a68_terseLabel_en-US" xlink:label="lab_cah_OpioidLitigationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Litigation [Axis]</link:label>
    <link:label id="lab_cah_OpioidLitigationAxis_label_en-US" xlink:label="lab_cah_OpioidLitigationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Litigation [Axis]</link:label>
    <link:label id="lab_cah_OpioidLitigationAxis_documentation_en-US" xlink:label="lab_cah_OpioidLitigationAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis" xlink:href="cah-20210331.xsd#cah_OpioidLitigationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_OpioidLitigationAxis" xlink:to="lab_cah_OpioidLitigationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_AdditionalStockOptionPlanDataTableTextBlock_bbaf3065-980d-4035-9956-fdcc385bac27_terseLabel_en-US" xlink:label="lab_cah_AdditionalStockOptionPlanDataTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Additional Data Related to Stock Option Activity</link:label>
    <link:label id="lab_cah_AdditionalStockOptionPlanDataTableTextBlock_label_en-US" xlink:label="lab_cah_AdditionalStockOptionPlanDataTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Stock Option Plan Data [Table Text Block]</link:label>
    <link:label id="lab_cah_AdditionalStockOptionPlanDataTableTextBlock_documentation_en-US" xlink:label="lab_cah_AdditionalStockOptionPlanDataTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A disclosure of additional data related to all stock option activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AdditionalStockOptionPlanDataTableTextBlock" xlink:href="cah-20210331.xsd#cah_AdditionalStockOptionPlanDataTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_AdditionalStockOptionPlanDataTableTextBlock" xlink:to="lab_cah_AdditionalStockOptionPlanDataTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_b44190f6-7720-4798-9964-b805f38eb4f8_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_5b8fec1f-a0cf-4b0e-a93a-135fc09708ef_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares, without par value:</link:label>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a68a8d0b-8edb-4019-92ff-f1e4e466294d_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c6892287-2c81-4e24-a85b-52cbd90a1ed9_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares&#8211;basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_288f4f98-e4e9-491f-88a2-3935cc71acf4_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares in treasury</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_bcd63fe3-9021-4075-b24e-de199447a169_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury, balance at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_f391413f-7161-4a83-b9d6-58a04e1f10f7_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury, balance at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_5fbe73a1-ad95-4103-aff6-49147bd6856f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments and other</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_AggregateAnnualAssessment_4c3f35b1-f380-4bfa-87ae-e6d93fa5e4fb_terseLabel_en-US" xlink:label="lab_cah_AggregateAnnualAssessment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Annual Assessment</link:label>
    <link:label id="lab_cah_AggregateAnnualAssessment_label_en-US" xlink:label="lab_cah_AggregateAnnualAssessment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Annual Assessment</link:label>
    <link:label id="lab_cah_AggregateAnnualAssessment_documentation_en-US" xlink:label="lab_cah_AggregateAnnualAssessment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Annual Assessment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AggregateAnnualAssessment" xlink:href="cah-20210331.xsd#cah_AggregateAnnualAssessment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_AggregateAnnualAssessment" xlink:to="lab_cah_AggregateAnnualAssessment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_a24583e0-2951-4f5d-9538-5110868b6264_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_9e0ca329-9de8-4727-ad61-75ac9cc79c4a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee- Related Costs</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_7e7c51e0-b484-42f0-9f73-401ed0c776ad_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_d5406f15-cb70-4954-ba30-55c6345996ef_negatedLabel_en-US" xlink:label="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of investments</link:label>
    <link:label id="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_label_en-US" xlink:label="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of available-for-sale securities and other investments</link:label>
    <link:label id="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_documentation_en-US" xlink:label="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash outflow from purchases of available-for-sale securities and other investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Purchaseofavailableforsalesecuritiesandotherinvestments" xlink:href="cah-20210331.xsd#cah_Purchaseofavailableforsalesecuritiesandotherinvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_Purchaseofavailableforsalesecuritiesandotherinvestments" xlink:to="lab_cah_Purchaseofavailableforsalesecuritiesandotherinvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f068d41f-67bf-4dd3-88b7-1de6cf420c5d_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4e481326-9df2-4575-b47c-dd3eea21fd73_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fb2880eb-6b7b-4156-aa94-926ea5e4edf8_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_b8bfc781-7ce3-43de-b343-e4d01c53ccaa_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated annual amortization of intangible assets - Year One</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_b3ec004f-5fa5-4c3a-810c-7a310d3a3da4_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_39e2d962-91eb-4ca3-9271-aab7fe44edd9_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_49941d24-01fc-4595-b6d8-306d029e528f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for/(benefit from) income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_198e7367-994f-4124-9618-60c4c96d9419_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_LossContingencyLawsuitsNumber_34e7ea7e-5515-4c05-9bec-73cc1b401db6_verboseLabel_en-US" xlink:label="lab_cah_LossContingencyLawsuitsNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Lawsuits, Number</link:label>
    <link:label id="lab_cah_LossContingencyLawsuitsNumber_label_en-US" xlink:label="lab_cah_LossContingencyLawsuitsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Lawsuits, Number</link:label>
    <link:label id="lab_cah_LossContingencyLawsuitsNumber_documentation_en-US" xlink:label="lab_cah_LossContingencyLawsuitsNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Lawsuits, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LossContingencyLawsuitsNumber" xlink:href="cah-20210331.xsd#cah_LossContingencyLawsuitsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_LossContingencyLawsuitsNumber" xlink:to="lab_cah_LossContingencyLawsuitsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_ada53a50-cc8f-4075-9ca1-d08a5781f84d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairments and (gain)/loss on disposal of assets, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Assets and Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:to="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_c0e18dad-14f3-45e8-892a-9cd38e509e1a_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_58f0b0a6-af34-4699-a7cb-ab9a8c46ce37_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2d7206e5-4ede-46a5-bf75-dd2daa3cf4ee_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_8ed15974-05e2-49f8-ac7a-2ef04337134f_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets by Reportable Segment</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Assets from Segment to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_63045328-5cd6-4c74-b969-d3d276b2bc9b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_cd855656-e133-464c-a36b-e4a9cda2aca1_terseLabel_en-US" xlink:label="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenue from External Customers by Geographic Area [Line Items]</link:label>
    <link:label id="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_label_en-US" xlink:label="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Revenue from External Customers by Geographic Area [Line Items]</link:label>
    <link:label id="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_documentation_en-US" xlink:label="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Segment Revenue from External Customers by Geographic Area [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems" xlink:href="cah-20210331.xsd#cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems" xlink:to="lab_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_164fe98a-c266-4f83-a211-704458b933fb_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_5b817e9b-20f2-46e0-a10e-8cff9dfb737a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_414837ea-acd3-41e1-b18e-5fbf5dcf7d40_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_76439b6d-4476-45c6-849c-756d2f16e046_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Intangible</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3b87a73b-d518-420e-80be-789fb40c6df4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_fcb4ce88-24d2-4a6c-82d1-f2297f9aaaf2_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_a3470ee6-c1d5-488c-aabf-fbf2879a06b0_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_291d190d-bca3-4dbd-846f-bb8a0846fb19_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_72fb2e3f-f3bd-45b8-9db7-e2cc5fc68cc9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_ab0cc54f-eb30-4b03-ad71-78e62c21b67e_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b89c700a-8348-41c6-ba27-c5f7f546421b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_ba271877-f6e2-4acd-90e3-67e81dc8762c_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_2210dfdc-c37a-4349-a3e2-d8e7a5206c48_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares, authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_930716bd-9bc3-408f-8be7-abe497355620_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_54e316f2-973e-4426-aec1-0621149c7e2e_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_29ca993f-093b-4785-b5f3-03b811456003_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4dcc129f-dbd8-4cea-96d8-2f5c65a5cb03_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_29ab9910-3773-4e96-aa1a-47d74450bc74_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_c081afc2-3404-42f3-b50a-33ccfca3713a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2b6b769e-f037-4bb8-99bd-f5473a8a2284_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_386ef509-e381-426f-86f1-e4a724ebdc42_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_345a92b7-914e-41ba-a56f-53bffdfb9ea8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_d5d2cdb8-3d96-47c0-aa5f-4c4da31e9ff3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_5e8561ed-a8a3-4b92-bb76-90de93b9c89f_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7287c613-d7b4-4b30-8130-35c9a2ee601b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_2ddaebdb-5154-4c47-9192-8d3ea138681b_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TaxMattersAgreementDomain_f89134fc-6a7c-4e23-b315-0460a950e77c_terseLabel_en-US" xlink:label="lab_cah_TaxMattersAgreementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matters Agreement [Domain]</link:label>
    <link:label id="lab_cah_TaxMattersAgreementDomain_label_en-US" xlink:label="lab_cah_TaxMattersAgreementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matters Agreement [Domain]</link:label>
    <link:label id="lab_cah_TaxMattersAgreementDomain_documentation_en-US" xlink:label="lab_cah_TaxMattersAgreementDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Tax Matters Agreement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementDomain" xlink:href="cah-20210331.xsd#cah_TaxMattersAgreementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TaxMattersAgreementDomain" xlink:to="lab_cah_TaxMattersAgreementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_07d86e61-f3c5-4ddf-8a4e-973b278ec8c9_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares in treasury, at cost: 36 million shares and 34 million shares at March&#160;31, 2021 and June 30, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_9184977e-db8a-4158-b8ee-1a66be42b94a_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury, balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_97e836f5-9de4-47ae-80ac-2ee31b2d83d5_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury, balance at end of period</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_TaxMattersAgreementAxis_8d6901a1-e208-4208-9af0-ab5671d25240_terseLabel_en-US" xlink:label="lab_cah_TaxMattersAgreementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matters Agreement [Axis]</link:label>
    <link:label id="lab_cah_TaxMattersAgreementAxis_label_en-US" xlink:label="lab_cah_TaxMattersAgreementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matters Agreement [Axis]</link:label>
    <link:label id="lab_cah_TaxMattersAgreementAxis_documentation_en-US" xlink:label="lab_cah_TaxMattersAgreementAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Matters Agreement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementAxis" xlink:href="cah-20210331.xsd#cah_TaxMattersAgreementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_TaxMattersAgreementAxis" xlink:to="lab_cah_TaxMattersAgreementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FacilityClosingMember_8e652628-26c4-45ab-8b61-58008e006d5a_terseLabel_en-US" xlink:label="lab_us-gaap_FacilityClosingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Exit and Other Costs</link:label>
    <link:label id="lab_us-gaap_FacilityClosingMember_label_en-US" xlink:label="lab_us-gaap_FacilityClosingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Closing [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FacilityClosingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FacilityClosingMember" xlink:to="lab_us-gaap_FacilityClosingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_9b44c0d1-47fd-410c-b89b-4282712add27_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_cah_A3.2Notesdue2022Member_84dba8a4-d0c1-48a6-9c36-a8731a1fef69_terseLabel_en-US" xlink:label="lab_cah_A3.2Notesdue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.2% Notes due 2022 [Member]</link:label>
    <link:label id="lab_cah_A3.2Notesdue2022Member_label_en-US" xlink:label="lab_cah_A3.2Notesdue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.2% Notes due 2022 [Member]</link:label>
    <link:label id="lab_cah_A3.2Notesdue2022Member_documentation_en-US" xlink:label="lab_cah_A3.2Notesdue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.2% Notes due 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A3.2Notesdue2022Member" xlink:href="cah-20210331.xsd#cah_A3.2Notesdue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cah_A3.2Notesdue2022Member" xlink:to="lab_cah_A3.2Notesdue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_ab5fddeb-3d65-4329-983a-bca681193654_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_be0d8474-fd6f-44ba-b7c0-c4ff3b8de69d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_c7f2fef1-2676-45ef-a0dc-675f262fff83_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_2e6be30d-72df-46a5-ad9d-0c992303adf9_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_a91ea7df-3d73-42bb-99d1-59c9c48c926c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2535a34c-64ce-49ab-a45c-84b51699c9a6_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Financial Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_5ec2cc2b-c442-4723-9d03-14a479eee97d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_4dd4b9f9-b691-4105-8e95-387cbf44fb95_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings/(loss) per common share attributable to Cardinal Health, Inc.:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsAxis_255c3377-de91-414a-8435-d540e6c5511d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsAxis_label_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsAxis" xlink:to="lab_us-gaap_SubsegmentsAxis" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>cah-20210331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:9b2cc92e-6994-4968-bb0f-b1e44b26b0f5,g:c415e902-95ac-4ff9-bfda-46a36d4f42b5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cardinal.com/role/CoverPage" xlink:type="simple" xlink:href="cah-20210331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_084e56bf-a6ec-4b6b-a0aa-57625789e34f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_14e238b2-070c-4cf4-a572-a1683117929d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_084e56bf-a6ec-4b6b-a0aa-57625789e34f" xlink:to="loc_dei_DocumentType_14e238b2-070c-4cf4-a572-a1683117929d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_3ba43a0e-8d5a-4aa1-a853-4eae15a75dc6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_084e56bf-a6ec-4b6b-a0aa-57625789e34f" xlink:to="loc_dei_DocumentQuarterlyReport_3ba43a0e-8d5a-4aa1-a853-4eae15a75dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_27232d90-774a-4fb2-be2a-5fcf8182aaf0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_084e56bf-a6ec-4b6b-a0aa-57625789e34f" xlink:to="loc_dei_DocumentPeriodEndDate_27232d90-774a-4fb2-be2a-5fcf8182aaf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_3dd1c45e-ff10-4ca3-a159-96c198c3bbea" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_084e56bf-a6ec-4b6b-a0aa-57625789e34f" xlink:to="loc_dei_DocumentTransitionReport_3dd1c45e-ff10-4ca3-a159-96c198c3bbea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_545847ab-4119-49ee-ae3e-bedcf8e0d58b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_084e56bf-a6ec-4b6b-a0aa-57625789e34f" xlink:to="loc_dei_EntityFileNumber_545847ab-4119-49ee-ae3e-bedcf8e0d58b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_fab37151-c5fd-4ce0-ad60-fa88a093da97" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_084e56bf-a6ec-4b6b-a0aa-57625789e34f" xlink:to="loc_dei_EntityRegistrantName_fab37151-c5fd-4ce0-ad60-fa88a093da97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_9e973d76-fdc2-45b2-bafd-f047d4f3c1d4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_084e56bf-a6ec-4b6b-a0aa-57625789e34f" xlink:to="loc_dei_EntityCentralIndexKey_9e973d76-fdc2-45b2-bafd-f047d4f3c1d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_66cc267c-c181-4540-93dc-dc5ed6f9c6e2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_084e56bf-a6ec-4b6b-a0aa-57625789e34f" xlink:to="loc_dei_CurrentFiscalYearEndDate_66cc267c-c181-4540-93dc-dc5ed6f9c6e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_339c8d0c-2ec4-4246-aae6-0fdc6b6cc793" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_084e56bf-a6ec-4b6b-a0aa-57625789e34f" xlink:to="loc_dei_DocumentFiscalYearFocus_339c8d0c-2ec4-4246-aae6-0fdc6b6cc793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_0bf91ede-94fc-4305-ad8e-53a3fb1e7bee" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_084e56bf-a6ec-4b6b-a0aa-57625789e34f" xlink:to="loc_dei_DocumentFiscalPeriodFocus_0bf91ede-94fc-4305-ad8e-53a3fb1e7bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_00b25582-2bd0-469f-9703-30415832a956" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_084e56bf-a6ec-4b6b-a0aa-57625789e34f" xlink:to="loc_dei_AmendmentFlag_00b25582-2bd0-469f-9703-30415832a956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_48f2ab75-88bc-4f16-acb0-4cc99e269127" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_084e56bf-a6ec-4b6b-a0aa-57625789e34f" xlink:to="loc_dei_EntityIncorporationStateCountryCode_48f2ab75-88bc-4f16-acb0-4cc99e269127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_7d50fba0-d9ba-4d14-b607-e1844960bbe5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_084e56bf-a6ec-4b6b-a0aa-57625789e34f" xlink:to="loc_dei_EntityTaxIdentificationNumber_7d50fba0-d9ba-4d14-b607-e1844960bbe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_70fe9040-13f4-4005-9a1d-be60778d9c27" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_084e56bf-a6ec-4b6b-a0aa-57625789e34f" xlink:to="loc_dei_EntityAddressAddressLine1_70fe9040-13f4-4005-9a1d-be60778d9c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_e99abaac-547d-4d20-9c98-6111152dd3a0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_084e56bf-a6ec-4b6b-a0aa-57625789e34f" xlink:to="loc_dei_EntityAddressCityOrTown_e99abaac-547d-4d20-9c98-6111152dd3a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_c43a45c1-7f7b-4cfa-ad39-a241f5e89280" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_084e56bf-a6ec-4b6b-a0aa-57625789e34f" xlink:to="loc_dei_EntityAddressStateOrProvince_c43a45c1-7f7b-4cfa-ad39-a241f5e89280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_164fd0e1-0594-47a6-bace-c73902e66442" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_084e56bf-a6ec-4b6b-a0aa-57625789e34f" xlink:to="loc_dei_EntityAddressPostalZipCode_164fd0e1-0594-47a6-bace-c73902e66442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_14ecd2be-4cab-4b24-901a-485596ec2b8f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_084e56bf-a6ec-4b6b-a0aa-57625789e34f" xlink:to="loc_dei_CityAreaCode_14ecd2be-4cab-4b24-901a-485596ec2b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_ab14ac3f-5b88-4458-8704-8167949879ad" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_084e56bf-a6ec-4b6b-a0aa-57625789e34f" xlink:to="loc_dei_LocalPhoneNumber_ab14ac3f-5b88-4458-8704-8167949879ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_5b12d64d-eb05-49b2-8e9a-72859ab31086" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_084e56bf-a6ec-4b6b-a0aa-57625789e34f" xlink:to="loc_dei_Security12bTitle_5b12d64d-eb05-49b2-8e9a-72859ab31086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_28480cec-15cf-4316-85b7-d324f3bfff34" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_084e56bf-a6ec-4b6b-a0aa-57625789e34f" xlink:to="loc_dei_TradingSymbol_28480cec-15cf-4316-85b7-d324f3bfff34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_c88f8881-3222-4a43-8d11-f58b8f05010f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_084e56bf-a6ec-4b6b-a0aa-57625789e34f" xlink:to="loc_dei_SecurityExchangeName_c88f8881-3222-4a43-8d11-f58b8f05010f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_8f893e94-5a64-465e-82e2-391a17fc8790" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_084e56bf-a6ec-4b6b-a0aa-57625789e34f" xlink:to="loc_dei_EntityCurrentReportingStatus_8f893e94-5a64-465e-82e2-391a17fc8790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_7b9a0d2d-6d61-4101-a4bf-63a82f086e41" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_084e56bf-a6ec-4b6b-a0aa-57625789e34f" xlink:to="loc_dei_EntityInteractiveDataCurrent_7b9a0d2d-6d61-4101-a4bf-63a82f086e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_f0e8a24f-42aa-426e-bf46-7de83eb2b666" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_084e56bf-a6ec-4b6b-a0aa-57625789e34f" xlink:to="loc_dei_EntityFilerCategory_f0e8a24f-42aa-426e-bf46-7de83eb2b666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_237381e0-b929-42dd-9a71-bf185377e8f3" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_084e56bf-a6ec-4b6b-a0aa-57625789e34f" xlink:to="loc_dei_EntitySmallBusiness_237381e0-b929-42dd-9a71-bf185377e8f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_08a57a39-c0d2-4aa8-99ba-32fb98411457" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_084e56bf-a6ec-4b6b-a0aa-57625789e34f" xlink:to="loc_dei_EntityEmergingGrowthCompany_08a57a39-c0d2-4aa8-99ba-32fb98411457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_731566cd-7d21-46ec-8d21-8a6dbb142c8a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_084e56bf-a6ec-4b6b-a0aa-57625789e34f" xlink:to="loc_dei_EntityShellCompany_731566cd-7d21-46ec-8d21-8a6dbb142c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_4f3da38d-c3b8-4083-b517-36934dcb8340" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_084e56bf-a6ec-4b6b-a0aa-57625789e34f" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_4f3da38d-c3b8-4083-b517-36934dcb8340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" xlink:type="simple" xlink:href="cah-20210331.xsd#CondensedConsolidatedStatementsofEarnings"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_cc78201c-cdc8-4683-b213-92a10ccba059" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_9636956d-aa9e-4bfe-8a66-da785bb9a260" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cc78201c-cdc8-4683-b213-92a10ccba059" xlink:to="loc_us-gaap_Revenues_9636956d-aa9e-4bfe-8a66-da785bb9a260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_3c1d4768-9ec0-4539-bb43-94ba88d7921f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cc78201c-cdc8-4683-b213-92a10ccba059" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_3c1d4768-9ec0-4539-bb43-94ba88d7921f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_32ddb906-fe53-465e-902d-a3603277ae5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cc78201c-cdc8-4683-b213-92a10ccba059" xlink:to="loc_us-gaap_GrossProfit_32ddb906-fe53-465e-902d-a3603277ae5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_8141371d-cb07-40a8-9413-03660486b8e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cc78201c-cdc8-4683-b213-92a10ccba059" xlink:to="loc_us-gaap_OperatingExpensesAbstract_8141371d-cb07-40a8-9413-03660486b8e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2f680a47-34cd-4506-9bd0-ac0bdb7e210b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8141371d-cb07-40a8-9413-03660486b8e7" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_2f680a47-34cd-4506-9bd0-ac0bdb7e210b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_03ad4fc5-a0b5-4dd1-afe3-3f15d2943b51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8141371d-cb07-40a8-9413-03660486b8e7" xlink:to="loc_us-gaap_RestructuringCharges_03ad4fc5-a0b5-4dd1-afe3-3f15d2943b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Amortizationandotheracquisitionrelatedcosts_cc5bbd27-775d-4718-aaac-169087750009" xlink:href="cah-20210331.xsd#cah_Amortizationandotheracquisitionrelatedcosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8141371d-cb07-40a8-9413-03660486b8e7" xlink:to="loc_cah_Amortizationandotheracquisitionrelatedcosts_cc5bbd27-775d-4718-aaac-169087750009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_f5cce15b-b54e-4a6e-b5f9-2ff5385567e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8141371d-cb07-40a8-9413-03660486b8e7" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_f5cce15b-b54e-4a6e-b5f9-2ff5385567e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_f6cd0d55-cc3d-4a2b-b0bd-384cf9bcf297" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8141371d-cb07-40a8-9413-03660486b8e7" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_f6cd0d55-cc3d-4a2b-b0bd-384cf9bcf297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_183404de-76ab-4270-8e61-d6b22c6a5a87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cc78201c-cdc8-4683-b213-92a10ccba059" xlink:to="loc_us-gaap_OperatingIncomeLoss_183404de-76ab-4270-8e61-d6b22c6a5a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_219bf48b-cc19-410a-9534-d1bb50d61179" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cc78201c-cdc8-4683-b213-92a10ccba059" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_219bf48b-cc19-410a-9534-d1bb50d61179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_6101642c-fcca-41f0-a312-f0b8799741a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cc78201c-cdc8-4683-b213-92a10ccba059" xlink:to="loc_us-gaap_InterestExpense_6101642c-fcca-41f0-a312-f0b8799741a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_b898d2bf-54f9-4bc9-bfe1-1496e4c4b33a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cc78201c-cdc8-4683-b213-92a10ccba059" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_b898d2bf-54f9-4bc9-bfe1-1496e4c4b33a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2383f569-1f36-4720-b7ec-88daaa1d71dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cc78201c-cdc8-4683-b213-92a10ccba059" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2383f569-1f36-4720-b7ec-88daaa1d71dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_33b91173-5c1d-4c69-8002-8d60acde355b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cc78201c-cdc8-4683-b213-92a10ccba059" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_33b91173-5c1d-4c69-8002-8d60acde355b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_53fef6e8-cf42-411a-87ac-ce5177cfcc69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cc78201c-cdc8-4683-b213-92a10ccba059" xlink:to="loc_us-gaap_ProfitLoss_53fef6e8-cf42-411a-87ac-ce5177cfcc69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d3fc44a0-3ae6-4af4-9523-b0489b8e741e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cc78201c-cdc8-4683-b213-92a10ccba059" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d3fc44a0-3ae6-4af4-9523-b0489b8e741e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_692a9267-0038-49a8-a8ba-22fb1a5864a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cc78201c-cdc8-4683-b213-92a10ccba059" xlink:to="loc_us-gaap_NetIncomeLoss_692a9267-0038-49a8-a8ba-22fb1a5864a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_a9cb7763-c9be-45db-91fb-c225d7982515" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cc78201c-cdc8-4683-b213-92a10ccba059" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_a9cb7763-c9be-45db-91fb-c225d7982515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_92743a50-2c8e-499e-922e-1eb61f2fd267" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_a9cb7763-c9be-45db-91fb-c225d7982515" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_92743a50-2c8e-499e-922e-1eb61f2fd267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_3d0b090c-0594-4f1a-be85-276ede737a86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_a9cb7763-c9be-45db-91fb-c225d7982515" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_3d0b090c-0594-4f1a-be85-276ede737a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_58c92add-56dc-4e57-898c-c480833a7da7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cc78201c-cdc8-4683-b213-92a10ccba059" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_58c92add-56dc-4e57-898c-c480833a7da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_0fd2ad7f-7df5-4066-8561-6bfe941657ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cc78201c-cdc8-4683-b213-92a10ccba059" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_0fd2ad7f-7df5-4066-8561-6bfe941657ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_690d28a9-a171-486e-898e-2a1e3b48ff6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_0fd2ad7f-7df5-4066-8561-6bfe941657ec" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_690d28a9-a171-486e-898e-2a1e3b48ff6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a788e2d9-ba7a-46ac-8e1b-2c1bc2e174d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_0fd2ad7f-7df5-4066-8561-6bfe941657ec" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a788e2d9-ba7a-46ac-8e1b-2c1bc2e174d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_0b9f9160-e46e-4569-baed-dcb46346dcc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cc78201c-cdc8-4683-b213-92a10ccba059" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_0b9f9160-e46e-4569-baed-dcb46346dcc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="cah-20210331.xsd#CondensedConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9fd0652b-6d17-41c3-96b6-6a8149de2256" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_68d421dc-f2c4-4640-989f-e621268b7b77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9fd0652b-6d17-41c3-96b6-6a8149de2256" xlink:to="loc_us-gaap_ProfitLoss_68d421dc-f2c4-4640-989f-e621268b7b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_3cd03f21-48b3-4c22-94bc-1bf248ea1ac3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9fd0652b-6d17-41c3-96b6-6a8149de2256" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_3cd03f21-48b3-4c22-94bc-1bf248ea1ac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_95caec9b-9ea6-4df1-9fef-d66a097f8bc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_3cd03f21-48b3-4c22-94bc-1bf248ea1ac3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_95caec9b-9ea6-4df1-9fef-d66a097f8bc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_30d5885d-0089-49a2-a857-6fadad090781" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_3cd03f21-48b3-4c22-94bc-1bf248ea1ac3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax_30d5885d-0089-49a2-a857-6fadad090781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6089511c-3e6a-4875-b5c6-67d7415268f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_3cd03f21-48b3-4c22-94bc-1bf248ea1ac3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6089511c-3e6a-4875-b5c6-67d7415268f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_01ca3686-1e31-4fba-bbb1-1a8e5626efde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9fd0652b-6d17-41c3-96b6-6a8149de2256" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_01ca3686-1e31-4fba-bbb1-1a8e5626efde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_19c4a38a-d309-475a-9beb-15ae49524e03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9fd0652b-6d17-41c3-96b6-6a8149de2256" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_19c4a38a-d309-475a-9beb-15ae49524e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_3e25800c-401a-442a-a20b-401314c3f2ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9fd0652b-6d17-41c3-96b6-6a8149de2256" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_3e25800c-401a-442a-a20b-401314c3f2ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="cah-20210331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_d280f439-e3c9-4f8b-9139-f147643a3f83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_0c4846d5-2f10-4229-b526-31195a5c92ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d280f439-e3c9-4f8b-9139-f147643a3f83" xlink:to="loc_us-gaap_AssetsAbstract_0c4846d5-2f10-4229-b526-31195a5c92ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1eb8e640-8823-4ac5-9d1f-6b4e2296178c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0c4846d5-2f10-4229-b526-31195a5c92ba" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1eb8e640-8823-4ac5-9d1f-6b4e2296178c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32232f2c-0123-41c7-9b30-ba8b49e5b402" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1eb8e640-8823-4ac5-9d1f-6b4e2296178c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32232f2c-0123-41c7-9b30-ba8b49e5b402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_b4c282fc-096a-4a77-bd24-9131e0bbb45f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1eb8e640-8823-4ac5-9d1f-6b4e2296178c" xlink:to="loc_us-gaap_ReceivablesNetCurrent_b4c282fc-096a-4a77-bd24-9131e0bbb45f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_cd40f9ff-f996-4d37-aa8b-60e79caa0045" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1eb8e640-8823-4ac5-9d1f-6b4e2296178c" xlink:to="loc_us-gaap_InventoryNet_cd40f9ff-f996-4d37-aa8b-60e79caa0045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_14169fb0-3963-48f6-9062-be92dfde8816" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1eb8e640-8823-4ac5-9d1f-6b4e2296178c" xlink:to="loc_us-gaap_OtherAssetsCurrent_14169fb0-3963-48f6-9062-be92dfde8816" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_4b3d9766-a11d-44a3-a154-2f21f31beec3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1eb8e640-8823-4ac5-9d1f-6b4e2296178c" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_4b3d9766-a11d-44a3-a154-2f21f31beec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_00bb3193-9813-4e53-9db4-6785e287cd0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1eb8e640-8823-4ac5-9d1f-6b4e2296178c" xlink:to="loc_us-gaap_AssetsCurrent_00bb3193-9813-4e53-9db4-6785e287cd0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2b97f76c-cb5b-41d4-89fa-0ceff8c2f88c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0c4846d5-2f10-4229-b526-31195a5c92ba" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2b97f76c-cb5b-41d4-89fa-0ceff8c2f88c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_1603aab5-2a6f-4f07-a4f2-366f026af655" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0c4846d5-2f10-4229-b526-31195a5c92ba" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_1603aab5-2a6f-4f07-a4f2-366f026af655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_57806cb3-e9a3-48ae-b5cd-3724be59e576" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0c4846d5-2f10-4229-b526-31195a5c92ba" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_57806cb3-e9a3-48ae-b5cd-3724be59e576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0dc6887c-8b8f-434f-95e8-206caadd0e06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0c4846d5-2f10-4229-b526-31195a5c92ba" xlink:to="loc_us-gaap_Assets_0dc6887c-8b8f-434f-95e8-206caadd0e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2f3a7e49-984a-45b5-8c1f-8d842f4d08c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d280f439-e3c9-4f8b-9139-f147643a3f83" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2f3a7e49-984a-45b5-8c1f-8d842f4d08c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_65c2f870-54f1-4b71-b3eb-1d3468e73092" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2f3a7e49-984a-45b5-8c1f-8d842f4d08c1" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_65c2f870-54f1-4b71-b3eb-1d3468e73092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_7b5fa7ad-66ff-46df-a4d8-d1273d25fae6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_65c2f870-54f1-4b71-b3eb-1d3468e73092" xlink:to="loc_us-gaap_AccountsPayableCurrent_7b5fa7ad-66ff-46df-a4d8-d1273d25fae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_5caf955c-2d85-4dd4-86cb-2e53ec62f3d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_65c2f870-54f1-4b71-b3eb-1d3468e73092" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_5caf955c-2d85-4dd4-86cb-2e53ec62f3d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_6e545734-963b-49c6-9299-fcc901d67fe0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_65c2f870-54f1-4b71-b3eb-1d3468e73092" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_6e545734-963b-49c6-9299-fcc901d67fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_3d841334-73f0-4a4a-86d4-0d1c681cad8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_65c2f870-54f1-4b71-b3eb-1d3468e73092" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_3d841334-73f0-4a4a-86d4-0d1c681cad8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5d05ec0b-188b-45a1-a41c-3dafbf2d37b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_65c2f870-54f1-4b71-b3eb-1d3468e73092" xlink:to="loc_us-gaap_LiabilitiesCurrent_5d05ec0b-188b-45a1-a41c-3dafbf2d37b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_8782dfd5-9950-4329-a811-a39afc4e32f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2f3a7e49-984a-45b5-8c1f-8d842f4d08c1" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_8782dfd5-9950-4329-a811-a39afc4e32f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_d43f2a15-208b-4ac5-ac99-7c62e929a9e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2f3a7e49-984a-45b5-8c1f-8d842f4d08c1" xlink:to="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_d43f2a15-208b-4ac5-ac99-7c62e929a9e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_da97d3cc-2502-47a6-acf1-d6e902d06db6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2f3a7e49-984a-45b5-8c1f-8d842f4d08c1" xlink:to="loc_us-gaap_StockholdersEquityAbstract_da97d3cc-2502-47a6-acf1-d6e902d06db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_eda51173-7e8e-4c38-b558-e4703a684d90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_da97d3cc-2502-47a6-acf1-d6e902d06db6" xlink:to="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_eda51173-7e8e-4c38-b558-e4703a684d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_a0a46ab2-1770-4743-9216-7a169403af64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_eda51173-7e8e-4c38-b558-e4703a684d90" xlink:to="loc_us-gaap_PreferredStockValue_a0a46ab2-1770-4743-9216-7a169403af64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_e0b753e8-2668-4dc5-abd0-76ad187c124e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_da97d3cc-2502-47a6-acf1-d6e902d06db6" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_e0b753e8-2668-4dc5-abd0-76ad187c124e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_5dfa010f-31bf-4d6b-8282-8e15d764eb7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_e0b753e8-2668-4dc5-abd0-76ad187c124e" xlink:to="loc_us-gaap_CommonStockValue_5dfa010f-31bf-4d6b-8282-8e15d764eb7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ea3577d5-130a-4a44-9b11-f031d5bb335c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_da97d3cc-2502-47a6-acf1-d6e902d06db6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ea3577d5-130a-4a44-9b11-f031d5bb335c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_82840bdc-89ff-451a-b225-aae66f494c96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_da97d3cc-2502-47a6-acf1-d6e902d06db6" xlink:to="loc_us-gaap_TreasuryStockValue_82840bdc-89ff-451a-b225-aae66f494c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_709b1a55-69a8-43d7-9467-aae33fcda7b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_da97d3cc-2502-47a6-acf1-d6e902d06db6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_709b1a55-69a8-43d7-9467-aae33fcda7b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c0717fc2-8129-43fe-9dac-6eed59f67869" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_da97d3cc-2502-47a6-acf1-d6e902d06db6" xlink:to="loc_us-gaap_StockholdersEquity_c0717fc2-8129-43fe-9dac-6eed59f67869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_2e7b10b5-3a20-400a-8598-f58f62f53a3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_da97d3cc-2502-47a6-acf1-d6e902d06db6" xlink:to="loc_us-gaap_MinorityInterest_2e7b10b5-3a20-400a-8598-f58f62f53a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6d1b9cb3-0143-45b2-8502-54825b6ed8ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_da97d3cc-2502-47a6-acf1-d6e902d06db6" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6d1b9cb3-0143-45b2-8502-54825b6ed8ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_cce623c5-5123-48d7-bab2-37942618129b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2f3a7e49-984a-45b5-8c1f-8d842f4d08c1" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_cce623c5-5123-48d7-bab2-37942618129b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_57538a4d-1716-4257-925b-e9e8ebf377f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d280f439-e3c9-4f8b-9139-f147643a3f83" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_57538a4d-1716-4257-925b-e9e8ebf377f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_723f48ce-9626-4c10-be50-f61e0b6faca4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d280f439-e3c9-4f8b-9139-f147643a3f83" xlink:to="loc_us-gaap_PreferredStockSharesIssued_723f48ce-9626-4c10-be50-f61e0b6faca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_e3626a4d-4059-47ac-8e66-4deb64705665" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d280f439-e3c9-4f8b-9139-f147643a3f83" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_e3626a4d-4059-47ac-8e66-4deb64705665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_8a2e1c0e-68de-46c5-aa04-9a276ba19515" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d280f439-e3c9-4f8b-9139-f147643a3f83" xlink:to="loc_us-gaap_CommonStockSharesIssued_8a2e1c0e-68de-46c5-aa04-9a276ba19515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_abd4b50b-fcbb-4654-ac75-f7e8de85a9c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d280f439-e3c9-4f8b-9139-f147643a3f83" xlink:to="loc_us-gaap_TreasuryStockShares_abd4b50b-fcbb-4654-ac75-f7e8de85a9c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="cah-20210331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_ed0faed9-859a-4fc1-a721-f30c46c7a2b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2e06a17c-5ebd-4c55-be18-65f788871744" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ed0faed9-859a-4fc1-a721-f30c46c7a2b9" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2e06a17c-5ebd-4c55-be18-65f788871744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_e13dfad6-5dce-4d1a-893c-8c643121ba3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ed0faed9-859a-4fc1-a721-f30c46c7a2b9" xlink:to="loc_us-gaap_PreferredStockSharesIssued_e13dfad6-5dce-4d1a-893c-8c643121ba3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_732e9a60-7595-42a2-9694-df204d41b367" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ed0faed9-859a-4fc1-a721-f30c46c7a2b9" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_732e9a60-7595-42a2-9694-df204d41b367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_50dfa975-c885-4d5d-a05b-3fb1894317dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ed0faed9-859a-4fc1-a721-f30c46c7a2b9" xlink:to="loc_us-gaap_CommonStockSharesIssued_50dfa975-c885-4d5d-a05b-3fb1894317dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_60d6bc10-2bbc-40e3-b668-1f198e1d205a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ed0faed9-859a-4fc1-a721-f30c46c7a2b9" xlink:to="loc_us-gaap_TreasuryStockShares_60d6bc10-2bbc-40e3-b668-1f198e1d205a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="cah-20210331.xsd#CondensedConsolidatedStatementsofShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_6204ec85-5c10-4193-8e28-d6b26207ec68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d1ae6588-091c-41d9-86f2-6b4bacc3e607" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_6204ec85-5c10-4193-8e28-d6b26207ec68" xlink:to="loc_us-gaap_StatementTable_d1ae6588-091c-41d9-86f2-6b4bacc3e607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1dd759c9-479b-4415-b634-4572862c3645" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d1ae6588-091c-41d9-86f2-6b4bacc3e607" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1dd759c9-479b-4415-b634-4572862c3645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_49e176b4-4b76-4b7b-a4d6-2e0729cf23f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1dd759c9-479b-4415-b634-4572862c3645" xlink:to="loc_us-gaap_EquityComponentDomain_49e176b4-4b76-4b7b-a4d6-2e0729cf23f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5acc2cce-3ddf-4286-bd01-a6dcc3a242e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_49e176b4-4b76-4b7b-a4d6-2e0729cf23f7" xlink:to="loc_us-gaap_CommonStockMember_5acc2cce-3ddf-4286-bd01-a6dcc3a242e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_b4aa59b0-b702-4d82-9112-0b1c34648260" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_49e176b4-4b76-4b7b-a4d6-2e0729cf23f7" xlink:to="loc_us-gaap_RetainedEarningsMember_b4aa59b0-b702-4d82-9112-0b1c34648260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_0d778d73-0d07-45e2-9305-2cade3bed52f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_49e176b4-4b76-4b7b-a4d6-2e0729cf23f7" xlink:to="loc_us-gaap_TreasuryStockMember_0d778d73-0d07-45e2-9305-2cade3bed52f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_83f1f4a4-00c3-4a5c-959e-ebf5ccdd7cdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_49e176b4-4b76-4b7b-a4d6-2e0729cf23f7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_83f1f4a4-00c3-4a5c-959e-ebf5ccdd7cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_361c08a1-1d15-4f75-8873-4d1a41b43d4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_49e176b4-4b76-4b7b-a4d6-2e0729cf23f7" xlink:to="loc_us-gaap_NoncontrollingInterestMember_361c08a1-1d15-4f75-8873-4d1a41b43d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_dbf8a4b6-3350-402b-b4c6-1028f6fef940" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d1ae6588-091c-41d9-86f2-6b4bacc3e607" xlink:to="loc_us-gaap_StatementLineItems_dbf8a4b6-3350-402b-b4c6-1028f6fef940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_c167b80d-965d-4a99-b763-2a5b68275dc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dbf8a4b6-3350-402b-b4c6-1028f6fef940" xlink:to="loc_us-gaap_CommonStockSharesIssued_c167b80d-965d-4a99-b763-2a5b68275dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_beef5691-ce32-4ce3-9ed1-d92c29ca811f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dbf8a4b6-3350-402b-b4c6-1028f6fef940" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_beef5691-ce32-4ce3-9ed1-d92c29ca811f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_563158d3-82a7-42bb-8282-6b4ee4d23f92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dbf8a4b6-3350-402b-b4c6-1028f6fef940" xlink:to="loc_us-gaap_TreasuryStockShares_563158d3-82a7-42bb-8282-6b4ee4d23f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_62f76eed-e594-4c85-aa1f-71d54c1486a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dbf8a4b6-3350-402b-b4c6-1028f6fef940" xlink:to="loc_us-gaap_TreasuryStockValue_62f76eed-e594-4c85-aa1f-71d54c1486a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f9686a27-bc71-46a3-b134-1d50e19e1f45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dbf8a4b6-3350-402b-b4c6-1028f6fef940" xlink:to="loc_us-gaap_ProfitLoss_f9686a27-bc71-46a3-b134-1d50e19e1f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4b0f101f-aed9-41b4-aea5-8358bd422412" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dbf8a4b6-3350-402b-b4c6-1028f6fef940" xlink:to="loc_us-gaap_NetIncomeLoss_4b0f101f-aed9-41b4-aea5-8358bd422412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_30efd520-6fd1-48bb-92b4-98095de3636d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dbf8a4b6-3350-402b-b4c6-1028f6fef940" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_30efd520-6fd1-48bb-92b4-98095de3636d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6b12da8c-68c3-463a-a8d6-ba2890ecb110" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dbf8a4b6-3350-402b-b4c6-1028f6fef940" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6b12da8c-68c3-463a-a8d6-ba2890ecb110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0c2865cf-b44e-4835-b064-c58e7141fd6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dbf8a4b6-3350-402b-b4c6-1028f6fef940" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_0c2865cf-b44e-4835-b064-c58e7141fd6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_a6ffce9e-c5b2-4142-aa5a-815f03a1b731" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dbf8a4b6-3350-402b-b4c6-1028f6fef940" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_a6ffce9e-c5b2-4142-aa5a-815f03a1b731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_56d447fa-ba0e-43d6-af25-bab37bab556f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dbf8a4b6-3350-402b-b4c6-1028f6fef940" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_56d447fa-ba0e-43d6-af25-bab37bab556f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_5e07db3d-e1ff-4795-98bb-12c034917461" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dbf8a4b6-3350-402b-b4c6-1028f6fef940" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_5e07db3d-e1ff-4795-98bb-12c034917461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_a7491a7c-d64c-48f7-9107-2ef74cebf597" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Dividends"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dbf8a4b6-3350-402b-b4c6-1028f6fef940" xlink:to="loc_us-gaap_Dividends_a7491a7c-d64c-48f7-9107-2ef74cebf597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOtherShares_a4187946-0cea-48f7-b6cd-69acfbbfcb35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOtherShares"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dbf8a4b6-3350-402b-b4c6-1028f6fef940" xlink:to="loc_us-gaap_StockholdersEquityOtherShares_a4187946-0cea-48f7-b6cd-69acfbbfcb35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_da3b3f79-36a2-4e1e-939b-6ac18ec61ad7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dbf8a4b6-3350-402b-b4c6-1028f6fef940" xlink:to="loc_us-gaap_StockholdersEquityOther_da3b3f79-36a2-4e1e-939b-6ac18ec61ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_f255abd6-71fe-46ba-b6de-8b92cafbbf86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dbf8a4b6-3350-402b-b4c6-1028f6fef940" xlink:to="loc_us-gaap_CommonStockSharesIssued_f255abd6-71fe-46ba-b6de-8b92cafbbf86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1e7d2649-3daa-4927-a233-e2a195a708c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dbf8a4b6-3350-402b-b4c6-1028f6fef940" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1e7d2649-3daa-4927-a233-e2a195a708c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_22d42cf8-18bb-4c7a-96c3-3e63d7f57f4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dbf8a4b6-3350-402b-b4c6-1028f6fef940" xlink:to="loc_us-gaap_TreasuryStockShares_22d42cf8-18bb-4c7a-96c3-3e63d7f57f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_a2cbec8c-bf03-4b8e-a919-b5c0ad642af5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dbf8a4b6-3350-402b-b4c6-1028f6fef940" xlink:to="loc_us-gaap_TreasuryStockValue_a2cbec8c-bf03-4b8e-a919-b5c0ad642af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_d8a8c4a7-f93a-4daf-b97b-6f406e836334" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dbf8a4b6-3350-402b-b4c6-1028f6fef940" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_d8a8c4a7-f93a-4daf-b97b-6f406e836334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="cah-20210331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0a01e2aa-974c-468b-9bde-d41e4334bb92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d7bd27cf-46d0-47ab-bb7e-11c591cd2740" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0a01e2aa-974c-468b-9bde-d41e4334bb92" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d7bd27cf-46d0-47ab-bb7e-11c591cd2740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7dea0203-073d-4566-b84b-652d4c34bedc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d7bd27cf-46d0-47ab-bb7e-11c591cd2740" xlink:to="loc_us-gaap_ProfitLoss_7dea0203-073d-4566-b84b-652d4c34bedc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d08522df-f9b8-4ddd-b817-3ec81980fccf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d7bd27cf-46d0-47ab-bb7e-11c591cd2740" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d08522df-f9b8-4ddd-b817-3ec81980fccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_6bca8dee-c574-40a2-a530-af9a35a483fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d08522df-f9b8-4ddd-b817-3ec81980fccf" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_6bca8dee-c574-40a2-a530-af9a35a483fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_6be06cf2-c401-4877-a0e0-7099bf515ac2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d08522df-f9b8-4ddd-b817-3ec81980fccf" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_6be06cf2-c401-4877-a0e0-7099bf515ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6dbe1ded-6cba-4aac-887a-e3fbe6ee34cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d08522df-f9b8-4ddd-b817-3ec81980fccf" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_6dbe1ded-6cba-4aac-887a-e3fbe6ee34cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_c59ba186-d0ba-4cf2-8371-b335f4878ea5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d08522df-f9b8-4ddd-b817-3ec81980fccf" xlink:to="loc_us-gaap_ShareBasedCompensation_c59ba186-d0ba-4cf2-8371-b335f4878ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_fc478351-6d68-489b-b83a-6981f4a3823f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d08522df-f9b8-4ddd-b817-3ec81980fccf" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_fc478351-6d68-489b-b83a-6981f4a3823f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_22d01691-d229-4b27-abd8-6349e431957a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d08522df-f9b8-4ddd-b817-3ec81980fccf" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_22d01691-d229-4b27-abd8-6349e431957a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_3bd7dc7c-9552-4594-b083-cd6da80b188d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_22d01691-d229-4b27-abd8-6349e431957a" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_3bd7dc7c-9552-4594-b083-cd6da80b188d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_f749f944-707a-445e-bdc2-c8a1d21d5ccc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_22d01691-d229-4b27-abd8-6349e431957a" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_f749f944-707a-445e-bdc2-c8a1d21d5ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_fc97b2fd-ecd6-4a28-9f26-3c6fef96ce8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_22d01691-d229-4b27-abd8-6349e431957a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_fc97b2fd-ecd6-4a28-9f26-3c6fef96ce8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_a6904d41-b626-4ed4-aef3-70b8c21f1157" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_22d01691-d229-4b27-abd8-6349e431957a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_a6904d41-b626-4ed4-aef3-70b8c21f1157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_17da7ded-aac8-4dc4-a6f3-9e8dfe0f8302" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d7bd27cf-46d0-47ab-bb7e-11c591cd2740" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_17da7ded-aac8-4dc4-a6f3-9e8dfe0f8302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7a79aef9-d8f1-4a30-a3e3-606c30eadc5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0a01e2aa-974c-468b-9bde-d41e4334bb92" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7a79aef9-d8f1-4a30-a3e3-606c30eadc5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_527dfc1b-763a-4a11-8d7f-c6e41516050c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7a79aef9-d8f1-4a30-a3e3-606c30eadc5b" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_527dfc1b-763a-4a11-8d7f-c6e41516050c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ca166c9f-3a9f-4ee6-b02b-ac8cab540a37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7a79aef9-d8f1-4a30-a3e3-606c30eadc5b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ca166c9f-3a9f-4ee6-b02b-ac8cab540a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_685bd0e9-fdcd-4211-8ec7-fb26cd7e5d54" xlink:href="cah-20210331.xsd#cah_Purchaseofavailableforsalesecuritiesandotherinvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7a79aef9-d8f1-4a30-a3e3-606c30eadc5b" xlink:to="loc_cah_Purchaseofavailableforsalesecuritiesandotherinvestments_685bd0e9-fdcd-4211-8ec7-fb26cd7e5d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_e4717555-ac21-44e6-a87e-ec0d7923727c" xlink:href="cah-20210331.xsd#cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7a79aef9-d8f1-4a30-a3e3-606c30eadc5b" xlink:to="loc_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments_e4717555-ac21-44e6-a87e-ec0d7923727c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets_dfabdbf6-4fc7-466d-a50f-a16ba06855a6" xlink:href="cah-20210331.xsd#cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7a79aef9-d8f1-4a30-a3e3-606c30eadc5b" xlink:to="loc_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets_dfabdbf6-4fc7-466d-a50f-a16ba06855a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_220b9bef-c69a-42aa-9b8a-da87bea26d35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7a79aef9-d8f1-4a30-a3e3-606c30eadc5b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_220b9bef-c69a-42aa-9b8a-da87bea26d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0f0581fd-6009-4e85-8ca9-53bd65824455" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0a01e2aa-974c-468b-9bde-d41e4334bb92" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0f0581fd-6009-4e85-8ca9-53bd65824455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_6035548e-d94a-4290-b094-393b6e959225" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0f0581fd-6009-4e85-8ca9-53bd65824455" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebt_6035548e-d94a-4290-b094-393b6e959225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromHedgeFinancingActivities_73978357-a3bd-465b-8ec2-f4629a58e341" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromHedgeFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0f0581fd-6009-4e85-8ca9-53bd65824455" xlink:to="loc_us-gaap_PaymentsForProceedsFromHedgeFinancingActivities_73978357-a3bd-465b-8ec2-f4629a58e341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_a66be87a-7515-4091-94ed-d9fd9a9b3167" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0f0581fd-6009-4e85-8ca9-53bd65824455" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_a66be87a-7515-4091-94ed-d9fd9a9b3167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_46dd3bc9-15a8-470f-9ae9-fb450c6b0bf8" xlink:href="cah-20210331.xsd#cah_Netproceedstaxwithholdingsfromsharebasedcompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0f0581fd-6009-4e85-8ca9-53bd65824455" xlink:to="loc_cah_Netproceedstaxwithholdingsfromsharebasedcompensation_46dd3bc9-15a8-470f-9ae9-fb450c6b0bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_23d14509-404c-4fce-86b1-b08697933c0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0f0581fd-6009-4e85-8ca9-53bd65824455" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_23d14509-404c-4fce-86b1-b08697933c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_dc9c336c-104e-465d-8331-758900563cdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0f0581fd-6009-4e85-8ca9-53bd65824455" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_dc9c336c-104e-465d-8331-758900563cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3cd1e30b-4ae8-4656-8b51-42294daf0421" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0f0581fd-6009-4e85-8ca9-53bd65824455" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3cd1e30b-4ae8-4656-8b51-42294daf0421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_de7433d0-2b82-4f5c-9bd9-5216adabe0f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0a01e2aa-974c-468b-9bde-d41e4334bb92" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_de7433d0-2b82-4f5c-9bd9-5216adabe0f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CashReclassifiedToAssetHeldForSale_9442df22-0201-45c6-9432-38d2c946e188" xlink:href="cah-20210331.xsd#cah_CashReclassifiedToAssetHeldForSale"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0a01e2aa-974c-468b-9bde-d41e4334bb92" xlink:to="loc_cah_CashReclassifiedToAssetHeldForSale_9442df22-0201-45c6-9432-38d2c946e188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9aba9510-4ce6-4804-b4af-fbc3656644e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0a01e2aa-974c-468b-9bde-d41e4334bb92" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9aba9510-4ce6-4804-b4af-fbc3656644e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_eab20a59-0951-4c3a-894a-5d4e752c5ca2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0a01e2aa-974c-468b-9bde-d41e4334bb92" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_eab20a59-0951-4c3a-894a-5d4e752c5ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6406e3be-2c29-4988-add8-caa1a34f9fe2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0a01e2aa-974c-468b-9bde-d41e4334bb92" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6406e3be-2c29-4988-add8-caa1a34f9fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="cah-20210331.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b6fecc27-5475-47c7-ad7a-d3dc2fc7b53d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_e56ad8ac-eed2-4a1e-a94f-2fa69388bf7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b6fecc27-5475-47c7-ad7a-d3dc2fc7b53d" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_e56ad8ac-eed2-4a1e-a94f-2fa69388bf7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="cah-20210331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6f31bc1e-37e2-49b9-a8fc-4dcb2e0430e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c7823b11-8464-4c28-a087-c834936b1a02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6f31bc1e-37e2-49b9-a8fc-4dcb2e0430e7" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c7823b11-8464-4c28-a087-c834936b1a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_168a0a70-7a9e-486c-aa4f-69665599f7dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6f31bc1e-37e2-49b9-a8fc-4dcb2e0430e7" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_168a0a70-7a9e-486c-aa4f-69665599f7dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeRecentFinancialAccountingStandardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b0b4b83e-a332-4665-9335-f1457ccf434f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/Assetsheldforsale" xlink:type="simple" xlink:href="cah-20210331.xsd#Assetsheldforsale"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/Assetsheldforsale" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_fa7be860-d9ab-4a75-b620-863d6a550070" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_0cd1098e-e7bb-42c3-b8d1-41dcab525b98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_fa7be860-d9ab-4a75-b620-863d6a550070" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_0cd1098e-e7bb-42c3-b8d1-41dcab525b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsTables" xlink:type="simple" xlink:href="cah-20210331.xsd#DiscontinuedOperationsandDisposalGroupsTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_5102249f-036c-4c63-a8fc-4285c2198baf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_1eb2fc56-c538-427e-9c2c-d56269487690" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_5102249f-036c-4c63-a8fc-4285c2198baf" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_1eb2fc56-c538-427e-9c2c-d56269487690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#DiscontinuedOperationsandDisposalGroupsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_7ac83ade-7694-4294-823e-837de5ec22e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_efc8b54d-fa4f-4a22-80e8-e337d7f0408b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_7ac83ade-7694-4294-823e-837de5ec22e9" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_efc8b54d-fa4f-4a22-80e8-e337d7f0408b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4cb1215b-3190-49eb-aa71-4caf1fc5abf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_efc8b54d-fa4f-4a22-80e8-e337d7f0408b" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4cb1215b-3190-49eb-aa71-4caf1fc5abf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_475346ca-736e-47ee-8a3d-07a193addb7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_4cb1215b-3190-49eb-aa71-4caf1fc5abf2" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_475346ca-736e-47ee-8a3d-07a193addb7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_19326386-0eb3-4647-b90e-dd4d8e1e1055" xlink:href="cah-20210331.xsd#cah_CordisDivestitureAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_efc8b54d-fa4f-4a22-80e8-e337d7f0408b" xlink:to="loc_cah_CordisDivestitureAxis_19326386-0eb3-4647-b90e-dd4d8e1e1055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_7933dd2c-c89e-432c-8967-231436da77ed" xlink:href="cah-20210331.xsd#cah_CordisDivestitureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureAxis_19326386-0eb3-4647-b90e-dd4d8e1e1055" xlink:to="loc_cah_CordisDivestitureDomain_7933dd2c-c89e-432c-8967-231436da77ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_19295a9d-fc92-4990-96dd-f489a836f8c9" xlink:href="cah-20210331.xsd#cah_CordisDivestitureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureDomain_7933dd2c-c89e-432c-8967-231436da77ed" xlink:to="loc_cah_CordisDivestitureMember_19295a9d-fc92-4990-96dd-f489a836f8c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e4b3b01e-cf5a-4080-9666-736aa91c63fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_efc8b54d-fa4f-4a22-80e8-e337d7f0408b" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e4b3b01e-cf5a-4080-9666-736aa91c63fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_9da44bdd-9007-4a96-8af3-fbd02384d620" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e4b3b01e-cf5a-4080-9666-736aa91c63fc" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_9da44bdd-9007-4a96-8af3-fbd02384d620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_b5d564e3-00b6-429f-9f84-cd8646f9cc07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e4b3b01e-cf5a-4080-9666-736aa91c63fc" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1_b5d564e3-00b6-429f-9f84-cd8646f9cc07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_3b025337-5bd6-4cc9-83d6-88b1692e0a45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e4b3b01e-cf5a-4080-9666-736aa91c63fc" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_3b025337-5bd6-4cc9-83d6-88b1692e0a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DisposalGroupIncludingDiscontinuedOperationGoodwillAndOtherIntangiblesNet_035a7a6c-b7e2-45f6-bf25-08210dc48b76" xlink:href="cah-20210331.xsd#cah_DisposalGroupIncludingDiscontinuedOperationGoodwillAndOtherIntangiblesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e4b3b01e-cf5a-4080-9666-736aa91c63fc" xlink:to="loc_cah_DisposalGroupIncludingDiscontinuedOperationGoodwillAndOtherIntangiblesNet_035a7a6c-b7e2-45f6-bf25-08210dc48b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_82ebad87-8f33-45f1-9456-1fdde68b9758" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e4b3b01e-cf5a-4080-9666-736aa91c63fc" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_82ebad87-8f33-45f1-9456-1fdde68b9758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_WriteDownOfAssetsHeldForSale_2d2ba27c-c0aa-424b-bb1c-2d24bee75572" xlink:href="cah-20210331.xsd#cah_WriteDownOfAssetsHeldForSale"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e4b3b01e-cf5a-4080-9666-736aa91c63fc" xlink:to="loc_cah_WriteDownOfAssetsHeldForSale_2d2ba27c-c0aa-424b-bb1c-2d24bee75572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_b6009a8b-ab85-4e01-9c9d-8e61447d3718" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e4b3b01e-cf5a-4080-9666-736aa91c63fc" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_b6009a8b-ab85-4e01-9c9d-8e61447d3718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_09cab8d6-ada0-448e-8ce2-9c6b0f8aa797" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e4b3b01e-cf5a-4080-9666-736aa91c63fc" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_09cab8d6-ada0-448e-8ce2-9c6b0f8aa797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_e88d7d97-830b-48a3-82c0-a1338f2dd6a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e4b3b01e-cf5a-4080-9666-736aa91c63fc" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent_e88d7d97-830b-48a3-82c0-a1338f2dd6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_096ee39a-5fd3-4a17-bba2-94385730bda9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e4b3b01e-cf5a-4080-9666-736aa91c63fc" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_096ee39a-5fd3-4a17-bba2-94385730bda9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses_4a4829ea-8912-4b71-8060-d6d1b04434ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e4b3b01e-cf5a-4080-9666-736aa91c63fc" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses_4a4829ea-8912-4b71-8060-d6d1b04434ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_1bf2135f-5e33-4d34-8eb7-78f23d058643" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e4b3b01e-cf5a-4080-9666-736aa91c63fc" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_1bf2135f-5e33-4d34-8eb7-78f23d058643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_cc270032-912a-4af2-ac8a-ab47438b9b49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e4b3b01e-cf5a-4080-9666-736aa91c63fc" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_cc270032-912a-4af2-ac8a-ab47438b9b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_883eca56-9d0f-42c4-955b-faf3fc9aacc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e4b3b01e-cf5a-4080-9666-736aa91c63fc" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_883eca56-9d0f-42c4-955b-faf3fc9aacc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeverance" xlink:type="simple" xlink:href="cah-20210331.xsd#RestructuringandEmployeeSeverance"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeverance" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract_0c7dc706-e94d-45f7-bb1e-c0452fb9dbb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_67c1e08a-783b-442e-b827-cbc7f0782bac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_0c7dc706-e94d-45f7-bb1e-c0452fb9dbb7" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_67c1e08a-783b-442e-b827-cbc7f0782bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables" xlink:type="simple" xlink:href="cah-20210331.xsd#RestructuringandEmployeeSeveranceTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract_b209b53f-9540-45fd-8ca8-5c4c78dd72db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_baaa44af-8a84-473b-819a-cce7a73cbd10" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_b209b53f-9540-45fd-8ca8-5c4c78dd72db" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_baaa44af-8a84-473b-819a-cce7a73cbd10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_74c274e8-a6a9-4401-a09c-25e7af5809d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_b209b53f-9540-45fd-8ca8-5c4c78dd72db" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_74c274e8-a6a9-4401-a09c-25e7af5809d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract_1573e4c5-ef1e-4f8b-a405-045bd1c81294" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_f451d694-9365-4fdc-a5bc-f1c0a3c8aae2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_1573e4c5-ef1e-4f8b-a405-045bd1c81294" xlink:to="loc_us-gaap_SeveranceCosts1_f451d694-9365-4fdc-a5bc-f1c0a3c8aae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FacilityExitAndOtherCosts_1265a327-886b-4389-84e7-ff5a2fbed41a" xlink:href="cah-20210331.xsd#cah_FacilityExitAndOtherCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_1573e4c5-ef1e-4f8b-a405-045bd1c81294" xlink:to="loc_cah_FacilityExitAndOtherCosts_1265a327-886b-4389-84e7-ff5a2fbed41a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_fab6e1f4-d1b1-4621-b4f1-dcb317adef8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_1573e4c5-ef1e-4f8b-a405-045bd1c81294" xlink:to="loc_us-gaap_RestructuringCharges_fab6e1f4-d1b1-4621-b4f1-dcb317adef8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesAbstract_46accfaa-f809-4f3d-85ff-518d8a9b2acc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringChargesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_aebfba1b-2257-41db-9bed-dcfb6fc7ca0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_46accfaa-f809-4f3d-85ff-518d8a9b2acc" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_aebfba1b-2257-41db-9bed-dcfb6fc7ca0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_93a8785c-4ce0-4e65-a68c-2bf254e23c4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_aebfba1b-2257-41db-9bed-dcfb6fc7ca0d" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_93a8785c-4ce0-4e65-a68c-2bf254e23c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_cc452652-b0e1-4b86-a83a-46c796fb7ad5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_93a8785c-4ce0-4e65-a68c-2bf254e23c4a" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_cc452652-b0e1-4b86-a83a-46c796fb7ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_851f9271-4685-4948-af7c-cbbc1dca5705" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_cc452652-b0e1-4b86-a83a-46c796fb7ad5" xlink:to="loc_us-gaap_EmployeeSeveranceMember_851f9271-4685-4948-af7c-cbbc1dca5705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember_89bc9316-3970-41ca-8229-64bc8b2d9eaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FacilityClosingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_cc452652-b0e1-4b86-a83a-46c796fb7ad5" xlink:to="loc_us-gaap_FacilityClosingMember_89bc9316-3970-41ca-8229-64bc8b2d9eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_dd26959f-9a9b-4eb8-91c0-695fc3b1d084" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_aebfba1b-2257-41db-9bed-dcfb6fc7ca0d" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_dd26959f-9a9b-4eb8-91c0-695fc3b1d084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_3498a397-ef6d-4844-b9cf-e62502b6f8ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_dd26959f-9a9b-4eb8-91c0-695fc3b1d084" xlink:to="loc_us-gaap_RestructuringReserveRollForward_3498a397-ef6d-4844-b9cf-e62502b6f8ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_90301ac0-e034-4489-82b6-4dc6164cc018" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_3498a397-ef6d-4844-b9cf-e62502b6f8ae" xlink:to="loc_us-gaap_RestructuringReserve_90301ac0-e034-4489-82b6-4dc6164cc018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts_67f7915a-4e95-4c24-9350-3b5e2c41af93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_3498a397-ef6d-4844-b9cf-e62502b6f8ae" xlink:to="loc_us-gaap_RestructuringCosts_67f7915a-4e95-4c24-9350-3b5e2c41af93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_59d08818-ad40-4876-9b01-b9bd28e6811d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_3498a397-ef6d-4844-b9cf-e62502b6f8ae" xlink:to="loc_us-gaap_PaymentsForRestructuring_59d08818-ad40-4876-9b01-b9bd28e6811d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_3c8b6e40-d872-4ed4-8dbf-eb88a3911e88" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_3498a397-ef6d-4844-b9cf-e62502b6f8ae" xlink:to="loc_us-gaap_RestructuringReserve_3c8b6e40-d872-4ed4-8dbf-eb88a3911e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#RestructuringandEmployeeSeveranceNarativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cah_NarativeAbstract_40d4d472-d512-44c5-a817-c534b2a71b1f" xlink:href="cah-20210331.xsd#cah_NarativeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_37cbce92-f7d8-4ab5-8d89-6210a3fe6daa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_NarativeAbstract_40d4d472-d512-44c5-a817-c534b2a71b1f" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_37cbce92-f7d8-4ab5-8d89-6210a3fe6daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_3536a510-daa6-47cd-b89a-437089924315" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_37cbce92-f7d8-4ab5-8d89-6210a3fe6daa" xlink:to="loc_us-gaap_RestructuringPlanAxis_3536a510-daa6-47cd-b89a-437089924315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_7c7f9398-2c0b-4e79-b8d6-964bb9dc2f74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_3536a510-daa6-47cd-b89a-437089924315" xlink:to="loc_us-gaap_RestructuringPlanDomain_7c7f9398-2c0b-4e79-b8d6-964bb9dc2f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLocationAxis_7ee71570-32b3-4554-8360-d976a5924c24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_37cbce92-f7d8-4ab5-8d89-6210a3fe6daa" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLocationAxis_7ee71570-32b3-4554-8360-d976a5924c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLocationDomain_45827447-dd2e-44f3-82e4-e35a1f81f6a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLocationAxis_7ee71570-32b3-4554-8360-d976a5924c24" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLocationDomain_45827447-dd2e-44f3-82e4-e35a1f81f6a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_1328f8bc-d7c9-4938-bb62-c871d93ae933" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_37cbce92-f7d8-4ab5-8d89-6210a3fe6daa" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_1328f8bc-d7c9-4938-bb62-c871d93ae933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCosts_e46e3b93-6b12-4846-bfbe-7b0db871b4aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestructuringCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1328f8bc-d7c9-4938-bb62-c871d93ae933" xlink:to="loc_us-gaap_RestructuringCosts_e46e3b93-6b12-4846-bfbe-7b0db871b4aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_6fc4dc6c-9e73-43bf-b8b3-66338b10fb55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1328f8bc-d7c9-4938-bb62-c871d93ae933" xlink:to="loc_us-gaap_SeveranceCosts1_6fc4dc6c-9e73-43bf-b8b3-66338b10fb55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FacilityExitAndOtherCosts_10f46ca9-4414-4383-a334-9718e2fec361" xlink:href="cah-20210331.xsd#cah_FacilityExitAndOtherCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1328f8bc-d7c9-4938-bb62-c871d93ae933" xlink:to="loc_cah_FacilityExitAndOtherCosts_10f46ca9-4414-4383-a334-9718e2fec361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets" xlink:type="simple" xlink:href="cah-20210331.xsd#GoodwillandOtherIntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a8d97ea5-0168-48db-8ff8-3d7d34a7a869" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_d5e31546-264c-4257-8f26-7ec216dab5e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a8d97ea5-0168-48db-8ff8-3d7d34a7a869" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_d5e31546-264c-4257-8f26-7ec216dab5e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables" xlink:type="simple" xlink:href="cah-20210331.xsd#GoodwillandOtherIntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a5b65e84-c8e0-4809-8a5b-4cade4edaa72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_7829d163-81e7-48d2-b383-e82269b94ae0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a5b65e84-c8e0-4809-8a5b-4cade4edaa72" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_7829d163-81e7-48d2-b383-e82269b94ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_5dddd7f0-b705-418a-89b2-5468aa127002" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a5b65e84-c8e0-4809-8a5b-4cade4edaa72" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_5dddd7f0-b705-418a-89b2-5468aa127002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fb838a21-c258-48c0-9f51-89adc9b4a3c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_8fef61c5-618f-4775-a97c-90ac4efe1156" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fb838a21-c258-48c0-9f51-89adc9b4a3c2" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_8fef61c5-618f-4775-a97c-90ac4efe1156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_b01c3768-018b-48fe-9536-6ede095b8593" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_8fef61c5-618f-4775-a97c-90ac4efe1156" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_b01c3768-018b-48fe-9536-6ede095b8593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_fb5f7283-45ca-4af7-978f-5e38dd5cf726" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_b01c3768-018b-48fe-9536-6ede095b8593" xlink:to="loc_us-gaap_SegmentDomain_fb5f7283-45ca-4af7-978f-5e38dd5cf726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_fc64afb7-a849-4568-b5ae-e43d9e4c5436" xlink:href="cah-20210331.xsd#cah_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_fb5f7283-45ca-4af7-978f-5e38dd5cf726" xlink:to="loc_cah_PharmaceuticalMember_fc64afb7-a849-4568-b5ae-e43d9e4c5436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_e9ea8308-58cb-4418-afdc-8de90b6b0996" xlink:href="cah-20210331.xsd#cah_MedicalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_fb5f7283-45ca-4af7-978f-5e38dd5cf726" xlink:to="loc_cah_MedicalMember_e9ea8308-58cb-4418-afdc-8de90b6b0996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_3302a011-d98f-4619-85ae-0ae37718875b" xlink:href="cah-20210331.xsd#cah_CordisDivestitureAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_8fef61c5-618f-4775-a97c-90ac4efe1156" xlink:to="loc_cah_CordisDivestitureAxis_3302a011-d98f-4619-85ae-0ae37718875b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_0c548130-785e-4cc6-81b3-0078fa6d042b" xlink:href="cah-20210331.xsd#cah_CordisDivestitureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureAxis_3302a011-d98f-4619-85ae-0ae37718875b" xlink:to="loc_cah_CordisDivestitureDomain_0c548130-785e-4cc6-81b3-0078fa6d042b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_3447f670-1441-400b-9caa-13f011cb7c7a" xlink:href="cah-20210331.xsd#cah_CordisDivestitureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureDomain_0c548130-785e-4cc6-81b3-0078fa6d042b" xlink:to="loc_cah_CordisDivestitureMember_3447f670-1441-400b-9caa-13f011cb7c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_2559f467-c75c-43bb-bd4f-1d902b8fbadc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_8fef61c5-618f-4775-a97c-90ac4efe1156" xlink:to="loc_us-gaap_GoodwillLineItems_2559f467-c75c-43bb-bd4f-1d902b8fbadc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_6e4b0f5c-c5f3-47ae-8628-ed7e5c0fa1ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_2559f467-c75c-43bb-bd4f-1d902b8fbadc" xlink:to="loc_us-gaap_GoodwillRollForward_6e4b0f5c-c5f3-47ae-8628-ed7e5c0fa1ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_38ea9843-9ee0-40e9-bb87-eee192e96bf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_6e4b0f5c-c5f3-47ae-8628-ed7e5c0fa1ea" xlink:to="loc_us-gaap_Goodwill_38ea9843-9ee0-40e9-bb87-eee192e96bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_3b83651e-d012-420e-9280-ddd3833a8766" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_6e4b0f5c-c5f3-47ae-8628-ed7e5c0fa1ea" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_3b83651e-d012-420e-9280-ddd3833a8766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_6bb29733-8e15-4d53-83e0-292bd23c4c90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_6e4b0f5c-c5f3-47ae-8628-ed7e5c0fa1ea" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_6bb29733-8e15-4d53-83e0-292bd23c4c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_12a6264f-ce51-439d-9766-8d4333790c6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_6e4b0f5c-c5f3-47ae-8628-ed7e5c0fa1ea" xlink:to="loc_us-gaap_Goodwill_12a6264f-ce51-439d-9766-8d4333790c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_6a9c5daf-9fd8-490b-8964-bb9a18615a74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_2559f467-c75c-43bb-bd4f-1d902b8fbadc" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_6a9c5daf-9fd8-490b-8964-bb9a18615a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_0f65ed08-5911-4c0b-a763-4b170c28aa1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fb838a21-c258-48c0-9f51-89adc9b4a3c2" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_0f65ed08-5911-4c0b-a763-4b170c28aa1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_99cc2cd9-1bfd-4944-90e9-e476ad0033b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_1d61cd53-a88a-4390-a5b6-728acd426257" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_99cc2cd9-1bfd-4944-90e9-e476ad0033b0" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_1d61cd53-a88a-4390-a5b6-728acd426257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_be2eef0e-8a89-4aed-baad-df1a0e0cd06d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_1d61cd53-a88a-4390-a5b6-728acd426257" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_be2eef0e-8a89-4aed-baad-df1a0e0cd06d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_576283c7-32c8-4220-9cdc-01a3c9223234" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_be2eef0e-8a89-4aed-baad-df1a0e0cd06d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_576283c7-32c8-4220-9cdc-01a3c9223234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IPRDTrademarksandOtherMember_9559903c-476c-4762-9cd6-212dd0c1d22f" xlink:href="cah-20210331.xsd#cah_IPRDTrademarksandOtherMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_576283c7-32c8-4220-9cdc-01a3c9223234" xlink:to="loc_cah_IPRDTrademarksandOtherMember_9559903c-476c-4762-9cd6-212dd0c1d22f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_48a40ce0-7ed3-48c9-9d9d-364bbb0a0883" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_1d61cd53-a88a-4390-a5b6-728acd426257" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_48a40ce0-7ed3-48c9-9d9d-364bbb0a0883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_a609ee68-e392-4579-9202-d7ff045946bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_48a40ce0-7ed3-48c9-9d9d-364bbb0a0883" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_a609ee68-e392-4579-9202-d7ff045946bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_63d3ba2a-23da-46fe-87d1-32dbff43e9d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_99cc2cd9-1bfd-4944-90e9-e476ad0033b0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_63d3ba2a-23da-46fe-87d1-32dbff43e9d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ad2f1370-e02f-4d7a-b26e-8b26b354fe2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_63d3ba2a-23da-46fe-87d1-32dbff43e9d2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ad2f1370-e02f-4d7a-b26e-8b26b354fe2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8cf402c5-c97f-4501-b82b-cf1ad6ba940d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ad2f1370-e02f-4d7a-b26e-8b26b354fe2d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8cf402c5-c97f-4501-b82b-cf1ad6ba940d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_c099bc17-b2f0-4eae-88bd-f4373a499545" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8cf402c5-c97f-4501-b82b-cf1ad6ba940d" xlink:to="loc_us-gaap_CustomerRelationshipsMember_c099bc17-b2f0-4eae-88bd-f4373a499545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TrademarksAndPatentsMember_f11f7618-f4e9-4c6c-a037-6223049c0dbe" xlink:href="cah-20210331.xsd#cah_TrademarksAndPatentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8cf402c5-c97f-4501-b82b-cf1ad6ba940d" xlink:to="loc_cah_TrademarksAndPatentsMember_f11f7618-f4e9-4c6c-a037-6223049c0dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_7517011b-a02a-4195-ba60-4c8a89834a81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8cf402c5-c97f-4501-b82b-cf1ad6ba940d" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_7517011b-a02a-4195-ba60-4c8a89834a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ec18f13c-bd95-4cf3-96d0-e6987d74a804" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_63d3ba2a-23da-46fe-87d1-32dbff43e9d2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ec18f13c-bd95-4cf3-96d0-e6987d74a804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b1849cf1-890f-43e6-a750-0bf0b4b5d2b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ec18f13c-bd95-4cf3-96d0-e6987d74a804" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_b1849cf1-890f-43e6-a750-0bf0b4b5d2b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_774917a7-b1b0-4de1-8b4b-dc85aea1d6d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ec18f13c-bd95-4cf3-96d0-e6987d74a804" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_774917a7-b1b0-4de1-8b4b-dc85aea1d6d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4387a40b-72e6-4b8b-aa0f-39e253e0f2a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ec18f13c-bd95-4cf3-96d0-e6987d74a804" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4387a40b-72e6-4b8b-aa0f-39e253e0f2a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_09c3a637-e216-4206-853b-8338669afc99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_ec18f13c-bd95-4cf3-96d0-e6987d74a804" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_09c3a637-e216-4206-853b-8338669afc99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_07d30dff-b260-4e08-8d98-d9cf2277aafe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_99cc2cd9-1bfd-4944-90e9-e476ad0033b0" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_07d30dff-b260-4e08-8d98-d9cf2277aafe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5209bf82-2c84-4e22-ab57-8f8062282b9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_99cc2cd9-1bfd-4944-90e9-e476ad0033b0" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5209bf82-2c84-4e22-ab57-8f8062282b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#GoodwillandOtherIntangibleAssetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_46ab3ee1-fd7a-465e-866a-05821b93a121" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7fe35dfa-f164-4e04-872f-203327d6d299" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_46ab3ee1-fd7a-465e-866a-05821b93a121" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7fe35dfa-f164-4e04-872f-203327d6d299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9ada2c15-e031-4cd0-918f-b4000f27f847" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7fe35dfa-f164-4e04-872f-203327d6d299" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9ada2c15-e031-4cd0-918f-b4000f27f847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4db72a9b-eb14-43fb-904b-10fd5cd5d5ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9ada2c15-e031-4cd0-918f-b4000f27f847" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_4db72a9b-eb14-43fb-904b-10fd5cd5d5ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_d5f64b2d-c23c-4d35-bce4-56f7b65377dc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7fe35dfa-f164-4e04-872f-203327d6d299" xlink:to="loc_srt_ConsolidationItemsAxis_d5f64b2d-c23c-4d35-bce4-56f7b65377dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_ce4bc601-8c3b-47ed-95b6-b0866f8ad34a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_d5f64b2d-c23c-4d35-bce4-56f7b65377dc" xlink:to="loc_srt_ConsolidationItemsDomain_ce4bc601-8c3b-47ed-95b6-b0866f8ad34a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2f3cb5ab-612c-4269-acdc-4a4be163c844" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7fe35dfa-f164-4e04-872f-203327d6d299" xlink:to="loc_srt_RangeAxis_2f3cb5ab-612c-4269-acdc-4a4be163c844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d3bdf1fa-e575-44e0-95e6-c7b9b4b8ce4a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2f3cb5ab-612c-4269-acdc-4a4be163c844" xlink:to="loc_srt_RangeMember_d3bdf1fa-e575-44e0-95e6-c7b9b4b8ce4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_0cb9de22-9436-4c27-8734-c1ccab2d8623" xlink:href="cah-20210331.xsd#cah_CordisDivestitureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7fe35dfa-f164-4e04-872f-203327d6d299" xlink:to="loc_cah_CordisDivestitureAxis_0cb9de22-9436-4c27-8734-c1ccab2d8623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_cd6120c6-cf39-4b08-b779-042f6cf8add4" xlink:href="cah-20210331.xsd#cah_CordisDivestitureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureAxis_0cb9de22-9436-4c27-8734-c1ccab2d8623" xlink:to="loc_cah_CordisDivestitureDomain_cd6120c6-cf39-4b08-b779-042f6cf8add4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_8552629f-7037-42d6-8d91-5e9c401135fb" xlink:href="cah-20210331.xsd#cah_CordisDivestitureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureDomain_cd6120c6-cf39-4b08-b779-042f6cf8add4" xlink:to="loc_cah_CordisDivestitureMember_8552629f-7037-42d6-8d91-5e9c401135fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_335965a3-39af-446b-b187-1f3ab4ea5f9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7fe35dfa-f164-4e04-872f-203327d6d299" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_335965a3-39af-446b-b187-1f3ab4ea5f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_0a996425-f4d4-4c3c-b200-d7f19bb13881" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_335965a3-39af-446b-b187-1f3ab4ea5f9e" xlink:to="loc_us-gaap_Goodwill_0a996425-f4d4-4c3c-b200-d7f19bb13881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_89bac0d7-4e1f-4d74-8bf4-74b3c100b1cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_335965a3-39af-446b-b187-1f3ab4ea5f9e" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_89bac0d7-4e1f-4d74-8bf4-74b3c100b1cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_1beb9ec2-a3b2-411f-bdcd-c93da9bafdd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_46ab3ee1-fd7a-465e-866a-05821b93a121" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_1beb9ec2-a3b2-411f-bdcd-c93da9bafdd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_304aae26-ed86-42ed-acfa-c652106ae353" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_46ab3ee1-fd7a-465e-866a-05821b93a121" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_304aae26-ed86-42ed-acfa-c652106ae353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_d2adf9a2-f9de-4838-9a28-1a86db591e19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_46ab3ee1-fd7a-465e-866a-05821b93a121" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_d2adf9a2-f9de-4838-9a28-1a86db591e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_a1664798-5784-4c40-8ec4-b6e806f7ce30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_46ab3ee1-fd7a-465e-866a-05821b93a121" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_a1664798-5784-4c40-8ec4-b6e806f7ce30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_92b2815e-3842-4281-a87c-b52b07bad609" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_46ab3ee1-fd7a-465e-866a-05821b93a121" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_92b2815e-3842-4281-a87c-b52b07bad609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2ca321c5-fd5f-4211-8e8b-06ac41a1e14f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_46ab3ee1-fd7a-465e-866a-05821b93a121" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2ca321c5-fd5f-4211-8e8b-06ac41a1e14f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings" xlink:type="simple" xlink:href="cah-20210331.xsd#LongTermObligationsandOtherShortTermBorrowings"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract_45722743-9a55-42ab-8957-63ce8b15e720" xlink:href="cah-20210331.xsd#cah_LongTermObligationsandOtherShortTermBorrowingsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_96f482c5-b551-4dc0-85cc-fc73ee9ed859" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract_45722743-9a55-42ab-8957-63ce8b15e720" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_96f482c5-b551-4dc0-85cc-fc73ee9ed859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsTables" xlink:type="simple" xlink:href="cah-20210331.xsd#LongTermObligationsandOtherShortTermBorrowingsTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract_7935a886-0a01-48f7-8275-f8f6f83de89a" xlink:href="cah-20210331.xsd#cah_LongTermObligationsandOtherShortTermBorrowingsAbstract"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#LongTermObligationsandOtherShortTermBorrowingsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract_d765e213-9f99-4ae6-912b-c7172e8496c8" xlink:href="cah-20210331.xsd#cah_LongTermObligationsandOtherShortTermBorrowingsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_730fca25-b422-48b8-ac8d-4f6b9bac54ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract_d765e213-9f99-4ae6-912b-c7172e8496c8" xlink:to="loc_us-gaap_DebtInstrumentTable_730fca25-b422-48b8-ac8d-4f6b9bac54ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_eaee2051-fc29-44cd-a14b-bde971914933" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_730fca25-b422-48b8-ac8d-4f6b9bac54ff" xlink:to="loc_us-gaap_DebtInstrumentAxis_eaee2051-fc29-44cd-a14b-bde971914933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3a42f6d9-7f71-4c4d-a0c1-61d86aaadc3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_eaee2051-fc29-44cd-a14b-bde971914933" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3a42f6d9-7f71-4c4d-a0c1-61d86aaadc3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A2.4Notesdue2020Member_7bbed007-8335-4caf-9bc8-b28b9a899ab8" xlink:href="cah-20210331.xsd#cah_A2.4Notesdue2020Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3a42f6d9-7f71-4c4d-a0c1-61d86aaadc3c" xlink:to="loc_cah_A2.4Notesdue2020Member_7bbed007-8335-4caf-9bc8-b28b9a899ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A2.616Notesdue2022Member_11f28d95-e8c6-42a5-91aa-1c3ae7a7ec24" xlink:href="cah-20210331.xsd#cah_A2.616Notesdue2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3a42f6d9-7f71-4c4d-a0c1-61d86aaadc3c" xlink:to="loc_cah_A2.616Notesdue2022Member_11f28d95-e8c6-42a5-91aa-1c3ae7a7ec24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A3.41Notesdue2027Member_b4ee601e-0f61-47af-b3ce-f3b9811da55c" xlink:href="cah-20210331.xsd#cah_A3.41Notesdue2027Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3a42f6d9-7f71-4c4d-a0c1-61d86aaadc3c" xlink:to="loc_cah_A3.41Notesdue2027Member_b4ee601e-0f61-47af-b3ce-f3b9811da55c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember_8977ae8f-bdca-43f5-b7b6-f55df46f6bc5" xlink:href="cah-20210331.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3a42f6d9-7f71-4c4d-a0c1-61d86aaadc3c" xlink:to="loc_cah_CommittedReceivablesSalesFacilityProgramMember_8977ae8f-bdca-43f5-b7b6-f55df46f6bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A4.6Notesdue2043Member_e8130a59-5979-4140-9919-b6605a90235d" xlink:href="cah-20210331.xsd#cah_A4.6Notesdue2043Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3a42f6d9-7f71-4c4d-a0c1-61d86aaadc3c" xlink:to="loc_cah_A4.6Notesdue2043Member_e8130a59-5979-4140-9919-b6605a90235d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A4.9Notesdue2045Member_25ec80a0-1b7d-4910-9763-dc2818432d26" xlink:href="cah-20210331.xsd#cah_A4.9Notesdue2045Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3a42f6d9-7f71-4c4d-a0c1-61d86aaadc3c" xlink:to="loc_cah_A4.9Notesdue2045Member_25ec80a0-1b7d-4910-9763-dc2818432d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A4.368Notesdue2047Member_85f6c3b6-5d29-497b-8e80-a56a83394e84" xlink:href="cah-20210331.xsd#cah_A4.368Notesdue2047Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3a42f6d9-7f71-4c4d-a0c1-61d86aaadc3c" xlink:to="loc_cah_A4.368Notesdue2047Member_85f6c3b6-5d29-497b-8e80-a56a83394e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FloatingRateNotesdue2022Member_91f6e297-85c7-44f7-8201-c9ab9077d01e" xlink:href="cah-20210331.xsd#cah_FloatingRateNotesdue2022Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3a42f6d9-7f71-4c4d-a0c1-61d86aaadc3c" xlink:to="loc_cah_FloatingRateNotesdue2022Member_91f6e297-85c7-44f7-8201-c9ab9077d01e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A3.2Notesdue2022Member_9b8d657d-e2cb-4c84-8350-bd6c22e5c703" xlink:href="cah-20210331.xsd#cah_A3.2Notesdue2022Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3a42f6d9-7f71-4c4d-a0c1-61d86aaadc3c" xlink:to="loc_cah_A3.2Notesdue2022Member_9b8d657d-e2cb-4c84-8350-bd6c22e5c703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_543153c0-2a11-4a41-b9cd-c4aa43fa6111" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_730fca25-b422-48b8-ac8d-4f6b9bac54ff" xlink:to="loc_us-gaap_CreditFacilityAxis_543153c0-2a11-4a41-b9cd-c4aa43fa6111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_c81b06a4-f742-4e1a-91e6-24bedd56adfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_543153c0-2a11-4a41-b9cd-c4aa43fa6111" xlink:to="loc_us-gaap_CreditFacilityDomain_c81b06a4-f742-4e1a-91e6-24bedd56adfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_cc0748aa-c7fc-4c6f-821e-630ddd67b8cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_c81b06a4-f742-4e1a-91e6-24bedd56adfb" xlink:to="loc_us-gaap_CommercialPaperMember_cc0748aa-c7fc-4c6f-821e-630ddd67b8cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_079e31b3-04b5-4943-99d9-966f3aa4732e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_c81b06a4-f742-4e1a-91e6-24bedd56adfb" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_079e31b3-04b5-4943-99d9-966f3aa4732e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ShortTermCreditFacilitiesMember_9dd65a3c-7515-47ea-bf30-00b84f4e8d7a" xlink:href="cah-20210331.xsd#cah_ShortTermCreditFacilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_c81b06a4-f742-4e1a-91e6-24bedd56adfb" xlink:to="loc_cah_ShortTermCreditFacilitiesMember_9dd65a3c-7515-47ea-bf30-00b84f4e8d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CommittedReceivablesSalesFacilityProgramMember_29a756ee-78f9-4eef-8ae3-3694a677c658" xlink:href="cah-20210331.xsd#cah_CommittedReceivablesSalesFacilityProgramMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_c81b06a4-f742-4e1a-91e6-24bedd56adfb" xlink:to="loc_cah_CommittedReceivablesSalesFacilityProgramMember_29a756ee-78f9-4eef-8ae3-3694a677c658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_5f40ac11-46ef-4b8f-8786-15c8e69fbb30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_730fca25-b422-48b8-ac8d-4f6b9bac54ff" xlink:to="loc_us-gaap_DebtInstrumentLineItems_5f40ac11-46ef-4b8f-8786-15c8e69fbb30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalLongTermandShortTermObligations_270dd90a-11ae-44bf-abf3-7d84de2b525e" xlink:href="cah-20210331.xsd#cah_TotalLongTermandShortTermObligations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5f40ac11-46ef-4b8f-8786-15c8e69fbb30" xlink:to="loc_cah_TotalLongTermandShortTermObligations_270dd90a-11ae-44bf-abf3-7d84de2b525e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_c8057e38-8db8-447d-9cf2-ac34f715f9bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5f40ac11-46ef-4b8f-8786-15c8e69fbb30" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_c8057e38-8db8-447d-9cf2-ac34f715f9bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NotesPayableRepurchased_095cf3ff-0631-4955-adb7-b0c86c40afaa" xlink:href="cah-20210331.xsd#cah_NotesPayableRepurchased"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5f40ac11-46ef-4b8f-8786-15c8e69fbb30" xlink:to="loc_cah_NotesPayableRepurchased_095cf3ff-0631-4955-adb7-b0c86c40afaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_dee1d999-174f-4565-957c-2fc015aa2465" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5f40ac11-46ef-4b8f-8786-15c8e69fbb30" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_dee1d999-174f-4565-957c-2fc015aa2465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_91c754af-28e4-403a-8504-9fa78e5a9fbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5f40ac11-46ef-4b8f-8786-15c8e69fbb30" xlink:to="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_91c754af-28e4-403a-8504-9fa78e5a9fbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_c0815207-d715-4702-9a2d-c52e37bbbd50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_7aa136bc-85aa-4e5c-a800-2b92602c25e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c0815207-d715-4702-9a2d-c52e37bbbd50" xlink:to="loc_us-gaap_DebtInstrumentTable_7aa136bc-85aa-4e5c-a800-2b92602c25e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_1a18eaa1-4890-4322-a5b6-963095cd9457" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7aa136bc-85aa-4e5c-a800-2b92602c25e1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_1a18eaa1-4890-4322-a5b6-963095cd9457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_45b082c4-5460-44f3-9cc3-c6a452fccfcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_1a18eaa1-4890-4322-a5b6-963095cd9457" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_45b082c4-5460-44f3-9cc3-c6a452fccfcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_75ed1bde-7794-4af5-918c-ff06a429adf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7aa136bc-85aa-4e5c-a800-2b92602c25e1" xlink:to="loc_us-gaap_DebtInstrumentAxis_75ed1bde-7794-4af5-918c-ff06a429adf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_525a50db-ea85-4c29-a220-91ce5350769f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_75ed1bde-7794-4af5-918c-ff06a429adf9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_525a50db-ea85-4c29-a220-91ce5350769f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A2.4Notesdue2020Member_f7089326-0042-43f0-9b3e-45304993e707" xlink:href="cah-20210331.xsd#cah_A2.4Notesdue2020Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_525a50db-ea85-4c29-a220-91ce5350769f" xlink:to="loc_cah_A2.4Notesdue2020Member_f7089326-0042-43f0-9b3e-45304993e707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A2.616Notesdue2022Member_b363fff7-93f7-492f-b98a-7aa9522b5c37" xlink:href="cah-20210331.xsd#cah_A2.616Notesdue2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_525a50db-ea85-4c29-a220-91ce5350769f" xlink:to="loc_cah_A2.616Notesdue2022Member_b363fff7-93f7-492f-b98a-7aa9522b5c37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A3.2Notesdue2022Member_4092a062-eafb-495e-8a0a-514b4ebb3715" xlink:href="cah-20210331.xsd#cah_A3.2Notesdue2022Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_525a50db-ea85-4c29-a220-91ce5350769f" xlink:to="loc_cah_A3.2Notesdue2022Member_4092a062-eafb-495e-8a0a-514b4ebb3715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_FloatingRateNotesdue2022Member_90860741-b6d5-43e2-9de5-8be3a97ccca6" xlink:href="cah-20210331.xsd#cah_FloatingRateNotesdue2022Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_525a50db-ea85-4c29-a220-91ce5350769f" xlink:to="loc_cah_FloatingRateNotesdue2022Member_90860741-b6d5-43e2-9de5-8be3a97ccca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A3.41Notesdue2027Member_ea9c7431-d3ba-484d-b9b2-8b4f7a8e6c8d" xlink:href="cah-20210331.xsd#cah_A3.41Notesdue2027Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_525a50db-ea85-4c29-a220-91ce5350769f" xlink:to="loc_cah_A3.41Notesdue2027Member_ea9c7431-d3ba-484d-b9b2-8b4f7a8e6c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A4.6Notesdue2043Member_821adb29-07c6-4186-9156-bd0e23904af1" xlink:href="cah-20210331.xsd#cah_A4.6Notesdue2043Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_525a50db-ea85-4c29-a220-91ce5350769f" xlink:to="loc_cah_A4.6Notesdue2043Member_821adb29-07c6-4186-9156-bd0e23904af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A4.9Notesdue2045Member_8a16c904-866d-45c0-a4ac-6edadc53be61" xlink:href="cah-20210331.xsd#cah_A4.9Notesdue2045Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_525a50db-ea85-4c29-a220-91ce5350769f" xlink:to="loc_cah_A4.9Notesdue2045Member_8a16c904-866d-45c0-a4ac-6edadc53be61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_A4.368Notesdue2047Member_d3d95e0f-26e0-4e0f-b0b2-a4c1bd04b01f" xlink:href="cah-20210331.xsd#cah_A4.368Notesdue2047Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_525a50db-ea85-4c29-a220-91ce5350769f" xlink:to="loc_cah_A4.368Notesdue2047Member_d3d95e0f-26e0-4e0f-b0b2-a4c1bd04b01f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_2c049a6c-d0e9-4761-9a9c-27537184bfea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7aa136bc-85aa-4e5c-a800-2b92602c25e1" xlink:to="loc_us-gaap_DebtInstrumentLineItems_2c049a6c-d0e9-4761-9a9c-27537184bfea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalLongTermandShortTermObligations_e02bf44d-86e2-4139-8b78-eadc077080d0" xlink:href="cah-20210331.xsd#cah_TotalLongTermandShortTermObligations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2c049a6c-d0e9-4761-9a9c-27537184bfea" xlink:to="loc_cah_TotalLongTermandShortTermObligations_e02bf44d-86e2-4139-8b78-eadc077080d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_fbd81a94-0a20-42e9-9c52-bf31cd376a90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2c049a6c-d0e9-4761-9a9c-27537184bfea" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_fbd81a94-0a20-42e9-9c52-bf31cd376a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_16eb91d8-84d2-4865-abad-ad87b8f848bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_2c049a6c-d0e9-4761-9a9c-27537184bfea" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_16eb91d8-84d2-4865-abad-ad87b8f848bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation" xlink:type="simple" xlink:href="cah-20210331.xsd#CommitmentsContingentLiabilitiesandLitigation"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9d4126df-608c-43da-9b4a-afa306c35c08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_83aa8f85-b3d6-4c39-9c27-a67f6b5543db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9d4126df-608c-43da-9b4a-afa306c35c08" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_83aa8f85-b3d6-4c39-9c27-a67f6b5543db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#CommitmentsContingentLiabilitiesandLitigationDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_30f0343a-8dab-4fc0-a711-ad77d883a578" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_77d77986-218d-46eb-9c04-9d1f0f237ef8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_30f0343a-8dab-4fc0-a711-ad77d883a578" xlink:to="loc_us-gaap_LossContingenciesTable_77d77986-218d-46eb-9c04-9d1f0f237ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GownRecallAxis_a41c34c3-4bb2-4fcb-acb4-b224cc0fbe27" xlink:href="cah-20210331.xsd#cah_GownRecallAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_77d77986-218d-46eb-9c04-9d1f0f237ef8" xlink:to="loc_cah_GownRecallAxis_a41c34c3-4bb2-4fcb-acb4-b224cc0fbe27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_GownRecallDomain_1e63fcd2-4daa-4a27-9053-6d00c8c2e0aa" xlink:href="cah-20210331.xsd#cah_GownRecallDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_GownRecallAxis_a41c34c3-4bb2-4fcb-acb4-b224cc0fbe27" xlink:to="loc_cah_GownRecallDomain_1e63fcd2-4daa-4a27-9053-6d00c8c2e0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_ddbb7c5c-fa83-422d-9446-4cd5980e5806" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_77d77986-218d-46eb-9c04-9d1f0f237ef8" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_ddbb7c5c-fa83-422d-9446-4cd5980e5806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7dc01931-54c5-4de6-b739-0a12d1d55ed2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_ddbb7c5c-fa83-422d-9446-4cd5980e5806" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7dc01931-54c5-4de6-b739-0a12d1d55ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_870927a3-4e9f-4792-9a71-f4300bdad3ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_77d77986-218d-46eb-9c04-9d1f0f237ef8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_870927a3-4e9f-4792-9a71-f4300bdad3ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0877b631-78b1-4d54-ae76-d71dce6e682f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_870927a3-4e9f-4792-9a71-f4300bdad3ee" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0877b631-78b1-4d54-ae76-d71dce6e682f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_cb9cf933-004d-42b6-9ff8-eef670c3feb1" xlink:href="cah-20210331.xsd#cah_OpioidLitigationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_77d77986-218d-46eb-9c04-9d1f0f237ef8" xlink:to="loc_cah_OpioidLitigationAxis_cb9cf933-004d-42b6-9ff8-eef670c3feb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_6341c95b-1df8-4d6a-8474-e030ba3136b8" xlink:href="cah-20210331.xsd#cah_OpioidLitigationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationAxis_cb9cf933-004d-42b6-9ff8-eef670c3feb1" xlink:to="loc_cah_OpioidLitigationDomain_6341c95b-1df8-4d6a-8474-e030ba3136b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_64c7592b-cdc6-4d42-a9fc-cefd6920e0ea" xlink:href="cah-20210331.xsd#cah_TotalOpioidLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationDomain_6341c95b-1df8-4d6a-8474-e030ba3136b8" xlink:to="loc_cah_TotalOpioidLitigationMember_64c7592b-cdc6-4d42-a9fc-cefd6920e0ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeAxis_6a75f797-74dc-4eb2-a249-47919fd73e0d" xlink:href="cah-20210331.xsd#cah_LawsuitTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_77d77986-218d-46eb-9c04-9d1f0f237ef8" xlink:to="loc_cah_LawsuitTypeAxis_6a75f797-74dc-4eb2-a249-47919fd73e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LawsuitTypeDomain_5e8e17c1-12c1-4356-8365-26512de26ec7" xlink:href="cah-20210331.xsd#cah_LawsuitTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_LawsuitTypeAxis_6a75f797-74dc-4eb2-a249-47919fd73e0d" xlink:to="loc_cah_LawsuitTypeDomain_5e8e17c1-12c1-4356-8365-26512de26ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ClassActionLawsuitsMember_5ff4cc43-5acc-48d3-85ec-6cffa44710bf" xlink:href="cah-20210331.xsd#cah_ClassActionLawsuitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_LawsuitTypeDomain_5e8e17c1-12c1-4356-8365-26512de26ec7" xlink:to="loc_cah_ClassActionLawsuitsMember_5ff4cc43-5acc-48d3-85ec-6cffa44710bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_9dbd1acb-cd74-43b5-b820-73b8cb2b322c" xlink:href="cah-20210331.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_LawsuitTypeDomain_5e8e17c1-12c1-4356-8365-26512de26ec7" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_9dbd1acb-cd74-43b5-b820-73b8cb2b322c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeAxis_bad5dcb7-f0a7-4117-9cd1-900612ccd943" xlink:href="cah-20210331.xsd#cah_PlaintiffTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_77d77986-218d-46eb-9c04-9d1f0f237ef8" xlink:to="loc_cah_PlaintiffTypeAxis_bad5dcb7-f0a7-4117-9cd1-900612ccd943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PlaintiffTypeDomain_c797710b-6199-459f-8cf2-9d804ce9e285" xlink:href="cah-20210331.xsd#cah_PlaintiffTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_PlaintiffTypeAxis_bad5dcb7-f0a7-4117-9cd1-900612ccd943" xlink:to="loc_cah_PlaintiffTypeDomain_c797710b-6199-459f-8cf2-9d804ce9e285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PrivatePartiesMember_0c4ea8d4-f960-436d-84d8-10123afe9528" xlink:href="cah-20210331.xsd#cah_PrivatePartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_PlaintiffTypeDomain_c797710b-6199-459f-8cf2-9d804ce9e285" xlink:to="loc_cah_PrivatePartiesMember_0c4ea8d4-f960-436d-84d8-10123afe9528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementAxis_f8a5f4f9-0f27-4e41-922f-55a20aea934b" xlink:href="cah-20210331.xsd#cah_TaxMattersAgreementAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_77d77986-218d-46eb-9c04-9d1f0f237ef8" xlink:to="loc_cah_TaxMattersAgreementAxis_f8a5f4f9-0f27-4e41-922f-55a20aea934b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementDomain_561b708e-b90a-4de0-b8cf-a38c73c021e8" xlink:href="cah-20210331.xsd#cah_TaxMattersAgreementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_TaxMattersAgreementAxis_f8a5f4f9-0f27-4e41-922f-55a20aea934b" xlink:to="loc_cah_TaxMattersAgreementDomain_561b708e-b90a-4de0-b8cf-a38c73c021e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_faf1dd2a-7d96-466d-915b-dcb28ff35abd" xlink:href="cah-20210331.xsd#cah_TotalOpioidLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_TaxMattersAgreementDomain_561b708e-b90a-4de0-b8cf-a38c73c021e8" xlink:to="loc_cah_TotalOpioidLitigationMember_faf1dd2a-7d96-466d-915b-dcb28ff35abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_eaea1373-9f31-47a3-99b7-6b31be81f1c9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_77d77986-218d-46eb-9c04-9d1f0f237ef8" xlink:to="loc_srt_StatementGeographicalAxis_eaea1373-9f31-47a3-99b7-6b31be81f1c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e92ffcbd-ff9c-4394-b51c-48b937e3aa5f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_eaea1373-9f31-47a3-99b7-6b31be81f1c9" xlink:to="loc_srt_SegmentGeographicalDomain_e92ffcbd-ff9c-4394-b51c-48b937e3aa5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AlamedaCountyMember_f67688f1-140d-49e9-a719-d20fea1cb601" xlink:href="cah-20210331.xsd#cah_AlamedaCountyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e92ffcbd-ff9c-4394-b51c-48b937e3aa5f" xlink:to="loc_cah_AlamedaCountyMember_f67688f1-140d-49e9-a719-d20fea1cb601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OtherJurisdictionsMember_769466c1-1f43-44ae-a2ec-8c0b4d2d015f" xlink:href="cah-20210331.xsd#cah_OtherJurisdictionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e92ffcbd-ff9c-4394-b51c-48b937e3aa5f" xlink:to="loc_cah_OtherJurisdictionsMember_769466c1-1f43-44ae-a2ec-8c0b4d2d015f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_41cb52be-5d66-40cb-ad89-d049a0db0a34" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_77d77986-218d-46eb-9c04-9d1f0f237ef8" xlink:to="loc_srt_RangeAxis_41cb52be-5d66-40cb-ad89-d049a0db0a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f136467f-725c-4c9f-9b98-a8084d54c2d3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_41cb52be-5d66-40cb-ad89-d049a0db0a34" xlink:to="loc_srt_RangeMember_f136467f-725c-4c9f-9b98-a8084d54c2d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2d591bec-86fa-4347-bbc1-81855c5fec6e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f136467f-725c-4c9f-9b98-a8084d54c2d3" xlink:to="loc_srt_MinimumMember_2d591bec-86fa-4347-bbc1-81855c5fec6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2f7272c6-3c66-4972-8ca9-1e749680863b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f136467f-725c-4c9f-9b98-a8084d54c2d3" xlink:to="loc_srt_MaximumMember_2f7272c6-3c66-4972-8ca9-1e749680863b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_b55b7992-aa41-463f-907d-e2309f8bf319" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_77d77986-218d-46eb-9c04-9d1f0f237ef8" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_b55b7992-aa41-463f-907d-e2309f8bf319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_720947f9-a6b7-47f3-a3dd-2ee630d6f67e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_b55b7992-aa41-463f-907d-e2309f8bf319" xlink:to="loc_us-gaap_LossContingencyNatureDomain_720947f9-a6b7-47f3-a3dd-2ee630d6f67e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsMember_e1014869-bd79-433c-9ed4-f5281b72c611" xlink:href="cah-20210331.xsd#cah_OpioidLawsuitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_720947f9-a6b7-47f3-a3dd-2ee630d6f67e" xlink:to="loc_cah_OpioidLawsuitsMember_e1014869-bd79-433c-9ed4-f5281b72c611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_135fdd69-2238-4b31-aa51-bc97bd776534" xlink:href="cah-20210331.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_720947f9-a6b7-47f3-a3dd-2ee630d6f67e" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_135fdd69-2238-4b31-aa51-bc97bd776534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_b10232f5-1863-4e0d-934a-57a45a96590b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_77d77986-218d-46eb-9c04-9d1f0f237ef8" xlink:to="loc_srt_MajorCustomersAxis_b10232f5-1863-4e0d-934a-57a45a96590b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_69ed50d5-0aaf-49d0-82d6-a3dbbae6dac3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_b10232f5-1863-4e0d-934a-57a45a96590b" xlink:to="loc_srt_NameOfMajorCustomerDomain_69ed50d5-0aaf-49d0-82d6-a3dbbae6dac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CVSHealthMember_ebbac0da-068a-4a10-9a76-786a79a6bcb6" xlink:href="cah-20210331.xsd#cah_CVSHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_69ed50d5-0aaf-49d0-82d6-a3dbbae6dac3" xlink:to="loc_cah_CVSHealthMember_ebbac0da-068a-4a10-9a76-786a79a6bcb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_34b5284b-1dfa-45e7-97a8-5a0c2f4a4891" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_77d77986-218d-46eb-9c04-9d1f0f237ef8" xlink:to="loc_srt_LitigationCaseAxis_34b5284b-1dfa-45e7-97a8-5a0c2f4a4891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_a49568b6-fd77-4dbe-9bc6-0b49fda6bc06" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_34b5284b-1dfa-45e7-97a8-5a0c2f4a4891" xlink:to="loc_srt_LitigationCaseTypeDomain_a49568b6-fd77-4dbe-9bc6-0b49fda6bc06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsStateDomain_e96154f3-ec50-4490-8bdb-3c480b8a2da5" xlink:href="cah-20210331.xsd#cah_OpioidLawsuitsStateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_a49568b6-fd77-4dbe-9bc6-0b49fda6bc06" xlink:to="loc_cah_OpioidLawsuitsStateDomain_e96154f3-ec50-4490-8bdb-3c480b8a2da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLawsuitsMember_7f444d01-f966-46eb-a08e-01c6ca742823" xlink:href="cah-20210331.xsd#cah_OpioidLawsuitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_a49568b6-fd77-4dbe-9bc6-0b49fda6bc06" xlink:to="loc_cah_OpioidLawsuitsMember_7f444d01-f966-46eb-a08e-01c6ca742823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProductLiabilityLawsuitsMember_9a269e39-b86d-429c-9106-913bbd1987c2" xlink:href="cah-20210331.xsd#cah_ProductLiabilityLawsuitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_a49568b6-fd77-4dbe-9bc6-0b49fda6bc06" xlink:to="loc_cah_ProductLiabilityLawsuitsMember_9a269e39-b86d-429c-9106-913bbd1987c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NewYorkOpioidStewardshipActMember_dc438868-8f33-4b26-8169-36aa485d88bf" xlink:href="cah-20210331.xsd#cah_NewYorkOpioidStewardshipActMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_a49568b6-fd77-4dbe-9bc6-0b49fda6bc06" xlink:to="loc_cah_NewYorkOpioidStewardshipActMember_dc438868-8f33-4b26-8169-36aa485d88bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DOJInvestigationMember_eb34df32-ec00-4852-86a6-748983d45626" xlink:href="cah-20210331.xsd#cah_DOJInvestigationMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_a49568b6-fd77-4dbe-9bc6-0b49fda6bc06" xlink:to="loc_cah_DOJInvestigationMember_eb34df32-ec00-4852-86a6-748983d45626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_b0f6192e-2624-4d87-8ddf-6d501fe09be8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_77d77986-218d-46eb-9c04-9d1f0f237ef8" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_b0f6192e-2624-4d87-8ddf-6d501fe09be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_cf48f691-099a-4922-b3d2-baab9f0f87be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_b0f6192e-2624-4d87-8ddf-6d501fe09be8" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_cf48f691-099a-4922-b3d2-baab9f0f87be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_b6710810-9c88-4595-a5f9-75077db9ab4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_cf48f691-099a-4922-b3d2-baab9f0f87be" xlink:to="loc_us-gaap_SubsequentEventMember_b6710810-9c88-4595-a5f9-75077db9ab4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_bd0442df-5061-4186-b6c2-8b148c009b09" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_77d77986-218d-46eb-9c04-9d1f0f237ef8" xlink:to="loc_srt_StatementScenarioAxis_bd0442df-5061-4186-b6c2-8b148c009b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_09add7d3-0d27-4ddb-bc37-db2b03380881" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_bd0442df-5061-4186-b6c2-8b148c009b09" xlink:to="loc_srt_ScenarioUnspecifiedDomain_09add7d3-0d27-4ddb-bc37-db2b03380881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_f320bb6d-defc-4296-9860-4a03ad73ee74" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_09add7d3-0d27-4ddb-bc37-db2b03380881" xlink:to="loc_srt_ScenarioForecastMember_f320bb6d-defc-4296-9860-4a03ad73ee74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_4abe5425-6968-4571-8eb8-ece987728529" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_77d77986-218d-46eb-9c04-9d1f0f237ef8" xlink:to="loc_us-gaap_LossContingenciesLineItems_4abe5425-6968-4571-8eb8-ece987728529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_e45b6f9e-869d-4a8f-8831-5ae2f05d4ad7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4abe5425-6968-4571-8eb8-ece987728529" xlink:to="loc_us-gaap_InventoryNet_e45b6f9e-869d-4a8f-8831-5ae2f05d4ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermPurchaseCommitmentPeriod_84ae2fba-f2a7-43de-85dd-c3970383d67b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermPurchaseCommitmentPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4abe5425-6968-4571-8eb8-ece987728529" xlink:to="loc_us-gaap_LongtermPurchaseCommitmentPeriod_84ae2fba-f2a7-43de-85dd-c3970383d67b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MaximumQuarterlyPayment_71351497-b780-4733-9d3c-1942a567369d" xlink:href="cah-20210331.xsd#cah_MaximumQuarterlyPayment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4abe5425-6968-4571-8eb8-ece987728529" xlink:to="loc_cah_MaximumQuarterlyPayment_71351497-b780-4733-9d3c-1942a567369d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_LossContingencyLawsuitsNumber_cb7c16a8-b67e-43da-bf54-b822d7c63b61" xlink:href="cah-20210331.xsd#cah_LossContingencyLawsuitsNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4abe5425-6968-4571-8eb8-ece987728529" xlink:to="loc_cah_LossContingencyLawsuitsNumber_cb7c16a8-b67e-43da-bf54-b822d7c63b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NumberofStateAttorneysGeneralfilinglawsuits_add6b5f7-59ab-495b-946f-102bbed9288f" xlink:href="cah-20210331.xsd#cah_NumberofStateAttorneysGeneralfilinglawsuits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4abe5425-6968-4571-8eb8-ece987728529" xlink:to="loc_cah_NumberofStateAttorneysGeneralfilinglawsuits_add6b5f7-59ab-495b-946f-102bbed9288f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_d7b4c230-887c-4763-b379-3253350eb0f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4abe5425-6968-4571-8eb8-ece987728529" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_d7b4c230-887c-4763-b379-3253350eb0f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_869346d6-d528-445c-8965-68afa8ab1640" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationReserve"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4abe5425-6968-4571-8eb8-ece987728529" xlink:to="loc_us-gaap_LitigationReserve_869346d6-d528-445c-8965-68afa8ab1640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_1bcabac8-7c00-43ce-903e-a561f9ff2db0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4abe5425-6968-4571-8eb8-ece987728529" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_1bcabac8-7c00-43ce-903e-a561f9ff2db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_b67b0fd8-9e47-4cdb-a761-17513ebeabfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4abe5425-6968-4571-8eb8-ece987728529" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_b67b0fd8-9e47-4cdb-a761-17513ebeabfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_3a55a5a0-dabd-4d17-ad5c-ef32081ddd42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4abe5425-6968-4571-8eb8-ece987728529" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_3a55a5a0-dabd-4d17-ad5c-ef32081ddd42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRecallExpense_b10d7dd6-2883-41a6-81ad-8c6b7856905a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRecallExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4abe5425-6968-4571-8eb8-ece987728529" xlink:to="loc_us-gaap_InventoryRecallExpense_b10d7dd6-2883-41a6-81ad-8c6b7856905a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_4a0dc763-146e-4dea-8291-5404db367519" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4abe5425-6968-4571-8eb8-ece987728529" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_4a0dc763-146e-4dea-8291-5404db367519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3a193004-268a-46cb-9242-57f4f05de47d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4abe5425-6968-4571-8eb8-ece987728529" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3a193004-268a-46cb-9242-57f4f05de47d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e5caf2e3-536c-4695-beda-f99d40056740" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4abe5425-6968-4571-8eb8-ece987728529" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_e5caf2e3-536c-4695-beda-f99d40056740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_e5508ab8-88c7-4a24-a93d-cd4f8b7b4f1d" xlink:href="cah-20210331.xsd#cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4abe5425-6968-4571-8eb8-ece987728529" xlink:to="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_e5508ab8-88c7-4a24-a93d-cd4f8b7b4f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AggregateAnnualAssessment_92b859db-e7ee-49f5-9b42-c3a6e6706c5d" xlink:href="cah-20210331.xsd#cah_AggregateAnnualAssessment"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4abe5425-6968-4571-8eb8-ece987728529" xlink:to="loc_cah_AggregateAnnualAssessment_92b859db-e7ee-49f5-9b42-c3a6e6706c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProceedsFromSettlementsOfClassActionLawsuits_27bfdf2b-e0a1-4f73-ac34-78f8443ca8f4" xlink:href="cah-20210331.xsd#cah_ProceedsFromSettlementsOfClassActionLawsuits"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4abe5425-6968-4571-8eb8-ece987728529" xlink:to="loc_cah_ProceedsFromSettlementsOfClassActionLawsuits_27bfdf2b-e0a1-4f73-ac34-78f8443ca8f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/IncomeTaxes" xlink:type="simple" xlink:href="cah-20210331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4511fd57-6d7a-46ce-b53d-e4f91284c15f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_26a17c55-4456-4b0d-adb5-66db664b888f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4511fd57-6d7a-46ce-b53d-e4f91284c15f" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_26a17c55-4456-4b0d-adb5-66db664b888f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_cc8bcc89-4e05-4120-bf2f-7c4b5790b6bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_fa7e9997-1815-4242-98c5-73e74fa2f279" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cc8bcc89-4e05-4120-bf2f-7c4b5790b6bf" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_fa7e9997-1815-4242-98c5-73e74fa2f279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_0919bde3-2e13-4eec-8839-8aaa64c23126" xlink:href="cah-20210331.xsd#cah_OpioidLitigationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_fa7e9997-1815-4242-98c5-73e74fa2f279" xlink:to="loc_cah_OpioidLitigationAxis_0919bde3-2e13-4eec-8839-8aaa64c23126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_3c644663-0f00-411e-a3e5-e21a9bd21038" xlink:href="cah-20210331.xsd#cah_OpioidLitigationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationAxis_0919bde3-2e13-4eec-8839-8aaa64c23126" xlink:to="loc_cah_OpioidLitigationDomain_3c644663-0f00-411e-a3e5-e21a9bd21038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_d6b25bf1-d4f4-4053-ad38-4b50b53764a3" xlink:href="cah-20210331.xsd#cah_TotalOpioidLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationDomain_3c644663-0f00-411e-a3e5-e21a9bd21038" xlink:to="loc_cah_TotalOpioidLitigationMember_d6b25bf1-d4f4-4053-ad38-4b50b53764a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterAxis_fb5e1025-49fe-4aa8-8d7f-5c9b804ec1f4" xlink:href="cah-20210331.xsd#cah_TaxMatterAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_fa7e9997-1815-4242-98c5-73e74fa2f279" xlink:to="loc_cah_TaxMatterAxis_fb5e1025-49fe-4aa8-8d7f-5c9b804ec1f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMatterDomain_02ecccaf-c032-450b-96a6-72a064d5741c" xlink:href="cah-20210331.xsd#cah_TaxMatterDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_TaxMatterAxis_fb5e1025-49fe-4aa8-8d7f-5c9b804ec1f4" xlink:to="loc_cah_TaxMatterDomain_02ecccaf-c032-450b-96a6-72a064d5741c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PatientRecoveryBusinessMember_7605ddd6-b9e7-4fe5-858f-9499b6ccd05e" xlink:href="cah-20210331.xsd#cah_PatientRecoveryBusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_TaxMatterDomain_02ecccaf-c032-450b-96a6-72a064d5741c" xlink:to="loc_cah_PatientRecoveryBusinessMember_7605ddd6-b9e7-4fe5-858f-9499b6ccd05e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CareFusionMember_e838b6d3-e520-4b35-8961-528c86a7ac99" xlink:href="cah-20210331.xsd#cah_CareFusionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_TaxMatterDomain_02ecccaf-c032-450b-96a6-72a064d5741c" xlink:to="loc_cah_CareFusionMember_e838b6d3-e520-4b35-8961-528c86a7ac99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a8536c55-09f3-4b3a-93a9-190e175f23ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_fa7e9997-1815-4242-98c5-73e74fa2f279" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a8536c55-09f3-4b3a-93a9-190e175f23ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c0b9452b-fecb-4df4-a3a3-ea541f352991" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a8536c55-09f3-4b3a-93a9-190e175f23ca" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c0b9452b-fecb-4df4-a3a3-ea541f352991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PatientRecoveryBusinessMember_c4c97058-57ba-403f-a5f2-9b772c887e8d" xlink:href="cah-20210331.xsd#cah_PatientRecoveryBusinessMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c0b9452b-fecb-4df4-a3a3-ea541f352991" xlink:to="loc_cah_PatientRecoveryBusinessMember_c4c97058-57ba-403f-a5f2-9b772c887e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementAxis_18419650-a89a-4cb6-81b8-fe1a3a069f99" xlink:href="cah-20210331.xsd#cah_TaxMattersAgreementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_fa7e9997-1815-4242-98c5-73e74fa2f279" xlink:to="loc_cah_TaxMattersAgreementAxis_18419650-a89a-4cb6-81b8-fe1a3a069f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TaxMattersAgreementDomain_3bc6b1ca-88c2-4180-9224-78530bff940e" xlink:href="cah-20210331.xsd#cah_TaxMattersAgreementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_TaxMattersAgreementAxis_18419650-a89a-4cb6-81b8-fe1a3a069f99" xlink:to="loc_cah_TaxMattersAgreementDomain_3bc6b1ca-88c2-4180-9224-78530bff940e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CareFusionMember_51da63d7-d23c-493b-adae-c7bb1b773739" xlink:href="cah-20210331.xsd#cah_CareFusionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_TaxMattersAgreementDomain_3bc6b1ca-88c2-4180-9224-78530bff940e" xlink:to="loc_cah_CareFusionMember_51da63d7-d23c-493b-adae-c7bb1b773739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_2f8bb1b1-eebf-42e3-9dac-744eca2eddc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_fa7e9997-1815-4242-98c5-73e74fa2f279" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_2f8bb1b1-eebf-42e3-9dac-744eca2eddc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_d77207ed-dceb-481f-8035-90fa8d68181a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2f8bb1b1-eebf-42e3-9dac-744eca2eddc0" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_d77207ed-dceb-481f-8035-90fa8d68181a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_f4cd1258-6965-428e-9ce6-91164648bf93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d77207ed-dceb-481f-8035-90fa8d68181a" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_f4cd1258-6965-428e-9ce6-91164648bf93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_765172b8-7ffd-41f4-8878-59e2cdc7c808" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_fa7e9997-1815-4242-98c5-73e74fa2f279" xlink:to="loc_srt_RangeAxis_765172b8-7ffd-41f4-8878-59e2cdc7c808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_35586f79-109b-4cac-bc8d-6f2b9b1b30c1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_765172b8-7ffd-41f4-8878-59e2cdc7c808" xlink:to="loc_srt_RangeMember_35586f79-109b-4cac-bc8d-6f2b9b1b30c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_594ae1ec-777f-4621-9804-e9e3eb11361c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_35586f79-109b-4cac-bc8d-6f2b9b1b30c1" xlink:to="loc_srt_MinimumMember_594ae1ec-777f-4621-9804-e9e3eb11361c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f732605b-9b68-4eb9-b962-474be1c865e6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_35586f79-109b-4cac-bc8d-6f2b9b1b30c1" xlink:to="loc_srt_MaximumMember_f732605b-9b68-4eb9-b962-474be1c865e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NetOperatingLossCarrybackAxis_6c9d02e2-c3de-4dfe-ae55-c061d0eedf94" xlink:href="cah-20210331.xsd#cah_NetOperatingLossCarrybackAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_fa7e9997-1815-4242-98c5-73e74fa2f279" xlink:to="loc_cah_NetOperatingLossCarrybackAxis_6c9d02e2-c3de-4dfe-ae55-c061d0eedf94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CARESActDomain_733ff0d3-9a01-4678-8702-401c07b7c8dc" xlink:href="cah-20210331.xsd#cah_CARESActDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_NetOperatingLossCarrybackAxis_6c9d02e2-c3de-4dfe-ae55-c061d0eedf94" xlink:to="loc_cah_CARESActDomain_733ff0d3-9a01-4678-8702-401c07b7c8dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NetOperatingLossCarrybackMember_ed58fd56-0f92-457d-a13e-f9d9fb71e1ad" xlink:href="cah-20210331.xsd#cah_NetOperatingLossCarrybackMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CARESActDomain_733ff0d3-9a01-4678-8702-401c07b7c8dc" xlink:to="loc_cah_NetOperatingLossCarrybackMember_ed58fd56-0f92-457d-a13e-f9d9fb71e1ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_e195e344-1a34-4b15-a599-02fd550baba2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_fa7e9997-1815-4242-98c5-73e74fa2f279" xlink:to="loc_srt_StatementScenarioAxis_e195e344-1a34-4b15-a599-02fd550baba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_0adfa7f7-c87b-4fa9-954c-491de6671f09" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_e195e344-1a34-4b15-a599-02fd550baba2" xlink:to="loc_srt_ScenarioUnspecifiedDomain_0adfa7f7-c87b-4fa9-954c-491de6671f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_ef397ce8-6d92-4ca0-9ca7-840d88641c77" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_0adfa7f7-c87b-4fa9-954c-491de6671f09" xlink:to="loc_srt_ScenarioForecastMember_ef397ce8-6d92-4ca0-9ca7-840d88641c77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_84ebd8c4-bc39-4c2f-acae-a68c447378f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_fa7e9997-1815-4242-98c5-73e74fa2f279" xlink:to="loc_us-gaap_TaxCreditCarryforwardLineItems_84ebd8c4-bc39-4c2f-acae-a68c447378f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_379c312d-20b9-4992-bf62-8cf0e206d862" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_84ebd8c4-bc39-4c2f-acae-a68c447378f6" xlink:to="loc_us-gaap_LitigationReserve_379c312d-20b9-4992-bf62-8cf0e206d862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_87b9e517-04e5-4515-b3db-48b305a0ac21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_84ebd8c4-bc39-4c2f-acae-a68c447378f6" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_87b9e517-04e5-4515-b3db-48b305a0ac21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_00415474-5791-4d77-bd8c-7fd63ac5ef01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_84ebd8c4-bc39-4c2f-acae-a68c447378f6" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_00415474-5791-4d77-bd8c-7fd63ac5ef01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_b7ae3a1b-2586-4fa4-8184-58df0c425a41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_84ebd8c4-bc39-4c2f-acae-a68c447378f6" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_b7ae3a1b-2586-4fa4-8184-58df0c425a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_3bdba151-5dcb-4afd-bf53-df94e5e20e2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_84ebd8c4-bc39-4c2f-acae-a68c447378f6" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_3bdba151-5dcb-4afd-bf53-df94e5e20e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_08241f0d-3a34-451a-a335-2fc125092c3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_84ebd8c4-bc39-4c2f-acae-a68c447378f6" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_08241f0d-3a34-451a-a335-2fc125092c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OpenTaxYear_affc2716-d4c0-48f3-9233-d4ade6fac49d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OpenTaxYear"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_84ebd8c4-bc39-4c2f-acae-a68c447378f6" xlink:to="loc_us-gaap_OpenTaxYear_affc2716-d4c0-48f3-9233-d4ade6fac49d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_IndemnificationReceivable_0362bf29-ee5b-4a34-97ed-49327e993a73" xlink:href="cah-20210331.xsd#cah_IndemnificationReceivable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_84ebd8c4-bc39-4c2f-acae-a68c447378f6" xlink:to="loc_cah_IndemnificationReceivable_0362bf29-ee5b-4a34-97ed-49327e993a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_23cef2a7-b101-4082-a5b5-baa88c1ee332" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_84ebd8c4-bc39-4c2f-acae-a68c447378f6" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_23cef2a7-b101-4082-a5b5-baa88c1ee332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_cfb4cd45-bf83-4956-ac08-4aa4e9205c1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_84ebd8c4-bc39-4c2f-acae-a68c447378f6" xlink:to="loc_us-gaap_LitigationSettlementExpense_cfb4cd45-bf83-4956-ac08-4aa4e9205c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_8ca1f60a-9794-469f-ad26-c081379cdc78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_84ebd8c4-bc39-4c2f-acae-a68c447378f6" xlink:to="loc_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent_8ca1f60a-9794-469f-ad26-c081379cdc78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReceivable_78a28168-0559-4444-87a4-7f91f6e04b99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReceivable"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_84ebd8c4-bc39-4c2f-acae-a68c447378f6" xlink:to="loc_us-gaap_IncomeTaxReceivable_78a28168-0559-4444-87a4-7f91f6e04b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="cah-20210331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9710ab6a-afed-4e13-9f88-1b638f4a5f4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_1cf9aae4-9888-4b71-b500-40057de4eb3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9710ab6a-afed-4e13-9f88-1b638f4a5f4d" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_1cf9aae4-9888-4b71-b500-40057de4eb3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="cah-20210331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_107c6582-3b08-4be9-a79e-5936dea4b82f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_62b7d41b-23b7-4386-850b-1afd814e6280" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_107c6582-3b08-4be9-a79e-5936dea4b82f" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_62b7d41b-23b7-4386-850b-1afd814e6280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1851903d-5fd1-4178-9711-fb922fc1ba86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4e29db3-4dd7-4b0c-b571-c1e05604db6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1851903d-5fd1-4178-9711-fb922fc1ba86" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4e29db3-4dd7-4b0c-b571-c1e05604db6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_cd171f5f-402e-4465-a4a1-35f06e486b62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4e29db3-4dd7-4b0c-b571-c1e05604db6c" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_cd171f5f-402e-4465-a4a1-35f06e486b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_055f4327-dff6-4d6a-971d-6f50e4e646f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_cd171f5f-402e-4465-a4a1-35f06e486b62" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_055f4327-dff6-4d6a-971d-6f50e4e646f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_7569c7bf-2cad-4f1f-9053-23c616c4a1a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_055f4327-dff6-4d6a-971d-6f50e4e646f9" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_7569c7bf-2cad-4f1f-9053-23c616c4a1a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsNonrecurringMember_d0cccadd-b01f-4e74-b5f5-768d47028869" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_055f4327-dff6-4d6a-971d-6f50e4e646f9" xlink:to="loc_us-gaap_FairValueMeasurementsNonrecurringMember_d0cccadd-b01f-4e74-b5f5-768d47028869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_97f65cab-0e6f-4865-9a94-8b6da6d8f1c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4e29db3-4dd7-4b0c-b571-c1e05604db6c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_97f65cab-0e6f-4865-9a94-8b6da6d8f1c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0f444bad-9c7f-4b6e-b535-e3a113ef2cfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_97f65cab-0e6f-4865-9a94-8b6da6d8f1c8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0f444bad-9c7f-4b6e-b535-e3a113ef2cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_c03fb0b3-7ccc-4bcf-87c8-03ae0efc5759" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0f444bad-9c7f-4b6e-b535-e3a113ef2cfb" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_c03fb0b3-7ccc-4bcf-87c8-03ae0efc5759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e15c7e8a-af67-4f1e-a6f0-1b008a54300b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0f444bad-9c7f-4b6e-b535-e3a113ef2cfb" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e15c7e8a-af67-4f1e-a6f0-1b008a54300b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_1920d1ee-58eb-4c03-8bfa-88ce3cd3d7b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0f444bad-9c7f-4b6e-b535-e3a113ef2cfb" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_1920d1ee-58eb-4c03-8bfa-88ce3cd3d7b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a5b89362-6f62-4134-868e-d9d46c36225d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4e29db3-4dd7-4b0c-b571-c1e05604db6c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a5b89362-6f62-4134-868e-d9d46c36225d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_5ec05768-7ad3-492b-af97-f2c77ea3e1a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a5b89362-6f62-4134-868e-d9d46c36225d" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_5ec05768-7ad3-492b-af97-f2c77ea3e1a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a561a531-47a6-48a0-ac12-9f14049232d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5ec05768-7ad3-492b-af97-f2c77ea3e1a2" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a561a531-47a6-48a0-ac12-9f14049232d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_fe6e8f96-f979-4dcb-ba59-1bdb689d6742" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5ec05768-7ad3-492b-af97-f2c77ea3e1a2" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_fe6e8f96-f979-4dcb-ba59-1bdb689d6742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_db43d31b-6e56-47a7-ae08-785debefd162" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_5ec05768-7ad3-492b-af97-f2c77ea3e1a2" xlink:to="loc_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet_db43d31b-6e56-47a7-ae08-785debefd162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_cf0a3365-c1df-499b-96b9-40bbbad46d28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a5b89362-6f62-4134-868e-d9d46c36225d" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_cf0a3365-c1df-499b-96b9-40bbbad46d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_01be9cbd-1d42-42a0-8e25-343b8f34151a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a5b89362-6f62-4134-868e-d9d46c36225d" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_01be9cbd-1d42-42a0-8e25-343b8f34151a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_8746447c-2e40-4382-9be1-4dfe7593236c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a5b89362-6f62-4134-868e-d9d46c36225d" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_8746447c-2e40-4382-9be1-4dfe7593236c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstruments" xlink:type="simple" xlink:href="cah-20210331.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_76f81746-faee-4a83-9194-8bd80dc85a6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_04f9e2d4-eb05-4c00-a67b-8c95f308bd51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_76f81746-faee-4a83-9194-8bd80dc85a6d" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_04f9e2d4-eb05-4c00-a67b-8c95f308bd51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="cah-20210331.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_bd6230e2-e219-491f-80af-90fbbd9b23f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_272105ef-bd94-4753-b15c-47e0d51a49bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_bd6230e2-e219-491f-80af-90fbbd9b23f1" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_272105ef-bd94-4753-b15c-47e0d51a49bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_3c9db6cd-a263-4d33-bf3e-a5e10381f062" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_b4e0fd6c-7af5-47dc-8a24-5ec3a6687a0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_3c9db6cd-a263-4d33-bf3e-a5e10381f062" xlink:to="loc_us-gaap_DerivativeTable_b4e0fd6c-7af5-47dc-8a24-5ec3a6687a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9cc5800d-fb68-4b93-9e6b-f6f79f005188" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_b4e0fd6c-7af5-47dc-8a24-5ec3a6687a0b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9cc5800d-fb68-4b93-9e6b-f6f79f005188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ebc54879-c083-4d21-8da7-8948d9106b83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9cc5800d-fb68-4b93-9e6b-f6f79f005188" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ebc54879-c083-4d21-8da7-8948d9106b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_d5b15ab0-7554-4b53-accd-fcb64d4174a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ebc54879-c083-4d21-8da7-8948d9106b83" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_d5b15ab0-7554-4b53-accd-fcb64d4174a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ac151f90-e871-4bab-820e-7826a0bbc8cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_b4e0fd6c-7af5-47dc-8a24-5ec3a6687a0b" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ac151f90-e871-4bab-820e-7826a0bbc8cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_89711d1c-85b9-4825-8c0b-ebf8507af399" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ac151f90-e871-4bab-820e-7826a0bbc8cf" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_89711d1c-85b9-4825-8c0b-ebf8507af399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2dd24ef7-58bb-4bd4-8955-1e7c8000cb9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_89711d1c-85b9-4825-8c0b-ebf8507af399" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2dd24ef7-58bb-4bd4-8955-1e7c8000cb9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_2a3b5edf-42aa-4199-8c03-14b843202252" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_b4e0fd6c-7af5-47dc-8a24-5ec3a6687a0b" xlink:to="loc_us-gaap_HedgingDesignationAxis_2a3b5edf-42aa-4199-8c03-14b843202252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_dcfd8767-0c00-4b81-8f02-ee8aa12822cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_2a3b5edf-42aa-4199-8c03-14b843202252" xlink:to="loc_us-gaap_HedgingDesignationDomain_dcfd8767-0c00-4b81-8f02-ee8aa12822cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_f924b5c0-172e-452b-8607-768c97b7282f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_dcfd8767-0c00-4b81-8f02-ee8aa12822cb" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_f924b5c0-172e-452b-8607-768c97b7282f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_de6d8eb8-3a0d-4768-b694-33ea779442a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_dcfd8767-0c00-4b81-8f02-ee8aa12822cb" xlink:to="loc_us-gaap_NondesignatedMember_de6d8eb8-3a0d-4768-b694-33ea779442a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7ed1a106-ef3d-415b-8333-2344dc00e2fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_b4e0fd6c-7af5-47dc-8a24-5ec3a6687a0b" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7ed1a106-ef3d-415b-8333-2344dc00e2fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_bcbe3499-13aa-4e0c-8ef6-6201ff90eca7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_7ed1a106-ef3d-415b-8333-2344dc00e2fa" xlink:to="loc_us-gaap_HedgingRelationshipDomain_bcbe3499-13aa-4e0c-8ef6-6201ff90eca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_154cd688-8f10-48db-bc4b-e8a892517033" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_bcbe3499-13aa-4e0c-8ef6-6201ff90eca7" xlink:to="loc_us-gaap_FairValueHedgingMember_154cd688-8f10-48db-bc4b-e8a892517033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_083a17cb-cc65-4c43-bc43-b7e504feeb62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_b4e0fd6c-7af5-47dc-8a24-5ec3a6687a0b" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_083a17cb-cc65-4c43-bc43-b7e504feeb62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c23bbce3-8f2b-46ee-b76d-b64a92484d47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_083a17cb-cc65-4c43-bc43-b7e504feeb62" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c23bbce3-8f2b-46ee-b76d-b64a92484d47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_a6a7ae15-1a79-480e-8655-93cb83fa2e43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c23bbce3-8f2b-46ee-b76d-b64a92484d47" xlink:to="loc_us-gaap_CashFlowHedgingMember_a6a7ae15-1a79-480e-8655-93cb83fa2e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_2bc30f33-70bd-4e7d-a1ad-488b30e50e82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c23bbce3-8f2b-46ee-b76d-b64a92484d47" xlink:to="loc_us-gaap_InterestRateSwapMember_2bc30f33-70bd-4e7d-a1ad-488b30e50e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_f565d8fb-0502-47a5-929e-8aa57a99c149" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrencySwapMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c23bbce3-8f2b-46ee-b76d-b64a92484d47" xlink:to="loc_us-gaap_CurrencySwapMember_f565d8fb-0502-47a5-929e-8aa57a99c149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_2b5ff947-3eab-4cf8-bc7f-be7f29ffef69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c23bbce3-8f2b-46ee-b76d-b64a92484d47" xlink:to="loc_us-gaap_ForeignExchangeContractMember_2b5ff947-3eab-4cf8-bc7f-be7f29ffef69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_c5d10dd3-ca8d-4097-ae46-13759e92b43e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_b4e0fd6c-7af5-47dc-8a24-5ec3a6687a0b" xlink:to="loc_us-gaap_DerivativeLineItems_c5d10dd3-ca8d-4097-ae46-13759e92b43e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_f6cf0d4b-3a46-4176-86c3-8914cb66c18b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_c5d10dd3-ca8d-4097-ae46-13759e92b43e" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_f6cf0d4b-3a46-4176-86c3-8914cb66c18b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount_a1b75f60-d04e-4733-8fa8-b9e00c39f313" xlink:href="cah-20210331.xsd#cah_DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_c5d10dd3-ca8d-4097-ae46-13759e92b43e" xlink:to="loc_cah_DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount_a1b75f60-d04e-4733-8fa8-b9e00c39f313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_a62a8c56-aa10-4df8-8b94-7ffd1069fae4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_c5d10dd3-ca8d-4097-ae46-13759e92b43e" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_a62a8c56-aa10-4df8-8b94-7ffd1069fae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_e3704719-81e5-4859-a781-32eec8dc6214" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_c5d10dd3-ca8d-4097-ae46-13759e92b43e" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_e3704719-81e5-4859-a781-32eec8dc6214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_e81dc017-ab4e-4ca5-825a-896ed4b6da66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_c5d10dd3-ca8d-4097-ae46-13759e92b43e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_e81dc017-ab4e-4ca5-825a-896ed4b6da66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_f1a2d26c-5d2d-461e-a8b8-ebf14bf98d06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_c5d10dd3-ca8d-4097-ae46-13759e92b43e" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_f1a2d26c-5d2d-461e-a8b8-ebf14bf98d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_ba8785a0-b80c-43c2-b703-9b039baa23c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_c5d10dd3-ca8d-4097-ae46-13759e92b43e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax_ba8785a0-b80c-43c2-b703-9b039baa23c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredGainLossOnDiscontinuationOfInterestRateFairValueHedge_4a562566-0a28-436a-9e29-171cfb7f9ffc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredGainLossOnDiscontinuationOfInterestRateFairValueHedge"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_c5d10dd3-ca8d-4097-ae46-13759e92b43e" xlink:to="loc_us-gaap_DeferredGainLossOnDiscontinuationOfInterestRateFairValueHedge_4a562566-0a28-436a-9e29-171cfb7f9ffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_DerivativesHedgeDiscontinuancesHeadingInstrumentTerminatedAmount_5d71ba3f-825e-4322-aee9-328825296f27" xlink:href="cah-20210331.xsd#cah_DerivativesHedgeDiscontinuancesHeadingInstrumentTerminatedAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_c5d10dd3-ca8d-4097-ae46-13759e92b43e" xlink:to="loc_cah_DerivativesHedgeDiscontinuancesHeadingInstrumentTerminatedAmount_5d71ba3f-825e-4322-aee9-328825296f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_7adbbff1-b88a-49ea-ac39-981ae907831c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9a17d5ac-6a74-4f7e-b0d2-7b6ce190f365" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_7adbbff1-b88a-49ea-ac39-981ae907831c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9a17d5ac-6a74-4f7e-b0d2-7b6ce190f365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cb38d5bc-ab5a-4aee-802d-fe7e57ed319a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9a17d5ac-6a74-4f7e-b0d2-7b6ce190f365" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cb38d5bc-ab5a-4aee-802d-fe7e57ed319a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_82abb655-0178-41e3-baf3-67c1972c9242" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cb38d5bc-ab5a-4aee-802d-fe7e57ed319a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_82abb655-0178-41e3-baf3-67c1972c9242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_88f6fef2-7183-4053-b3dd-20f1539dbed5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_82abb655-0178-41e3-baf3-67c1972c9242" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_88f6fef2-7183-4053-b3dd-20f1539dbed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_08fd4039-2179-41c8-8e22-fe4fb7be5dda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9a17d5ac-6a74-4f7e-b0d2-7b6ce190f365" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_08fd4039-2179-41c8-8e22-fe4fb7be5dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_e57a2cb5-dc8a-4772-8099-9bb46a6c4084" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_08fd4039-2179-41c8-8e22-fe4fb7be5dda" xlink:to="loc_us-gaap_DebtInstrumentFairValue_e57a2cb5-dc8a-4772-8099-9bb46a6c4084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings_36cd688b-de15-47b3-baa2-fa61bcab8d45" xlink:href="cah-20210331.xsd#cah_CarryingAmountofLongTermandotherShortTermBorrowings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_08fd4039-2179-41c8-8e22-fe4fb7be5dda" xlink:to="loc_cah_CarryingAmountofLongTermandotherShortTermBorrowings_36cd688b-de15-47b3-baa2-fa61bcab8d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="cah-20210331.xsd#ShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c3a35c22-e2ed-43cb-b2ed-4a9edf81a76f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1b5082ed-6da5-4b7e-8727-1b4e6815c0e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c3a35c22-e2ed-43cb-b2ed-4a9edf81a76f" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1b5082ed-6da5-4b7e-8727-1b4e6815c0e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityTables" xlink:type="simple" xlink:href="cah-20210331.xsd#ShareholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_06f7a1fb-b445-43f2-9ab2-dab14fa1af0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_15db6a86-71ae-4923-b27e-4a40eeac91fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_06f7a1fb-b445-43f2-9ab2-dab14fa1af0e" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_15db6a86-71ae-4923-b27e-4a40eeac91fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#ShareholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_cc6ff01f-fb98-4ab6-aa4e-863150ae8e16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1b5f72f1-7be8-41e9-ad1b-e0a67b0c14d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_cc6ff01f-fb98-4ab6-aa4e-863150ae8e16" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1b5f72f1-7be8-41e9-ad1b-e0a67b0c14d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_5cf26586-07f8-484d-83c6-6e8f09a3c001" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1b5f72f1-7be8-41e9-ad1b-e0a67b0c14d3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_5cf26586-07f8-484d-83c6-6e8f09a3c001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c7059d68-66fa-4fd7-83e4-c8947455ab52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_5cf26586-07f8-484d-83c6-6e8f09a3c001" xlink:to="loc_us-gaap_EquityComponentDomain_c7059d68-66fa-4fd7-83e4-c8947455ab52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_81429178-3ef5-4200-b81a-24044c1f57b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c7059d68-66fa-4fd7-83e4-c8947455ab52" xlink:to="loc_us-gaap_TreasuryStockMember_81429178-3ef5-4200-b81a-24044c1f57b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_94ed4260-0973-463d-934d-b3550e55e6e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1b5f72f1-7be8-41e9-ad1b-e0a67b0c14d3" xlink:to="loc_us-gaap_ClassOfStockLineItems_94ed4260-0973-463d-934d-b3550e55e6e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_371ae0bc-78c7-4a13-9851-81870820b1ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_94ed4260-0973-463d-934d-b3550e55e6e3" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_371ae0bc-78c7-4a13-9851-81870820b1ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_ea650f3c-237b-461f-94f8-7f99a5a68a8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_94ed4260-0973-463d-934d-b3550e55e6e3" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_ea650f3c-237b-461f-94f8-7f99a5a68a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_20bcae50-a0e8-4e98-afc4-5c24b059c1dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_94ed4260-0973-463d-934d-b3550e55e6e3" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_20bcae50-a0e8-4e98-afc4-5c24b059c1dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a73d4c28-2e87-4cbd-a6c3-69fb22691c14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_ac023935-7ad1-44bc-b62c-d2e9f6d55033" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a73d4c28-2e87-4cbd-a6c3-69fb22691c14" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_ac023935-7ad1-44bc-b62c-d2e9f6d55033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_38e230fb-baa1-4d8f-8be8-1814d0f9de06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_ac023935-7ad1-44bc-b62c-d2e9f6d55033" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_38e230fb-baa1-4d8f-8be8-1814d0f9de06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_56884ca5-c796-4a45-9bc8-fc103d7ed309" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_38e230fb-baa1-4d8f-8be8-1814d0f9de06" xlink:to="loc_us-gaap_EquityComponentDomain_56884ca5-c796-4a45-9bc8-fc103d7ed309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_26daa73c-3463-4564-9810-63ca9b1b9df9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_56884ca5-c796-4a45-9bc8-fc103d7ed309" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_26daa73c-3463-4564-9810-63ca9b1b9df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_8e41f3a4-eaee-4df3-86e7-33a6a5a1d6b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_56884ca5-c796-4a45-9bc8-fc103d7ed309" xlink:to="loc_us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember_8e41f3a4-eaee-4df3-86e7-33a6a5a1d6b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_386e7a93-7bc0-41d0-b180-a5545c8192e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_56884ca5-c796-4a45-9bc8-fc103d7ed309" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_386e7a93-7bc0-41d0-b180-a5545c8192e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ea6b4e14-c710-4f7b-a6f2-421671ecd181" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_56884ca5-c796-4a45-9bc8-fc103d7ed309" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ea6b4e14-c710-4f7b-a6f2-421671ecd181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_99eac9f5-c427-4333-95cd-ecf005525d45" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_ac023935-7ad1-44bc-b62c-d2e9f6d55033" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_99eac9f5-c427-4333-95cd-ecf005525d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_1ab0a059-fc38-42da-b964-bb909f40de76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems_99eac9f5-c427-4333-95cd-ecf005525d45" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_1ab0a059-fc38-42da-b964-bb909f40de76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5b4a6763-4641-401f-9cbb-611c3c0f9316" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_1ab0a059-fc38-42da-b964-bb909f40de76" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5b4a6763-4641-401f-9cbb-611c3c0f9316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_1949fa44-a1aa-4f8e-b5a4-b1e0b464e384" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_1ab0a059-fc38-42da-b964-bb909f40de76" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_1949fa44-a1aa-4f8e-b5a4-b1e0b464e384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_3250b5b7-a50d-4514-9618-ddd6463acf32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_1ab0a059-fc38-42da-b964-bb909f40de76" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_3250b5b7-a50d-4514-9618-ddd6463acf32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a6bd44c6-a083-44f6-9fa2-4913aa669544" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_1ab0a059-fc38-42da-b964-bb909f40de76" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_a6bd44c6-a083-44f6-9fa2-4913aa669544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c40219ec-4ad8-499e-b7fd-3888b0ad57d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_1ab0a059-fc38-42da-b964-bb909f40de76" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c40219ec-4ad8-499e-b7fd-3888b0ad57d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc" xlink:type="simple" xlink:href="cah-20210331.xsd#EarningsPerShareAttributabletoCardinalHealthInc"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_092179b9-aab2-4ba3-b860-376c1921ac1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_d611c8c7-ffa7-4e6f-b73e-f8863fda77c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_092179b9-aab2-4ba3-b860-376c1921ac1c" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_d611c8c7-ffa7-4e6f-b73e-f8863fda77c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables" xlink:type="simple" xlink:href="cah-20210331.xsd#EarningsPerShareAttributabletoCardinalHealthIncTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7b6125d2-5f48-45e9-be2c-b4df09182fb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_1991c9ce-413c-4941-90e3-716546432991" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7b6125d2-5f48-45e9-be2c-b4df09182fb9" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_1991c9ce-413c-4941-90e3-716546432991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3573b5cd-4f76-4503-a475-f884db8e8f97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_54c0ede8-2354-49c5-bc76-57b0979f65f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3573b5cd-4f76-4503-a475-f884db8e8f97" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_54c0ede8-2354-49c5-bc76-57b0979f65f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss_1c54de28-c8d6-400f-8463-fedbadc9b3d1" xlink:href="cah-20210331.xsd#cah_Sharesthatwouldbeantidilutiveasaresultofnetloss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3573b5cd-4f76-4503-a475-f884db8e8f97" xlink:to="loc_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss_1c54de28-c8d6-400f-8463-fedbadc9b3d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_870aa869-5335-489e-bff0-419764d4bc7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b3f65bc5-0447-4fb9-a616-db900de44efd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_870aa869-5335-489e-bff0-419764d4bc7e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b3f65bc5-0447-4fb9-a616-db900de44efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_e911a6ff-2b4a-4fa0-9ee2-1bfcdd732ee4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_870aa869-5335-489e-bff0-419764d4bc7e" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_e911a6ff-2b4a-4fa0-9ee2-1bfcdd732ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_9084ef4a-ede1-4053-b046-d274510b6e98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_e911a6ff-2b4a-4fa0-9ee2-1bfcdd732ee4" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_9084ef4a-ede1-4053-b046-d274510b6e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_21a7a1dd-95b0-491e-ab05-9bd6589226db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_870aa869-5335-489e-bff0-419764d4bc7e" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_21a7a1dd-95b0-491e-ab05-9bd6589226db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformation" xlink:type="simple" xlink:href="cah-20210331.xsd#SegmentInformation"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_c2dddf45-74f6-47fb-b6d1-77ccca57dd97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_abcf7e12-2610-43d0-8321-504155118bf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c2dddf45-74f6-47fb-b6d1-77ccca57dd97" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_abcf7e12-2610-43d0-8321-504155118bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="cah-20210331.xsd#SegmentInformationTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_121f5b97-f741-4960-865d-e15e2dbc2dca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_8e4f0e33-1a38-4314-a695-76d030d0820c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_121f5b97-f741-4960-865d-e15e2dbc2dca" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_8e4f0e33-1a38-4314-a695-76d030d0820c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_9a556062-bd4a-4517-a249-3157f4c7fd55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_121f5b97-f741-4960-865d-e15e2dbc2dca" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_9a556062-bd4a-4517-a249-3157f4c7fd55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_f6f0f52b-d5bb-4e4f-8e41-5239617bb0db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_121f5b97-f741-4960-865d-e15e2dbc2dca" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_f6f0f52b-d5bb-4e4f-8e41-5239617bb0db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_e25b83b7-a41b-4f10-99d7-e9ca10b8e1dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_121f5b97-f741-4960-865d-e15e2dbc2dca" xlink:to="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock_e25b83b7-a41b-4f10-99d7-e9ca10b8e1dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationNarrativeDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#SegmentInformationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_b33fa12d-3739-418a-a4f8-e4ca68ed5256" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9efaaf42-0f14-45d9-a933-0292f975a92a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_b33fa12d-3739-418a-a4f8-e4ca68ed5256" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9efaaf42-0f14-45d9-a933-0292f975a92a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SterileSurgicalGownRecallAxis_5aa9f09d-dae8-4cf1-960f-a652b73b6093" xlink:href="cah-20210331.xsd#cah_SterileSurgicalGownRecallAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9efaaf42-0f14-45d9-a933-0292f975a92a" xlink:to="loc_cah_SterileSurgicalGownRecallAxis_5aa9f09d-dae8-4cf1-960f-a652b73b6093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SterileSurgicalGownRecallDomain_7bc74d22-999a-4942-a737-02c00ff59ece" xlink:href="cah-20210331.xsd#cah_SterileSurgicalGownRecallDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_SterileSurgicalGownRecallAxis_5aa9f09d-dae8-4cf1-960f-a652b73b6093" xlink:to="loc_cah_SterileSurgicalGownRecallDomain_7bc74d22-999a-4942-a737-02c00ff59ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SterileSurgicalGownRecallMember_5cc8ffe0-d814-4afb-b298-53694ebe058c" xlink:href="cah-20210331.xsd#cah_SterileSurgicalGownRecallMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_SterileSurgicalGownRecallDomain_7bc74d22-999a-4942-a737-02c00ff59ece" xlink:to="loc_cah_SterileSurgicalGownRecallMember_5cc8ffe0-d814-4afb-b298-53694ebe058c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationAxis_8f2246e0-d602-4346-a6e5-1ca5642dbaf2" xlink:href="cah-20210331.xsd#cah_OpioidLitigationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9efaaf42-0f14-45d9-a933-0292f975a92a" xlink:to="loc_cah_OpioidLitigationAxis_8f2246e0-d602-4346-a6e5-1ca5642dbaf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_OpioidLitigationDomain_91148723-2176-4631-bdb3-9540982c560e" xlink:href="cah-20210331.xsd#cah_OpioidLitigationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationAxis_8f2246e0-d602-4346-a6e5-1ca5642dbaf2" xlink:to="loc_cah_OpioidLitigationDomain_91148723-2176-4631-bdb3-9540982c560e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_TotalOpioidLitigationMember_6fa9e015-3e33-4c0d-b78f-e38a4bfd34ed" xlink:href="cah-20210331.xsd#cah_TotalOpioidLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_OpioidLitigationDomain_91148723-2176-4631-bdb3-9540982c560e" xlink:to="loc_cah_TotalOpioidLitigationMember_6fa9e015-3e33-4c0d-b78f-e38a4bfd34ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_9ec044be-25ea-489f-8339-52a65cafe1c1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9efaaf42-0f14-45d9-a933-0292f975a92a" xlink:to="loc_srt_LitigationCaseAxis_9ec044be-25ea-489f-8339-52a65cafe1c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_0503bca2-6f7f-41dd-87c6-dcbe6dc33eb2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_9ec044be-25ea-489f-8339-52a65cafe1c1" xlink:to="loc_srt_LitigationCaseTypeDomain_0503bca2-6f7f-41dd-87c6-dcbe6dc33eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NewYorkOpioidStewardshipActMember_988ed933-1038-409a-9048-091876ce63b7" xlink:href="cah-20210331.xsd#cah_NewYorkOpioidStewardshipActMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_0503bca2-6f7f-41dd-87c6-dcbe6dc33eb2" xlink:to="loc_cah_NewYorkOpioidStewardshipActMember_988ed933-1038-409a-9048-091876ce63b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_609a57bd-f26e-4a8b-8c7f-b56a2721fd57" xlink:href="cah-20210331.xsd#cah_CordisDivestitureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9efaaf42-0f14-45d9-a933-0292f975a92a" xlink:to="loc_cah_CordisDivestitureAxis_609a57bd-f26e-4a8b-8c7f-b56a2721fd57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_05d407b3-0788-476b-a437-49a8deb4cf20" xlink:href="cah-20210331.xsd#cah_CordisDivestitureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureAxis_609a57bd-f26e-4a8b-8c7f-b56a2721fd57" xlink:to="loc_cah_CordisDivestitureDomain_05d407b3-0788-476b-a437-49a8deb4cf20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_a36fba51-9862-4140-8e4c-f15c9df6ea90" xlink:href="cah-20210331.xsd#cah_CordisDivestitureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureDomain_05d407b3-0788-476b-a437-49a8deb4cf20" xlink:to="loc_cah_CordisDivestitureMember_a36fba51-9862-4140-8e4c-f15c9df6ea90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_5140f9dc-eb23-43db-8449-6147a37c585a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9efaaf42-0f14-45d9-a933-0292f975a92a" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_5140f9dc-eb23-43db-8449-6147a37c585a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_73dbc06b-e7e8-4833-b02b-10ab7e675ad7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5140f9dc-eb23-43db-8449-6147a37c585a" xlink:to="loc_us-gaap_SegmentDomain_73dbc06b-e7e8-4833-b02b-10ab7e675ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_36662086-a714-4c83-a20f-736127126a25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9efaaf42-0f14-45d9-a933-0292f975a92a" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_36662086-a714-4c83-a20f-736127126a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_ecd7f25e-ca71-4ad7-bb66-5f2f0c645866" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36662086-a714-4c83-a20f-736127126a25" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_ecd7f25e-ca71-4ad7-bb66-5f2f0c645866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRecallExpense_04208cd5-b7e0-405b-b72d-ac0aa6f28da2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRecallExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36662086-a714-4c83-a20f-736127126a25" xlink:to="loc_us-gaap_InventoryRecallExpense_04208cd5-b7e0-405b-b72d-ac0aa6f28da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProjectCostsOnInvestmentAndOtherSpending_fd73c14d-e37c-49db-97ad-b2c743c4b4d4" xlink:href="cah-20210331.xsd#cah_ProjectCostsOnInvestmentAndOtherSpending"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36662086-a714-4c83-a20f-736127126a25" xlink:to="loc_cah_ProjectCostsOnInvestmentAndOtherSpending_fd73c14d-e37c-49db-97ad-b2c743c4b4d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_cea43f2c-3c2e-4292-901a-cc782a1e358e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36662086-a714-4c83-a20f-736127126a25" xlink:to="loc_us-gaap_NumberOfReportableSegments_cea43f2c-3c2e-4292-901a-cc782a1e358e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_6152fa21-63e5-414a-a77e-1e2293f60a99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36662086-a714-4c83-a20f-736127126a25" xlink:to="loc_us-gaap_NumberOfOperatingSegments_6152fa21-63e5-414a-a77e-1e2293f60a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_241f7ea5-a633-44c6-95c9-8571f8115445" xlink:href="cah-20210331.xsd#cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36662086-a714-4c83-a20f-736127126a25" xlink:to="loc_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct_241f7ea5-a633-44c6-95c9-8571f8115445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_WriteDownOfAssetsHeldForSale_a853ae6d-f118-42b9-adfa-2a6bb9eb80da" xlink:href="cah-20210331.xsd#cah_WriteDownOfAssetsHeldForSale"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_36662086-a714-4c83-a20f-736127126a25" xlink:to="loc_cah_WriteDownOfAssetsHeldForSale_a853ae6d-f118-42b9-adfa-2a6bb9eb80da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_afc19eaf-b5f3-4c31-9bb6-457a5967ec92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_b33fa12d-3739-418a-a4f8-e4ca68ed5256" xlink:to="loc_us-gaap_NumberOfOperatingSegments_afc19eaf-b5f3-4c31-9bb6-457a5967ec92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_9050a846-c9d4-420a-a445-4f47222ef033" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_b33fa12d-3739-418a-a4f8-e4ca68ed5256" xlink:to="loc_us-gaap_NumberOfReportableSegments_9050a846-c9d4-420a-a445-4f47222ef033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ProjectCostsOnInvestmentAndOtherSpending_6b113b7b-1065-4297-9446-6fa3a2638e07" xlink:href="cah-20210331.xsd#cah_ProjectCostsOnInvestmentAndOtherSpending"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_b33fa12d-3739-418a-a4f8-e4ca68ed5256" xlink:to="loc_cah_ProjectCostsOnInvestmentAndOtherSpending_6b113b7b-1065-4297-9446-6fa3a2638e07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#SegmentInformationRevenuebyReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_7f2ca0d1-42a8-4307-bbe9-a5c4e8617cb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_73e57dab-5998-4598-9b19-bf69f9e97862" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_7f2ca0d1-42a8-4307-bbe9-a5c4e8617cb7" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_73e57dab-5998-4598-9b19-bf69f9e97862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_7718022b-e0ae-4d8e-9a90-58cad557d571" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_73e57dab-5998-4598-9b19-bf69f9e97862" xlink:to="loc_us-gaap_SubsegmentsAxis_7718022b-e0ae-4d8e-9a90-58cad557d571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_f8e1f78e-1b61-4550-9d5b-9f5110bedb79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_7718022b-e0ae-4d8e-9a90-58cad557d571" xlink:to="loc_us-gaap_SubsegmentsDomain_f8e1f78e-1b61-4550-9d5b-9f5110bedb79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalDistributionandSpecialtyMember_bf50c32e-14ac-4c4d-bf5e-ab539e5c0b77" xlink:href="cah-20210331.xsd#cah_PharmaceuticalDistributionandSpecialtyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_f8e1f78e-1b61-4550-9d5b-9f5110bedb79" xlink:to="loc_cah_PharmaceuticalDistributionandSpecialtyMember_bf50c32e-14ac-4c4d-bf5e-ab539e5c0b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_NuclearPrecisionHealthServicesMember_28cc9233-9446-4176-ba79-fd4beb1154cf" xlink:href="cah-20210331.xsd#cah_NuclearPrecisionHealthServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_f8e1f78e-1b61-4550-9d5b-9f5110bedb79" xlink:to="loc_cah_NuclearPrecisionHealthServicesMember_28cc9233-9446-4176-ba79-fd4beb1154cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicaldistributionandproductsMember_1d610b5f-7b58-43b8-ae85-e3b54353fcad" xlink:href="cah-20210331.xsd#cah_MedicaldistributionandproductsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_f8e1f78e-1b61-4550-9d5b-9f5110bedb79" xlink:to="loc_cah_MedicaldistributionandproductsMember_1d610b5f-7b58-43b8-ae85-e3b54353fcad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CardinalHealthAtHomeMember_33c098a5-8f3e-470d-b456-c44d376f08f5" xlink:href="cah-20210331.xsd#cah_CardinalHealthAtHomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_f8e1f78e-1b61-4550-9d5b-9f5110bedb79" xlink:to="loc_cah_CardinalHealthAtHomeMember_33c098a5-8f3e-470d-b456-c44d376f08f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_f5f7d3f2-f7ed-4363-b646-eeebdacbc7cf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_73e57dab-5998-4598-9b19-bf69f9e97862" xlink:to="loc_srt_ConsolidationItemsAxis_f5f7d3f2-f7ed-4363-b646-eeebdacbc7cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_6bd2f737-1609-4da1-800c-64167d77da6d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_f5f7d3f2-f7ed-4363-b646-eeebdacbc7cf" xlink:to="loc_srt_ConsolidationItemsDomain_6bd2f737-1609-4da1-800c-64167d77da6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_5c57d2a0-539c-4f1f-b27a-fa55fb758a39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_6bd2f737-1609-4da1-800c-64167d77da6d" xlink:to="loc_us-gaap_OperatingSegmentsMember_5c57d2a0-539c-4f1f-b27a-fa55fb758a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_f5432687-42ba-485b-a71a-d039d93410e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_6bd2f737-1609-4da1-800c-64167d77da6d" xlink:to="loc_us-gaap_CorporateNonSegmentMember_f5432687-42ba-485b-a71a-d039d93410e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_28d2e0b2-edcf-4622-b0af-9a7d6f414193" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_73e57dab-5998-4598-9b19-bf69f9e97862" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_28d2e0b2-edcf-4622-b0af-9a7d6f414193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3317e79f-dee3-48e8-b559-07f91a96d2ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_28d2e0b2-edcf-4622-b0af-9a7d6f414193" xlink:to="loc_us-gaap_SegmentDomain_3317e79f-dee3-48e8-b559-07f91a96d2ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_b91e2801-6631-4743-8a3f-9c389183760d" xlink:href="cah-20210331.xsd#cah_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3317e79f-dee3-48e8-b559-07f91a96d2ae" xlink:to="loc_cah_PharmaceuticalMember_b91e2801-6631-4743-8a3f-9c389183760d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_a5b4e9a2-ebb6-4778-a3c5-22aa0726265b" xlink:href="cah-20210331.xsd#cah_MedicalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3317e79f-dee3-48e8-b559-07f91a96d2ae" xlink:to="loc_cah_MedicalMember_a5b4e9a2-ebb6-4778-a3c5-22aa0726265b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_654e1993-afcb-462c-960c-05076cf4e587" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_73e57dab-5998-4598-9b19-bf69f9e97862" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_654e1993-afcb-462c-960c-05076cf4e587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_631a2ff8-72fd-47e1-b02a-fc1f635fdf73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_654e1993-afcb-462c-960c-05076cf4e587" xlink:to="loc_us-gaap_Revenues_631a2ff8-72fd-47e1-b02a-fc1f635fdf73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#SegmentInformationSegmentProfitbyReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_b105a8bd-996d-4aec-a374-91a5c5461333" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_ebbcf790-8a4e-4722-823a-cce794a477a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_b105a8bd-996d-4aec-a374-91a5c5461333" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_ebbcf790-8a4e-4722-823a-cce794a477a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8b208f5a-ff2f-4d2a-b47b-66a84dbb7971" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_ebbcf790-8a4e-4722-823a-cce794a477a9" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8b208f5a-ff2f-4d2a-b47b-66a84dbb7971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f620a08b-ff3c-4437-9535-666df4b03822" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_8b208f5a-ff2f-4d2a-b47b-66a84dbb7971" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_f620a08b-ff3c-4437-9535-666df4b03822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_656034f2-7b02-45fb-955b-c7918f7b8c24" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_ebbcf790-8a4e-4722-823a-cce794a477a9" xlink:to="loc_srt_ConsolidationItemsAxis_656034f2-7b02-45fb-955b-c7918f7b8c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_ef7446ca-b814-45b0-a508-7b59ce1872ae" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_656034f2-7b02-45fb-955b-c7918f7b8c24" xlink:to="loc_srt_ConsolidationItemsDomain_ef7446ca-b814-45b0-a508-7b59ce1872ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_55ba15c1-7b84-4984-a405-acc84bdc1318" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_ef7446ca-b814-45b0-a508-7b59ce1872ae" xlink:to="loc_us-gaap_OperatingSegmentsMember_55ba15c1-7b84-4984-a405-acc84bdc1318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_3cb48c2a-2837-4ccc-88a1-63cc6eb25daa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_ef7446ca-b814-45b0-a508-7b59ce1872ae" xlink:to="loc_us-gaap_CorporateNonSegmentMember_3cb48c2a-2837-4ccc-88a1-63cc6eb25daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_483a8021-04f6-417f-bb98-4264d12fcf8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_ebbcf790-8a4e-4722-823a-cce794a477a9" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_483a8021-04f6-417f-bb98-4264d12fcf8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_1036f40f-7131-406d-9f5b-c998cec87206" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_483a8021-04f6-417f-bb98-4264d12fcf8c" xlink:to="loc_us-gaap_SegmentDomain_1036f40f-7131-406d-9f5b-c998cec87206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_18ea738d-3df2-4386-bb69-b7ea0119e66f" xlink:href="cah-20210331.xsd#cah_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1036f40f-7131-406d-9f5b-c998cec87206" xlink:to="loc_cah_PharmaceuticalMember_18ea738d-3df2-4386-bb69-b7ea0119e66f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_42340755-803c-4784-af14-98487af42c08" xlink:href="cah-20210331.xsd#cah_MedicalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_1036f40f-7131-406d-9f5b-c998cec87206" xlink:to="loc_cah_MedicalMember_42340755-803c-4784-af14-98487af42c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_fa2f1697-30c6-4a70-8091-6e1af92c3485" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_ebbcf790-8a4e-4722-823a-cce794a477a9" xlink:to="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_fa2f1697-30c6-4a70-8091-6e1af92c3485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_579cd751-8eef-40a2-80c6-eae8bd916b6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_fa2f1697-30c6-4a70-8091-6e1af92c3485" xlink:to="loc_us-gaap_OperatingIncomeLoss_579cd751-8eef-40a2-80c6-eae8bd916b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_2fd086f2-9dbe-4e67-b84f-ebc6e0ce2124" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_bee1ec1c-5b3a-4665-8b02-a4c15e3b49f9" xlink:href="cah-20210331.xsd#cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2fd086f2-9dbe-4e67-b84f-ebc6e0ce2124" xlink:to="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_bee1ec1c-5b3a-4665-8b02-a4c15e3b49f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_97be6c76-cd22-47b0-a241-1a86a4a761b1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_bee1ec1c-5b3a-4665-8b02-a4c15e3b49f9" xlink:to="loc_srt_ConsolidationItemsAxis_97be6c76-cd22-47b0-a241-1a86a4a761b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_e172664d-4941-4a53-878e-656ec5b677c6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_97be6c76-cd22-47b0-a241-1a86a4a761b1" xlink:to="loc_srt_ConsolidationItemsDomain_e172664d-4941-4a53-878e-656ec5b677c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_941ae1c2-b0e8-4910-b8be-720a7bfd213f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_e172664d-4941-4a53-878e-656ec5b677c6" xlink:to="loc_us-gaap_OperatingSegmentsMember_941ae1c2-b0e8-4910-b8be-720a7bfd213f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_e058e81f-4b2c-4668-a753-e45a979b8de0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_e172664d-4941-4a53-878e-656ec5b677c6" xlink:to="loc_us-gaap_CorporateNonSegmentMember_e058e81f-4b2c-4668-a753-e45a979b8de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_53f25bf5-7f79-4af1-88d3-3021c69d2888" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_bee1ec1c-5b3a-4665-8b02-a4c15e3b49f9" xlink:to="loc_srt_StatementGeographicalAxis_53f25bf5-7f79-4af1-88d3-3021c69d2888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_16eccae0-11b4-4438-bbd9-6c49dc827416" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_53f25bf5-7f79-4af1-88d3-3021c69d2888" xlink:to="loc_srt_SegmentGeographicalDomain_16eccae0-11b4-4438-bbd9-6c49dc827416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_ddb4c30d-9921-43b6-bc28-39481a89f32a" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_16eccae0-11b4-4438-bbd9-6c49dc827416" xlink:to="loc_country_US_ddb4c30d-9921-43b6-bc28-39481a89f32a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_5319a89b-95d5-4974-816e-dc116f52d236" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_16eccae0-11b4-4438-bbd9-6c49dc827416" xlink:to="loc_us-gaap_NonUsMember_5319a89b-95d5-4974-816e-dc116f52d236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_c2bc7360-2605-42ee-879b-4d8cb02b34ea" xlink:href="cah-20210331.xsd#cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable_bee1ec1c-5b3a-4665-8b02-a4c15e3b49f9" xlink:to="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_c2bc7360-2605-42ee-879b-4d8cb02b34ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_0b63fc45-3211-44d8-8f97-fe146fe478f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems_c2bc7360-2605-42ee-879b-4d8cb02b34ea" xlink:to="loc_us-gaap_Revenues_0b63fc45-3211-44d8-8f97-fe146fe478f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#SegmentInformationAssetsbyReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_4f48ed79-a29a-48d9-a5fb-9756aaf980aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2374bedf-689d-4785-b802-91512bbc30e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4f48ed79-a29a-48d9-a5fb-9756aaf980aa" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2374bedf-689d-4785-b802-91512bbc30e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_ef636eca-ee34-4bb2-bbd8-5f0f8c0392d2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2374bedf-689d-4785-b802-91512bbc30e4" xlink:to="loc_srt_ConsolidationItemsAxis_ef636eca-ee34-4bb2-bbd8-5f0f8c0392d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_47a2f88c-4257-4268-a505-70dadde061e2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_ef636eca-ee34-4bb2-bbd8-5f0f8c0392d2" xlink:to="loc_srt_ConsolidationItemsDomain_47a2f88c-4257-4268-a505-70dadde061e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_e78a3ab4-c67f-4910-98af-f84f2f30378b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_47a2f88c-4257-4268-a505-70dadde061e2" xlink:to="loc_us-gaap_OperatingSegmentsMember_e78a3ab4-c67f-4910-98af-f84f2f30378b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_0d3ac88c-522a-4fa8-8b20-527de722832b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_47a2f88c-4257-4268-a505-70dadde061e2" xlink:to="loc_us-gaap_CorporateNonSegmentMember_0d3ac88c-522a-4fa8-8b20-527de722832b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_e259e43a-aa3c-4582-8fd5-4525d569c0b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2374bedf-689d-4785-b802-91512bbc30e4" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_e259e43a-aa3c-4582-8fd5-4525d569c0b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_66fe2199-6b6e-4d14-8cd7-44003605ba86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_e259e43a-aa3c-4582-8fd5-4525d569c0b4" xlink:to="loc_us-gaap_SegmentDomain_66fe2199-6b6e-4d14-8cd7-44003605ba86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_PharmaceuticalMember_7bc338ec-fc11-4fd3-8b2b-ca958c3768a5" xlink:href="cah-20210331.xsd#cah_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_66fe2199-6b6e-4d14-8cd7-44003605ba86" xlink:to="loc_cah_PharmaceuticalMember_7bc338ec-fc11-4fd3-8b2b-ca958c3768a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_MedicalMember_a3c3e9a3-4f49-4637-9a60-fbf5b4f9ab2a" xlink:href="cah-20210331.xsd#cah_MedicalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_66fe2199-6b6e-4d14-8cd7-44003605ba86" xlink:to="loc_cah_MedicalMember_a3c3e9a3-4f49-4637-9a60-fbf5b4f9ab2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureAxis_d85c2563-107b-438e-882b-a0a8a8a2d8f1" xlink:href="cah-20210331.xsd#cah_CordisDivestitureAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2374bedf-689d-4785-b802-91512bbc30e4" xlink:to="loc_cah_CordisDivestitureAxis_d85c2563-107b-438e-882b-a0a8a8a2d8f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureDomain_f1c7a9a6-bb13-47e7-939a-bacde5acf2f4" xlink:href="cah-20210331.xsd#cah_CordisDivestitureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureAxis_d85c2563-107b-438e-882b-a0a8a8a2d8f1" xlink:to="loc_cah_CordisDivestitureDomain_f1c7a9a6-bb13-47e7-939a-bacde5acf2f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_CordisDivestitureMember_49505474-2a7b-4796-afcd-575556e99be9" xlink:href="cah-20210331.xsd#cah_CordisDivestitureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cah_CordisDivestitureDomain_f1c7a9a6-bb13-47e7-939a-bacde5acf2f4" xlink:to="loc_cah_CordisDivestitureMember_49505474-2a7b-4796-afcd-575556e99be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_daf10bcc-cc5e-4383-8572-9324f89b0429" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_2374bedf-689d-4785-b802-91512bbc30e4" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_daf10bcc-cc5e-4383-8572-9324f89b0429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_6a7ca0f3-9cf0-4c88-aa86-704562925916" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_daf10bcc-cc5e-4383-8572-9324f89b0429" xlink:to="loc_us-gaap_Assets_6a7ca0f3-9cf0-4c88-aa86-704562925916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_16e5e7d8-887c-4b19-825d-0127d009d0d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_daf10bcc-cc5e-4383-8572-9324f89b0429" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_16e5e7d8-887c-4b19-825d-0127d009d0d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="cah-20210331.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5655b098-abb6-4c20-b2e1-3359321d0c80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_cc4b081e-60ac-4122-a933-dd34c19952b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5655b098-abb6-4c20-b2e1-3359321d0c80" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_cc4b081e-60ac-4122-a933-dd34c19952b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="cah-20210331.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_854fd716-91b5-4166-8571-f2a72395fc31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_ac9226fd-f4c0-47c3-a379-8d9b936818f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_854fd716-91b5-4166-8571-f2a72395fc31" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_ac9226fd-f4c0-47c3-a379-8d9b936818f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_b6a52776-937f-44cc-82d4-57f8c5a7e38f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_854fd716-91b5-4166-8571-f2a72395fc31" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_b6a52776-937f-44cc-82d4-57f8c5a7e38f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_AdditionalStockOptionPlanDataTableTextBlock_ee0988ed-bddb-4a61-9626-efbc581ad0ad" xlink:href="cah-20210331.xsd#cah_AdditionalStockOptionPlanDataTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_854fd716-91b5-4166-8571-f2a72395fc31" xlink:to="loc_cah_AdditionalStockOptionPlanDataTableTextBlock_ee0988ed-bddb-4a61-9626-efbc581ad0ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_43559a21-14bc-4bdb-8a77-668a570235de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_854fd716-91b5-4166-8571-f2a72395fc31" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_43559a21-14bc-4bdb-8a77-668a570235de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_6e6d2f8e-8c29-4c92-99b0-4477ef790ddc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_854fd716-91b5-4166-8571-f2a72395fc31" xlink:to="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_6e6d2f8e-8c29-4c92-99b0-4477ef790ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#ShareBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3873dd5e-8ef5-43fe-9e5f-fe51ab5d5bf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d203c6e-68f0-42a8-9dac-c8b1b5124d97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3873dd5e-8ef5-43fe-9e5f-fe51ab5d5bf0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d203c6e-68f0-42a8-9dac-c8b1b5124d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6034abb0-6cc8-4b2a-bf27-5980423f0388" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d203c6e-68f0-42a8-9dac-c8b1b5124d97" xlink:to="loc_us-gaap_AwardTypeAxis_6034abb0-6cc8-4b2a-bf27-5980423f0388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cfe8d313-566e-41a9-8576-a42305357c58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6034abb0-6cc8-4b2a-bf27-5980423f0388" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cfe8d313-566e-41a9-8576-a42305357c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5bca0462-2f22-417e-88d0-ab04c05f15fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cfe8d313-566e-41a9-8576-a42305357c58" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5bca0462-2f22-417e-88d0-ab04c05f15fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_860b8b81-d158-4c7e-86b4-46e11f0864a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cfe8d313-566e-41a9-8576-a42305357c58" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_860b8b81-d158-4c7e-86b4-46e11f0864a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_b58f7cee-9311-46c9-97b2-899c57999145" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cfe8d313-566e-41a9-8576-a42305357c58" xlink:to="loc_us-gaap_PerformanceSharesMember_b58f7cee-9311-46c9-97b2-899c57999145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a36af3a9-66d5-41e7-89a2-cd4a8f8c31c1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d203c6e-68f0-42a8-9dac-c8b1b5124d97" xlink:to="loc_srt_RangeAxis_a36af3a9-66d5-41e7-89a2-cd4a8f8c31c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ab0831b0-c33a-48e8-89a7-116037f62c85" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a36af3a9-66d5-41e7-89a2-cd4a8f8c31c1" xlink:to="loc_srt_RangeMember_ab0831b0-c33a-48e8-89a7-116037f62c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d67aa3f2-08da-435f-bca1-a4d74cb527ee" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ab0831b0-c33a-48e8-89a7-116037f62c85" xlink:to="loc_srt_MinimumMember_d67aa3f2-08da-435f-bca1-a4d74cb527ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e59b003a-03f9-4859-b55f-935babc488f5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ab0831b0-c33a-48e8-89a7-116037f62c85" xlink:to="loc_srt_MaximumMember_e59b003a-03f9-4859-b55f-935babc488f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7af49d7c-2e5c-4d4e-82bf-d45112fffd1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8d203c6e-68f0-42a8-9dac-c8b1b5124d97" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7af49d7c-2e5c-4d4e-82bf-d45112fffd1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_VestingPeriodinyearsforShares_4ea24209-8b25-49ef-8a80-7a759c071574" xlink:href="cah-20210331.xsd#cah_VestingPeriodinyearsforShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7af49d7c-2e5c-4d4e-82bf-d45112fffd1b" xlink:to="loc_cah_VestingPeriodinyearsforShares_4ea24209-8b25-49ef-8a80-7a759c071574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_d35412d5-8fa7-4b96-9cb8-8d22739ad9c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7af49d7c-2e5c-4d4e-82bf-d45112fffd1b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_d35412d5-8fa7-4b96-9cb8-8d22739ad9c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_982e73b6-cd04-4b92-a5c4-1a146e01fb59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7af49d7c-2e5c-4d4e-82bf-d45112fffd1b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_982e73b6-cd04-4b92-a5c4-1a146e01fb59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_dba3e1ab-d6ca-459e-8fef-60209b6d897b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7af49d7c-2e5c-4d4e-82bf-d45112fffd1b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_dba3e1ab-d6ca-459e-8fef-60209b6d897b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7ecb1b28-a212-4ad9-abb0-4249a178bf22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7af49d7c-2e5c-4d4e-82bf-d45112fffd1b" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7ecb1b28-a212-4ad9-abb0-4249a178bf22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_cah_ExercisablePeriodOfPlansInYears_794cde8a-1c04-48fa-b9f4-1ae60595680a" xlink:href="cah-20210331.xsd#cah_ExercisablePeriodOfPlansInYears"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7af49d7c-2e5c-4d4e-82bf-d45112fffd1b" xlink:to="loc_cah_ExercisablePeriodOfPlansInYears_794cde8a-1c04-48fa-b9f4-1ae60595680a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_eb74a119-24a4-4170-a029-72b9aa329a15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7af49d7c-2e5c-4d4e-82bf-d45112fffd1b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_eb74a119-24a4-4170-a029-72b9aa329a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_08203027-e801-47c8-9a76-4ace4ff04e64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9e2c147b-115a-441f-8930-c858535c99d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_08203027-e801-47c8-9a76-4ace4ff04e64" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9e2c147b-115a-441f-8930-c858535c99d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_624623d0-4e1f-43ac-9744-f334081692c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9e2c147b-115a-441f-8930-c858535c99d0" xlink:to="loc_us-gaap_AwardTypeAxis_624623d0-4e1f-43ac-9744-f334081692c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04613bee-d5df-498a-babd-1c14cf38329d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_624623d0-4e1f-43ac-9744-f334081692c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04613bee-d5df-498a-babd-1c14cf38329d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_38c1272d-4474-4d11-a057-58a74c6870c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04613bee-d5df-498a-babd-1c14cf38329d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_38c1272d-4474-4d11-a057-58a74c6870c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_bcd0df7a-53b1-4fdd-878f-b1d39caf2e70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04613bee-d5df-498a-babd-1c14cf38329d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_bcd0df7a-53b1-4fdd-878f-b1d39caf2e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_f6502dc7-58b5-4a25-9e6a-894c9b41fa8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_04613bee-d5df-498a-babd-1c14cf38329d" xlink:to="loc_us-gaap_PerformanceSharesMember_f6502dc7-58b5-4a25-9e6a-894c9b41fa8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1eca2c18-1060-4359-af75-61f209451479" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9e2c147b-115a-441f-8930-c858535c99d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1eca2c18-1060-4359-af75-61f209451479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_e1a784cd-c2d3-4d27-a811-571a487fad67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1eca2c18-1060-4359-af75-61f209451479" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_e1a784cd-c2d3-4d27-a811-571a487fad67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cdd90cf8-963a-4286-bd6f-729c3b14c52e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d959790d-dd51-40be-bbeb-4d8811c1fbbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cdd90cf8-963a-4286-bd6f-729c3b14c52e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d959790d-dd51-40be-bbeb-4d8811c1fbbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_92cc1b18-f881-4f01-b8c7-9e95ab26014f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d959790d-dd51-40be-bbeb-4d8811c1fbbc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_92cc1b18-f881-4f01-b8c7-9e95ab26014f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_77cf8ae2-4e01-41ca-b28c-95e2f3cc7968" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d959790d-dd51-40be-bbeb-4d8811c1fbbc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_77cf8ae2-4e01-41ca-b28c-95e2f3cc7968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2c2c37f9-5221-4460-b6b7-20446b2ce44d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d959790d-dd51-40be-bbeb-4d8811c1fbbc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2c2c37f9-5221-4460-b6b7-20446b2ce44d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_81e4f9b7-af83-4d9b-afd4-c42e6ce65870" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d959790d-dd51-40be-bbeb-4d8811c1fbbc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_81e4f9b7-af83-4d9b-afd4-c42e6ce65870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_359a37a5-08f5-4bb2-8261-1a5e51ae6017" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d959790d-dd51-40be-bbeb-4d8811c1fbbc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_359a37a5-08f5-4bb2-8261-1a5e51ae6017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_bcb27424-b664-4ccd-b4dd-fc4152aca1ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cdd90cf8-963a-4286-bd6f-729c3b14c52e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_bcb27424-b664-4ccd-b4dd-fc4152aca1ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_acd47b36-03bc-4846-9ca6-4cd4a8c90012" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cdd90cf8-963a-4286-bd6f-729c3b14c52e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_acd47b36-03bc-4846-9ca6-4cd4a8c90012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ca9f2e19-4332-4380-b118-4fcc667438da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_acd47b36-03bc-4846-9ca6-4cd4a8c90012" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ca9f2e19-4332-4380-b118-4fcc667438da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_eb7da529-943f-40e6-8295-0c925271afc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_acd47b36-03bc-4846-9ca6-4cd4a8c90012" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_eb7da529-943f-40e6-8295-0c925271afc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c6876f41-a9de-455a-b91c-33dec1e1e854" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_acd47b36-03bc-4846-9ca6-4cd4a8c90012" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c6876f41-a9de-455a-b91c-33dec1e1e854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_f9d219d2-5c13-4fc8-addb-75f8df59cc96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_acd47b36-03bc-4846-9ca6-4cd4a8c90012" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_f9d219d2-5c13-4fc8-addb-75f8df59cc96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f66716ee-270c-4933-a4be-986e9ca5437c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_acd47b36-03bc-4846-9ca6-4cd4a8c90012" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f66716ee-270c-4933-a4be-986e9ca5437c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_d7eae444-8e28-43e5-9ef1-a15dea106533" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_acd47b36-03bc-4846-9ca6-4cd4a8c90012" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_d7eae444-8e28-43e5-9ef1-a15dea106533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ddbc438a-4e7e-4a28-a814-20fdc0cf2dd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a8651bdd-1344-43bf-b820-710d479c2dcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ddbc438a-4e7e-4a28-a814-20fdc0cf2dd4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a8651bdd-1344-43bf-b820-710d479c2dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_38bfb84b-1e7f-4a31-b08e-a8eaf21781d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a8651bdd-1344-43bf-b820-710d479c2dcc" xlink:to="loc_us-gaap_AwardTypeAxis_38bfb84b-1e7f-4a31-b08e-a8eaf21781d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75a76bea-4e9d-473f-a6e3-9b2c59b58467" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_38bfb84b-1e7f-4a31-b08e-a8eaf21781d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75a76bea-4e9d-473f-a6e3-9b2c59b58467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_20859eed-6e79-4235-9f28-8963e8a602ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75a76bea-4e9d-473f-a6e3-9b2c59b58467" xlink:to="loc_us-gaap_EmployeeStockOptionMember_20859eed-6e79-4235-9f28-8963e8a602ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_259e2d62-5c7b-4704-bcf4-35843bb254e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a8651bdd-1344-43bf-b820-710d479c2dcc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_259e2d62-5c7b-4704-bcf4-35843bb254e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_b8bb1456-3407-4881-9aaa-24b6b43a23eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_259e2d62-5c7b-4704-bcf4-35843bb254e9" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_b8bb1456-3407-4881-9aaa-24b6b43a23eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_901191b3-35b2-447d-a39c-3a63426d727f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_259e2d62-5c7b-4704-bcf4-35843bb254e9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_901191b3-35b2-447d-a39c-3a63426d727f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_552f0e0a-e294-4205-baa6-bf680ad36843" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_259e2d62-5c7b-4704-bcf4-35843bb254e9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_552f0e0a-e294-4205-baa6-bf680ad36843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_9a65c720-6722-4626-8f2d-ed8fc19c378c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_259e2d62-5c7b-4704-bcf4-35843bb254e9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_9a65c720-6722-4626-8f2d-ed8fc19c378c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_504f5a60-6fca-4880-82cc-339e23341257" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_259e2d62-5c7b-4704-bcf4-35843bb254e9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_504f5a60-6fca-4880-82cc-339e23341257" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_759719c2-5b52-4b26-924d-d6d12480c990" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5ab87cb0-eb81-4477-aa3f-751f0d47f9df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_759719c2-5b52-4b26-924d-d6d12480c990" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5ab87cb0-eb81-4477-aa3f-751f0d47f9df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5cba3707-a894-43df-b7a6-68ab0cd20a5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5ab87cb0-eb81-4477-aa3f-751f0d47f9df" xlink:to="loc_us-gaap_AwardTypeAxis_5cba3707-a894-43df-b7a6-68ab0cd20a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56acf6e1-c731-4342-b6ce-8a0c27dc4da6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5cba3707-a894-43df-b7a6-68ab0cd20a5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56acf6e1-c731-4342-b6ce-8a0c27dc4da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e7cba01b-cbc5-4cdf-989a-56f2d4290c94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56acf6e1-c731-4342-b6ce-8a0c27dc4da6" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e7cba01b-cbc5-4cdf-989a-56f2d4290c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2c379b97-c22a-423b-b2fa-149075cecbf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56acf6e1-c731-4342-b6ce-8a0c27dc4da6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2c379b97-c22a-423b-b2fa-149075cecbf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dcd9fea5-0349-44ff-b3d6-7ba136fccec0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5ab87cb0-eb81-4477-aa3f-751f0d47f9df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dcd9fea5-0349-44ff-b3d6-7ba136fccec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e2262912-9516-4144-afe3-556e456c9997" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dcd9fea5-0349-44ff-b3d6-7ba136fccec0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e2262912-9516-4144-afe3-556e456c9997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_cbde331f-74f8-4f9f-877e-4478121a069f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dcd9fea5-0349-44ff-b3d6-7ba136fccec0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_cbde331f-74f8-4f9f-877e-4478121a069f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bb32f4b4-08f5-4752-b659-72fb2664a3c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dcd9fea5-0349-44ff-b3d6-7ba136fccec0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bb32f4b4-08f5-4752-b659-72fb2664a3c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b5745935-4a71-485b-8592-3b379310300f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bb32f4b4-08f5-4752-b659-72fb2664a3c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b5745935-4a71-485b-8592-3b379310300f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5b0b7dc3-37f7-419f-8e3b-ae5aa96820f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bb32f4b4-08f5-4752-b659-72fb2664a3c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5b0b7dc3-37f7-419f-8e3b-ae5aa96820f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e2695733-3db2-4d71-8dc4-a9956064a2e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bb32f4b4-08f5-4752-b659-72fb2664a3c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_e2695733-3db2-4d71-8dc4-a9956064a2e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_af3f6f7f-9472-4979-9036-d0722f8d5942" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bb32f4b4-08f5-4752-b659-72fb2664a3c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_af3f6f7f-9472-4979-9036-d0722f8d5942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_065b8168-eb67-4810-9160-20e6815aff54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_bb32f4b4-08f5-4752-b659-72fb2664a3c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_065b8168-eb67-4810-9160-20e6815aff54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a7e74f25-7932-4e0f-8961-5ab8728c83a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dcd9fea5-0349-44ff-b3d6-7ba136fccec0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a7e74f25-7932-4e0f-8961-5ab8728c83a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_61cb8a2f-5ba1-46b0-9660-f47342060f06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a7e74f25-7932-4e0f-8961-5ab8728c83a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_61cb8a2f-5ba1-46b0-9660-f47342060f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_76ef8e39-6036-4e54-8470-ec0cf79c01c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a7e74f25-7932-4e0f-8961-5ab8728c83a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_76ef8e39-6036-4e54-8470-ec0cf79c01c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_be0b4bf6-c893-4859-9d56-691cfa524bc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a7e74f25-7932-4e0f-8961-5ab8728c83a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_be0b4bf6-c893-4859-9d56-691cfa524bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_bc930b0e-c624-40dc-a948-f38772a63c4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a7e74f25-7932-4e0f-8961-5ab8728c83a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_bc930b0e-c624-40dc-a948-f38772a63c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5e066563-d2f4-4d60-ba8b-d960d8fee30e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a7e74f25-7932-4e0f-8961-5ab8728c83a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5e066563-d2f4-4d60-ba8b-d960d8fee30e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" xlink:type="simple" xlink:href="cah-20210331.xsd#ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails"/>
  <link:presentationLink xlink:role="http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7eaf0935-9654-40db-b48b-3af387cc2dc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7cf36ce3-d974-41b7-b6d0-b732a19f50d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7eaf0935-9654-40db-b48b-3af387cc2dc8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7cf36ce3-d974-41b7-b6d0-b732a19f50d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_72e773e9-a6e3-4607-b145-163e80c82aca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7cf36ce3-d974-41b7-b6d0-b732a19f50d4" xlink:to="loc_us-gaap_AwardTypeAxis_72e773e9-a6e3-4607-b145-163e80c82aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f466a809-2e40-476b-9db0-63d916c7c23a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_72e773e9-a6e3-4607-b145-163e80c82aca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f466a809-2e40-476b-9db0-63d916c7c23a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_033bcd04-3604-4912-b5a5-9169adf3aef4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f466a809-2e40-476b-9db0-63d916c7c23a" xlink:to="loc_us-gaap_PerformanceSharesMember_033bcd04-3604-4912-b5a5-9169adf3aef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66de9fbc-44f2-4263-8b8c-010250845647" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7cf36ce3-d974-41b7-b6d0-b732a19f50d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66de9fbc-44f2-4263-8b8c-010250845647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_e5b74250-fc9c-4470-b381-ced00f818a68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66de9fbc-44f2-4263-8b8c-010250845647" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_e5b74250-fc9c-4470-b381-ced00f818a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_297adc2a-4884-42e1-b4f8-dd934544e359" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66de9fbc-44f2-4263-8b8c-010250845647" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_297adc2a-4884-42e1-b4f8-dd934544e359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b7cf0f57-7100-4033-a152-5f852098d614" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_297adc2a-4884-42e1-b4f8-dd934544e359" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b7cf0f57-7100-4033-a152-5f852098d614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4b31ef29-2201-4f05-8969-90cf2837dc98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_297adc2a-4884-42e1-b4f8-dd934544e359" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4b31ef29-2201-4f05-8969-90cf2837dc98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_035dbed1-f6ae-4c65-b997-ba101f10b245" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_297adc2a-4884-42e1-b4f8-dd934544e359" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_035dbed1-f6ae-4c65-b997-ba101f10b245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3234ee24-2270-4c99-a0f5-d853754633a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_297adc2a-4884-42e1-b4f8-dd934544e359" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3234ee24-2270-4c99-a0f5-d853754633a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a6bcf269-9224-4f6b-9ce2-3bba38b2031d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_297adc2a-4884-42e1-b4f8-dd934544e359" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a6bcf269-9224-4f6b-9ce2-3bba38b2031d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_56292dcf-88bb-4af5-9197-df7a25b3e7cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66de9fbc-44f2-4263-8b8c-010250845647" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_56292dcf-88bb-4af5-9197-df7a25b3e7cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9b1e08da-3f5b-4d1a-ac7c-dd4958ed5ee9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_56292dcf-88bb-4af5-9197-df7a25b3e7cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9b1e08da-3f5b-4d1a-ac7c-dd4958ed5ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_52cb128d-cd9f-4b55-a97e-8f3e95666398" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_56292dcf-88bb-4af5-9197-df7a25b3e7cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_52cb128d-cd9f-4b55-a97e-8f3e95666398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_96147130-70a1-4b1e-aeda-625e8f7d7fdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_56292dcf-88bb-4af5-9197-df7a25b3e7cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_96147130-70a1-4b1e-aeda-625e8f7d7fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_818c800e-18db-4a98-8a84-ba10ae9d2e54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_56292dcf-88bb-4af5-9197-df7a25b3e7cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_818c800e-18db-4a98-8a84-ba10ae9d2e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8c405f66-f944-4993-be8b-283149c6c805" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_56292dcf-88bb-4af5-9197-df7a25b3e7cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8c405f66-f944-4993-be8b-283149c6c805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_407ab7dd-fd05-4b8c-8b0a-94a5b3a59567" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66de9fbc-44f2-4263-8b8c-010250845647" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_407ab7dd-fd05-4b8c-8b0a-94a5b3a59567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f7fae39a-51a7-4e2e-a0c2-1a8387f68191" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66de9fbc-44f2-4263-8b8c-010250845647" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f7fae39a-51a7-4e2e-a0c2-1a8387f68191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_847e990e-e37e-4394-b2b9-4b20b7203eb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_66de9fbc-44f2-4263-8b8c-010250845647" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_847e990e-e37e-4394-b2b9-4b20b7203eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>cah-20210331_g1.jpg
<TEXT>
begin 644 cah-20210331_g1.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0OP"_:#TVZUGX"?'#P?XWL[*41WMWX0\36NIQ6[G)"NUM(X0G!P"1T-?AO\
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M18H+:Y=WW9^=-R1@IYG]0NIZ9INM:?-I.L:?!=VMQ&8[BVN8EDCE0]596!#
M^AIFB:%HGAK2X=#\.:/:Z?96ZD06=E;K%%&"<X5%  Y)/ [T ?A3_P '._[,
MWBOX2_M4?LZ?\%;9?V?+3XG?#KP9I6EZ'\3_  OJ&EI>63VUK>27<:7<<B.@
MAN([JXA\UU:-'CC#<NBMS_[-O_!07]C?_@H9_P %'_AC\ O^"6G_  0O^!DG
M@=A;W?Q,\3_$'X$Z1!?Z!&LX>:\@EL&:*V6&)<1M*6,T[*BA#@O^_MQ;P7<#
MVMU DL4J%)(Y%#*ZD8((/4$=JS_"_@KP;X(LY-/\%^$M,T>WEDWRP:781VZ.
MV,;BL:@$X[T :=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5YSX>_:__96\5V?C?4_#_P"T3X,N
M;/X:7\EC\0;Y?$5N+?PY<QEA)%>REPENRE&#!R-NTYQ7$?\ !4K]K=_V%/\
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MX2_\'3=E\.--_P""0W[&.G?!S6=1U'PA;Z?81^%=0UB%8[NZTU= MQ;2SHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 ?E[_P '>^OZGH__  1PU;3K"X*1:K\0]"M;U0?]9$))9PI_X'#&
M?^ UTO[4&A:?X8_X-8;KP]I:H+>R_9%T>&(H,!@NC6HW?4]2><DUUG_!RY\
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M3E8V-E<30C/0$7.NVYQZJ1ZX /V=HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH H^)_#.@>-/#6H^#O%>D
MPW^EZM8S66I6-RNZ.YMY4*21L.ZLK$$>AKY(_P"",'_!.CXP?\$N?@9XU_9=
M\9_$[1_%/@Q?B+J&L?#"XLVF^V6.DW.W%I=K)&J"0,GF$QLX+S2<X K[%HH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "OBW_@EI_P3$^(7['7QS^/_
M .US^TAXXT#Q-\3?CGX^EU.6[\/^>UMI.C*[R6UA&TZ(^5:5@V% *PP#DIFO
MM*B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***\S_ &RO^36?
M'7_8O3_R% 'IE%?B710!^VE%?B710!^VE%?B710!^VE%?B77Z3?\$M/^364_
M[&&\_E'0!]'4444 %%%% !167X@\9^&O"TL<.NZEY#3*6C'DNV0.OW0:S_\
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MHH **** /,/C_P#\A+3O^N$G_H0KSZO0?C__ ,A+3O\ KA)_Z$*\^H ****
M"BBB@ J?2_\ D)6__7=/_0A4%3Z7_P A*W_Z[I_Z$* /HFBBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:KI<.I7,.GW<Y;EI);..W<N>7W;SRU 'Z/4444 %%%% !1110 4444 %%%%
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MN?#S_H8/_)2;_P"(H_X6Y\//^A@_\E)O_B* .DHKF_\ A;GP\_Z&#_R4F_\
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M-(-S;2%^]Z /V3^$?_)*?#'_ &+UE_Z(2NAKGOA'_P DI\,?]B]9?^B$KH:
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M\&/^1[@_ZX2?^@U[+7C7P8_Y'N#_ *X2?^@U[+0 4444 %>9_ME?\FL^.O\
ML7I_Y"O3*\S_ &RO^36?'7_8O3_R% 'Y+T444 %%%% !1110 5^DW_!+3_DU
ME/\ L8;S^4=?FS7Z3?\ !+3_ )-93_L8;S^4= 'T=1110 4444 >8?'_ /Y"
M6G?]<)/_ $(5Y]7H/Q__ .0EIW_7"3_T(5Y]0 4444 %%%% !4^E_P#(2M_^
MNZ?^A"H*GTO_ )"5O_UW3_T(4 ?1-%%% !1110 4444 %%%% !1110 4444
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MA(4 <GC[*M/V+OC183SW-C\"O%\,ER^^YDB\(E6E;^\Q#_,?<U8_X9"^/?\
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M )Y#'2N?_P"%F?'O_HSWQO\ ^ S?_&Z /0:*\^_X69\>_P#HSWQO_P" S?\
MQNC_ (69\>_^C/?&_P#X#-_\;H ]!HKS[_A9GQ[_ .C/?&__ (#-_P#&Z/\
MA9GQ[_Z,]\;_ /@,W_QN@#T&I]+_ .0E;_\ 7=/_ $(5YO\ \+,^/?\ T9[X
MW_\  9O_ (W3[7XI?'NVN8[C_ACOQNWER!L?9V&<'/\ SSH ^SJ*^=O^&SOC
MW_T8AXW_ ._S?_&*/^&SOCW_ -&(>-_^_P W_P 8H ^B:*\O^!/QX^)'Q9UZ
M]TGQK^SEX@\&06MH)H;[5Y"4G?<%\M<QIS@D]^ :]0H **** "BBB@ HHHH
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M"8VATS4-9N9;0[#]U9(0DJC^[*I[U]M4 %%%% !1110 4444 %%%% !1110
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MPLL?C9^S=\4](\8>%M1=X[;5]'N-Z"1#AXG4@-%(I^]&X5ER,@9H [BBBB@
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M%A_P2G_:E\!'5("@\;?$'X-6VFZ'8&&V>823W2WDC1JYCV(0AR\B#C.1\_\
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M^P3HGP6^/W@W^P/$UGXP\4WUQIG]HVUUL@O-?O[NW?S+:22,[X)HGP&RN[#
M,"  >:_\%=/ GB']G?6/AS_P6*^!WAJX_M[X$AK;XEZ)9PA)M>^'UVR_VG:,
MH(#26A(O8@QVHT4K8)Q4/[!O[(VK_MA_ KXQ_ME_M2_VYX?\5_M<Z%/96D6G
M7*0ZEX0\!R6\EOI&FV[NLBP7!M93=RL%P9[@%EW1U]%_\%)OA'\0OC[_ ,$^
M/C;\#_A+X?\ [6\4^+_A7KNC^'=+^UPP?:[VXL9HH8O,F=(X]SLHW.RJ,Y)
MYJFEA^TS\"O^";&G:!\%?A5#K_Q<\+_!^RL/#WA*YU2UBBFUV'3HX4ADGDE2
M#RUG&6/F!65#M;D&@#Y@_;#\!_"+4?VCOV0O^"8G[(_ABUD\4?!KQ_H7CC6;
MS3X$SX)\'Z3"\<HN98U BDU'=';+%@>;YCNR@!"<[_@IQ^QX^D_MY_LZ?MJ>
M/_C=XF\3ZG>_M1>%] \#>%KJ18-(\(:3)IM[)=Q6\$?$]Q<W-JDTES+E]HCB
M4*L?S97_  2RT[_@I-^R3#IG@CXG_P#!'+Q-<>)_B'XJM+WXX_'G7OCYX6O+
M[4KN:54N=3E@AE:5K:VC>0PV41.R)-B9=F9OJ[_@HA\!?BQ\=-:_9[N_A7X4
M_M2/P-^T?H/BGQ2WVZ"#[%I-M9:C'-<_OG3S-KSQ#RX]TAWY"D D 'T?1110
M 4444 %%%% !7P)_P<1^+D\ ?LL?"'QY)X-UCQ$NB?M1^ []O#_AVQ%UJ&IB
M'4&D^RVL+,HFGDV[$C+ ,[*,C.:^^Z^6/^"L'[.'QG_:6^'/P@T'X)^#?[:N
M_"W[1_@KQ3KL7]HVUM]ETFPU 37=SF>1 _EQ_-Y:%I&Z*K'B@!?V-/\ @H-I
M/[6'Q9N/AQ%_P38_:-^$KVFBS:BOBCXN_"FWT73)-DD4?V:.XCNI29V$I94V
MC*1R'(VX/P]\7/#O[4G[#?QO\>_\$4/V5-(O[/PU^U+KCZY\"?%MHG^C_#W2
M[QW;Q?!]X;%M(P\]JB8VM?1\EVQ7[#U\L?M&?LX?&?QY_P %6OV:_P!I3PIX
M-^U^"O '@_QS8^+M:_M&VC^P3ZA;V"6:>2\@FE\QH)1F-'"[?F*Y&0#>TS_@
MG+^R1\*[_P""?CJ"WGTG1?V9_"NI6/@32[J\@32K*.XM88I]1NA)'EKE(K<L
M+C>NTRS.<ER1^;/QPU5?C_\ L_\ [7'[6?PGTF31?@Y^TM\<?AGX)\)7*HUF
MOB*PMM5M-,UK7(UX AOS-) )#@R1P%VY.3]9_P#!;OX<?M]_'ZY^&OP&_9V_
M9)USXH?!V[U&?4OC?H_AWXDZ1X;N=?@AV_8]%:>^G1UM99-TEQY:,9$18PR;
MF-'Q0^&'[:W_  4(_8!^(O[,7BS_ ()^6W[-&N>%[?P]?_!B&_\ B%H^M6%Y
MJ&FWJWUO JZ42+&")["VA;<,;+L[ ?+84 =#^U_X;\.?!_\ X*N?L6>-OA_H
M-GI$NMCQEX#U9-+MEA^T:*-!?4+:T8( ##!<V$3HG1,MM W&OMNOA/X.Z#^V
ME^W'^WA\*?VF?VFOV-=1^"/A;X#^&]<>RT_7O%&GZE=Z]XGU6V2PF^SBRDD
ML;>U^T;9W*-*UP,)@';]V4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
#'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>cah-20210331_g2.jpg
<TEXT>
begin 644 cah-20210331_g2.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^SEI'Q/L_@EJWQ_\$VOC3441]/\ "-QXJLTU2Z5UW(T=JT@E<,O(*J<CD5^
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9^S_ /##QY#:IXGG\&6NB66I:D][87-Y''';$QMY$%M$2Q<MEV) &TM]G_\
M!0A(I_\ @\1_9LWJKK_PB&E,,C(R$UD@_G@U^X^D:/I'A_3(=%T'2[:QL[9-
MEO:6D"Q11+_=55 "CV JS0!^./\ P>O_ /*-SX:?]EPM/_3/JM<__P '1O\
MRK]? S_L</!__J/:A7[744 ?B#_P<-_\JRW[/O\ W('_ *C\]?//_!>;0/'>
MD?L2_P#!.'XU?$3P%JOBGX'^&_AAX=7QIHUA+)'#+<M8:3(]O-(I B>XM(Y8
MHG."-DN",G/](E5M8T;2/$.F3:+K^E6U]9W*;+BTO(%EBE7T96!##V(H _EA
M_P""L?[>/[(G[57Q'_9K^)_[#/[&^H_"[X"?"CQL;>;Q1+X*M=%L]1U6YGT^
MXN;=$M2T;M!;V",S%RY,C$@#:S_8G_!??P_\9/\ @F7_ ,%G/@[_ ,%Q_ 'P
MPO?%?@-;"VL/%DEB2$AN4M[BPG@DE4%8/M&GW"B%W^5I(Y!SMP?W:T;1=&\.
MZ9#HGA_2;:PLK==MO:6<"Q11+G.%10 HR>PI^HZ=I^KV,VEZM80W5M<1E)[>
MXB#QR*>JLK9!!]#0!^)G[+W_  7._;O_ ."P/_!6[X>^"/\ @G3X=\1^!O@'
MX>L[>?XMQ>)_#VGW9N+5)7FN))IMDOV1Y5"6L"13;RQ,AR-P3Y:^(FF_LY?\
M$/O^"U/QKOO^"FO[!5A\6/@Q\6KZ_P!:\ ZQJ/@/3M:^RBYO&O(WLUU$"%FB
M\Z2UN$#I("J/RNP/_2=X:\)>%?!FG?V/X/\ #.GZ3:&0N;73;*."/<>K;4 &
M3@<^U'B7PGX5\9Z=_8_C#PUI^JVGF!_LNI623Q[AT;:X(R/6@#\GO^#=SX]V
M/[;?Q_\ BC^T;\+O^"47P1^#'PBT5[G3_AO\0/"?POMM&\0ZB);A=MC+<P?N
M[@+ A:X,(5%D:)/FY-? /_!(O_@I7I?_  ;[_M8_M)?LC_M7_LX?$#6M:\1^
M*+6W\-:3X3L(I+F6^M)KU(%$<\L>^"ZCNHGCFC\PD*I5) X(_IIT[3M/TBQB
MTO2;"&UMK>,)!;V\02.-1T557  'H*J7GA#PEJ.OVWBO4/"^G3ZI9H4L]2FL
MHVN(%.<JDA&Y1R> >YH _"3_ (-8[[XJ:S_P5L_;#\2?'+P/)X9\9:P)=3\4
M>')9-SZ7?76LS7$ULQ_O1O*4/?*G->6_\$(?VV]'_P""<?\ P62^//[%WQQ^
M$_B%O$WQH^,-MX<TN:W$<<6EW$.I:CB6<2$,T4BWB.C(#N&#T8&OZ/JS)/!/
M@R7Q,OC67PEIC:RD?EIJS6$9NE3&-HEV[P,$C&>] 'X:?\$'O#&E>-O^"^7_
M  4-\&Z[&SV.K^(/&-E>(IP6BE\4SHX'_ 6-?/G_  3:_P""E_B[_@V)^+?Q
MO_8*_;;_ &</%>NVEWX@&J>%+[0?*A^V31HT"72?:&5)+2ZA6W82H2T1C92C
ML2J?TPUE>)_ ?@?QL(!XS\&:3J_V5BUM_:FG17'E$]2OF*=IX'3TH _"WX9?
M&?\ X+:?\%)O^"$7[6GQQ^,5_J]U;>+K>V_X4SX;L?#4%I>S:,FHI<:RMNT$
M,<UY;-8E[:(OO:79*H+<5\7_  A_;A_8BN_^"'OB+]A;]F3_ ()]:OJW[1FH
M^&-0E^)/CJS\(6\_V/2K2[-]=:K+J +7(A2TB""(JB1MNYP!YO\ 5LJJBA$4
M  8  X K.T3P;X0\-7UYJ?ASPIINGW.HR>9J%Q96,<3W+Y)W2,H!<Y).3GJ?
M6@#^<CXI^)=#U[_@RF^'.G:1=1/-H_Q+FL]2BC8DPSGQ+J<X5LDX)CFB?'I(
M,<5^W7_!'C_E%!^S;_V0_P ,?^FRWKZ/HH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1OA!H6G/<W/B(W'VJ_=4MD24R[]L E78P:.T*L" 35[5?^":?_!PA_P72_:
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MB+1M#M8M;&CZQ:K/;3W,'A;3Q TD;@J^R21)0&&-T:GG&*\<USX+_MX?#?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M +&"]_\ 2[0*\O\ ^#D3_E!I^P9_V)^B?^HS:5ZA_P '6W_)T_[!?_8P7O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7,_&7XB_\*D^%FN_$
MO^Q_[0_L73GNOL7VCRO.V_P[]K;?K@_2NFKS/]LK_DUGQU_V+T_\A0!\X_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *\S_ &RO^36?'7_8O3_R%>F5YG^V5_R:SXZ_[%Z?^0H
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MHHH *_2;_@EI_P FLI_V,-Y_*.OS9K])O^"6G_)K*?\ 8PWG\HZ /HZBBB@
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MXPT*"Y\Z&SU:PNFMKE89/XXBR;T)Y"N 22"2 ?>E%%% !1110 4444 %%%%
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M-/LT9P, ]2I- 'JU%>)_\+<^(?\ T,'_ )*0_P#Q%'_"W/B'_P!#!_Y*0_\
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M\%?#+XO^!-,TP7#SBV_X1^YF_>/C<=TLK-S@<9Q0!],45X7_ ,(#_P %!/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%_;S_:1T'P7HO[->JZO/KGAKXMW%IK6L7MMK"11SWUR$*7,FR=E+F,,0J $
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MU/0=%\<^-M,TF\\4ZP-*\-VNH7B12:G?&*286\"L<R2>5#*^U<G;&QZ"MV@
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MV:P6UK'DL0JJ.I8LS,<EF8LQ)))Z6O./"G[87[)GCOXSZA^SEX)_:;\ :O\
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MDE+_ #W.HSB.!II3A5*%$W($V_J[7Q#_ ,%4O^3T_P!AS_LX"]_]1_4*^WJ
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M_L^S;DCK\SN?JS'N:^6O^"OO_!5#]C7XL?\ !0.Z_P""9O[8O[5ES\+O@/\
M#NULM1^+4&DZ'JUY??$35)%CN(= $FG6TS6VGQ1O&]PY*M([&)0"N] #A/A=
M8VGCO_@G=\-OV9M$L;[3_@/^T/\ \%#[G3?A_P"'YS+;B?X8?;;C4$LT1CYD
M=O-<6+X7C]W-G)#9;[1^)_P@^$_[%W_!;7]F;6/V</AKHO@RQ^-_@;QIX/\
M'.E>&=+CL;*_72;"WU73IG@@58S-'Y=Q&)2N[RV"9P *\]_;'_:P_90_:]_8
MC^$7[>/_  3LOY?&WPU_96_:/\/:KXJL?#/@^_LI+#1K"T\C4(;:SN;>&1EM
MK+4[>?\ =IL"1-@C8VWJ?"W[2_P/_P""I_\ P5_^!GQ(_8Z\:IXS\!_LZ^!?
M%.N>+O&NFVLPTY=5UVTM].LM-621%S<B 7,S*!\JY!(8,M 'Z.4444 %%%%
M!1110!\H?\%TO^4/W[1/_9+]1_\ 0!7RW^RS^UQ_P; ?%.T^'/P0T+PE^SUJ
MWCKQ''H^AV>ER?!&(SWFK7 AMTA,CZ:%+O.X7<S8R<EL<U]2?\%TO^4/W[1/
M_9+]1_\ 0!7LO[.GPU^'5K\$? FJ6W@'1([F/PKI<L=PFE0B19!;1$.&"Y#
M\YZYH ^*OV\/L/\ P2E_X*/>#_\ @JCHZ?V;\(?BQ#:?#_\ :3CMHC]GTV<?
M+HGB*15Z")O]%EDQ\L1"J"\M7O\ @G7\!OBC^VMH'QH_X*G_ ! UN_\ !7CG
M]HKPS=^'?@C?W%EYMUX$\#I')'I4T<1=/WUQ*RZE(@<*Y\HADR<>@?\ !Q%#
M#/\ \$6?C^D\2NH\(P, ZY (O[4@_4$ CW%>]>+/C=\/_P!E+]B6Z_:"\?JU
MOX;\ _#4:QJ,-G$-_P!GM;$2&*)> 68($1>,D@4 ?G-_P4__ &!OV4/V&_\
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MR,U^IE?"W[1^A:)XB_X+X_L_:=X@T:TOK?\ X4%XU;R+RW65-PO=-P=K C-
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M'"_L]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%  0",$52
MT+PYX>\+6)TSPSH-EIUL96D-O86J0H78Y9MJ #)/)/4U=HH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH I6WAOP[9
MZW<>);30;*+4KN-8[O4([5%GF1?NJ\@&Y@.P)XJ[110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
24444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>cah-20210331_g3.jpg
<TEXT>
begin 644 cah-20210331_g3.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBMXR_P"$X\/VNBV7Q;%SJX;3?$EO=WUI')&+=$7RTBU VDL2EF 6$;M[A9
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M\&:3?:C8X^Q7]YIT4LUO@[AL=E+)@\\$<UK4 ?DC_P $^?\ E3LU_P#[-O\
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M!@$@'T;1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH ^3_P#@N1^RQJG[9/\ P2E^-'P1\-Z8UYK3^%3K&@6T29DFOM.ECOXH8_\
M;E-MY(]?-QT-?.W_  2MT*P_X*M_\&UGAO\ 9IA^(H\/7NJ?#F\^'FJ:Q_9W
MVUM(DLI7M(F:#S8O,_T9+>0)YB_+(O(K].:\*_8<_P"">'[/O_!/*Q\>>'_V
M;GURRT/Q]XUN/%-[X=U#4$FLM,O9U"R+9(L:M#$42)=C,^!$@!X.0#Y=LO\
M@@+]C_X(A7?_  1L_P"&LMWVK6!?_P#"Q_\ A!,;<:VFJ;/[/^W<_<\K/VCO
MOQ_#7L&F?\$L_P"SO^".S?\ !)O_ (7IOW?#>;PG_P )_P#\(QC[Y8_:?L/V
MGMN_U?G]OO5];T4 ?.'_  2?_P""??\ P[ _8E\.?L<_\+;_ .$X_P"$?U#4
M;K_A(_[ _LSS_M5W+<;?L_GS[-OF;<^8<XS@9Q7'_P#!:O\ X)2?\/@_V6-
M_9H_X7U_PKO^P_B!:^)_[;_X1;^U_/\ )L;ZU^S^3]JMMN?MN_?O./*QM.[*
M_7]% 'XD_%?_ (- ?$_C#Q'IOPF\#_\ !3/QGI?P#M]675&^%]_9W-U'IMTV
M3<-91M=_9E9RS[)7C+QB3#F8J6?[8_X**?\ !$WX9_MH?\$W/!W_  35^#7Q
M/7X5>%O ^JZ7<:)?KX<_M<K!96\\(B>,W-N7>0SEWE+DE@Q()8D?;U% 'YT?
M\%(O^" W_#P?]AKX"_L7_P##6/\ PB/_  I'1[&Q_P"$D_X03[?_ &U]GTR&
MQW_9_MT/V;=Y7F8\R3&[;DXW'J/^"K?_  1._P"'G7Q4^ OQ,_X:8_X0C_A2
M.H3W7V+_ (0S^TO[:\R>PEV[_MD'V;'V'&=LF?-SCY<-]WT4 ?#'[;/_  1<
M_P"&Q?\ @J5\$_\ @I7_ ,-)_P#".?\ "G;?2XO^$+_X0[[9_:_V/4KF]S]L
M^V1_9]_VC9_J9-NS=SG:.8_X++?\&_?PQ_X*E>-_#_[1OPX^,U_\*?C#X8MH
MK>R\8:;8F>*^@AD,L"SHDD4B2Q.28[B-PZ!L%7"H$_0ZB@#\M/\ @EY_P;6Z
M=^R#^U4O[=?[:/[5^L?'3XHZ?N;P[>:M;3"#3YC&8A=RR7,\TUW.L?RQEBBQ
M9)"LP1T]D\3?\$7/^$B_X+>^'O\ @LG_ ,-)^3_8.CO8?\*X_P"$.W>?NT2Y
MTO?_ &A]L&W_ (^?-Q]G/W-F>=P^YZ* /AC]O#_@BY_PVU_P4L^!?_!1#_AI
M/_A&?^%+7&ER_P#"'_\ "'?;?[9^QZH]_C[7]LB^S[]_E_ZJ3;C=S]VO*/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *\S_;*_Y-9\=?\ 8O3_ ,A7IE>9_ME?\FL^.O\
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MH **** "I]+_ .0E;_\ 7=/_ $(5!4^E_P#(2M_^NZ?^A"@#Z)HHHH ****
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M_"B7]J#P'^S3\=-?GTKX?:+Y7B;QD8[&6X.KR@N+6RV1*28\J2^< A_[R+D
M]F_X)E_M8_$;]L;X':[\4?B7IVF6EW9^-;K3;.WTJ!TC2V2VM9D#;F8LP,[
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?#O]G37=:BU+5]"LC+X@U"#)CN-3NKF2[O'0D E#<3R[20"5QP.@]@J?2_\
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M\MH[B-)0C,H<+( P5F&0<$CF@#T__A;GQ#_Z&#_R4A_^(H_X6Y\0_P#H8/\
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M;_\ 7=/_ $(5!4^E_P#(2M_^NZ?^A"@#Z)HHHH **** "BBB@ HHHH ****
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M_@2*UL[=(+:+_A%Y6V1HH51DN2<  9))JS_P@/\ P4$_Z+_X$_\ "4D_^*H
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MLQ).X8XQ7H- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]RJDF!9&D1(R^-Y5E7)% 'Z$4444 %%%% !1110 5YW^UM\"M3_:9_9J\:?
MC0?B;K_@O4O$NA36ND^+?#&JSV5]I%X,/;W4<L#I(-DJHS*& =0R'Y6(KT2B
M@#\P?A9_P65^)WP^_P""46O2?%306U#]JOX=>*4^#]QX'?$ESKGCIV^S:;.B
MMCSHKE +UG&U76*Y"'Y17HWAS_@B/K_C?]G_ .&_A/X]?\%)_P!I^T\;^&_#
MC1^+]<\ _&>ZL(M:U.XF:YN9I!+'*65))##" 5"PQ1KMSDGB_&_[,OP5O_\
M@Z/\*?$"Y\%PG4+C]F>X\870$C>3<:[::E_9%MJ,D6=KSQV-U+"CD$J-I&",
MU^EE 'Y+_P#!OM^PWXB^/7[(/P2_X*/_ !;_ ."@?[3>O>+;^;4+_4?"FJ_&
M*XNO#MXUOJ5Y9I%+9S1NTD9CA0LK2'+9.0, <O\ \$O?^":GC'_@H/\ LG7'
M[4/Q'_X*E?M>>&O%6I>/?$]G!'X0^.%Q!86:V>KW5O!Y<$L4A"A(DRN_!YQM
MXQ]0_P#!LO\ \H.?@1_V#];_ /3_ *C4/_!NKJ.GZ1_P2YM]4U:_AM;6W^)G
MC:2XN;B4)'$@\07Q+,S8"@#N: .B_P""/_[1'[1FNZG\:/V#/VP_'Z^,/B3^
MSIXUM=(G\;&U6";Q'H.H6HO-(O[B->%N'@#A\9SL4EG8L[?:=?G[_P $B_$N
MF_M%?M__ +;?[<WPZOX]0\ >-?'GA;PCX0UNV8-;ZHWAS2'M;NY@<<30M-=8
M65<HP'!.#7Z!4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 445P?Q\_:E_9K_96T*Q\4?M+_'OPAX TW4[LVNG7_C#Q#;Z
M=#<SA2YBC>=U#OM!;:.< F@#O*^*OB[_ ,&]O_!*'XU?%?5?BYXK_9RN;*Y\
M0W_V[Q1HOAWQ=J>F:3K5QNW>;<65K<)"6+<G8JAB26R22?6_!?\ P5-_X)J_
M$C7U\*?#[]O;X0ZYJCVMS<IIVD_$'3[B=H;>"2XGD")*6*QPQ22,<?*D;,>
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MOAS>_#Y?BU9>/]$F\*OI?]IKXFBU6%M/-EL\S[2+@-Y9AV?-YF[;MYSBN?\
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M9U?PG\)O%$_[0D7@K2(;&U30;F"WCT.UO%MU6,S?;5$L:,/,$:JV"FPKZO\
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MV>ER?!&(SWFK7 AMTA,CZ:%+O.X7<S8R<EL<U]2?\%TO^4/W[1/_ &2_4?\
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MF2*W15QO9G++Y>:X3]D#XN_\$A/VNO\ @G[\5O\ @D+_ ,$I?CY)XJ\3ZO\
M!CQ)<7\VK>&-8L[W5;RZ@6SFUB^N[^S@CGN)+N[MB_S9PP"J(X\* </^U1^Q
MS^S]^Q7_ ,$%_A3^V1\'?AEI&F_$[X,6G@?X@6GCRSL535=0U&>^T\ZJ]S=*
M!-<1W,=W=>9&[,K#8NW"*!^P=?C#\8/VZ/@[_P % O\ @E3\+_\ @D;\-KC4
M6_: \<3^$? ?C[X:S:/<1:AX0.DWED^MWE\CH!#:Q1V,Q#D_,LJX!(<+^SU
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ! (P15+0O#GA[
MPM8G3/#.@V6G6QE:0V]A:I"A=CEFVH ,D\D]35VB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"E;>&_#MGK=QXEM
M-!LHM2NXUCN]0CM46>9%^ZKR ;F [ GBKM%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
..444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>cah-20210331_g4.jpg
<TEXT>
begin 644 cah-20210331_g4.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*&OOG_@W-\.6'A3_ (+D?M]^$?"4$-E:Z;XPUZSTR(QEHX(X_$UXD8V@C*J
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M *+%_P"6]J/_ ,CT >VT5XE_P\7_ &-O^BQ?^6]J/_R/1_P\7_8V_P"BQ?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV(Y-</QDT3XN?&;5_%/A[XKSQM9Z)/$\8\.(CSN%MV>:120TL; A$&8%RI'
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M&I7K>(?$1>2+2M6CLT6.UO%F#PW7VDPX&]VR[A7;]-_V*?@??_LT_L@_#+X
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M $(4 ?1-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT&2":7=&_P!N49& .AP:^D?^%7?#/_HG>A?^"B'_ .)H_P"%7?#/_HG>A?\
M@HA_^)H ^5Y/VAO@+-&T4OQ6T!D92&5K]""#U!&:Y+X'ZQ^R%^SOX$_X5S\+
M?'^@V.EG5M0U)HCJ,99I[R[FNYB2,9'F3,%'\*!5'"BOM7_A5WPS_P"B=Z%_
MX*(?_B:/^%7?#/\ Z)WH7_@HA_\ B: /EG_AHKX$_P#16=!_\&*?XT?\-%?
MG_HK.@_^#%/\:^IO^%7?#/\ Z)WH7_@HA_\ B:/^%7?#/_HG>A?^"B'_ .)H
M ^39/C5^S7+K4?B67Q]X6;48H3#%J#3PF=(SR4#_ '@I],XJY_PT5\"?^BLZ
M#_X,4_QKZF_X5=\,_P#HG>A?^"B'_P")H_X5=\,_^B=Z%_X*(?\ XF@#YY^&
M7[4W[.OA[Q9%J>L?&/088%B=6?[:&P2,#A<FO3/^&Y_V1_\ HO6@_P#?Y_\
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M_P"R/_T7K0?^_P __P 37=?\*N^&?_1.]"_\%$/_ ,31_P *N^&?_1.]"_\
M!1#_ /$T <+_ ,-S_LC_ /1>M!_[_/\ _$T?\-S_ +(__1>M!_[_ #__ !-=
MU_PJ[X9_]$[T+_P40_\ Q-'_  J[X9_]$[T+_P %$/\ \30!X3\7_P!K3]FO
MQ3?64VA?&C09UAB=9#]L"X)(Q][%<?\ \-%? G_HK.@_^#%/\:^IO^%7?#/_
M *)WH7_@HA_^)H_X5=\,_P#HG>A?^"B'_P")H ^6?^&BO@3_ -%9T'_P8I_C
M1_PT5\"?^BLZ#_X,4_QKZF_X5=\,_P#HG>A?^"B'_P")H_X5=\,_^B=Z%_X*
M(?\ XF@#Y9_X:*^!/_16=!_\&*?XT?\ #17P)_Z*SH/_ (,4_P :^IO^%7?#
M/_HG>A?^"B'_ .)H_P"%7?#/_HG>A?\ @HA_^)H ^6?^&BO@3_T5G0?_  8I
M_C4MA^T?\!H;Z&:7XMZ"%2568_V@G !^M?4/_"KOAG_T3O0O_!1#_P#$T?\
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MYJ/]F7%Y<V&HZ5KFGM9ZEH^H6\ABN;"\MV),%Q$X*LF2.C*65E8^HT %%%%
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MM].^)FJ^ +<>';=4>2-YI;R&[D41K)$\;,H;# CJ#7+^&_\ @XN\'>.-*O\
MQE\./^"5W[7GBWPKINJWMA/XM\(?"RWU*PD:TG>"=HY(KTAU1XW!Z$;3G&#0
M!^C-%>7?L=?MC_ #]O#X#:7^T;^S9XQ.L>'-3DD@<3V[075A=Q';-:7,+_-#
M-&W#*>H*LI965CZC0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!\??\%^OB%XL^&'_!'#]H#Q5X*OI;:_?P.VG^="
M2&6"\N8;.?!'(_<SR#/;-?1'[,GPM\"_!']G3P+\(/AEI]O:^'_#7A+3].TB
M*U0*GD16Z(K<<$L!N)ZDL222<T?M-?L_> OVKOV>O&G[-?Q/@D?0/''AJ[T;
M4V@($L4<\3)YL9.0)$)#J>S(I[5^8?Q!\0_\'$?P3_9O\-_L+_#7]F#5-?\
M''P_U2P@\"_M!^!O&NBQZ-XGTNT5H8H]:T_4E,D2M 5\]=R.\D2LC]W /4/^
M":'[/WP7\:?M ?MN_L8^,_A_I>O?#/PY^T=IWB;0O#EY!NL[+4;RRMM0E6)
M<(L5U#&ZHN%5AT&:I?$7XH_&WQE_P7D^!5U^VW\!KCX4^#_"</C73/V==:L=
M8M]8@\<:M>6XMYFO[B%Q_9C/I\(FALWC8L[$&5F4+7&_L:_LV?\ !1&V_8&^
M.GP^\)6'B[X<_M>'XSMX_P#&'B/7X%MM \:ZA)>+/'9Z=>1.R3:7-8VRVI *
M^3(Y#A%)%>H0^&?V]_\ @IM^UW\#/&G[0O[#NH? 3X=? CQ1)XQUI_$_B^PU
M+4/$/B!;22WMK.Q6R=@MK$TSR//)M$JX"A2.0#]%**** "BBB@ HHHH ****
M "O@;X^Z?8_%3_@XH^!7@3QVB7.E?#S]G?Q)XQ\*6=PH:-=9N=2M].DF"G@R
M+;<J>2N,C'6OOFOCW_@IQ^R%^TEXU^)/PO\ V]_V$(=&N_C-\&+B^BM_"OB"
M\%K8^,M OHU2]TB6<\0RG8DD$KG9')DG&0R@#/\ @OY\.O"/Q%_X) _'(>*X
MT27P]X/?Q#H=]G;+9:E82)<VTL3\&.3S(PFY2"1(R]&(/5V">-]*_9KTG]O;
MX$_LGZ3\1?C_ .*?A3X=M+BRF\0PZ'+J\+B&=X);V=62&*%KBXG"["6*[!@L
M"/S6_;SC_P""Z/[<L_B^U\9_L1_%/P=^SKKO]@R?%[X5KXFT'6-;EM;*[MVO
M8/#1MO*N)#-'"7='9A*Q?9C<(S]N_&3XB_\ !0/]GO\ :,T']J[]F;]G?Q;\
M8O@=XZ^%FG6%S\'K+5[72-6\$ZK$3+!>16MZR)LE@E6":('S(WCRW"!2 9W_
M  ;[ZS'J/P ^,#?$".^TKXOZE^T+XFUWXY>#+[3UMAX:\1WSQ2-9VP66436?
MV=+=HK@.PFRS<'('WO7R)_P2F_9A_:(^&5Y\8_VL_P!KCPGIWA;XB?'WQ^GB
M'4/ VE:HE]'X9TZVM8[2PL9+F/\ =W%PL2,TLD?R,7&.AKZ[H **** "BBB@
M HHHH *_.C_@MII/BS]AGXA>!?\ @N+\#?#IO]4^%$(\,_&+P]!<+ ?$W@R_
MG6/86/WI;6\DBEB'3,A9CB,"OT7KY8_X+9?LX?&?]KG_ ()<?%W]G/\ 9Y\&
M_P#"0^,O%&CV<&A:-_:-M:?:9$U&UF8>;<R1Q)B.-VR[J/EP.2 0!G_!(W]D
M;QS^S?\ L[7WQ6_:$N(K_P"-'QIUN3QO\7=43G9J-T-T.G1G)VV]G 4MT0$H
M"LA3 ?%>=6W_ "LXWO\ V8A;?^II/7W'X>M9['0+&RNH]DL-G$DBY!PP0 C(
MXZU\L0?LS?&Y/^"ZEU^V0W@G'PWD_9,@\&)XC_M*VYUQ?$\U\;3[/YGG_P#'
MLRR>9Y?E<[=^[Y: .#^)O_*R!\+?^S4/$/\ Z?+6J7_!;S3-.\*?&#]B;X\Z
M"B6_B[2OVP_#'AG3]1C7]\=*UF*ZM]2M@1SLDBBC+=L1\]<U0_X*!^ _^"B'
MPM_X*J?#W]NG]C3]@O\ X7CH^C_!34O".KZ;_P +2TCPS]FN;G4DN0_F7S,S
MX2(<+$5._P"\",&+X<_ S_@I1_P43_;,^%_[1/\ P4-_9A\._ GX;? [5+G7
M_"?PRLO']MXEU+7_ !&\+06][=75F!!'!;*SR1J K[VP0RL2@!^B%%%% !11
M10 4444 %,N+>WO+>2TNX$EBE0I+%(H974C!!!X(([4^B@#\3M8_9<_:,\$_
MM1>(/^#;[P--/9_ 7XB>)X_B?I_B2WU#9/HOPX>XDEU?PY$ 0T>_5$AMHV&X
M^7=2LX*R$#]I/#?AS0?!WAVP\(^%='M].TO2K**STW3[.(1PVUO$@2.)%'"J
MJJ% '   KY9\0?LS?&Z^_P""X7AO]L"U\$[OAU8?LR:AX3N_$7]I6P\O6)->
MANTMOLYD\\Y@1G\P1F,8P6#<5]9T ?"'_!LO_P H.?@1_P!@_6__ $_ZC1_P
M;B?\HR+'_LJ'C7_U(;ZN\_X(8_LS?&[]CK_@E7\)OV;OVCO!/_".>-/#-GJB
M:YHO]I6UY]F:;5[VXC'G6LDD3YBFC;Y';&[!P00/D3]@SQ%_P7._X)Z_L]W7
M[+'@[_@B9;>-(+7QGK^I:9XUO/VC_#NGQ31W^IW%W&[V0\V0*@F (\S<P'12
M<  ]R_X)B:9IWPY_X*V?M_\ P3\$HEKX7M?%W@3Q1!ID"[8H-6UC0YI]2D '
M&^62&.1O]X9]3]^5\I?\$J_V+_C5^S/X3^(7QR_:W\0Z-JGQI^-_C5_%/Q#?
MPZ7;3]+"Q+!9:3;,_P TD-K NT,<G<[C<X"L?JV@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBOCW_@K!^U=^V?^S_KW
MP-^$7[#2?#E/&'Q>^(T_AP7?Q.L+V?3K9$TZXN]Y^QR)(IS#C(#]<8[@ ^PJ
M*^+?@=X=_P"#@_\ X679+^TC\2/V2E\'O:7JZC)X*T/Q')J44QM)A:O$ERZ1
M.JW1@:1692T0D"L&((V_^"97_!1;Q!^TK^SQX[N/VPK#0?!'Q5^!WB34M!^-
M^D63/#I^FR6IDE34(?.=W%E-:J)4D9B"8Y<$JN: /K>BOS?\.?\ !7/]K_5?
MV&Y?VS[7X"Z!>WGQK^,UIX,_9.\#W5O<V,EW8WMP\%AJ6M3M(Y594BGNBL:1
M@11H V)0Z>@? K]L/_@H7\$/VY/ G[%/_!2?0_A)JB_&+P[J]]\,_&?P@@U&
MUBCU'2H4N+[3;RWOY9&(^SOYL<R%0=F"I)/E@'W!17P/^T!_P6F\-6/_  4O
M^$O_  3T_9@TZ'Q.=1^(TN@?&/Q>;"673]!F6PNIDT>&=2J-J!:$O(,L(4A9
M"I=F\K[XH **** "BBB@ HHHH **_-U_VH?^"X'[3'[7?QY^%O[$FK_LS:3X
M,^$/CZ'PY;GXG:1KIU&X9]/M[O>6LI6C<?OB,X0\=.YU_P!HK]K#_@L'_P $
M_/V4--_:N_:\TGX(>,-/\+_$RU_X6MIWPIT35RUOX(G6WA>^M3=S*XO;>X:5
MW4H\;1.I.SRW) /T+HKY0_X*0?\ !07Q)^S_ / ?P#%^QU9:!XU^*OQS\1:=
MH?P3TN^9YM.OS<A)YM3G\EU<V-O:%IGD5@!NBR0&S7$?%G]K'_@I=\7_ -KG
MQ3^Q1^P+I7PAM;[X0>$=%O/BM\1?BIIFIM97NKZE;O/;6.GV=E,'13%'YSR/
M))L$@3&Y09 #[FHK\^-*_P""S/Q3?_@GSJOQ7U7X Z4W[06E?&M_@F?AQ9ZJ
MYTJ[\>?:TMD2*X/S_8C'(MV<G<(U9-Y($A[G]ES]KW]NWX>_MGZ?^PK_ ,%*
M?#GPQEUGQQX)N_$WPR\;_">._M].U V,D*:CI4]O?222BXB$\<RR*0C1'D!L
M@ 'V=1110 4444 %%%% !17A_P#P4J_:.\>?LA?L$_%C]ISX7V.F7/B'P/X,
MN]6T>WUFW>6TDGB7*B5(W1F3U 93[U\N^"YO^#G3QQX.TGQKIGC_ /8EBMM8
MTR"]MXI]'\5!T26-9%#88C(##."1GO0!^B5%?(GP:_;E^.'AO_@J'XV_X)V_
MM:Z5X;LXM;\+P>+O@)XCT*RFMUU[3$RFHV,_FS2![RVE&0$VEX4:0HH*YRV_
MX*3>/O$G[:7QLT?P5I.CM\ ?V9O %S<_%CQ7_9TMQJ&I>)TMWO'TNP=9EB"V
MMJFZ?*.PE*Q$+N#4 ?9]%?E_?_\ !3C_ (*T_!?]F_PE_P %0OVF?@Q\%+/]
MGWQ'=Z1?>(/ V@3ZF?%OAGP[JL\$-I?O=RR?9;J=/M,$DL*Q)P^T;"&*>S_\
M%H?^"P/@G_@F1\#=5TGP#IZ^*_C3JOABZU+P9X)M[.6Y%K:1AQ+K%^L6##80
M;'8LS*96C,:D8=XP#[9HK ^%'B74?&GPN\->,=86,7>K:!9WET(5*H))8$=M
MH).!EC@9-;] !1110 4444 %%%?#O_!0_P#:J_X*/^'/VYOA;^Q5_P $]9O@
M[::CXT\ ZYXCU74?BYINI30(MA<6T>R-K"0,I(N.A1@<=1W /N*BOB'P7I__
M  <.:1X5\<ZG\6O%G[*6HW]OX&O9O %CX,T;7R]QX@1XGMH;K[7+&@M9(UGB
M9E<,CR1OR%93TO[-7_!6WX,?$_\ X)8S?\%)?BWM\.0^$?#MW_PL[P_M*3Z/
MKUC^ZO-,6.0[A(UP%6%'.]UN(,\O0!]<T5^=TG_!0O\ X*9V/[.'[/W@>Y^"
M7P]A_:2_:9U?4KOPUH.KVU];:!X*T*VMOMTDNI;96N+BXAM'M]\:M$6EG9
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M_P"Q/^%,?$";Q/\ V=_8_P!I_MCS-/N+/[/YGG)]GQY^_?MDSMV[><@ X_\
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M%CQ!JFEZCIWC?7+;PS'I=EK=K<S3@0FSC8K&HM9(X& /S;"W5JQ?V5OV-?\
MAF;XT_'+XP?\+'_MO_A<_P 0(?$_]G?V/]F_L?R]/M[/[/YGG/\ :,^1OW[8
M\;MNWC)]OH _)[_@@_\ L>:EH/[5GQ:U/XM?%2^\:V?[*7B/4_@Y\"K?58\O
MHFC/.VH3W#$DA[EX;FUM!( I6"V\L?(5"_8__!2'_@H;;?L8^&]!^%WPB\#2
M^/\ XY_$RXDTSX1_#.P.9-1NP/FO;H@C[/86^1)-,Q4!5(##EDZ/]C3]B;_A
MD?XB?'#Q[_PLS_A(/^%R_%BY\:_9/[&^R?V/YUM!!]DW>=)]HQY&[S<1YW8V
M#&3\U_'S_@C]^WAXU_X*$^-O^"@?[-W_  5KA^&.L>*]!L]!T_2Y_P!G_2_$
M3Z+H]NB'[%!<:A>'8CSJ]Q)Y<<6]Y#N!VK@ \D^,7[%GB']A;X8_L4^"/B3X
M[3Q/XN\3?MT:=XL^+7BGRML6K>*]5LM4DFG1< +&'Q#&=H)6-"0K,17T+^W<
M'N/^"SW[!D%@";B%OBA/=[3TL_\ A'(4;(]#,]MSZC\*VO$'_!,W]HOX]_L2
M:U^S/^VY_P %!=1^)/CU/&]MXI^'OQAT?X:Z=X;N_"-]9_9I=/:*RM':*<PW
M,,TC.S*TB73QY3:KB_\ LB?\$_/VCO"/[3\O[:G[>O[5^G_%CX@Z;X.?PIX)
M@\/^#4T32O#^G2S)-=3) )9#)=W+Q1;Y<KM53&H*X"@'UQ1110 4444 %%%%
M 'RA_P %TO\ E#]^T3_V2_4?_0!7E?[(G[*__!:_2;7X8>+?'/\ P58\%:OX
M%MH]$O-8\(0? RRMY[W25$+RV*W0EW1N\ :(3 94MNQD5]6?MT_LP?\ #:?[
M'_Q$_91_X3C_ (1K_A/O"]SH_P#;_P#9GVS[!YHQYOD>;%YN/[N]<^HKO_A[
MX4_X0/P#H?@?[?\ :_[&T>VL?M7E>7YWDQ+'OVY.W.W.,G&<9- 'P]_P<2?#
MJ]T']B&/]OGX7Z__ &#\4_V:]>M?&'P^\0I ),;IX;:\L)5/W[:XADQ)'T<Q
M(#E<@^^_\$ROV2O"_P"QA^QCX/\ A+HVKRZQJU]:'7O&GB>[&;G7]=O\7-]?
MS,<LS22N0NXDK&D:9.VM7_@H=^R'_P -Z_L6_$#]D'_A87_"*?\ "=:.EA_P
MD/\ 9/V[[#MGBEW^1YL7F_ZO&/,7KG/&*Z/XQ?!KQQX[_97\0_L__#7XNR^#
MM?U7P3/H.D^.+?2S<2Z3-):F!;V. 31[G3.]5\Q<,!\W% 'Q+^TKX[U#_@M;
M^T@W[ WP%627]GGX8>,[.\_:)^(Z+FU\2:E83I<P>%-.?I-B>.-[J9>(PB@,
M#M$OKG_!<[P5X.A_X)8?M'_$6+PGIJ^(+CX.7NFSZXMC&+R2SC+RQVS38WF)
M9)9'"$[0TC$#))KPO]G+_@C#_P %:?V2/@SH?[/?[.G_  7HM/"_@_PY;M#I
M&C6?[)7AR18@SL[LTDMT\DLC.S,TDC,[,Q+,2<U]O_MT_LP?\-I_L?\ Q$_9
M1_X3C_A&O^$^\+W.C_V__9GVS[!YHQYOD>;%YN/[N]<^HH ZC]GO_D@?@?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
9HH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>cah-20210331_g5.jpg
<TEXT>
begin 644 cah-20210331_g5.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@!
MD (4 P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#?6DQ4X8)-"S(V#P<'BOYF?^#?;_ ()._"K_ (*O?%+X^^%OVG_'_BV+X<^
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MCX-?&3PKXMT6V9EN-8\,>(;:_M8F R0TL#LBD#DY/ K\[?V-?^"V/B_]J/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** .;^,?PJ\'_';X1^*?@C\0K)KG0?&/AV]T36[=&
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M;ZB@#D/VA/\ D@?CC_L3]3_])9*_&W_@R0M;:^_9/^.EE>V\<T,WCVP26*5
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MEY$S037D\\T4H2(3))#%;Q(@06_!";4'LW[)O_!"[_@H3_P2,_X+0>%?'?[
M-QJ_C']GK6DM8_'FJ>(/$5A:O%I4\DD5S9W<.^,WEQ;8%U$\,(!/ECY<N" ?
MNA17R5^UQ_P6T_8"_8<_:63]E/\ :2^(.JZ%XF?P9<>)_/\ [%DDLA8Q6UW<
M8\Y3S,XLY42( L\C1H,EQ2?L??\ !:_]AC]LC]D7QK^W%X:\2ZYX-^'7P]U6
M73_%6L^/]+6R%M*D4,OR^5),LI99X0J(S2,TJ)LW,H(!];45^97PR_X.V?\
M@CY\2?C#!\)YO&OC;PY:W=Z+:U\9>)O"@M]'=BVU6:1)GFAC)(^>6%%4<N4
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M_P#!*KPAH_B3]JOQM?QW_B)Y1X>\+^'M.^V:EJ*Q;?-D2,LB)&N]07E=%RP
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M NHZDS+;/=+&\4EI.R@LD4T;D;@"5=(FP0I! /G/_@M;_P $>O\ @GU\&O\
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M#4G33Q8V]PZ@7"OM$TMU*9#C]YY2[B=HQA_\&T?PD\#_  "_X+W_ +8/P/\
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MMTWD-.268 [B(E /W<HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8_M$_LK_ !'@\2^&;VXDMGF6"2">SNH\>9;7$,@5X95W*2K#E65E+*RL?5:
M"BBB@ HHHH **** "BBB@ HHHH **^<OV8?^"EOP=_:9_;"^,W[#5IX1UWPS
MX_\ @O?0C5=.U]8 NKV$W,6H69BD8M 5>!CO"LHN8<CYN/HV@ HHHH ****
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MQMDA>UG=$,L7E",*Q5<@<#%?;7_!X=X8T31/^"/'AK0]/L42VT?XM:%%IT8
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MRW87/F;2#C;S7Z)_\&^OQ\_:$^/7[#=A-^T%^QHWP=?PM;Z9H'A2!M%N+/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKX7T_1_[1^S^3]J^S6T<'F^7N;9NV;MNYL9QDXS7444 ?%'_  6X_P""//\
MP^/^"W@WX0?\-$_\*Y_X1+Q1)K']H_\ "(_VO]KW6SP>5Y?VNV\O&_=NW-TQ
MCO7U0OP7\':S\!5_9Y^(>G6WB'0+GPD/#VMVMY;XBU&T-M]FE1TR<+(FX%<G
M ;&>]=?10!^<7_!);_@W]G_X)8>/OBE86G[7A^(?PJ^*>CRZ?JWPRUKP"+8*
MH=Q [W8OY%E9;>:>"3$""82Y(38JU\O^-_\ @T7^-GA36?%_PM_9!_X*I^+/
M ?P5\=WWFZ_\/KFQO)@\!/\ J)U@O8H=0VJ JO*B$J K9QN/[>T4 >*?\$]O
MV#_@M_P3<_95\._LH? J.ZETG1!)->ZKJ!4W6JWTS;Y[N8J -[M@  81%1!P
MHKY$_9G_ .#<3X1?LW?\%>O$'_!4[3?CF=1M-0UK6M9T#X;?\(@(8](U#4D=
M)91>?:V$J)Y]R400)M\Q,$>6-WZ344 ?+_\ P5D_X)6_ _\ X*U?LSGX!?%O
M5[K0M3TS4!J7A#Q?IULLMQHUZ$*%O+8J)H71BLD)9=PVD,K(C+\$?L]?\&JG
MQ0U+X[^!/B#_ ,%'_P#@HWXC^-_@[X8M'_PB/@2^@O'@\J-D:.V9[NZF%O:Y
MBB#P1)^\5 F]0HK]EZ* /AC]O#_@BY_PVU_P4L^!?_!1#_AI/_A&?^%+7&ER
M_P#"'_\ "'?;?[9^QZH]_C[7]LB^S[]_E_ZJ3;C=S]VK'_!8?_@C7_P]B\5?
M!CQ-_P -'?\ " _\*B\07NI^1_PB']J_VM]H>Q?R\_:[?R-OV+&[$F?,Z#;\
MWV_10!\ _P#!</\ X(7^'?\ @KM8^"?'?A#XUS?#KXC?#^29-%\1#3FNH+JU
ME=)##*J21NC1R()(Y4;*EI 5;<"GS#XA_P"#2GQA\6+GP3\6?V@/^"HOC+QG
M\5M!\00WOB+QIXNT"YUD7UA;M$UKIMN+C45DMTC99296>3>91A(PN&_9RB@#
MX._X+._\$,OAU_P5??PE\5O"_P 8+_X8_%KP$-GAGQWIMF9]UN)?/2WF1)(I
M!Y<V9(I8Y%:)I)#A]V*\K_X)M?\ !N?XD_9M_;(A_P""@/[>O[:>O?'WXFZ/
M;F+PK=:U%<-'8/Y1A6YEFNIYI;B1(V98D.Q(B=P#,%*?J+10!^./[<_AN3]N
MO_@ZH_9\^ 6AQ?;-$_9Z\$1>,_%[H-W]GWBS/?0[AVW2'1A_VWSVY_8ZO"OV
M=?\ @GA^S]^S1^TY\6?VO_!DFNZGX\^,NH07'BK5_$&H)<?9X8=PBM+0+&GD
MVZ@HNPEB1#%ECL%>ZT %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% 'D?[7O[5'_#*GA32?$__  @G
M]O?VIJ+6OD?VI]E\K$9?=N\J3=TQC ^M> _\/B_^K=/_ "[O_N2NA_X*\_\
M)*?"G_8PR?\ HAJ^!* /MK_A\7_U;I_Y=W_W)1_P^+_ZMT_\N[_[DKXEHH ^
MVO\ A\7_ -6Z?^7=_P#<E'_#XO\ ZMT_\N[_ .Y*^):* /MK_A\7_P!6Z?\
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MXK>+?CA'XE^#'PUO<>&/A1IUKK/C^]3)2?4+FXBM[2RR.K(LS2$=,ALC=&*
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MH&F^/--N+*ZU._N]2MK&[0K)!;RR?N\J>5W!?, ])!WKF/\ @C%_R0CXB?\
M99=7_P#26QK[ HH ^;OVIC_POW]J#X;_ +)-I^^TG3)O^$W\>H.5-I:/LLK9
MQT99;D_,AYQ&&YKY0^&5[9C]L3P_K5KJ,I^+]Q^TEK5IXFB^U2?:_P#A'A$H
M*O&3@6PC#;#C&%.TX7C],K;PSX;LM=N?%%GX?L8M3O8DBO-1BM$6>=$^XKR
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M_P#HO6@_]_G_ /B:/^&Y_P!D?_HO6@_]_G_^)KNO^%7?#/\ Z)WH7_@HA_\
MB:/^%7?#/_HG>A?^"B'_ .)H X7_ (;G_9'_ .B]:#_W^?\ ^)KRCQS^T[^S
MYK'BR^U/3?C!H,D$TNZ-_MRC(P!T.#7TC_PJ[X9_]$[T+_P40_\ Q-'_  J[
MX9_]$[T+_P %$/\ \30!\L_\-%? G_HK.@_^#%/\:/\ AHKX$_\ 16=!_P#!
MBG^-?4W_  J[X9_]$[T+_P %$/\ \31_PJ[X9_\ 1.]"_P#!1#_\30!\L_\
M#17P)_Z*SH/_ (,4_P :/^&BO@3_ -%9T'_P8I_C7U-_PJ[X9_\ 1.]"_P#!
M1#_\31_PJ[X9_P#1.]"_\%$/_P 30!\L_P##17P)_P"BLZ#_ .#%/\:/^&BO
M@3_T5G0?_!BG^-?4W_"KOAG_ -$[T+_P40__ !-'_"KOAG_T3O0O_!1#_P#$
MT ?//PR_:F_9U\/>+(M3UCXQZ## L3JS_;0V"1@<+DUZ9_PW/^R/_P!%ZT'_
M +_/_P#$UW7_  J[X9_]$[T+_P %$/\ \31_PJ[X9_\ 1.]"_P#!1#_\30!P
MO_#<_P"R/_T7K0?^_P __P 31_PW/^R/_P!%ZT'_ +_/_P#$UW7_  J[X9_]
M$[T+_P %$/\ \31_PJ[X9_\ 1.]"_P#!1#_\30!PO_#<_P"R/_T7K0?^_P _
M_P 37#?M+_M;?LU?$'X!^+/!7A#XTZ#=ZGJ>C2P65M]K\OS)#T&YP%'U) KW
M/_A5WPS_ .B=Z%_X*(?_ (FC_A5WPS_Z)WH7_@HA_P#B: /Q^_X0[4?^@QH/
M_A3V/_QZC_A#M1_Z#&@_^%/8_P#QZOV!_P"%7?#/_HG>A?\ @HA_^)H_X5=\
M,_\ HG>A?^"B'_XF@#\?O^$.U'_H,:#_ .%/8_\ QZC_ (0[4?\ H,:#_P"%
M/8__ !ZOV!_X5=\,_P#HG>A?^"B'_P")H_X5=\,_^B=Z%_X*(?\ XF@#\?O^
M$.U'_H,:#_X4]C_\>H_X0[4?^@QH/_A3V/\ \>K]@?\ A5WPS_Z)WH7_ (*(
M?_B:/^%7?#/_ *)WH7_@HA_^)H _'[_A#M1_Z#&@_P#A3V/_ ,>K[<_8'_:,
M^!'P5^ :^"OB;\6M!TS4QK-S.;;^T$F_=OLVG=$67G!XSFOJ7_A5WPS_ .B=
MZ%_X*(?_ (FC_A5WPS_Z)WH7_@HA_P#B: .%_P"&Y_V1_P#HO6@_]_G_ /B:
M/^&Y_P!D?_HO6@_]_G_^)KNO^%7?#/\ Z)WH7_@HA_\ B:/^%7?#/_HG>A?^
M"B'_ .)H X7_ (;G_9'_ .B]:#_W^?\ ^)H_X;G_ &1_^B]:#_W^?_XFNZ_X
M5=\,_P#HG>A?^"B'_P")H_X5=\,_^B=Z%_X*(?\ XF@#PGXO_M:?LU^*;ZRF
MT+XT:#.L,3K(?M@7!)&/O8KC_P#AHKX$_P#16=!_\&*?XU]3?\*N^&?_ $3O
M0O\ P40__$T?\*N^&?\ T3O0O_!1#_\ $T ?+/\ PT5\"?\ HK.@_P#@Q3_&
MC_AHKX$_]%9T'_P8I_C7U-_PJ[X9_P#1.]"_\%$/_P 31_PJ[X9_]$[T+_P4
M0_\ Q- 'RS_PT5\"?^BLZ#_X,4_QH_X:*^!/_16=!_\ !BG^-?4W_"KOAG_T
M3O0O_!1#_P#$T?\ "KOAG_T3O0O_  40_P#Q- 'RS_PT5\"?^BLZ#_X,4_QJ
M6P_:/^ T-]#-+\6]!"I*K,?[03@ _6OJ'_A5WPS_ .B=Z%_X*(?_ (FC_A5W
MPS_Z)WH7_@HA_P#B: .%_P"&Y_V1_P#HO6@_]_G_ /B:/^&Y_P!D?_HO6@_]
M_G_^)KNO^%7?#/\ Z)WH7_@HA_\ B:/^%7?#/_HG>A?^"B'_ .)H R_AG^T%
M\%_C+?76F?"_XB:=K=Q91"6ZBLG),:$X#'('&>*[&L_1O"7A3PY*\_A[PSI]
M@\B[9'LK*.(N/0E0,BM"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **CN[NTL+66_O[F."""-I)IIG"I&@&2S$\  #))KX U3_
M (. _ 'B&76?'7[-W[ /[0OQ<^%?AR]GM]5^+G@3P7%+I-R(&*SS6 EF22^A
MC*MND55'RD],,0#] Z*\+_X>2_L;2?L,2_\ !1VR^,5I=?"6+0O[4;Q#;0.S
ME?,$/V;R<>8+GSR+?R" _FD(0#7%?LF?\%9?A5^T]\;K?]G'QA^SM\7/@[XU
MUCP])KWA'0_C!X2CTQ_$FFQE1+-9O%/,CO$'0R0L5D16SM(#%0#ZIHHHH **
M** "BBB@ HHHH ***\<_;@_;K^ 7_!/WX/1_&'X\ZCJ<J7^J0Z3X:\->'-.-
M[J_B+4YL^386-LI!GG?!P,JH )9E'- 'L=%?$/P?_P""W/@C6OC7X5^!O[6G
M[&?QE_9[O?B#>K9?#_6_BIX=B@TK6KUN4L/M4,KK;W;\;89 ,GY=P8J&],_;
M+_X*:?#']D/XI>'_ -G[2/@E\2OBQ\2?$>BS:W:^ /A/X=CU'4+728I/+?4;
MGSIH8X+<R@Q*Q?<\@VJIP2 #Z2HKR[]CO]L#X,_MR_ VQ^/GP.O-1_LRXO+F
MPU'2M<T]K/4M'U"WD,5S87ENQ)@N(G!5DR1T92RLK'U&@ HHHH **** "BBB
M@ HHKP_]GG]O+X6_M"?M*_%S]DBT\*^(/#7CGX/:G:Q:WI/B2&",ZG8749DM
M=4LC%+)YUK*N/F.UT+*'52P% 'N%%?,/QQ_X*B_#_P"%7[0GC;]F/X=_L^?$
MOXI^+/AU\/K?Q7XPL?AMHD%\UBES.L5KI^UYT=[Z96\](54_N5:0L #7SX/^
M#C/2&^+#? =?^"1?[8I\;+X=&OMX2'PMMO[1&E&<VXOOL_VWS/(,P,7FXV[P
M5SGB@#](:*^&OC3_ ,%Q/#7P9\0_#GX>M_P3R_:1\1^-/B+X"E\6P> ?#7@2
MWN-:T6RCNC;2+?6ANE>&17"DX#*!(F6R<5V/[&/_  6)^ '[7WQPNOV7/$'P
M9^*WP;^*,.E-J=EX!^-?@LZ)?ZM9(</<6?[R1)T7J1N#$!F"E49@ ?6E%%%
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M"CQ+J/C3X7>&O&.L+&+O5M L[RZ$*E4$DL".VT$G RQP,FM^@ HHHH ****
M"BBOAW_@H?\ M5?\%'_#G[<WPM_8J_X)ZS?!VTU'QIX!USQ'JNH_%S3=2F@1
M;"XMH]D;6$@921<="C XZCN ?<5%?$/@O3_^#AS2/"OCG4_BUXL_92U&_M_
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M:'0-$GO_ /A*_!FDZQ/'!I.JWUQ+(;6Y0M-;F:..-&43IM (8+^F% !1110
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MTV?7%L8Q>26<9>6.V:;&\Q+)+(X0G:&D8@9)->%_LY?\$8?^"M/[)'P9T/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
B444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>cah-20210331_g6.jpg
<TEXT>
begin 644 cah-20210331_g6.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXQ:^&[NXFA2# @5#>WCJ(P-F\A,=*^'/VO=(_9Q^(/\ P27^(7C_ /X)X?\
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M#]HC0_&>G2WGBQ_LOVEKF1/+BEDCGE,=U$DDKFW6,(F%W9 /Z/?^&K_V;_\
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M)=NDUW<VT,,N/,2V>-%?SE4%N 0<X'-?>?\ P0L_X+:G]HK_ ()F^(/VA/\
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M (-^OAY^U1^SU\/]-\.?$GPCI_A#6-'^(NCSM%J>NW=\UL)WEG5LR[O/>Y0
M_NC"OE[%!! /3/\ @XA_X*7^-;?]N_X-?\$\?@1_P4;;X%:'+>2R?&?QIX<O
M3'=^'Y)1#):BZ>.2*1$$#&01+(BR?:%+DA5Q[W^ROX]^)'P&_;^O6^-7_!9G
MPK\0_AMX-_9OL=4UKP5JNJ21ZHP@TO3YKCQ3<PF-DB@E437)/GN56Z7);DU\
M3_MS? OX+_M(?\%;O^">WCSXV? [0+S5/CU\/-(UCXP6EUIXVZ]>O8P@_:EX
MWE%58P.,! .U>S_#+X0?#'7O^#L?XQ? /6? ^GW/@R]_9<A\/W?AN6 &TETM
M],T>V:T9.\1A)C*_W3B@#Z"_X(4?\%J?^'G7B_XN^&?BU\0O"-EXGL/'EX?A
M[X%T0A94\,6\-LBW8+9>X#2R$O*QP6?"JB@*/T@K\7?^#1']G7X&V'A?X]?'
M"S^%VCQ^+M"^,^K>&]'\0I:@75II!@M9#9(_:+>H;;ZBOVBH **** "BBB@
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MJ301SH"7"NB@[P#G\W_A]_P:O?&+6]6\'?!;]KO_ (*E^,?B3^SW\/-82_\
M#'PF;2YK99E0MY=O([7<B0HJ,T>Y%9A&\BQ>1OR/V0HH ^._VM/^"3%G^TY_
MP40_9_\ V\=.^-\7AFW^!$4D<'@N#PF+A-61G+*JW N8Q:A00H BD&!VZ5+X
M-_X)2?\ ")?\%DO%G_!6S_A?7VC_ (2CX?Q^&/\ A7__  BVS[-LALX_M'V[
M[4=^?LF=GD+_ *S&[Y<GZ_HH _.O_@F9_P $1?C5_P $V/VV_B!\9_!?[<=_
MJWP?\8ZGJ>IP_"=M%DB7[9=NK1S3R?:#&\D"+Y8E$>9% RJ=OT4HHH ****
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M<=2__!4'_@GNG[3\/[&)_:Z\%'XFW%PEM#X475096N7&5M?- \K[0V0!!O\
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M;=E\>OVI?BK^P=^P/\6;G_@I=H7POU[Q;J6E7/CI_&.J/#<_$-7DMM^GP^7
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M(+YG_"4?9I+=_+\K[<OV+=Y&-VZ?&_H<<L_X*9?\$*O%7[5?[5VF_P#!0/\
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MI&@Z1!Y=O:J\CROM7U:1W<DY)9B3R:ZN@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT?\ #0?_ %*/_D__ /:Z /2**\W_ .&@_P#J4?\ R?\ _M=26OQ\^TW,=O\
M\(GM\R0+G[?G&3C_ )YT >B4444 %%%% !1110 4444 %%%% !1110 4444
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M $(4 ?1-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)_Z#7LM>-?!C_D>X/^N$G_H->RT %%%% !7Q-_P7]^ '[-/[3W_!/'6?@_\
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M1M9\#7K$Z=:6$T">1%;1 E8VBA7&X*&+J#G!8'^E/_@EI_R:RG_8PWG\HZ_
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M^"A?[&OAGXA_M'ZW\!_!\GAN]\>7.M^)=.\1%+C4KB*>95+QM%(RK$"_!!+
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MXKZ0H _9/X1_\DI\,?\ 8O67_HA*Z&N>^$?_ "2GPQ_V+UE_Z(2NAH ****
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M$M/^364_[&&\_E'7YLU^DW_!+3_DUE/^QAO/Y1T ?1U%%% !1110!YA\?_\
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MP^T+0]5^.6@Q75GHUK!<Q?:"VR1(E5AD @X((R"16S_PW/\ LC_]%ZT'_O\
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M?_1.]"_\%$/_ ,30!X3\7_VM/V:_%-]93:%\:-!G6&)UD/VP+@DC'WL5Q_\
MPT5\"?\ HK.@_P#@Q3_&OJ;_ (5=\,_^B=Z%_P""B'_XFC_A5WPS_P"B=Z%_
MX*(?_B: /EG_ (:*^!/_ $5G0?\ P8I_C1_PT5\"?^BLZ#_X,4_QKZF_X5=\
M,_\ HG>A?^"B'_XFC_A5WPS_ .B=Z%_X*(?_ (F@#Y9_X:*^!/\ T5G0?_!B
MG^-'_#17P)_Z*SH/_@Q3_&OJ;_A5WPS_ .B=Z%_X*(?_ (FC_A5WPS_Z)WH7
M_@HA_P#B: /EG_AHKX$_]%9T'_P8I_C4MA^T?\!H;Z&:7XMZ"%2568_V@G !
M^M?4/_"KOAG_ -$[T+_P40__ !-'_"KOAG_T3O0O_!1#_P#$T <+_P -S_LC
M_P#1>M!_[_/_ /$T?\-S_LC_ /1>M!_[_/\ _$UW7_"KOAG_ -$[T+_P40__
M !-'_"KOAG_T3O0O_!1#_P#$T 9?PS_:"^"_QEOKK3/A?\1-.UNXLHA+=163
MDF-"<!CD#C/%=C6?HWA+PIX<E>?P]X9T^P>1=LCV5E'$7'H2H&16A0 4444
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MLWBGF1WB#H9(6*R(K9VD!BH!]4T444 %%%% !1110 4444 %%%>.?MP?MU_
M+_@G[\'H_C#\>=1U.5+_ %2'2?#7AKPYIQO=7\1:G-GR;"QME(,\[X.!E5 !
M+,HYH ]CHKXA^#__  6Y\$:U\:_"OP-_:T_8S^,O[/=[\0;U;+X?ZW\5/#L4
M&E:U>MREA]JAE=;>[?C;#(!D_+N#%0WIG[9?_!33X8_LA_%+P_\ L_:1\$OB
M5\6/B3XCT6;6[7P!\)_#L>HZA:Z3%)Y;ZC<^=-#'!;F4&)6+[GD&U5."0 ?2
M5%>7?L=_M@?!G]N7X&V/Q\^!UYJ/]F7%Y<V&HZ5KFGM9ZEH^H6\ABN;"\MV)
M,%Q$X*LF2.C*65E8^HT %%%% !1110 4444 %%%>'_L\_MY?"W]H3]I7XN?L
MD6GA7Q!X:\<_![4[6+6])\20P1G4["ZC,EKJED8I9/.M95Q\QVNA90ZJ6 H
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M@<3V[075A=Q';-:7,+_-#-&W#*>H*LI965CZC0 4444 %%%% !1110 4444
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MC'PI9W"AHUUFYU*WTZ28*>#(MMRIY*XR,=:^^:^/?^"G'[(7[27C7XD_"_\
M;W_80AT:[^,WP8N+Z*W\*^(+P6MCXRT"^C5+W2)9SQ#*=B202N=D<F2<9#*
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MPY#X1\.W?_"SO#^TI/H^O6/[J\TQ8Y#N$C7 584<[W6X@SR] 'US17YW2?\
M!0O_ (*9V/[.'[/W@>Y^"7P]A_:2_:9U?4KOPUH.KVU];:!X*T*VMOMTDNI;
M96N+BXAM'M]\:M$6EG9  8]K]I^SC_P4)_:7^$W[0?Q/_9#_ ."G^D_#^T\2
M> OA0WQ0T?QO\+X[N/2]8\*QS26]V\EM>2/+;W%O-'M(WE7#Y 4 ,X!]NT5^
M9_@W_@J#_P %-_!?P^^&G_!0+]J#X'?"K2OV;_BGXDTJT.@:)/?_ /"5^#-)
MUB>.#2=5OKB60VMRA::W,T<<:,HG3: 0P7],* "BBB@ HHHH **** "BBB@
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MDGF(Y@0,A&:Q?V5?V+?^"K?P?^-_A_QM^T=_P6:3XJ^!-,2Y75_AVG[.6@Z
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MZ;X.?PIX)@\/^#4T32O#^G2S)-=3) )9#)=W+Q1;Y<KM53&H*X"@'UQ1110
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M>L+?XZ_$KX:BW!M=5\1Z+<26:IUP(+FXFM+JX0@B9[;GHFW]=:\(\3?L3?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
<B@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>cah-20210331_g7.jpg
<TEXT>
begin 644 cah-20210331_g7.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%_P>_P""H'QF_P"#DW]K'0O^"5_[2?A+X9>,+71;"?Q%JWC"(/!=:;]ETE3
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M[:4%XXY8KB+Y)H52)XW&!L#!CG:/T4HH **** "BBB@ HHHH **** "BBB@
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M[^7%'^&*^4?V^O#MKXO_ .#=_P#X)[>$[Z>6*#5/B!]DFE@?:Z)))>(2I[,
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M"NW^-O[2'QZ\->$?"M[)''IVLZIJ*B.^=T+HEN$W-<,R N%C#$J"V, FL/\
M9A_;H_8P_P""A/@K6[G]DS]I+1?&5K9P_9M9/AS4I+>_TX3*P1VC8)/;EL-L
MD*KDH=IRIQ^-?[3?[%'[:_[4_P#P2O\ ^"??[7?[,?PN\.?%V\^#?@.(ZI\*
MO&445W;:U&\-GY)^QS21K?(L=EY;P*WFLNS8&PV/3_\ @@C^U1^R#XO_ ."E
M_C3P%X\_X)=W_P"S#^TIK?@ITOM+TN6^T_1-1L83;R311Z/(L,=C*WE1SC,4
MF\12.)5+%7 /JW_@@!^UA\9OBK\*_BU^QG^U%\0-2\5?$[]F_P"*NI>$M<\2
M:U=-/>:QIS7$YL;V>1R6=F\JYC#'[R01G)))K] *_)__ ()D/)X8_P"#EW]N
MOP7X?E TF_\ #WA_4KU(Q\IN_L]F^21QN#75Q[Y)]Z_6"@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOTF_X):?\FLI_P!C#>?RCK\V:_2;_@EI_P FLI_V,-Y_*.@#Z.HHHH ****
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MHHH *_2;_@EI_P FLI_V,-Y_*.OS9K])O^"6G_)K*?\ 8PWG\HZ /HZBBB@
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M: \3Z?HY1=/MY%Z/#+?RIO4\?N5Z\"@"EXN_;C_;ST?X)?L\_"Y/@[X$TO\
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MNQ>3RHU"KN;S1DX'7%?L_P#\*N^&?_1.]"_\%$/_ ,31_P *N^&?_1.]"_\
M!1#_ /$T >6?#K]M']E;0OA]H6AZK\<M!BNK/1K6"YB^T%MDB1*K#(!!P01D
M$BMG_AN?]D?_ *+UH/\ W^?_ .)KNO\ A5WPS_Z)WH7_ (*(?_B:/^%7?#/_
M *)WH7_@HA_^)H X7_AN?]D?_HO6@_\ ?Y__ (FC_AN?]D?_ *+UH/\ W^?_
M .)KNO\ A5WPS_Z)WH7_ (*(?_B:/^%7?#/_ *)WH7_@HA_^)H X7_AN?]D?
M_HO6@_\ ?Y__ (FO*/'/[3O[/FL>++[4]-^,&@R032[HW^W*,C '0X-?2/\
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M9%J>L?&/088%B=6?[:&P2,#A<FO3/^&Y_P!D?_HO6@_]_G_^)KNO^%7?#/\
MZ)WH7_@HA_\ B:/^%7?#/_HG>A?^"B'_ .)H X7_ (;G_9'_ .B]:#_W^?\
M^)H_X;G_ &1_^B]:#_W^?_XFNZ_X5=\,_P#HG>A?^"B'_P")H_X5=\,_^B=Z
M%_X*(?\ XF@#A?\ AN?]D?\ Z+UH/_?Y_P#XFN&_:7_:V_9J^(/P#\6>"O"'
MQIT&[U/4]&E@LK;[7Y?F2'H-S@*/J2!7N?\ PJ[X9_\ 1.]"_P#!1#_\31_P
MJ[X9_P#1.]"_\%$/_P 30!^/W_"':C_T&-!_\*>Q_P#CU'_"':C_ -!C0?\
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M -%ZT'_O\_\ \37=?\*N^&?_ $3O0O\ P40__$T?\*N^&?\ T3O0O_!1#_\
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M\*N^&?\ T3O0O_!1#_\ $T <+_PW/^R/_P!%ZT'_ +_/_P#$T?\ #<_[(_\
MT7K0?^_S_P#Q-=U_PJ[X9_\ 1.]"_P#!1#_\31_PJ[X9_P#1.]"_\%$/_P 3
M0!E_#/\ :"^"_P 9;ZZTSX7_ !$T[6[BRB$MU%9.28T)P&.0.,\5V-9^C>$O
M"GAR5Y_#WAG3[!Y%VR/964<1<>A*@9%:% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 45'=W=I86LM_?W,<$$$;2333.%2- ,EF
M)X  &237P!JG_!P'X \0RZSXZ_9N_8!_:%^+GPK\.7L]OJOQ<\">"XI=)N1
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MOF>09@8O-QMW@KG/% 'Z0T5\-?&G_@N)X:^#/B'X<_#UO^">7[2/B/QI\1?
M4OBV#P#X:\"6]QK6BV4=T;:1;ZT-TKPR*X4G 90)$RV3BNQ_8Q_X+$_ #]K[
MXX77[+GB#X,_%;X-_%&'2FU.R\ _&OP6=$O]6LD.'N+/]Y(DZ+U(W!B S!2J
M,P /K2BBB@ HHHH **** "BBO/OVK?V@;3]E/]G+QA^TAJ?PY\1>+++P7HLF
MK:CH/A2&&34)[6+#3O"D\L:,8XM\I!<$K&P7<V%(!Z#17GWPV_:C^!_Q3_9C
MTO\ ;"\->.K1/A]JOA!?$RZ]=R!([;3O(\^22;D^68T#>8IY1D8'D&OE4_\
M!<0:S\(? WQS^%__  2Z_:H\<^'/B#I,^J:#>>#?AW;7Y2S2Y>"*6<)=_N?/
M">=$I.YHG1\ ,* /NNBO@[]BK_@NWX=_;K\2^#8?A)_P3=_:;M/"7C6^:WT[
MXF:KX MQX=MU1Y(WFEO(;N11&LD3QLRAL,".H-<OX;_X.+O!WCC2K_QE\./^
M"5W[7GBWPKINJWMA/XM\(?"RWU*PD:TG>"=HY(KTAU1XW!Z$;3G&#0!^C-%>
M7?L=?MC_   _;P^ VE_M&_LV>,3K'AS4Y)('$]NT%U87<1VS6ES"_P T,T;<
M,IZ@JREE96/J- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% 'Q]_P7Z^(7BSX8?\$</V@/%7@J^EMK]_ [:?YT)(98
M+RYALY\$<C]S/(,]LU]$?LR?"WP+\$?V=/ OP@^&6GV]KX?\->$M/T[2(K5
MJ>1%;HBMQP2P&XGJ2Q)))S1^TU^S]X"_:N_9Z\:?LU_$^"1] \<>&KO1M3:
M@2Q1SQ,GFQDY D0D.I[,BGM7YA_$'Q#_ ,'$?P3_ &;_  W^PO\ #7]F#5-?
M\<?#_5+"#P+^T'X&\:Z+'HWB?2[16ABCUK3]24R1*T!7SUW([R1*R/W< ]0_
MX)H?L_?!?QI^T!^V[^QCXS^'^EZ]\,_#G[1VG>)M"\.7D&ZSLM1O+*VU"58D
M!PBQ74,;JBX56'09JE\1?BC\;?&7_!>3X%77[;?P&N/A3X/\)P^-=,_9UUJQ
MUBWUB#QQJUY;BWF:_N(7']F,^GPB:&S>-BSL09690M<;^QK^S9_P41MOV!OC
MI\/O"5AXN^'/[7A^,[>/_&'B/7X%MM \:ZA)>+/'9Z=>1.R3:7-8VRVI *^3
M(Y#A%)%>H0^&?V]_^"FW[7?P,\:?M"_L.ZA\!/AU\"/%$GC'6G\3^+[#4M0\
M0^(%M)+>VL[%;)V"VL33/(\\FT2K@*%(Y /T4HHHH **** "BBB@ HHHH *^
M!OC[I]C\5/\ @XH^!7@3QVB7.E?#S]G?Q)XQ\*6=PH:-=9N=2M].DF"G@R+;
M<J>2N,C'6OOFOCW_ (*<?LA?M)>-?B3\+_V]_P!A"'1KOXS?!BXOHK?PKX@O
M!:V/C+0+Z-4O=(EG/$,IV))!*YV1R9)QD,H S_@OY\.O"/Q%_P""0/QR'BN-
M$E\/>#W\0Z'?9VRV6I6$B7-M+$_!CD\R,)N4@D2,O1B#U=@GC?2OV:])_;V^
M!/[)^D_$7X_^*?A3X=M+BRF\0PZ'+J\+B&=X);V=62&*%KBXG"["6*[!@L"/
MS6_;SC_X+H_MRS^+[7QG^Q'\4_!W[.NN_P!@R?%[X5KXFT'6-;EM;*[MVO8/
M#1MO*N)#-'"7='9A*Q?9C<(S]N_&3XB_\% _V>_VC-!_:N_9F_9W\6_&+X'>
M.OA9IUA<_!ZRU>UTC5O!.JQ$RP7D5K>LB;)8)5@FB!\R-X\MP@4@&=_P;[ZS
M'J/P ^,#?$".^TKXOZE^T+XFUWXY>#+[3UMAX:\1WSQ2-9VP66436?V=+=HK
M@.PFRS<'('WO7R)_P2F_9A_:(^&5Y\8_VL_VN/">G>%OB)\??'Z>(=0\#:5J
MB7T?AG3K:UCM+"QDN8_W=Q<+$C-+)'\C%QCH:^NZ "BBB@ HHHH **** "OS
MH_X+::3XL_89^(7@7_@N+\#?#IO]4^%$(\,_&+P]!<+ ?$W@R_G6/86/WI;6
M\DBEB'3,A9CB,"OT7KY8_P""V7[.'QG_ &N?^"7'Q=_9S_9Y\&_\)#XR\4:/
M9P:%HW]HVUI]ID34;69AYMS)'$F(XW;+NH^7 Y(! &?\$C?V1O'/[-_[.U]\
M5OVA+B*_^-'QIUN3QO\ %W5$YV:C=#=#IT9R=MO9P%+=$!* K(4P'Q7G5M_R
MLXWO_9B%M_ZFD]?<?AZUGL= L;*ZCV2PV<22+D'#! ",CCK7RQ!^S-\;D_X+
MJ77[9#>"<?#>3]DR#P8GB/\ M*VYUQ?$\U\;3[/YGG_\>S+)YGE^5SMW[OEH
M X/XF_\ *R!\+?\ LU#Q#_Z?+6J7_!;S3-.\*?&#]B;X\Z"B6_B[2OVP_#'A
MG3]1C7]\=*UF*ZM]2M@1SLDBBC+=L1\]<U0_X*!^ _\ @HA\+?\ @JI\/?VZ
M?V-/V"_^%XZ/H_P4U+PCJ^F_\+2TCPS]FN;G4DN0_F7S,SX2(<+$5._[P(P8
MOAS\#/\ @I1_P43_ &S/A?\ M$_\%#?V8?#OP)^&WP.U2YU_PG\,K+Q_;>)=
M2U_Q&\+06][=75F!!'!;*SR1J K[VP0RL2@!^B%%%% !1110 4444 %,N+>W
MO+>2TNX$EBE0I+%(H974C!!!X(([4^B@#\3M8_9<_:,\$_M1>(/^#;[P--/9
M_ 7XB>)X_B?I_B2WU#9/HOPX>XDEU?PY$ 0T>_5$AMHV&X^7=2LX*R$#]I/#
M?AS0?!WAVP\(^%='M].TO2K**STW3[.(1PVUO$@2.)%'"JJJ% '   KY9\0?
MLS?&Z^_X+A>&_P!L"U\$[OAU8?LR:AX3N_$7]I6P\O6)->ANTMOLYD\\Y@1G
M\P1F,8P6#<5]9T ?"'_!LO\ \H.?@1_V#];_ /3_ *C1_P &XG_*,BQ_[*AX
MU_\ 4AOJ[S_@AC^S-\;OV.O^"5?PF_9N_:.\$_\ ".>-/#-GJB:YHO\ :5M>
M?9FFU>]N(QYUK))$^8IHV^1VQNP<$$#Y$_8,\1?\%SO^">O[/=U^RQX._P""
M)EMXT@M?&>OZEIGC6\_:/\.Z?%-'?ZG<7<;O9#S9 J"8 CS-S =%)P #W+_@
MF)IFG?#G_@K9^W_\$_!*):^%[7Q=X$\40:9 NV*#5M8T.:?4I !QOEDACD;_
M 'AGU/WY7RE_P2K_ &+_ (U?LS^$_B%\<OVM_$.C:I\:?C?XU?Q3\0W\.EVT
M_2PL2P66DVS/\TD-K NT,<G<[C<X"L?JV@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBOCW_ (*P?M7?MG_L_P"O? WX
M1?L-)\.4\8?%[XC3^'!=_$ZPO9].MD33KB[WG['(DBG,.,@/UQCN #["HKXM
M^!WAW_@X/_X679+^TC\2/V2E\'O:7JZC)X*T/Q')J44QM)A:O$ERZ1.JW1@:
M1692T0D"L&((V_\ @F5_P46\0?M*_L\>.[C]L*PT'P1\5?@=XDU+0?C?I%DS
MPZ?ILEJ9)4U"'SG=Q936JB5)&8@F.7!*KF@#ZWHK\W_#G_!7/]K_ %7]AN7]
ML^U^ N@7MY\:_C-:>#/V3O ]U;W-C)=V-[</!8:EK4[2.565(I[HK&D8$4:
M-B4.GH'P*_;#_P""A?P0_;D\"?L4_P#!2?0_A)JB_&+P[J]]\,_&?P@@U&UB
MCU'2H4N+[3;RWOY9&(^SOYL<R%0=F"I)/E@'W!17P/\ M ?\%IO#5C_P4O\
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MQS26]V\EM>2/+;W%O-'M(WE7#Y 4 ,X!]NT5^9_@W_@J#_P4W\%_#[X:?\%
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M/B!-XG_L[^Q_M/\ ;'F:?<6?V?S/.3[/CS]^_;)G;MV\Y'M] !1110 4444
M%%%% 'Y&_ GX%?\ !2WXL?\ !0?]LK5?V'_V\/#7PET2U^-EI%K.E:Y\+[;7
MGO;K^Q+$B=99G4Q (578.,C/>OT=^"OP5^*UW^RG%\"?VY/B3HWQ8\0:II>H
MZ=XWURV\,QZ79:W:W,TX$)LXV*QJ+62.!@#\VPMU:L7]E;]C7_AF;XT_'+XP
M?\+'_MO_ (7/\0(?$_\ 9W]C_9O['\O3[>S^S^9YS_:,^1OW[8\;MNWC)]OH
M _)[_@@_^QYJ6@_M6?%K4_BU\5+[QK9_LI>(]3^#GP*M]5CR^B:,\[:A/<,2
M2'N7AN;6T$@"E8+;RQ\A4+]C_P#!2'_@H;;?L8^&]!^%WPB\#2^/_CG\3+B3
M3/A'\,[ YDU&[ ^:]NB"/L]A;Y$DTS%0%4@,.63H_P!C3]B;_AD?XB?'#Q[_
M ,+,_P"$@_X7+\6+GQK]D_L;[)_8_G6T$'V3=YTGVC'D;O-Q'G=C8,9/S7\?
M/^"/W[>'C7_@H3XV_P""@?[-W_!6N'X8ZQXKT&ST'3]+G_9_TOQ$^BZ/;HA^
MQ07&H7AV(\ZO<2>7'%O>0[@=JX /)/C%^Q9XA_86^&/[%/@CXD^.T\3^+O$W
M[=&G>+/BUXI\K;%JWBO5;+5))IT7 "QA\0QG:"5C0D*S$5]"_MW![C_@L]^P
M9!8 FXA;XH3W>T]+/_A'(4;(]#,]MSZC\*VO$'_!,W]HOX]_L2:U^S/^VY_P
M4%U'XD^/4\;VWBGX>_&'1_AKIWAN[\(WUG]FET]HK*T=HIS#<PS2,[,K2)=/
M'E-JN+_[(G_!/S]H[PC^T_+^VI^WK^U?I_Q8^(.F^#G\*>"8/#_@U-$TKP_I
MTLR374R0"60R7=R\46^7*[54QJ"N H!]<4444 %%%% !1110!\H?\%TO^4/W
M[1/_ &2_4?\ T 5Y7^R)^RO_ ,%K])M?AAXM\<_\%6/!6K^!;:/1+S6/"$'P
M,LK>>]TE1"\MBMT)=T;O &B$P&5+;L9%?5G[=/[,'_#:?['_ ,1/V4?^$X_X
M1K_A/O"]SH_]O_V9]L^P>:,>;Y'FQ>;C^[O7/J*[_P"'OA3_ (0/P#H?@?[?
M]K_L;1[:Q^U>5Y?G>3$L>_;D[<[<XR<9QDT ?#W_  <2?#J]T']B&/\ ;Y^%
M^O\ ]@_%/]FO7K7QA\/O$*0"3&Z>&VO+"53]^VN(9,21]',2 Y7(/OO_  3*
M_9*\+_L8?L8^#_A+HVKRZQJU]:'7O&GB>[&;G7]=O\7-]?S,<LS22N0NXDK&
MD:9.VM7_ (*'?LA_\-Z_L6_$#]D'_A87_"*?\)UHZ6'_  D/]D_;OL.V>*7?
MY'FQ>;_J\8\Q>N<\8KH_C%\&O''CO]E?Q#^S_P##7XNR^#M?U7P3/H.D^.+?
M2S<2Z3-):F!;V. 31[G3.]5\Q<,!\W% 'Q+^TKX[U#_@M;^T@W[ WP%627]G
MGX8>,[.\_:)^(Z+FU\2:E83I<P>%-.?I-B>.-[J9>(PB@,#M$OKG_!<[P5X.
MA_X)8?M'_$6+PGIJ^(+CX.7NFSZXMC&+R2SC+RQVS38WF)9)9'"$[0TC$#))
MKPO]G+_@C#_P5I_9(^#.A_L]_LZ?\%Z+3POX/\.6[0Z1HUG^R5X<D6(,[.[-
M)+=/)+(SLS-)(S.S,2S$G-?;_P"W3^S!_P -I_L?_$3]E'_A./\ A&O^$^\+
MW.C_ -O_ -F?;/L'FC'F^1YL7FX_N[USZB@#J/V>_P#D@?@?_L3],_\ 26.N
MOK'^'OA3_A _ .A^!_M_VO\ L;1[:Q^U>5Y?G>3$L>_;D[<[<XR<9QDUL4 %
M%%% !1110 5^9O\ P4Z^'G[5?Q._X+._L_\ AG]CC]HC2OAAXQ_X4GXOE'B?
M6/",6MPBU6\T_P V#[-*RKEB5P^<C;[U^F5>(>._V-?^$V_;^^'_ .W/_P +
M'^S?\(+\/];\,?\ "+_V/O\ MW]H3VTOVC[3YP\KR_L^-GE-NWYW+C! ,_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
4* "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>cah-20210331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cah="http://www.cardinal.com/20210331"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cah-20210331.xsd" xlink:type="simple"/>
    <context id="i67ba371541c247eb885ce35370b4c954_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i087768a01b964091a69bb564b8374aa2_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="ia48bb06cca3d4969bdeb6e18237b4224_D20190701-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia19c49a9fdf94744a98048c92ed6d989_D20200701-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="if2d5ee4c8487424fb522d83601a9e4ed_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:NetOperatingLossCarrybackAxis">cah:NetOperatingLossCarrybackMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i95e27bf6690f452f80d7e0a0bf7a1856_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:NetOperatingLossCarrybackAxis">cah:NetOperatingLossCarrybackMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ibe76498d80224b4f96b532177a01467f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib19c0c691fb5445d9011b91ede443228_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i95b9c22031624339add2f629ea1f1aae_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2e48fd2c42b44627b6da89b6438745df_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i44fa84a0c3ec48fcb9c8521f508b477d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if86f35ae66d245c78bacd2478b7f05b7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i29ae1a4981b842e1a0eab772d873665f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i04980c8bb80847f688361a08698a8057_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i08d5fdbf648840f09c9f0acc3309de18_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib9dbcfd0b21e415c99ceac87f678613b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3ca53978778d45b291d32f2884428093_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6c4059f309d347d8b4ac8135e44ee042_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia7c7911192d9467a8120c5a8745e0ab4_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ibc405b4ba93d4f15a1821281ca6c82e7_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i0233856860d24d818336b00e3025a695_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i354467a0724c4e4cb8b779d18d807a9f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id4419c8027c549be9d1aa39851d2726a_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6de9849e852143f7be17f87669ee8388_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i60045d83318a4375a6adbff989fd1e0b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0384aad99f0b44cfb95e1fcfadf13ba7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i42416177b60446508042e47a8082a323_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iea8dfdedd1e94a78a4b76f76961b61a8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia2cae46a03fd4761a321a79b8d0f6b0f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6824c1c4ebaf4b5cbe01e36215bb8c94_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i87c6427dabe74d41be38b4708d40f760_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i92429500105f487686a760c50a01dbd4_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i097b90d861534948b48b5e94e8d68dbc_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="id5d2c55efe634921802f5f63cff13133_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i227cc70eba254c68b508a19a38a4772e_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i08c6b70579ab4b44b051a8e476cdc0bc_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i873b7175bb9c48f9a92364ddc30859a3_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i4adeac1e746a4298af939e62c0d13228_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ic22356641f7147aa93c0793fd724bac3_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ie21bd48f8a9a4cb0a6e3c0240434f025_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="iea0558a3dad14a5aa6f2a5ea17404724_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ibccb3acafd0d46549dd7845b502cc7d7_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i5da09f4564644c32a41c69fe1bca282b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if50ad56426144e3086cf7b567a121bdc_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i39fcecca1a1841798fed70b14788390b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if4123e12a9da4e40840720f78bc466d9_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic3a494cf37a0408c9c5282b7bacaf665_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i81dedbde5d2a466c9175f53824dd0c39_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if8b3edc49b1248e896c9ddae3b113611_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia3fc7d942b0147c78cd1b3b94f6611b5_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1c2d8220369a4176bd9a77e28f267fbd_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ib49cffead70d458293f7ab1592b008ac_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ia1be2640350446e5a3a575482a87bbcc_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ib7133a081957418da4808a2430c8abf0_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="if5179121c7a146c08a655a8cfcdaa830_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i77e8dc2fb46740f7886bcac833bb3946_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i51326a843a1e4ac4879b831c1444fdeb_D20190701-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i1cad0474bd2f40d886d9d8a4cf2c72fe_D20190701-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i19b4605df85247908370653224b13cab_D20190701-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i8e9b39d228bb4305a9f94d21ff2986b6_D20190701-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i0c0e121749714201bffca84925398633_D20190701-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i7cdd3ec3331046ec97e3ab5eeb7a43e0_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:CordisDivestitureAxis">cah:CordisDivestitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i872f564c51c449338d43396b08fe7bbf_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:CordisDivestitureAxis">cah:CordisDivestitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i98ac083d3c7d4cab941676ec328bb04b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i821455dffe794014b8f8a131073f0e3a_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="id5e179139d574d23982bca2fd8e461fd_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if42abb6c898a48ab9033252b5dbfcbee_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ibb3bd6687f4e44aab8db611ebf43f7d0_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib963f36549774070a638555f5486bde0_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ibb77c6fda9c84c43ba66e9e82d862e1d_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i9b24380305684bfe8bdfbb78576d14d2_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i88705ecfe8f9467188b5fdceaff0c86b_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib6f5e23cdbdc462981ce1345c1d0a482_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i81339315e2c14539bee8f1c43e550ae5_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:CordisDivestitureAxis">cah:CordisDivestitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i03c64db735f449b18a2b4bbcb90984f0_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:CordisDivestitureAxis">cah:CordisDivestitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ice72f79525cf4aaa96a799b1808b8a8b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i33dcb67f0d874581b55d12fa93285854_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib86a8f16995f4394b90a5c5d09547673_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">cah:IPRDTrademarksandOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if58ac855c7a34cfa8030c801c94150d0_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ifb5b051f9d274a4db0185de02ba05dcb_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6a9ff348b06a48ae9bb2eb719908affb_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ice8a5553e38b49b6ad19d2aaa439d996_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1197b65c014b476eb038f49933bfc8b8_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3d099e35f5894d5e9a24b39c60d6719a_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id75e1c542b0d4277aef6f4524dc533d0_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">cah:IPRDTrademarksandOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie4f1de5725004793a5eb735884c24d4e_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ibc713be36ac74ca6995d6707e0fd4741_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">cah:TrademarksAndPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i6c1148a859034784a3e672c820ea0c9d_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="icdab92a7a6fd41b39bd57e54be7e769f_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:FloatingRateNotesdue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9f3611b603314fb097f4abad927ac3d9_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A2.616Notesdue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i504e4cad981b4ed993b975460c7fc7ac_D20190701-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A2.4Notesdue2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia090211208aa441088c4d8069f02dbfb_D20190701-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A2.616Notesdue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i49a27c7578bd41088dddfb606868d281_D20190701-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A3.2Notesdue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia6234f8623c6430bb624a2926a712aa6_D20190701-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:FloatingRateNotesdue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="if1eda4e509ce43798df227d81709d323_D20190701-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A3.41Notesdue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6db532c36ac040349356f496d49a51e5_D20190701-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A4.6Notesdue2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia3cfcd32bbbd409a8721be1d572e5196_D20190701-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A4.9Notesdue2045Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i47aa282752004df79e631b50e9d85ec0_D20190701-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:A4.368Notesdue2047Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i78b6ef34025b4452a5b896401fa40e7c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5f24903888fe442faadd663a0aba2ff7_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i604f1c37ba004bdaa7f5e22b3f373f12_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">cah:ShortTermCreditFacilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">cah:CommittedReceivablesSalesFacilityProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i33f590b1fd8b44a8a08a2e3ea0f1b1bd_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">cah:CVSHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6c69ca015f5c476994fba9d5d8aef33b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i12b52de2a6014b01b5857d8d032e2d95_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:NewYorkOpioidStewardshipActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia2b0385b5ab44d27a7dc86dee405b359_I20210503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-03</instant>
        </period>
    </context>
    <context id="i3cc62b61cd8d43428ee9e8e27d88fc65_I20210503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsStateDomain</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-03</instant>
        </period>
    </context>
    <context id="ib9e03386e8bb45b9bfa0b58a7c283f07_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i32ccdaa0f4af4c919f10cbbfa4cc9a79_D20190701-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i9f40d9e3a7db48b09daa5018d3017966_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7e4a5266c9ee4255be61beea0051e346_I20210503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-03</instant>
        </period>
    </context>
    <context id="i807f09109de94752a25bb7a0eae4766f_I20210503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:OpioidLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ClassActionLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:PlaintiffTypeAxis">cah:PrivatePartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-03</instant>
        </period>
    </context>
    <context id="ica111f2089a54b038384fbd2c3ed75c2_D20210503-20210503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-03</startDate>
            <endDate>2021-05-03</endDate>
        </period>
    </context>
    <context id="i1bf34677339c4ce196bf82617b72b6c2_D20210503-20210503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cah:AlamedaCountyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-03</startDate>
            <endDate>2021-05-03</endDate>
        </period>
    </context>
    <context id="i0c6a6bb892f345c4b3edac4aec0d217d_D20210503-20210503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-03</startDate>
            <endDate>2021-05-03</endDate>
        </period>
    </context>
    <context id="i22d9e3f7ffff422283088171ae8c7f53_D20210503-20210503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">cah:OtherJurisdictionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-03</startDate>
            <endDate>2021-05-03</endDate>
        </period>
    </context>
    <context id="i39e08dcc3f9f4795a07a40686f4f773d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i901bacdc1d384d90bd9435b24ae9e637_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:LawsuitTypeAxis">cah:ProductLiabilityLawsuitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i200d0dbf02ed453d87b6ed7ec2d17a53_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">cah:DOJInvestigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6be08e009bc84db19fea6af132f4df1c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i64ace7956a934516b089799b59bc6227_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i352533a8ebdc4e1ea369fbf8d0b0cb22_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i2a9345a4d82147cbb391e59d3476b6af_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:OpioidLitigationAxis">cah:TotalOpioidLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ided1be8f67714ed8b59a2a7328872d54_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ibfa1be8946614c2b9007346f625163d2_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if4bf28e522354f2395213116e925d1b9_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0e66f2887db842aa8968fdf63602e73d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:CareFusionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2d53fc1dcd044ba08aabb87d0bbbcb75_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:CareFusionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i49fd517f759e4c02bee7665cf6f0fc34_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:PatientRecoveryBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i68ba2e46a7674cc8991710f46cdcb0b6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:TaxMatterAxis">cah:PatientRecoveryBusinessMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i31c9d1ab6ad74ad6be84ceec57e39a73_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="id1c063a9eef24440b68b23b7cc020697_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ieb9fc5025c56429290c144a9ab02add4_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia215aea801f34ad985846f37619f80f0_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1f7d6a255b6d43b7a97b861817531138_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i80081b312cf4449bb7fe8a2f4e5535d7_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i9020f748109a4007908680bcbacb5e56_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i2bde8641630642bf8d5434c1fadce5ef_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i5987d078d03f4fc38046fb86086b6b1e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i949ddfae3947416db45abfd64c94adeb_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i87eabc19117047338578608b2ee7dcd4_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i334e47c1f3ff45dcb6b4856094c8f1c0_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i58ec7cecb23b4f45bed4e5c64a8bb562_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if1af6bf6a64a4c77ba66fed4c716d945_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia42786050a004af0aedbbe0f8357c727_D20190701-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia8c1b38a8f8d4adf9f86653e53b0dd5c_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i532e1aadd9b146e7ae42838aec9fcb8c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic014c1b02128475ba87eda0763cfdcc4_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib3205d5053724d48900805160556c3d0_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ifa27c7b19457466dabe317a3abbbb6df_D20190701-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6794b69d98f24573ba346bd46b22a10a_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i06a14268e5cb46ffb7dbf7a3ce7660f6_D20190701-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie14f3bec98e9401e9d0262da4f2de10b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9ef4ab475d104948a5835edf958fa41a_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i10d07f0a48104550b0a508675603448e_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie27ad5c522f44e8b90817308ed523e4d_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i2b25597e1abd4762a53125bd127a7fc6_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie2cfce8a58cc495e9d881af0122e343d_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0ecadae65dfb4b55ab6336e5e1372f5e_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6b80eecd6d274b6099620f1435d44f65_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib1282072a9944c75994cdaf150f6cae9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9e2d2af534744410b83b2b8c23ceae67_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i678e5905c5c04646a1adad096e2142a5_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="icb95c38f699b498bae7eccc1951e60ef_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id77fcd8f97ce44d28130b582a93ca388_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i98a550bd18584222b45f6e22795837d8_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i497d93eb01e34fc299e07f6c11433ddc_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i13210788c384499eb6bd49c7ac901881_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie15bd6a384d84a93aa0435432170a9e0_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i754a245950334f9994b76f93229c450a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie00acdc941434982aa3c874289a0f3fd_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i980f0fff0b9a4c3190c440190a0f45b0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i66cd600a4fa943049ca88903270b5e37_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i0a6b387b92814c6dbccb36d4616b973b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4b2f4f39f2f9421c9376d5aeb5d1ebba_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic430db4eef8d4096927747687050f4ab_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i133a2afe200e422e8417d692d3db7c24_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic3be9b6146804373965da8f26eb058f6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="idb553ffd18cb495b81f622bdfcdbd4c4_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i38499692778a4677a3d0205a54dabc5e_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i1a204b9287bf45b1a70bdb9303162867_D20190701-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:PharmaceuticalDistributionandSpecialtyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ibd1495b463924bf7a6a21f64497f4f5f_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6d2aa45f535e4ad78bb4d60e6ab599cf_D20190701-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:NuclearPrecisionHealthServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="idaf142075796467695d26aed7ffad5a6_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7633f1494ae14d6db19bb6de3dd5dc7d_D20190701-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia66d6c475fbc4a4f93c1eed3e22397fe_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iee665c670791489a9810213babe512b3_D20190701-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:MedicaldistributionandproductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic1306a7b737e45e5b5d2f6b30e1ae7c8_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8294a10e67a64ee889ba04da6c8dda53_D20190701-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">cah:CardinalHealthAtHomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia6b13c1180504c8e8b9bbe3e3b0affe6_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iac89152bf6b649d09d16a732e7fe9fd7_D20190701-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ifdac359205cd4b9894e9c5b6bc9a75f9_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7571f4a1493c40f1948e2aa7d8298511_D20190701-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="if00aae22cda442e2907fd2752c87fb3d_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic8024f13f805493da1022a38d9655ca3_D20190701-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i155df096ff374a49874a1b86694a8d78_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i7ba2131531c140b1887cc40420a68d24_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i3c2e770d82df4fb29415150ac2904bdd_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic1dce9a8c75d4af4a876d4bf69e8bed9_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia08f0b8f481d48ddaf2634a007190de5_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i627973ec4999405b88953cf1981248fe_D20190701-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i4c43376b1a4b4c3fb49e50efec9c4eb9_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i437975c25f184124919229aca35a0a19_D20190701-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ibbb9380a5af84ba6ae989a20e860a444_D20190701-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cah:SterileSurgicalGownRecallAxis">cah:SterileSurgicalGownRecallMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="icb1b5bacb6bb401e8fe737bb56674184_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ia56ac1f95221479a8866de7ff447bece_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i22ff8eca14d54d0e88769fe944e5fac0_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib8ac06c44c654f11a21c85f88fe7ba70_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">cah:MedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i1b9e31e1c7394a41915dce3992145e0c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie599ab9917894d65ad37cc3447647eae_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i5489b32b324b43e7b31fefeae25b8dc6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iadf80adca21245ef9ca13b43ebeba09d_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i675bcdf093c842b683f5f42b5d7c6dd5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i56e3ff286a3f4cc79923baab49b0ed00_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ida44dc7e8fef4822b90092a960bfd60d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie5fccbaecaed42a78b6b4926ea168dc1_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i8a89c112cd7f42b3a5456dc100a7ede7_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic52a8031a6f841969982b87db2a42528_D20190701-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i96b93fe596a142948ea01b57dd171ae6_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i26baad0d41684101ab66f22954853d05_D20190701-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i04a5e9e5e39042d4954e45ee16242fba_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ifacfc13c40bb4c9bb653687d05e0441a_D20190701-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ib6304faf17b842ef9c340762418125fc_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i77e9bd39dd824727aafae148f4111ead_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i5226be778dfe441d9f2c92df26a11158_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic86b7d6cb21f44eaad860256ec1bfebc_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iae78c99bef954f35b10d2bf1557917a0_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if622e969bb1c456795db4df9e45f0a4b_D20200701-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9f362429a27e4da98d58d075d240086a_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia7e27cac65544c18a83f69a3c9f73b79_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000721371</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="stateag">
        <measure>cah:StateAG</measure>
    </unit>
    <unit id="lawsuit">
        <measure>cah:lawsuit</measure>
    </unit>
    <unit id="plaintiff">
        <measure>cah:plaintiff</measure>
    </unit>
    <unit id="jpy">
        <measure>iso4217:JPY</measure>
    </unit>
    <unit id="segment">
        <measure>cah:segment</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV80L2ZyYWc6ZTExMTZiMDUwMWEzNDVlMDljNTcxYzZmMDA2Njk0MzgvdGFibGU6OTVjNjAwYTU5NTZjNDRkY2JhZWQwMDQ4ZmY0MTFjMjUvdGFibGVyYW5nZTo5NWM2MDBhNTk1NmM0NGRjYmFlZDAwNDhmZjQxMWMyNV8yLTEtMS0xLTA_0658527b-c543-47cd-8948-ba7b4e35c01b">0000721371</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV80L2ZyYWc6ZTExMTZiMDUwMWEzNDVlMDljNTcxYzZmMDA2Njk0MzgvdGFibGU6OTVjNjAwYTU5NTZjNDRkY2JhZWQwMDQ4ZmY0MTFjMjUvdGFibGVyYW5nZTo5NWM2MDBhNTk1NmM0NGRjYmFlZDAwNDhmZjQxMWMyNV8zLTEtMS0xLTA_6e646d91-b960-4afe-b1f5-283dd59ecc40">--06-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV80L2ZyYWc6ZTExMTZiMDUwMWEzNDVlMDljNTcxYzZmMDA2Njk0MzgvdGFibGU6OTVjNjAwYTU5NTZjNDRkY2JhZWQwMDQ4ZmY0MTFjMjUvdGFibGVyYW5nZTo5NWM2MDBhNTk1NmM0NGRjYmFlZDAwNDhmZjQxMWMyNV80LTEtMS0xLTA_6f12bef4-2060-48ea-ba67-e54594a646ee">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV80L2ZyYWc6ZTExMTZiMDUwMWEzNDVlMDljNTcxYzZmMDA2Njk0MzgvdGFibGU6OTVjNjAwYTU5NTZjNDRkY2JhZWQwMDQ4ZmY0MTFjMjUvdGFibGVyYW5nZTo5NWM2MDBhNTk1NmM0NGRjYmFlZDAwNDhmZjQxMWMyNV81LTEtMS0xLTA_46e23ead-d5a2-445c-9eec-0cad12109146">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV80L2ZyYWc6ZTExMTZiMDUwMWEzNDVlMDljNTcxYzZmMDA2Njk0MzgvdGFibGU6OTVjNjAwYTU5NTZjNDRkY2JhZWQwMDQ4ZmY0MTFjMjUvdGFibGVyYW5nZTo5NWM2MDBhNTk1NmM0NGRjYmFlZDAwNDhmZjQxMWMyNV82LTEtMS0xLTA_1de50e9c-4064-4ccc-9c98-bf517e069494">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xL2ZyYWc6Y2RkMTE2MzFmOGFhNGM5YzhhNTU5MDdmOWI3ZDA3OGIvdGV4dHJlZ2lvbjpjZGQxMTYzMWY4YWE0YzljOGE1NTkwN2Y5YjdkMDc4Yl84NQ_3638c5bb-20d8-41a1-9658-abde8813d28b">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xL2ZyYWc6Y2RkMTE2MzFmOGFhNGM5YzhhNTU5MDdmOWI3ZDA3OGIvdGFibGU6YzQ0YWI1M2NjODNhNDU4ZGE5NDk0ZGZmZjU4YTgxOTcvdGFibGVyYW5nZTpjNDRhYjUzY2M4M2E0NThkYTk0OTRkZmZmNThhODE5N18wLTAtMS0xLTA_94c75c1e-4f36-4474-9f8a-ae996db50ada">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xL2ZyYWc6Y2RkMTE2MzFmOGFhNGM5YzhhNTU5MDdmOWI3ZDA3OGIvdGV4dHJlZ2lvbjpjZGQxMTYzMWY4YWE0YzljOGE1NTkwN2Y5YjdkMDc4Yl8xMjI_9f91a8e2-5c55-44b5-a674-11d2ad066847">2021-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xL2ZyYWc6Y2RkMTE2MzFmOGFhNGM5YzhhNTU5MDdmOWI3ZDA3OGIvdGFibGU6NmJlMTUxZDFkMmIxNDdhNmE2NzJiYzgxMDU3MDMwYzAvdGFibGVyYW5nZTo2YmUxNTFkMWQyYjE0N2E2YTY3MmJjODEwNTcwMzBjMF8wLTAtMS0xLTA_94b6e4c1-f3d7-47dd-b1c6-e4e46a4f617e">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xL2ZyYWc6Y2RkMTE2MzFmOGFhNGM5YzhhNTU5MDdmOWI3ZDA3OGIvdGV4dHJlZ2lvbjpjZGQxMTYzMWY4YWE0YzljOGE1NTkwN2Y5YjdkMDc4Yl8xNTgw_74fdb068-88ad-4d96-b934-fa2946fb3664">1-11373</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xL2ZyYWc6Y2RkMTE2MzFmOGFhNGM5YzhhNTU5MDdmOWI3ZDA3OGIvdGV4dHJlZ2lvbjpjZGQxMTYzMWY4YWE0YzljOGE1NTkwN2Y5YjdkMDc4Yl8xNTgx_a46857ef-2268-4df8-b565-282872a6d70e">Cardinal Health, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xL2ZyYWc6Y2RkMTE2MzFmOGFhNGM5YzhhNTU5MDdmOWI3ZDA3OGIvdGFibGU6ZTRkYTk4NDlhZjk1NGRkYjg2ZGJlOTllMjY3YTFjYjAvdGFibGVyYW5nZTplNGRhOTg0OWFmOTU0ZGRiODZkYmU5OWUyNjdhMWNiMF8wLTAtMS0xLTA_e3764a9b-2557-4da4-8c43-24428ad05065">OH</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xL2ZyYWc6Y2RkMTE2MzFmOGFhNGM5YzhhNTU5MDdmOWI3ZDA3OGIvdGFibGU6ZTRkYTk4NDlhZjk1NGRkYjg2ZGJlOTllMjY3YTFjYjAvdGFibGVyYW5nZTplNGRhOTg0OWFmOTU0ZGRiODZkYmU5OWUyNjdhMWNiMF8wLTYtMS0xLTA_ffd308b9-1625-4631-98bf-d5d16e852bdd">31-0958666</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xL2ZyYWc6Y2RkMTE2MzFmOGFhNGM5YzhhNTU5MDdmOWI3ZDA3OGIvdGFibGU6ZTRkYTk4NDlhZjk1NGRkYjg2ZGJlOTllMjY3YTFjYjAvdGFibGVyYW5nZTplNGRhOTg0OWFmOTU0ZGRiODZkYmU5OWUyNjdhMWNiMF8zLTAtMS0xLTA_6ae7c4f5-dd69-47ea-be8b-6cefa7b8f465">7000 Cardinal Place</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xL2ZyYWc6Y2RkMTE2MzFmOGFhNGM5YzhhNTU5MDdmOWI3ZDA3OGIvdGFibGU6ZTRkYTk4NDlhZjk1NGRkYjg2ZGJlOTllMjY3YTFjYjAvdGFibGVyYW5nZTplNGRhOTg0OWFmOTU0ZGRiODZkYmU5OWUyNjdhMWNiMF8zLTItMS0xLTA_16a7993d-5cc2-4af7-9489-5f67088b70b8">Dublin</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xL2ZyYWc6Y2RkMTE2MzFmOGFhNGM5YzhhNTU5MDdmOWI3ZDA3OGIvdGFibGU6ZTRkYTk4NDlhZjk1NGRkYjg2ZGJlOTllMjY3YTFjYjAvdGFibGVyYW5nZTplNGRhOTg0OWFmOTU0ZGRiODZkYmU5OWUyNjdhMWNiMF8zLTQtMS0xLTA_71bab862-7027-4623-b224-8e4132aedc43">OH</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xL2ZyYWc6Y2RkMTE2MzFmOGFhNGM5YzhhNTU5MDdmOWI3ZDA3OGIvdGFibGU6ZTRkYTk4NDlhZjk1NGRkYjg2ZGJlOTllMjY3YTFjYjAvdGFibGVyYW5nZTplNGRhOTg0OWFmOTU0ZGRiODZkYmU5OWUyNjdhMWNiMF8zLTYtMS0xLTA_205ba8c0-f555-4afe-a52b-a2439e23e5e7">43017</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xL2ZyYWc6Y2RkMTE2MzFmOGFhNGM5YzhhNTU5MDdmOWI3ZDA3OGIvdGFibGU6ZTRkYTk4NDlhZjk1NGRkYjg2ZGJlOTllMjY3YTFjYjAvdGFibGVyYW5nZTplNGRhOTg0OWFmOTU0ZGRiODZkYmU5OWUyNjdhMWNiMF82LTQtMS0xLTA_059cdcae-0727-49db-8fb3-3db566419dba">(614)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xL2ZyYWc6Y2RkMTE2MzFmOGFhNGM5YzhhNTU5MDdmOWI3ZDA3OGIvdGFibGU6ZTRkYTk4NDlhZjk1NGRkYjg2ZGJlOTllMjY3YTFjYjAvdGFibGVyYW5nZTplNGRhOTg0OWFmOTU0ZGRiODZkYmU5OWUyNjdhMWNiMF82LTYtMS0xLTA_011403af-76e3-408f-a72f-3f4b1f9c63f3">757-5000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xL2ZyYWc6Y2RkMTE2MzFmOGFhNGM5YzhhNTU5MDdmOWI3ZDA3OGIvdGFibGU6MGZkOGE4MGNlMTYyNDBiMWI0Yjc0NjVlNDM4MDY3MWYvdGFibGVyYW5nZTowZmQ4YTgwY2UxNjI0MGIxYjRiNzQ2NWU0MzgwNjcxZl8yLTAtMS0xLTA_013490a8-225e-4002-b46e-49642fc6b78e">Common shares (without par value)</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xL2ZyYWc6Y2RkMTE2MzFmOGFhNGM5YzhhNTU5MDdmOWI3ZDA3OGIvdGFibGU6MGZkOGE4MGNlMTYyNDBiMWI0Yjc0NjVlNDM4MDY3MWYvdGFibGVyYW5nZTowZmQ4YTgwY2UxNjI0MGIxYjRiNzQ2NWU0MzgwNjcxZl8yLTEtMS0xLTA_09b4367e-e79e-4b42-9d91-2ee741b2c8c2">CAH</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xL2ZyYWc6Y2RkMTE2MzFmOGFhNGM5YzhhNTU5MDdmOWI3ZDA3OGIvdGFibGU6MGZkOGE4MGNlMTYyNDBiMWI0Yjc0NjVlNDM4MDY3MWYvdGFibGVyYW5nZTowZmQ4YTgwY2UxNjI0MGIxYjRiNzQ2NWU0MzgwNjcxZl8yLTItMS0xLTA_c040d187-72d7-47f7-b877-681b2d7f4fa5">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xL2ZyYWc6Y2RkMTE2MzFmOGFhNGM5YzhhNTU5MDdmOWI3ZDA3OGIvdGV4dHJlZ2lvbjpjZGQxMTYzMWY4YWE0YzljOGE1NTkwN2Y5YjdkMDc4Yl8xNTgy_0db3cc20-215c-4b0e-bd84-0bc282a3d7ca">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xL2ZyYWc6Y2RkMTE2MzFmOGFhNGM5YzhhNTU5MDdmOWI3ZDA3OGIvdGV4dHJlZ2lvbjpjZGQxMTYzMWY4YWE0YzljOGE1NTkwN2Y5YjdkMDc4Yl8xNTgz_7e54f21b-a976-4c5c-a516-d3c6724ca715">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xL2ZyYWc6Y2RkMTE2MzFmOGFhNGM5YzhhNTU5MDdmOWI3ZDA3OGIvdGFibGU6ZTg5ODdiODllNWRjNDEyY2E4ZTFiMDE3NjQyYmVmZjQvdGFibGVyYW5nZTplODk4N2I4OWU1ZGM0MTJjYThlMWIwMTc2NDJiZWZmNF8wLTAtMS0xLTA_c071050b-04ec-43c4-9589-2bc861b4e9a1">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xL2ZyYWc6Y2RkMTE2MzFmOGFhNGM5YzhhNTU5MDdmOWI3ZDA3OGIvdGFibGU6ZTg5ODdiODllNWRjNDEyY2E4ZTFiMDE3NjQyYmVmZjQvdGFibGVyYW5nZTplODk4N2I4OWU1ZGM0MTJjYThlMWIwMTc2NDJiZWZmNF8xLTQtMS0xLTA_f1e6be38-48e3-4142-955f-33416d2f60fe">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xL2ZyYWc6Y2RkMTE2MzFmOGFhNGM5YzhhNTU5MDdmOWI3ZDA3OGIvdGFibGU6ZTg5ODdiODllNWRjNDEyY2E4ZTFiMDE3NjQyYmVmZjQvdGFibGVyYW5nZTplODk4N2I4OWU1ZGM0MTJjYThlMWIwMTc2NDJiZWZmNF8yLTQtMS0xLTA_e4fb2b95-447d-4f68-90be-f11fccbbccee">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xL2ZyYWc6Y2RkMTE2MzFmOGFhNGM5YzhhNTU5MDdmOWI3ZDA3OGIvdGV4dHJlZ2lvbjpjZGQxMTYzMWY4YWE0YzljOGE1NTkwN2Y5YjdkMDc4Yl8xNTg0_cf7c1637-328f-400e-bea8-695bc2e82017">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i087768a01b964091a69bb564b8374aa2_I20210430"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xL2ZyYWc6Y2RkMTE2MzFmOGFhNGM5YzhhNTU5MDdmOWI3ZDA3OGIvdGV4dHJlZ2lvbjpjZGQxMTYzMWY4YWE0YzljOGE1NTkwN2Y5YjdkMDc4Yl8xNTc4_d0d16d70-0604-4b53-85af-0182ed9d3527"
      unitRef="shares">290147927</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia48bb06cca3d4969bdeb6e18237b4224_D20190701-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV80OS9mcmFnOmY4NTcyZGI5ZDg3MjRmMmI5MzRkOTExZGE4NjNhZjE5L3RleHRyZWdpb246Zjg1NzJkYjlkODcyNGYyYjkzNGQ5MTFkYTg2M2FmMTlfMTA0NDUzNjA0ODEyNTk_d75a112c-e833-40ea-a866-b2fa89033254"
      unitRef="usd">488000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia19c49a9fdf94744a98048c92ed6d989_D20200701-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV80OS9mcmFnOmY4NTcyZGI5ZDg3MjRmMmI5MzRkOTExZGE4NjNhZjE5L3RleHRyZWdpb246Zjg1NzJkYjlkODcyNGYyYjkzNGQ5MTFkYTg2M2FmMTlfMTA0NDUzNjA0ODEyNzM_7fe79880-c57f-41a9-a126-ca85bd2f30e0"
      unitRef="usd">37000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if2d5ee4c8487424fb522d83601a9e4ed_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV80OS9mcmFnOmY4NTcyZGI5ZDg3MjRmMmI5MzRkOTExZGE4NjNhZjE5L3RleHRyZWdpb246Zjg1NzJkYjlkODcyNGYyYjkzNGQ5MTFkYTg2M2FmMTlfMTA0NDUzNjA0ODEyMTA_4b03f236-d976-4408-9244-d82e018f0810"
      unitRef="usd">419000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxReceivable
      contextRef="i95e27bf6690f452f80d7e0a0bf7a1856_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV80OS9mcmFnOmY4NTcyZGI5ZDg3MjRmMmI5MzRkOTExZGE4NjNhZjE5L3RleHRyZWdpb246Zjg1NzJkYjlkODcyNGYyYjkzNGQ5MTFkYTg2M2FmMTlfMTA0NDUzNjA0ODExOTU_dbf99d17-fde6-43c9-9fe8-21d9f61fb298"
      unitRef="usd">974000000</us-gaap:IncomeTaxReceivable>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMjE2L2ZyYWc6YWI0NjBiMmJmNzE5NDUwNzkxMGQyNDM1M2U2MDIwN2IvdGV4dHJlZ2lvbjphYjQ2MGIyYmY3MTk0NTA3OTEwZDI0MzUzZTYwMjA3Yl8yNzY_407d73a9-d30d-49fc-ab54-bf8d1bd62eec"
      unitRef="usd">200000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMjE2L2ZyYWc6YWI0NjBiMmJmNzE5NDUwNzkxMGQyNDM1M2U2MDIwN2IvdGV4dHJlZ2lvbjphYjQ2MGIyYmY3MTk0NTA3OTEwZDI0MzUzZTYwMjA3Yl8yNzY_ba84e18a-409e-4c7f-a903-b9ad007a600d"
      unitRef="usd">200000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:Revenues
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMi0xLTEtMS0w_56cc19c2-517c-4429-b2ed-25cd5e12a068"
      unitRef="usd">39275000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMi0zLTEtMS0w_671d8b9f-780d-48c4-b489-dfe2e4fb46e7"
      unitRef="usd">39157000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMi01LTEtMS0w_c589282b-2ddc-4700-bddb-6be3df7174a6"
      unitRef="usd">119881000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMi03LTEtMS0w_e7dbf0c4-9b32-4270-a175-1abd725f0a29"
      unitRef="usd">116233000000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMy0xLTEtMS0w_3a7a5369-d1eb-474a-aebe-5587a9700a02"
      unitRef="usd">37463000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMy0zLTEtMS0w_41b77d9b-1f31-47d3-b633-aea440f820a2"
      unitRef="usd">37272000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMy01LTEtMS0w_48310487-16f2-4d50-af9a-4da00405290a"
      unitRef="usd">114578000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMy03LTEtMS0w_2fa62bce-56ff-44f7-aa16-4b5c0e36c723"
      unitRef="usd">110955000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfNC0xLTEtMS0w_4b4536c4-af84-4f92-bbb4-9c4cb8408160"
      unitRef="usd">1812000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfNC0zLTEtMS0w_7debb2ed-97f2-4287-a8da-c1998f3a0bf0"
      unitRef="usd">1885000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfNC01LTEtMS0w_ec96066f-ffb0-49c3-b8d7-2cecabd4ab34"
      unitRef="usd">5303000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfNC03LTEtMS0w_3f62acb0-8701-4e72-a2f7-ae9a496b58fa"
      unitRef="usd">5278000000</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfNy0xLTEtMS0w_74e4e4b0-ce7c-4661-b1f7-1de57fcdfea6"
      unitRef="usd">1120000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfNy0zLTEtMS0w_7d58764f-8900-4182-8440-d9259bb958f4"
      unitRef="usd">1165000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfNy01LTEtMS0w_299fb40a-3958-414d-be13-a4166886d42b"
      unitRef="usd">3404000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfNy03LTEtMS0w_c0de216e-58cf-42ec-9df9-b63e015748ca"
      unitRef="usd">3435000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:RestructuringCharges
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfOC0xLTEtMS0w_8228f454-1050-4a20-956b-080bb6c15188"
      unitRef="usd">24000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfOC0zLTEtMS0w_3b03fcbb-18cc-469b-8808-0fadf5c2af8c"
      unitRef="usd">-6000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfOC01LTEtMS0w_41c8ea20-4491-4e18-be1b-e9f68a3ad83c"
      unitRef="usd">81000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfOC03LTEtMS0w_2889d211-1b49-48e8-a325-ee5e6574a2d7"
      unitRef="usd">80000000</us-gaap:RestructuringCharges>
    <cah:Amortizationandotheracquisitionrelatedcosts
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfOS0xLTEtMS0w_cbedbbdb-0ae9-404c-9724-980ef29a8107"
      unitRef="usd">111000000</cah:Amortizationandotheracquisitionrelatedcosts>
    <cah:Amortizationandotheracquisitionrelatedcosts
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfOS0zLTEtMS0w_9f8bdad6-605c-4ccb-a15f-8f1ef9e1b351"
      unitRef="usd">130000000</cah:Amortizationandotheracquisitionrelatedcosts>
    <cah:Amortizationandotheracquisitionrelatedcosts
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfOS01LTEtMS0w_4256fca7-31da-46c5-a20c-73ff77b137ef"
      unitRef="usd">345000000</cah:Amortizationandotheracquisitionrelatedcosts>
    <cah:Amortizationandotheracquisitionrelatedcosts
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfOS03LTEtMS0w_ba3e90aa-809a-4472-9ae0-67696563800c"
      unitRef="usd">395000000</cah:Amortizationandotheracquisitionrelatedcosts>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTAtMS0xLTEtMA_1950949d-e394-4001-ba28-fa8e076c6cf9"
      unitRef="usd">-69000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTAtMy0xLTEtMA_346dbdca-cac2-4a4d-8a53-668a05a48ae3"
      unitRef="usd">1000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTAtNS0xLTEtMA_222026dc-eca7-47ca-9478-592369c092b2"
      unitRef="usd">-78000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTAtNy0xLTEtMA_c3c6c1a3-4e34-4a77-93eb-0a6124433f6e"
      unitRef="usd">-7000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTEtMS0xLTEtMA_ca15c65f-8e1f-461a-ab71-96bd3f9991f2"
      unitRef="usd">-15000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTEtMy0xLTEtMA_f2c014e9-0ce0-44c8-a7ae-7837f968874b"
      unitRef="usd">-35000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTEtNS0xLTEtMA_b49bbf1b-f1e4-4f9f-b463-36b23c311434"
      unitRef="usd">-1085000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTEtNy0xLTEtMA_6b838bdb-7947-4bfd-8226-f5e8c0c8cbca"
      unitRef="usd">-5729000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:OperatingIncomeLoss
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTItMS0xLTEtMA_b6a49899-fc0a-4be2-8ad9-0dc25b0131b5"
      unitRef="usd">473000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTItMy0xLTEtMA_f018e686-e3ed-4199-80bf-231d10b330cd"
      unitRef="usd">562000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTItNS0xLTEtMA_18622733-3e2f-46a6-8f5f-99b2d9027c09"
      unitRef="usd">310000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTItNy0xLTEtMA_c9914652-5894-4c2e-96be-b85d68d71e05"
      unitRef="usd">-4368000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTQtMS0xLTEtMA_bd7b0dff-b677-4b29-b9eb-620eba11aaa1"
      unitRef="usd">12000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTQtMy0xLTEtMA_8cafc47b-a0a5-4313-90f0-21094d24fe53"
      unitRef="usd">-19000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTQtNS0xLTEtMA_a36a574f-5daf-4063-9fc2-87e7550aaff1"
      unitRef="usd">31000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTQtNy0xLTEtMA_c4c62ac4-c12d-48c7-afbe-cd5dfb300cab"
      unitRef="usd">-21000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InterestExpense
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTUtMS0xLTEtMA_a74d1990-22d8-46a8-9eac-339a45f12afe"
      unitRef="usd">45000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTUtMy0xLTEtMA_ce7819a2-746f-41e7-a895-9228908f46b5"
      unitRef="usd">60000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTUtNS0xLTEtMA_366c4577-cfaf-4ac4-b335-3beccb4b1a99"
      unitRef="usd">136000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTUtNy0xLTEtMA_e2f7624d-3395-4ffb-8775-5d26e3281fb1"
      unitRef="usd">189000000</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTYtMS0xLTEtMA_626ba75a-31f5-407c-8e77-e5bdac5d154e"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTYtMy0xLTEtMA_4a0c4870-f0bc-4ae2-aab2-08242e02603a"
      unitRef="usd">-5000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTYtNS0xLTEtMA_f9c789fa-182d-4ece-8f7b-99ddda8d1470"
      unitRef="usd">-1000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTYtNy0xLTEtMA_28401bbc-51b3-4b63-8256-4c0e3d11ddf1"
      unitRef="usd">-9000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTctMS0xLTEtMA_71d250bb-2c2d-48d2-bf2d-49c86164bc2e"
      unitRef="usd">440000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTctMy0xLTEtMA_b0e61b96-7371-4f9e-81ef-dabf3abc3c99"
      unitRef="usd">478000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTctNS0xLTEtMA_d5865c49-2c0f-4aa7-ae39-c504626b8e04"
      unitRef="usd">204000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTctNy0xLTEtMA_ad2a0c85-8368-4991-b74c-1185b2dd0051"
      unitRef="usd">-4587000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTktMS0xLTEtMA_15b110d6-2546-491e-acf6-a066607b76dc"
      unitRef="usd">-320000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTktMy0xLTEtMA_cea00296-4a00-4d84-b178-69e674be7670"
      unitRef="usd">-127000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTktNS0xLTEtMA_347409ec-e8bb-460f-b651-8d3b12407f53"
      unitRef="usd">293000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMTktNy0xLTEtMA_17a2f871-1b0c-4916-a3e8-e005db5438ef"
      unitRef="usd">237000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMjAtMS0xLTEtMA_4ad53a3e-63ba-4087-8af5-9263f80b86aa"
      unitRef="usd">120000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMjAtMy0xLTEtMA_9a6b93cf-28ab-47de-bd34-2e02358c3eab"
      unitRef="usd">351000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMjAtNS0xLTEtMA_42135be7-6365-42b2-9fe0-272f72233492"
      unitRef="usd">497000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMjAtNy0xLTEtMA_791f8c03-2f0d-41ff-83f0-39b87e441852"
      unitRef="usd">-4350000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMjUtMS0xLTEtMA_8764ebd7-5694-44fe-9c7e-24c3f0b796dd"
      unitRef="usd">1000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMjUtMy0xLTEtMA_248eea37-cf71-46bf-b056-c8d64c620ef4"
      unitRef="usd">1000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMjUtNS0xLTEtMA_5fbf0ca7-5912-418f-9d5f-d588c8c7917b"
      unitRef="usd">2000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMjUtNy0xLTEtMA_8efe09b9-7aa5-4ceb-ab69-64c53e61a2a6"
      unitRef="usd">2000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMjYtMS0xLTEtMA_6f31cafe-fbf4-42e9-a34c-33d2e94fcd58"
      unitRef="usd">119000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMjYtMy0xLTEtMA_01a51326-51e8-4267-b586-a2cc9ba3111e"
      unitRef="usd">350000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMjYtNS0xLTEtMA_9379545d-c00b-411f-89d7-a995131f50d4"
      unitRef="usd">495000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMjYtNy0xLTEtMA_d5bd07bd-6b51-4db8-bd5e-b7c8b6b0f839"
      unitRef="usd">-4352000000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMjktMS0xLTEtMA_affc9b23-cc0a-4ec9-8339-34f08da4a244"
      unitRef="usdPerShare">0.41</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMjktMy0xLTEtMA_4ebd4fc2-9afc-426f-ba87-d20afe664346"
      unitRef="usdPerShare">1.20</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMjktNS0xLTEtMA_0a801354-594b-43ca-8c22-dcf5c5765e61"
      unitRef="usdPerShare">1.69</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMjktNy0xLTEtMA_21c99149-20ee-4beb-b20f-6968730bfb90"
      unitRef="usdPerShare">-14.84</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMzAtMS0xLTEtMA_c2ac6d02-e82e-4015-be6a-6c61c1d51c3c"
      unitRef="usdPerShare">0.40</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMzAtMy0xLTEtMA_352b551a-f2b7-4417-aafb-d73ca0acf2b1"
      unitRef="usdPerShare">1.19</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMzAtNS0xLTEtMA_375660f4-70f0-444b-a0b9-9d06fd36b76f"
      unitRef="usdPerShare">1.68</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMzAtNy0xLTEtMA_1c0e151b-f152-495b-9108-b0e6beea1164"
      unitRef="usdPerShare">-14.84</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMzMtMS0xLTEtMA_425390a2-1142-4bd3-8071-64a686d42b1b"
      unitRef="shares">292000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMzMtMy0xLTEtMA_8c7dccbc-06a4-4ec3-8ac8-9d34f149a9ac"
      unitRef="shares">292000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMzMtNS0xLTEtMA_4e218e0f-994f-4c23-9df2-bcffb61899ef"
      unitRef="shares">293000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMzMtNy0xLTEtMA_449a7c39-4e68-49a9-87b7-dd665afc06f7"
      unitRef="shares">293000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMzQtMS0xLTEtMA_3071e4db-fce6-4fe2-ac31-493deae66d91"
      unitRef="shares">294000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMzQtMy0xLTEtMA_1370e119-3d6d-49a9-babc-27c65a2c9a0a"
      unitRef="shares">294000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMzQtNS0xLTEtMA_ce2e7602-8da7-4c33-abda-a15ea4666612"
      unitRef="shares">294000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMzQtNy0xLTEtMA_17498a88-24e5-4f4e-8f1c-022e30d42dfd"
      unitRef="shares">293000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMzYtMS0xLTEtMA_2497126d-41f1-4bf3-a116-ce30c86e7183"
      unitRef="usdPerShare">0.4859</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMzYtMy0xLTEtMA_5881196f-3299-4ac1-b8b8-ad1a7f468b9f"
      unitRef="usdPerShare">0.4811</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMzYtNS0xLTEtMA_c62835a7-25f0-49d1-b57f-ad9de0d4d0ab"
      unitRef="usdPerShare">1.4577</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82MS9mcmFnOjgzNDRmZjNjNGYwNjQzNmRiNWNlNDBkZDcwYzBlMDI2L3RhYmxlOmNiNGM0MjQ2YWZlMTQ5NGI5ZDRjNzQ0NWJlOGRhOTA0L3RhYmxlcmFuZ2U6Y2I0YzQyNDZhZmUxNDk0YjlkNGM3NDQ1YmU4ZGE5MDRfMzYtNy0xLTEtMA_54fbd032-2d35-4e58-b8ad-913f67e7c4fa"
      unitRef="usdPerShare">1.4433</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:ProfitLoss
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfMi0xLTEtMS0w_e3cea534-3385-42f9-a242-a1d5df28b031"
      unitRef="usd">120000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfMi0zLTEtMS0w_d57143cd-df99-4f49-a7ae-faae066a02fe"
      unitRef="usd">351000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfMi01LTEtMS0w_147e9f60-62b5-4edc-a39a-5438299180b0"
      unitRef="usd">497000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfMi03LTEtMS0w_8bb81636-98e6-4c5c-9d61-3e3c675b93dd"
      unitRef="usd">-4350000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfNS0xLTEtMS0w_7583fcf8-2d73-426a-9ee9-06f295da4bac"
      unitRef="usd">9000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfNS0zLTEtMS0w_e1835c03-1848-4488-834a-2a3f298b70a5"
      unitRef="usd">-17000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfNS01LTEtMS0w_6f9e5db3-9584-4a8a-9334-878aeab3e65c"
      unitRef="usd">42000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfNS03LTEtMS0w_100f868b-0da1-47a5-87e3-d162287f33f8"
      unitRef="usd">-35000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfNy0xLTEtMS0w_e23df289-d996-46c1-bdf7-59f4f169f1a0"
      unitRef="usd">-4000000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfNy0zLTEtMS0w_69ae2534-b434-4158-a187-7b5b1caad4b0"
      unitRef="usd">-21000000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfNy01LTEtMS0w_fa0e5bfc-6c87-4102-8841-ec3df54f8950"
      unitRef="usd">14000000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfNy03LTEtMS0w_0fdaa1e7-3683-48b5-b478-635b510a900c"
      unitRef="usd">-27000000</us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfOC0xLTEtMS0w_78f7d6e7-d388-4f67-9231-a1c0393b18c1"
      unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfOC0zLTEtMS0w_caf10055-62d7-4a4d-9f95-f5226a96b848"
      unitRef="usd">-38000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfOC01LTEtMS0w_46a8ac9d-2b1a-4b51-8780-97d327f16755"
      unitRef="usd">56000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfOC03LTEtMS0w_dd018013-5498-4e75-a66a-42307c300449"
      unitRef="usd">-62000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfMTAtMS0xLTEtMA_057c5062-59b7-4d85-8a6c-bbcc090f6e4b"
      unitRef="usd">125000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfMTAtMy0xLTEtMA_55a67ba0-3309-4a0f-bf7a-ec9535260fe7"
      unitRef="usd">313000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfMTAtNS0xLTEtMA_cc5f9712-ddfe-4820-bcb2-54020c570c90"
      unitRef="usd">553000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfMTAtNy0xLTEtMA_0f2f2c17-1e53-4878-99d8-a61af923f2a0"
      unitRef="usd">-4412000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfMTItMS0xLTEtMA_3c34e1ed-cfbd-4e78-8216-85beb76f1386"
      unitRef="usd">1000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfMTItMy0xLTEtMA_4c152b76-c719-48fe-a590-71b2febfdea8"
      unitRef="usd">1000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfMTItNS0xLTEtMA_61948d2a-b441-4fc9-8f7f-7cfbd62a28fb"
      unitRef="usd">2000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfMTItNy0xLTEtMA_19911738-11ea-4ea7-8369-192e0b3ea34d"
      unitRef="usd">2000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfMTQtMS0xLTEtMA_e0985496-e0f9-4d72-9094-785261ca707e"
      unitRef="usd">124000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfMTQtMy0xLTEtMA_47ceefdd-838e-4d21-a6ad-ea54448a7b90"
      unitRef="usd">312000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfMTQtNS0xLTEtMA_da633c4c-11da-4c40-8d34-b9c42d996964"
      unitRef="usd">551000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82NC9mcmFnOmFiNmQyNTMzOGFiNDRjMzU5YmVjYjAxMjIyM2MzMWNkL3RhYmxlOjQ3M2U2N2Q3YTVlNjRhYTRiNWZjZjg1MDk2YjY4Y2Y0L3RhYmxlcmFuZ2U6NDczZTY3ZDdhNWU2NGFhNGI1ZmNmODUwOTZiNjhjZjRfMTQtNy0xLTEtMA_609e0525-fd65-496e-82ea-49ba60a872a7"
      unitRef="usd">-4414000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfNC0xLTEtMS0w_8d6464cc-f4e1-40a4-8de4-646e56ff829a"
      unitRef="usd">3499000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfNC0zLTEtMS0w_8dfc8a0c-1964-4837-b4ca-ee85d32b1ca3"
      unitRef="usd">2771000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ReceivablesNetCurrent
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfNS0xLTEtMS0w_58d8b8ac-e263-4800-9ee7-b1de539e3beb"
      unitRef="usd">8727000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfNS0zLTEtMS0w_93ee814c-f840-4f1a-ae10-6ba5004ff1de"
      unitRef="usd">8264000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfNi0xLTEtMS0w_55b8ab84-508c-42bb-86ae-ceb3f068857f"
      unitRef="usd">14329000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfNi0zLTEtMS0w_55813dd6-e617-4955-a168-29149b72dd81"
      unitRef="usd">13198000000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfOC0xLTEtMS0w_63a55b27-810a-442b-a5ba-4d8fbefc384d"
      unitRef="usd">2715000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfOC0zLTEtMS0w_ae6c053d-b591-4562-9aa0-879ed0e6117f"
      unitRef="usd">1707000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfOS0xLTEtMS0xNDgy_0095f4a7-2ccc-4cde-8ca0-8728f41d9c76"
      unitRef="usd">1092000000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfOS0zLTEtMS0xNDgy_0153826b-4546-4ae5-8e7b-8e2effd0991a"
      unitRef="usd">0</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:AssetsCurrent
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfOS0xLTEtMS0w_d9191bf3-7539-42b9-870e-b9b85390f984"
      unitRef="usd">30362000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfOS0zLTEtMS0w_6c7c8cdb-6aa8-4483-99e6-ad9f632de89a"
      unitRef="usd">25940000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMTEtMS0xLTEtMA_a9789d2a-232b-422c-9914-2350c416b560"
      unitRef="usd">2315000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMTEtMy0xLTEtMA_5c320732-ec79-4ae1-ac1d-998dc38d4a9b"
      unitRef="usd">2366000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMTItMS0xLTEtMA_5455334d-8d21-4aa1-ac63-6802b690340c"
      unitRef="usd">10179000000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMTItMy0xLTEtMA_525756da-fd56-4646-a13a-5d835ef7c26f"
      unitRef="usd">11275000000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMTQtMS0xLTEtMA_04c1b15f-25f1-4ab7-8f2a-83fdd9b5f36c"
      unitRef="usd">1018000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMTQtMy0xLTEtMA_397f0f12-d4ba-42d7-8b49-c0ce20fdfb90"
      unitRef="usd">1185000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMTUtMS0xLTEtMA_ebda2034-dcec-43b6-842b-275ecf9c7f19"
      unitRef="usd">43874000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMTUtMy0xLTEtMA_2ab0a664-19fd-4a33-9c05-9c29a7c24b42"
      unitRef="usd">40766000000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMTktMS0xLTEtMA_c886399b-d81a-423c-8f01-317d0d475a55"
      unitRef="usd">22641000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMTktMy0xLTEtMA_509ba256-28a4-49cf-9d25-00a918448529"
      unitRef="usd">21374000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMjAtMS0xLTEtMA_2768e2b1-c8e8-41d2-affe-34c35e4ed448"
      unitRef="usd">16000000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMjAtMy0xLTEtMA_9f62d65f-38d8-414b-bc4d-3f6d01d0fc71"
      unitRef="usd">10000000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMjEtMS0xLTEtMA_edf54153-f92f-4fe9-9591-b9068ed142f6"
      unitRef="usd">2573000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMjEtMy0xLTEtMA_79cc0093-e5b5-481a-9fe9-78cdfec23057"
      unitRef="usd">2231000000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMjItMS0xLTEtMjI1OA_7ac23b53-c840-40f2-919e-f3ce782662c9"
      unitRef="usd">93000000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMjItMy0xLTEtMjI2MQ_2423880b-2b76-490e-995b-c9d584099303"
      unitRef="usd">0</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:LiabilitiesCurrent
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMjItMS0xLTEtMA_5f285416-1082-4fa9-b50f-fb9fff30170c"
      unitRef="usd">25323000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMjItMy0xLTEtMA_ff55d3bf-b94e-4913-b589-87de654f4c7d"
      unitRef="usd">23615000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMjQtMS0xLTEtMA_a9755a4d-8ee8-41ab-adf3-9821b6938c37"
      unitRef="usd">6715000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMjQtMy0xLTEtMA_da5f7f11-975d-48da-85fd-d81001c6c244"
      unitRef="usd">6765000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMjUtMS0xLTEtMA_43ac5cee-1854-4edf-b84e-242de148bb05"
      unitRef="usd">10042000000</us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent>
    <us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMjUtMy0xLTEtMA_1fbcc555-8812-4e73-bf71-48fbf8009f76"
      unitRef="usd">8594000000</us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjVhMDUzZDA5NjkxOTRjNWNiMTM5NzA1NDc3YTJiZmU0XzE1_733722a4-56e4-4549-a8c3-762725b5d7a1"
      unitRef="shares">500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjVhMDUzZDA5NjkxOTRjNWNiMTM5NzA1NDc3YTJiZmU0XzE1_94ce358b-fba3-480b-9dfd-d000f6be23f4"
      unitRef="shares">500000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjVhMDUzZDA5NjkxOTRjNWNiMTM5NzA1NDc3YTJiZmU0XzMz_01eaecab-dae4-4dd4-af6d-4ca00acb8716"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMjktMC0xLTEtMC90ZXh0cmVnaW9uOjVhMDUzZDA5NjkxOTRjNWNiMTM5NzA1NDc3YTJiZmU0XzMz_4226bbb7-ea6e-4a6f-91dd-059acb50877e"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMjktMS0xLTEtMA_723e89b6-82f0-4b06-bc4b-eaef23db4fcf"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMjktMy0xLTEtMA_007f50da-5a8e-4423-b9d1-f8b3b70cff53"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjU1ODE1ZjRjMzRlZjQ4OTM4ZjQ4ZTMzZGFjMzEzMmMxXzE1_8ecfaeed-4511-4533-8afd-d331db279afc"
      unitRef="shares">755000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjU1ODE1ZjRjMzRlZjQ4OTM4ZjQ4ZTMzZGFjMzEzMmMxXzE1_fc6b8855-547e-4ef6-8320-c582f88ca65d"
      unitRef="shares">755000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjU1ODE1ZjRjMzRlZjQ4OTM4ZjQ4ZTMzZGFjMzEzMmMxXzMz_4e27243f-65f6-40ff-9162-4db55517d9cb"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjU1ODE1ZjRjMzRlZjQ4OTM4ZjQ4ZTMzZGFjMzEzMmMxXzMz_efdc2d5c-08d3-4931-ab56-88ac7d24e05c"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMzEtMS0xLTEtMA_6eb3201f-c011-4757-880b-2cb172d1490e"
      unitRef="usd">2807000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMzEtMy0xLTEtMA_7748e048-ee08-4325-83ec-d9fbe3e74119"
      unitRef="usd">2789000000</us-gaap:CommonStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMzItMS0xLTEtMA_20ca4cd0-519b-40d5-9440-756031da53e3"
      unitRef="usd">1233000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMzItMy0xLTEtMA_f603ecdc-94cd-426a-a658-9f80f4ac6347"
      unitRef="usd">1170000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockShares
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmM0ODY2ZmZmZDFlNDQ3ODQ5ZTJmZTVlNTIwNzk3MTVhXzQw_2785de67-32e1-45c1-b8f3-4895d8013f2c"
      unitRef="shares">36000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMzMtMC0xLTEtMC90ZXh0cmVnaW9uOmM0ODY2ZmZmZDFlNDQ3ODQ5ZTJmZTVlNTIwNzk3MTVhXzU1_d59b0fe0-cf53-4ac0-96f1-681a06c9804c"
      unitRef="shares">34000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMzMtMS0xLTEtMA_c6c5172c-7183-4922-af6c-7a2bbcf60662"
      unitRef="usd">2202000000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMzMtMy0xLTEtMA_4c81516f-83e3-4928-9e22-4973c093d362"
      unitRef="usd">2066000000</us-gaap:TreasuryStockValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMzQtMS0xLTEtMA_127084ca-1588-411b-a3fe-b2aaabf80ee0"
      unitRef="usd">-48000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMzQtMy0xLTEtMA_d6a56bc0-9633-4987-9519-255dc2da4903"
      unitRef="usd">-104000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMzUtMS0xLTEtMA_4ea90574-f9d5-4154-95a9-00cc4dd40eae"
      unitRef="usd">1790000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMzUtMy0xLTEtMA_afedd7a0-02f4-4cec-8c2d-71e920fe52b6"
      unitRef="usd">1789000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMzYtMS0xLTEtMA_93050808-f424-4200-a98e-3e48778a18cd"
      unitRef="usd">4000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMzYtMy0xLTEtMA_7f6ace14-cfab-464f-be14-bc5e374b958f"
      unitRef="usd">3000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMzctMS0xLTEtMA_775d3f76-0bd5-427b-9f76-73043ad1352b"
      unitRef="usd">1794000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMzctMy0xLTEtMA_0333594f-4d56-47e8-ba66-32def5a41811"
      unitRef="usd">1792000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMzgtMS0xLTEtMA_71e1052b-057f-4fbd-8cc7-efcc43d82705"
      unitRef="usd">43874000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV82Ny9mcmFnOjJkYmY1Nzc3MmZiMjQyZGU4ODQyNTU5ZTM3Y2MxYWVmL3RhYmxlOmM2MDE5MTI4OWI3ODRhOGZiMjQ5YWNmZTkwNzY3ZTQ3L3RhYmxlcmFuZ2U6YzYwMTkxMjg5Yjc4NGE4ZmIyNDlhY2ZlOTA3NjdlNDdfMzgtMy0xLTEtMA_de78042b-8237-42f6-9c25-fecf2fd4ecba"
      unitRef="usd">40766000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="i95b9c22031624339add2f629ea1f1aae_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfMy0xLTEtMS0w_b7a53eef-942d-4dae-8ab3-810d4f24746f"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i95b9c22031624339add2f629ea1f1aae_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfMy0zLTEtMS0w_18b3b0f7-434b-4d27-9f71-0820f8d39be2"
      unitRef="usd">2778000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2e48fd2c42b44627b6da89b6438745df_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfMy01LTEtMS0w_e410f163-1c1f-48da-b8eb-b9ace336f227"
      unitRef="usd">1255000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="i44fa84a0c3ec48fcb9c8521f508b477d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfMy03LTEtMS0w_87b3ca18-1ddd-4b2b-b9f6-2f5705b08091"
      unitRef="shares">-33000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i44fa84a0c3ec48fcb9c8521f508b477d_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfMy05LTEtMS0w_1630c1a4-e8fa-40aa-9369-332e4c55844b"
      unitRef="usd">-2009000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if86f35ae66d245c78bacd2478b7f05b7_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfMy0xMS0xLTEtMA_72671d8b-475c-45c6-84f0-8408781407be"
      unitRef="usd">-53000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i29ae1a4981b842e1a0eab772d873665f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfMy0xMy0xLTEtMA_f9e27980-7d2e-4342-afa4-33d1b7ce842f"
      unitRef="usd">4000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i04980c8bb80847f688361a08698a8057_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfMy0xNS0xLTEtMA_4fc5e509-7ad9-4378-acb3-a6faaf79dd8f"
      unitRef="usd">1975000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfNC01LTEtMS0w_6f31cafe-fbf4-42e9-a34c-33d2e94fcd58"
      unitRef="usd">119000000</us-gaap:NetIncomeLoss>
    <us-gaap:ProfitLoss
      contextRef="i08d5fdbf648840f09c9f0acc3309de18_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfNC0xMy0xLTEtMA_72a8ccf7-2c49-40c1-a613-e6d12be905e2"
      unitRef="usd">1000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfNC0xNS0xLTEtMA_5a421752-5fe6-4076-bcd7-827e667b33ff"
      unitRef="usd">120000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfNS0xMS0xLTEtMA_78f7d6e7-d388-4f67-9231-a1c0393b18c1"
      unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfNS0xNS0xLTEtMA_74e952ed-1729-4f19-b293-a279da8900c8"
      unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ib9dbcfd0b21e415c99ceac87f678613b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfNy0xLTEtMS0w_f1aa2ed2-e6ba-4e83-85ac-41516afd6b84"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib9dbcfd0b21e415c99ceac87f678613b_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfNy0zLTEtMS0w_55334912-e126-4080-b4cd-df2da4aef989"
      unitRef="usd">29000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i3ca53978778d45b291d32f2884428093_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfNy03LTEtMS0w_d96c30c5-51e9-4f4a-ac09-ce4be86e586a"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i3ca53978778d45b291d32f2884428093_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfNy05LTEtMS0w_6cf4b25a-1539-43e9-b026-a850ac416c8a"
      unitRef="usd">7000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfNy0xNS0xLTEtMA_0b9e9fa4-6bf6-445b-ba96-48aadf485a4d"
      unitRef="usd">36000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i3ca53978778d45b291d32f2884428093_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfOC03LTEtMS0w_c830fd20-f38d-4c1e-bd9a-78fd1ee54eed"
      unitRef="shares">4000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i3ca53978778d45b291d32f2884428093_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfOC05LTEtMS0w_4779da49-e8f8-4c55-802f-63cdde872ce3"
      unitRef="usd">200000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfOC0xNS0xLTEtMA_ef472fca-52ff-45e2-a63d-677d168e8246"
      unitRef="usd">200000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:Dividends
      contextRef="i6c4059f309d347d8b4ac8135e44ee042_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfOS01LTEtMS0w_15757b08-8f31-4c38-81dd-48619cf8ce16"
      unitRef="usd">143000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfOS0xNS0xLTEtMA_9d972fe0-6bd8-4e1d-9456-0fc85b4be92e"
      unitRef="usd">143000000</us-gaap:Dividends>
    <us-gaap:StockholdersEquityOther
      contextRef="ib9dbcfd0b21e415c99ceac87f678613b_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfMTAtMy0xLTEtMA_c54c84c0-80db-427d-9064-8521f6846089"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityOther
      contextRef="i6c4059f309d347d8b4ac8135e44ee042_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfMTAtNS0xLTEtMA_e8dd15d4-0c59-49ee-925b-00758cf270b6"
      unitRef="usd">-2000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="i3ca53978778d45b291d32f2884428093_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfMTAtNy0xLTEtMjkwMA_bd444973-db82-4039-8f35-b2a77aaa202d"
      unitRef="shares">-1000000</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOther
      contextRef="i08d5fdbf648840f09c9f0acc3309de18_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfMTAtMTMtMS0xLTA_152b2a74-a789-4cb9-b01d-e5b1008f49fb"
      unitRef="usd">1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfMTAtMTUtMS0xLTA_a285a63d-3778-4ce4-a7d5-9c6b9ff3500c"
      unitRef="usd">1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesIssued
      contextRef="ia7c7911192d9467a8120c5a8745e0ab4_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfMTItMS0xLTEtMA_9b818f8c-4bf7-47f1-8be5-d17779386816"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia7c7911192d9467a8120c5a8745e0ab4_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfMTItMy0xLTEtMA_9a3de837-e88c-48c3-8aec-3c0ac964c12a"
      unitRef="usd">2807000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibc405b4ba93d4f15a1821281ca6c82e7_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfMTItNS0xLTEtMA_d6657acc-7df1-4b77-8fbb-8fde9a6a530f"
      unitRef="usd">1233000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="i0233856860d24d818336b00e3025a695_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfMTItNy0xLTEtMA_3b1eced2-d7a4-45ef-ad54-503d989045c3"
      unitRef="shares">36000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i0233856860d24d818336b00e3025a695_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfMTItOS0xLTEtMA_5c73f073-fb23-4f3a-8452-516610dc0744"
      unitRef="usd">2202000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i354467a0724c4e4cb8b779d18d807a9f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfMTItMTEtMS0xLTA_66bc2c81-8c4a-46d7-bdee-840635b4d61e"
      unitRef="usd">-48000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id4419c8027c549be9d1aa39851d2726a_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfMTItMTMtMS0xLTA_b087d8fb-10cd-436e-ada6-08795e4bafc4"
      unitRef="usd">4000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjIwNGFjN2FjMWFmNjQ0MzNhYTZlN2UxZjdhZjMzYjExL3RhYmxlcmFuZ2U6MjA0YWM3YWMxYWY2NDQzM2FhNmU3ZTFmN2FmMzNiMTFfMTItMTUtMS0xLTA_4b213184-7da8-4e05-805b-a9b939f3d2fc"
      unitRef="usd">1794000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="i6de9849e852143f7be17f87669ee8388_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfMS0xLTEtMS0w_106e61bd-1449-49e9-97be-bdabd6b045fc"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6de9849e852143f7be17f87669ee8388_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfMS0zLTEtMS0w_578632f4-c9ea-416b-aa6b-f76086d77ae7"
      unitRef="usd">2752000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i60045d83318a4375a6adbff989fd1e0b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfMS01LTEtMS0w_8d660774-5665-4a70-acd6-434176bb80e7"
      unitRef="usd">449000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="i0384aad99f0b44cfb95e1fcfadf13ba7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfMS03LTEtMS0w_47c8122b-6ca6-4bb6-88ec-26fb7c485ec2"
      unitRef="shares">35000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i0384aad99f0b44cfb95e1fcfadf13ba7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfMS05LTEtMS0w_91743e20-854b-4df0-b97f-d47cc197a6f6"
      unitRef="usd">2099000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i42416177b60446508042e47a8082a323_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfMS0xMS0xLTEtMA_2479c3f8-2fee-433c-94f8-441652d03e6a"
      unitRef="usd">-103000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iea8dfdedd1e94a78a4b76f76961b61a8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfMS0xMy0xLTEtMA_96b7246f-4567-4657-82c0-5a08d5773fd9"
      unitRef="usd">3000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia2cae46a03fd4761a321a79b8d0f6b0f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfMS0xNS0xLTEtMA_a41cf648-2071-48d6-8496-6f24428fb68d"
      unitRef="usd">1002000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfMi01LTEtMS0w_fe5a3cf1-1d04-4373-8469-2a8c0703df2e"
      unitRef="usd">350000000</us-gaap:NetIncomeLoss>
    <us-gaap:ProfitLoss
      contextRef="i6824c1c4ebaf4b5cbe01e36215bb8c94_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfMi0xMy0xLTEtMA_c7567f67-2110-4362-b60b-b00bd6b68597"
      unitRef="usd">1000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfMi0xNS0xLTEtMA_c8f540e6-8c12-47db-9995-67a5a92944eb"
      unitRef="usd">351000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i87c6427dabe74d41be38b4708d40f760_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfMy0xMS0xLTEtMA_47e42bab-d22e-4374-876a-d682f23b18a5"
      unitRef="usd">-38000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfMy0xNS0xLTEtMA_4c17ee17-47e7-457c-81dd-8ea2a362d6ac"
      unitRef="usd">-38000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i92429500105f487686a760c50a01dbd4_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfNS0xLTEtMS0w_a928a9ee-8e1c-4957-b18f-ac3e94a4f167"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i92429500105f487686a760c50a01dbd4_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfNS0zLTEtMS0w_17e78bd9-1e68-4887-bfe7-6840f16e98ab"
      unitRef="usd">22000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i097b90d861534948b48b5e94e8d68dbc_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfNS03LTEtMS0w_59d9644c-7667-4e11-8586-828b686eed43"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i097b90d861534948b48b5e94e8d68dbc_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfNS05LTEtMS0w_3f9bee6d-1bb4-402d-89f9-70a47017205c"
      unitRef="usd">13000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfNS0xNS0xLTEtMA_da1a4f2e-89eb-4179-809c-d7fc22f4c2ab"
      unitRef="usd">35000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:Dividends
      contextRef="id5d2c55efe634921802f5f63cff13133_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfNy01LTEtMS0w_ab5e5fcd-aca1-4591-a1b3-dafc03c26517"
      unitRef="usd">142000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfNy0xNS0xLTEtMA_6e555643-3f73-4192-ba0f-520185874aa7"
      unitRef="usd">142000000</us-gaap:Dividends>
    <us-gaap:StockholdersEquityOther
      contextRef="id5d2c55efe634921802f5f63cff13133_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfOC01LTEtMS0w_68c1fd46-5886-4185-a869-ff758d0eaf8f"
      unitRef="usd">1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i6824c1c4ebaf4b5cbe01e36215bb8c94_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfOC0xMy0xLTEtMA_3c29961f-5822-4be6-8aa0-8bb560862dd8"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfOC0xNS0xLTEtMA_f2d222a6-ee21-4bf2-ae5f-66ebe7b37956"
      unitRef="usd">-2000000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesIssued
      contextRef="i227cc70eba254c68b508a19a38a4772e_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfMTAtMS0xLTEtMA_b7bbe8d2-4acb-4f31-83d1-c1aa7b0bfe89"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i227cc70eba254c68b508a19a38a4772e_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfMTAtMy0xLTEtMA_6685d888-1e92-41e8-85c2-3d778795668c"
      unitRef="usd">2774000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i08c6b70579ab4b44b051a8e476cdc0bc_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfMTAtNS0xLTEtMA_01b753d5-dd31-45a5-ab7b-d76df7337297"
      unitRef="usd">656000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="i873b7175bb9c48f9a92364ddc30859a3_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfMTAtNy0xLTEtMA_049eddc3-14c9-41de-8ee7-5f2601b3fc19"
      unitRef="shares">35000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i873b7175bb9c48f9a92364ddc30859a3_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfMTAtOS0xLTEtMA_77a7b543-98a9-4fcf-81e7-31fd17bf179f"
      unitRef="usd">2086000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4adeac1e746a4298af939e62c0d13228_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfMTAtMTEtMS0xLTA_8b1b2256-a5ba-4593-a361-03a404ffc42c"
      unitRef="usd">-141000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic22356641f7147aa93c0793fd724bac3_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfMTAtMTMtMS0xLTA_a9ac4358-de7a-4eaf-ad5b-6c25968d350e"
      unitRef="usd">3000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie21bd48f8a9a4cb0a6e3c0240434f025_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOjYwODE0MmE4YjQ4NjQ4NGI4YTI3NzYwMGI4YWFmNWY3L3RhYmxlcmFuZ2U6NjA4MTQyYThiNDg2NDg0YjhhMjc3NjAwYjhhYWY1ZjdfMTAtMTUtMS0xLTA_1870a408-98bc-48f1-9eb0-1be3b23be463"
      unitRef="usd">1206000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="iea0558a3dad14a5aa6f2a5ea17404724_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfMy0xLTEtMS0w_8f034cbc-21c1-471c-9030-db50b103f37c"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iea0558a3dad14a5aa6f2a5ea17404724_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfMy0zLTEtMS0w_a621f27b-50fd-4154-8080-4665ddb44ee9"
      unitRef="usd">2789000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibccb3acafd0d46549dd7845b502cc7d7_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfMy01LTEtMS0w_c72a4f04-724d-4b9f-a0b1-eb81d5f04928"
      unitRef="usd">1170000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="i5da09f4564644c32a41c69fe1bca282b_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfMy03LTEtMS0w_635e020a-079d-422d-b567-10a4dc110469"
      unitRef="shares">-35000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i5da09f4564644c32a41c69fe1bca282b_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfMy05LTEtMS0w_b21d7425-3820-45a8-8506-a1e76c8a09da"
      unitRef="usd">-2066000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if50ad56426144e3086cf7b567a121bdc_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfMy0xMS0xLTEtMA_3208aeba-1be0-4a6b-a04c-8d7a7de00441"
      unitRef="usd">-104000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i39fcecca1a1841798fed70b14788390b_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfMy0xMy0xLTEtMA_59c3ba05-72c8-451e-8d66-d1d0d076c1fa"
      unitRef="usd">3000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfMy0xNS0xLTEtMA_7d8892f7-21f4-4ee8-91b4-8b8cadf75d11"
      unitRef="usd">1792000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfNC01LTEtMS0w_8646542c-72f5-4486-8478-eb4c974578af"
      unitRef="usd">495000000</us-gaap:NetIncomeLoss>
    <us-gaap:ProfitLoss
      contextRef="if4123e12a9da4e40840720f78bc466d9_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfNC0xMy0xLTEtMA_44eb3b17-4662-444b-8fbb-6414719b3852"
      unitRef="usd">2000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfNC0xNS0xLTEtMA_daa3d69b-4303-48fa-ba0b-75b11958a9a4"
      unitRef="usd">497000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ic3a494cf37a0408c9c5282b7bacaf665_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfNS0xMS0xLTEtMA_ae690a74-8eb4-49d5-b340-ef836e1f49bb"
      unitRef="usd">56000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfNS0xNS0xLTEtMA_84a4fa20-a6d0-4e3c-9784-e692645f2115"
      unitRef="usd">56000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i81dedbde5d2a466c9175f53824dd0c39_D20200701-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfNy0xLTEtMS0w_66d836fa-3b26-454f-aa0b-17ea78b6d163"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i81dedbde5d2a466c9175f53824dd0c39_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfNy0zLTEtMS0w_2d4746ae-8dde-47eb-85d2-229513e3d479"
      unitRef="usd">18000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfNy03LTEtMS0w_a4940cba-0d88-4365-9330-a60bcd08a431"
      unitRef="shares">2000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if8b3edc49b1248e896c9ddae3b113611_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfNy05LTEtMS0w_2aa17525-326c-4a5d-8bb4-e0d7444dfbc7"
      unitRef="usd">64000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfNy0xNS0xLTEtMA_26d1d99e-9d48-436c-b98a-a4e9f1157855"
      unitRef="usd">82000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i81dedbde5d2a466c9175f53824dd0c39_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfOC0zLTEtMS0w_9c4bbae2-98e5-4607-8bb4-b9a8c1a4afce"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="if8b3edc49b1248e896c9ddae3b113611_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfOC03LTEtMS0w_8cfd733e-9b77-402b-9bf1-110ccfa9d0fb"
      unitRef="shares">4000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="if8b3edc49b1248e896c9ddae3b113611_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfOC05LTEtMS0w_7f911b16-9417-475e-bd00-4d78bd23dfce"
      unitRef="usd">200000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfOC0xNS0xLTEtMA_2a33d0ff-ecf6-48c1-98cf-9dba15ec1072"
      unitRef="usd">200000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:Dividends
      contextRef="ia3fc7d942b0147c78cd1b3b94f6611b5_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfOS01LTEtMS0w_dece6f23-fb65-4bfa-abae-55cad3803c3c"
      unitRef="usd">432000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfOS0xNS0xLTEtMA_06130a71-fd61-4f5a-bb8c-f4bc73cf61dd"
      unitRef="usd">432000000</us-gaap:Dividends>
    <us-gaap:StockholdersEquityOther
      contextRef="ia3fc7d942b0147c78cd1b3b94f6611b5_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfMTAtNS0xLTEtMA_c3ad66a6-e9e4-4a71-b455-8adac988286d"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityOtherShares
      contextRef="if8b3edc49b1248e896c9ddae3b113611_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfMTAtNy0xLTEtMA_737bd99b-8e41-4d85-8fa8-1149d335a78b"
      unitRef="shares">-1000000</us-gaap:StockholdersEquityOtherShares>
    <us-gaap:StockholdersEquityOther
      contextRef="if4123e12a9da4e40840720f78bc466d9_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfMTAtMTMtMS0xLTA_444ca20c-00ee-42d2-a4b5-b16c5a78b525"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfMTAtMTUtMS0xLTA_622a3f76-d1a9-419e-92a1-c80c37b14bee"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesIssued
      contextRef="ia7c7911192d9467a8120c5a8745e0ab4_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfMTItMS0xLTEtMA_450c6f8e-5bbd-44ff-9214-0311c8ef433b"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia7c7911192d9467a8120c5a8745e0ab4_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfMTItMy0xLTEtMA_2f252bab-5a3a-492f-94f1-e3fb6437f3e8"
      unitRef="usd">2807000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibc405b4ba93d4f15a1821281ca6c82e7_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfMTItNS0xLTEtMA_62b16732-2318-44e1-b62b-2410f7545236"
      unitRef="usd">1233000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="i0233856860d24d818336b00e3025a695_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfMTItNy0xLTEtMA_8f248521-859f-4b00-bbab-2ea91d1c248f"
      unitRef="shares">36000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i0233856860d24d818336b00e3025a695_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfMTItOS0xLTEtMA_1d273fa9-5672-4138-aae4-f77d01abcfbd"
      unitRef="usd">2202000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i354467a0724c4e4cb8b779d18d807a9f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfMTItMTEtMS0xLTA_0e0f422f-edf9-49af-9100-84569ba72036"
      unitRef="usd">-48000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id4419c8027c549be9d1aa39851d2726a_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfMTItMTMtMS0xLTA_2778dede-25d6-49df-b66d-669eb5a72bea"
      unitRef="usd">4000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmU3NTNlMDc3NTU3YTRjNzA4ZjE3NzExMGZhOTNmOTkzL3RhYmxlcmFuZ2U6ZTc1M2UwNzc1NTdhNGM3MDhmMTc3MTEwZmE5M2Y5OTNfMTItMTUtMS0xLTA_c2a08aaf-79ba-4887-be79-7b8c0582bdeb"
      unitRef="usd">1794000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="i1c2d8220369a4176bd9a77e28f267fbd_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfMS0xLTEtMS0w_796fdd52-644d-4821-b26f-d4d1af7be44d"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1c2d8220369a4176bd9a77e28f267fbd_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfMS0zLTEtMS0w_e2173227-bc37-4271-a4c6-abcdc4fda1d1"
      unitRef="usd">2763000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib49cffead70d458293f7ab1592b008ac_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfMS01LTEtMS0w_ed931475-654d-4db1-a225-b4c88a446259"
      unitRef="usd">5434000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="ia1be2640350446e5a3a575482a87bbcc_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfMS03LTEtMS0w_2178df6c-87b5-4445-9f35-29f4b691cb7a"
      unitRef="shares">28000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="ia1be2640350446e5a3a575482a87bbcc_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfMS05LTEtMS0w_4db58e53-fc42-41e1-97d3-c2ac81536007"
      unitRef="usd">1790000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib7133a081957418da4808a2430c8abf0_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfMS0xMS0xLTEtMA_0bf3dfb9-9df0-412c-933a-ea71acc23240"
      unitRef="usd">-79000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if5179121c7a146c08a655a8cfcdaa830_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfMS0xMy0xLTEtMA_dbf5a2f1-4813-42a1-a58a-24e99198d65e"
      unitRef="usd">2000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i77e8dc2fb46740f7886bcac833bb3946_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfMS0xNS0xLTEtMA_cfe424ca-8975-4262-b0cc-dbe34cb026d0"
      unitRef="usd">6330000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfMi01LTEtMS0w_05c6d16f-2379-42b9-8977-2c097521111f"
      unitRef="usd">-4352000000</us-gaap:NetIncomeLoss>
    <us-gaap:ProfitLoss
      contextRef="i51326a843a1e4ac4879b831c1444fdeb_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfMi0xMy0xLTEtMA_1e8f29c2-5177-4db7-bcdb-668c1819306d"
      unitRef="usd">2000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfMi0xNS0xLTEtMA_a772f2ba-bc6f-4d42-8d47-5c8528db5718"
      unitRef="usd">-4350000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i1cad0474bd2f40d886d9d8a4cf2c72fe_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfMy0xMS0xLTEtMA_c4a04796-2f9f-4c7d-9132-3b0a2b4c9824"
      unitRef="usd">-62000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfMy0xNS0xLTEtMA_c4d27c8c-751d-45ea-9f32-4df97d43fe6e"
      unitRef="usd">-62000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i19b4605df85247908370653224b13cab_D20190701-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfNS0xLTEtMS0w_9170f564-e17e-4948-874c-d55152951b5c"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i19b4605df85247908370653224b13cab_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfNS0zLTEtMS0w_7f7947b8-e86a-4575-b3ff-10b426900a73"
      unitRef="usd">11000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i8e9b39d228bb4305a9f94d21ff2986b6_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfNS03LTEtMS0w_ea33bb89-759a-4b7e-979b-58938ea0e896"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8e9b39d228bb4305a9f94d21ff2986b6_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfNS05LTEtMS0w_ac0d506c-0dc4-4bcb-a2aa-0fb9e823ebf9"
      unitRef="usd">54000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfNS0xNS0xLTEtMA_e15d0de0-6b19-4861-a00a-70566a2bdfe4"
      unitRef="usd">65000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i8e9b39d228bb4305a9f94d21ff2986b6_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfNi03LTEtMS0w_a08e5657-6015-427e-977f-0f8d3f874d92"
      unitRef="shares">7000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i8e9b39d228bb4305a9f94d21ff2986b6_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfNi05LTEtMS0w_e25a25c3-e224-4318-a517-4a8e1e6fec22"
      unitRef="usd">350000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfNi0xNS0xLTEtMA_14b31c96-4364-41e5-8f30-0a8b5bdb0972"
      unitRef="usd">350000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:Dividends
      contextRef="i0c0e121749714201bffca84925398633_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfNy01LTEtMS0w_caa1ddbe-23df-42a9-a32e-064bfca76b1c"
      unitRef="usd">426000000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfNy0xNS0xLTEtMA_95a02721-2da1-48ac-a37f-7b220534edbd"
      unitRef="usd">426000000</us-gaap:Dividends>
    <us-gaap:StockholdersEquityOther
      contextRef="i0c0e121749714201bffca84925398633_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfOC01LTEtMS0w_4b9904dd-f95d-435e-8914-e1d9726884cf"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i51326a843a1e4ac4879b831c1444fdeb_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfOC0xMy0xLTEtMA_7cadc154-33b4-4961-9e8a-f55f91ad8e4f"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfOC0xNS0xLTEtMA_ca7f303c-7ebf-494a-af91-fe981651d85f"
      unitRef="usd">-1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesIssued
      contextRef="i227cc70eba254c68b508a19a38a4772e_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfOS0xLTEtMS0w_c7de0338-9607-47e1-bcb9-9015b9aa57be"
      unitRef="shares">327000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i227cc70eba254c68b508a19a38a4772e_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfOS0zLTEtMS0w_db4a8621-1be3-4cc1-9a41-a84be3061c64"
      unitRef="usd">2774000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i08c6b70579ab4b44b051a8e476cdc0bc_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfOS01LTEtMS0w_cb6896f4-af5a-4696-953c-93bbb3259315"
      unitRef="usd">656000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockShares
      contextRef="i873b7175bb9c48f9a92364ddc30859a3_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfOS03LTEtMS0w_c9bf95f2-58c9-4d46-8ff4-a1f4ec693bc9"
      unitRef="shares">35000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i873b7175bb9c48f9a92364ddc30859a3_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfOS05LTEtMS0w_d95b8daf-aadc-4cca-937b-2765b01ab62c"
      unitRef="usd">2086000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4adeac1e746a4298af939e62c0d13228_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfOS0xMS0xLTEtMA_40d3f9c6-30cf-41fd-847f-2270eb5ddd98"
      unitRef="usd">-141000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic22356641f7147aa93c0793fd724bac3_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfOS0xMy0xLTEtMA_557bc588-09e6-45d0-82e6-47fd79cfac99"
      unitRef="usd">3000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie21bd48f8a9a4cb0a6e3c0240434f025_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83MC9mcmFnOjg3Y2QzYjNkMWRkYjRmYTY5YjBmYWQ1ZGIzMTI0OWQxL3RhYmxlOmNmMzhjZDVkYzU1NTQ3NmI4NjE2ZTA1Mzg1OWNmZTdmL3RhYmxlcmFuZ2U6Y2YzOGNkNWRjNTU1NDc2Yjg2MTZlMDUzODU5Y2ZlN2ZfOS0xNS0xLTEtMA_bcc99c2a-44b5-480b-b32a-07a90a65a54d"
      unitRef="usd">1206000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMy0xLTEtMS0w_8d59979a-d102-4298-b0bd-66f6f5f8f632"
      unitRef="usd">497000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMy0zLTEtMS0w_97a6034c-25da-4642-a3b0-ee60dbee74c0"
      unitRef="usd">-4350000000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfNi0xLTEtMS0w_528c784d-84c0-4e46-90fd-abe6152360cc"
      unitRef="usd">603000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfNi0zLTEtMS0w_e665f607-34c5-4c87-993c-3f821e47731e"
      unitRef="usd">688000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfOC0xLTEtMS0w_03a9b502-684d-48e1-a28c-fde7865f77e8"
      unitRef="usd">-78000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfOC0zLTEtMS0w_7d37ec29-660b-4070-a891-c5a5c378c20f"
      unitRef="usd">-7000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfOS0xLTEtMS0w_7c9fce04-0999-49de-ab1b-428c472b229a"
      unitRef="usd">-1000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfOS0zLTEtMS0w_4c6e0c45-99dd-4bc8-b8d0-a11c8ace23e7"
      unitRef="usd">-9000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ShareBasedCompensation
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMTAtMS0xLTEtMA_dc584b65-4312-4e0d-b21f-446d0fd60bfd"
      unitRef="usd">84000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMTAtMy0xLTEtMA_daa1d8fd-9946-406a-a848-6aeb56b3ae51"
      unitRef="usd">68000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMTItMS0xLTEtMA_d0bcab1b-cbb1-4805-9c3b-b8b6ec0e7238"
      unitRef="usd">49000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMTItMy0xLTEtMA_6f83922f-f40d-4e8e-8b01-192db549323c"
      unitRef="usd">86000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMTQtMS0xLTEtMA_7d5835ca-1cf2-46e8-bb26-d92fbe544911"
      unitRef="usd">511000000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMTQtMy0xLTEtMA_d76960a4-d491-4c85-9da3-757cd03dd43f"
      unitRef="usd">653000000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMTUtMS0xLTEtMA_baf3dfce-946b-43de-84c5-bfd3fc29f5d0"
      unitRef="usd">1323000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMTUtMy0xLTEtMA_305b8f76-be15-431a-a049-b6dfbbfef745"
      unitRef="usd">8000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMTYtMS0xLTEtMA_5e88361c-7662-4815-96ca-bd49875b95d8"
      unitRef="usd">1267000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMTYtMy0xLTEtMA_a0badb99-3233-4c46-823c-db7fbff46efc"
      unitRef="usd">448000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMTctMS0xLTEtMA_08140757-2269-406a-9e8d-e7be0e0eca3d"
      unitRef="usd">-1019000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMTctMy0xLTEtMA_709d79c1-4964-414a-b865-0d209a5d32dd"
      unitRef="usd">-5425000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMTgtMS0xLTEtMA_485960b0-818e-4640-a45a-e695273521ba"
      unitRef="usd">1764000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMTgtMy0xLTEtMA_0f833f66-abed-451d-9bfe-bf6bbe5b7764"
      unitRef="usd">1720000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMjEtMS0xLTEtMA_6fc5f9f4-02e7-4fa5-bfd8-18a650e39c5b"
      unitRef="usd">3000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMjEtMy0xLTEtMA_daab24d1-9821-4221-9557-8e2320f672dc"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMjItMS0xLTEtMA_fba75219-89aa-49da-aef2-e737d1b22fbf"
      unitRef="usd">274000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMjItMy0xLTEtMA_19aff834-1f3e-47fb-a5d2-4fec46f74c5e"
      unitRef="usd">239000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <cah:Purchaseofavailableforsalesecuritiesandotherinvestments
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMjMtMS0xLTEtMA_6d8905df-b883-40ba-aba5-aaccbaa26e26"
      unitRef="usd">18000000</cah:Purchaseofavailableforsalesecuritiesandotherinvestments>
    <cah:Purchaseofavailableforsalesecuritiesandotherinvestments
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMjMtMy0xLTEtMA_2ce04a0d-c0e0-4f29-8203-46dd39c85b26"
      unitRef="usd">18000000</cah:Purchaseofavailableforsalesecuritiesandotherinvestments>
    <cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMjQtMS0xLTEtMA_bf4390bf-be70-4015-a0ae-a80451842448"
      unitRef="usd">5000000</cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments>
    <cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMjQtMy0xLTEtMA_fb94cd46-3ab4-4dfd-8b18-c2a4b32fdd66"
      unitRef="usd">6000000</cah:Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments>
    <cah:Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMjYtMS0xLTEtMA_67151cb8-bf18-4be9-9534-93ceb6609bc4"
      unitRef="usd">0</cah:Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets>
    <cah:Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMjYtMy0xLTEtMA_0b9cccf9-d51e-448a-9d36-910b0772032b"
      unitRef="usd">2000000</cah:Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMjctMS0xLTEtMA_dcebcd3e-c04a-45b9-a0d0-0650f7ba6ccc"
      unitRef="usd">-290000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMjctMy0xLTEtMA_44676097-2262-423d-96ea-aa9e0b1566ce"
      unitRef="usd">-249000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebt
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMzAtMS0xLTEtMA_93ee4577-14da-428f-95b7-8862fc567abb"
      unitRef="usd">0</us-gaap:ProceedsFromRepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebt
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMzAtMy0xLTEtMA_94669e68-7a27-43e3-b3c2-5d88a8811406"
      unitRef="usd">-2000000</us-gaap:ProceedsFromRepaymentsOfShortTermDebt>
    <us-gaap:PaymentsForProceedsFromHedgeFinancingActivities
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMzEtMS0xLTEtMjcyOQ_2a443e33-a5d4-45b9-ba3b-5577858380ad"
      unitRef="usd">-18000000</us-gaap:PaymentsForProceedsFromHedgeFinancingActivities>
    <us-gaap:PaymentsForProceedsFromHedgeFinancingActivities
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMzEtMy0xLTEtMjczMg_b0303bcf-0cf9-447b-af62-426addaee672"
      unitRef="usd">0</us-gaap:PaymentsForProceedsFromHedgeFinancingActivities>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMzEtMS0xLTEtMA_abd93ab2-d8dc-45e7-a880-25eb3ee2e0ca"
      unitRef="usd">53000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMzEtMy0xLTEtMA_704c9bad-6bab-40ec-91f8-e06b9d7772b1"
      unitRef="usd">888000000</us-gaap:RepaymentsOfLongTermDebt>
    <cah:Netproceedstaxwithholdingsfromsharebasedcompensation
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMzItMS0xLTEtMA_42466281-b2fc-43ef-895e-946c4ed53787"
      unitRef="usd">-1000000</cah:Netproceedstaxwithholdingsfromsharebasedcompensation>
    <cah:Netproceedstaxwithholdingsfromsharebasedcompensation
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMzItMy0xLTEtMA_a19452a1-9f25-4e30-8534-2a4c35bfa90e"
      unitRef="usd">-4000000</cah:Netproceedstaxwithholdingsfromsharebasedcompensation>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMzQtMS0xLTEtMA_8a0bcc00-1e75-40b5-8594-d252cb0c1a31"
      unitRef="usd">432000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMzQtMy0xLTEtMA_d6cff701-59c4-4676-b7d7-aa768be6e45c"
      unitRef="usd">428000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMzUtMS0xLTEtMA_ff7cddd8-6edf-431b-b617-adbc00e00764"
      unitRef="usd">200000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMzUtMy0xLTEtMA_e9f22f82-de0f-48e6-a0d7-cc10aaa2ec1b"
      unitRef="usd">350000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMzYtMS0xLTEtMA_0a3cf9a5-b1ad-4f03-ad24-d578367fa37f"
      unitRef="usd">-668000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMzYtMy0xLTEtMA_8953b3d8-f609-48b1-a5ad-641526464803"
      unitRef="usd">-1672000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMzgtMS0xLTEtMA_837e606c-5433-43b9-838a-581ee4cbeebc"
      unitRef="usd">8000000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMzgtMy0xLTEtMA_8a51f671-baf2-4eb1-b40f-471ade4894ed"
      unitRef="usd">-1000000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <cah:CashReclassifiedToAssetHeldForSale
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMzktMS0xLTEtMjcxMQ_14476c86-467f-43ff-8d89-3bd232e748c6"
      unitRef="usd">-86000000</cah:CashReclassifiedToAssetHeldForSale>
    <cah:CashReclassifiedToAssetHeldForSale
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfMzktMy0xLTEtMjcxNg_02a32748-5dbe-4990-83f9-d81c2996447a"
      unitRef="usd">0</cah:CashReclassifiedToAssetHeldForSale>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfNDAtMS0xLTEtMA_c8b8b80e-d9ca-462d-8097-663169b343bd"
      unitRef="usd">728000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfNDAtMy0xLTEtMA_cfadfcb2-6039-4953-a4cf-cb4550073560"
      unitRef="usd">-202000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfNDEtMS0xLTEtMA_8dfc8a0c-1964-4837-b4ca-ee85d32b1ca3"
      unitRef="usd">2771000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i77e8dc2fb46740f7886bcac833bb3946_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfNDEtMy0xLTEtMA_330614b0-4433-499f-afdd-e4dfdd8e50d3"
      unitRef="usd">2531000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfNDItMS0xLTEtMA_a8bd8869-00ba-4611-ab15-75132775c4cd"
      unitRef="usd">3499000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie21bd48f8a9a4cb0a6e3c0240434f025_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83My9mcmFnOmEzYzRmODBlNmRmYjQwYTBiNzA4MTIzZjNlODIyZjFjL3RhYmxlOjQxNGQxODA5MGVmZTRkODBiMDBhZmM5YmU2YzVhMWRhL3RhYmxlcmFuZ2U6NDE0ZDE4MDkwZWZlNGQ4MGIwMGFmYzliZTZjNWExZGFfNDItMy0xLTEtMA_cae6d4b3-3e66-4263-a0d1-7895602980f8"
      unitRef="usd">2329000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83OS9mcmFnOmE1MWE2ODU2YTQ4ZDQ2Mzg4OTI1ZjBiNWU0YTZkYzFhL3RleHRyZWdpb246YTUxYTY4NTZhNDhkNDYzODg5MjVmMGI1ZTRhNmRjMWFfMzc5MQ_6dfb594a-d562-4e03-a812-3b3cd6fa623e">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;1. Basis of Presentation and Summary of Significant Accounting Policies &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;References to "we," "our," and similar pronouns is in this Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2021 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context requires otherwise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our fiscal year ends on June 30. References to fiscal 2021 and 2020 in these condensed consolidated financial statements are to the fiscal years ending or ended June&#160;30, 2021 and June&#160;30, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The COVID-19 pandemic ("COVID-19") continues to affect the U.S. and global economies, and as previously disclosed in our Fiscal 2020 Form 10-K, the pandemic began to materially affect our businesses during the three months ended March 31, 2020. The length and severity of the pandemic and of the related economic impacts to our businesses and operations are uncertain, including its ongoing impacts to our businesses and results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.&#160;In addition, financial results presented for this fiscal 2021 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June&#160;30, 2021. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2020 (the "2020 Form 10-K").&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Recently Adopted Financial Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued amended accounting guidance that will require entities to measure credit losses on trade and other receivables, held-to-maturity debt securities, loans and other instruments using an "expected credit loss" model that considers historical experience, current conditions and reasonable supportable forecasts. This guidance also requires that credit losses on available-for-sale debt securities with unrealized losses be recognized as allowances rather than as deductions in the amortized cost of the securities. We consider historical experience, the current economic environment, customer credit ratings or bankruptcies, and reasonable and supportable forecasts to develop our allowance for credit losses. We review these factors quarterly to determine if any adjustments are needed to the allowance. This guidance was effective beginning the first quarter of fiscal 2021 and did not have a material impact on our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83OS9mcmFnOmE1MWE2ODU2YTQ4ZDQ2Mzg4OTI1ZjBiNWU0YTZkYzFhL3RleHRyZWdpb246YTUxYTY4NTZhNDhkNDYzODg5MjVmMGI1ZTRhNmRjMWFfMzc5NA_4768fe4c-f31c-46aa-a7b7-ff68451bca24">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;References to "we," "our," and similar pronouns is in this Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2021 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context requires otherwise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our fiscal year ends on June 30. References to fiscal 2021 and 2020 in these condensed consolidated financial statements are to the fiscal years ending or ended June&#160;30, 2021 and June&#160;30, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The COVID-19 pandemic ("COVID-19") continues to affect the U.S. and global economies, and as previously disclosed in our Fiscal 2020 Form 10-K, the pandemic began to materially affect our businesses during the three months ended March 31, 2020. The length and severity of the pandemic and of the related economic impacts to our businesses and operations are uncertain, including its ongoing impacts to our businesses and results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.&#160;In addition, financial results presented for this fiscal 2021 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June&#160;30, 2021. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2020 (the "2020 Form 10-K").&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV83OS9mcmFnOmE1MWE2ODU2YTQ4ZDQ2Mzg4OTI1ZjBiNWU0YTZkYzFhL3RleHRyZWdpb246YTUxYTY4NTZhNDhkNDYzODg5MjVmMGI1ZTRhNmRjMWFfMzc5NQ_b6e3828b-e814-4a5d-9dbd-9e6b2b93410b">&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Recently Adopted Financial Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued amended accounting guidance that will require entities to measure credit losses on trade and other receivables, held-to-maturity debt securities, loans and other instruments using an "expected credit loss" model that considers historical experience, current conditions and reasonable supportable forecasts. This guidance also requires that credit losses on available-for-sale debt securities with unrealized losses be recognized as allowances rather than as deductions in the amortized cost of the securities. We consider historical experience, the current economic environment, customer credit ratings or bankruptcies, and reasonable and supportable forecasts to develop our allowance for credit losses. We review these factors quarterly to determine if any adjustments are needed to the allowance. This guidance was effective beginning the first quarter of fiscal 2021 and did not have a material impact on our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTk0L2ZyYWc6OTJhMzMyZjgzOTNlNDMwNDkwZDFhNTk3MmYyYWQzOWQvdGV4dHJlZ2lvbjo5MmEzMzJmODM5M2U0MzA0OTBkMWE1OTcyZjJhZDM5ZF80Mzk4MDQ2NTI3MzUy_b98a5da9-8b3f-4178-a728-2db6b13eee05">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;2. Assets Held for Sale&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We classify assets and liabilities (the &#x201c;disposal group&#x201d;) as held for sale when management commits to a plan to sell the disposal group in its present condition and at a price that is reasonable in relation to its current fair value. We also consider whether an active program to locate a buyer has been initiated and if it is probable that the sale will occur within one year without significant changes to the plan to sell. Upon classification of the disposal group as held for sale, we assess the assets for impairment and cease related depreciation and amortization.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 12, 2021, we signed a definitive agreement with Hellman &amp;amp; Friedman to sell our Cordis business for gross proceeds of $927&#160;million in cash, subject to customary purchase price adjustments, and we will retain certain working capital accounts and certain liabilities. The transaction is expected to close in the first quarter of fiscal 2022, subject to customary closing conditions and regulatory clearances. Cardinal Health will retain liability associated with lawsuits related to inferior vena cava ("IVC") filters in the U.S. and Canada, as well as authority for these matters discussed in &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ib6bf45669ad94861b0c50dbc2f4371ce_97" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 6&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2021, we met the criteria for the related assets and liabilities of the Cordis business to be classified as held for sale. In connection with the planned divestiture, we allocated $388&#160;million of goodwill from the Medical Unit (within our Medical Segment) to the Cordis disposal group based on the estimated relative fair values of the business to be disposed of and the portion of the reporting unit that will be retained. We determined that the sale of the Cordis business does not meet the criteria to be classified as discontinued operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2021, the book value of the disposal group exceeded its fair value less costs to sell. Accordingly, we recognized a $58 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;million pre-tax write-down on the disposal group in impairments and (gain)/loss on disposal of assets in our condensed consolidated statement of earnings/(loss). This write-down includes a $2 million gain related to currency translation adjustments in accumulated other comprehensive income. We recorded a net tax expense of $7 million associated with the impact of the write-down and the required tax adjustments triggered by held for sale accounting.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents information related to the assets and liabilities that were classified as held for sale at March&#160;31, 2021 related to the Cordis planned divestiture in the condensed consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;86&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Inventories, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;175&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;88&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill and other intangibles, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;779&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Write-down of assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,082&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;59&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred income taxes and other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;34&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total liabilities related to assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;93&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration
      contextRef="i7cdd3ec3331046ec97e3ab5eeb7a43e0_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTk0L2ZyYWc6OTJhMzMyZjgzOTNlNDMwNDkwZDFhNTk3MmYyYWQzOWQvdGV4dHJlZ2lvbjo5MmEzMzJmODM5M2U0MzA0OTBkMWE1OTcyZjJhZDM5ZF8zMjk4NTM0ODk5NTMz_6a25bcea-30d1-46d7-8eb3-0db495670100"
      unitRef="usd">927000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1
      contextRef="i7cdd3ec3331046ec97e3ab5eeb7a43e0_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTk0L2ZyYWc6OTJhMzMyZjgzOTNlNDMwNDkwZDFhNTk3MmYyYWQzOWQvdGV4dHJlZ2lvbjo5MmEzMzJmODM5M2U0MzA0OTBkMWE1OTcyZjJhZDM5ZF8zMjk4NTM0ODk5NTQ4_954a771a-4b93-4caa-a4ed-9a2764360175"
      unitRef="usd">388000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1>
    <cah:WriteDownOfAssetsHeldForSale
      contextRef="i7cdd3ec3331046ec97e3ab5eeb7a43e0_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTk0L2ZyYWc6OTJhMzMyZjgzOTNlNDMwNDkwZDFhNTk3MmYyYWQzOWQvdGV4dHJlZ2lvbjo5MmEzMzJmODM5M2U0MzA0OTBkMWE1OTcyZjJhZDM5ZF8zMjk4NTM0ODk5NTEy_a8cc8edb-131c-4e11-9dd0-0427ccbeafff"
      unitRef="usd">-58000000</cah:WriteDownOfAssetsHeldForSale>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses
      contextRef="i872f564c51c449338d43396b08fe7bbf_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTk0L2ZyYWc6OTJhMzMyZjgzOTNlNDMwNDkwZDFhNTk3MmYyYWQzOWQvdGV4dHJlZ2lvbjo5MmEzMzJmODM5M2U0MzA0OTBkMWE1OTcyZjJhZDM5ZF8zMjk4NTM0ODk5NDkz_7a7c5ebd-654a-4489-bf02-95a6a3a127ca"
      unitRef="usd">2000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses>
    <us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation
      contextRef="i872f564c51c449338d43396b08fe7bbf_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTk0L2ZyYWc6OTJhMzMyZjgzOTNlNDMwNDkwZDFhNTk3MmYyYWQzOWQvdGV4dHJlZ2lvbjo5MmEzMzJmODM5M2U0MzA0OTBkMWE1OTcyZjJhZDM5ZF8xNTk0MjkxODYyMDI2NA_9fa34553-5ef2-447f-b60d-11e2438691e3"
      unitRef="usd">7000000</us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTk0L2ZyYWc6OTJhMzMyZjgzOTNlNDMwNDkwZDFhNTk3MmYyYWQzOWQvdGV4dHJlZ2lvbjo5MmEzMzJmODM5M2U0MzA0OTBkMWE1OTcyZjJhZDM5ZF80Mzk4MDQ2NTI3MzUz_b8f431a0-1375-48c8-8494-87223c479882">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents information related to the assets and liabilities that were classified as held for sale at March&#160;31, 2021 related to the Cordis planned divestiture in the condensed consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.246%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;86&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Inventories, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;175&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;88&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill and other intangibles, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;779&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Write-down of assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,082&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;59&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred income taxes and other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;34&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total liabilities related to assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;93&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
      contextRef="i7cdd3ec3331046ec97e3ab5eeb7a43e0_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTk0L2ZyYWc6OTJhMzMyZjgzOTNlNDMwNDkwZDFhNTk3MmYyYWQzOWQvdGFibGU6MjY4NzJkODJmZjA3NDY2ZmJjNTJlY2I0YjkwNTE5NzMvdGFibGVyYW5nZToyNjg3MmQ4MmZmMDc0NjZmYmM1MmVjYjRiOTA1MTk3M18xLTEtMS0xLTI0MzQ_c9c89c76-f394-48ce-92d8-78c635e87ad5"
      unitRef="usd">86000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1
      contextRef="i7cdd3ec3331046ec97e3ab5eeb7a43e0_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTk0L2ZyYWc6OTJhMzMyZjgzOTNlNDMwNDkwZDFhNTk3MmYyYWQzOWQvdGFibGU6MjY4NzJkODJmZjA3NDY2ZmJjNTJlY2I0YjkwNTE5NzMvdGFibGVyYW5nZToyNjg3MmQ4MmZmMDc0NjZmYmM1MmVjYjRiOTA1MTk3M18yLTEtMS0xLTI0MzQ_a2d6a614-bcf3-486f-a163-153930b0acf4"
      unitRef="usd">175000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventory1>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment
      contextRef="i7cdd3ec3331046ec97e3ab5eeb7a43e0_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTk0L2ZyYWc6OTJhMzMyZjgzOTNlNDMwNDkwZDFhNTk3MmYyYWQzOWQvdGFibGU6MjY4NzJkODJmZjA3NDY2ZmJjNTJlY2I0YjkwNTE5NzMvdGFibGVyYW5nZToyNjg3MmQ4MmZmMDc0NjZmYmM1MmVjYjRiOTA1MTk3M180LTEtMS0xLTI0MzQ_48a396ba-9437-41fe-a4eb-f7726c6197b8"
      unitRef="usd">88000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
    <cah:DisposalGroupIncludingDiscontinuedOperationGoodwillAndOtherIntangiblesNet
      contextRef="i7cdd3ec3331046ec97e3ab5eeb7a43e0_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTk0L2ZyYWc6OTJhMzMyZjgzOTNlNDMwNDkwZDFhNTk3MmYyYWQzOWQvdGFibGU6MjY4NzJkODJmZjA3NDY2ZmJjNTJlY2I0YjkwNTE5NzMvdGFibGVyYW5nZToyNjg3MmQ4MmZmMDc0NjZmYmM1MmVjYjRiOTA1MTk3M181LTEtMS0xLTI0MzQ_21518460-d533-4219-87eb-44276f808df1"
      unitRef="usd">779000000</cah:DisposalGroupIncludingDiscontinuedOperationGoodwillAndOtherIntangiblesNet>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets
      contextRef="i7cdd3ec3331046ec97e3ab5eeb7a43e0_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTk0L2ZyYWc6OTJhMzMyZjgzOTNlNDMwNDkwZDFhNTk3MmYyYWQzOWQvdGFibGU6MjY4NzJkODJmZjA3NDY2ZmJjNTJlY2I0YjkwNTE5NzMvdGFibGVyYW5nZToyNjg3MmQ4MmZmMDc0NjZmYmM1MmVjYjRiOTA1MTk3M182LTEtMS0xLTI0MzQ_bf2e83b1-01bf-4f77-9e96-4efa0fdd08b4"
      unitRef="usd">12000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets>
    <cah:WriteDownOfAssetsHeldForSale
      contextRef="i7cdd3ec3331046ec97e3ab5eeb7a43e0_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTk0L2ZyYWc6OTJhMzMyZjgzOTNlNDMwNDkwZDFhNTk3MmYyYWQzOWQvdGFibGU6MjY4NzJkODJmZjA3NDY2ZmJjNTJlY2I0YjkwNTE5NzMvdGFibGVyYW5nZToyNjg3MmQ4MmZmMDc0NjZmYmM1MmVjYjRiOTA1MTk3M183LTEtMS0xLTIzOTY_3812ddd6-f740-420e-ad76-6f9b1b70318c"
      unitRef="usd">-58000000</cah:WriteDownOfAssetsHeldForSale>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="i7cdd3ec3331046ec97e3ab5eeb7a43e0_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTk0L2ZyYWc6OTJhMzMyZjgzOTNlNDMwNDkwZDFhNTk3MmYyYWQzOWQvdGFibGU6MjY4NzJkODJmZjA3NDY2ZmJjNTJlY2I0YjkwNTE5NzMvdGFibGVyYW5nZToyNjg3MmQ4MmZmMDc0NjZmYmM1MmVjYjRiOTA1MTk3M184LTEtMS0xLTIwODA_429a835b-4e1c-4e8a-a55c-65912a0c7388"
      unitRef="usd">1082000000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="i7cdd3ec3331046ec97e3ab5eeb7a43e0_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTk0L2ZyYWc6OTJhMzMyZjgzOTNlNDMwNDkwZDFhNTk3MmYyYWQzOWQvdGFibGU6MjY4NzJkODJmZjA3NDY2ZmJjNTJlY2I0YjkwNTE5NzMvdGFibGVyYW5nZToyNjg3MmQ4MmZmMDc0NjZmYmM1MmVjYjRiOTA1MTk3M184LTEtMS0xLTIwODA_4923bed0-9e1d-45ee-be8f-47a1c08a1a35"
      unitRef="usd">1082000000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities
      contextRef="i7cdd3ec3331046ec97e3ab5eeb7a43e0_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTk0L2ZyYWc6OTJhMzMyZjgzOTNlNDMwNDkwZDFhNTk3MmYyYWQzOWQvdGFibGU6MjY4NzJkODJmZjA3NDY2ZmJjNTJlY2I0YjkwNTE5NzMvdGFibGVyYW5nZToyNjg3MmQ4MmZmMDc0NjZmYmM1MmVjYjRiOTA1MTk3M18xMC0xLTEtMS0yNDM4_b7926305-c78f-4c2b-8027-08d60c091c0d"
      unitRef="usd">59000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent
      contextRef="i7cdd3ec3331046ec97e3ab5eeb7a43e0_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTk0L2ZyYWc6OTJhMzMyZjgzOTNlNDMwNDkwZDFhNTk3MmYyYWQzOWQvdGFibGU6MjY4NzJkODJmZjA3NDY2ZmJjNTJlY2I0YjkwNTE5NzMvdGFibGVyYW5nZToyNjg3MmQ4MmZmMDc0NjZmYmM1MmVjYjRiOTA1MTk3M18xMS0xLTEtMS0yNDM4_694b429e-c988-4708-87cc-fb150feca207"
      unitRef="usd">34000000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="i7cdd3ec3331046ec97e3ab5eeb7a43e0_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTk0L2ZyYWc6OTJhMzMyZjgzOTNlNDMwNDkwZDFhNTk3MmYyYWQzOWQvdGFibGU6MjY4NzJkODJmZjA3NDY2ZmJjNTJlY2I0YjkwNTE5NzMvdGFibGVyYW5nZToyNjg3MmQ4MmZmMDc0NjZmYmM1MmVjYjRiOTA1MTk3M18xMi0xLTEtMS0yMDkx_d16d7826-eba6-45c5-87a9-48032385ac23"
      unitRef="usd">93000000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RleHRyZWdpb246YzcyNmFkYTIwMDlkNDJlMGJlOGQyYmZlM2Q3ZDk4NTFfOTE5_ef9a6cb4-6e34-452e-92e8-74ba6c1c8fcc">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;3. Restructuring and Employee Severance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes restructuring and employee severance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-related&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility exit and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total restructuring and employee severance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-related&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;45&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility exit and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;36&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total restructuring and employee severance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;81&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of vendor transition fees, professional, project management and other service fees to support divestitures, accelerated depreciation, lease costs associated with vacant facilities, equipment relocation costs, project consulting fees, costs associated with restructuring our delivery of information technology infrastructure services and certain other divestiture-related costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restructuring costs during both the three and nine months ended March&#160;31, 2021 and 2020 were primarily related to the implementation of certain enterprise-wide cost-savings measures. The income during the three months ended March&#160;31, 2020 was due to changes in estimates for severance previously accrued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes activity related to liabilities associated with restructuring and employee severance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.237%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.237%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.241%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-&lt;br/&gt;Related Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility Exit&lt;br/&gt;and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;96&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;59&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;56&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;25&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;81&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RleHRyZWdpb246YzcyNmFkYTIwMDlkNDJlMGJlOGQyYmZlM2Q3ZDk4NTFfOTI2_de71d468-3c1b-4e6c-9bbd-0d3632fa2413">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes restructuring and employee severance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-related&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility exit and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total restructuring and employee severance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;24&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.974%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.592%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-related&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;45&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility exit and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;36&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total restructuring and employee severance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;81&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:SeveranceCosts1
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RhYmxlOjBkMDRhMGJhZmY0NjRkZTg4YWUwMWNiZWZlYjIyNGEyL3RhYmxlcmFuZ2U6MGQwNGEwYmFmZjQ2NGRlODhhZTAxY2JlZmViMjI0YTJfMi0xLTEtMS0w_26a64b5c-aea6-4073-9b76-6d88348e2a7b"
      unitRef="usd">13000000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RhYmxlOjBkMDRhMGJhZmY0NjRkZTg4YWUwMWNiZWZlYjIyNGEyL3RhYmxlcmFuZ2U6MGQwNGEwYmFmZjQ2NGRlODhhZTAxY2JlZmViMjI0YTJfMi0zLTEtMS0w_e8a94eef-e375-4571-b72a-9becfc606429"
      unitRef="usd">-15000000</us-gaap:SeveranceCosts1>
    <cah:FacilityExitAndOtherCosts
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RhYmxlOjBkMDRhMGJhZmY0NjRkZTg4YWUwMWNiZWZlYjIyNGEyL3RhYmxlcmFuZ2U6MGQwNGEwYmFmZjQ2NGRlODhhZTAxY2JlZmViMjI0YTJfMy0xLTEtMS0w_6cdf5379-b021-4c70-bef7-a96fd3f81ca4"
      unitRef="usd">11000000</cah:FacilityExitAndOtherCosts>
    <cah:FacilityExitAndOtherCosts
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RhYmxlOjBkMDRhMGJhZmY0NjRkZTg4YWUwMWNiZWZlYjIyNGEyL3RhYmxlcmFuZ2U6MGQwNGEwYmFmZjQ2NGRlODhhZTAxY2JlZmViMjI0YTJfMy0zLTEtMS0w_9fefa071-0790-4bde-af46-cf8e853278ac"
      unitRef="usd">9000000</cah:FacilityExitAndOtherCosts>
    <us-gaap:RestructuringCharges
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RhYmxlOjBkMDRhMGJhZmY0NjRkZTg4YWUwMWNiZWZlYjIyNGEyL3RhYmxlcmFuZ2U6MGQwNGEwYmFmZjQ2NGRlODhhZTAxY2JlZmViMjI0YTJfNC0xLTEtMS0w_3de30764-1a40-490e-aa52-31674299c598"
      unitRef="usd">24000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RhYmxlOjBkMDRhMGJhZmY0NjRkZTg4YWUwMWNiZWZlYjIyNGEyL3RhYmxlcmFuZ2U6MGQwNGEwYmFmZjQ2NGRlODhhZTAxY2JlZmViMjI0YTJfNC0zLTEtMS0w_d784e584-16a9-4e75-abf3-97fb1e6330f6"
      unitRef="usd">-6000000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RhYmxlOjJmNmQ0M2I5MmEyODQ4YjA4ZWRlNzQ5NTNkODhmYjRkL3RhYmxlcmFuZ2U6MmY2ZDQzYjkyYTI4NDhiMDhlZGU3NDk1M2Q4OGZiNGRfMi0xLTEtMS0w_74157cc8-292e-45e5-bc4f-7515beeed972"
      unitRef="usd">45000000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RhYmxlOjJmNmQ0M2I5MmEyODQ4YjA4ZWRlNzQ5NTNkODhmYjRkL3RhYmxlcmFuZ2U6MmY2ZDQzYjkyYTI4NDhiMDhlZGU3NDk1M2Q4OGZiNGRfMi0zLTEtMS0w_5bfb01ef-daa5-4321-878d-12988091e5d2"
      unitRef="usd">47000000</us-gaap:SeveranceCosts1>
    <cah:FacilityExitAndOtherCosts
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RhYmxlOjJmNmQ0M2I5MmEyODQ4YjA4ZWRlNzQ5NTNkODhmYjRkL3RhYmxlcmFuZ2U6MmY2ZDQzYjkyYTI4NDhiMDhlZGU3NDk1M2Q4OGZiNGRfMy0xLTEtMS0w_74217a14-13f1-4c98-94b2-5aa0c8b190f5"
      unitRef="usd">36000000</cah:FacilityExitAndOtherCosts>
    <cah:FacilityExitAndOtherCosts
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RhYmxlOjJmNmQ0M2I5MmEyODQ4YjA4ZWRlNzQ5NTNkODhmYjRkL3RhYmxlcmFuZ2U6MmY2ZDQzYjkyYTI4NDhiMDhlZGU3NDk1M2Q4OGZiNGRfMy0zLTEtMS0w_3294b3b3-63f6-484f-85c2-4caf7b106bd4"
      unitRef="usd">33000000</cah:FacilityExitAndOtherCosts>
    <us-gaap:RestructuringCharges
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RhYmxlOjJmNmQ0M2I5MmEyODQ4YjA4ZWRlNzQ5NTNkODhmYjRkL3RhYmxlcmFuZ2U6MmY2ZDQzYjkyYTI4NDhiMDhlZGU3NDk1M2Q4OGZiNGRfNC0xLTEtMS0w_ef6e9751-136d-4319-86cf-6fe770aebb8d"
      unitRef="usd">81000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RhYmxlOjJmNmQ0M2I5MmEyODQ4YjA4ZWRlNzQ5NTNkODhmYjRkL3RhYmxlcmFuZ2U6MmY2ZDQzYjkyYTI4NDhiMDhlZGU3NDk1M2Q4OGZiNGRfNC0zLTEtMS0w_4ab4a7b3-71a8-4642-ad1a-4ce25905f344"
      unitRef="usd">80000000</us-gaap:RestructuringCharges>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RleHRyZWdpb246YzcyNmFkYTIwMDlkNDJlMGJlOGQyYmZlM2Q3ZDk4NTFfOTEz_f6da560f-21af-45b5-b6ec-19799aac3c04">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes activity related to liabilities associated with restructuring and employee severance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.237%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.237%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.241%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee-&lt;br/&gt;Related Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Facility Exit&lt;br/&gt;and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;96&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;59&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;56&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;25&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;81&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="i98ac083d3c7d4cab941676ec328bb04b_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RhYmxlOmVjMmIxOGE1MjdkNjRiMWFhNTJhNjcyMzA4YTg0MDJkL3RhYmxlcmFuZ2U6ZWMyYjE4YTUyN2Q2NGIxYWE1MmE2NzIzMDhhODQwMmRfMS0xLTEtMS0w_c9296721-c6e9-47bd-94b2-3251ed074f82"
      unitRef="usd">68000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i821455dffe794014b8f8a131073f0e3a_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RhYmxlOmVjMmIxOGE1MjdkNjRiMWFhNTJhNjcyMzA4YTg0MDJkL3RhYmxlcmFuZ2U6ZWMyYjE4YTUyN2Q2NGIxYWE1MmE2NzIzMDhhODQwMmRfMS0zLTEtMS0w_357707f9-fa79-4488-a5cc-c8520c1cbc0a"
      unitRef="usd">28000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RhYmxlOmVjMmIxOGE1MjdkNjRiMWFhNTJhNjcyMzA4YTg0MDJkL3RhYmxlcmFuZ2U6ZWMyYjE4YTUyN2Q2NGIxYWE1MmE2NzIzMDhhODQwMmRfMS01LTEtMS0w_e837a217-2001-47c0-a031-b444ec69d7ad"
      unitRef="usd">96000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCosts
      contextRef="id5e179139d574d23982bca2fd8e461fd_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RhYmxlOmVjMmIxOGE1MjdkNjRiMWFhNTJhNjcyMzA4YTg0MDJkL3RhYmxlcmFuZ2U6ZWMyYjE4YTUyN2Q2NGIxYWE1MmE2NzIzMDhhODQwMmRfMi0xLTEtMS0w_e8476476-2474-4383-9174-f08845f2a2e9"
      unitRef="usd">37000000</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="if42abb6c898a48ab9033252b5dbfcbee_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RhYmxlOmVjMmIxOGE1MjdkNjRiMWFhNTJhNjcyMzA4YTg0MDJkL3RhYmxlcmFuZ2U6ZWMyYjE4YTUyN2Q2NGIxYWE1MmE2NzIzMDhhODQwMmRfMi0zLTEtMS0w_c379c210-6832-4a31-a2f8-f80c41246f74"
      unitRef="usd">22000000</us-gaap:RestructuringCosts>
    <us-gaap:RestructuringCosts
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RhYmxlOmVjMmIxOGE1MjdkNjRiMWFhNTJhNjcyMzA4YTg0MDJkL3RhYmxlcmFuZ2U6ZWMyYjE4YTUyN2Q2NGIxYWE1MmE2NzIzMDhhODQwMmRfMi01LTEtMS0w_1fdf5c36-1bac-4f2e-b255-384ca0818b69"
      unitRef="usd">59000000</us-gaap:RestructuringCosts>
    <us-gaap:PaymentsForRestructuring
      contextRef="id5e179139d574d23982bca2fd8e461fd_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RhYmxlOmVjMmIxOGE1MjdkNjRiMWFhNTJhNjcyMzA4YTg0MDJkL3RhYmxlcmFuZ2U6ZWMyYjE4YTUyN2Q2NGIxYWE1MmE2NzIzMDhhODQwMmRfMy0xLTEtMS0w_e77e2075-e851-4114-99a3-2f36943a48f8"
      unitRef="usd">49000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="if42abb6c898a48ab9033252b5dbfcbee_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RhYmxlOmVjMmIxOGE1MjdkNjRiMWFhNTJhNjcyMzA4YTg0MDJkL3RhYmxlcmFuZ2U6ZWMyYjE4YTUyN2Q2NGIxYWE1MmE2NzIzMDhhODQwMmRfMy0zLTEtMS0w_77e73c2b-101e-454c-aeac-476f9ac05b29"
      unitRef="usd">25000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RhYmxlOmVjMmIxOGE1MjdkNjRiMWFhNTJhNjcyMzA4YTg0MDJkL3RhYmxlcmFuZ2U6ZWMyYjE4YTUyN2Q2NGIxYWE1MmE2NzIzMDhhODQwMmRfMy01LTEtMS0w_16ee61d2-c838-49d6-bf72-dc9b0c45c558"
      unitRef="usd">74000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve
      contextRef="ibb3bd6687f4e44aab8db611ebf43f7d0_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RhYmxlOmVjMmIxOGE1MjdkNjRiMWFhNTJhNjcyMzA4YTg0MDJkL3RhYmxlcmFuZ2U6ZWMyYjE4YTUyN2Q2NGIxYWE1MmE2NzIzMDhhODQwMmRfNC0xLTEtMS0w_6b7b1d4e-3420-4e6f-9fc0-a5017eee1b32"
      unitRef="usd">56000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ib963f36549774070a638555f5486bde0_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RhYmxlOmVjMmIxOGE1MjdkNjRiMWFhNTJhNjcyMzA4YTg0MDJkL3RhYmxlcmFuZ2U6ZWMyYjE4YTUyN2Q2NGIxYWE1MmE2NzIzMDhhODQwMmRfNC0zLTEtMS0w_6498c44c-08c2-400f-9856-bfb45b2f113e"
      unitRef="usd">25000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84Mi9mcmFnOmM3MjZhZGEyMDA5ZDQyZTBiZThkMmJmZTNkN2Q5ODUxL3RhYmxlOmVjMmIxOGE1MjdkNjRiMWFhNTJhNjcyMzA4YTg0MDJkL3RhYmxlcmFuZ2U6ZWMyYjE4YTUyN2Q2NGIxYWE1MmE2NzIzMDhhODQwMmRfNC01LTEtMS0w_fd5f4f36-1de3-4259-840c-445a8246ea9d"
      unitRef="usd">81000000</us-gaap:RestructuringReserve>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RleHRyZWdpb246MzU5NWE5MGE0YmIwNGI2NzhkY2RkNzcwZjZjMzUwMGRfNTMw_7e01ec7e-7d65-4e11-a61b-0d5d0aa53882">&lt;div style="display:inline-block;vertical-align:top;width:48.214%"&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;4. Goodwill and Other Intangible Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of goodwill by segment and in total:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.482%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,357&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill acquired, net of purchase price adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;15&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reclassified to assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(388)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(388)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,659&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,327&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,986&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the planned divestiture of our Cordis business, during the three months ended March 31, 2021, we allocated and reclassified $388&#160;million of goodwill from the Medical Unit (within our Medical Segment) to the Cordis disposal group based on the estimated relative fair values of the business to be disposed of and the portion of the reporting unit that will be retained, discussed further in &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ib6bf45669ad94861b0c50dbc2f4371ce_1194" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 2&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.215%"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Other Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize other intangible assets by class at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted- Average Remaining Amortization Period (Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Indefinite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D, trademarks and other&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total indefinite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Definite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,331&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,925&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,406&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks, trade names and patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;551&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;319&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;232&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,031&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;488&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;543&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total definite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,913&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,732&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,181&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,925&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,732&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,193&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.308%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.643%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.312%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Indefinite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D, trademarks and other&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total indefinite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Definite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks, trade names and patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total definite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total amortization of intangible assets was $109 million and $129 million for the three months ended March 31, 2021 and 2020, respectively, and $337 million and $385 million for the nine months ended March&#160;31, 2021 and 2020, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2021 through 2025 is as follows: $91 million, $314 million, $287 million, $263 million and $238 million.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March 31, 2021, other intangible assets of $391 million was reclassified to assets held for sale in connection with the planned divestiture of our Cordis business, discussed further in &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ib6bf45669ad94861b0c50dbc2f4371ce_1194" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 2&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RleHRyZWdpb246MzU5NWE5MGE0YmIwNGI2NzhkY2RkNzcwZjZjMzUwMGRfNTIz_4e665d8c-06a4-4618-b0b9-e88650ccf9ec">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the carrying amount of goodwill by segment and in total:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.482%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8,357&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill acquired, net of purchase price adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;15&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reclassified to assets held for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(388)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(388)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,659&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,327&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,986&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="ibb77c6fda9c84c43ba66e9e82d862e1d_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOmQ0ZjU1MGI2MDUwODQxZTg4MmUyNGViZGRhODU5MTE5L3RhYmxlcmFuZ2U6ZDRmNTUwYjYwNTA4NDFlODgyZTI0ZWJkZGE4NTkxMTlfMS0xLTEtMS0w_0fe40f28-63a5-42fa-9f6d-76941a428cfc"
      unitRef="usd">2657000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i9b24380305684bfe8bdfbb78576d14d2_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOmQ0ZjU1MGI2MDUwODQxZTg4MmUyNGViZGRhODU5MTE5L3RhYmxlcmFuZ2U6ZDRmNTUwYjYwNTA4NDFlODgyZTI0ZWJkZGE4NTkxMTlfMS0zLTEtMS0w_c8365f5a-19e3-4b98-9957-9f1e2069edc1"
      unitRef="usd">5700000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOmQ0ZjU1MGI2MDUwODQxZTg4MmUyNGViZGRhODU5MTE5L3RhYmxlcmFuZ2U6ZDRmNTUwYjYwNTA4NDFlODgyZTI0ZWJkZGE4NTkxMTlfMS01LTEtMS0w_436af2bb-5217-42c0-93d2-2350e0082c55"
      unitRef="usd">8357000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i88705ecfe8f9467188b5fdceaff0c86b_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOmQ0ZjU1MGI2MDUwODQxZTg4MmUyNGViZGRhODU5MTE5L3RhYmxlcmFuZ2U6ZDRmNTUwYjYwNTA4NDFlODgyZTI0ZWJkZGE4NTkxMTlfMi0xLTEtMS0w_bdcfcedf-54e9-47a5-a3ac-18afed32b77d"
      unitRef="usd">2000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ib6f5e23cdbdc462981ce1345c1d0a482_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOmQ0ZjU1MGI2MDUwODQxZTg4MmUyNGViZGRhODU5MTE5L3RhYmxlcmFuZ2U6ZDRmNTUwYjYwNTA4NDFlODgyZTI0ZWJkZGE4NTkxMTlfMi0zLTEtMS0w_7b4e6b92-8b44-41c3-936b-1e1dcc5def25"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOmQ0ZjU1MGI2MDUwODQxZTg4MmUyNGViZGRhODU5MTE5L3RhYmxlcmFuZ2U6ZDRmNTUwYjYwNTA4NDFlODgyZTI0ZWJkZGE4NTkxMTlfMi01LTEtMS0w_3d7bd649-fd4a-43ea-b94e-7f47d4a0e738"
      unitRef="usd">2000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i88705ecfe8f9467188b5fdceaff0c86b_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOmQ0ZjU1MGI2MDUwODQxZTg4MmUyNGViZGRhODU5MTE5L3RhYmxlcmFuZ2U6ZDRmNTUwYjYwNTA4NDFlODgyZTI0ZWJkZGE4NTkxMTlfMy0xLTEtMS0w_1ea6d8cf-05f0-4e4e-8172-4b5e3d410d81"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ib6f5e23cdbdc462981ce1345c1d0a482_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOmQ0ZjU1MGI2MDUwODQxZTg4MmUyNGViZGRhODU5MTE5L3RhYmxlcmFuZ2U6ZDRmNTUwYjYwNTA4NDFlODgyZTI0ZWJkZGE4NTkxMTlfMy0zLTEtMS0w_bb19b1a1-cf4f-40be-8897-cf99ae0507fe"
      unitRef="usd">15000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOmQ0ZjU1MGI2MDUwODQxZTg4MmUyNGViZGRhODU5MTE5L3RhYmxlcmFuZ2U6ZDRmNTUwYjYwNTA4NDFlODgyZTI0ZWJkZGE4NTkxMTlfMy01LTEtMS0w_3c6e8803-7378-4bc2-9032-00c910a90c6e"
      unitRef="usd">15000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1
      contextRef="i81339315e2c14539bee8f1c43e550ae5_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOmQ0ZjU1MGI2MDUwODQxZTg4MmUyNGViZGRhODU5MTE5L3RhYmxlcmFuZ2U6ZDRmNTUwYjYwNTA4NDFlODgyZTI0ZWJkZGE4NTkxMTlfNC0xLTEtMS0yNjU5_78a30237-3f4e-4fe7-a111-9bde19248840"
      unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1
      contextRef="i03c64db735f449b18a2b4bbcb90984f0_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOmQ0ZjU1MGI2MDUwODQxZTg4MmUyNGViZGRhODU5MTE5L3RhYmxlcmFuZ2U6ZDRmNTUwYjYwNTA4NDFlODgyZTI0ZWJkZGE4NTkxMTlfNC0zLTEtMS0yNjY5_1ef59bd6-7d00-495f-92ba-8bcd24d2426e"
      unitRef="usd">388000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1
      contextRef="i7cdd3ec3331046ec97e3ab5eeb7a43e0_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOmQ0ZjU1MGI2MDUwODQxZTg4MmUyNGViZGRhODU5MTE5L3RhYmxlcmFuZ2U6ZDRmNTUwYjYwNTA4NDFlODgyZTI0ZWJkZGE4NTkxMTlfNC01LTEtMS0yNjcz_6ffd43f5-05b0-4e00-bdd9-da47e6058ed9"
      unitRef="usd">388000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1>
    <us-gaap:Goodwill
      contextRef="ice72f79525cf4aaa96a799b1808b8a8b_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOmQ0ZjU1MGI2MDUwODQxZTg4MmUyNGViZGRhODU5MTE5L3RhYmxlcmFuZ2U6ZDRmNTUwYjYwNTA4NDFlODgyZTI0ZWJkZGE4NTkxMTlfNC0xLTEtMS0w_31a693d2-9e23-4be7-a5d9-6ff0aceb8202"
      unitRef="usd">2659000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i33dcb67f0d874581b55d12fa93285854_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOmQ0ZjU1MGI2MDUwODQxZTg4MmUyNGViZGRhODU5MTE5L3RhYmxlcmFuZ2U6ZDRmNTUwYjYwNTA4NDFlODgyZTI0ZWJkZGE4NTkxMTlfNC0zLTEtMS0w_9ec8ea4e-42c5-49bf-840f-cc1536e0c8af"
      unitRef="usd">5327000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOmQ0ZjU1MGI2MDUwODQxZTg4MmUyNGViZGRhODU5MTE5L3RhYmxlcmFuZ2U6ZDRmNTUwYjYwNTA4NDFlODgyZTI0ZWJkZGE4NTkxMTlfNC01LTEtMS0w_21f20969-a829-4128-8356-0db4344e3f7d"
      unitRef="usd">7986000000</us-gaap:Goodwill>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1
      contextRef="i7cdd3ec3331046ec97e3ab5eeb7a43e0_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RleHRyZWdpb246MzU5NWE5MGE0YmIwNGI2NzhkY2RkNzcwZjZjMzUwMGRfMzI5ODUzNDg4ODMwMg_954a771a-4b93-4caa-a4ed-9a2764360175"
      unitRef="usd">388000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RleHRyZWdpb246MzU5NWE5MGE0YmIwNGI2NzhkY2RkNzcwZjZjMzUwMGRfNTE1_f787796a-055c-4251-a4ad-f29598805116">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize other intangible assets by class at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.596%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.070%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted- Average Remaining Amortization Period (Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Indefinite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D, trademarks and other&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total indefinite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Definite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,331&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,925&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,406&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks, trade names and patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;551&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;319&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;232&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,031&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;488&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;543&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total definite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,913&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,732&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,181&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,925&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,732&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2,193&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.308%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.643%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.312%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gross&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net&lt;br/&gt;Intangible&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Indefinite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D, trademarks and other&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total indefinite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Definite-life intangibles:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks, trade names and patents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Developed technology and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total definite-life intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total other intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ib86a8f16995f4394b90a5c5d09547673_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjQ5ZjUzYWUzZmM1MjQ3M2NhYmRmY2IyYzJkNDgyYTk3L3RhYmxlcmFuZ2U6NDlmNTNhZTNmYzUyNDczY2FiZGZjYjJjMmQ0ODJhOTdfMy0xLTEtMS0w_7baac895-289f-4893-8fc4-2b8cbe967701"
      unitRef="usd">12000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ib86a8f16995f4394b90a5c5d09547673_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjQ5ZjUzYWUzZmM1MjQ3M2NhYmRmY2IyYzJkNDgyYTk3L3RhYmxlcmFuZ2U6NDlmNTNhZTNmYzUyNDczY2FiZGZjYjJjMmQ0ODJhOTdfMy01LTEtMS0w_4179a66d-2a80-4640-94ba-478a6a424ac9"
      unitRef="usd">12000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjQ5ZjUzYWUzZmM1MjQ3M2NhYmRmY2IyYzJkNDgyYTk3L3RhYmxlcmFuZ2U6NDlmNTNhZTNmYzUyNDczY2FiZGZjYjJjMmQ0ODJhOTdfNC0xLTEtMS0w_0d288a12-088e-4535-93a1-737f97419b68"
      unitRef="usd">12000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjQ5ZjUzYWUzZmM1MjQ3M2NhYmRmY2IyYzJkNDgyYTk3L3RhYmxlcmFuZ2U6NDlmNTNhZTNmYzUyNDczY2FiZGZjYjJjMmQ0ODJhOTdfNC01LTEtMS0w_e35eb47b-b5cf-46f1-a85d-efa421b1acf9"
      unitRef="usd">12000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="if58ac855c7a34cfa8030c801c94150d0_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjQ5ZjUzYWUzZmM1MjQ3M2NhYmRmY2IyYzJkNDgyYTk3L3RhYmxlcmFuZ2U6NDlmNTNhZTNmYzUyNDczY2FiZGZjYjJjMmQ0ODJhOTdfNy0xLTEtMS0w_8a10e0cb-22da-4157-bad6-e2ba32600d03"
      unitRef="usd">3331000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if58ac855c7a34cfa8030c801c94150d0_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjQ5ZjUzYWUzZmM1MjQ3M2NhYmRmY2IyYzJkNDgyYTk3L3RhYmxlcmFuZ2U6NDlmNTNhZTNmYzUyNDczY2FiZGZjYjJjMmQ0ODJhOTdfNy0zLTEtMS0w_e7a76886-7a43-4af9-9a6c-ccbd70a501c4"
      unitRef="usd">1925000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="if58ac855c7a34cfa8030c801c94150d0_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjQ5ZjUzYWUzZmM1MjQ3M2NhYmRmY2IyYzJkNDgyYTk3L3RhYmxlcmFuZ2U6NDlmNTNhZTNmYzUyNDczY2FiZGZjYjJjMmQ0ODJhOTdfNy01LTEtMS0w_21a38ecb-4a36-42b0-a5bd-34895e2baf63"
      unitRef="usd">1406000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="ifb5b051f9d274a4db0185de02ba05dcb_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjQ5ZjUzYWUzZmM1MjQ3M2NhYmRmY2IyYzJkNDgyYTk3L3RhYmxlcmFuZ2U6NDlmNTNhZTNmYzUyNDczY2FiZGZjYjJjMmQ0ODJhOTdfNy03LTEtMS0w_f20b6f5c-ff3b-4b51-8da8-1de710de5e50">P11Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i6a9ff348b06a48ae9bb2eb719908affb_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjQ5ZjUzYWUzZmM1MjQ3M2NhYmRmY2IyYzJkNDgyYTk3L3RhYmxlcmFuZ2U6NDlmNTNhZTNmYzUyNDczY2FiZGZjYjJjMmQ0ODJhOTdfOC0xLTEtMS0w_e38f88d0-6feb-4227-9577-1936dc61540a"
      unitRef="usd">551000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6a9ff348b06a48ae9bb2eb719908affb_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjQ5ZjUzYWUzZmM1MjQ3M2NhYmRmY2IyYzJkNDgyYTk3L3RhYmxlcmFuZ2U6NDlmNTNhZTNmYzUyNDczY2FiZGZjYjJjMmQ0ODJhOTdfOC0zLTEtMS0w_81da435f-61af-4151-bfa1-b3642f0c857e"
      unitRef="usd">319000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6a9ff348b06a48ae9bb2eb719908affb_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjQ5ZjUzYWUzZmM1MjQ3M2NhYmRmY2IyYzJkNDgyYTk3L3RhYmxlcmFuZ2U6NDlmNTNhZTNmYzUyNDczY2FiZGZjYjJjMmQ0ODJhOTdfOC01LTEtMS0w_43add388-bec0-490e-a0a7-a5db86c5a28b"
      unitRef="usd">232000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="ice8a5553e38b49b6ad19d2aaa439d996_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjQ5ZjUzYWUzZmM1MjQ3M2NhYmRmY2IyYzJkNDgyYTk3L3RhYmxlcmFuZ2U6NDlmNTNhZTNmYzUyNDczY2FiZGZjYjJjMmQ0ODJhOTdfOC03LTEtMS0w_94ba132f-3627-408e-af6a-df63f98c8c61">P9Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i1197b65c014b476eb038f49933bfc8b8_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjQ5ZjUzYWUzZmM1MjQ3M2NhYmRmY2IyYzJkNDgyYTk3L3RhYmxlcmFuZ2U6NDlmNTNhZTNmYzUyNDczY2FiZGZjYjJjMmQ0ODJhOTdfOS0xLTEtMS0w_96a7eeae-a5c2-414c-b093-1227073d77c5"
      unitRef="usd">1031000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i1197b65c014b476eb038f49933bfc8b8_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjQ5ZjUzYWUzZmM1MjQ3M2NhYmRmY2IyYzJkNDgyYTk3L3RhYmxlcmFuZ2U6NDlmNTNhZTNmYzUyNDczY2FiZGZjYjJjMmQ0ODJhOTdfOS0zLTEtMS0w_c63925e7-abef-4188-ad3b-462afb925b1d"
      unitRef="usd">488000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i1197b65c014b476eb038f49933bfc8b8_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjQ5ZjUzYWUzZmM1MjQ3M2NhYmRmY2IyYzJkNDgyYTk3L3RhYmxlcmFuZ2U6NDlmNTNhZTNmYzUyNDczY2FiZGZjYjJjMmQ0ODJhOTdfOS01LTEtMS0w_90c78239-9c01-40ef-994f-c3bf1b797014"
      unitRef="usd">543000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i3d099e35f5894d5e9a24b39c60d6719a_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjQ5ZjUzYWUzZmM1MjQ3M2NhYmRmY2IyYzJkNDgyYTk3L3RhYmxlcmFuZ2U6NDlmNTNhZTNmYzUyNDczY2FiZGZjYjJjMmQ0ODJhOTdfOS03LTEtMS0w_f2c400ab-eefe-43d0-b57c-176984540b2f">P10Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjQ5ZjUzYWUzZmM1MjQ3M2NhYmRmY2IyYzJkNDgyYTk3L3RhYmxlcmFuZ2U6NDlmNTNhZTNmYzUyNDczY2FiZGZjYjJjMmQ0ODJhOTdfMTAtMS0xLTEtMA_57f05783-4e7f-4f2f-9612-01c7586c2a2d"
      unitRef="usd">4913000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjQ5ZjUzYWUzZmM1MjQ3M2NhYmRmY2IyYzJkNDgyYTk3L3RhYmxlcmFuZ2U6NDlmNTNhZTNmYzUyNDczY2FiZGZjYjJjMmQ0ODJhOTdfMTAtMy0xLTEtMA_7226e932-7c4a-41b2-a7a1-3766ca5b279a"
      unitRef="usd">2732000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjQ5ZjUzYWUzZmM1MjQ3M2NhYmRmY2IyYzJkNDgyYTk3L3RhYmxlcmFuZ2U6NDlmNTNhZTNmYzUyNDczY2FiZGZjYjJjMmQ0ODJhOTdfMTAtNS0xLTEtMA_7c257c2b-2e01-4256-8d57-dc726a054162"
      unitRef="usd">2181000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjQ5ZjUzYWUzZmM1MjQ3M2NhYmRmY2IyYzJkNDgyYTk3L3RhYmxlcmFuZ2U6NDlmNTNhZTNmYzUyNDczY2FiZGZjYjJjMmQ0ODJhOTdfMTAtNy0xLTEtMA_8c96e4f8-681f-4022-9633-ed8def836e1b">P11Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjQ5ZjUzYWUzZmM1MjQ3M2NhYmRmY2IyYzJkNDgyYTk3L3RhYmxlcmFuZ2U6NDlmNTNhZTNmYzUyNDczY2FiZGZjYjJjMmQ0ODJhOTdfMTEtMS0xLTEtMA_deab5c41-c100-40f7-9ce6-7800335351c6"
      unitRef="usd">4925000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjQ5ZjUzYWUzZmM1MjQ3M2NhYmRmY2IyYzJkNDgyYTk3L3RhYmxlcmFuZ2U6NDlmNTNhZTNmYzUyNDczY2FiZGZjYjJjMmQ0ODJhOTdfMTEtMy0xLTEtMA_15a86b0b-5ff0-4ee0-94df-9e48b5365558"
      unitRef="usd">2732000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjQ5ZjUzYWUzZmM1MjQ3M2NhYmRmY2IyYzJkNDgyYTk3L3RhYmxlcmFuZ2U6NDlmNTNhZTNmYzUyNDczY2FiZGZjYjJjMmQ0ODJhOTdfMTEtNS0xLTEtMA_a824d4bc-a9ab-4f5e-abfb-fa8af2e6bacb"
      unitRef="usd">2193000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="id75e1c542b0d4277aef6f4524dc533d0_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjA4OWIwZWU4NWZlYjQ4Mzg5Yzc0NTVjZjcwMTk4MGU1L3RhYmxlcmFuZ2U6MDg5YjBlZTg1ZmViNDgzODljNzQ1NWNmNzAxOTgwZTVfMy0xLTEtMS0w_2f726d34-ed0b-4e47-a7aa-e91bdd03ed52"
      unitRef="usd">23000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="id75e1c542b0d4277aef6f4524dc533d0_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjA4OWIwZWU4NWZlYjQ4Mzg5Yzc0NTVjZjcwMTk4MGU1L3RhYmxlcmFuZ2U6MDg5YjBlZTg1ZmViNDgzODljNzQ1NWNmNzAxOTgwZTVfMy01LTEtMS0w_ade80b03-2d82-4ab1-a8d8-b93f77ce9b18"
      unitRef="usd">23000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjA4OWIwZWU4NWZlYjQ4Mzg5Yzc0NTVjZjcwMTk4MGU1L3RhYmxlcmFuZ2U6MDg5YjBlZTg1ZmViNDgzODljNzQ1NWNmNzAxOTgwZTVfNC0xLTEtMS0w_13b289d0-8ea6-46bf-a3a7-12c836e94775"
      unitRef="usd">23000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjA4OWIwZWU4NWZlYjQ4Mzg5Yzc0NTVjZjcwMTk4MGU1L3RhYmxlcmFuZ2U6MDg5YjBlZTg1ZmViNDgzODljNzQ1NWNmNzAxOTgwZTVfNC01LTEtMS0w_2601f059-09f8-4eb8-8b07-8bdf22597991"
      unitRef="usd">23000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ie4f1de5725004793a5eb735884c24d4e_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjA4OWIwZWU4NWZlYjQ4Mzg5Yzc0NTVjZjcwMTk4MGU1L3RhYmxlcmFuZ2U6MDg5YjBlZTg1ZmViNDgzODljNzQ1NWNmNzAxOTgwZTVfNy0xLTEtMS0w_eac396dd-5efd-4f26-b06c-d8f79c37ee1a"
      unitRef="usd">3554000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie4f1de5725004793a5eb735884c24d4e_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjA4OWIwZWU4NWZlYjQ4Mzg5Yzc0NTVjZjcwMTk4MGU1L3RhYmxlcmFuZ2U6MDg5YjBlZTg1ZmViNDgzODljNzQ1NWNmNzAxOTgwZTVfNy0zLTEtMS0w_cc51216a-4a1e-4eaa-9791-a9fab82f1fb6"
      unitRef="usd">1828000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie4f1de5725004793a5eb735884c24d4e_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjA4OWIwZWU4NWZlYjQ4Mzg5Yzc0NTVjZjcwMTk4MGU1L3RhYmxlcmFuZ2U6MDg5YjBlZTg1ZmViNDgzODljNzQ1NWNmNzAxOTgwZTVfNy01LTEtMS0w_0ae6f645-f069-46d0-9f98-c768d4e39090"
      unitRef="usd">1726000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ibc713be36ac74ca6995d6707e0fd4741_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjA4OWIwZWU4NWZlYjQ4Mzg5Yzc0NTVjZjcwMTk4MGU1L3RhYmxlcmFuZ2U6MDg5YjBlZTg1ZmViNDgzODljNzQ1NWNmNzAxOTgwZTVfOC0xLTEtMS0w_b3d9120c-c18e-4e70-b94b-5a200066c5c1"
      unitRef="usd">673000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ibc713be36ac74ca6995d6707e0fd4741_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjA4OWIwZWU4NWZlYjQ4Mzg5Yzc0NTVjZjcwMTk4MGU1L3RhYmxlcmFuZ2U6MDg5YjBlZTg1ZmViNDgzODljNzQ1NWNmNzAxOTgwZTVfOC0zLTEtMS0w_c0cedcf0-ce98-47c9-9bfd-fd5a06e152f3"
      unitRef="usd">341000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ibc713be36ac74ca6995d6707e0fd4741_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjA4OWIwZWU4NWZlYjQ4Mzg5Yzc0NTVjZjcwMTk4MGU1L3RhYmxlcmFuZ2U6MDg5YjBlZTg1ZmViNDgzODljNzQ1NWNmNzAxOTgwZTVfOC01LTEtMS0w_a9d00f61-b0cf-4d59-8aba-548d232c4a4c"
      unitRef="usd">332000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i6c1148a859034784a3e672c820ea0c9d_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjA4OWIwZWU4NWZlYjQ4Mzg5Yzc0NTVjZjcwMTk4MGU1L3RhYmxlcmFuZ2U6MDg5YjBlZTg1ZmViNDgzODljNzQ1NWNmNzAxOTgwZTVfOS0xLTEtMS0w_dd014c19-2827-4b0f-a6e3-64776ae90491"
      unitRef="usd">1604000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6c1148a859034784a3e672c820ea0c9d_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjA4OWIwZWU4NWZlYjQ4Mzg5Yzc0NTVjZjcwMTk4MGU1L3RhYmxlcmFuZ2U6MDg5YjBlZTg1ZmViNDgzODljNzQ1NWNmNzAxOTgwZTVfOS0zLTEtMS0w_ed8c6848-2a28-4d36-baaf-c06ab5a2dcb0"
      unitRef="usd">767000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6c1148a859034784a3e672c820ea0c9d_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjA4OWIwZWU4NWZlYjQ4Mzg5Yzc0NTVjZjcwMTk4MGU1L3RhYmxlcmFuZ2U6MDg5YjBlZTg1ZmViNDgzODljNzQ1NWNmNzAxOTgwZTVfOS01LTEtMS0w_ef9f914c-6db8-4ef4-9512-58237c105261"
      unitRef="usd">837000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjA4OWIwZWU4NWZlYjQ4Mzg5Yzc0NTVjZjcwMTk4MGU1L3RhYmxlcmFuZ2U6MDg5YjBlZTg1ZmViNDgzODljNzQ1NWNmNzAxOTgwZTVfMTAtMS0xLTEtMA_6b1babbe-98db-4ce2-b6cd-e18405590ed1"
      unitRef="usd">5831000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjA4OWIwZWU4NWZlYjQ4Mzg5Yzc0NTVjZjcwMTk4MGU1L3RhYmxlcmFuZ2U6MDg5YjBlZTg1ZmViNDgzODljNzQ1NWNmNzAxOTgwZTVfMTAtMy0xLTEtMA_df2b0408-811f-46a6-9d97-eaae61a5f611"
      unitRef="usd">2936000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjA4OWIwZWU4NWZlYjQ4Mzg5Yzc0NTVjZjcwMTk4MGU1L3RhYmxlcmFuZ2U6MDg5YjBlZTg1ZmViNDgzODljNzQ1NWNmNzAxOTgwZTVfMTAtNS0xLTEtMA_964eb98e-629e-4b58-85c9-715e338fc25e"
      unitRef="usd">2895000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjA4OWIwZWU4NWZlYjQ4Mzg5Yzc0NTVjZjcwMTk4MGU1L3RhYmxlcmFuZ2U6MDg5YjBlZTg1ZmViNDgzODljNzQ1NWNmNzAxOTgwZTVfMTEtMS0xLTEtMA_cea658fc-047a-4801-ad42-715eb6fcc49f"
      unitRef="usd">5854000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjA4OWIwZWU4NWZlYjQ4Mzg5Yzc0NTVjZjcwMTk4MGU1L3RhYmxlcmFuZ2U6MDg5YjBlZTg1ZmViNDgzODljNzQ1NWNmNzAxOTgwZTVfMTEtMy0xLTEtMA_36a09b00-3f2d-408b-b28b-9917c6f42238"
      unitRef="usd">2936000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RhYmxlOjA4OWIwZWU4NWZlYjQ4Mzg5Yzc0NTVjZjcwMTk4MGU1L3RhYmxlcmFuZ2U6MDg5YjBlZTg1ZmViNDgzODljNzQ1NWNmNzAxOTgwZTVfMTEtNS0xLTEtMA_c5fe8704-d1af-4ce9-bee9-e028a1fd7f09"
      unitRef="usd">2918000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RleHRyZWdpb246MzU5NWE5MGE0YmIwNGI2NzhkY2RkNzcwZjZjMzUwMGRfMjY1_959727a6-b112-473e-b0c3-02c60c2c947b"
      unitRef="usd">109000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RleHRyZWdpb246MzU5NWE5MGE0YmIwNGI2NzhkY2RkNzcwZjZjMzUwMGRfMjcy_92165799-f39a-4885-9640-e071a144e731"
      unitRef="usd">129000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RleHRyZWdpb246MzU5NWE5MGE0YmIwNGI2NzhkY2RkNzcwZjZjMzUwMGRfMzMx_0c43305d-f2d9-4d45-8aa9-ef5b38397781"
      unitRef="usd">337000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RleHRyZWdpb246MzU5NWE5MGE0YmIwNGI2NzhkY2RkNzcwZjZjMzUwMGRfMzM4_f8bc277d-d945-426d-a6f0-6fb10b6a2f55"
      unitRef="usd">385000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RleHRyZWdpb246MzU5NWE5MGE0YmIwNGI2NzhkY2RkNzcwZjZjMzUwMGRfNDg1_697753d1-6c5b-41a4-8104-7472aa6acf45"
      unitRef="usd">91000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RleHRyZWdpb246MzU5NWE5MGE0YmIwNGI2NzhkY2RkNzcwZjZjMzUwMGRfNDg5_2bf69b09-e59c-4007-a71c-f947f1349cb5"
      unitRef="usd">314000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RleHRyZWdpb246MzU5NWE5MGE0YmIwNGI2NzhkY2RkNzcwZjZjMzUwMGRfNDkz_07b5319a-ace8-479d-8ec8-2a9791f4cf3a"
      unitRef="usd">287000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RleHRyZWdpb246MzU5NWE5MGE0YmIwNGI2NzhkY2RkNzcwZjZjMzUwMGRfNDk3_07afe53a-ce5f-4d42-a671-7964ebc4eb72"
      unitRef="usd">263000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RleHRyZWdpb246MzU5NWE5MGE0YmIwNGI2NzhkY2RkNzcwZjZjMzUwMGRfNTA0_624480c3-f64c-4a9e-a5be-0245832ae7a1"
      unitRef="usd">238000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets
      contextRef="i7cdd3ec3331046ec97e3ab5eeb7a43e0_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV84NS9mcmFnOjM1OTVhOTBhNGJiMDRiNjc4ZGNkZDc3MGY2YzM1MDBkL3RleHRyZWdpb246MzU5NWE5MGE0YmIwNGI2NzhkY2RkNzcwZjZjMzUwMGRfNTQ5NzU1ODE0NTY0Mw_b0ff5ac5-a916-43c7-8360-9326e173bbd6"
      unitRef="usd">391000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85NC9mcmFnOjQxMWM1N2FkMjg3ZjRlYjJhMDIyMDllODY4NDg3YWU4L3RleHRyZWdpb246NDExYzU3YWQyODdmNGViMmEwMjIwOWU4Njg0ODdhZThfMjM3MQ_abaaa361-5426-4bd2-99eb-7fe100137ece">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;5. Long-Term Obligations and Other Short-Term Borrowings&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Long-Term Debt and Other Short-Term Borrowings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2021 and June&#160;30, 2020, we had total long-term obligations, including the current portion and other short-term borrowings, of $6.7 billion and $6.8 billion, respectively. All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These obligations are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $22.6 billion and $21.4 billion at March&#160;31, 2021 and June&#160;30, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended March&#160;31, 2021, we early repurchased $40 million of the Floating Rate Notes due 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and $2 million of the 2.616% Notes due 2022. The repurchases were paid for with available cash. In connection with the early debt repurchases, we recorded a $1 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;loss on early extinguishment of debt during the nine months ended March&#160;31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2019, we repaid the full principal of the 2.4% Notes due 2019 at maturity for $450&#160;million. During the nine months ended March 31, 2020, we early repurchased $247&#160;million of the 2.616% Notes due 2022, $11&#160;million of the 3.2% Notes due 2022, $20&#160;million of the Floating Rate Notes due 2022, $104&#160;million of the 3.41% Notes due 2027, $6&#160;million of the 4.6% Notes due 2043, $5&#160;million of the 4.9% Notes due 2045, and $35&#160;million of the 4.368% Notes due 2047. The repurchases were paid for with available cash and other short-term borrowings. In connection with the early debt repurchases, we recorded a $9 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;loss on early extinguishment of debt during the nine months ended March 31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Other Financing Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to cash and equivalents and operating cash flow, other sources of liquidity include a&#160;$2.0 billion&#160;commercial paper program backed by a $2.0 billion&#160;revolving credit facility. We also have a&#160;$1.0 billion&#160;committed receivables sales facility. At&#160;March&#160;31, 2021, we had no amounts outstanding under our commercial paper program, revolving credit facility, or our committed receivables sales facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2019, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (&#x201c;CHF&#x201d;) through September 30, 2022. CHF was organized for&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health, Inc. in accordance with GAAP, CHF is a separate legal entity from Cardinal Health, Inc. and from our &lt;/span&gt;&lt;/div&gt;subsidiary that sells receivables to CHF. CHF is designed to be a special purpose, bankruptcy-remote entity whose assets are available solely to satisfy the claims of its creditors. Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1 beginning March 2021. As of March&#160;31, 2021, we were in compliance with this financial covenant.</us-gaap:DebtDisclosureTextBlock>
    <cah:TotalLongTermandShortTermObligations
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85NC9mcmFnOjQxMWM1N2FkMjg3ZjRlYjJhMDIyMDllODY4NDg3YWU4L3RleHRyZWdpb246NDExYzU3YWQyODdmNGViMmEwMjIwOWU4Njg0ODdhZThfMTcx_d124ec3e-6d5b-4675-b747-edef4094bd21"
      unitRef="usd">6700000000</cah:TotalLongTermandShortTermObligations>
    <cah:TotalLongTermandShortTermObligations
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85NC9mcmFnOjQxMWM1N2FkMjg3ZjRlYjJhMDIyMDllODY4NDg3YWU4L3RleHRyZWdpb246NDExYzU3YWQyODdmNGViMmEwMjIwOWU4Njg0ODdhZThfMTc4_f4528731-9a98-4afc-9cd4-9448feca7de0"
      unitRef="usd">6800000000</cah:TotalLongTermandShortTermObligations>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85NC9mcmFnOjQxMWM1N2FkMjg3ZjRlYjJhMDIyMDllODY4NDg3YWU4L3RleHRyZWdpb246NDExYzU3YWQyODdmNGViMmEwMjIwOWU4Njg0ODdhZThfNTU3_61747931-bd91-44d9-8589-bd1a1e322b17"
      unitRef="usd">22600000000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85NC9mcmFnOjQxMWM1N2FkMjg3ZjRlYjJhMDIyMDllODY4NDg3YWU4L3RleHRyZWdpb246NDExYzU3YWQyODdmNGViMmEwMjIwOWU4Njg0ODdhZThfNTY0_dd65287c-3a67-4494-ae32-2cb824d0c34d"
      unitRef="usd">21400000000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <cah:NotesPayableRepurchased
      contextRef="icdab92a7a6fd41b39bd57e54be7e769f_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85NC9mcmFnOjQxMWM1N2FkMjg3ZjRlYjJhMDIyMDllODY4NDg3YWU4L3RleHRyZWdpb246NDExYzU3YWQyODdmNGViMmEwMjIwOWU4Njg0ODdhZThfNjM0_2237b9cb-23fe-4765-b1c4-10a5461daa72"
      unitRef="usd">40000000</cah:NotesPayableRepurchased>
    <cah:NotesPayableRepurchased
      contextRef="i9f3611b603314fb097f4abad927ac3d9_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85NC9mcmFnOjQxMWM1N2FkMjg3ZjRlYjJhMDIyMDllODY4NDg3YWU4L3RleHRyZWdpb246NDExYzU3YWQyODdmNGViMmEwMjIwOWU4Njg0ODdhZThfNjUx_a33973dd-18cd-413a-ac92-3bda1d8c16eb"
      unitRef="usd">2000000</cah:NotesPayableRepurchased>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85NC9mcmFnOjQxMWM1N2FkMjg3ZjRlYjJhMDIyMDllODY4NDg3YWU4L3RleHRyZWdpb246NDExYzU3YWQyODdmNGViMmEwMjIwOWU4Njg0ODdhZThfNzc3_f9c789fa-182d-4ece-8f7b-99ddda8d1470"
      unitRef="usd">-1000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <cah:NotesPayableRepurchased
      contextRef="i504e4cad981b4ed993b975460c7fc7ac_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85NC9mcmFnOjQxMWM1N2FkMjg3ZjRlYjJhMDIyMDllODY4NDg3YWU4L3RleHRyZWdpb246NDExYzU3YWQyODdmNGViMmEwMjIwOWU4Njg0ODdhZThfOTQw_3a55296e-fd39-47f3-90c9-b7632d45eda2"
      unitRef="usd">450000000</cah:NotesPayableRepurchased>
    <cah:NotesPayableRepurchased
      contextRef="ia090211208aa441088c4d8069f02dbfb_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85NC9mcmFnOjQxMWM1N2FkMjg3ZjRlYjJhMDIyMDllODY4NDg3YWU4L3RleHRyZWdpb246NDExYzU3YWQyODdmNGViMmEwMjIwOWU4Njg0ODdhZThfOTk4_74aa96b9-34ca-4bf1-9f70-9c4c624821eb"
      unitRef="usd">247000000</cah:NotesPayableRepurchased>
    <cah:NotesPayableRepurchased
      contextRef="i49a27c7578bd41088dddfb606868d281_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85NC9mcmFnOjQxMWM1N2FkMjg3ZjRlYjJhMDIyMDllODY4NDg3YWU4L3RleHRyZWdpb246NDExYzU3YWQyODdmNGViMmEwMjIwOWU4Njg0ODdhZThfMTAxMg_bc6c83b1-2c02-4381-909d-c61e26cac6fd"
      unitRef="usd">11000000</cah:NotesPayableRepurchased>
    <cah:NotesPayableRepurchased
      contextRef="ia6234f8623c6430bb624a2926a712aa6_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85NC9mcmFnOjQxMWM1N2FkMjg3ZjRlYjJhMDIyMDllODY4NDg3YWU4L3RleHRyZWdpb246NDExYzU3YWQyODdmNGViMmEwMjIwOWU4Njg0ODdhZThfMTAyNg_f0c8820c-8fd1-4253-a53d-29d691666916"
      unitRef="usd">20000000</cah:NotesPayableRepurchased>
    <cah:NotesPayableRepurchased
      contextRef="if1eda4e509ce43798df227d81709d323_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85NC9mcmFnOjQxMWM1N2FkMjg3ZjRlYjJhMDIyMDllODY4NDg3YWU4L3RleHRyZWdpb246NDExYzU3YWQyODdmNGViMmEwMjIwOWU4Njg0ODdhZThfMTA0MA_cc687cf5-e02d-448b-a959-64f0344803b0"
      unitRef="usd">104000000</cah:NotesPayableRepurchased>
    <cah:NotesPayableRepurchased
      contextRef="i6db532c36ac040349356f496d49a51e5_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85NC9mcmFnOjQxMWM1N2FkMjg3ZjRlYjJhMDIyMDllODY4NDg3YWU4L3RleHRyZWdpb246NDExYzU3YWQyODdmNGViMmEwMjIwOWU4Njg0ODdhZThfMTA1NA_0a42897d-73db-403b-9a36-47ac6555ef0d"
      unitRef="usd">6000000</cah:NotesPayableRepurchased>
    <cah:NotesPayableRepurchased
      contextRef="ia3cfcd32bbbd409a8721be1d572e5196_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85NC9mcmFnOjQxMWM1N2FkMjg3ZjRlYjJhMDIyMDllODY4NDg3YWU4L3RleHRyZWdpb246NDExYzU3YWQyODdmNGViMmEwMjIwOWU4Njg0ODdhZThfMTA2Nw_d913183f-caa8-4cab-a6d7-90525243f592"
      unitRef="usd">5000000</cah:NotesPayableRepurchased>
    <cah:NotesPayableRepurchased
      contextRef="i47aa282752004df79e631b50e9d85ec0_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85NC9mcmFnOjQxMWM1N2FkMjg3ZjRlYjJhMDIyMDllODY4NDg3YWU4L3RleHRyZWdpb246NDExYzU3YWQyODdmNGViMmEwMjIwOWU4Njg0ODdhZThfMTA4NQ_9b2a0aab-3e69-42ef-8237-ab7029cf93d7"
      unitRef="usd">35000000</cah:NotesPayableRepurchased>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85NC9mcmFnOjQxMWM1N2FkMjg3ZjRlYjJhMDIyMDllODY4NDg3YWU4L3RleHRyZWdpb246NDExYzU3YWQyODdmNGViMmEwMjIwOWU4Njg0ODdhZThfMzI5ODUzNDg4NTg0Nw_28401bbc-51b3-4b63-8256-4c0e3d11ddf1"
      unitRef="usd">-9000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i78b6ef34025b4452a5b896401fa40e7c_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85NC9mcmFnOjQxMWM1N2FkMjg3ZjRlYjJhMDIyMDllODY4NDg3YWU4L3RleHRyZWdpb246NDExYzU3YWQyODdmNGViMmEwMjIwOWU4Njg0ODdhZThfMTQ2OA_c4ebdbea-730b-449c-85f8-b8e728ec344e"
      unitRef="usd">2000000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i5f24903888fe442faadd663a0aba2ff7_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85NC9mcmFnOjQxMWM1N2FkMjg3ZjRlYjJhMDIyMDllODY4NDg3YWU4L3RleHRyZWdpb246NDExYzU3YWQyODdmNGViMmEwMjIwOWU4Njg0ODdhZThfMTUwOA_d4a77e0d-490b-4430-b1b0-0b92d682fd23"
      unitRef="usd">2000000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i604f1c37ba004bdaa7f5e22b3f373f12_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85NC9mcmFnOjQxMWM1N2FkMjg3ZjRlYjJhMDIyMDllODY4NDg3YWU4L3RleHRyZWdpb246NDExYzU3YWQyODdmNGViMmEwMjIwOWU4Njg0ODdhZThfMTU1Mw_5b3f4ef8-6709-454f-821d-7c1fe6a680c9"
      unitRef="usd">1000000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85Ny9mcmFnOjQyNjdmNTQxNzNkZjQzM2JiOWMyNjI4YzE2MzY3OWIzL3RleHRyZWdpb246NDI2N2Y1NDE3M2RmNDMzYmI5YzI2MjhjMTYzNjc5YjNfMTU0MTM_caa3bc9b-093f-4b61-b64e-81167e390c95">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;6. Commitments, Contingent Liabilities and Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Generic Sourcing Venture with CVS Health Corporation ("CVS Health")&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of 10 years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. Due to the achievement of predetermined milestones, we are required to make quarterly payments of $45.6 million to CVS Health for the remainder of the initial term.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;New York Opioid Stewardship Act&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2018, the State of New York passed a budget which included the Opioid Stewardship Act (the "OSA"). The OSA created an aggregate $100&#160;million annual assessment on all manufacturers and distributors licensed to sell or distribute opioids in New York. Under the OSA, each licensed manufacturer and distributor would be required to pay a portion of the assessment based on its share of the total morphine milligram equivalents sold or distributed in New York during the applicable calendar year, beginning in 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The constitutionality of portions of the OSA has been challenged in court. In December 2018, the OSA was ruled unconstitutional by the U.S. district court for the Southern District of New York. Subsequently, New York passed a new statute that modified the assessment going forward and limited the OSA to two years (2017 and 2018). The U.S. Court of Appeals for the Second Circuit reversed the district court's decision on procedural grounds. In February 2021, the Second Circuit stayed the effect of the ruling pending a petition to the U.S. Supreme Court to review the Second Circuit's opinion. If the U.S. Supreme Court declines to take the case, or if it ultimately upholds the Second Circuit's ruling, New York State would likely seek to collect amounts allegedly owed under the OSA. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accrue contingencies if it is probable that a liability has been incurred and the amount can be estimated. Because of the Second Circuit ruling, we recorded an aggregate accrual of $41&#160;million for calendar year 2017 and 2018 in the nine months ended March 31, 2021 based on the estimated payment amount, which is our best estimate of the OSA payments probable at March 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.214%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We become involved from time to time in disputes, litigation and regulatory matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we determine that products we source, manufacture or market do not meet our specifications, regulatory requirements, or published standards. When we or a regulatory agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions have led to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, product liability claims and lawsuits and can lead to action by regulators. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we become aware through employees, internal audits or other parties of possible compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have been named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.215%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges in our condensed consolidated statements of earnings/(loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Opioid Lawsuits and Investigations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmaceutical wholesale distributors, including us, have been named as defendants in approximately 3,300 lawsuits relating to the distribution of prescription opioid pain medications. The lawsuits seek equitable relief and monetary damages based on a variety of legal theories including various common law claims, such as public nuisance, negligence and unjust enrichment as well as violations of controlled substance laws, the Racketeer Influenced and Corrupt Organizations Act and various other statutes. These lawsuits also name pharmaceutical manufacturers, retail pharmacy chains and other entities as defendants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;States &amp;amp; Political Subdivisions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Approximately 2,800 of these lawsuits have been filed by counties, municipalities, cities and political subdivisions in various federal, state, and other courts. The vast majority of these lawsuits were filed in U.S. federal court and have been transferred for consolidated pre-trial proceedings in a Multi-District Litigation proceeding in the U.S. District Court for the Northern District of Ohio (the &#x201c;MDL&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, 25 state attorneys general have filed lawsuits against distributors, including us, in various state courts. We have also received requests, civil investigative demands, subpoenas or requests for information from additional state attorneys general offices and governmental authorities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2019, we agreed in principle to a global settlement framework with a leadership group of state attorneys general; the framework is designed to resolve pending and future opioid lawsuits and claims by states and political subdivisions, but not private plaintiffs (the "Settlement Framework"). This Settlement Framework is the basis for the continued negotiation of definitive terms and documentation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of these discussions, we have recorded total pre-tax charges of $1.02&#160;billion and $5.63&#160;billion in litigation charges/(recoveries), net in the nine months ended March&#160;31, 2021 and 2020, respectively. In total, we have $6.59&#160;billion accrued at March&#160;31, 2021, included in deferred income taxes and other liabilities in the condensed consolidated balance sheets, which represents the cash component. We are unable to estimate the range of possible loss associated with these matters. Definitive terms for a settlement pursuant to the Settlement Framework continue to be negotiated, and there is no assurance that the necessary parties will agree to a definitive settlement agreement or that the contingencies to any agreement will be satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.214%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ultimate loss may differ materially from this accrual, whether as a result of settlement discussions, a judicial decision or verdict or otherwise, but we are not able to estimate a range of reasonably possible additional losses for these matters. We continue to strongly dispute the allegations made in these lawsuits and reaching an agreement in principle on a global settlement framework is not an admission of liability or wrongdoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although COVID-19 continues to cause some uncertainty with respect to trial dates, trials are resuming in certain jurisdictions. A trial in West Virginia in the Cabell County and City of Huntington cases began on May 3, 2021. A liability-only trial in the cases brought by the New York Attorney General and Nassau and Suffolk Counties is currently scheduled for June 2021 and trials in the cases brought by the Ohio and Washington Attorneys General are scheduled to begin in September 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Private Plaintiffs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Settlement Framework does not address claims by private parties, which includes unions and other health and welfare funds, hospital systems and other healthcare providers, businesses and individuals. Private parties had brought approximately 430 lawsuits as of May 3, 2021. Of these, 127 are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs. A trial in one case is currently scheduled to begin in October 2021; however trial dates remain uncertain due in part to circumstances arising from the COVID-19 pandemic. We are vigorously defending ourselves in these matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Insurance Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are involved in legal proceedings with two insurers related to the availability of insurance coverage for the lawsuits described above. In October 2020, we filed a complaint for declaratory judgment against National Union Fire Insurance Company of Pittsburgh, PA (&#x201c;National Union&#x201d;) seeking a declaration that National Union is obligated to reimburse us for defense costs incurred in connection with the lawsuits described above. In January, 2021, Swiss Re International SE commenced an arbitration in London seeking a determination that it does not have an obligation to reimburse us for defense and indemnity expenses incurred in connection with the lawsuits described above. We have not recorded a receivable for any recoveries related to these insurance litigation matters as of March 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Department of Justice Investigations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have received federal grand jury subpoenas issued in connection with investigations being conducted by the U.S. Attorney's Office for the Eastern District of New York and the Fraud Section of the U.S. Department of Justice ("DOJ"). We have also received civil requests for information from other DOJ offices. We believe that these investigations concern operation of our anti-diversion program, our anti-diversion policies and procedures, and distribution of certain controlled substances. We are cooperating with these requests. We are unable to predict the outcome of any of these investigations. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.215%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cordis Product Liability Lawsuits&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of May 3, 2021, we are named as a defendant in 396 product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by approximately 5,046 plaintiffs that allege personal injuries associated with the use of Cordis OptEase and TrapEase inferior vena cava ("IVC") filter products. Another 31 lawsuits involving similar claims by approximately 36 plaintiffs are pending in other jurisdictions. These lawsuits seek a variety of remedies, including unspecified monetary damages. We continue to vigorously defend ourselves in these lawsuits and are engaged in resolution discussions with certain plaintiffs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2021, we had a total of $514 million net of estimated insurance recoveries, accrued for losses and legal defense costs related to the Cordis IVC filter lawsuits which are presented on a gross basis in the condensed consolidated balance sheets. We believe there is a range of estimated losses with respect to these matters. Because no amount within the range is a better estimate than any other amount within the range, we have accrued the minimum amount in the range. We estimate the high end of the range to be approximately $1.01 billion, net of estimated insurance recoveries. The sale of the Cordis disposal group does not include product liability related to the IVC filters in the U.S. and Canada, which we will retain. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;SEC Investigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, we received a subpoena from the U.S. Securities and Exchange Commission requesting the production of documents from 2015 through 2019 relating to inventory in the Cordis business, analysis of goodwill of the Medical segment and other matters. We are cooperating with this inquiry and cannot predict its outcome or duration. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shareholder Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2019, the Louisiana Sheriffs' Pension &amp;amp; Relief Fund filed a purported class action complaint against Cardinal Health and certain current and former officers and employees in the United States District Court for the Southern District of Ohio purportedly on behalf of all purchasers of our common shares between March 2015 and May 2018. In June 2020, the court appointed 1199 SEIU Health Care Employees Pension Fund as lead plaintiff and a consolidated amended complaint was filed in September 2020. The amended complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities and Exchange Act of 1934 by making misrepresentations and omissions related to the acquisition integration of the Cordis business and inventory and supply chain problems within the Cordis business, and seeks to recover unspecified damages and equitable relief for the alleged misstatements and omissions. The complaint also alleges that one of the individual defendants violated Section 20A of the Exchange Act because he sold shares of Cardinal Health stock during the time period. In November 2020, we filed a motion to dismiss the amended complaint. We believe that the claims asserted in this complaint are without merit and intend to vigorously defend against them. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Specialty Solutions DOJ Investigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018, the United States Attorney&#x2019;s Office for the District of Massachusetts (the "USAO") commenced an investigation pertaining to the U.S. federal healthcare fraud and abuse laws. These requests sought, among other things, documents and information relating to discounts and rebates offered or provided to certain Specialty Solutions customers. We are cooperating with these requests and are engaged in resolution discussions with the USAO. In connection with these discussions, we recorded $13 million of expense within litigation charges/(recoveries) on our condensed consolidated statement of operations during the three months ended March&#160;31, 2021. We are not able to estimate a range of reasonably possible additional losses or other remedial measures for this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Civil Litigation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Generic Pharmaceutical Pricing Antitrust Litigation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, pharmaceutical distributors including us were added as defendants in a civil class action lawsuit filed by indirect purchasers of generic drugs, such as hospitals and retail pharmacies. The indirect purchaser case is part of a multidistrict litigation consisting of multiple individual class action matters consolidated in the Eastern District of Pennsylvania. The indirect purchaser plaintiffs allege that pharmaceutical distributors encouraged manufacturers to increase prices, provided anti-competitive pricing information to manufacturers and improperly engaged in customer allocation. We have filed a motion to dismiss the complaints and we intend to vigorously defend ourselves. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Active Pharmaceutical Ingredient Impurity Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Many participants in the pharmaceutical supply chain, including active pharmaceutical ingredient ("API") manufacturers, finished dose manufacturers, repackagers, distributors, and retailers have been named as defendants in lawsuits arising out of recalls of certain medications due to alleged impurities in the active pharmaceutical ingredients or finished product. &lt;/span&gt;&lt;/div&gt;In February 2019, a Multidistrict Litigation was created in the U.S. District Court for the District of New Jersey (the &#x201c;Sartan MDL&#x201d;) alleging API impurities in certain generic blood pressure medications. We have been named as a defendant in the Sartan MDL. We are vigorously defending ourselves in this matter.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LongtermPurchaseCommitmentPeriod
      contextRef="i33f590b1fd8b44a8a08a2e3ea0f1b1bd_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85Ny9mcmFnOjQyNjdmNTQxNzNkZjQzM2JiOWMyNjI4YzE2MzY3OWIzL3RleHRyZWdpb246NDI2N2Y1NDE3M2RmNDMzYmI5YzI2MjhjMTYzNjc5YjNfMjU0_65f1704c-ba10-4862-9bd2-540e751fa150">P10Y</us-gaap:LongtermPurchaseCommitmentPeriod>
    <cah:MaximumQuarterlyPayment
      contextRef="i33f590b1fd8b44a8a08a2e3ea0f1b1bd_D20200701-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85Ny9mcmFnOjQyNjdmNTQxNzNkZjQzM2JiOWMyNjI4YzE2MzY3OWIzL3RleHRyZWdpb246NDI2N2Y1NDE3M2RmNDMzYmI5YzI2MjhjMTYzNjc5YjNfNDU1_1fc3792b-6506-42a1-830d-24451d5e1563"
      unitRef="usd">45600000</cah:MaximumQuarterlyPayment>
    <cah:AggregateAnnualAssessment
      contextRef="i6c69ca015f5c476994fba9d5d8aef33b_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85Ny9mcmFnOjQyNjdmNTQxNzNkZjQzM2JiOWMyNjI4YzE2MzY3OWIzL3RleHRyZWdpb246NDI2N2Y1NDE3M2RmNDMzYmI5YzI2MjhjMTYzNjc5YjNfNjk0_7f1c844b-5f9f-4e21-b880-38f7c3333b3b"
      unitRef="usd">100000000</cah:AggregateAnnualAssessment>
    <cah:EstimatedLiabilityForNewYorkOpioidStewardshipAct
      contextRef="i12b52de2a6014b01b5857d8d032e2d95_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85Ny9mcmFnOjQyNjdmNTQxNzNkZjQzM2JiOWMyNjI4YzE2MzY3OWIzL3RleHRyZWdpb246NDI2N2Y1NDE3M2RmNDMzYmI5YzI2MjhjMTYzNjc5YjNfMTgwNQ_4d568cce-2a74-47b4-ae93-bff4145093b7"
      unitRef="usd">41000000</cah:EstimatedLiabilityForNewYorkOpioidStewardshipAct>
    <cah:LossContingencyLawsuitsNumber
      contextRef="ia2b0385b5ab44d27a7dc86dee405b359_I20210503"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85Ny9mcmFnOjQyNjdmNTQxNzNkZjQzM2JiOWMyNjI4YzE2MzY3OWIzL3RleHRyZWdpb246NDI2N2Y1NDE3M2RmNDMzYmI5YzI2MjhjMTYzNjc5YjNfNTQwNQ_56f44e5f-53aa-49e1-8c19-753a566e8e59"
      unitRef="number">3300</cah:LossContingencyLawsuitsNumber>
    <cah:LossContingencyLawsuitsNumber
      contextRef="i3cc62b61cd8d43428ee9e8e27d88fc65_I20210503"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85Ny9mcmFnOjQyNjdmNTQxNzNkZjQzM2JiOWMyNjI4YzE2MzY3OWIzL3RleHRyZWdpb246NDI2N2Y1NDE3M2RmNDMzYmI5YzI2MjhjMTYzNjc5YjNfNTk2OA_0d39cca5-0b22-4291-9657-8e1f5b614c49"
      unitRef="number">2800</cah:LossContingencyLawsuitsNumber>
    <cah:NumberofStateAttorneysGeneralfilinglawsuits
      contextRef="ia2b0385b5ab44d27a7dc86dee405b359_I20210503"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85Ny9mcmFnOjQyNjdmNTQxNzNkZjQzM2JiOWMyNjI4YzE2MzY3OWIzL3RleHRyZWdpb246NDI2N2Y1NDE3M2RmNDMzYmI5YzI2MjhjMTYzNjc5YjNfNjM3Ng_94158410-37b3-42b4-abdd-ec901f4c34d1"
      unitRef="stateag">25</cah:NumberofStateAttorneysGeneralfilinglawsuits>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="ib9e03386e8bb45b9bfa0b58a7c283f07_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85Ny9mcmFnOjQyNjdmNTQxNzNkZjQzM2JiOWMyNjI4YzE2MzY3OWIzL3RleHRyZWdpb246NDI2N2Y1NDE3M2RmNDMzYmI5YzI2MjhjMTYzNjc5YjNfNzUwMw_089202f4-34a0-4f24-b2a6-730e01801ccc"
      unitRef="usd">-1020000000.00</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i32ccdaa0f4af4c919f10cbbfa4cc9a79_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85Ny9mcmFnOjQyNjdmNTQxNzNkZjQzM2JiOWMyNjI4YzE2MzY3OWIzL3RleHRyZWdpb246NDI2N2Y1NDE3M2RmNDMzYmI5YzI2MjhjMTYzNjc5YjNfNzUxMA_8ef151f9-98cc-4148-a8a2-1e0e26e2206b"
      unitRef="usd">-5630000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:LitigationReserve
      contextRef="i9f40d9e3a7db48b09daa5018d3017966_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85Ny9mcmFnOjQyNjdmNTQxNzNkZjQzM2JiOWMyNjI4YzE2MzY3OWIzL3RleHRyZWdpb246NDI2N2Y1NDE3M2RmNDMzYmI5YzI2MjhjMTYzNjc5YjNfNzYzNw_274c7e5a-d354-4268-8041-230dd1e234ae"
      unitRef="usd">6590000000</us-gaap:LitigationReserve>
    <cah:LossContingencyLawsuitsNumber
      contextRef="i7e4a5266c9ee4255be61beea0051e346_I20210503"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85Ny9mcmFnOjQyNjdmNTQxNzNkZjQzM2JiOWMyNjI4YzE2MzY3OWIzL3RleHRyZWdpb246NDI2N2Y1NDE3M2RmNDMzYmI5YzI2MjhjMTYzNjc5YjNfODk2OQ_fae07bd6-f069-4029-820a-ad67802908cd"
      unitRef="lawsuit">430</cah:LossContingencyLawsuitsNumber>
    <cah:LossContingencyLawsuitsNumber
      contextRef="i807f09109de94752a25bb7a0eae4766f_I20210503"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85Ny9mcmFnOjQyNjdmNTQxNzNkZjQzM2JiOWMyNjI4YzE2MzY3OWIzL3RleHRyZWdpb246NDI2N2Y1NDE3M2RmNDMzYmI5YzI2MjhjMTYzNjc5YjNfOTAxNQ_f770185c-24a0-4e22-a422-8cb22c2d6af7"
      unitRef="lawsuit">127</cah:LossContingencyLawsuitsNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="ica111f2089a54b038384fbd2c3ed75c2_D20210503-20210503"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85Ny9mcmFnOjQyNjdmNTQxNzNkZjQzM2JiOWMyNjI4YzE2MzY3OWIzL3RleHRyZWdpb246NDI2N2Y1NDE3M2RmNDMzYmI5YzI2MjhjMTYzNjc5YjNfMTAzOTA_8b6d0ddd-e364-4866-89f7-bf2f31a4a903"
      unitRef="lawsuit">396</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i1bf34677339c4ce196bf82617b72b6c2_D20210503-20210503"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85Ny9mcmFnOjQyNjdmNTQxNzNkZjQzM2JiOWMyNjI4YzE2MzY3OWIzL3RleHRyZWdpb246NDI2N2Y1NDE3M2RmNDMzYmI5YzI2MjhjMTYzNjc5YjNfMTA1MTM_ffd82853-505b-4066-9796-98cbde942224"
      unitRef="plaintiff">5046</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i0c6a6bb892f345c4b3edac4aec0d217d_D20210503-20210503"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85Ny9mcmFnOjQyNjdmNTQxNzNkZjQzM2JiOWMyNjI4YzE2MzY3OWIzL3RleHRyZWdpb246NDI2N2Y1NDE3M2RmNDMzYmI5YzI2MjhjMTYzNjc5YjNfMTA2NjQ_ffa86e44-38db-43c7-a322-76c2862d9624"
      unitRef="lawsuit">31</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="i22d9e3f7ffff422283088171ae8c7f53_D20210503-20210503"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85Ny9mcmFnOjQyNjdmNTQxNzNkZjQzM2JiOWMyNjI4YzE2MzY3OWIzL3RleHRyZWdpb246NDI2N2Y1NDE3M2RmNDMzYmI5YzI2MjhjMTYzNjc5YjNfMTA3MTg_088346ad-306a-4b39-997b-529b5ddae36c"
      unitRef="plaintiff">36</us-gaap:LossContingencyNumberOfPlaintiffs>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i39e08dcc3f9f4795a07a40686f4f773d_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85Ny9mcmFnOjQyNjdmNTQxNzNkZjQzM2JiOWMyNjI4YzE2MzY3OWIzL3RleHRyZWdpb246NDI2N2Y1NDE3M2RmNDMzYmI5YzI2MjhjMTYzNjc5YjNfMTEwMDU_afdc15dc-f21c-4dcd-a475-e5da99a11ee9"
      unitRef="usd">514000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="i901bacdc1d384d90bd9435b24ae9e637_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85Ny9mcmFnOjQyNjdmNTQxNzNkZjQzM2JiOWMyNjI4YzE2MzY3OWIzL3RleHRyZWdpb246NDI2N2Y1NDE3M2RmNDMzYmI5YzI2MjhjMTYzNjc5YjNfMTE0OTc_98d9a4d5-6a2d-40f0-ba65-69226c4cbeed"
      unitRef="usd">1010000000.00</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i200d0dbf02ed453d87b6ed7ec2d17a53_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85Ny9mcmFnOjQyNjdmNTQxNzNkZjQzM2JiOWMyNjI4YzE2MzY3OWIzL3RleHRyZWdpb246NDI2N2Y1NDE3M2RmNDMzYmI5YzI2MjhjMTYzNjc5YjNfMTM0MDk_3351def5-371a-4ae8-b26f-c48d2642626f"
      unitRef="usd">-13000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <cah:ProceedsFromSettlementsOfClassActionLawsuits
      contextRef="i6be08e009bc84db19fea6af132f4df1c_D20210401-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV85Ny9mcmFnOjQyNjdmNTQxNzNkZjQzM2JiOWMyNjI4YzE2MzY3OWIzL3RleHRyZWdpb246NDI2N2Y1NDE3M2RmNDMzYmI5YzI2MjhjMTYzNjc5YjNfNTQ5NzU1ODE3MjE4MA_efa5188a-633e-4207-9ba7-e07cacb616bc"
      unitRef="usd">100000000</cah:ProceedsFromSettlementsOfClassActionLawsuits>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzkwNzE_dc610499-1014-47ac-a22a-553f718146d4">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;7. Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fluctuations in our provision for/(benefit from) income taxes as a percentage of pretax earnings (&#x201c;effective tax rate&#x201d;) are generally due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Tax Effects of Self-Insurance Pre-tax Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended March&#160;31, 2021, our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation. This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes. The net operating loss was carried back and adjusted our taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security ("CARES") Act enacted by the United States Congress in March 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accordingly, our provision for income taxes during the nine months ended March&#160;31, 2021 included a $419 million benefit from the net operating loss carryback primarily to reflect the difference between the federal statutory income tax rate during the fiscal years from 2015 to 2018 (35 percent for fiscal 2015, 2016, and 2017 and 28 percent for fiscal 2018) and the current federal statutory income tax rate of 21 percent.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have filed for a federal income tax refund of $974 million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have recorded a current asset on our condensed consolidated balance sheet at March&#160;31, 2021. We also increased our non-current deferred tax liability by approximately $700 million during the nine months ended March&#160;31, 2021 related to this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of tax law; however, it is possible that the tax authorities could challenge these tax benefits or that the tax law could change. The actual amount of the tax benefit may differ materially from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Tax Effects of Opioid Litigation Charges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the $1.02 billion and $5.63 billion pre-tax charges for the opioid litigation, during the nine months ended March&#160;31, 2021 and 2020, respectively, the net tax benefits are $37 million and $488 million for fiscal 2021 and 2020, respectively. Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized tax benefits of $35 million and $468 million, respectively. Due to our assessment of non-deductibility for certain components considered in the fiscal 2021 and 2020 charges, the tax benefit for fiscal 2021 compared to fiscal 2020 resulted in a relatively lower tax benefit. Our assumptions and estimates around this benefit and uncertain tax &lt;/span&gt;&lt;/div&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.214%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;position require significant judgment and the actual amount of tax benefit related to uncertain tax positions may differ materially from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings/(loss) before income taxes for the year-to-date period to compute our provision for/(benefit from) income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In conjunction with the initial opioid litigation accrual during the nine months ended March 31, 2020, the tax effect of the charge was treated as a discrete item because it was considered unusual or infrequent. However, the tax effect of the charge during the three months ended September 30, 2020 was included in our estimated annual effective tax rate because it was no longer considered unusual or infrequent. The inclusion of the relatively lower tax benefit of the current fiscal year charge in our estimated annual effective tax rate significantly increased the estimated annual effective tax rate for fiscal 2021. As such, the amount of tax expense increased by approximately $140 million during the three months ended March&#160;31, 2021 while the amount of tax benefit increased by approximately $180 million during the nine months ended March&#160;31, 2021 compared to the tax impacts that would have been recognized without the opioid litigation charge. As stated above, the benefit as of the end of fiscal 2021 is expected to be $37 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the U.S. Tax Cuts and Jobs Act ("Tax Act"); however, these estimates require significant judgment since the definitive settlement terms and documentation, including provisions related to deductibility, under the Settlement Framework have not been negotiated and the U.S. tax law governing deductibility was changed by the Tax Act. Further, it is possible that the tax authorities could challenge our interpretation of the Tax Act or the estimates and assumptions used to assess the future deductibility of these benefits or that the tax law could change. The actual amount of the tax benefit related to uncertain tax positions may differ materially from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Effective Tax Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended&#160;March&#160;31, 2021&#160;and&#160;2020, the effective tax rate was&#160;72.8 percent and&#160;26.8&#160;percent, respectively. The change in the effective tax rate compared to the prior period was primarily due to the adverse tax impacts of the opioid litigation accrual, the resolution of certain transfer pricing matters with the IRS and withholding taxes for planned distributions from foreign subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended&#160;March&#160;31, 2021&#160;and&#160;2020, the effective tax rate was (143.3)&#160;percent and&#160;5.2&#160;percent, &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.215%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;respectively. Included in the effective tax rate for the nine months ended March&#160;31, 2021 was the $419 million benefit from a net operating loss carryback primarily related to a self-insurance pre-tax loss. Included in both the nine months ended March&#160;31, 2021 and 2020 were net tax benefits related to the treatment of the tax impacts of opioid litigation charges. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Unrecognized Tax Benefits&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2021 and June&#160;30, 2020, we had $785 million and $998 million of unrecognized tax benefits, respectively. The March&#160;31, 2021 and June&#160;30, 2020 balances include $703 million and $753 million of unrecognized tax benefits, respectively, that if recognized, would have an impact on the effective tax rate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2021 and June&#160;30, 2020, we had $73 million and $146 million, respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the provision for/(benefit from) income taxes in the condensed consolidated statements of earnings/(loss). These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of IRS and other audit issues, reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between zero and a net decrease of up to $90 million, exclusive of penalties and interest.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Tax Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2011 through the current fiscal year. Tax laws are complex and subject to varying interpretations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), a subsidiary of Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. The indemnification receivable was $119 million and $176 million at March&#160;31, 2021 and June&#160;30, 2020, respectively, and is included in prepaid expenses and other assets and other assets in the condensed consolidated balance sheets. The indemnification receivable was reduced based on the ongoing negotiations with the IRS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the acquisition of the Patient Recovery Business, Medtronic plc is obligated to indemnify us for certain tax exposures and transaction taxes related to periods prior to the acquisition under the purchase agreement. The indemnification receivable was $19 million at both March&#160;31, 2021 and June&#160;30, 2020, &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;respectively, and is included in other assets in the condensed consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future adjustments to the financial statements may be necessary as final tax regulations related to U.S. Tax Reform are issued. We will assess any impact as additional guidance is issued.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if2d5ee4c8487424fb522d83601a9e4ed_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzEwOTY_4b03f236-d976-4408-9244-d82e018f0810"
      unitRef="usd">419000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxReceivable
      contextRef="i95e27bf6690f452f80d7e0a0bf7a1856_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzE0NjM_dbf99d17-fde6-43c9-9fe8-21d9f61fb298"
      unitRef="usd">974000000</us-gaap:IncomeTaxReceivable>
    <us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent
      contextRef="i95e27bf6690f452f80d7e0a0bf7a1856_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzE3NTE_8e37e07f-b42b-4ed6-a690-e5ae10d58cf4"
      unitRef="usd">700000000</us-gaap:DeferredTaxAndOtherLiabilitiesNoncurrent>
    <us-gaap:LitigationSettlementExpense
      contextRef="ib9e03386e8bb45b9bfa0b58a7c283f07_D20200701-20210331"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzIxNjc_cf1785e7-fdb9-4ef0-a6ca-a22606c2c490"
      unitRef="usd">1020000000.00</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i32ccdaa0f4af4c919f10cbbfa4cc9a79_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzIxNzQ_6b5d54da-be7d-49d2-93d0-bfc45ecdeb23"
      unitRef="usd">5630000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia19c49a9fdf94744a98048c92ed6d989_D20200701-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzIyODQ_7fe79880-c57f-41a9-a126-ca85bd2f30e0"
      unitRef="usd">37000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia48bb06cca3d4969bdeb6e18237b4224_D20190701-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzIyOTE_d75a112c-e833-40ea-a866-b2fa89033254"
      unitRef="usd">488000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i64ace7956a934516b089799b59bc6227_I20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzI1ODE_5d351a53-a799-4846-8a5c-16d4305f66f3"
      unitRef="usd">35000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i352533a8ebdc4e1ea369fbf8d0b0cb22_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzI1ODg_b4ca8382-ec39-43f5-9c80-bc1d9b687b6a"
      unitRef="usd">468000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2a9345a4d82147cbb391e59d3476b6af_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzU0OTc1NTgxNTEyNzY_203377f9-a47b-4a09-98c0-418df3e79391"
      unitRef="usd">-140000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ib9e03386e8bb45b9bfa0b58a7c283f07_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzU0OTc1NTgxNTEyOTU_7313bd39-e6b8-4c4c-a337-44b51e52cf88"
      unitRef="usd">180000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia19c49a9fdf94744a98048c92ed6d989_D20200701-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzU0OTc1NTgxNTEzMDM_7fe79880-c57f-41a9-a126-ca85bd2f30e0"
      unitRef="usd">37000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzU0NTg_17592b4e-429f-4abd-b571-abbd15ad45e4"
      unitRef="number">0.728</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzU0NzM_35dbd54c-1fcc-4402-965d-3eafa7538bb1"
      unitRef="number">0.268</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzU4MjE_29d1cc2c-e488-479c-934e-0cece025dbb8"
      unitRef="number">-1.433</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzU4MzY_9897c642-d9e2-4895-b3e2-e02a095936c9"
      unitRef="number">0.052</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if2d5ee4c8487424fb522d83601a9e4ed_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzU5NDg_4b03f236-d976-4408-9244-d82e018f0810"
      unitRef="usd">419000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzYyNTY_3ed02d9f-03ff-457b-888e-9a3e7ff0ef1d"
      unitRef="usd">785000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzYyNjM_6adbdbb3-4dfc-48cf-9d64-d21cf8813142"
      unitRef="usd">998000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzYzNDE_1ab86fcd-d81d-45af-89d4-e0e46e344b0f"
      unitRef="usd">703000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzYzNDg_2f4eab21-e26d-44b0-ab48-8078b16817e6"
      unitRef="usd">753000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzY0ODU_49357af9-e9b9-46aa-b811-e2b197db0965"
      unitRef="usd">73000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzY0OTI_e88f33e0-2c32-4155-a20b-30990fab079f"
      unitRef="usd">146000000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="ided1be8f67714ed8b59a2a7328872d54_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzczNzU_6cd0ac14-472b-45bd-881a-0af0665e62ec"
      unitRef="usd">0</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="ibfa1be8946614c2b9007346f625163d2_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5Xzc0MDY_98c4154b-ce06-4363-a627-1c238eedb040"
      unitRef="usd">90000000</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:OpenTaxYear
      contextRef="if4bf28e522354f2395213116e925d1b9_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5XzU0OTc1NTgxNTEyNDQ_f47a1064-dbd1-419b-9788-51e581495756">2011</us-gaap:OpenTaxYear>
    <cah:IndemnificationReceivable
      contextRef="i0e66f2887db842aa8968fdf63602e73d_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5Xzg0MDA_04c5cbff-fd4b-4153-b966-f1b3bc1653bb"
      unitRef="usd">119000000</cah:IndemnificationReceivable>
    <cah:IndemnificationReceivable
      contextRef="i2d53fc1dcd044ba08aabb87d0bbbcb75_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5Xzg0MDc_910bb01a-1d0a-443e-bdae-5f3da7db158e"
      unitRef="usd">176000000</cah:IndemnificationReceivable>
    <cah:IndemnificationReceivable
      contextRef="i49fd517f759e4c02bee7665cf6f0fc34_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5Xzg3ODE_22b846b9-7ec8-49ca-9f92-ffa97b641666"
      unitRef="usd">19000000</cah:IndemnificationReceivable>
    <cah:IndemnificationReceivable
      contextRef="i68ba2e46a7674cc8991710f46cdcb0b6_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDAvZnJhZzoyMWZiMTM3ZjI5ZGU0ZmU3YjhhNWE0YzUwNWFlYTk2OS90ZXh0cmVnaW9uOjIxZmIxMzdmMjlkZTRmZTdiOGE1YTRjNTA1YWVhOTY5Xzg3ODE_58f59b60-54c9-41c3-a7cc-3a8b8956fc44"
      unitRef="usd">19000000</cah:IndemnificationReceivable>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90ZXh0cmVnaW9uOjhlZTlkMTgxZGU4NzQ5NTA5ZGRlOGNjOTJiNmRiNThhXzEyMzM_f5a10dd5-9fde-40e1-8ee1-04bd46f59490">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;8. Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Assets and (Liabilities) Measured on a Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,944&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,944&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other investments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;118&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;118&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contracts (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;41&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;41&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other investments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contracts (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;The fair value of interest rate swaps, foreign currency contracts, commodity contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Assets and (Liabilities) Measured on a Nonrecurring Basis&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities held for sale of $1.1&#160;billion and $93 million, respectively, at March&#160;31, 2021 are primarily related to the planned divestiture of our Cordis business. These estimated fair values utilized Level 3 unobservable inputs based on expected sales proceeds following a competitive bidding process. See &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ib6bf45669ad94861b0c50dbc2f4371ce_1194" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 2&lt;/a&gt;&lt;/span&gt; for additional information regarding assets and liabilities held for sale.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90ZXh0cmVnaW9uOjhlZTlkMTgxZGU4NzQ5NTA5ZGRlOGNjOTJiNmRiNThhXzEyMzY_a46dd327-ef9c-4bf9-b77c-d2d0e5aa04d8">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,944&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,944&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other investments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;118&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;118&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contracts (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;41&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;41&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.938%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other investments (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Forward contracts (2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;The fair value of interest rate swaps, foreign currency contracts, commodity contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Assets and (Liabilities) Measured on a Nonrecurring Basis&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities held for sale of $1.1&#160;billion and $93 million, respectively, at March&#160;31, 2021 are primarily related to the planned divestiture of our Cordis business. These estimated fair values utilized Level 3 unobservable inputs based on expected sales proceeds following a competitive bidding process. See &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ib6bf45669ad94861b0c50dbc2f4371ce_1194" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 2&lt;/a&gt;&lt;/span&gt; for additional information regarding assets and liabilities held for sale.</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i31c9d1ab6ad74ad6be84ceec57e39a73_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90YWJsZTozNDk0ZWUyYWIyMmI0NzAyYjc2YTYzYWFiMDk3NDlkNS90YWJsZXJhbmdlOjM0OTRlZTJhYjIyYjQ3MDJiNzZhNjNhYWIwOTc0OWQ1XzMtMS0xLTEtMA_50d0818b-cae8-4bf3-99cd-c3a345c451c5"
      unitRef="usd">1944000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id1c063a9eef24440b68b23b7cc020697_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90YWJsZTozNDk0ZWUyYWIyMmI0NzAyYjc2YTYzYWFiMDk3NDlkNS90YWJsZXJhbmdlOjM0OTRlZTJhYjIyYjQ3MDJiNzZhNjNhYWIwOTc0OWQ1XzMtMy0xLTEtMA_3f8ce857-f9b2-4f2a-8e62-a3bed40a34d3"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ieb9fc5025c56429290c144a9ab02add4_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90YWJsZTozNDk0ZWUyYWIyMmI0NzAyYjc2YTYzYWFiMDk3NDlkNS90YWJsZXJhbmdlOjM0OTRlZTJhYjIyYjQ3MDJiNzZhNjNhYWIwOTc0OWQ1XzMtNS0xLTEtMA_a436fe26-e716-42fc-a1b6-3421116c32a7"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia215aea801f34ad985846f37619f80f0_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90YWJsZTozNDk0ZWUyYWIyMmI0NzAyYjc2YTYzYWFiMDk3NDlkNS90YWJsZXJhbmdlOjM0OTRlZTJhYjIyYjQ3MDJiNzZhNjNhYWIwOTc0OWQ1XzMtNy0xLTEtMA_51663c83-359a-47d4-b4e4-fc29279f5519"
      unitRef="usd">1944000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i31c9d1ab6ad74ad6be84ceec57e39a73_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90YWJsZTozNDk0ZWUyYWIyMmI0NzAyYjc2YTYzYWFiMDk3NDlkNS90YWJsZXJhbmdlOjM0OTRlZTJhYjIyYjQ3MDJiNzZhNjNhYWIwOTc0OWQ1XzUtMS0xLTEtMA_a148a4dc-1edb-4a89-8c99-c29ea9cce1b6"
      unitRef="usd">118000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="id1c063a9eef24440b68b23b7cc020697_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90YWJsZTozNDk0ZWUyYWIyMmI0NzAyYjc2YTYzYWFiMDk3NDlkNS90YWJsZXJhbmdlOjM0OTRlZTJhYjIyYjQ3MDJiNzZhNjNhYWIwOTc0OWQ1XzUtMy0xLTEtMA_341df822-4812-401f-b381-3cba09444905"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ieb9fc5025c56429290c144a9ab02add4_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90YWJsZTozNDk0ZWUyYWIyMmI0NzAyYjc2YTYzYWFiMDk3NDlkNS90YWJsZXJhbmdlOjM0OTRlZTJhYjIyYjQ3MDJiNzZhNjNhYWIwOTc0OWQ1XzUtNS0xLTEtMA_56cfb8ab-0480-4418-997c-2dd98788b42b"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ia215aea801f34ad985846f37619f80f0_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90YWJsZTozNDk0ZWUyYWIyMmI0NzAyYjc2YTYzYWFiMDk3NDlkNS90YWJsZXJhbmdlOjM0OTRlZTJhYjIyYjQ3MDJiNzZhNjNhYWIwOTc0OWQ1XzUtNy0xLTEtMA_f9e8d67d-965f-4450-983c-6479b24b97fa"
      unitRef="usd">118000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="i31c9d1ab6ad74ad6be84ceec57e39a73_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90YWJsZTozNDk0ZWUyYWIyMmI0NzAyYjc2YTYzYWFiMDk3NDlkNS90YWJsZXJhbmdlOjM0OTRlZTJhYjIyYjQ3MDJiNzZhNjNhYWIwOTc0OWQ1XzYtMS0xLTEtMA_fc8242b2-2f07-4cae-ad7b-6dcf3622498f"
      unitRef="usd">0</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="id1c063a9eef24440b68b23b7cc020697_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90YWJsZTozNDk0ZWUyYWIyMmI0NzAyYjc2YTYzYWFiMDk3NDlkNS90YWJsZXJhbmdlOjM0OTRlZTJhYjIyYjQ3MDJiNzZhNjNhYWIwOTc0OWQ1XzYtMy0xLTEtMA_1d25dac7-b2a2-44fd-9626-77ea45fec9da"
      unitRef="usd">41000000</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="ieb9fc5025c56429290c144a9ab02add4_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90YWJsZTozNDk0ZWUyYWIyMmI0NzAyYjc2YTYzYWFiMDk3NDlkNS90YWJsZXJhbmdlOjM0OTRlZTJhYjIyYjQ3MDJiNzZhNjNhYWIwOTc0OWQ1XzYtNS0xLTEtMA_afb15200-a8af-4fe4-a5f1-03d2d560e2f3"
      unitRef="usd">0</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="ia215aea801f34ad985846f37619f80f0_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90YWJsZTozNDk0ZWUyYWIyMmI0NzAyYjc2YTYzYWFiMDk3NDlkNS90YWJsZXJhbmdlOjM0OTRlZTJhYjIyYjQ3MDJiNzZhNjNhYWIwOTc0OWQ1XzYtNy0xLTEtMA_c16ff2e7-c1cb-43af-a9d1-7beab1e065fa"
      unitRef="usd">41000000</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1f7d6a255b6d43b7a97b861817531138_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90YWJsZToyMzYwYTE2ZGRiZmM0MGJhOTFhNDZkMjM5MzcxMmUwYS90YWJsZXJhbmdlOjIzNjBhMTZkZGJmYzQwYmE5MWE0NmQyMzkzNzEyZTBhXzMtMS0xLTEtMA_5f99a255-b3fd-4974-ba38-0200bd826e9b"
      unitRef="usd">721000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i80081b312cf4449bb7fe8a2f4e5535d7_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90YWJsZToyMzYwYTE2ZGRiZmM0MGJhOTFhNDZkMjM5MzcxMmUwYS90YWJsZXJhbmdlOjIzNjBhMTZkZGJmYzQwYmE5MWE0NmQyMzkzNzEyZTBhXzMtMy0xLTEtMA_3c1c5c3d-adc9-4fd9-bca3-ef13df41056c"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9020f748109a4007908680bcbacb5e56_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90YWJsZToyMzYwYTE2ZGRiZmM0MGJhOTFhNDZkMjM5MzcxMmUwYS90YWJsZXJhbmdlOjIzNjBhMTZkZGJmYzQwYmE5MWE0NmQyMzkzNzEyZTBhXzMtNS0xLTEtMA_bd944a78-4246-4bad-8cbe-256d1fe88046"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2bde8641630642bf8d5434c1fadce5ef_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90YWJsZToyMzYwYTE2ZGRiZmM0MGJhOTFhNDZkMjM5MzcxMmUwYS90YWJsZXJhbmdlOjIzNjBhMTZkZGJmYzQwYmE5MWE0NmQyMzkzNzEyZTBhXzMtNy0xLTEtMA_5593b75b-09aa-4f53-8ab5-915be9b27730"
      unitRef="usd">721000000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i1f7d6a255b6d43b7a97b861817531138_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90YWJsZToyMzYwYTE2ZGRiZmM0MGJhOTFhNDZkMjM5MzcxMmUwYS90YWJsZXJhbmdlOjIzNjBhMTZkZGJmYzQwYmE5MWE0NmQyMzkzNzEyZTBhXzUtMS0xLTEtMA_5f9e516d-d036-4cb3-ae7a-47da965904ec"
      unitRef="usd">114000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i80081b312cf4449bb7fe8a2f4e5535d7_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90YWJsZToyMzYwYTE2ZGRiZmM0MGJhOTFhNDZkMjM5MzcxMmUwYS90YWJsZXJhbmdlOjIzNjBhMTZkZGJmYzQwYmE5MWE0NmQyMzkzNzEyZTBhXzUtMy0xLTEtMA_80d59e42-0ca3-4941-b9a5-5752a2a7a2c6"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i9020f748109a4007908680bcbacb5e56_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90YWJsZToyMzYwYTE2ZGRiZmM0MGJhOTFhNDZkMjM5MzcxMmUwYS90YWJsZXJhbmdlOjIzNjBhMTZkZGJmYzQwYmE5MWE0NmQyMzkzNzEyZTBhXzUtNS0xLTEtMA_fced72dc-2586-45ae-8128-4dfc9f31873a"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i2bde8641630642bf8d5434c1fadce5ef_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90YWJsZToyMzYwYTE2ZGRiZmM0MGJhOTFhNDZkMjM5MzcxMmUwYS90YWJsZXJhbmdlOjIzNjBhMTZkZGJmYzQwYmE5MWE0NmQyMzkzNzEyZTBhXzUtNy0xLTEtMA_7a3431fa-dc7e-42b2-8184-da155a9e2551"
      unitRef="usd">114000000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="i1f7d6a255b6d43b7a97b861817531138_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90YWJsZToyMzYwYTE2ZGRiZmM0MGJhOTFhNDZkMjM5MzcxMmUwYS90YWJsZXJhbmdlOjIzNjBhMTZkZGJmYzQwYmE5MWE0NmQyMzkzNzEyZTBhXzYtMS0xLTEtMA_54fe9620-6512-44a7-ac97-0f846618c261"
      unitRef="usd">0</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="i80081b312cf4449bb7fe8a2f4e5535d7_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90YWJsZToyMzYwYTE2ZGRiZmM0MGJhOTFhNDZkMjM5MzcxMmUwYS90YWJsZXJhbmdlOjIzNjBhMTZkZGJmYzQwYmE5MWE0NmQyMzkzNzEyZTBhXzYtMy0xLTEtMA_d4fb827d-d4d0-4a15-911f-1f17b2683387"
      unitRef="usd">53000000</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="i9020f748109a4007908680bcbacb5e56_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90YWJsZToyMzYwYTE2ZGRiZmM0MGJhOTFhNDZkMjM5MzcxMmUwYS90YWJsZXJhbmdlOjIzNjBhMTZkZGJmYzQwYmE5MWE0NmQyMzkzNzEyZTBhXzYtNS0xLTEtMA_5a6f1344-d66f-4994-9c24-29ec2aec0f6c"
      unitRef="usd">0</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet
      contextRef="i2bde8641630642bf8d5434c1fadce5ef_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90YWJsZToyMzYwYTE2ZGRiZmM0MGJhOTFhNDZkMjM5MzcxMmUwYS90YWJsZXJhbmdlOjIzNjBhMTZkZGJmYzQwYmE5MWE0NmQyMzkzNzEyZTBhXzYtNy0xLTEtMA_e23843f3-1ffe-484d-9271-53b36d19fe81"
      unitRef="usd">53000000</us-gaap:DerivativeAssetsLiabilitiesAtFairValueNet>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="i5987d078d03f4fc38046fb86086b6b1e_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90ZXh0cmVnaW9uOjhlZTlkMTgxZGU4NzQ5NTA5ZGRlOGNjOTJiNmRiNThhXzQzOTgwNDY1MTQzOTk_8cc18e40-254a-4deb-8004-7e6b7b19f4a0"
      unitRef="usd">1100000000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDMvZnJhZzo4ZWU5ZDE4MWRlODc0OTUwOWRkZThjYzkyYjZkYjU4YS90ZXh0cmVnaW9uOjhlZTlkMTgxZGU4NzQ5NTA5ZGRlOGNjOTJiNmRiNThhXzMyOTg1MzQ4ODY1MTY_7ac23b53-c840-40f2-919e-f3ce782662c9"
      unitRef="usd">93000000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzgxMTc_04d878b6-268a-4c19-b1e3-31f92598a91d">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;9. Financial Instruments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments. These derivative instruments are adjusted to current fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated investment grade or better. We do not have significant exposure to any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Interest Rate Risk Management&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities along with both fixed-rate and variable-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Currency Exchange Risk Management&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments and anticipated foreign currency revenue and expenses.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Commodity Price Risk Management&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Fair Value Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the condensed consolidated statements of &lt;/span&gt;&lt;/div&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.214%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;earnings/(loss). For the three and nine months ended March&#160;31, 2021 and 2020, there was no gain or loss recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the three and nine months ended March&#160;31, 2021, we unwound certain interest rate swap contracts with the notional amount of $550&#160;million. In connection with the unwind of these contracts, we received cash proceeds of $18&#160;million. The related gain will be recognized in interest expense, net in our statements of earnings/(loss) over the remaining term of the debt agreement, which matures in March 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the three and nine months ended March&#160;31, 2021, we entered into a pay-floating interest rate swap with total notional amounts of $200&#160;million. This swap has been designated as fair value hedges of our fixed rate debt and is included in deferred income taxes and other liabilities in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the debt repayment as described in &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ib6bf45669ad94861b0c50dbc2f4371ce_94" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 5&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, two pay-floating interest rate swaps with notional amounts of $200 million matured in the second quarter of fiscal 2020. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Cash Flow Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the nine months ended March&#160;31, 2020, we entered into forward interest rate swaps with a total notional amount of $200&#160;million to hedge probable, but not firmly committed, future transactions associated with our debt. During the three and nine months ended March&#160;31, 2021, we terminated these swaps &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;and reclassified an immaterial deferred gain from accumulated other comprehensive loss into interest expense, net in our condensed consolidated statements of earnings/(loss) because the forecasted transactions were probable of not occurring&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. At March&#160;31, 2021, we had no outstanding forward interest rate swaps designated as cash-flow hedges.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Pre-tax gain and loss recognized in other comprehensive loss was a $13&#160;million gain and a $20&#160;million loss during the three months ended March&#160;31, 2021 and 2020, respectively, and a $20&#160;million gain and a $20&#160;million loss in the nine months ended March&#160;31, 2021 and 2020, respectively. Gains and losses recognized in accumulated other comprehensive loss and reclassified into earnings were immaterial for the three and nine months ended March&#160;31, 2021 and 2020. All gains and losses currently included within accumulated other comprehensive loss associated with our &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.215%"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;cash flow hedges to be reclassified into net earnings within the next 12 months are immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Net Investment Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2019, we entered into a &#xa5;64.0 billion ($600 million) cross-currency swap maturing in 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cross-currency swaps designated as net investment hedges are marked to market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive loss until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pre-tax gain and loss from net investment hedges recorded in the foreign currency translation component of accumulated other comprehensive loss was a $49&#160;million gain and a $18&#160;million gain during the three months ended March&#160;31, 2021 and 2020, respectively, and a $3&#160;million loss and a $35&#160;million gain during the nine months ended March&#160;31, 2021 and 2020, respectively. Gains recognized in interest expense, net in the condensed consolidated statements of earnings/(loss) for the portion of the net investment hedges excluded from the assessment of hedge effectiveness were $5&#160;million during the three months ended March&#160;31, 2021 and 2020, and $14&#160;million and $11&#160;million during the nine months ended March&#160;31, 2021 and 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Economic (Non-Designated) Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. We recorded a $4 million loss and $7 million loss during the nine months ended March&#160;31, 2021 and 2020, respectively. The principal currencies managed through foreign currency contracts are Chinese renminbi, Canadian dollar, European euro and Japanese yen.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of cash and equivalents, trade receivables, accounts payable and other accrued liabilities at March&#160;31, 2021 and June&#160;30, 2020 approximate fair value due to their short-term maturities.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,177&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,731&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.&lt;/span&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzMyODA_1b58bee9-3a3a-4819-a584-5735c586516e"
      unitRef="usd">0</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzMyODA_2fad7b25-70b4-4ef7-821d-881863601977"
      unitRef="usd">0</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzMyODA_798173f9-9964-4d01-8f67-89644f5f1df4"
      unitRef="usd">0</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzMyODA_ced2585f-12eb-4739-bd06-5ad6982c9dd8"
      unitRef="usd">0</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <cah:DerivativesHedgeDiscontinuancesHeadingInstrumentTerminatedAmount
      contextRef="i949ddfae3947416db45abfd64c94adeb_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzQzOTgwNDY1NDEzODg_745ff314-a1b2-4f74-9430-53107ad115bf"
      unitRef="usd">550000000</cah:DerivativesHedgeDiscontinuancesHeadingInstrumentTerminatedAmount>
    <us-gaap:DeferredGainLossOnDiscontinuationOfInterestRateFairValueHedge
      contextRef="i87eabc19117047338578608b2ee7dcd4_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzQzOTgwNDY1NDE0MDI_a24a270f-2184-4d77-ac39-aa22872d975c"
      unitRef="usd">18000000</us-gaap:DeferredGainLossOnDiscontinuationOfInterestRateFairValueHedge>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i949ddfae3947416db45abfd64c94adeb_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzQzOTgwNDY1NDEzNzQ_fd0cc4aa-a759-4a1e-b9ba-5bebc8883379"
      unitRef="usd">200000000</us-gaap:DerivativeLiabilityNotionalAmount>
    <cah:DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount
      contextRef="i949ddfae3947416db45abfd64c94adeb_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzM1Njk_8f09cf9c-51d6-4fcb-a192-5354796ee381"
      unitRef="usd">200000000</cah:DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i334e47c1f3ff45dcb6b4856094c8f1c0_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzMyOTg1MzQ4OTQ4NDA_c85276ea-8c5a-45ca-8226-94fa48e2683d"
      unitRef="usd">200000000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax
      contextRef="i58ec7cecb23b4f45bed4e5c64a8bb562_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzQ0NzI_5c9ae38c-d57f-4059-90dc-e628f38f5c49"
      unitRef="usd">13000000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax
      contextRef="if1af6bf6a64a4c77ba66fed4c716d945_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzMyOTg1MzQ4OTY4NjA_db69537a-b091-4c93-bbdc-2fcb25fa373f"
      unitRef="usd">20000000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax
      contextRef="if1af6bf6a64a4c77ba66fed4c716d945_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzQzOTgwNDY1MjQ4NTc_db69537a-b091-4c93-bbdc-2fcb25fa373f"
      unitRef="usd">20000000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax
      contextRef="ia42786050a004af0aedbbe0f8357c727_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzQzOTgwNDY1NDA5MzY_a5623e8e-4292-4cc9-987b-3bde2f3dff71"
      unitRef="usd">20000000</us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="ia8c1b38a8f8d4adf9f86653e53b0dd5c_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzUyMTI_fde73531-887b-4b24-8049-719d26a52a39"
      unitRef="jpy">64000000000.0</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="ia8c1b38a8f8d4adf9f86653e53b0dd5c_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzUyMTY_8a72e78e-601a-47ec-8e11-ed0d94651566"
      unitRef="usd">600000000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="i532e1aadd9b146e7ae42838aec9fcb8c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzU5NDA_a460193a-b43a-4cc4-80c1-c874cb7db0ee"
      unitRef="usd">49000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="ic014c1b02128475ba87eda0763cfdcc4_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzU5NTQ_a4009024-b5dc-43cb-bbba-e26acd2e1889"
      unitRef="usd">18000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="ib3205d5053724d48900805160556c3d0_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzYwMjM_e00f10d2-1b32-46fa-816a-70aab41c44d7"
      unitRef="usd">3000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="ifa27c7b19457466dabe317a3abbbb6df_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzYwMzc_1435582e-c883-4523-8d99-4d3cee65fe3e"
      unitRef="usd">35000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="ic014c1b02128475ba87eda0763cfdcc4_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzYzMDI_49559073-4396-42df-8721-a3b4d9a64e82"
      unitRef="usd">5000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i532e1aadd9b146e7ae42838aec9fcb8c_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzYzMDI_b1add902-c5c0-4481-bf1d-df2dd8772eb4"
      unitRef="usd">5000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="ib3205d5053724d48900805160556c3d0_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzYzNTA_1d27525e-1658-4652-b949-a2d45b77913f"
      unitRef="usd">14000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="ifa27c7b19457466dabe317a3abbbb6df_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzYzNTc_bd9aac94-a747-44ff-9b66-5e51d35afb53"
      unitRef="usd">11000000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i6794b69d98f24573ba346bd46b22a10a_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzcyNzM_89b7a395-cdc2-413c-8452-7a6fa178f797"
      unitRef="usd">4000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="i06a14268e5cb46ffb7dbf7a3ce7660f6_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzcyODU_0cb5fe03-8b08-478d-bb2c-9c937910be68"
      unitRef="usd">-7000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90ZXh0cmVnaW9uOjRhNDU0ZWY0MmVjODQ0ZDQ4ZjgzZDJlOTllMDc3ZGUzXzgxMjI_6e0f623a-becc-415e-b3ee-c771bf6502e9">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.062%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Estimated fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;7,177&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Carrying amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;6,731&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:DebtInstrumentFairValue
      contextRef="ie14f3bec98e9401e9d0262da4f2de10b_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90YWJsZTo4NjJkNzBlOTkxYTI0ZDA1YTgyNzc3NDVjMjM3ODNhYi90YWJsZXJhbmdlOjg2MmQ3MGU5OTFhMjRkMDVhODI3Nzc0NWMyMzc4M2FiXzEtMS0xLTEtMA_8d98a938-87fe-4fe5-ba49-b5fda9b2e451"
      unitRef="usd">7177000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i9ef4ab475d104948a5835edf958fa41a_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90YWJsZTo4NjJkNzBlOTkxYTI0ZDA1YTgyNzc3NDVjMjM3ODNhYi90YWJsZXJhbmdlOjg2MmQ3MGU5OTFhMjRkMDVhODI3Nzc0NWMyMzc4M2FiXzEtMy0xLTEtMA_a3411dbb-d2c4-4ef4-b82e-d0825c39d775"
      unitRef="usd">7273000000</us-gaap:DebtInstrumentFairValue>
    <cah:CarryingAmountofLongTermandotherShortTermBorrowings
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90YWJsZTo4NjJkNzBlOTkxYTI0ZDA1YTgyNzc3NDVjMjM3ODNhYi90YWJsZXJhbmdlOjg2MmQ3MGU5OTFhMjRkMDVhODI3Nzc0NWMyMzc4M2FiXzItMS0xLTEtMA_aa8517fe-731c-4084-a251-91cc96b8c723"
      unitRef="usd">6731000000</cah:CarryingAmountofLongTermandotherShortTermBorrowings>
    <cah:CarryingAmountofLongTermandotherShortTermBorrowings
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDYvZnJhZzo0YTQ1NGVmNDJlYzg0NGQ0OGY4M2QyZTk5ZTA3N2RlMy90YWJsZTo4NjJkNzBlOTkxYTI0ZDA1YTgyNzc3NDVjMjM3ODNhYi90YWJsZXJhbmdlOjg2MmQ3MGU5OTFhMjRkMDVhODI3Nzc0NWMyMzc4M2FiXzItMy0xLTEtMA_bab0863f-bc5c-48dc-a0ea-c4e0e95947a9"
      unitRef="usd">6775000000</cah:CarryingAmountofLongTermandotherShortTermBorrowings>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90ZXh0cmVnaW9uOmFlMzIyYjFkYmM3ZjRiYTBiOWFhNzk1NjdhOWE4YTMzXzY0NQ_06e666b7-ec49-4562-94eb-cb207fba0fcf">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;10. Shareholders' Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended March&#160;31, 2021, we repurchased 3.7 million common shares having an aggregate cost of $200 million. The average price paid per common share was $54.40. These repurchases were made under an accelerated share repurchase ("ASR") program, which began on February 9, 2021 and was completed on March 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended March 31, 2020, we repurchased 7.3 million common shares having an aggregate cost of $350 million. The average price paid per common share was $48.00. These repurchases were made under an ASR program, which began on August 20, 2019 and was completed on December 4, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We funded the repurchases with available cash and short-term borrowings. The common shares repurchased are held in treasury to be used for general corporate purposes.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.050%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign&lt;br/&gt;Currency&lt;br/&gt;Translation&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized&lt;br/&gt;Gain/(Loss) on&lt;br/&gt;Derivatives,&lt;br/&gt;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated Other&lt;br/&gt;Comprehensive&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income, before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;53&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified to earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other comprehensive income attributable to Cardinal Health, Inc. net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;56&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="if8b3edc49b1248e896c9ddae3b113611_D20200701-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90ZXh0cmVnaW9uOmFlMzIyYjFkYmM3ZjRiYTBiOWFhNzk1NjdhOWE4YTMzXzU0OTc1NTgxMzk2NDI_0ac54078-d43d-4e42-864a-3ce8c75e009b"
      unitRef="shares">3700000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i3ca53978778d45b291d32f2884428093_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90ZXh0cmVnaW9uOmFlMzIyYjFkYmM3ZjRiYTBiOWFhNzk1NjdhOWE4YTMzXzU0OTc1NTgxMzk2NDI_67c5031b-d3f1-44d4-909e-57f249f400d1"
      unitRef="shares">3700000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90ZXh0cmVnaW9uOmFlMzIyYjFkYmM3ZjRiYTBiOWFhNzk1NjdhOWE4YTMzXzU0OTc1NTgxMzk2MTM_407d73a9-d30d-49fc-ab54-bf8d1bd62eec"
      unitRef="usd">200000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90ZXh0cmVnaW9uOmFlMzIyYjFkYmM3ZjRiYTBiOWFhNzk1NjdhOWE4YTMzXzU0OTc1NTgxMzk2MTM_ba84e18a-409e-4c7f-a903-b9ad007a600d"
      unitRef="usd">200000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="if8b3edc49b1248e896c9ddae3b113611_D20200701-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90ZXh0cmVnaW9uOmFlMzIyYjFkYmM3ZjRiYTBiOWFhNzk1NjdhOWE4YTMzXzU0OTc1NTgxMzk2NTQ_3e279028-f05b-4eff-a835-da5e09916f9a"
      unitRef="usdPerShare">54.40</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i3ca53978778d45b291d32f2884428093_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90ZXh0cmVnaW9uOmFlMzIyYjFkYmM3ZjRiYTBiOWFhNzk1NjdhOWE4YTMzXzU0OTc1NTgxMzk2NTQ_4f7729f9-db1d-4e69-a12b-8a7e3069b913"
      unitRef="usdPerShare">54.40</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i8e9b39d228bb4305a9f94d21ff2986b6_D20190701-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90ZXh0cmVnaW9uOmFlMzIyYjFkYmM3ZjRiYTBiOWFhNzk1NjdhOWE4YTMzXzU0OTc1NTgxNDA0NTk_c0aef39e-b993-4f79-a007-4085b0b7b6e9"
      unitRef="shares">7300000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90ZXh0cmVnaW9uOmFlMzIyYjFkYmM3ZjRiYTBiOWFhNzk1NjdhOWE4YTMzXzU0OTc1NTgxNDA0NDE_23de761d-f6c5-4b41-8dba-ff274c12d2ef"
      unitRef="usd">350000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i8e9b39d228bb4305a9f94d21ff2986b6_D20190701-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90ZXh0cmVnaW9uOmFlMzIyYjFkYmM3ZjRiYTBiOWFhNzk1NjdhOWE4YTMzXzU0OTc1NTgxNDA0NzY_760ad2e4-5c1d-4b43-a252-e5e40ea04587"
      unitRef="usdPerShare">48.00</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90ZXh0cmVnaW9uOmFlMzIyYjFkYmM3ZjRiYTBiOWFhNzk1NjdhOWE4YTMzXzY1Mw_8d5fa712-e214-48b0-bba8-7a1b57066646">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.875%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.050%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign&lt;br/&gt;Currency&lt;br/&gt;Translation&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized&lt;br/&gt;Gain/(Loss) on&lt;br/&gt;Derivatives,&lt;br/&gt;net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accumulated Other&lt;br/&gt;Comprehensive&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income, before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;53&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified to earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other comprehensive income attributable to Cardinal Health, Inc. net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;56&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i10d07f0a48104550b0a508675603448e_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90YWJsZTo1MWZhZDUzMDdiYzQ0OTc5YWM2NjhjODlmM2NmZWIwNy90YWJsZXJhbmdlOjUxZmFkNTMwN2JjNDQ5NzlhYzY2OGM4OWYzY2ZlYjA3XzEtMS0xLTEtMA_d99c2db0-0db0-4203-ba68-4f9691152246"
      unitRef="usd">-92000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie27ad5c522f44e8b90817308ed523e4d_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90YWJsZTo1MWZhZDUzMDdiYzQ0OTc5YWM2NjhjODlmM2NmZWIwNy90YWJsZXJhbmdlOjUxZmFkNTMwN2JjNDQ5NzlhYzY2OGM4OWYzY2ZlYjA3XzEtMy0xLTEtMA_643d4a75-46a9-4ff9-b3f3-371046deb5a2"
      unitRef="usd">-12000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2b25597e1abd4762a53125bd127a7fc6_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90YWJsZTo1MWZhZDUzMDdiYzQ0OTc5YWM2NjhjODlmM2NmZWIwNy90YWJsZXJhbmdlOjUxZmFkNTMwN2JjNDQ5NzlhYzY2OGM4OWYzY2ZlYjA3XzEtNS0xLTEtMA_34e77afe-aba6-480e-97b8-4d1066d3d35a"
      unitRef="usd">-104000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ie2cfce8a58cc495e9d881af0122e343d_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90YWJsZTo1MWZhZDUzMDdiYzQ0OTc5YWM2NjhjODlmM2NmZWIwNy90YWJsZXJhbmdlOjUxZmFkNTMwN2JjNDQ5NzlhYzY2OGM4OWYzY2ZlYjA3XzItMS0xLTEtMA_22bd83c0-15b1-4fed-9582-04372191b391"
      unitRef="usd">42000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i0ecadae65dfb4b55ab6336e5e1372f5e_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90YWJsZTo1MWZhZDUzMDdiYzQ0OTc5YWM2NjhjODlmM2NmZWIwNy90YWJsZXJhbmdlOjUxZmFkNTMwN2JjNDQ5NzlhYzY2OGM4OWYzY2ZlYjA3XzItMy0xLTEtMA_3b07f49c-fcab-4212-9a3c-37906d3244c9"
      unitRef="usd">11000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ic3a494cf37a0408c9c5282b7bacaf665_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90YWJsZTo1MWZhZDUzMDdiYzQ0OTc5YWM2NjhjODlmM2NmZWIwNy90YWJsZXJhbmdlOjUxZmFkNTMwN2JjNDQ5NzlhYzY2OGM4OWYzY2ZlYjA3XzItNS0xLTEtMA_37f2c3e5-e821-4b03-bc53-3a1c8b718f0d"
      unitRef="usd">53000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ie2cfce8a58cc495e9d881af0122e343d_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90YWJsZTo1MWZhZDUzMDdiYzQ0OTc5YWM2NjhjODlmM2NmZWIwNy90YWJsZXJhbmdlOjUxZmFkNTMwN2JjNDQ5NzlhYzY2OGM4OWYzY2ZlYjA3XzMtMS0xLTEtMA_cf9ffed9-2208-4073-9799-f597d0e7488d"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i0ecadae65dfb4b55ab6336e5e1372f5e_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90YWJsZTo1MWZhZDUzMDdiYzQ0OTc5YWM2NjhjODlmM2NmZWIwNy90YWJsZXJhbmdlOjUxZmFkNTMwN2JjNDQ5NzlhYzY2OGM4OWYzY2ZlYjA3XzMtMy0xLTEtMA_a4bbbe8d-79a1-48f0-8c8e-3c0695688beb"
      unitRef="usd">-3000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ic3a494cf37a0408c9c5282b7bacaf665_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90YWJsZTo1MWZhZDUzMDdiYzQ0OTc5YWM2NjhjODlmM2NmZWIwNy90YWJsZXJhbmdlOjUxZmFkNTMwN2JjNDQ5NzlhYzY2OGM4OWYzY2ZlYjA3XzMtNS0xLTEtMA_d8c8fef3-feb9-46fa-bb45-855de7a6ea47"
      unitRef="usd">-3000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie2cfce8a58cc495e9d881af0122e343d_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90YWJsZTo1MWZhZDUzMDdiYzQ0OTc5YWM2NjhjODlmM2NmZWIwNy90YWJsZXJhbmdlOjUxZmFkNTMwN2JjNDQ5NzlhYzY2OGM4OWYzY2ZlYjA3XzQtMS0xLTEtMA_f5751945-18f0-47b8-b9fc-b7261202fcda"
      unitRef="usd">42000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i0ecadae65dfb4b55ab6336e5e1372f5e_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90YWJsZTo1MWZhZDUzMDdiYzQ0OTc5YWM2NjhjODlmM2NmZWIwNy90YWJsZXJhbmdlOjUxZmFkNTMwN2JjNDQ5NzlhYzY2OGM4OWYzY2ZlYjA3XzQtMy0xLTEtMA_77fb82dc-3121-4958-b9af-6a1cfe4f124e"
      unitRef="usd">14000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6b80eecd6d274b6099620f1435d44f65_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90YWJsZTo1MWZhZDUzMDdiYzQ0OTc5YWM2NjhjODlmM2NmZWIwNy90YWJsZXJhbmdlOjUxZmFkNTMwN2JjNDQ5NzlhYzY2OGM4OWYzY2ZlYjA3XzQtNS0xLTEtMA_6c4ab9a4-6433-454c-9138-d35059cd8d15"
      unitRef="usd">56000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib1282072a9944c75994cdaf150f6cae9_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90YWJsZTo1MWZhZDUzMDdiYzQ0OTc5YWM2NjhjODlmM2NmZWIwNy90YWJsZXJhbmdlOjUxZmFkNTMwN2JjNDQ5NzlhYzY2OGM4OWYzY2ZlYjA3XzUtMS0xLTEtMA_0e1335f5-154e-4e68-b646-cb26a3ab4e17"
      unitRef="usd">-50000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9e2d2af534744410b83b2b8c23ceae67_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90YWJsZTo1MWZhZDUzMDdiYzQ0OTc5YWM2NjhjODlmM2NmZWIwNy90YWJsZXJhbmdlOjUxZmFkNTMwN2JjNDQ5NzlhYzY2OGM4OWYzY2ZlYjA3XzUtMy0xLTEtMA_454bb963-0adf-45bd-9ea4-a8d0cbd5e0b5"
      unitRef="usd">2000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i678e5905c5c04646a1adad096e2142a5_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMDkvZnJhZzphZTMyMmIxZGJjN2Y0YmEwYjlhYTc5NTY3YTlhOGEzMy90YWJsZTo1MWZhZDUzMDdiYzQ0OTc5YWM2NjhjODlmM2NmZWIwNy90YWJsZXJhbmdlOjUxZmFkNTMwN2JjNDQ5NzlhYzY2OGM4OWYzY2ZlYjA3XzUtNS0xLTEtMA_e3686501-aaab-4c96-83af-f34917e8b067"
      unitRef="usd">-48000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTIvZnJhZzpjNDI3MTY1ODMzOWQ0N2Q1YmE5Njc4YmYxODdiNThkZS90ZXh0cmVnaW9uOmM0MjcxNjU4MzM5ZDQ3ZDViYTk2NzhiZjE4N2I1OGRlXzU5OQ_bdb27f7c-e9de-4571-838b-7487f0b109c7">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;11. Earnings/(Loss) Per Share Attributable to Cardinal Health, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares&#x2013;basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;292&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock options, restricted share units and performance share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average common shares&#x2013;diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;294&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares&#x2013;basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;293&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock options, restricted share units and performance share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average common shares&#x2013;diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;294&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The potentially dilutive employee stock options, restricted share units and performance share units that were anti-dilutive were 3 million for the three months ended March&#160;31, 2021 and 4 million for the nine months ended March&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The potentially dilutive employee stock options, restricted share units and performance share units that were anti-dilutive were 4 million for the three months ended March&#160;31, 2020 and 7 million for the nine months ended March&#160;31, 2020 (2 million of which were anti-dilutive as a result of the year-to-date net loss).&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTIvZnJhZzpjNDI3MTY1ODMzOWQ0N2Q1YmE5Njc4YmYxODdiNThkZS90ZXh0cmVnaW9uOmM0MjcxNjU4MzM5ZDQ3ZDViYTk2NzhiZjE4N2I1OGRlXzU5OA_a57ca60b-43d8-415a-9505-34d0f8781575">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares&#x2013;basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;292&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock options, restricted share units and performance share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average common shares&#x2013;diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;294&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares&#x2013;basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;293&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock options, restricted share units and performance share units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average common shares&#x2013;diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;294&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTIvZnJhZzpjNDI3MTY1ODMzOWQ0N2Q1YmE5Njc4YmYxODdiNThkZS90YWJsZToyOGZiZDk2YTMyYzc0NDI3YTg0ODQwY2RkMjUzYmJjMi90YWJsZXJhbmdlOjI4ZmJkOTZhMzJjNzQ0MjdhODQ4NDBjZGQyNTNiYmMyXzItMS0xLTEtMA_1a1df912-308b-4ac2-9f44-cd98bb7c1b5b"
      unitRef="shares">292000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTIvZnJhZzpjNDI3MTY1ODMzOWQ0N2Q1YmE5Njc4YmYxODdiNThkZS90YWJsZToyOGZiZDk2YTMyYzc0NDI3YTg0ODQwY2RkMjUzYmJjMi90YWJsZXJhbmdlOjI4ZmJkOTZhMzJjNzQ0MjdhODQ4NDBjZGQyNTNiYmMyXzItMy0xLTEtMA_cf8630cb-2c48-418f-a47c-befb0eddeba5"
      unitRef="shares">292000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTIvZnJhZzpjNDI3MTY1ODMzOWQ0N2Q1YmE5Njc4YmYxODdiNThkZS90YWJsZToyOGZiZDk2YTMyYzc0NDI3YTg0ODQwY2RkMjUzYmJjMi90YWJsZXJhbmdlOjI4ZmJkOTZhMzJjNzQ0MjdhODQ4NDBjZGQyNTNiYmMyXzQtMS0xLTEtMA_a1f52a86-ab34-4790-a849-c7ce973518ec"
      unitRef="shares">2000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTIvZnJhZzpjNDI3MTY1ODMzOWQ0N2Q1YmE5Njc4YmYxODdiNThkZS90YWJsZToyOGZiZDk2YTMyYzc0NDI3YTg0ODQwY2RkMjUzYmJjMi90YWJsZXJhbmdlOjI4ZmJkOTZhMzJjNzQ0MjdhODQ4NDBjZGQyNTNiYmMyXzQtMy0xLTEtMA_aa8cefb5-f6a9-42b5-a4b5-64f1b7fc611e"
      unitRef="shares">2000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTIvZnJhZzpjNDI3MTY1ODMzOWQ0N2Q1YmE5Njc4YmYxODdiNThkZS90YWJsZToyOGZiZDk2YTMyYzc0NDI3YTg0ODQwY2RkMjUzYmJjMi90YWJsZXJhbmdlOjI4ZmJkOTZhMzJjNzQ0MjdhODQ4NDBjZGQyNTNiYmMyXzUtMS0xLTEtMA_356d7a37-b8e0-4380-aac5-f9803cb9d4e5"
      unitRef="shares">294000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTIvZnJhZzpjNDI3MTY1ODMzOWQ0N2Q1YmE5Njc4YmYxODdiNThkZS90YWJsZToyOGZiZDk2YTMyYzc0NDI3YTg0ODQwY2RkMjUzYmJjMi90YWJsZXJhbmdlOjI4ZmJkOTZhMzJjNzQ0MjdhODQ4NDBjZGQyNTNiYmMyXzUtMy0xLTEtMA_1b14bbee-bcdd-484a-b148-6d288d36c022"
      unitRef="shares">294000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTIvZnJhZzpjNDI3MTY1ODMzOWQ0N2Q1YmE5Njc4YmYxODdiNThkZS90YWJsZTpjMTJmMjdkOGY5OGI0ZTEyYThhYTJkMDU0ZjY2OTRhMC90YWJsZXJhbmdlOmMxMmYyN2Q4Zjk4YjRlMTJhOGFhMmQwNTRmNjY5NGEwXzItMS0xLTEtMA_78b4b7e9-ae5d-4b57-82d7-482964882a4a"
      unitRef="shares">293000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTIvZnJhZzpjNDI3MTY1ODMzOWQ0N2Q1YmE5Njc4YmYxODdiNThkZS90YWJsZTpjMTJmMjdkOGY5OGI0ZTEyYThhYTJkMDU0ZjY2OTRhMC90YWJsZXJhbmdlOmMxMmYyN2Q4Zjk4YjRlMTJhOGFhMmQwNTRmNjY5NGEwXzItMy0xLTEtMA_822567d9-9657-4105-95ec-672ab3944d35"
      unitRef="shares">293000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTIvZnJhZzpjNDI3MTY1ODMzOWQ0N2Q1YmE5Njc4YmYxODdiNThkZS90YWJsZTpjMTJmMjdkOGY5OGI0ZTEyYThhYTJkMDU0ZjY2OTRhMC90YWJsZXJhbmdlOmMxMmYyN2Q4Zjk4YjRlMTJhOGFhMmQwNTRmNjY5NGEwXzQtMS0xLTEtMA_4a120701-7337-47bd-83ba-7311ded26fdb"
      unitRef="shares">1000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTIvZnJhZzpjNDI3MTY1ODMzOWQ0N2Q1YmE5Njc4YmYxODdiNThkZS90YWJsZTpjMTJmMjdkOGY5OGI0ZTEyYThhYTJkMDU0ZjY2OTRhMC90YWJsZXJhbmdlOmMxMmYyN2Q4Zjk4YjRlMTJhOGFhMmQwNTRmNjY5NGEwXzQtMy0xLTEtMA_6cd3192d-3d19-4675-955f-2dedbcd53781"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTIvZnJhZzpjNDI3MTY1ODMzOWQ0N2Q1YmE5Njc4YmYxODdiNThkZS90YWJsZTpjMTJmMjdkOGY5OGI0ZTEyYThhYTJkMDU0ZjY2OTRhMC90YWJsZXJhbmdlOmMxMmYyN2Q4Zjk4YjRlMTJhOGFhMmQwNTRmNjY5NGEwXzUtMS0xLTEtMA_620f0e08-dc48-4bb4-b405-8b5f530f7afb"
      unitRef="shares">294000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTIvZnJhZzpjNDI3MTY1ODMzOWQ0N2Q1YmE5Njc4YmYxODdiNThkZS90YWJsZTpjMTJmMjdkOGY5OGI0ZTEyYThhYTJkMDU0ZjY2OTRhMC90YWJsZXJhbmdlOmMxMmYyN2Q4Zjk4YjRlMTJhOGFhMmQwNTRmNjY5NGEwXzUtMy0xLTEtMA_615dcb45-4ca8-4259-9a97-01cd3527c331"
      unitRef="shares">293000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTIvZnJhZzpjNDI3MTY1ODMzOWQ0N2Q1YmE5Njc4YmYxODdiNThkZS90ZXh0cmVnaW9uOmM0MjcxNjU4MzM5ZDQ3ZDViYTk2NzhiZjE4N2I1OGRlXzI5Mw_82200c87-d780-40db-a74e-5c17089e47b1"
      unitRef="shares">3000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTIvZnJhZzpjNDI3MTY1ODMzOWQ0N2Q1YmE5Njc4YmYxODdiNThkZS90ZXh0cmVnaW9uOmM0MjcxNjU4MzM5ZDQ3ZDViYTk2NzhiZjE4N2I1OGRlXzQzOTgwNDY1MTIwMTI_a9621d7f-9c88-4ba2-b1aa-68fcf643ed09"
      unitRef="shares">4000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTIvZnJhZzpjNDI3MTY1ODMzOWQ0N2Q1YmE5Njc4YmYxODdiNThkZS90ZXh0cmVnaW9uOmM0MjcxNjU4MzM5ZDQ3ZDViYTk2NzhiZjE4N2I1OGRlXzQ2NA_0df0bba0-4779-472a-86c7-82c34317f6ed"
      unitRef="shares">4000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTIvZnJhZzpjNDI3MTY1ODMzOWQ0N2Q1YmE5Njc4YmYxODdiNThkZS90ZXh0cmVnaW9uOmM0MjcxNjU4MzM5ZDQ3ZDViYTk2NzhiZjE4N2I1OGRlXzQzOTgwNDY1MTIwMjI_9fad1ce8-20bd-4749-a299-8966c1325e0a"
      unitRef="shares">7000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <cah:Sharesthatwouldbeantidilutiveasaresultofnetloss
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTIvZnJhZzpjNDI3MTY1ODMzOWQ0N2Q1YmE5Njc4YmYxODdiNThkZS90ZXh0cmVnaW9uOmM0MjcxNjU4MzM5ZDQ3ZDViYTk2NzhiZjE4N2I1OGRlXzUxOQ_2f01e0be-ef1e-4037-bd03-bde9cd12682e"
      unitRef="shares">2000000</cah:Sharesthatwouldbeantidilutiveasaresultofnetloss>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90ZXh0cmVnaW9uOmNhOGZiZWMxNWUyNDRiODE5MzFhMWE0MWMwMWIxZmVmXzUyODA_623b2a89-9ee7-4a9a-9e2d-6a1bf37023df">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;12. Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our operations are principally managed on a products and services basis and are comprised of two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; provides pharmacy management services to hospitals as well as medication therapy management and patient outcomes services to hospitals, other healthcare providers and payers; and repackages generic pharmaceuticals and over-the-counter healthcare products. &lt;/span&gt;&lt;/div&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.214%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. This segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present revenue for each reportable segment and disaggregated revenue within our two reportable segments and Corporate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical Distribution and Specialty Solutions (1) (2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;34,903&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;34,899&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nuclear and Precision Health Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;201&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;213&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;35,104&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;35,112&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical distribution and products (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,638&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,539&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cardinal Health at-Home Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;536&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;512&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,174&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,051&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;39,278&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;39,163&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;39,275&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;39,157&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical Distribution and Specialty Solutions (1) (2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;106,859&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;103,612&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nuclear and Precision Health Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;593&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;642&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;107,452&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;104,254&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical distribution and products (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10,805&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10,483&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cardinal Health at-Home Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,636&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,508&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12,441&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11,991&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;119,893&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;116,245&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;119,881&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;116,233&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Products and services offered by our Specialty Solutions division are referred to as &#x201c;specialty pharmaceutical products and services."&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/&gt;&lt;div style="display:inline-block;vertical-align:top;width:48.215%"&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present revenue by geographic area:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.482%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;38,089&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;38,073&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,189&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,090&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;39,278&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;39,163&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;39,275&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;39,157&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.906%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;116,425&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;113,053&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,468&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,192&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;119,893&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;116,245&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;119,881&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;116,233&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Profit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&amp;amp;A") expenses. Segment SG&amp;amp;A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial, and customer care shared services, human resources, information technology, and legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation methodologies. The results attributable to noncontrolling interests are recorded within segment profit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not allocate the following items to our segments: last-in first-out, or ("LIFO"), inventory charges/(credits); surgical gown recall costs; restructuring and employee severance; amortization and other acquisition-related costs; impairments and (gain)/loss on disposal of assets; litigation (recoveries)/charges, net; state opioid assessment related to prior fiscal years; other (income)/expense, net; interest expense, net; loss on early extinguishment of debt; and provision for income taxes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $4 million and $17 million for the three months ended March&#160;31, 2021 and 2020, and $15 million and $37 million for the nine months ended March&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the planned divestiture of the Cordis business, we recognized a $58&#160;million pre-tax write-down of the net assets held for sale&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;during the three and nine months ended March&#160;31, 2021, which was retained at Corporate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the opioid litigation as discussed further in &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ib6bf45669ad94861b0c50dbc2f4371ce_97" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 6&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, we recognized pre-tax charges of $1.02 billion and $5.63&#160;billion&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;during the nine months ended March&#160;31, 2021 and 2020, respectively, which were retained at Corporate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the New York Opioid Stewardship Act as discussed further in &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="#ib6bf45669ad94861b0c50dbc2f4371ce_97" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Note 6&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, we recognized a pre-tax charge of $41&#160;million during the nine months ended March&#160;31, 2021, related to calendar year 2017 and 2018 assessments, which was retained at Corporate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with a voluntary recall for certain surgical gowns and a voluntary recall and field actions for surgical procedure packs containing affected gowns, we recognized a pre-tax charge of $95&#160;million during the nine months ended March&#160;31, 2020 which was retained at Corporate.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present segment profit by reportable segment and Corporate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;511&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;174&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total segment profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;685&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(212)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total operating earnings&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;473&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,326&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;640&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total segment profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,966&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,656)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,305)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total operating earnings/(loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;310&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,368)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents total assets for each reportable segment and Corporate at: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.503%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;23,078&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;15,280&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,516&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;43,874&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Assets of $1.1 billion classified as held for sale related to the Cordis planned divestiture were included within Medical at March&#160;31, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90ZXh0cmVnaW9uOmNhOGZiZWMxNWUyNDRiODE5MzFhMWE0MWMwMWIxZmVmXzEwMQ_20c440b5-3ed0-4650-b6dd-b5d5253af641"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90ZXh0cmVnaW9uOmNhOGZiZWMxNWUyNDRiODE5MzFhMWE0MWMwMWIxZmVmXzEwMQ_f06cd0a0-9d00-4d1f-983a-ba01b900bd5c"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90ZXh0cmVnaW9uOmNhOGZiZWMxNWUyNDRiODE5MzFhMWE0MWMwMWIxZmVmXzE4NDc_20c440b5-3ed0-4650-b6dd-b5d5253af641"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90ZXh0cmVnaW9uOmNhOGZiZWMxNWUyNDRiODE5MzFhMWE0MWMwMWIxZmVmXzE4NDc_f06cd0a0-9d00-4d1f-983a-ba01b900bd5c"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90ZXh0cmVnaW9uOmNhOGZiZWMxNWUyNDRiODE5MzFhMWE0MWMwMWIxZmVmXzUyOTI_11d0b71b-cb46-4c17-a956-3085fab1c9c2">&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical Distribution and Specialty Solutions (1) (2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;34,903&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;34,899&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nuclear and Precision Health Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;201&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;213&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;35,104&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;35,112&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical distribution and products (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,638&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,539&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cardinal Health at-Home Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;536&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;512&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,174&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4,051&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;39,278&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;39,163&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;39,275&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;39,157&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.591%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical Distribution and Specialty Solutions (1) (2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;106,859&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;103,612&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nuclear and Precision Health Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;593&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;642&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;107,452&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;104,254&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical distribution and products (3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10,805&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;10,483&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cardinal Health at-Home Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,636&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,508&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical segment revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;12,441&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;11,991&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;119,893&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;116,245&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (4)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;119,881&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;116,233&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Products and services offered by our Specialty Solutions division are referred to as &#x201c;specialty pharmaceutical products and services."&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="icb95c38f699b498bae7eccc1951e60ef_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo3NDk5NTZlZWViNDU0ZWNhYTk0YzM4MTkxMDVhZjdjZi90YWJsZXJhbmdlOjc0OTk1NmVlZWI0NTRlY2FhOTRjMzgxOTEwNWFmN2NmXzItMS0xLTEtMA_d6a725c4-1693-4470-9b54-b354acd556e1"
      unitRef="usd">34903000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id77fcd8f97ce44d28130b582a93ca388_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo3NDk5NTZlZWViNDU0ZWNhYTk0YzM4MTkxMDVhZjdjZi90YWJsZXJhbmdlOjc0OTk1NmVlZWI0NTRlY2FhOTRjMzgxOTEwNWFmN2NmXzItMy0xLTEtMA_c8bc0056-0fa4-48d4-87ed-daeb4d9831d6"
      unitRef="usd">34899000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i98a550bd18584222b45f6e22795837d8_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo3NDk5NTZlZWViNDU0ZWNhYTk0YzM4MTkxMDVhZjdjZi90YWJsZXJhbmdlOjc0OTk1NmVlZWI0NTRlY2FhOTRjMzgxOTEwNWFmN2NmXzMtMS0xLTEtMA_b75d0443-d7e3-4c8a-851d-9afdacf8ea43"
      unitRef="usd">201000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i497d93eb01e34fc299e07f6c11433ddc_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo3NDk5NTZlZWViNDU0ZWNhYTk0YzM4MTkxMDVhZjdjZi90YWJsZXJhbmdlOjc0OTk1NmVlZWI0NTRlY2FhOTRjMzgxOTEwNWFmN2NmXzMtMy0xLTEtMA_faa91c85-495b-43c0-a129-8e53c30e4a52"
      unitRef="usd">213000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i13210788c384499eb6bd49c7ac901881_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo3NDk5NTZlZWViNDU0ZWNhYTk0YzM4MTkxMDVhZjdjZi90YWJsZXJhbmdlOjc0OTk1NmVlZWI0NTRlY2FhOTRjMzgxOTEwNWFmN2NmXzQtMS0xLTEtMA_69c5501f-d972-45df-97b7-77a8d87b1947"
      unitRef="usd">35104000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie15bd6a384d84a93aa0435432170a9e0_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo3NDk5NTZlZWViNDU0ZWNhYTk0YzM4MTkxMDVhZjdjZi90YWJsZXJhbmdlOjc0OTk1NmVlZWI0NTRlY2FhOTRjMzgxOTEwNWFmN2NmXzQtMy0xLTEtMA_a7c9d931-6b9b-42e3-9dfe-ce95f7847477"
      unitRef="usd">35112000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i754a245950334f9994b76f93229c450a_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo3NDk5NTZlZWViNDU0ZWNhYTk0YzM4MTkxMDVhZjdjZi90YWJsZXJhbmdlOjc0OTk1NmVlZWI0NTRlY2FhOTRjMzgxOTEwNWFmN2NmXzUtMS0xLTEtMA_e39cbdc7-542e-4d93-90f9-fc640824a0d7"
      unitRef="usd">3638000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie00acdc941434982aa3c874289a0f3fd_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo3NDk5NTZlZWViNDU0ZWNhYTk0YzM4MTkxMDVhZjdjZi90YWJsZXJhbmdlOjc0OTk1NmVlZWI0NTRlY2FhOTRjMzgxOTEwNWFmN2NmXzUtMy0xLTEtMA_e426cdd1-6dee-493d-9314-60490019d088"
      unitRef="usd">3539000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i980f0fff0b9a4c3190c440190a0f45b0_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo3NDk5NTZlZWViNDU0ZWNhYTk0YzM4MTkxMDVhZjdjZi90YWJsZXJhbmdlOjc0OTk1NmVlZWI0NTRlY2FhOTRjMzgxOTEwNWFmN2NmXzYtMS0xLTEtMA_8c9c0a62-c3ef-4fdc-a51b-b5238ba7bbcb"
      unitRef="usd">536000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i66cd600a4fa943049ca88903270b5e37_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo3NDk5NTZlZWViNDU0ZWNhYTk0YzM4MTkxMDVhZjdjZi90YWJsZXJhbmdlOjc0OTk1NmVlZWI0NTRlY2FhOTRjMzgxOTEwNWFmN2NmXzYtMy0xLTEtMA_093b91c5-eef9-49ae-95e8-1f99fe57b47a"
      unitRef="usd">512000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0a6b387b92814c6dbccb36d4616b973b_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo3NDk5NTZlZWViNDU0ZWNhYTk0YzM4MTkxMDVhZjdjZi90YWJsZXJhbmdlOjc0OTk1NmVlZWI0NTRlY2FhOTRjMzgxOTEwNWFmN2NmXzctMS0xLTEtMA_e07ff9e5-8863-43ee-ad1c-ff5cfccd9c67"
      unitRef="usd">4174000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4b2f4f39f2f9421c9376d5aeb5d1ebba_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo3NDk5NTZlZWViNDU0ZWNhYTk0YzM4MTkxMDVhZjdjZi90YWJsZXJhbmdlOjc0OTk1NmVlZWI0NTRlY2FhOTRjMzgxOTEwNWFmN2NmXzctMy0xLTEtMA_27ec3a3d-74f7-4d67-85f3-c6178109ca1c"
      unitRef="usd">4051000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic430db4eef8d4096927747687050f4ab_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo3NDk5NTZlZWViNDU0ZWNhYTk0YzM4MTkxMDVhZjdjZi90YWJsZXJhbmdlOjc0OTk1NmVlZWI0NTRlY2FhOTRjMzgxOTEwNWFmN2NmXzgtMS0xLTEtMA_62863918-78bf-4c7a-ba8b-73dd661e8020"
      unitRef="usd">39278000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i133a2afe200e422e8417d692d3db7c24_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo3NDk5NTZlZWViNDU0ZWNhYTk0YzM4MTkxMDVhZjdjZi90YWJsZXJhbmdlOjc0OTk1NmVlZWI0NTRlY2FhOTRjMzgxOTEwNWFmN2NmXzgtMy0xLTEtMA_5ceea359-acf5-400b-9792-423f4e215da9"
      unitRef="usd">39163000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic3be9b6146804373965da8f26eb058f6_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo3NDk5NTZlZWViNDU0ZWNhYTk0YzM4MTkxMDVhZjdjZi90YWJsZXJhbmdlOjc0OTk1NmVlZWI0NTRlY2FhOTRjMzgxOTEwNWFmN2NmXzktMS0xLTEtMA_15d4e839-3799-4e83-985c-abc515ba10bf"
      unitRef="usd">-3000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idb553ffd18cb495b81f622bdfcdbd4c4_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo3NDk5NTZlZWViNDU0ZWNhYTk0YzM4MTkxMDVhZjdjZi90YWJsZXJhbmdlOjc0OTk1NmVlZWI0NTRlY2FhOTRjMzgxOTEwNWFmN2NmXzktMy0xLTEtMA_d5947291-4daa-48bb-b65d-6d4fec1f65bf"
      unitRef="usd">-6000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo3NDk5NTZlZWViNDU0ZWNhYTk0YzM4MTkxMDVhZjdjZi90YWJsZXJhbmdlOjc0OTk1NmVlZWI0NTRlY2FhOTRjMzgxOTEwNWFmN2NmXzEwLTEtMS0xLTA_4eeeaf57-3665-48d2-b84d-a2d404e7ecd9"
      unitRef="usd">39275000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo3NDk5NTZlZWViNDU0ZWNhYTk0YzM4MTkxMDVhZjdjZi90YWJsZXJhbmdlOjc0OTk1NmVlZWI0NTRlY2FhOTRjMzgxOTEwNWFmN2NmXzEwLTMtMS0xLTA_c80004a1-3cd8-43ac-90be-b29c320f5808"
      unitRef="usd">39157000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i38499692778a4677a3d0205a54dabc5e_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo0NTVjODlkYTU0NzY0NjgxYjczY2RjOGJjNDJjNzJiOC90YWJsZXJhbmdlOjQ1NWM4OWRhNTQ3NjQ2ODFiNzNjZGM4YmM0MmM3MmI4XzItMS0xLTEtMA_588a5ecc-f957-4a52-9165-55c4542e1e3a"
      unitRef="usd">106859000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1a204b9287bf45b1a70bdb9303162867_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo0NTVjODlkYTU0NzY0NjgxYjczY2RjOGJjNDJjNzJiOC90YWJsZXJhbmdlOjQ1NWM4OWRhNTQ3NjQ2ODFiNzNjZGM4YmM0MmM3MmI4XzItMy0xLTEtMA_6bec33cf-4a60-4acd-8262-ea94c8540bb7"
      unitRef="usd">103612000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibd1495b463924bf7a6a21f64497f4f5f_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo0NTVjODlkYTU0NzY0NjgxYjczY2RjOGJjNDJjNzJiOC90YWJsZXJhbmdlOjQ1NWM4OWRhNTQ3NjQ2ODFiNzNjZGM4YmM0MmM3MmI4XzMtMS0xLTEtMA_5e72ee8b-33fc-401b-bd40-bbfde7f7a7e3"
      unitRef="usd">593000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6d2aa45f535e4ad78bb4d60e6ab599cf_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo0NTVjODlkYTU0NzY0NjgxYjczY2RjOGJjNDJjNzJiOC90YWJsZXJhbmdlOjQ1NWM4OWRhNTQ3NjQ2ODFiNzNjZGM4YmM0MmM3MmI4XzMtMy0xLTEtMA_00c79876-a717-447c-905b-6aaeb3882911"
      unitRef="usd">642000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idaf142075796467695d26aed7ffad5a6_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo0NTVjODlkYTU0NzY0NjgxYjczY2RjOGJjNDJjNzJiOC90YWJsZXJhbmdlOjQ1NWM4OWRhNTQ3NjQ2ODFiNzNjZGM4YmM0MmM3MmI4XzQtMS0xLTEtMA_3ce67dbf-b29d-4b2d-a10f-ec4e1b549d7c"
      unitRef="usd">107452000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7633f1494ae14d6db19bb6de3dd5dc7d_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo0NTVjODlkYTU0NzY0NjgxYjczY2RjOGJjNDJjNzJiOC90YWJsZXJhbmdlOjQ1NWM4OWRhNTQ3NjQ2ODFiNzNjZGM4YmM0MmM3MmI4XzQtMy0xLTEtMA_c2d7a065-5dba-4b3f-9db9-535ceef2c3a3"
      unitRef="usd">104254000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia66d6c475fbc4a4f93c1eed3e22397fe_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo0NTVjODlkYTU0NzY0NjgxYjczY2RjOGJjNDJjNzJiOC90YWJsZXJhbmdlOjQ1NWM4OWRhNTQ3NjQ2ODFiNzNjZGM4YmM0MmM3MmI4XzUtMS0xLTEtMA_433dc246-bf2a-4abf-a954-3afefed981c6"
      unitRef="usd">10805000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iee665c670791489a9810213babe512b3_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo0NTVjODlkYTU0NzY0NjgxYjczY2RjOGJjNDJjNzJiOC90YWJsZXJhbmdlOjQ1NWM4OWRhNTQ3NjQ2ODFiNzNjZGM4YmM0MmM3MmI4XzUtMy0xLTEtMA_e719f29b-10e7-4550-a6e4-f0961417db2e"
      unitRef="usd">10483000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic1306a7b737e45e5b5d2f6b30e1ae7c8_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo0NTVjODlkYTU0NzY0NjgxYjczY2RjOGJjNDJjNzJiOC90YWJsZXJhbmdlOjQ1NWM4OWRhNTQ3NjQ2ODFiNzNjZGM4YmM0MmM3MmI4XzYtMS0xLTEtMA_30316a4d-8428-46f7-8693-7d847f75d663"
      unitRef="usd">1636000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8294a10e67a64ee889ba04da6c8dda53_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo0NTVjODlkYTU0NzY0NjgxYjczY2RjOGJjNDJjNzJiOC90YWJsZXJhbmdlOjQ1NWM4OWRhNTQ3NjQ2ODFiNzNjZGM4YmM0MmM3MmI4XzYtMy0xLTEtMA_62916ff3-8642-4e2b-8678-f98d02773463"
      unitRef="usd">1508000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia6b13c1180504c8e8b9bbe3e3b0affe6_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo0NTVjODlkYTU0NzY0NjgxYjczY2RjOGJjNDJjNzJiOC90YWJsZXJhbmdlOjQ1NWM4OWRhNTQ3NjQ2ODFiNzNjZGM4YmM0MmM3MmI4XzctMS0xLTEtMA_f613616b-a204-45f2-b0a1-97f2e7d8364c"
      unitRef="usd">12441000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iac89152bf6b649d09d16a732e7fe9fd7_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo0NTVjODlkYTU0NzY0NjgxYjczY2RjOGJjNDJjNzJiOC90YWJsZXJhbmdlOjQ1NWM4OWRhNTQ3NjQ2ODFiNzNjZGM4YmM0MmM3MmI4XzctMy0xLTEtMA_dd28cc95-a1fc-4724-bb88-a3477e05c986"
      unitRef="usd">11991000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifdac359205cd4b9894e9c5b6bc9a75f9_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo0NTVjODlkYTU0NzY0NjgxYjczY2RjOGJjNDJjNzJiOC90YWJsZXJhbmdlOjQ1NWM4OWRhNTQ3NjQ2ODFiNzNjZGM4YmM0MmM3MmI4XzgtMS0xLTEtMA_76852d10-2f39-403b-bbe4-d6e28c472947"
      unitRef="usd">119893000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7571f4a1493c40f1948e2aa7d8298511_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo0NTVjODlkYTU0NzY0NjgxYjczY2RjOGJjNDJjNzJiOC90YWJsZXJhbmdlOjQ1NWM4OWRhNTQ3NjQ2ODFiNzNjZGM4YmM0MmM3MmI4XzgtMy0xLTEtMA_fa933c18-b753-41f2-8b98-cd3fc27c0ed5"
      unitRef="usd">116245000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if00aae22cda442e2907fd2752c87fb3d_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo0NTVjODlkYTU0NzY0NjgxYjczY2RjOGJjNDJjNzJiOC90YWJsZXJhbmdlOjQ1NWM4OWRhNTQ3NjQ2ODFiNzNjZGM4YmM0MmM3MmI4XzktMS0xLTEtMA_94004ba1-6990-4f95-9763-562d3fc59a3c"
      unitRef="usd">-12000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic8024f13f805493da1022a38d9655ca3_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo0NTVjODlkYTU0NzY0NjgxYjczY2RjOGJjNDJjNzJiOC90YWJsZXJhbmdlOjQ1NWM4OWRhNTQ3NjQ2ODFiNzNjZGM4YmM0MmM3MmI4XzktMy0xLTEtMA_eb701b2d-a679-4556-8b00-5c3d966ec8a5"
      unitRef="usd">-12000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo0NTVjODlkYTU0NzY0NjgxYjczY2RjOGJjNDJjNzJiOC90YWJsZXJhbmdlOjQ1NWM4OWRhNTQ3NjQ2ODFiNzNjZGM4YmM0MmM3MmI4XzEwLTEtMS0xLTA_bb69f61f-954d-418a-8b77-aa4e695427f4"
      unitRef="usd">119881000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo0NTVjODlkYTU0NzY0NjgxYjczY2RjOGJjNDJjNzJiOC90YWJsZXJhbmdlOjQ1NWM4OWRhNTQ3NjQ2ODFiNzNjZGM4YmM0MmM3MmI4XzEwLTMtMS0xLTA_e7dbf0c4-9b32-4270-a175-1abd725f0a29"
      unitRef="usd">116233000000</us-gaap:Revenues>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90ZXh0cmVnaW9uOmNhOGZiZWMxNWUyNDRiODE5MzFhMWE0MWMwMWIxZmVmXzUyNzU_378df650-4636-4920-a41e-b449f955a5c4">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present revenue by geographic area:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.482%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.215%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;38,089&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;38,073&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,189&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,090&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;39,278&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;39,163&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;39,275&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;39,157&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.906%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.586%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;116,425&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;113,053&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,468&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3,192&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Total segment revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;119,893&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;116,245&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;119,881&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;116,233&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:Revenues
      contextRef="i155df096ff374a49874a1b86694a8d78_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo1ZDYyMzRhOTA4M2E0OGFiOTU5ODE3MWU3OTVmN2MxNy90YWJsZXJhbmdlOjVkNjIzNGE5MDgzYTQ4YWI5NTk4MTcxZTc5NWY3YzE3XzItMS0xLTEtMA_d3240e02-a638-495b-a472-a30e8acad610"
      unitRef="usd">38089000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7ba2131531c140b1887cc40420a68d24_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo1ZDYyMzRhOTA4M2E0OGFiOTU5ODE3MWU3OTVmN2MxNy90YWJsZXJhbmdlOjVkNjIzNGE5MDgzYTQ4YWI5NTk4MTcxZTc5NWY3YzE3XzItMy0xLTEtMA_6a8fb8a9-e60c-4b7c-b9c7-698718827754"
      unitRef="usd">38073000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3c2e770d82df4fb29415150ac2904bdd_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo1ZDYyMzRhOTA4M2E0OGFiOTU5ODE3MWU3OTVmN2MxNy90YWJsZXJhbmdlOjVkNjIzNGE5MDgzYTQ4YWI5NTk4MTcxZTc5NWY3YzE3XzMtMS0xLTEtMA_bde05350-7354-4671-95c8-86165c63f8c6"
      unitRef="usd">1189000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic1dce9a8c75d4af4a876d4bf69e8bed9_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo1ZDYyMzRhOTA4M2E0OGFiOTU5ODE3MWU3OTVmN2MxNy90YWJsZXJhbmdlOjVkNjIzNGE5MDgzYTQ4YWI5NTk4MTcxZTc5NWY3YzE3XzMtMy0xLTEtMA_e4cf9e12-0152-4c6a-8269-eaafdde4b82e"
      unitRef="usd">1090000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic430db4eef8d4096927747687050f4ab_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo1ZDYyMzRhOTA4M2E0OGFiOTU5ODE3MWU3OTVmN2MxNy90YWJsZXJhbmdlOjVkNjIzNGE5MDgzYTQ4YWI5NTk4MTcxZTc5NWY3YzE3XzQtMS0xLTEtMA_9950a6bf-d349-4a28-96af-c241cc3d69d4"
      unitRef="usd">39278000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i133a2afe200e422e8417d692d3db7c24_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo1ZDYyMzRhOTA4M2E0OGFiOTU5ODE3MWU3OTVmN2MxNy90YWJsZXJhbmdlOjVkNjIzNGE5MDgzYTQ4YWI5NTk4MTcxZTc5NWY3YzE3XzQtMy0xLTEtMA_b172961c-c069-4e1f-922e-085f64baaf4d"
      unitRef="usd">39163000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic3be9b6146804373965da8f26eb058f6_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo1ZDYyMzRhOTA4M2E0OGFiOTU5ODE3MWU3OTVmN2MxNy90YWJsZXJhbmdlOjVkNjIzNGE5MDgzYTQ4YWI5NTk4MTcxZTc5NWY3YzE3XzUtMS0xLTEtMA_adfc09be-870d-4e24-b1a6-c56b82aafeaf"
      unitRef="usd">-3000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idb553ffd18cb495b81f622bdfcdbd4c4_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo1ZDYyMzRhOTA4M2E0OGFiOTU5ODE3MWU3OTVmN2MxNy90YWJsZXJhbmdlOjVkNjIzNGE5MDgzYTQ4YWI5NTk4MTcxZTc5NWY3YzE3XzUtMy0xLTEtMA_6a1f5de9-226a-49bb-85fd-ce780d36ca7d"
      unitRef="usd">-6000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo1ZDYyMzRhOTA4M2E0OGFiOTU5ODE3MWU3OTVmN2MxNy90YWJsZXJhbmdlOjVkNjIzNGE5MDgzYTQ4YWI5NTk4MTcxZTc5NWY3YzE3XzYtMS0xLTEtMA_b359e378-20a2-4763-b9e9-85a0cab38578"
      unitRef="usd">39275000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo1ZDYyMzRhOTA4M2E0OGFiOTU5ODE3MWU3OTVmN2MxNy90YWJsZXJhbmdlOjVkNjIzNGE5MDgzYTQ4YWI5NTk4MTcxZTc5NWY3YzE3XzYtMy0xLTEtMA_9e5154cb-6529-4ea1-9983-d82d58fc8246"
      unitRef="usd">39157000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia08f0b8f481d48ddaf2634a007190de5_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTpjMzAxMGI2YWFiNzk0YWY1OTNjMWVmMzVjMjI5ZDdkMS90YWJsZXJhbmdlOmMzMDEwYjZhYWI3OTRhZjU5M2MxZWYzNWMyMjlkN2QxXzItMS0xLTEtMA_f85550e0-df54-42a4-b19b-b68ac282d910"
      unitRef="usd">116425000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i627973ec4999405b88953cf1981248fe_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTpjMzAxMGI2YWFiNzk0YWY1OTNjMWVmMzVjMjI5ZDdkMS90YWJsZXJhbmdlOmMzMDEwYjZhYWI3OTRhZjU5M2MxZWYzNWMyMjlkN2QxXzItMy0xLTEtMA_cbc9d1f2-f4a9-4772-98e9-31140b5bb022"
      unitRef="usd">113053000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4c43376b1a4b4c3fb49e50efec9c4eb9_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTpjMzAxMGI2YWFiNzk0YWY1OTNjMWVmMzVjMjI5ZDdkMS90YWJsZXJhbmdlOmMzMDEwYjZhYWI3OTRhZjU5M2MxZWYzNWMyMjlkN2QxXzMtMS0xLTEtMA_8e6dad60-b917-412e-8d6e-6015e47abdc5"
      unitRef="usd">3468000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i437975c25f184124919229aca35a0a19_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTpjMzAxMGI2YWFiNzk0YWY1OTNjMWVmMzVjMjI5ZDdkMS90YWJsZXJhbmdlOmMzMDEwYjZhYWI3OTRhZjU5M2MxZWYzNWMyMjlkN2QxXzMtMy0xLTEtMA_2df40dea-adc4-4369-8a7b-0aa56900547e"
      unitRef="usd">3192000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifdac359205cd4b9894e9c5b6bc9a75f9_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTpjMzAxMGI2YWFiNzk0YWY1OTNjMWVmMzVjMjI5ZDdkMS90YWJsZXJhbmdlOmMzMDEwYjZhYWI3OTRhZjU5M2MxZWYzNWMyMjlkN2QxXzQtMS0xLTEtMA_844872c1-e95e-40ae-bda8-c7c1e7bc3fc0"
      unitRef="usd">119893000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7571f4a1493c40f1948e2aa7d8298511_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTpjMzAxMGI2YWFiNzk0YWY1OTNjMWVmMzVjMjI5ZDdkMS90YWJsZXJhbmdlOmMzMDEwYjZhYWI3OTRhZjU5M2MxZWYzNWMyMjlkN2QxXzQtMy0xLTEtMA_c11f3f68-88b5-4ae1-a5a6-79ec4a2715b3"
      unitRef="usd">116245000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if00aae22cda442e2907fd2752c87fb3d_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTpjMzAxMGI2YWFiNzk0YWY1OTNjMWVmMzVjMjI5ZDdkMS90YWJsZXJhbmdlOmMzMDEwYjZhYWI3OTRhZjU5M2MxZWYzNWMyMjlkN2QxXzUtMS0xLTEtMA_b9622cfb-9503-41e4-b5ef-b2432a4689f3"
      unitRef="usd">-12000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic8024f13f805493da1022a38d9655ca3_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTpjMzAxMGI2YWFiNzk0YWY1OTNjMWVmMzVjMjI5ZDdkMS90YWJsZXJhbmdlOmMzMDEwYjZhYWI3OTRhZjU5M2MxZWYzNWMyMjlkN2QxXzUtMy0xLTEtMA_de873f1d-b419-44f2-bbe4-af09841da98f"
      unitRef="usd">-12000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTpjMzAxMGI2YWFiNzk0YWY1OTNjMWVmMzVjMjI5ZDdkMS90YWJsZXJhbmdlOmMzMDEwYjZhYWI3OTRhZjU5M2MxZWYzNWMyMjlkN2QxXzYtMS0xLTEtMA_7cd06e8d-7e1d-4045-8c62-13e7c9a22a18"
      unitRef="usd">119881000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTpjMzAxMGI2YWFiNzk0YWY1OTNjMWVmMzVjMjI5ZDdkMS90YWJsZXJhbmdlOmMzMDEwYjZhYWI3OTRhZjU5M2MxZWYzNWMyMjlkN2QxXzYtMy0xLTEtMA_9683c241-fd44-43a5-a235-0bcb9c78a76f"
      unitRef="usd">116233000000</us-gaap:Revenues>
    <cah:ProjectCostsOnInvestmentAndOtherSpending
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90ZXh0cmVnaW9uOmNhOGZiZWMxNWUyNDRiODE5MzFhMWE0MWMwMWIxZmVmXzQzMjA_0cc0da1f-a808-47f9-9b1a-56a0f950dfa5"
      unitRef="usd">4000000</cah:ProjectCostsOnInvestmentAndOtherSpending>
    <cah:ProjectCostsOnInvestmentAndOtherSpending
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90ZXh0cmVnaW9uOmNhOGZiZWMxNWUyNDRiODE5MzFhMWE0MWMwMWIxZmVmXzQzMjc_882ef099-7855-407c-8600-e0463a4fb730"
      unitRef="usd">17000000</cah:ProjectCostsOnInvestmentAndOtherSpending>
    <cah:ProjectCostsOnInvestmentAndOtherSpending
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90ZXh0cmVnaW9uOmNhOGZiZWMxNWUyNDRiODE5MzFhMWE0MWMwMWIxZmVmXzQzNzI_34043b75-2ffd-494b-912c-a196d983960f"
      unitRef="usd">15000000</cah:ProjectCostsOnInvestmentAndOtherSpending>
    <cah:ProjectCostsOnInvestmentAndOtherSpending
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90ZXh0cmVnaW9uOmNhOGZiZWMxNWUyNDRiODE5MzFhMWE0MWMwMWIxZmVmXzQzNzk_2efcc9c0-36fb-4b5d-b748-0f374797b52b"
      unitRef="usd">37000000</cah:ProjectCostsOnInvestmentAndOtherSpending>
    <cah:WriteDownOfAssetsHeldForSale
      contextRef="i7cdd3ec3331046ec97e3ab5eeb7a43e0_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90ZXh0cmVnaW9uOmNhOGZiZWMxNWUyNDRiODE5MzFhMWE0MWMwMWIxZmVmXzMyOTg1MzQ4OTAxNDk_a8cc8edb-131c-4e11-9dd0-0427ccbeafff"
      unitRef="usd">-58000000</cah:WriteDownOfAssetsHeldForSale>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="ib9e03386e8bb45b9bfa0b58a7c283f07_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90ZXh0cmVnaW9uOmNhOGZiZWMxNWUyNDRiODE5MzFhMWE0MWMwMWIxZmVmXzQ1MjQ_089202f4-34a0-4f24-b2a6-730e01801ccc"
      unitRef="usd">-1020000000.00</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="i32ccdaa0f4af4c919f10cbbfa4cc9a79_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90ZXh0cmVnaW9uOmNhOGZiZWMxNWUyNDRiODE5MzFhMWE0MWMwMWIxZmVmXzQ1MzE_8ef151f9-98cc-4148-a8a2-1e0e26e2206b"
      unitRef="usd">-5630000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <cah:EstimatedLiabilityForNewYorkOpioidStewardshipAct
      contextRef="i12b52de2a6014b01b5857d8d032e2d95_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90ZXh0cmVnaW9uOmNhOGZiZWMxNWUyNDRiODE5MzFhMWE0MWMwMWIxZmVmXzQ3Mjk_674db16e-3cf6-492b-a085-130504a4ae5a"
      unitRef="usd">41000000</cah:EstimatedLiabilityForNewYorkOpioidStewardshipAct>
    <us-gaap:InventoryRecallExpense
      contextRef="ibbb9380a5af84ba6ae989a20e860a444_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90ZXh0cmVnaW9uOmNhOGZiZWMxNWUyNDRiODE5MzFhMWE0MWMwMWIxZmVmXzQzOTgwNDY1MTc5NDQ_7a14e366-2a44-4a8d-85a9-eb0e348af52d"
      unitRef="usd">95000000</us-gaap:InventoryRecallExpense>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90ZXh0cmVnaW9uOmNhOGZiZWMxNWUyNDRiODE5MzFhMWE0MWMwMWIxZmVmXzUyODc_bf42d8da-8eb3-46a8-ae03-c5d18768a322">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present segment profit by reportable segment and Corporate:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;511&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;174&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total segment profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;685&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(212)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total operating earnings&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;473&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,326&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;640&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total segment profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1,966&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(1,656)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,305)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total operating earnings/(loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;310&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4,368)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:OperatingIncomeLoss
      contextRef="i13210788c384499eb6bd49c7ac901881_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo4NWNhYTdhYjlhNGU0YmFjODA4YWE2MzliMjI5YTAyNC90YWJsZXJhbmdlOjg1Y2FhN2FiOWE0ZTRiYWM4MDhhYTYzOWIyMjlhMDI0XzItMS0xLTEtMA_7c672516-7241-4975-a9ec-a0935184a3ad"
      unitRef="usd">511000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie15bd6a384d84a93aa0435432170a9e0_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo4NWNhYTdhYjlhNGU0YmFjODA4YWE2MzliMjI5YTAyNC90YWJsZXJhbmdlOjg1Y2FhN2FiOWE0ZTRiYWM4MDhhYTYzOWIyMjlhMDI0XzItMy0xLTEtMA_76ee3dbd-5ac7-41b4-bcd0-d1dfe3b878fc"
      unitRef="usd">534000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i0a6b387b92814c6dbccb36d4616b973b_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo4NWNhYTdhYjlhNGU0YmFjODA4YWE2MzliMjI5YTAyNC90YWJsZXJhbmdlOjg1Y2FhN2FiOWE0ZTRiYWM4MDhhYTYzOWIyMjlhMDI0XzMtMS0xLTEtMA_337a99e9-7e7e-40b2-ba47-8273b0368c3b"
      unitRef="usd">174000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4b2f4f39f2f9421c9376d5aeb5d1ebba_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo4NWNhYTdhYjlhNGU0YmFjODA4YWE2MzliMjI5YTAyNC90YWJsZXJhbmdlOjg1Y2FhN2FiOWE0ZTRiYWM4MDhhYTYzOWIyMjlhMDI0XzMtMy0xLTEtMA_d78a603a-8a1f-4a37-a689-91d334e0f461"
      unitRef="usd">178000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic430db4eef8d4096927747687050f4ab_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo4NWNhYTdhYjlhNGU0YmFjODA4YWE2MzliMjI5YTAyNC90YWJsZXJhbmdlOjg1Y2FhN2FiOWE0ZTRiYWM4MDhhYTYzOWIyMjlhMDI0XzQtMS0xLTEtMA_88f7a7ee-593d-41d9-9b7c-60a566bbde27"
      unitRef="usd">685000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i133a2afe200e422e8417d692d3db7c24_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo4NWNhYTdhYjlhNGU0YmFjODA4YWE2MzliMjI5YTAyNC90YWJsZXJhbmdlOjg1Y2FhN2FiOWE0ZTRiYWM4MDhhYTYzOWIyMjlhMDI0XzQtMy0xLTEtMA_cc01b2e9-99e2-4f18-956e-22540027be8d"
      unitRef="usd">712000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic3be9b6146804373965da8f26eb058f6_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo4NWNhYTdhYjlhNGU0YmFjODA4YWE2MzliMjI5YTAyNC90YWJsZXJhbmdlOjg1Y2FhN2FiOWE0ZTRiYWM4MDhhYTYzOWIyMjlhMDI0XzUtMS0xLTEtMA_4f05a13b-5f76-4cf7-9fcf-dfc06ea64d41"
      unitRef="usd">-212000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="idb553ffd18cb495b81f622bdfcdbd4c4_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo4NWNhYTdhYjlhNGU0YmFjODA4YWE2MzliMjI5YTAyNC90YWJsZXJhbmdlOjg1Y2FhN2FiOWE0ZTRiYWM4MDhhYTYzOWIyMjlhMDI0XzUtMy0xLTEtMA_cab1a206-a9df-4ca2-a611-8163c62aad33"
      unitRef="usd">-150000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo4NWNhYTdhYjlhNGU0YmFjODA4YWE2MzliMjI5YTAyNC90YWJsZXJhbmdlOjg1Y2FhN2FiOWE0ZTRiYWM4MDhhYTYzOWIyMjlhMDI0XzYtMS0xLTEtMA_2756cd7f-af74-4070-a9f0-e7d07fcc121f"
      unitRef="usd">473000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo4NWNhYTdhYjlhNGU0YmFjODA4YWE2MzliMjI5YTAyNC90YWJsZXJhbmdlOjg1Y2FhN2FiOWE0ZTRiYWM4MDhhYTYzOWIyMjlhMDI0XzYtMy0xLTEtMA_8a71da24-90fa-41f9-91a7-aa1a4b9ccdc9"
      unitRef="usd">562000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="idaf142075796467695d26aed7ffad5a6_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZToxYmVmM2EzYTFhMTE0ZjU2Yjg2NzA4ZjIxMWQyOTQxZS90YWJsZXJhbmdlOjFiZWYzYTNhMWExMTRmNTZiODY3MDhmMjExZDI5NDFlXzItMS0xLTEtMA_4a7d292f-2008-4501-a3ef-60a28c8ce690"
      unitRef="usd">1326000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7633f1494ae14d6db19bb6de3dd5dc7d_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZToxYmVmM2EzYTFhMTE0ZjU2Yjg2NzA4ZjIxMWQyOTQxZS90YWJsZXJhbmdlOjFiZWYzYTNhMWExMTRmNTZiODY3MDhmMjExZDI5NDFlXzItMy0xLTEtMA_dbda1495-471e-4913-9710-33b2d0e9817a"
      unitRef="usd">1394000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia6b13c1180504c8e8b9bbe3e3b0affe6_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZToxYmVmM2EzYTFhMTE0ZjU2Yjg2NzA4ZjIxMWQyOTQxZS90YWJsZXJhbmdlOjFiZWYzYTNhMWExMTRmNTZiODY3MDhmMjExZDI5NDFlXzMtMS0xLTEtMA_f82f088e-bd3c-4eb2-8a9b-fe441ac105c3"
      unitRef="usd">640000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iac89152bf6b649d09d16a732e7fe9fd7_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZToxYmVmM2EzYTFhMTE0ZjU2Yjg2NzA4ZjIxMWQyOTQxZS90YWJsZXJhbmdlOjFiZWYzYTNhMWExMTRmNTZiODY3MDhmMjExZDI5NDFlXzMtMy0xLTEtMA_26904d0c-0993-46d6-91d5-7e19f0833a0a"
      unitRef="usd">543000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ifdac359205cd4b9894e9c5b6bc9a75f9_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZToxYmVmM2EzYTFhMTE0ZjU2Yjg2NzA4ZjIxMWQyOTQxZS90YWJsZXJhbmdlOjFiZWYzYTNhMWExMTRmNTZiODY3MDhmMjExZDI5NDFlXzQtMS0xLTEtMA_63501def-8505-442c-9024-c2fbb8244010"
      unitRef="usd">1966000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7571f4a1493c40f1948e2aa7d8298511_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZToxYmVmM2EzYTFhMTE0ZjU2Yjg2NzA4ZjIxMWQyOTQxZS90YWJsZXJhbmdlOjFiZWYzYTNhMWExMTRmNTZiODY3MDhmMjExZDI5NDFlXzQtMy0xLTEtMA_5a437a85-0662-403f-a1fa-27a06ea46da7"
      unitRef="usd">1937000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="if00aae22cda442e2907fd2752c87fb3d_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZToxYmVmM2EzYTFhMTE0ZjU2Yjg2NzA4ZjIxMWQyOTQxZS90YWJsZXJhbmdlOjFiZWYzYTNhMWExMTRmNTZiODY3MDhmMjExZDI5NDFlXzUtMS0xLTEtMA_3c11891e-6339-44f5-ad43-3a49d667f66b"
      unitRef="usd">-1656000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic8024f13f805493da1022a38d9655ca3_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZToxYmVmM2EzYTFhMTE0ZjU2Yjg2NzA4ZjIxMWQyOTQxZS90YWJsZXJhbmdlOjFiZWYzYTNhMWExMTRmNTZiODY3MDhmMjExZDI5NDFlXzUtMy0xLTEtMA_37d0120e-8586-4fd5-94d6-f854e52e405f"
      unitRef="usd">-6305000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZToxYmVmM2EzYTFhMTE0ZjU2Yjg2NzA4ZjIxMWQyOTQxZS90YWJsZXJhbmdlOjFiZWYzYTNhMWExMTRmNTZiODY3MDhmMjExZDI5NDFlXzYtMS0xLTEtMA_22f56b63-8b5d-40bc-aaef-aac102297ce7"
      unitRef="usd">310000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZToxYmVmM2EzYTFhMTE0ZjU2Yjg2NzA4ZjIxMWQyOTQxZS90YWJsZXJhbmdlOjFiZWYzYTNhMWExMTRmNTZiODY3MDhmMjExZDI5NDFlXzYtMy0xLTEtMA_d2213eb4-a0eb-46ea-8282-33a9b812ba22"
      unitRef="usd">-4368000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90ZXh0cmVnaW9uOmNhOGZiZWMxNWUyNDRiODE5MzFhMWE0MWMwMWIxZmVmXzUyODk_27e7cf58-748f-4d04-9d2a-74d4e5a6d622">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents total assets for each reportable segment and Corporate at: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.503%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;23,078&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Medical (1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;15,280&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;5,516&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;43,874&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Assets of $1.1 billion classified as held for sale related to the Cordis planned divestiture were included within Medical at March&#160;31, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock>
    <us-gaap:Assets
      contextRef="icb1b5bacb6bb401e8fe737bb56674184_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo2MmYyOWJkYTk2MDc0ZjRiOTA2YWI3MDllMThkZjBmYy90YWJsZXJhbmdlOjYyZjI5YmRhOTYwNzRmNGI5MDZhYjcwOWUxOGRmMGZjXzEtMS0xLTEtMA_7dafa78d-474f-454b-8dae-a94994f71466"
      unitRef="usd">23078000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ia56ac1f95221479a8866de7ff447bece_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo2MmYyOWJkYTk2MDc0ZjRiOTA2YWI3MDllMThkZjBmYy90YWJsZXJhbmdlOjYyZjI5YmRhOTYwNzRmNGI5MDZhYjcwOWUxOGRmMGZjXzEtMy0xLTEtMA_281279c2-4c6b-4de2-ba6e-0209ba089ea2"
      unitRef="usd">22398000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i22ff8eca14d54d0e88769fe944e5fac0_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo2MmYyOWJkYTk2MDc0ZjRiOTA2YWI3MDllMThkZjBmYy90YWJsZXJhbmdlOjYyZjI5YmRhOTYwNzRmNGI5MDZhYjcwOWUxOGRmMGZjXzItMS0xLTEtMA_c6bd227e-2363-4867-9c53-b8ee8402a21a"
      unitRef="usd">15280000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ib8ac06c44c654f11a21c85f88fe7ba70_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo2MmYyOWJkYTk2MDc0ZjRiOTA2YWI3MDllMThkZjBmYy90YWJsZXJhbmdlOjYyZjI5YmRhOTYwNzRmNGI5MDZhYjcwOWUxOGRmMGZjXzItMy0xLTEtMA_24e56763-7d94-4459-aa4b-49e52fd74594"
      unitRef="usd">14691000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i1b9e31e1c7394a41915dce3992145e0c_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo2MmYyOWJkYTk2MDc0ZjRiOTA2YWI3MDllMThkZjBmYy90YWJsZXJhbmdlOjYyZjI5YmRhOTYwNzRmNGI5MDZhYjcwOWUxOGRmMGZjXzMtMS0xLTEtMA_eb0afa1d-91c4-42ca-87d3-d920fce383b5"
      unitRef="usd">5516000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ie599ab9917894d65ad37cc3447647eae_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo2MmYyOWJkYTk2MDc0ZjRiOTA2YWI3MDllMThkZjBmYy90YWJsZXJhbmdlOjYyZjI5YmRhOTYwNzRmNGI5MDZhYjcwOWUxOGRmMGZjXzMtMy0xLTEtMA_1a776ca8-7fce-4593-8f43-0741f52623d7"
      unitRef="usd">3677000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo2MmYyOWJkYTk2MDc0ZjRiOTA2YWI3MDllMThkZjBmYy90YWJsZXJhbmdlOjYyZjI5YmRhOTYwNzRmNGI5MDZhYjcwOWUxOGRmMGZjXzQtMS0xLTEtMA_228aee25-cd21-46e9-97c3-1c8ed684369a"
      unitRef="usd">43874000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90YWJsZTo2MmYyOWJkYTk2MDc0ZjRiOTA2YWI3MDllMThkZjBmYy90YWJsZXJhbmdlOjYyZjI5YmRhOTYwNzRmNGI5MDZhYjcwOWUxOGRmMGZjXzQtMy0xLTEtMA_380d4cbe-65bc-4bd8-bd7d-d46f70d177c3"
      unitRef="usd">40766000000</us-gaap:Assets>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="i03c64db735f449b18a2b4bbcb90984f0_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTUvZnJhZzpjYThmYmVjMTVlMjQ0YjgxOTMxYTFhNDFjMDFiMWZlZi90ZXh0cmVnaW9uOmNhOGZiZWMxNWUyNDRiODE5MzFhMWE0MWMwMWIxZmVmXzc2OTY1ODE0MDQyOTM_8772644a-fe61-4ced-8652-b142557a5109"
      unitRef="usd">1100000000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90ZXh0cmVnaW9uOjE1ZjA5M2Q1ZDEyMjQ5NDE4NTc3NzNlMTk1YTZjMWQwXzIzNjE_01ba82a8-aa5a-42aa-9812-096625f19167">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"&gt;13. Share-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We maintain stock incentive plans (collectively, the &#x201c;Plans&#x201d;) for the benefit of certain of our officers, directors and employees. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides total share-based compensation expense by type of award:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;20&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock option expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;33&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;56&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock option expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;28&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;84&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total tax benefit related to share-based compensation was $5 million for both the three months ended March&#160;31, 2021 and 2020, respectively, and $12 million for both the nine months ended March&#160;31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Restricted Share Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted share units granted under the Plans generally vest in equal annual installments over three years. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all transactions related to restricted share units under the Plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Share Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nonvested at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;48.96&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2021, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was $90 million, which is expected to be recognized over a weighted-average period of two years.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee stock options granted under the Plans generally vest in equal annual installments over three years and are exercisable for ten years from the grant date. All stock options are exercisable at a price equal to the market value of the common shares underlying the option on the grant date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all stock option transactions under the Plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.480%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.061%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise Price per&lt;br/&gt;Common Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;67.60&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercisable at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;67.80&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2021, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested stock options not yet recognized was $0.2 million, which is expected to be recognized over a weighted-average period of two years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables provide additional detail related to stock options:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Aggregate intrinsic value of outstanding options at period end&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Aggregate intrinsic value of exercisable options at period end&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining contractual life of outstanding options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining contractual life of exercisable options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Performance Share Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Performance share units vest over a 3-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from zero to 240 percent of the target award amount. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Performance&lt;br/&gt;Share Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nonvested at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;60.32&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At March&#160;31, 2021, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $41 million, which is expected to be recognized over a weighted-average period of two years if performance goals are achieved.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90ZXh0cmVnaW9uOjE1ZjA5M2Q1ZDEyMjQ5NDE4NTc3NzNlMTk1YTZjMWQwXzIzODI_25e93a8a-0ab7-437c-9a0b-85b06526d60a">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides total share-based compensation expense by type of award:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;20&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock option expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;13&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;33&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restricted share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;56&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock option expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance share unit expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;28&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;84&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5489b32b324b43e7b31fefeae25b8dc6_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpkZWE5YTIwZTI4OGM0NzRjYWU5ZTdjNzU3YzhhN2VmNS90YWJsZXJhbmdlOmRlYTlhMjBlMjg4YzQ3NGNhZTllN2M3NTdjOGE3ZWY1XzItMS0xLTEtMA_745b95ef-a8d2-4344-abc6-11520f2cafb6"
      unitRef="usd">20000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iadf80adca21245ef9ca13b43ebeba09d_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpkZWE5YTIwZTI4OGM0NzRjYWU5ZTdjNzU3YzhhN2VmNS90YWJsZXJhbmdlOmRlYTlhMjBlMjg4YzQ3NGNhZTllN2M3NTdjOGE3ZWY1XzItMy0xLTEtMA_c860018e-9b77-4d68-b8a8-52e05e5f588d"
      unitRef="usd">20000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i675bcdf093c842b683f5f42b5d7c6dd5_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpkZWE5YTIwZTI4OGM0NzRjYWU5ZTdjNzU3YzhhN2VmNS90YWJsZXJhbmdlOmRlYTlhMjBlMjg4YzQ3NGNhZTllN2M3NTdjOGE3ZWY1XzMtMS0xLTEtMA_3f7fa365-1fc8-4b01-b9d9-7195a63654f0"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i56e3ff286a3f4cc79923baab49b0ed00_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpkZWE5YTIwZTI4OGM0NzRjYWU5ZTdjNzU3YzhhN2VmNS90YWJsZXJhbmdlOmRlYTlhMjBlMjg4YzQ3NGNhZTllN2M3NTdjOGE3ZWY1XzMtMy0xLTEtMA_211289c4-91b5-4dd8-a610-dfeb847b2146"
      unitRef="usd">1000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ida44dc7e8fef4822b90092a960bfd60d_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpkZWE5YTIwZTI4OGM0NzRjYWU5ZTdjNzU3YzhhN2VmNS90YWJsZXJhbmdlOmRlYTlhMjBlMjg4YzQ3NGNhZTllN2M3NTdjOGE3ZWY1XzQtMS0xLTEtMA_d54fecf8-3159-4241-83d1-db2fd3ab938b"
      unitRef="usd">13000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie5fccbaecaed42a78b6b4926ea168dc1_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpkZWE5YTIwZTI4OGM0NzRjYWU5ZTdjNzU3YzhhN2VmNS90YWJsZXJhbmdlOmRlYTlhMjBlMjg4YzQ3NGNhZTllN2M3NTdjOGE3ZWY1XzQtMy0xLTEtMA_25894a44-f35b-431e-9c50-99cd75a2db41"
      unitRef="usd">6000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpkZWE5YTIwZTI4OGM0NzRjYWU5ZTdjNzU3YzhhN2VmNS90YWJsZXJhbmdlOmRlYTlhMjBlMjg4YzQ3NGNhZTllN2M3NTdjOGE3ZWY1XzUtMS0xLTEtMA_48bc164c-95d7-41c7-85e2-73066b1929fc"
      unitRef="usd">33000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpkZWE5YTIwZTI4OGM0NzRjYWU5ZTdjNzU3YzhhN2VmNS90YWJsZXJhbmdlOmRlYTlhMjBlMjg4YzQ3NGNhZTllN2M3NTdjOGE3ZWY1XzUtMy0xLTEtMA_b22b47c0-60ed-42eb-9564-185c84dd7c1e"
      unitRef="usd">27000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8a89c112cd7f42b3a5456dc100a7ede7_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZToxOGM5MGUyMjNjNWM0M2I2Yjg4NDAwYjM1NzYwZjcxYy90YWJsZXJhbmdlOjE4YzkwZTIyM2M1YzQzYjZiODg0MDBiMzU3NjBmNzFjXzItMS0xLTEtMA_9a589eab-8ed8-4ed4-87ba-21db54173abf"
      unitRef="usd">56000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic52a8031a6f841969982b87db2a42528_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZToxOGM5MGUyMjNjNWM0M2I2Yjg4NDAwYjM1NzYwZjcxYy90YWJsZXJhbmdlOjE4YzkwZTIyM2M1YzQzYjZiODg0MDBiMzU3NjBmNzFjXzItMy0xLTEtMA_ecb8a8fc-0efc-41b7-a0bf-bd95066658b6"
      unitRef="usd">53000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i96b93fe596a142948ea01b57dd171ae6_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZToxOGM5MGUyMjNjNWM0M2I2Yjg4NDAwYjM1NzYwZjcxYy90YWJsZXJhbmdlOjE4YzkwZTIyM2M1YzQzYjZiODg0MDBiMzU3NjBmNzFjXzMtMS0xLTEtMA_2130a233-ead2-4243-b7ee-eb92b238248f"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i26baad0d41684101ab66f22954853d05_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZToxOGM5MGUyMjNjNWM0M2I2Yjg4NDAwYjM1NzYwZjcxYy90YWJsZXJhbmdlOjE4YzkwZTIyM2M1YzQzYjZiODg0MDBiMzU3NjBmNzFjXzMtMy0xLTEtMA_abcaf34d-eaf9-4761-816b-f974bf4a03b6"
      unitRef="usd">3000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i04a5e9e5e39042d4954e45ee16242fba_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZToxOGM5MGUyMjNjNWM0M2I2Yjg4NDAwYjM1NzYwZjcxYy90YWJsZXJhbmdlOjE4YzkwZTIyM2M1YzQzYjZiODg0MDBiMzU3NjBmNzFjXzQtMS0xLTEtMA_031888ab-5db5-4cba-8492-eedf5467a25a"
      unitRef="usd">28000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifacfc13c40bb4c9bb653687d05e0441a_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZToxOGM5MGUyMjNjNWM0M2I2Yjg4NDAwYjM1NzYwZjcxYy90YWJsZXJhbmdlOjE4YzkwZTIyM2M1YzQzYjZiODg0MDBiMzU3NjBmNzFjXzQtMy0xLTEtMA_e8618710-9368-4bcb-82f7-4870297e0ba0"
      unitRef="usd">12000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZToxOGM5MGUyMjNjNWM0M2I2Yjg4NDAwYjM1NzYwZjcxYy90YWJsZXJhbmdlOjE4YzkwZTIyM2M1YzQzYjZiODg0MDBiMzU3NjBmNzFjXzUtMS0xLTEtMA_05f5cfbe-56b7-4554-8e19-55e5b30a1e1c"
      unitRef="usd">84000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZToxOGM5MGUyMjNjNWM0M2I2Yjg4NDAwYjM1NzYwZjcxYy90YWJsZXJhbmdlOjE4YzkwZTIyM2M1YzQzYjZiODg0MDBiMzU3NjBmNzFjXzUtMy0xLTEtMA_5ce0cafe-af67-44e5-920f-25424b2b6a6b"
      unitRef="usd">68000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i4a236c9400454873a09fc936aa60bf22_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90ZXh0cmVnaW9uOjE1ZjA5M2Q1ZDEyMjQ5NDE4NTc3NzNlMTk1YTZjMWQwXzI5NA_ca64b13a-834f-43ad-aec8-1c77a85ddf2a"
      unitRef="usd">5000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90ZXh0cmVnaW9uOjE1ZjA5M2Q1ZDEyMjQ5NDE4NTc3NzNlMTk1YTZjMWQwXzI5NA_d3176ce9-776a-49c5-bc9c-81710adeb209"
      unitRef="usd">5000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90ZXh0cmVnaW9uOjE1ZjA5M2Q1ZDEyMjQ5NDE4NTc3NzNlMTk1YTZjMWQwXzM0NA_681ac546-96a1-47fe-8122-9f01623960dd"
      unitRef="usd">12000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90ZXh0cmVnaW9uOjE1ZjA5M2Q1ZDEyMjQ5NDE4NTc3NzNlMTk1YTZjMWQwXzM0NA_ade8e185-4ef3-41b1-b3d8-f14d26d5f932"
      unitRef="usd">12000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i8a89c112cd7f42b3a5456dc100a7ede7_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90ZXh0cmVnaW9uOjE1ZjA5M2Q1ZDEyMjQ5NDE4NTc3NzNlMTk1YTZjMWQwXzQ5Mw_3bd3776f-07f6-4ae3-a949-dc1e41091130">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90ZXh0cmVnaW9uOjE1ZjA5M2Q1ZDEyMjQ5NDE4NTc3NzNlMTk1YTZjMWQwXzIzMzc_b9d1cad0-681b-4f87-9991-6bb523c3af95">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all transactions related to restricted share units under the Plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Share Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nonvested at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;48.96&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ib6304faf17b842ef9c340762418125fc_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpkMTZkZGFmMjlmOTI0MTAzYmRiNDc3OGQ1OThjZmQ2Ny90YWJsZXJhbmdlOmQxNmRkYWYyOWY5MjQxMDNiZGI0Nzc4ZDU5OGNmZDY3XzEtMS0xLTEtMA_d4bf324b-0b28-4d68-9b1e-822ccf5f73f9"
      unitRef="shares">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ib6304faf17b842ef9c340762418125fc_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpkMTZkZGFmMjlmOTI0MTAzYmRiNDc3OGQ1OThjZmQ2Ny90YWJsZXJhbmdlOmQxNmRkYWYyOWY5MjQxMDNiZGI0Nzc4ZDU5OGNmZDY3XzEtMy0xLTEtMA_7106b549-65a8-4ee8-9b6c-5172c3ececd4"
      unitRef="usdPerShare">45.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i8a89c112cd7f42b3a5456dc100a7ede7_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpkMTZkZGFmMjlmOTI0MTAzYmRiNDc3OGQ1OThjZmQ2Ny90YWJsZXJhbmdlOmQxNmRkYWYyOWY5MjQxMDNiZGI0Nzc4ZDU5OGNmZDY3XzItMS0xLTEtMA_f96860df-b853-4f11-afb8-f9c930cefbde"
      unitRef="shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i8a89c112cd7f42b3a5456dc100a7ede7_D20200701-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpkMTZkZGFmMjlmOTI0MTAzYmRiNDc3OGQ1OThjZmQ2Ny90YWJsZXJhbmdlOmQxNmRkYWYyOWY5MjQxMDNiZGI0Nzc4ZDU5OGNmZDY3XzItMy0xLTEtMA_158304d2-6790-4442-a70d-096ed09578d2"
      unitRef="usdPerShare">53.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i8a89c112cd7f42b3a5456dc100a7ede7_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpkMTZkZGFmMjlmOTI0MTAzYmRiNDc3OGQ1OThjZmQ2Ny90YWJsZXJhbmdlOmQxNmRkYWYyOWY5MjQxMDNiZGI0Nzc4ZDU5OGNmZDY3XzMtMS0xLTEtMA_c553996b-81e0-408a-bc13-df32f1f8f696"
      unitRef="shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i8a89c112cd7f42b3a5456dc100a7ede7_D20200701-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpkMTZkZGFmMjlmOTI0MTAzYmRiNDc3OGQ1OThjZmQ2Ny90YWJsZXJhbmdlOmQxNmRkYWYyOWY5MjQxMDNiZGI0Nzc4ZDU5OGNmZDY3XzMtMy0xLTEtMA_dc1f2106-4b33-42e3-a7ee-9b3ac7e01a79"
      unitRef="usdPerShare">49.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i8a89c112cd7f42b3a5456dc100a7ede7_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpkMTZkZGFmMjlmOTI0MTAzYmRiNDc3OGQ1OThjZmQ2Ny90YWJsZXJhbmdlOmQxNmRkYWYyOWY5MjQxMDNiZGI0Nzc4ZDU5OGNmZDY3XzQtMS0xLTEtMA_8d99e2a5-6c03-42fe-8fdd-9a54df96118d"
      unitRef="shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i8a89c112cd7f42b3a5456dc100a7ede7_D20200701-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpkMTZkZGFmMjlmOTI0MTAzYmRiNDc3OGQ1OThjZmQ2Ny90YWJsZXJhbmdlOmQxNmRkYWYyOWY5MjQxMDNiZGI0Nzc4ZDU5OGNmZDY3XzQtMy0xLTEtMA_13e660a4-37f3-45b3-9d99-1e3c082afab5"
      unitRef="usdPerShare">48.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i77e9bd39dd824727aafae148f4111ead_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpkMTZkZGFmMjlmOTI0MTAzYmRiNDc3OGQ1OThjZmQ2Ny90YWJsZXJhbmdlOmQxNmRkYWYyOWY5MjQxMDNiZGI0Nzc4ZDU5OGNmZDY3XzUtMS0xLTEtMA_62366d2f-3745-4ee3-870a-2b4960572c15"
      unitRef="shares">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i77e9bd39dd824727aafae148f4111ead_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpkMTZkZGFmMjlmOTI0MTAzYmRiNDc3OGQ1OThjZmQ2Ny90YWJsZXJhbmdlOmQxNmRkYWYyOWY5MjQxMDNiZGI0Nzc4ZDU5OGNmZDY3XzUtMy0xLTEtMA_77fb4146-f655-4dfa-9374-7e44b6a5b631"
      unitRef="usdPerShare">48.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i77e9bd39dd824727aafae148f4111ead_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90ZXh0cmVnaW9uOjE1ZjA5M2Q1ZDEyMjQ5NDE4NTc3NzNlMTk1YTZjMWQwXzg0MA_d9bd0af0-4aa4-43de-9e61-f1af56f86671"
      unitRef="usd">90000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i8a89c112cd7f42b3a5456dc100a7ede7_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90ZXh0cmVnaW9uOjE1ZjA5M2Q1ZDEyMjQ5NDE4NTc3NzNlMTk1YTZjMWQwXzkxMw_9d2a58ae-18f3-46a9-a69e-0cc4df7af50a">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i96b93fe596a142948ea01b57dd171ae6_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90ZXh0cmVnaW9uOjE1ZjA5M2Q1ZDEyMjQ5NDE4NTc3NzNlMTk1YTZjMWQwXzEwMjc_b5f428f0-39ca-4695-9ef1-795001a6d3c4">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <cah:ExercisablePeriodOfPlansInYears
      contextRef="i96b93fe596a142948ea01b57dd171ae6_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90ZXh0cmVnaW9uOjE1ZjA5M2Q1ZDEyMjQ5NDE4NTc3NzNlMTk1YTZjMWQwXzEwNTQ_87bf56a1-c44d-4550-b01e-3186b147b3f5">P10Y</cah:ExercisablePeriodOfPlansInYears>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90ZXh0cmVnaW9uOjE1ZjA5M2Q1ZDEyMjQ5NDE4NTc3NzNlMTk1YTZjMWQwXzIzNTc_5e797bdd-d70d-493c-bdd2-5b88fe15afda">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all stock option transactions under the Plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.616%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.480%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.061%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Stock&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise Price per&lt;br/&gt;Common Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;67.60&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercisable at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;67.80&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTo1Zjg0M2QwYjEzYWQ0MmM1YWYyODc4MTJjY2Y3MjZlOC90YWJsZXJhbmdlOjVmODQzZDBiMTNhZDQyYzVhZjI4NzgxMmNjZjcyNmU4XzEtMS0xLTEtMA_f4833571-1f97-4fd2-990c-7990eb631177"
      unitRef="shares">5000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ib19c0c691fb5445d9011b91ede443228_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTo1Zjg0M2QwYjEzYWQ0MmM1YWYyODc4MTJjY2Y3MjZlOC90YWJsZXJhbmdlOjVmODQzZDBiMTNhZDQyYzVhZjI4NzgxMmNjZjcyNmU4XzEtMy0xLTEtMA_e90a7ce9-3954-47f9-b0fa-3a013ec5ba16"
      unitRef="usdPerShare">65.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTo1Zjg0M2QwYjEzYWQ0MmM1YWYyODc4MTJjY2Y3MjZlOC90YWJsZXJhbmdlOjVmODQzZDBiMTNhZDQyYzVhZjI4NzgxMmNjZjcyNmU4XzItMS0xLTEtMA_d05ef15e-fa62-4035-9de1-a4cbd9f71347"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTo1Zjg0M2QwYjEzYWQ0MmM1YWYyODc4MTJjY2Y3MjZlOC90YWJsZXJhbmdlOjVmODQzZDBiMTNhZDQyYzVhZjI4NzgxMmNjZjcyNmU4XzItMy0xLTEtMA_127db55c-1ff9-4f1d-90ec-84aaf3db3b1b"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTo1Zjg0M2QwYjEzYWQ0MmM1YWYyODc4MTJjY2Y3MjZlOC90YWJsZXJhbmdlOjVmODQzZDBiMTNhZDQyYzVhZjI4NzgxMmNjZjcyNmU4XzMtMS0xLTEtMA_84ede452-bfd1-4f6d-b2be-e32dcad0e8c5"
      unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTo1Zjg0M2QwYjEzYWQ0MmM1YWYyODc4MTJjY2Y3MjZlOC90YWJsZXJhbmdlOjVmODQzZDBiMTNhZDQyYzVhZjI4NzgxMmNjZjcyNmU4XzMtMy0xLTEtMA_c968618a-ab21-4b6b-9a15-ca08982965a2"
      unitRef="usdPerShare">40.94</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTo1Zjg0M2QwYjEzYWQ0MmM1YWYyODc4MTJjY2Y3MjZlOC90YWJsZXJhbmdlOjVmODQzZDBiMTNhZDQyYzVhZjI4NzgxMmNjZjcyNmU4XzQtMS0xLTEtMA_a8c575b6-c8d0-49bd-bacb-0a55eed55a0c"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTo1Zjg0M2QwYjEzYWQ0MmM1YWYyODc4MTJjY2Y3MjZlOC90YWJsZXJhbmdlOjVmODQzZDBiMTNhZDQyYzVhZjI4NzgxMmNjZjcyNmU4XzQtMy0xLTEtMA_0e2a3adc-45d8-4339-b49c-55800d8b804f"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTo1Zjg0M2QwYjEzYWQ0MmM1YWYyODc4MTJjY2Y3MjZlOC90YWJsZXJhbmdlOjVmODQzZDBiMTNhZDQyYzVhZjI4NzgxMmNjZjcyNmU4XzUtMS0xLTEtMA_dd8a3b99-bd7f-47cd-8ba7-e75096b7751d"
      unitRef="shares">4000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTo1Zjg0M2QwYjEzYWQ0MmM1YWYyODc4MTJjY2Y3MjZlOC90YWJsZXJhbmdlOjVmODQzZDBiMTNhZDQyYzVhZjI4NzgxMmNjZjcyNmU4XzUtMy0xLTEtMA_f58f1d00-db7e-4031-b665-280ab903e845"
      unitRef="usdPerShare">67.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTo1Zjg0M2QwYjEzYWQ0MmM1YWYyODc4MTJjY2Y3MjZlOC90YWJsZXJhbmdlOjVmODQzZDBiMTNhZDQyYzVhZjI4NzgxMmNjZjcyNmU4XzYtMS0xLTEtMA_8e0b804e-5ea1-4093-b1e9-7ad99044333a"
      unitRef="shares">4000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ibe76498d80224b4f96b532177a01467f_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTo1Zjg0M2QwYjEzYWQ0MmM1YWYyODc4MTJjY2Y3MjZlOC90YWJsZXJhbmdlOjVmODQzZDBiMTNhZDQyYzVhZjI4NzgxMmNjZjcyNmU4XzYtMy0xLTEtMA_bc31219f-9c3d-4671-abc6-909e303fc90a"
      unitRef="usdPerShare">67.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i5226be778dfe441d9f2c92df26a11158_I20210331"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90ZXh0cmVnaW9uOjE1ZjA5M2Q1ZDEyMjQ5NDE4NTc3NzNlMTk1YTZjMWQwXzE0MjM_ee0cb9a8-f664-4788-9db1-3562c1aa2556"
      unitRef="usd">200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i96b93fe596a142948ea01b57dd171ae6_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90ZXh0cmVnaW9uOjE1ZjA5M2Q1ZDEyMjQ5NDE4NTc3NzNlMTk1YTZjMWQwXzE0OTY_92c3b7a1-80cc-4691-adea-1f8ccd641189">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <cah:AdditionalStockOptionPlanDataTableTextBlock
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90ZXh0cmVnaW9uOjE1ZjA5M2Q1ZDEyMjQ5NDE4NTc3NzNlMTk1YTZjMWQwXzIzNDU_bfeb23b9-e3f2-4071-85da-81945d63f70f">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables provide additional detail related to stock options:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Aggregate intrinsic value of outstanding options at period end&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Aggregate intrinsic value of exercisable options at period end&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;17&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.850%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.887%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.343%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining contractual life of outstanding options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining contractual life of exercisable options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</cah:AdditionalStockOptionPlanDataTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i5226be778dfe441d9f2c92df26a11158_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTo1MzMzMTI3ODhkZjM0MTQzYTFjYWQ5YTc3MjA3MDJiMi90YWJsZXJhbmdlOjUzMzMxMjc4OGRmMzQxNDNhMWNhZDlhNzcyMDcwMmIyXzEtMS0xLTEtMA_4e9c3a94-ff72-4223-a8bb-2bd59fa3664a"
      unitRef="usd">17000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ic86b7d6cb21f44eaad860256ec1bfebc_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTo1MzMzMTI3ODhkZjM0MTQzYTFjYWQ5YTc3MjA3MDJiMi90YWJsZXJhbmdlOjUzMzMxMjc4OGRmMzQxNDNhMWNhZDlhNzcyMDcwMmIyXzEtMy0xLTEtMA_f583331a-bf0d-4b9c-92d7-e7f71143a1ec"
      unitRef="usd">12000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i5226be778dfe441d9f2c92df26a11158_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTo1MzMzMTI3ODhkZjM0MTQzYTFjYWQ5YTc3MjA3MDJiMi90YWJsZXJhbmdlOjUzMzMxMjc4OGRmMzQxNDNhMWNhZDlhNzcyMDcwMmIyXzItMS0xLTEtMA_e90370a5-2d35-48c2-a88e-c74dee1bf8f9"
      unitRef="usd">17000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="ic86b7d6cb21f44eaad860256ec1bfebc_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTo1MzMzMTI3ODhkZjM0MTQzYTFjYWQ5YTc3MjA3MDJiMi90YWJsZXJhbmdlOjUzMzMxMjc4OGRmMzQxNDNhMWNhZDlhNzcyMDcwMmIyXzItMy0xLTEtMA_6bc2dd0c-6290-4863-9fc8-9a9dd4a41e4b"
      unitRef="usd">12000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i96b93fe596a142948ea01b57dd171ae6_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTowODdjODY2MjU1NDY0NWI5ODI3YTNkNWVkODA4YjRlYS90YWJsZXJhbmdlOjA4N2M4NjYyNTU0NjQ1Yjk4MjdhM2Q1ZWQ4MDhiNGVhXzEtMS0xLTEtMA_9cfb0595-2511-428f-bd3f-56baf01f1e76">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i26baad0d41684101ab66f22954853d05_D20190701-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTowODdjODY2MjU1NDY0NWI5ODI3YTNkNWVkODA4YjRlYS90YWJsZXJhbmdlOjA4N2M4NjYyNTU0NjQ1Yjk4MjdhM2Q1ZWQ4MDhiNGVhXzEtMy0xLTEtMA_a2241eec-17be-4056-a739-638b0705c040">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i96b93fe596a142948ea01b57dd171ae6_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTowODdjODY2MjU1NDY0NWI5ODI3YTNkNWVkODA4YjRlYS90YWJsZXJhbmdlOjA4N2M4NjYyNTU0NjQ1Yjk4MjdhM2Q1ZWQ4MDhiNGVhXzItMS0xLTEtMA_878f6670-c5f1-4f65-a5fe-bc01b3cff3cc">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i26baad0d41684101ab66f22954853d05_D20190701-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTowODdjODY2MjU1NDY0NWI5ODI3YTNkNWVkODA4YjRlYS90YWJsZXJhbmdlOjA4N2M4NjYyNTU0NjQ1Yjk4MjdhM2Q1ZWQ4MDhiNGVhXzItMy0xLTEtMA_6cd2ae63-6a37-4970-ab40-88eee38a6cdd">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <cah:VestingPeriodinyearsforShares
      contextRef="i04a5e9e5e39042d4954e45ee16242fba_D20200701-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90ZXh0cmVnaW9uOjE1ZjA5M2Q1ZDEyMjQ5NDE4NTc3NzNlMTk1YTZjMWQwXzE2Mzk_ae274305-37a7-4c80-b9ea-7a3fc6ddf579"
      unitRef="number">3</cah:VestingPeriodinyearsforShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="iae78c99bef954f35b10d2bf1557917a0_D20200701-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90ZXh0cmVnaW9uOjE1ZjA5M2Q1ZDEyMjQ5NDE4NTc3NzNlMTk1YTZjMWQwXzE4MDI_798b7689-7166-4c4c-9f52-05ccd4b2b8b8"
      unitRef="number">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="if622e969bb1c456795db4df9e45f0a4b_D20200701-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90ZXh0cmVnaW9uOjE1ZjA5M2Q1ZDEyMjQ5NDE4NTc3NzNlMTk1YTZjMWQwXzE4MDg_eee5259e-882a-4e0f-bc2a-7e0e7224bd4a"
      unitRef="number">2.40</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock
      contextRef="i67ba371541c247eb885ce35370b4c954_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90ZXh0cmVnaW9uOjE1ZjA5M2Q1ZDEyMjQ5NDE4NTc3NzNlMTk1YTZjMWQwXzIzNDE_c93f5b3c-1fbe-4f01-a6a1-3e544d7ad7ce">&lt;div style="margin-bottom:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.983%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.023%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:26.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;(in millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Performance&lt;br/&gt;Share Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant Date Fair&lt;br/&gt;Value per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Nonvested at June 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nonvested at March 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;1.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;60.32&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i9f362429a27e4da98d58d075d240086a_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpmZmU3OTJlNDQ5NTU0YTU5YjUxYzYyMTA3M2VkNjBlYS90YWJsZXJhbmdlOmZmZTc5MmU0NDk1NTRhNTliNTFjNjIxMDczZWQ2MGVhXzEtMS0xLTEtMA_dea9e879-cfa1-4852-8491-e0298380e6dd"
      unitRef="shares">1300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i9f362429a27e4da98d58d075d240086a_I20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpmZmU3OTJlNDQ5NTU0YTU5YjUxYzYyMTA3M2VkNjBlYS90YWJsZXJhbmdlOmZmZTc5MmU0NDk1NTRhNTliNTFjNjIxMDczZWQ2MGVhXzEtMy0xLTEtMA_985ed9cc-719d-4473-8d41-11719e439e1d"
      unitRef="usdPerShare">54.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i04a5e9e5e39042d4954e45ee16242fba_D20200701-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpmZmU3OTJlNDQ5NTU0YTU5YjUxYzYyMTA3M2VkNjBlYS90YWJsZXJhbmdlOmZmZTc5MmU0NDk1NTRhNTliNTFjNjIxMDczZWQ2MGVhXzItMS0xLTEtMA_48795e6e-7012-4352-8bb1-fc7eedf02f71"
      unitRef="shares">400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i04a5e9e5e39042d4954e45ee16242fba_D20200701-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpmZmU3OTJlNDQ5NTU0YTU5YjUxYzYyMTA3M2VkNjBlYS90YWJsZXJhbmdlOmZmZTc5MmU0NDk1NTRhNTliNTFjNjIxMDczZWQ2MGVhXzItMy0xLTEtMA_f91b81b9-0f8c-4e16-8864-19026eccb837"
      unitRef="usdPerShare">55.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i04a5e9e5e39042d4954e45ee16242fba_D20200701-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpmZmU3OTJlNDQ5NTU0YTU5YjUxYzYyMTA3M2VkNjBlYS90YWJsZXJhbmdlOmZmZTc5MmU0NDk1NTRhNTliNTFjNjIxMDczZWQ2MGVhXzMtMS0xLTEtMA_b1074afb-5d65-46ce-9514-a339d32870c4"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i04a5e9e5e39042d4954e45ee16242fba_D20200701-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpmZmU3OTJlNDQ5NTU0YTU5YjUxYzYyMTA3M2VkNjBlYS90YWJsZXJhbmdlOmZmZTc5MmU0NDk1NTRhNTliNTFjNjIxMDczZWQ2MGVhXzMtMy0xLTEtMA_766d0034-eee2-4c44-89af-77c9e1770244"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i04a5e9e5e39042d4954e45ee16242fba_D20200701-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpmZmU3OTJlNDQ5NTU0YTU5YjUxYzYyMTA3M2VkNjBlYS90YWJsZXJhbmdlOmZmZTc5MmU0NDk1NTRhNTliNTFjNjIxMDczZWQ2MGVhXzQtMS0xLTEtMA_e48292b6-0620-4568-9332-f065616dd4d5"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i04a5e9e5e39042d4954e45ee16242fba_D20200701-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpmZmU3OTJlNDQ5NTU0YTU5YjUxYzYyMTA3M2VkNjBlYS90YWJsZXJhbmdlOmZmZTc5MmU0NDk1NTRhNTliNTFjNjIxMDczZWQ2MGVhXzQtMy0xLTEtMA_eb3d82a6-a0f2-4cb7-ac84-1d36cac5278e"
      unitRef="usdPerShare">52.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ia7e27cac65544c18a83f69a3c9f73b79_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpmZmU3OTJlNDQ5NTU0YTU5YjUxYzYyMTA3M2VkNjBlYS90YWJsZXJhbmdlOmZmZTc5MmU0NDk1NTRhNTliNTFjNjIxMDczZWQ2MGVhXzUtMS0xLTEtMA_1245d44a-7d4f-4182-8663-d311bdcaf0ca"
      unitRef="shares">1600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ia7e27cac65544c18a83f69a3c9f73b79_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90YWJsZTpmZmU3OTJlNDQ5NTU0YTU5YjUxYzYyMTA3M2VkNjBlYS90YWJsZXJhbmdlOmZmZTc5MmU0NDk1NTRhNTliNTFjNjIxMDczZWQ2MGVhXzUtMy0xLTEtMA_8a61f100-7071-4f10-a065-d934a983b775"
      unitRef="usdPerShare">60.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ia7e27cac65544c18a83f69a3c9f73b79_I20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90ZXh0cmVnaW9uOjE1ZjA5M2Q1ZDEyMjQ5NDE4NTc3NzNlMTk1YTZjMWQwXzIyMTc_26dc771c-6e2c-4cd6-bc11-ccfa60af31b8"
      unitRef="usd">41000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i04a5e9e5e39042d4954e45ee16242fba_D20200701-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2YmY0NTY2OWFkOTQ4NjFiMGM1MGRiYzJmNDM3MWNlL3NlYzpiNmJmNDU2NjlhZDk0ODYxYjBjNTBkYmMyZjQzNzFjZV8xMTgvZnJhZzoxNWYwOTNkNWQxMjI0OTQxODU3NzczZTE5NWE2YzFkMC90ZXh0cmVnaW9uOjE1ZjA5M2Q1ZDEyMjQ5NDE4NTc3NzNlMTk1YTZjMWQwXzIyOTA_5cefecd5-a93e-47ea-8012-74ff51b2a5a5">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694840822264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-11373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Cardinal Health, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000721371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--06-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">OH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">31-0958666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7000 Cardinal Place<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Dublin<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">OH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">43017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(614)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">757-5000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common shares (without par value)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CAH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">290,147,927<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694840953832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Earnings - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 39,275<span></span>
</td>
<td class="nump">$ 39,157<span></span>
</td>
<td class="nump">$ 119,881<span></span>
</td>
<td class="nump">$ 116,233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="nump">37,463<span></span>
</td>
<td class="nump">37,272<span></span>
</td>
<td class="nump">114,578<span></span>
</td>
<td class="nump">110,955<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross margin</a></td>
<td class="nump">1,812<span></span>
</td>
<td class="nump">1,885<span></span>
</td>
<td class="nump">5,303<span></span>
</td>
<td class="nump">5,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Distribution, selling, general and administrative expenses</a></td>
<td class="nump">1,120<span></span>
</td>
<td class="nump">1,165<span></span>
</td>
<td class="nump">3,404<span></span>
</td>
<td class="nump">3,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring and employee severance</a></td>
<td class="nump">24<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_Amortizationandotheracquisitionrelatedcosts', window );">Amortization and other acquisition-related costs</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="nump">345<span></span>
</td>
<td class="nump">395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges', window );">Impairments and (gain)/loss on disposal of assets, net</a></td>
<td class="nump">69<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Litigation (recoveries)/charges, net</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">1,085<span></span>
</td>
<td class="nump">5,729<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating earnings/(loss)</a></td>
<td class="nump">473<span></span>
</td>
<td class="nump">562<span></span>
</td>
<td class="nump">310<span></span>
</td>
<td class="num">(4,368)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income)/expense, net</a></td>
<td class="num">(12)<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense, net</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="nump">189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on Extinguishment of Debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Earnings/(loss) before income taxes</a></td>
<td class="nump">440<span></span>
</td>
<td class="nump">478<span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="num">(4,587)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for/(benefit from) income taxes</a></td>
<td class="nump">320<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="num">(293)<span></span>
</td>
<td class="num">(237)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net earnings/(loss)</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">351<span></span>
</td>
<td class="nump">497<span></span>
</td>
<td class="num">(4,350)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Net earnings attributable to noncontrolling interests</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings/(loss) attributable to Cardinal Health, Inc.</a></td>
<td class="nump">$ 119<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
<td class="nump">$ 495<span></span>
</td>
<td class="num">$ (4,352)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Earnings/(loss) per common share attributable to Cardinal Health, Inc.:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Basic (in shares)</a></td>
<td class="nump">$ 0.41<span></span>
</td>
<td class="nump">$ 1.20<span></span>
</td>
<td class="nump">$ 1.69<span></span>
</td>
<td class="num">$ (14.84)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Income (Loss) from Continuing Operations, Per Diluted Share</a></td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="nump">$ 1.19<span></span>
</td>
<td class="nump">$ 1.68<span></span>
</td>
<td class="num">$ (14.84)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted-average number of common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">292<span></span>
</td>
<td class="nump">292<span></span>
</td>
<td class="nump">293<span></span>
</td>
<td class="nump">293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">294<span></span>
</td>
<td class="nump">294<span></span>
</td>
<td class="nump">294<span></span>
</td>
<td class="nump">293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Cash dividends declared per common share</a></td>
<td class="nump">$ 0.4859<span></span>
</td>
<td class="nump">$ 0.4811<span></span>
</td>
<td class="nump">$ 1.4577<span></span>
</td>
<td class="nump">$ 1.4433<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_Amortizationandotheracquisitionrelatedcosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of acquired intangible assets and changes in the fair value of contingent consideration obligations. This also represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_Amortizationandotheracquisitionrelatedcosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868656-224227<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868656-224227<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694840840536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net earnings/(loss)</a></td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">$ 351<span></span>
</td>
<td class="nump">$ 497<span></span>
</td>
<td class="num">$ (4,350)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income/(loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments and other</a></td>
<td class="nump">9<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax', window );">Net unrealized gain/(loss) on derivative instruments, net of tax</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income/(loss), net of tax</a></td>
<td class="nump">5<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="num">(62)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Total comprehensive income/(loss)</a></td>
<td class="nump">125<span></span>
</td>
<td class="nump">313<span></span>
</td>
<td class="nump">553<span></span>
</td>
<td class="num">(4,412)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Net earnings attributable to noncontrolling interests</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive income attributable to Cardinal Health, Inc.</a></td>
<td class="nump">$ 124<span></span>
</td>
<td class="nump">$ 312<span></span>
</td>
<td class="nump">$ 551<span></span>
</td>
<td class="num">$ (4,414)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694850500472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and equivalents</a></td>
<td class="nump">$ 3,499<span></span>
</td>
<td class="nump">$ 2,771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Trade receivables, net</a></td>
<td class="nump">8,727<span></span>
</td>
<td class="nump">8,264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">14,329<span></span>
</td>
<td class="nump">13,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">2,715<span></span>
</td>
<td class="nump">1,707<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Total assets held for sale</a></td>
<td class="nump">1,092<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">30,362<span></span>
</td>
<td class="nump">25,940<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,315<span></span>
</td>
<td class="nump">2,366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Goodwill and other intangibles, net</a></td>
<td class="nump">10,179<span></span>
</td>
<td class="nump">11,275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,018<span></span>
</td>
<td class="nump">1,185<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">43,874<span></span>
</td>
<td class="nump">40,766<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">22,641<span></span>
</td>
<td class="nump">21,374<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of long-term obligations and other short-term borrowings</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">2,573<span></span>
</td>
<td class="nump">2,231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation', window );">Disposal Group, Including Discontinued Operation, Liabilities</a></td>
<td class="nump">93<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">25,323<span></span>
</td>
<td class="nump">23,615<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term obligations, less current portion</a></td>
<td class="nump">6,715<span></span>
</td>
<td class="nump">6,765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent', window );">Deferred income taxes and other liabilities</a></td>
<td class="nump">10,042<span></span>
</td>
<td class="nump">8,594<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred shares, without par value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Authorized&#8212;500 thousand shares, Issued&#8212;none</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common shares, without par value:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Authorized&#8212;755 million shares, Issued&#8212;327 million shares at March&#160;31, 2021 and June 30, 2020, respectively</a></td>
<td class="nump">2,807<span></span>
</td>
<td class="nump">2,789<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">1,233<span></span>
</td>
<td class="nump">1,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Common shares in treasury, at cost: 36 million shares and 34 million shares at March&#160;31, 2021 and June 30, 2020, respectively</a></td>
<td class="num">(2,202)<span></span>
</td>
<td class="num">(2,066)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(48)<span></span>
</td>
<td class="num">(104)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Cardinal Health, Inc. shareholders' equity</a></td>
<td class="nump">1,790<span></span>
</td>
<td class="nump">1,789<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">1,794<span></span>
</td>
<td class="nump">1,792<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; equity</a></td>
<td class="nump">$ 43,874<span></span>
</td>
<td class="nump">$ 40,766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares, authorized</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred shares, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, authorized</a></td>
<td class="nump">755,000<span></span>
</td>
<td class="nump">755,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, issued</a></td>
<td class="nump">327,000<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Common shares in treasury</a></td>
<td class="nump">36,000<span></span>
</td>
<td class="nump">34,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting, and liabilities classified as noncurrent and other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694850504984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares, authorized</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred shares, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares, authorized</a></td>
<td class="nump">755,000<span></span>
</td>
<td class="nump">755,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares, issued</a></td>
<td class="nump">327,000<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Common shares in treasury</a></td>
<td class="nump">36,000<span></span>
</td>
<td class="nump">34,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694839244568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Shareholders' Equity - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income/(Loss)</div></th>
<th class="th"><div>Noncontrolling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at beginning of period (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period at Jun. 30, 2019</a></td>
<td class="nump">$ 6,330<span></span>
</td>
<td class="nump">$ 2,763<span></span>
</td>
<td class="nump">$ 5,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (79)<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at beginning of period (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at beginning of period at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,790)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</a></td>
<td class="num">(4,350)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="num">(4,352)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other Comprehensive Income (Loss), Net of Tax</a></td>
<td class="num">(62)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</a></td>
<td class="num">(62)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(62)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for Repurchase of Common Stock</a></td>
<td class="num">(350)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury shares acquired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends</a></td>
<td class="num">(426)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(426)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at end of period (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Mar. 31, 2020</a></td>
<td class="nump">1,206<span></span>
</td>
<td class="nump">$ 2,774<span></span>
</td>
<td class="nump">656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(141)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at end of period (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at end of period at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,086)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury Stock, Value, Acquired, Cost Method</a></td>
<td class="num">(350)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (350)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at beginning of period (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period at Dec. 31, 2019</a></td>
<td class="nump">1,002<span></span>
</td>
<td class="nump">$ 2,752<span></span>
</td>
<td class="nump">449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(103)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at beginning of period (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at beginning of period at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,099)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</a></td>
<td class="nump">351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other Comprehensive Income (Loss), Net of Tax</a></td>
<td class="num">(38)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</a></td>
<td class="num">(38)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends</a></td>
<td class="num">(142)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(142)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at end of period (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Mar. 31, 2020</a></td>
<td class="nump">$ 1,206<span></span>
</td>
<td class="nump">$ 2,774<span></span>
</td>
<td class="nump">656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(141)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at end of period (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at end of period at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,086)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at beginning of period (in shares) at Jun. 30, 2020</a></td>
<td class="nump">327,000<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period at Jun. 30, 2020</a></td>
<td class="nump">$ 1,792<span></span>
</td>
<td class="nump">$ 2,789<span></span>
</td>
<td class="nump">1,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(104)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at beginning of period (in shares) at Jun. 30, 2020</a></td>
<td class="num">(34,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at beginning of period at Jun. 30, 2020</a></td>
<td class="num">$ (2,066)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</a></td>
<td class="nump">497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="nump">495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other Comprehensive Income (Loss), Net of Tax</a></td>
<td class="nump">56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</a></td>
<td class="nump">$ 56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="nump">$ 82<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for Repurchase of Common Stock</a></td>
<td class="num">(200)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury shares acquired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends</a></td>
<td class="num">(432)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(432)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOtherShares', window );">Stockholders' Equity, Other Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at end of period (in shares) at Mar. 31, 2021</a></td>
<td class="nump">327,000<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Mar. 31, 2021</a></td>
<td class="nump">$ 1,794<span></span>
</td>
<td class="nump">$ 2,807<span></span>
</td>
<td class="nump">1,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at end of period (in shares) at Mar. 31, 2021</a></td>
<td class="num">(36,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at end of period at Mar. 31, 2021</a></td>
<td class="num">$ (2,202)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,202)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury Stock, Value, Acquired, Cost Method</a></td>
<td class="num">(200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at beginning of period (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period at Dec. 31, 2020</a></td>
<td class="nump">1,975<span></span>
</td>
<td class="nump">$ 2,778<span></span>
</td>
<td class="nump">1,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at beginning of period (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at beginning of period at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</a></td>
<td class="nump">120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="nump">119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other Comprehensive Income (Loss), Net of Tax</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for Repurchase of Common Stock</a></td>
<td class="num">(200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury shares acquired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends</a></td>
<td class="num">(143)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(143)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOtherShares', window );">Stockholders' Equity, Other Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance at end of period (in shares) at Mar. 31, 2021</a></td>
<td class="nump">327,000<span></span>
</td>
<td class="nump">327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Mar. 31, 2021</a></td>
<td class="nump">$ 1,794<span></span>
</td>
<td class="nump">$ 2,807<span></span>
</td>
<td class="nump">$ 1,233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (48)<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury, balance at end of period (in shares) at Mar. 31, 2021</a></td>
<td class="num">(36,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury, balance at end of period at Mar. 31, 2021</a></td>
<td class="num">$ (2,202)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,202)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury Stock, Value, Acquired, Cost Method</a></td>
<td class="num">$ (200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOtherShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of increase (decrease) in shares of stock classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOtherShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694841759944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net earnings/(loss)</a></td>
<td class="nump">$ 497<span></span>
</td>
<td class="num">$ (4,350)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net earnings/(loss) to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">603<span></span>
</td>
<td class="nump">688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges', window );">Impairments and (gain)/loss on disposal of assets, net</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on Extinguishment of Debt</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for bad debts</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities, net of effects from acquisitions and divestitures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Increase in trade receivables</a></td>
<td class="num">(511)<span></span>
</td>
<td class="num">(653)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Increase in inventories</a></td>
<td class="num">(1,323)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Increase in accounts payable</a></td>
<td class="nump">1,267<span></span>
</td>
<td class="nump">448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other accrued liabilities and operating items, net</a></td>
<td class="nump">1,019<span></span>
</td>
<td class="nump">5,425<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">1,764<span></span>
</td>
<td class="nump">1,720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition of subsidiaries, net of cash acquired</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Additions to property and equipment</a></td>
<td class="num">(274)<span></span>
</td>
<td class="num">(239)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_Purchaseofavailableforsalesecuritiesandotherinvestments', window );">Purchase of investments</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments', window );">Proceeds from investments</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets', window );">Proceeds from divestitures and disposal of property and equipment and held for sale assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(290)<span></span>
</td>
<td class="num">(249)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfShortTermDebt', window );">Net change in short-term borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromHedgeFinancingActivities', window );">Payments for (Proceeds from) Hedge, Financing Activities</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Reduction of long-term obligations</a></td>
<td class="num">(53)<span></span>
</td>
<td class="num">(888)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_Netproceedstaxwithholdingsfromsharebasedcompensation', window );">Net proceeds/(tax withholdings) from share-based compensation</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsCommonStock', window );">Dividends on common shares</a></td>
<td class="num">(432)<span></span>
</td>
<td class="num">(428)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for Repurchase of Common Stock</a></td>
<td class="num">(200)<span></span>
</td>
<td class="num">(350)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(668)<span></span>
</td>
<td class="num">(1,672)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effect of exchange rates changes on cash and equivalents</a></td>
<td class="nump">8<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_CashReclassifiedToAssetHeldForSale', window );">Cash Reclassified to Asset Held for Sale</a></td>
<td class="num">(86)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Total</a></td>
<td class="nump">728<span></span>
</td>
<td class="num">(202)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and equivalents at beginning of period</a></td>
<td class="nump">2,771<span></span>
</td>
<td class="nump">2,531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and equivalents at end of period</a></td>
<td class="nump">$ 3,499<span></span>
</td>
<td class="nump">$ 2,329<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_CashReclassifiedToAssetHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Reclassified to Asset Held for Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_CashReclassifiedToAssetHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_Netproceedstaxwithholdingsfromsharebasedcompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow/(outflow) associated with the amount received from holders exercising their stock options and paid by the company to satisfy an employee's income tax withholding obligation when shares are withheld from settlement of a share-based award to cover taxes. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_Netproceedstaxwithholdingsfromsharebasedcompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from divestitures and disposal of property and equipment and held for sale assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of available-for-sale securities and other investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_Purchaseofavailableforsalesecuritiesandotherinvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from purchases of available-for-sale securities and other investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_Purchaseofavailableforsalesecuritiesandotherinvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromHedgeFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash outflow or inflow for a financial contract that meets the hedge criteria as either cash flow hedge, fair value hedge or hedge of net investment in foreign operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromHedgeFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694835683928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">1. Basis of Presentation and Summary of Significant Accounting Policies </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to "we," "our," and similar pronouns is in this Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2021 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context requires otherwise.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fiscal year ends on June 30. References to fiscal 2021 and 2020 in these condensed consolidated financial statements are to the fiscal years ending or ended June&#160;30, 2021 and June&#160;30, 2020, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic ("COVID-19") continues to affect the U.S. and global economies, and as previously disclosed in our Fiscal 2020 Form 10-K, the pandemic began to materially affect our businesses during the three months ended March 31, 2020. The length and severity of the pandemic and of the related economic impacts to our businesses and operations are uncertain, including its ongoing impacts to our businesses and results of operations.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.&#160;In addition, financial results presented for this fiscal 2021 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June&#160;30, 2021. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2020 (the "2020 Form 10-K").</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Adopted Financial Accounting Standards</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued amended accounting guidance that will require entities to measure credit losses on trade and other receivables, held-to-maturity debt securities, loans and other instruments using an "expected credit loss" model that considers historical experience, current conditions and reasonable supportable forecasts. This guidance also requires that credit losses on available-for-sale debt securities with unrealized losses be recognized as allowances rather than as deductions in the amortized cost of the securities. We consider historical experience, the current economic environment, customer credit ratings or bankruptcies, and reasonable and supportable forecasts to develop our allowance for credit losses. We review these factors quarterly to determine if any adjustments are needed to the allowance. This guidance was effective beginning the first quarter of fiscal 2021 and did not have a material impact on our condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694834242312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Assets held for sale<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Disposal Groups, Including Discontinued Operations, Disclosure</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">2. Assets Held for Sale</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify assets and liabilities (the &#8220;disposal group&#8221;) as held for sale when management commits to a plan to sell the disposal group in its present condition and at a price that is reasonable in relation to its current fair value. We also consider whether an active program to locate a buyer has been initiated and if it is probable that the sale will occur within one year without significant changes to the plan to sell. Upon classification of the disposal group as held for sale, we assess the assets for impairment and cease related depreciation and amortization.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 12, 2021, we signed a definitive agreement with Hellman &amp; Friedman to sell our Cordis business for gross proceeds of $927&#160;million in cash, subject to customary purchase price adjustments, and we will retain certain working capital accounts and certain liabilities. The transaction is expected to close in the first quarter of fiscal 2022, subject to customary closing conditions and regulatory clearances. Cardinal Health will retain liability associated with lawsuits related to inferior vena cava ("IVC") filters in the U.S. and Canada, as well as authority for these matters discussed in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib6bf45669ad94861b0c50dbc2f4371ce_97" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2021, we met the criteria for the related assets and liabilities of the Cordis business to be classified as held for sale. In connection with the planned divestiture, we allocated $388&#160;million of goodwill from the Medical Unit (within our Medical Segment) to the Cordis disposal group based on the estimated relative fair values of the business to be disposed of and the portion of the reporting unit that will be retained. We determined that the sale of the Cordis business does not meet the criteria to be classified as discontinued operations. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2021, the book value of the disposal group exceeded its fair value less costs to sell. Accordingly, we recognized a $58 </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million pre-tax write-down on the disposal group in impairments and (gain)/loss on disposal of assets in our condensed consolidated statement of earnings/(loss). This write-down includes a $2 million gain related to currency translation adjustments in accumulated other comprehensive income. We recorded a net tax expense of $7 million associated with the impact of the write-down and the required tax adjustments triggered by held for sale accounting.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information related to the assets and liabilities that were classified as held for sale at March&#160;31, 2021 related to the Cordis planned divestiture in the condensed consolidated balance sheets:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.246%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and equivalents</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">86</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">175</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">88</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill and other intangibles, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">779</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Write-down of assets held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(58)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets held for sale</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,082</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">59</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">34</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total liabilities related to assets held for sale</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">93</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694835845000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Employee Severance<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring Charges [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring and Employee Severance</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">3. Restructuring and Employee Severance</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restructuring and employee severance:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">36</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">81</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated, duplicate payroll costs and retention bonuses incurred during transition periods. Facility exit and other costs primarily consist of vendor transition fees, professional, project management and other service fees to support divestitures, accelerated depreciation, lease costs associated with vacant facilities, equipment relocation costs, project consulting fees, costs associated with restructuring our delivery of information technology infrastructure services and certain other divestiture-related costs.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring costs during both the three and nine months ended March&#160;31, 2021 and 2020 were primarily related to the implementation of certain enterprise-wide cost-savings measures. The income during the three months ended March&#160;31, 2020 was due to changes in estimates for severance previously accrued.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity related to liabilities associated with restructuring and employee severance:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.237%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.237%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.241%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-<br/>Related Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility Exit<br/>and Other Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">96</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">59</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(74)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2021</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">56</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">25</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">81</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI http://asc.fasb.org/topic&amp;trid=2175745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694834289304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Other Intangible Assets</a></td>
<td class="text"><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">4. Goodwill and Other Intangible Assets</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill by segment and in total:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.739%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.171%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.482%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,657&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,700&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,357</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill acquired, net of purchase price adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments and other</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">15</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassified to assets held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(388)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(388)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2021</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,659</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,327</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,986</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the planned divestiture of our Cordis business, during the three months ended March 31, 2021, we allocated and reclassified $388&#160;million of goodwill from the Medical Unit (within our Medical Segment) to the Cordis disposal group based on the estimated relative fair values of the business to be disposed of and the portion of the reporting unit that will be retained, discussed further in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib6bf45669ad94861b0c50dbc2f4371ce_1194" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 2</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Intangible Assets</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize other intangible assets by class at:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:24.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.409%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted- Average Remaining Amortization Period (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IPR&amp;D, trademarks and other</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,331</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,925</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,406</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">551</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">319</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">232</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,031</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">488</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">543</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,913</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,732</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,181</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,925</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,732</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,193</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:42.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.308%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.643%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.312%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IPR&amp;D, trademarks and other</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,831&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,936&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,895&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,854&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,936&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,918&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total amortization of intangible assets was $109 million and $129 million for the three months ended March 31, 2021 and 2020, respectively, and $337 million and $385 million for the nine months ended March&#160;31, 2021 and 2020, respectively. Estimated annual amortization of intangible assets for the remainder of fiscal 2021 through 2025 is as follows: $91 million, $314 million, $287 million, $263 million and $238 million.</span></div></div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, other intangible assets of $391 million was reclassified to assets held for sale in connection with the planned divestiture of our Cordis business, discussed further in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib6bf45669ad94861b0c50dbc2f4371ce_1194" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 2</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694835829768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Obligations and Other Short-Term Borrowings<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract', window );"><strong>Long-Term Obligations and Other Short-Term Borrowings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long-Term Obligations and Other Short-Term Borrowings</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">5. Long-Term Obligations and Other Short-Term Borrowings</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Long-Term Debt and Other Short-Term Borrowings</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2021 and June&#160;30, 2020, we had total long-term obligations, including the current portion and other short-term borrowings, of $6.7 billion and $6.8 billion, respectively. All the notes represent unsecured obligations of Cardinal Health, Inc. and rank equally in right of payment with all of our existing and future unsecured and unsubordinated indebtedness. Interest is paid pursuant to the terms of the obligations. These obligations are effectively subordinated to the liabilities of our subsidiaries, including trade payables of $22.6 billion and $21.4 billion at March&#160;31, 2021 and June&#160;30, 2020, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March&#160;31, 2021, we early repurchased $40 million of the Floating Rate Notes due 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $2 million of the 2.616% Notes due 2022. The repurchases were paid for with available cash. In connection with the early debt repurchases, we recorded a $1 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">loss on early extinguishment of debt during the nine months ended March&#160;31, 2021. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we repaid the full principal of the 2.4% Notes due 2019 at maturity for $450&#160;million. During the nine months ended March 31, 2020, we early repurchased $247&#160;million of the 2.616% Notes due 2022, $11&#160;million of the 3.2% Notes due 2022, $20&#160;million of the Floating Rate Notes due 2022, $104&#160;million of the 3.41% Notes due 2027, $6&#160;million of the 4.6% Notes due 2043, $5&#160;million of the 4.9% Notes due 2045, and $35&#160;million of the 4.368% Notes due 2047. The repurchases were paid for with available cash and other short-term borrowings. In connection with the early debt repurchases, we recorded a $9 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">loss on early extinguishment of debt during the nine months ended March 31, 2020. </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Financing Arrangements</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to cash and equivalents and operating cash flow, other sources of liquidity include a&#160;$2.0 billion&#160;commercial paper program backed by a $2.0 billion&#160;revolving credit facility. We also have a&#160;$1.0 billion&#160;committed receivables sales facility. At&#160;March&#160;31, 2021, we had no amounts outstanding under our commercial paper program, revolving credit facility, or our committed receivables sales facility.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we renewed our committed receivables sales facility program through Cardinal Health Funding, LLC (&#8220;CHF&#8221;) through September 30, 2022. CHF was organized for</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the sole purpose of buying receivables and selling undivided interests in those receivables to third-party purchasers. Although consolidated with Cardinal Health, Inc. in accordance with GAAP, CHF is a separate legal entity from Cardinal Health, Inc. and from our </span></div>subsidiary that sells receivables to CHF. CHF is designed to be a special purpose, bankruptcy-remote entity whose assets are available solely to satisfy the claims of its creditors. Our revolving credit and committed receivables sales facilities require us to maintain a consolidated net leverage ratio of no more than 3.75-to-1 beginning March 2021. As of March&#160;31, 2021, we were in compliance with this financial covenant.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_LongTermObligationsandOtherShortTermBorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-Term Obligations and Other Short-Term Borrowings [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_LongTermObligationsandOtherShortTermBorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694834350856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments, Contingent Liabilities and Litigation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments, Contingent Liabilities and Litigation</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">6. Commitments, Contingent Liabilities and Litigation</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commitments</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Generic Sourcing Venture with CVS Health Corporation ("CVS Health")</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2014, we established Red Oak Sourcing, LLC ("Red Oak Sourcing"), a U.S.-based generic pharmaceutical sourcing venture with CVS Health for an initial term of 10 years. Red Oak Sourcing negotiates generic pharmaceutical supply contracts on behalf of its participants. Due to the achievement of predetermined milestones, we are required to make quarterly payments of $45.6 million to CVS Health for the remainder of the initial term.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New York Opioid Stewardship Act</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the State of New York passed a budget which included the Opioid Stewardship Act (the "OSA"). The OSA created an aggregate $100&#160;million annual assessment on all manufacturers and distributors licensed to sell or distribute opioids in New York. Under the OSA, each licensed manufacturer and distributor would be required to pay a portion of the assessment based on its share of the total morphine milligram equivalents sold or distributed in New York during the applicable calendar year, beginning in 2017.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The constitutionality of portions of the OSA has been challenged in court. In December 2018, the OSA was ruled unconstitutional by the U.S. district court for the Southern District of New York. Subsequently, New York passed a new statute that modified the assessment going forward and limited the OSA to two years (2017 and 2018). The U.S. Court of Appeals for the Second Circuit reversed the district court's decision on procedural grounds. In February 2021, the Second Circuit stayed the effect of the ruling pending a petition to the U.S. Supreme Court to review the Second Circuit's opinion. If the U.S. Supreme Court declines to take the case, or if it ultimately upholds the Second Circuit's ruling, New York State would likely seek to collect amounts allegedly owed under the OSA. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue contingencies if it is probable that a liability has been incurred and the amount can be estimated. Because of the Second Circuit ruling, we recorded an aggregate accrual of $41&#160;million for calendar year 2017 and 2018 in the nine months ended March 31, 2021 based on the estimated payment amount, which is our best estimate of the OSA payments probable at March 31, 2021.</span></div><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We become involved from time to time in disputes, litigation and regulatory matters.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we determine that products we source, manufacture or market do not meet our specifications, regulatory requirements, or published standards. When we or a regulatory agency identify a potential quality or regulatory issue, we investigate and take appropriate corrective action. Such actions have led to product recalls, costs to repair or replace affected products, temporary interruptions in product sales, product liability claims and lawsuits and can lead to action by regulators. Even absent an identified regulatory or quality issue or product recall, we can become subject to product liability claims and lawsuits.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we become aware through employees, internal audits or other parties of possible compliance matters, such as complaints or concerns relating to accounting, internal accounting controls, financial reporting, auditing, or other ethical matters or relating to compliance with laws such as healthcare fraud and abuse, anti-corruption or anti-bribery laws. When we become aware of such possible compliance matters, we investigate internally and take appropriate corrective action. In addition, from time to time, we receive subpoenas or requests for information from various federal or state agencies relating to our business or to the business of a customer, supplier or other industry participants. Internal investigations, subpoenas or requests for information could directly or indirectly lead to the assertion of claims or the commencement of legal proceedings against us or result in sanctions.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been named from time to time in qui tam actions initiated by private third parties. In such actions, the private parties purport to act on behalf of federal or state governments, allege that false claims have been submitted for payment by the government and may receive an award if their claims are successful. After a private party has filed a qui tam action, the government must investigate the private party's claim and determine whether to intervene in and take control over the litigation. These actions may remain under seal while the government makes this determination. If the government declines to intervene, the private party may nonetheless continue to pursue the litigation on his or her own purporting to act on behalf of the government.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue for contingencies related to disputes, litigation and regulatory matters if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Because these matters are inherently unpredictable and unfavorable developments or resolutions can occur, assessing contingencies is highly subjective and requires judgments about future events. We regularly review contingencies to determine whether our accruals and related disclosures are adequate. The amount of ultimate loss may differ from these estimates.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize income from the favorable outcome of litigation when we receive the associated cash or assets.</span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize estimated loss contingencies for certain litigation and regulatory matters and income from favorable resolution of litigation in litigation (recoveries)/charges in our condensed consolidated statements of earnings/(loss).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opioid Lawsuits and Investigations</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical wholesale distributors, including us, have been named as defendants in approximately 3,300 lawsuits relating to the distribution of prescription opioid pain medications. The lawsuits seek equitable relief and monetary damages based on a variety of legal theories including various common law claims, such as public nuisance, negligence and unjust enrichment as well as violations of controlled substance laws, the Racketeer Influenced and Corrupt Organizations Act and various other statutes. These lawsuits also name pharmaceutical manufacturers, retail pharmacy chains and other entities as defendants.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">States &amp; Political Subdivisions</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 2,800 of these lawsuits have been filed by counties, municipalities, cities and political subdivisions in various federal, state, and other courts. The vast majority of these lawsuits were filed in U.S. federal court and have been transferred for consolidated pre-trial proceedings in a Multi-District Litigation proceeding in the U.S. District Court for the Northern District of Ohio (the &#8220;MDL&#8221;).</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, 25 state attorneys general have filed lawsuits against distributors, including us, in various state courts. We have also received requests, civil investigative demands, subpoenas or requests for information from additional state attorneys general offices and governmental authorities. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, we agreed in principle to a global settlement framework with a leadership group of state attorneys general; the framework is designed to resolve pending and future opioid lawsuits and claims by states and political subdivisions, but not private plaintiffs (the "Settlement Framework"). This Settlement Framework is the basis for the continued negotiation of definitive terms and documentation. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these discussions, we have recorded total pre-tax charges of $1.02&#160;billion and $5.63&#160;billion in litigation charges/(recoveries), net in the nine months ended March&#160;31, 2021 and 2020, respectively. In total, we have $6.59&#160;billion accrued at March&#160;31, 2021, included in deferred income taxes and other liabilities in the condensed consolidated balance sheets, which represents the cash component. We are unable to estimate the range of possible loss associated with these matters. Definitive terms for a settlement pursuant to the Settlement Framework continue to be negotiated, and there is no assurance that the necessary parties will agree to a definitive settlement agreement or that the contingencies to any agreement will be satisfied. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because loss contingencies are inherently unpredictable and unfavorable developments or resolutions can occur, the assessment is highly subjective and requires judgments about future events. We regularly review these opioid litigation matters to determine whether our accrual is adequate. The amount of </span></div></div><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ultimate loss may differ materially from this accrual, whether as a result of settlement discussions, a judicial decision or verdict or otherwise, but we are not able to estimate a range of reasonably possible additional losses for these matters. We continue to strongly dispute the allegations made in these lawsuits and reaching an agreement in principle on a global settlement framework is not an admission of liability or wrongdoing.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although COVID-19 continues to cause some uncertainty with respect to trial dates, trials are resuming in certain jurisdictions. A trial in West Virginia in the Cabell County and City of Huntington cases began on May 3, 2021. A liability-only trial in the cases brought by the New York Attorney General and Nassau and Suffolk Counties is currently scheduled for June 2021 and trials in the cases brought by the Ohio and Washington Attorneys General are scheduled to begin in September 2021. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Private Plaintiffs</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Settlement Framework does not address claims by private parties, which includes unions and other health and welfare funds, hospital systems and other healthcare providers, businesses and individuals. Private parties had brought approximately 430 lawsuits as of May 3, 2021. Of these, 127 are purported class actions. The causes of action asserted by these plaintiffs are similar to those asserted by public plaintiffs. A trial in one case is currently scheduled to begin in October 2021; however trial dates remain uncertain due in part to circumstances arising from the COVID-19 pandemic. We are vigorously defending ourselves in these matters.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Insurance Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in legal proceedings with two insurers related to the availability of insurance coverage for the lawsuits described above. In October 2020, we filed a complaint for declaratory judgment against National Union Fire Insurance Company of Pittsburgh, PA (&#8220;National Union&#8221;) seeking a declaration that National Union is obligated to reimburse us for defense costs incurred in connection with the lawsuits described above. In January, 2021, Swiss Re International SE commenced an arbitration in London seeking a determination that it does not have an obligation to reimburse us for defense and indemnity expenses incurred in connection with the lawsuits described above. We have not recorded a receivable for any recoveries related to these insurance litigation matters as of March 31, 2021.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Department of Justice Investigations</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received federal grand jury subpoenas issued in connection with investigations being conducted by the U.S. Attorney's Office for the Eastern District of New York and the Fraud Section of the U.S. Department of Justice ("DOJ"). We have also received civil requests for information from other DOJ offices. We believe that these investigations concern operation of our anti-diversion program, our anti-diversion policies and procedures, and distribution of certain controlled substances. We are cooperating with these requests. We are unable to predict the outcome of any of these investigations. </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cordis Product Liability Lawsuits</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of May 3, 2021, we are named as a defendant in 396 product liability lawsuits coordinated in Alameda County Superior Court in California involving claims by approximately 5,046 plaintiffs that allege personal injuries associated with the use of Cordis OptEase and TrapEase inferior vena cava ("IVC") filter products. Another 31 lawsuits involving similar claims by approximately 36 plaintiffs are pending in other jurisdictions. These lawsuits seek a variety of remedies, including unspecified monetary damages. We continue to vigorously defend ourselves in these lawsuits and are engaged in resolution discussions with certain plaintiffs. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2021, we had a total of $514 million net of estimated insurance recoveries, accrued for losses and legal defense costs related to the Cordis IVC filter lawsuits which are presented on a gross basis in the condensed consolidated balance sheets. We believe there is a range of estimated losses with respect to these matters. Because no amount within the range is a better estimate than any other amount within the range, we have accrued the minimum amount in the range. We estimate the high end of the range to be approximately $1.01 billion, net of estimated insurance recoveries. The sale of the Cordis disposal group does not include product liability related to the IVC filters in the U.S. and Canada, which we will retain. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SEC Investigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, we received a subpoena from the U.S. Securities and Exchange Commission requesting the production of documents from 2015 through 2019 relating to inventory in the Cordis business, analysis of goodwill of the Medical segment and other matters. We are cooperating with this inquiry and cannot predict its outcome or duration. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholder Securities Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Louisiana Sheriffs' Pension &amp; Relief Fund filed a purported class action complaint against Cardinal Health and certain current and former officers and employees in the United States District Court for the Southern District of Ohio purportedly on behalf of all purchasers of our common shares between March 2015 and May 2018. In June 2020, the court appointed 1199 SEIU Health Care Employees Pension Fund as lead plaintiff and a consolidated amended complaint was filed in September 2020. The amended complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities and Exchange Act of 1934 by making misrepresentations and omissions related to the acquisition integration of the Cordis business and inventory and supply chain problems within the Cordis business, and seeks to recover unspecified damages and equitable relief for the alleged misstatements and omissions. The complaint also alleges that one of the individual defendants violated Section 20A of the Exchange Act because he sold shares of Cardinal Health stock during the time period. In November 2020, we filed a motion to dismiss the amended complaint. We believe that the claims asserted in this complaint are without merit and intend to vigorously defend against them. </span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Specialty Solutions DOJ Investigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the United States Attorney&#8217;s Office for the District of Massachusetts (the "USAO") commenced an investigation pertaining to the U.S. federal healthcare fraud and abuse laws. These requests sought, among other things, documents and information relating to discounts and rebates offered or provided to certain Specialty Solutions customers. We are cooperating with these requests and are engaged in resolution discussions with the USAO. In connection with these discussions, we recorded $13 million of expense within litigation charges/(recoveries) on our condensed consolidated statement of operations during the three months ended March&#160;31, 2021. We are not able to estimate a range of reasonably possible additional losses or other remedial measures for this matter.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Civil Litigation </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Generic Pharmaceutical Pricing Antitrust Litigation </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, pharmaceutical distributors including us were added as defendants in a civil class action lawsuit filed by indirect purchasers of generic drugs, such as hospitals and retail pharmacies. The indirect purchaser case is part of a multidistrict litigation consisting of multiple individual class action matters consolidated in the Eastern District of Pennsylvania. The indirect purchaser plaintiffs allege that pharmaceutical distributors encouraged manufacturers to increase prices, provided anti-competitive pricing information to manufacturers and improperly engaged in customer allocation. We have filed a motion to dismiss the complaints and we intend to vigorously defend ourselves. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Active Pharmaceutical Ingredient Impurity Litigation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many participants in the pharmaceutical supply chain, including active pharmaceutical ingredient ("API") manufacturers, finished dose manufacturers, repackagers, distributors, and retailers have been named as defendants in lawsuits arising out of recalls of certain medications due to alleged impurities in the active pharmaceutical ingredients or finished product. </span></div>In February 2019, a Multidistrict Litigation was created in the U.S. District Court for the District of New Jersey (the &#8220;Sartan MDL&#8221;) alleging API impurities in certain generic blood pressure medications. We have been named as a defendant in the Sartan MDL. We are vigorously defending ourselves in this matter.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694834095928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">7. Income Taxes</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in our provision for/(benefit from) income taxes as a percentage of pretax earnings (&#8220;effective tax rate&#8221;) are generally due to changes in international and U.S. state effective tax rates resulting from our business mix and discrete items. </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Effects of Self-Insurance Pre-tax Loss</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March&#160;31, 2021, our wholly-owned insurance subsidiary recorded a self-insurance pre-tax loss in its fiscal 2020 statutory financial statements primarily related to opioid litigation. This self-insurance pre-tax loss, which did not impact our pre-tax consolidated results, was deducted on our fiscal 2020 consolidated federal income tax return and contributed to a significant net operating loss for tax purposes. The net operating loss was carried back and adjusted our taxable income for fiscal 2015, 2016, 2017, and 2018 as permitted under the Coronavirus Aid, Relief and Economic Security ("CARES") Act enacted by the United States Congress in March 2020.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, our provision for income taxes during the nine months ended March&#160;31, 2021 included a $419 million benefit from the net operating loss carryback primarily to reflect the difference between the federal statutory income tax rate during the fiscal years from 2015 to 2018 (35 percent for fiscal 2015, 2016, and 2017 and 28 percent for fiscal 2018) and the current federal statutory income tax rate of 21 percent.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have filed for a federal income tax refund of $974 million as a result of the net operating loss carryback under the CARES Act, which we expect to receive within 12 months, and accordingly have recorded a current asset on our condensed consolidated balance sheet at March&#160;31, 2021. We also increased our non-current deferred tax liability by approximately $700 million during the nine months ended March&#160;31, 2021 related to this matter.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of tax law; however, it is possible that the tax authorities could challenge these tax benefits or that the tax law could change. The actual amount of the tax benefit may differ materially from these estimates.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Effects of Opioid Litigation Charges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the $1.02 billion and $5.63 billion pre-tax charges for the opioid litigation, during the nine months ended March&#160;31, 2021 and 2020, respectively, the net tax benefits are $37 million and $488 million for fiscal 2021 and 2020, respectively. Our tax benefits are estimates, which reflect our current assessment of the estimated future deductibility of the amount that may be paid under the accrual taken in connection with the opioid litigation and are net of unrecognized tax benefits of $35 million and $468 million, respectively. Due to our assessment of non-deductibility for certain components considered in the fiscal 2021 and 2020 charges, the tax benefit for fiscal 2021 compared to fiscal 2020 resulted in a relatively lower tax benefit. Our assumptions and estimates around this benefit and uncertain tax </span></div><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">position require significant judgment and the actual amount of tax benefit related to uncertain tax positions may differ materially from these estimates.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless an item is considered discrete because it is unusual or infrequent, the tax impact of the item is included in our estimated annual effective tax rate. When items are recognized through our estimated annual effective tax rate, we apply our estimated annual effective tax rate to the earnings/(loss) before income taxes for the year-to-date period to compute our provision for/(benefit from) income taxes for the current quarter and year-to-date period. The tax impacts of discrete items are recognized in their entirety in the period in which they occur.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the initial opioid litigation accrual during the nine months ended March 31, 2020, the tax effect of the charge was treated as a discrete item because it was considered unusual or infrequent. However, the tax effect of the charge during the three months ended September 30, 2020 was included in our estimated annual effective tax rate because it was no longer considered unusual or infrequent. The inclusion of the relatively lower tax benefit of the current fiscal year charge in our estimated annual effective tax rate significantly increased the estimated annual effective tax rate for fiscal 2021. As such, the amount of tax expense increased by approximately $140 million during the three months ended March&#160;31, 2021 while the amount of tax benefit increased by approximately $180 million during the nine months ended March&#160;31, 2021 compared to the tax impacts that would have been recognized without the opioid litigation charge. As stated above, the benefit as of the end of fiscal 2021 is expected to be $37 million.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made reasonable estimates and recorded amounts based on management's judgment and our current understanding of the U.S. Tax Cuts and Jobs Act ("Tax Act"); however, these estimates require significant judgment since the definitive settlement terms and documentation, including provisions related to deductibility, under the Settlement Framework have not been negotiated and the U.S. tax law governing deductibility was changed by the Tax Act. Further, it is possible that the tax authorities could challenge our interpretation of the Tax Act or the estimates and assumptions used to assess the future deductibility of these benefits or that the tax law could change. The actual amount of the tax benefit related to uncertain tax positions may differ materially from these estimates.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effective Tax Rate</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended&#160;March&#160;31, 2021&#160;and&#160;2020, the effective tax rate was&#160;72.8 percent and&#160;26.8&#160;percent, respectively. The change in the effective tax rate compared to the prior period was primarily due to the adverse tax impacts of the opioid litigation accrual, the resolution of certain transfer pricing matters with the IRS and withholding taxes for planned distributions from foreign subsidiaries.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended&#160;March&#160;31, 2021&#160;and&#160;2020, the effective tax rate was (143.3)&#160;percent and&#160;5.2&#160;percent, </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively. Included in the effective tax rate for the nine months ended March&#160;31, 2021 was the $419 million benefit from a net operating loss carryback primarily related to a self-insurance pre-tax loss. Included in both the nine months ended March&#160;31, 2021 and 2020 were net tax benefits related to the treatment of the tax impacts of opioid litigation charges. </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unrecognized Tax Benefits</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2021 and June&#160;30, 2020, we had $785 million and $998 million of unrecognized tax benefits, respectively. The March&#160;31, 2021 and June&#160;30, 2020 balances include $703 million and $753 million of unrecognized tax benefits, respectively, that if recognized, would have an impact on the effective tax rate. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2021 and June&#160;30, 2020, we had $73 million and $146 million, respectively, accrued for the payment of interest and penalties related to unrecognized tax benefits, which we recognize in the provision for/(benefit from) income taxes in the condensed consolidated statements of earnings/(loss). These balances are gross amounts before any tax benefits and are included in deferred income taxes and other liabilities in the condensed consolidated balance sheets. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that there could be a change in the amount of unrecognized tax benefits within the next 12 months due to activities of the U.S. Internal Revenue Service ("IRS") or other taxing authorities, possible settlement of IRS and other audit issues, reassessment of existing unrecognized tax benefits or the expiration of statutes of limitations. We estimate that the range of the possible change in unrecognized tax benefits within the next 12 months is between zero and a net decrease of up to $90 million, exclusive of penalties and interest.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Tax Matters</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions and various foreign jurisdictions. With few exceptions, we are subject to audit by taxing authorities for fiscal years 2011 through the current fiscal year. Tax laws are complex and subject to varying interpretations.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to a tax matters agreement with CareFusion Corporation ("CareFusion"), a subsidiary of Becton, Dickinson and Company. Under the tax matters agreement, CareFusion is obligated to indemnify us for certain tax exposures and transaction taxes prior to our fiscal 2010 spin-off of CareFusion. The indemnification receivable was $119 million and $176 million at March&#160;31, 2021 and June&#160;30, 2020, respectively, and is included in prepaid expenses and other assets and other assets in the condensed consolidated balance sheets. The indemnification receivable was reduced based on the ongoing negotiations with the IRS.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the acquisition of the Patient Recovery Business, Medtronic plc is obligated to indemnify us for certain tax exposures and transaction taxes related to periods prior to the acquisition under the purchase agreement. The indemnification receivable was $19 million at both March&#160;31, 2021 and June&#160;30, 2020, </span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively, and is included in other assets in the condensed consolidated balance sheet.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future adjustments to the financial statements may be necessary as final tax regulations related to U.S. Tax Reform are issued. We will assess any impact as additional guidance is issued.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694836171880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Disclosures</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">8. Fair Value Measurements</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Assets and (Liabilities) Measured on a Recurring Basis</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,944</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,944</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">118</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">118</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">41</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">41</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The fair value of interest rate swaps, foreign currency contracts, commodity contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Assets and (Liabilities) Measured on a Nonrecurring Basis</span></div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities held for sale of $1.1&#160;billion and $93 million, respectively, at March&#160;31, 2021 are primarily related to the planned divestiture of our Cordis business. These estimated fair values utilized Level 3 unobservable inputs based on expected sales proceeds following a competitive bidding process. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib6bf45669ad94861b0c50dbc2f4371ce_1194" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 2</a></span> for additional information regarding assets and liabilities held for sale.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694834312328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Financial Instruments</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">9. Financial Instruments </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize derivative financial instruments to manage exposure to certain risks related to our ongoing operations. The primary risks </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">managed through the use of derivative instruments include interest rate risk, currency exchange risk, and commodity price risk. We do not use derivative instruments for trading or speculative purposes. While the majority of our derivative instruments are designated as hedging instruments, we also enter into derivative instruments that are designed to hedge a risk, but are not designated as hedging instruments. These derivative instruments are adjusted to current fair value through earnings at the end of each period. We are exposed to counterparty credit risk on all of our derivative instruments. Accordingly, we have established and maintain strict counterparty credit guidelines and only enter into derivative instruments with major financial institutions that are rated investment grade or better. We do not have significant exposure to any one counterparty and we believe the risk of loss is remote. Additionally, we do not require collateral under these agreements.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Interest Rate Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the impact of interest rate changes. Our objective is to manage the impact of interest rate changes on cash flows and the market value of our borrowings. We utilize a mix of debt maturities along with both fixed-rate and variable-rate debt to manage changes in interest rates. In addition, we enter into interest rate swaps to further manage our exposure to interest rate variations related to our borrowings and to lower our overall borrowing costs.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Currency Exchange Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct business in several major international currencies and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce earnings and cash flow volatility associated with foreign exchange rate changes to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments and anticipated foreign currency revenue and expenses.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Commodity Price Risk Management</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to changes in the price of certain commodities. Our objective is to reduce earnings and cash flow volatility associated with forecasted purchases of these commodities to allow management to focus its attention on business operations. Accordingly, we enter into derivative contracts when possible to manage the price risk associated with certain forecasted purchases.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fair Value Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into pay-floating interest rate swaps to hedge the changes in the fair value of fixed-rate debt resulting from fluctuations in interest rates. These contracts are designated and qualify as fair value hedges. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps is directly offset by the change in fair value of the underlying debt. Both the derivative instrument and the underlying debt are adjusted to market value at the end of each period with any resulting gain or loss recorded in interest expense, net in the condensed consolidated statements of </span></div><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">earnings/(loss). For the three and nine months ended March&#160;31, 2021 and 2020, there was no gain or loss recorded to interest expense as changes in the market value of our derivative instruments offset changes in the market value of the underlying debt.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the three and nine months ended March&#160;31, 2021, we unwound certain interest rate swap contracts with the notional amount of $550&#160;million. In connection with the unwind of these contracts, we received cash proceeds of $18&#160;million. The related gain will be recognized in interest expense, net in our statements of earnings/(loss) over the remaining term of the debt agreement, which matures in March 2023.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the three and nine months ended March&#160;31, 2021, we entered into a pay-floating interest rate swap with total notional amounts of $200&#160;million. This swap has been designated as fair value hedges of our fixed rate debt and is included in deferred income taxes and other liabilities in the condensed consolidated balance sheets.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the debt repayment as described in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib6bf45669ad94861b0c50dbc2f4371ce_94" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 5</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, two pay-floating interest rate swaps with notional amounts of $200 million matured in the second quarter of fiscal 2020. </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cash Flow Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into derivative instruments to hedge our exposure to changes in cash flows attributable to interest rate, foreign currency and commodity price fluctuations associated with certain forecasted transactions. These derivative instruments are designated and qualify as cash flow hedges. Accordingly, the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss and reclassified into earnings in the same line item associated with the forecasted transaction and in the same period during which the hedged transaction affects earnings.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the nine months ended March&#160;31, 2020, we entered into forward interest rate swaps with a total notional amount of $200&#160;million to hedge probable, but not firmly committed, future transactions associated with our debt. During the three and nine months ended March&#160;31, 2021, we terminated these swaps </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and reclassified an immaterial deferred gain from accumulated other comprehensive loss into interest expense, net in our condensed consolidated statements of earnings/(loss) because the forecasted transactions were probable of not occurring</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. At March&#160;31, 2021, we had no outstanding forward interest rate swaps designated as cash-flow hedges.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pre-tax gain and loss recognized in other comprehensive loss was a $13&#160;million gain and a $20&#160;million loss during the three months ended March&#160;31, 2021 and 2020, respectively, and a $20&#160;million gain and a $20&#160;million loss in the nine months ended March&#160;31, 2021 and 2020, respectively. Gains and losses recognized in accumulated other comprehensive loss and reclassified into earnings were immaterial for the three and nine months ended March&#160;31, 2021 and 2020. All gains and losses currently included within accumulated other comprehensive loss associated with our </span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:115%">cash flow hedges to be reclassified into net earnings within the next 12 months are immaterial.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Net Investment Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We hedge the foreign currency risk associated with certain net investment positions in foreign subsidiaries. To accomplish this, we enter into cross-currency swaps that are designated as hedges of net investments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, we entered into a &#165;64.0 billion ($600 million) cross-currency swap maturing in 2022.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cross-currency swaps designated as net investment hedges are marked to market using the current spot exchange rate as of the end of the period, with gains and losses included in the foreign currency translation component of accumulated other comprehensive loss until the sale or substantial liquidation of the underlying net investments. To the extent the cross-currency swaps designated as net investment hedges are not highly effective, changes in carrying value attributable to the change in spot rates are recorded in earnings.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-tax gain and loss from net investment hedges recorded in the foreign currency translation component of accumulated other comprehensive loss was a $49&#160;million gain and a $18&#160;million gain during the three months ended March&#160;31, 2021 and 2020, respectively, and a $3&#160;million loss and a $35&#160;million gain during the nine months ended March&#160;31, 2021 and 2020, respectively. Gains recognized in interest expense, net in the condensed consolidated statements of earnings/(loss) for the portion of the net investment hedges excluded from the assessment of hedge effectiveness were $5&#160;million during the three months ended March&#160;31, 2021 and 2020, and $14&#160;million and $11&#160;million during the nine months ended March&#160;31, 2021 and 2020, respectively. </span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Economic (Non-Designated) Hedges</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into foreign currency contracts to manage our foreign exchange exposure related to sales transactions, intercompany financing transactions and other balance sheet items subject to revaluation that do not meet the requirements for hedge accounting treatment. Accordingly, these derivative instruments are adjusted to current market value at the end of each period through earnings. The gain or loss recorded on these instruments is substantially offset by the remeasurement adjustment on the foreign currency denominated asset or liability. The settlement of the derivative instrument and the remeasurement adjustment on the foreign currency denominated asset or liability are both recorded in other (income)/expense, net. We recorded a $4 million loss and $7 million loss during the nine months ended March&#160;31, 2021 and 2020, respectively. The principal currencies managed through foreign currency contracts are Chinese renminbi, Canadian dollar, European euro and Japanese yen.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and equivalents, trade receivables, accounts payable and other accrued liabilities at March&#160;31, 2021 and June&#160;30, 2020 approximate fair value due to their short-term maturities.</span></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.109%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.986%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated fair value</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,177</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,273&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying amount</span></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,731</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,775&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our long-term obligations and other short-term borrowings is estimated based on either the quoted market prices for the same or similar issues or other inputs derived from available market information, which represents a Level 2 measurement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694836162712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' Equity</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">10. Shareholders' Equity</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended March&#160;31, 2021, we repurchased 3.7 million common shares having an aggregate cost of $200 million. The average price paid per common share was $54.40. These repurchases were made under an accelerated share repurchase ("ASR") program, which began on February 9, 2021 and was completed on March 31, 2021.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended March 31, 2020, we repurchased 7.3 million common shares having an aggregate cost of $350 million. The average price paid per common share was $48.00. These repurchases were made under an ASR program, which began on August 20, 2019 and was completed on December 4, 2019.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We funded the repurchases with available cash and short-term borrowings. The common shares repurchased are held in treasury to be used for general corporate purposes.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Loss</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.097%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(104)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">53</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive income attributable to Cardinal Health, Inc. net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">56</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2021</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(50)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(48)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694835837656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share Attributable to Cardinal Health, Inc.<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share [Text Block]</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">11. Earnings/(Loss) Per Share Attributable to Cardinal Health, Inc.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.407%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares&#8211;basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">292</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares&#8211;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">294</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.407%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares&#8211;basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">293</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares&#8211;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">294</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potentially dilutive employee stock options, restricted share units and performance share units that were anti-dilutive were 3 million for the three months ended March&#160;31, 2021 and 4 million for the nine months ended March&#160;31, 2021.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potentially dilutive employee stock options, restricted share units and performance share units that were anti-dilutive were 4 million for the three months ended March&#160;31, 2020 and 7 million for the nine months ended March&#160;31, 2020 (2 million of which were anti-dilutive as a result of the year-to-date net loss).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694834303432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">12. Segment Information</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are principally managed on a products and services basis and are comprised of two operating segments, which are the same as our reportable segments: Pharmaceutical and Medical. The factors for determining the reportable segments include the manner in which management evaluates performance for purposes of allocating resources and assessing performance combined with the nature of the individual business activities.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products in the United States. This segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; provides pharmacy management services to hospitals as well as medication therapy management and patient outcomes services to hospitals, other healthcare providers and payers; and repackages generic pharmaceuticals and over-the-counter healthcare products. </span></div><div style="display:inline-block;vertical-align:top;width:48.214%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical and laboratory products, which are sold in the United States, Canada, Europe, Asia and other markets. In addition to distributing Cardinal Health branded products, this segment also distributes a broad range of national brand products and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States and Canada. This segment also distributes medical products to patients' homes in the United States through our Cardinal Health at-Home Solutions division.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present revenue for each reportable segment and disaggregated revenue within our two reportable segments and Corporate:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.593%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical Distribution and Specialty Solutions (1) (2)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">34,903</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">34,899</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">201</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">213</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">35,104</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">35,112</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical distribution and products (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,638</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,539</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health at-Home Solutions</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">536</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">512</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical segment revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,174</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,051</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39,278</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39,163</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39,275</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39,157</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.593%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical Distribution and Specialty Solutions (1) (2)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">106,859</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">103,612</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">593</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">642</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">107,452</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">104,254</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical distribution and products (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10,805</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10,483</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health at-Home Solutions</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,636</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,508</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical segment revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12,441</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11,991</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">119,893</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">116,245</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">119,881</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">116,233</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Products and services offered by our Specialty Solutions division are referred to as &#8220;specialty pharmaceutical products and services."</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div></div><div style="display:inline-block;max-width:3.571%;min-width:2.571%;vertical-align:top"/><div style="display:inline-block;vertical-align:top;width:48.215%"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present revenue by geographic area:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.482%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.215%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.217%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">38,089</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">38,073</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,189</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,090</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39,278</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39,163</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39,275</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39,157</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.906%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.217%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">116,425</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">113,053</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,468</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,192</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">119,893</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">116,245</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">119,881</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">116,233</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Profit</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate segment performance based on segment profit, among other measures. Segment profit is segment revenue, less segment cost of products sold, less segment distribution, selling, general and administrative ("SG&amp;A") expenses. Segment SG&amp;A expenses include share-based compensation expense as well as allocated corporate expenses for shared functions, including corporate management, corporate finance, financial, and customer care shared services, human resources, information technology, and legal and compliance, including certain litigation defense costs. Corporate expenses are allocated to the segments based on headcount, level of benefit provided and other ratable allocation methodologies. The results attributable to noncontrolling interests are recorded within segment profit.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not allocate the following items to our segments: last-in first-out, or ("LIFO"), inventory charges/(credits); surgical gown recall costs; restructuring and employee severance; amortization and other acquisition-related costs; impairments and (gain)/loss on disposal of assets; litigation (recoveries)/charges, net; state opioid assessment related to prior fiscal years; other (income)/expense, net; interest expense, net; loss on early extinguishment of debt; and provision for income taxes. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain investment spending, certain portions of enterprise-wide incentive compensation and other spending are not allocated to the segments. Investment spending generally includes the first-year spend for certain projects that require incremental investments in the form of additional operating expenses. Because approval for these projects is dependent on executive management, we retain these expenses at Corporate. Investment spending within Corporate was $4 million and $17 million for the three months ended March&#160;31, 2021 and 2020, and $15 million and $37 million for the nine months ended March&#160;31, 2021 and 2020, respectively.</span></div></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the planned divestiture of the Cordis business, we recognized a $58&#160;million pre-tax write-down of the net assets held for sale</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the three and nine months ended March&#160;31, 2021, which was retained at Corporate.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the opioid litigation as discussed further in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib6bf45669ad94861b0c50dbc2f4371ce_97" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we recognized pre-tax charges of $1.02 billion and $5.63&#160;billion</span><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the nine months ended March&#160;31, 2021 and 2020, respectively, which were retained at Corporate. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the New York Opioid Stewardship Act as discussed further in </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib6bf45669ad94861b0c50dbc2f4371ce_97" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 6</a></span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we recognized a pre-tax charge of $41&#160;million during the nine months ended March&#160;31, 2021, related to calendar year 2017 and 2018 assessments, which was retained at Corporate.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with a voluntary recall for certain surgical gowns and a voluntary recall and field actions for surgical procedure packs containing affected gowns, we recognized a pre-tax charge of $95&#160;million during the nine months ended March&#160;31, 2020 which was retained at Corporate.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present segment profit by reportable segment and Corporate:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">511</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">174</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">685</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">712&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(212)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating earnings</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">473</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">562&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,326</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,394&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">640</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">543&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,966</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,937&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,656)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,305)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating earnings/(loss)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">310</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,368)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total assets for each reportable segment and Corporate at: </span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:52.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.503%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">23,078</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,398&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">15,280</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,516</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/><td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,677&#160;</span></td><td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">43,874</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,766&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Assets of $1.1 billion classified as held for sale related to the Cordis planned divestiture were included within Medical at March&#160;31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694835594920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#ee2724;font-family:'Arial Narrow',sans-serif;font-size:13pt;font-weight:700;line-height:120%">13. Share-Based Compensation</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:16pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain stock incentive plans (collectively, the &#8220;Plans&#8221;) for the benefit of certain of our officers, directors and employees. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides total share-based compensation expense by type of award:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock option expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">33</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">56</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock option expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">28</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">84</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total tax benefit related to share-based compensation was $5 million for both the three months ended March&#160;31, 2021 and 2020, respectively, and $12 million for both the nine months ended March&#160;31, 2021 and 2020, respectively.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Restricted Share Units</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted share units granted under the Plans generally vest in equal annual installments over three years. Restricted share units accrue cash dividend equivalents that are payable upon vesting of the awards.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to restricted share units under the Plans:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:51.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.218%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.92&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.45&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at March 31, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">48.96</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2021, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested restricted share units not yet recognized was $90 million, which is expected to be recognized over a weighted-average period of two years.</span></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee stock options granted under the Plans generally vest in equal annual installments over three years and are exercisable for ten years from the grant date. All stock options are exercisable at a price equal to the market value of the common shares underlying the option on the grant date.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all stock option transactions under the Plans:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.616%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.480%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.061%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price per<br/>Common Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at June 30, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65.15&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.94&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding at March 31, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">67.60</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercisable at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">67.80</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2021, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested stock options not yet recognized was $0.2 million, which is expected to be recognized over a weighted-average period of two years. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide additional detail related to stock options:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate intrinsic value of outstanding options at period end</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate intrinsic value of exercisable options at period end</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining contractual life of outstanding options</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining contractual life of exercisable options</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5</span></td></tr></table></div><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Performance Share Units</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance share units vest over a 3-year performance period based on achievement of specific performance goals. Based on the extent to which the targets are achieved, vested shares may range from zero to 240 percent of the target award amount. Performance share units accrue cash dividend equivalents that are payable upon vesting of the awards.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:49.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.023%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.147%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance<br/>Share Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.24&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at March 31, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.6</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">60.32</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&#160;31, 2021, the total pre-tax compensation cost, net of estimated forfeitures, related to nonvested performance share units not yet recognized was $41 million, which is expected to be recognized over a weighted-average period of two years if performance goals are achieved.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694835807960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Financial Accounting Standards</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Recently Adopted Financial Accounting Standards</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued amended accounting guidance that will require entities to measure credit losses on trade and other receivables, held-to-maturity debt securities, loans and other instruments using an "expected credit loss" model that considers historical experience, current conditions and reasonable supportable forecasts. This guidance also requires that credit losses on available-for-sale debt securities with unrealized losses be recognized as allowances rather than as deductions in the amortized cost of the securities. We consider historical experience, the current economic environment, customer credit ratings or bankruptcies, and reasonable and supportable forecasts to develop our allowance for credit losses. We review these factors quarterly to determine if any adjustments are needed to the allowance. This guidance was effective beginning the first quarter of fiscal 2021 and did not have a material impact on our condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the accounts of all majority-owned or controlled subsidiaries, and all significant intercompany transactions and amounts have been eliminated. The results of businesses acquired or disposed of are included in the consolidated financial statements from the date of the acquisition or up to the date of disposal, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to "we," "our," and similar pronouns is in this Quarterly Report on Form 10-Q for the quarter ended March&#160;31, 2021 (this "Form 10-Q") refer to Cardinal Health, Inc. and its majority-owned or controlled subsidiaries unless the context requires otherwise.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fiscal year ends on June 30. References to fiscal 2021 and 2020 in these condensed consolidated financial statements are to the fiscal years ending or ended June&#160;30, 2021 and June&#160;30, 2020, respectively.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements have been prepared in accordance with the U.S. Securities and Exchange Commission ("SEC") instructions to Quarterly Reports on Form 10-Q and include the information and disclosures required by accounting principles generally accepted in the United States ("GAAP") for interim financial reporting. The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect amounts reported in the condensed consolidated financial statements and accompanying notes. Actual amounts may differ from these estimated amounts. </span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic ("COVID-19") continues to affect the U.S. and global economies, and as previously disclosed in our Fiscal 2020 Form 10-K, the pandemic began to materially affect our businesses during the three months ended March 31, 2020. The length and severity of the pandemic and of the related economic impacts to our businesses and operations are uncertain, including its ongoing impacts to our businesses and results of operations.</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, all adjustments necessary for a fair presentation of the condensed consolidated financial statements have been included. Except as disclosed elsewhere in this Form 10-Q, all such adjustments are of a normal and recurring nature.&#160;In addition, financial results presented for this fiscal 2021 interim period are not necessarily indicative of the results that may be expected for the full fiscal year ending June&#160;30, 2021. These condensed consolidated financial statements are unaudited and, accordingly, should be read in conjunction with the audited consolidated financial statements and related notes contained in our Annual Report on Form 10-K for the fiscal year ended June 30, 2020 (the "2020 Form 10-K").</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694835643480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations and Disposal Groups (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Disposal Groups, Including Discontinued Operations</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information related to the assets and liabilities that were classified as held for sale at March&#160;31, 2021 related to the Cordis planned divestiture in the condensed consolidated balance sheets:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.246%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and equivalents</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">86</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">175</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">88</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill and other intangibles, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">779</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Write-down of assets held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(58)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets held for sale</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,082</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">59</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">34</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total liabilities related to assets held for sale</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">93</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1474-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721677-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721659-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721671-107760<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721663-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694835623448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Employee Severance (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring Charges [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Summary of Restructuring and Employee Severance</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes restructuring and employee severance:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">24</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.974%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-related</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">45</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility exit and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">36</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total restructuring and employee severance</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">81</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity related to liabilities associated with restructuring and employee severance:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.237%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.237%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.241%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee-<br/>Related Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Facility Exit<br/>and Other Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">96</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">59</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments and other adjustments</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(74)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2021</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">56</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">25</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">81</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694835726120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill by Reportable Segment</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the carrying amount of goodwill by segment and in total:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.739%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.171%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.482%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,657&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,700&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8,357</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill acquired, net of purchase price adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency translation adjustments and other</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">15</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassified to assets held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(388)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(388)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2021</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,659</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,327</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,986</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize other intangible assets by class at:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:24.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.409%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted- Average Remaining Amortization Period (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IPR&amp;D, trademarks and other</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,331</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,925</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,406</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">551</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">319</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">232</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,031</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">488</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">543</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,913</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,732</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,181</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,925</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,732</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,193</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">N/A</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:42.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.308%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.643%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.312%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross<br/>Intangible</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net<br/>Intangible</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Indefinite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IPR&amp;D, trademarks and other</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total indefinite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Definite-life intangibles:</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks, trade names and patents</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">341&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">332&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Developed technology and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total definite-life intangibles</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,831&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,936&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,895&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total other intangible assets</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,854&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,936&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,918&#160;</span></td><td style="background-color:#ffffff;border-bottom:2.5pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694834322712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the fair values for assets and (liabilities) measured on a recurring basis at:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,944</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,944</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">118</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">118</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">41</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">41</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.937%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.938%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Level&#160;3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments (1)</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contracts (2)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The other investments balance includes investments in mutual funds, which offset fluctuations in deferred compensation liabilities. These mutual funds invest in the equity securities of companies with both large and small market capitalization and high quality fixed income debt securities. The fair value of these investments is determined using quoted market prices.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">The fair value of interest rate swaps, foreign currency contracts, commodity contracts, and net investment hedges is determined based on the present value of expected future cash flows considering the risks involved, including non-performance risk, and using discount rates appropriate for the respective maturities. Observable Level 2 inputs are used to determine the present value of expected future cash flows. The fair value of these derivative contracts, which are subject to master netting arrangements under certain circumstances, is presented on a gross basis in prepaid expenses and other, other assets, other accrued liabilities, and deferred income taxes and other liabilities within the condensed consolidated balance sheets.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Assets and (Liabilities) Measured on a Nonrecurring Basis</span></div><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities held for sale of $1.1&#160;billion and $93 million, respectively, at March&#160;31, 2021 are primarily related to the planned divestiture of our Cordis business. These estimated fair values utilized Level 3 unobservable inputs based on expected sales proceeds following a competitive bidding process. See </span><span style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#ib6bf45669ad94861b0c50dbc2f4371ce_1194" style="color:#0000ff;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 2</a></span> for additional information regarding assets and liabilities held for sale.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694834165080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair value of our long-term obligations and other short-term borrowings compared to the respective carrying amounts at:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.109%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.986%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.062%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Estimated fair value</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">7,177</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,273&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying amount</span></td><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">6,731</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,775&#160;</span></td><td style="border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694834322712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in the balance of accumulated other comprehensive loss by component and in total:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.097%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.492%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.875%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign<br/>Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized<br/>Gain/(Loss) on<br/>Derivatives,<br/>net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(92)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(104)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">53</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified to earnings</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other comprehensive income attributable to Cardinal Health, Inc. net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">56</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2021</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(50)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(48)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694834286600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the number of common shares used to compute basic and diluted earnings per share attributable to Cardinal Health, Inc.:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.407%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares&#8211;basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">292</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares&#8211;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">294</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.407%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares&#8211;basic</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">293</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock options, restricted share units and performance share units</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average common shares&#8211;diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">294</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694853261912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue [Table Text Block]</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.593%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical Distribution and Specialty Solutions (1) (2)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">34,903</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">34,899</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">201</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">213</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">35,104</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">35,112</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical distribution and products (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,638</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,539</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health at-Home Solutions</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">536</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">512</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical segment revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,174</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,051</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39,278</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39,163</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39,275</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39,157</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.591%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.593%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical Distribution and Specialty Solutions (1) (2)</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">106,859</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">103,612</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nuclear and Precision Health Solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">593</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">642</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical segment revenue</span></div></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">107,452</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">104,254</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical distribution and products (3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10,805</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">10,483</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardinal Health at-Home Solutions</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,636</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,508</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical segment revenue</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">12,441</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">11,991</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">119,893</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">116,245</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (4)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">119,881</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">116,233</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Products and services offered by our Specialty Solutions division are referred to as &#8220;specialty pharmaceutical products and services."</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.</span></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Revenue from External Customers by Geographic Areas [Table Text Block]</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present revenue by geographic area:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.482%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.215%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.217%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">38,089</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">38,073</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,189</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,090</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39,278</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39,163</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39,275</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">39,157</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:43.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.906%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.586%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.217%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">116,425</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">113,053</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,468</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,192</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Total segment revenue</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">119,893</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">116,245</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">119,881</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">116,233</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Segment Profit by Reportable Segment</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present segment profit by reportable segment and Corporate:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">511</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">534&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">174</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">685</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">712&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(212)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating earnings</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">473</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">562&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,326</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,394&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">640</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">543&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total segment profit</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1,966</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,937&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(1,656)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,305)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total operating earnings/(loss)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">310</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,368)</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock', window );">Assets by Reportable Segment</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total assets for each reportable segment and Corporate at: </span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:52.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.503%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">23,078</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,398&#160;</span></td><td style="background-color:#d1d1d1;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">15,280</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,691&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#d1d1d1;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">5,516</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#d1d1d1;padding:0 1pt"/><td colspan="2" style="background-color:#d1d1d1;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,677&#160;</span></td><td style="background-color:#d1d1d1;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total assets</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">43,874</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,766&#160;</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:10pt">Assets of $1.1 billion classified as held for sale related to the Cordis planned divestiture were included within Medical at March&#160;31, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694838084072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Total Share-based Compensation Expense by Type of Award</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides total share-based compensation expense by type of award:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">20</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock option expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">13</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">33</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted share unit expense</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">56</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock option expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance share unit expense</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">28</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total share-based compensation</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">84</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Transactions Under the Plans</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all stock option transactions under the Plans:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.616%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.480%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.061%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stock<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price per<br/>Common Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at June 30, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65.15&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.94&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding at March 31, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">67.60</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercisable at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">67.80</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_AdditionalStockOptionPlanDataTableTextBlock', window );">Schedule of Additional Data Related to Stock Option Activity</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide additional detail related to stock options:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate intrinsic value of outstanding options at period end</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate intrinsic value of exercisable options at period end</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.850%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.887%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.343%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.420%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in years)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining contractual life of outstanding options</span></td><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span></td><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="3" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining contractual life of exercisable options</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Transactions Related to Restricted Share Units Under the Plans</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to restricted share units under the Plans:</span></div><div style="margin-bottom:11pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:51.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.218%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.92&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.45&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at March 31, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">48.96</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock', window );">Schedule of Transactions Related to Performance Share Units Under the Plans</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes all transactions related to performance share units under the Plans (based on target award amounts):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.691%"><tr><td style="width:1.0%"/><td style="width:49.983%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.023%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.347%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.147%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline">(in millions, except per share amounts)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Performance<br/>Share Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant Date Fair<br/>Value per Share</span></td></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nonvested at June 30, 2020</span></td><td colspan="2" style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.24&#160;</span></td><td style="background-color:#cccccc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;padding:0 1pt"/><td colspan="2" style="background-color:#cccccc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cccccc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nonvested at March 31, 2021</span></td><td colspan="2" style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1.6</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:700;line-height:100%">60.32</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cccccc;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_AdditionalStockOptionPlanDataTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A disclosure of additional data related to all stock option activity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_AdditionalStockOptionPlanDataTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested performance-based units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694841059528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations and Disposal Groups (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Total assets held for sale</a></td>
<td class="nump">$ 1,092<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation', window );">Total liabilities held for sale</a></td>
<td class="nump">93<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_CordisDivestitureAxis=cah_CordisDivestitureMember', window );">Cordis Divestiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents', window );">Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents</a></td>
<td class="nump">86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1', window );">Disposal Group, Including Discontinued Operation, Inventory</a></td>
<td class="nump">175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment', window );">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment</a></td>
<td class="nump">88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_DisposalGroupIncludingDiscontinuedOperationGoodwillAndOtherIntangiblesNet', window );">Disposal Group, Including Discontinued Operation, Goodwill and other intangibles, net</a></td>
<td class="nump">779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets', window );">Disposal Group, Including Discontinued Operation, Other Assets</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_WriteDownOfAssetsHeldForSale', window );">Write-down of assets held for sale</a></td>
<td class="num">(58)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Total assets held for sale</a></td>
<td class="nump">1,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities', window );">Disposal Group, Including Discontinued Operation, Accrued Liabilities</a></td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent', window );">Disposal Group, Including Discontinued Operation, Deferred Tax Liabilities</a></td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation', window );">Total liabilities held for sale</a></td>
<td class="nump">93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses', window );">Disposal Group, Including Discontinued Operation, Foreign Currency Translation Gains (Losses)</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation', window );">Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1', window );">Disposal Group, Including Discontinued Operation, Goodwill</a></td>
<td class="nump">388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Disposal Group, Including Discontinued Operation, Consideration</a></td>
<td class="nump">$ 927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_DisposalGroupIncludingDiscontinuedOperationGoodwillAndOtherIntangiblesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group Including Discontinued Operation Goodwill and other intangibles, net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_DisposalGroupIncludingDiscontinuedOperationGoodwillAndOtherIntangiblesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_WriteDownOfAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Write-down of assets held for sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_WriteDownOfAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) on gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) in the disposal group, including discontinued operation, recognized in the statement of income as a result of the sale or complete or substantially complete liquidation of an investment in a foreign entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as goodwill attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as inventory attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2510-110228<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_CordisDivestitureAxis=cah_CordisDivestitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_CordisDivestitureAxis=cah_CordisDivestitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694832985160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring Charges [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Employee-related costs</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="num">$ (15)<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_FacilityExitAndOtherCosts', window );">Facility Exit and Other Costs</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Total restructuring and employee severance</a></td>
<td class="nump">$ 24<span></span>
</td>
<td class="num">$ (6)<span></span>
</td>
<td class="nump">$ 81<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_FacilityExitAndOtherCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_FacilityExitAndOtherCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694841738008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning Balance</a></td>
<td class="nump">$ 96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Additions</a></td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments and other adjustments</a></td>
<td class="num">(74)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending Balance</a></td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee- Related Costs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning Balance</a></td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Additions</a></td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments and other adjustments</a></td>
<td class="num">(49)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending Balance</a></td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember', window );">Facility Exit and Other Costs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning Balance</a></td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Additions</a></td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments and other adjustments</a></td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending Balance</a></td>
<td class="nump">$ 25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694844956232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring and Employee Severance Narative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCosts', window );">Restructuring Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Employee-related costs</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="num">$ (15)<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_FacilityExitAndOtherCosts', window );">Facility Exit and Other Costs</a></td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_FacilityExitAndOtherCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_FacilityExitAndOtherCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694841731480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">$ 8,357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, Transfers</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments and other</a></td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">7,986<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_CordisDivestitureAxis=cah_CordisDivestitureMember', window );">Cordis Divestiture</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1', window );">Disposal Group, Including Discontinued Operation, Goodwill</a></td>
<td class="nump">388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1', window );">Disposal Group, Including Discontinued Operation, Goodwill</a></td>
<td class="nump">388<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember', window );">Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">2,657<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, Transfers</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments and other</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">2,659<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember', window );">Pharmaceutical | Cordis Divestiture</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1', window );">Disposal Group, Including Discontinued Operation, Goodwill</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1', window );">Disposal Group, Including Discontinued Operation, Goodwill</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember', window );">Medical</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">5,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, Transfers</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments and other</a></td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">5,327<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember', window );">Medical | Cordis Divestiture</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1', window );">Disposal Group, Including Discontinued Operation, Goodwill</a></td>
<td class="nump">388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1', window );">Disposal Group, Including Discontinued Operation, Goodwill</a></td>
<td class="nump">$ 388<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as goodwill attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_CordisDivestitureAxis=cah_CordisDivestitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_CordisDivestitureAxis=cah_CordisDivestitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694764926488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net Intangible</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Intangible</a></td>
<td class="nump">4,913<span></span>
</td>
<td class="nump">5,831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">2,732<span></span>
</td>
<td class="nump">2,936<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Intangible</a></td>
<td class="nump">$ 2,181<span></span>
</td>
<td class="nump">2,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted- Average Remaining Amortization Period (Years)</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Intangible, Total other intangible assets</a></td>
<td class="nump">$ 4,925<span></span>
</td>
<td class="nump">5,854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Intangible, Total other intangible assets</a></td>
<td class="nump">2,193<span></span>
</td>
<td class="nump">2,918<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=cah_IPRDTrademarksandOtherMember', window );">IPR&amp;D, trademarks and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Net Intangible</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Intangible</a></td>
<td class="nump">3,331<span></span>
</td>
<td class="nump">3,554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">1,925<span></span>
</td>
<td class="nump">1,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Intangible</a></td>
<td class="nump">$ 1,406<span></span>
</td>
<td class="nump">1,726<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted- Average Remaining Amortization Period (Years)</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cah_TrademarksAndPatentsMember', window );">Trademarks, trade names and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Intangible</a></td>
<td class="nump">$ 551<span></span>
</td>
<td class="nump">673<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">319<span></span>
</td>
<td class="nump">341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Intangible</a></td>
<td class="nump">$ 232<span></span>
</td>
<td class="nump">332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted- Average Remaining Amortization Period (Years)</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Intangible</a></td>
<td class="nump">$ 1,031<span></span>
</td>
<td class="nump">1,604<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">488<span></span>
</td>
<td class="nump">767<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Intangible</a></td>
<td class="nump">$ 543<span></span>
</td>
<td class="nump">$ 837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted- Average Remaining Amortization Period (Years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=cah_IPRDTrademarksandOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=cah_IPRDTrademarksandOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cah_TrademarksAndPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=cah_TrademarksAndPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694850410968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Other Intangible Assets (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 7,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">109<span></span>
</td>
<td class="nump">$ 129<span></span>
</td>
<td class="nump">337<span></span>
</td>
<td class="nump">$ 385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Estimated annual amortization of intangible assets - Remainder of Fiscal Year</a></td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Estimated annual amortization of intangible assets - Year One</a></td>
<td class="nump">314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Estimated annual amortization of intangible assets - Year Two</a></td>
<td class="nump">287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Estimated annual amortization of intangible assets - Year Three</a></td>
<td class="nump">263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Estimated annual amortization of intangible assets - Year Four</a></td>
<td class="nump">238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_CordisDivestitureAxis=cah_CordisDivestitureMember', window );">Cordis Divestiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets', window );">Disposal Group, Including Discontinued Operation, Intangible Assets</a></td>
<td class="nump">$ 391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_CordisDivestitureAxis=cah_CordisDivestitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_CordisDivestitureAxis=cah_CordisDivestitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694836380056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Obligations and Other Short-Term Borrowings (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_TotalLongTermandShortTermObligations', window );">Total Long-Term and Short-Term Obligations</a></td>
<td class="nump">$ 6,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on Extinguishment of Debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">$ (5)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">$ (9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts Payable</a></td>
<td class="nump">22,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cah_A2.4Notesdue2020Member', window );">2.4% Notes due 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_NotesPayableRepurchased', window );">Notes Payable Repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cah_A2.616Notesdue2022Member', window );">2.616% Notes due 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_NotesPayableRepurchased', window );">Notes Payable Repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cah_A3.41Notesdue2027Member', window );">3.41% Notes due 2027 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_NotesPayableRepurchased', window );">Notes Payable Repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cah_CommittedReceivablesSalesFacilityProgramMember', window );">Committed Receivables Sales Facility Program [Member] | Short Term Credit Facilities Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cah_A4.6Notesdue2043Member', window );">4.6% Notes due 2043 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_NotesPayableRepurchased', window );">Notes Payable Repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cah_A4.9Notesdue2045Member', window );">4.9% Notes due 2045 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_NotesPayableRepurchased', window );">Notes Payable Repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cah_A4.368Notesdue2047Member', window );">4.368% Notes due 2047 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_NotesPayableRepurchased', window );">Notes Payable Repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cah_FloatingRateNotesdue2022Member', window );">Floating Rate Notes due 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_NotesPayableRepurchased', window );">Notes Payable Repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=cah_A3.2Notesdue2022Member', window );">3.2% Notes due 2022 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_NotesPayableRepurchased', window );">Notes Payable Repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_NotesPayableRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Principal Amount of Notes Payable Repurchased during the year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_NotesPayableRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_TotalLongTermandShortTermObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total Long-Term and Short-Term Obligations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_TotalLongTermandShortTermObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cah_A2.4Notesdue2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cah_A2.4Notesdue2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cah_A2.616Notesdue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cah_A2.616Notesdue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cah_A3.41Notesdue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cah_A3.41Notesdue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cah_CommittedReceivablesSalesFacilityProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cah_CommittedReceivablesSalesFacilityProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=cah_ShortTermCreditFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=cah_ShortTermCreditFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cah_A4.6Notesdue2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cah_A4.6Notesdue2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cah_A4.9Notesdue2045Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cah_A4.9Notesdue2045Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cah_A4.368Notesdue2047Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cah_A4.368Notesdue2047Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cah_FloatingRateNotesdue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cah_FloatingRateNotesdue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=cah_A3.2Notesdue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=cah_A3.2Notesdue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694835464568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_TotalLongTermandShortTermObligations', window );">Total Long-Term and Short-Term Obligations</a></td>
<td class="nump">$ 6,700<span></span>
</td>
<td class="nump">$ 6,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Long-term Debt and Lease Obligation, Current</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term Debt and Lease Obligation</a></td>
<td class="nump">$ 6,715<span></span>
</td>
<td class="nump">$ 6,765<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_TotalLongTermandShortTermObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total Long-Term and Short-Term Obligations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_TotalLongTermandShortTermObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694838527592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments, Contingent Liabilities and Litigation (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 03, 2021 </div>
<div>lawsuit </div>
<div>plaintiff </div>
<div>StateAG</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,329.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,329.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,198.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Gain (Loss) Related to Litigation Settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.0<span></span>
</td>
<td class="nump">$ 35.0<span></span>
</td>
<td class="nump">1,085.0<span></span>
</td>
<td class="nump">$ 5,729.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of Goods and Services Sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,463.0<span></span>
</td>
<td class="nump">37,272.0<span></span>
</td>
<td class="nump">114,578.0<span></span>
</td>
<td class="nump">110,955.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,120.0<span></span>
</td>
<td class="nump">$ 1,165.0<span></span>
</td>
<td class="nump">3,404.0<span></span>
</td>
<td class="nump">3,435.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other Accrued Liabilities, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,573.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,573.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,231.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_ProceedsFromSettlementsOfClassActionLawsuits', window );">Income from Settlements of Class Action Lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsStateDomain', window );">Opioid Lawsuits State [Domain] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_LossContingencyLawsuitsNumber', window );">Loss Contingency, Lawsuits, Number</a></td>
<td class="nump">2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember', window );">Opioid Lawsuits [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_LossContingencyLawsuitsNumber', window );">Loss Contingency, Lawsuits, Number</a></td>
<td class="nump">3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_NumberofStateAttorneysGeneralfilinglawsuits', window );">Number of State Attorneys General filing lawsuits | StateAG</a></td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_ProductLiabilityLawsuitsMember', window );">Product Liability Lawsuits | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Loss Contingency, New Claims Filed, Number | lawsuit</a></td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_NewYorkOpioidStewardshipActMember', window );">New York Opioid Stewardship Act [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct', window );">Estimated Liability for New York Opioid Stewardship Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_AggregateAnnualAssessment', window );">Aggregate Annual Assessment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_DOJInvestigationMember', window );">DOJ Investigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Gain (Loss) Related to Litigation Settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=cah_CVSHealthMember', window );">CVS Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermPurchaseCommitmentPeriod', window );">Long-term Purchase Commitment, Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_MaximumQuarterlyPayment', window );">Maximum quarterly payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=cah_ProductLiabilityLawsuitsMember', window );">Product Liability Lawsuits | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Loss Contingency, New Claims Filed, Number | lawsuit</a></td>
<td class="nump">396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=cah_AlamedaCountyMember', window );">Alameda County [Member] | Product Liability Lawsuits | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Loss Contingency, Number of Plaintiffs | plaintiff</a></td>
<td class="nump">5,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=cah_OtherJurisdictionsMember', window );">Other Jurisdictions [Member] | Product Liability Lawsuits | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Loss Contingency, Number of Plaintiffs | plaintiff</a></td>
<td class="nump">36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_PlaintiffTypeAxis=cah_PrivatePartiesMember', window );">Private Parties [Member] | Opioid Lawsuits [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_LossContingencyLawsuitsNumber', window );">Loss Contingency, Lawsuits, Number | lawsuit</a></td>
<td class="nump">430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_LawsuitTypeAxis=cah_ClassActionLawsuitsMember', window );">Class Action Lawsuits [Member] | Private Parties [Member] | Opioid Lawsuits [Member] | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_LossContingencyLawsuitsNumber', window );">Loss Contingency, Lawsuits, Number | lawsuit</a></td>
<td class="nump">127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_LawsuitTypeAxis=cah_ProductLiabilityLawsuitsMember', window );">Product Liability Lawsuits | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss Contingency Accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">514.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">514.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_LawsuitTypeAxis=cah_ProductLiabilityLawsuitsMember', window );">Product Liability Lawsuits | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss Contingency Accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,010.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,010.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember', window );">Total Opioid Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Gain (Loss) Related to Litigation Settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,020.0<span></span>
</td>
<td class="nump">$ 5,630.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserve', window );">Estimated Litigation Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,590.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,590.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_AggregateAnnualAssessment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate Annual Assessment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_AggregateAnnualAssessment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated Liability for New York Opioid Stewardship Act</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_LossContingencyLawsuitsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Lawsuits, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_LossContingencyLawsuitsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_MaximumQuarterlyPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Quarterly Payment for pharmaceutical sourcing venture if certain milestones are achieved.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_MaximumQuarterlyPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_NumberofStateAttorneysGeneralfilinglawsuits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of State Attorneys General filing lawsuits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_NumberofStateAttorneysGeneralfilinglawsuits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_ProceedsFromSettlementsOfClassActionLawsuits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Settlements of Class Action Lawsuits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_ProceedsFromSettlementsOfClassActionLawsuits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermPurchaseCommitmentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermPurchaseCommitmentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfPlaintiffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of plaintiffs that have filed claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfPlaintiffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsStateDomain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cah_OpioidLawsuitsStateDomain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cah_OpioidLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cah_OpioidLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cah_ProductLiabilityLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cah_ProductLiabilityLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cah_NewYorkOpioidStewardshipActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cah_NewYorkOpioidStewardshipActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cah_DOJInvestigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cah_DOJInvestigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=cah_CVSHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=cah_CVSHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=cah_ProductLiabilityLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=cah_ProductLiabilityLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=cah_AlamedaCountyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=cah_AlamedaCountyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=cah_OtherJurisdictionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=cah_OtherJurisdictionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_PlaintiffTypeAxis=cah_PrivatePartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_PlaintiffTypeAxis=cah_PrivatePartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_LawsuitTypeAxis=cah_ClassActionLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_LawsuitTypeAxis=cah_ClassActionLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_LawsuitTypeAxis=cah_ProductLiabilityLawsuitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_LawsuitTypeAxis=cah_ProductLiabilityLawsuitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694836693592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">$ 320<span></span>
</td>
<td class="nump">$ 127<span></span>
</td>
<td class="num">$ (293)<span></span>
</td>
<td class="num">$ (237)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="nump">703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">753<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized tax benefits, interest and penalties accrued</a></td>
<td class="nump">$ 73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective Income Tax Rate Reconciliation, Percent</a></td>
<td class="nump">72.80%<span></span>
</td>
<td class="nump">26.80%<span></span>
</td>
<td class="num">(143.30%)<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent', window );">Deferred income taxes and other liabilities</a></td>
<td class="nump">$ 10,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,594<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_NetOperatingLossCarrybackAxis=cah_NetOperatingLossCarrybackMember', window );">Net Operating Loss Carryback [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(419)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent', window );">Deferred income taxes and other liabilities</a></td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReceivable', window );">Income Taxes Receivable</a></td>
<td class="nump">974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Estimated range of decrease in unrecognized tax benefits within the next 12 months</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Estimated range of decrease in unrecognized tax benefits within the next 12 months</a></td>
<td class="nump">90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Internal Revenue Service (IRS) [Member] | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Tax Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_TaxMatterAxis=cah_PatientRecoveryBusinessMember', window );">Patient Recovery Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_IndemnificationReceivable', window );">Indemnification Receivable</a></td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_TaxMatterAxis=cah_CareFusionMember', window );">CareFusion [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_IndemnificationReceivable', window );">Indemnification Receivable</a></td>
<td class="nump">119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember', window );">Total Opioid Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserve', window );">Estimated Litigation Liability</a></td>
<td class="nump">6,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">$ 140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(180)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(488)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation Settlement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,020<span></span>
</td>
<td class="nump">$ 5,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember', window );">Total Opioid Litigation [Member] | Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (37)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_IndemnificationReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indemnification receivable from Patient recovery related to certain pre-acquisition tax exposures and transaction taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_IndemnificationReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting, and liabilities classified as noncurrent and other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of income taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Also called income tax refund receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in CCYY format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_NetOperatingLossCarrybackAxis=cah_NetOperatingLossCarrybackMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_NetOperatingLossCarrybackAxis=cah_NetOperatingLossCarrybackMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_TaxMatterAxis=cah_PatientRecoveryBusinessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_TaxMatterAxis=cah_PatientRecoveryBusinessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_TaxMatterAxis=cah_CareFusionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_TaxMatterAxis=cah_CareFusionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694841443112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1', window );">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation', window );">Disposal Group, Including Discontinued Operation, Liabilities</a></td>
<td class="nump">93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Total assets held for sale</a></td>
<td class="nump">1,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">1,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Other investments</a></td>
<td class="nump">118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Forward contracts</a></td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">1,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Other investments</a></td>
<td class="nump">118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Forward contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Other investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Forward contracts</a></td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Other investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet', window );">Forward contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Fair Value, Nonrecurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Total assets held for sale</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=117331979&amp;loc=d3e41228-113958<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694852390344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Narrative) (Details)<br> &#165; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>JPY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1', window );">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative Liability, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax', window );">Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredGainLossOnDiscontinuationOfInterestRateFairValueHedge', window );">Deferred Gain (Loss) on Discontinuation of Interest Rate Fair Value Hedge</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember', window );">Currency Swap [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative Liability, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="nump">&#165; 64,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest Income (Expense), Nonoperating, Net</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument | Fair Value Hedging | Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount', window );">Derivatives, Hedge Discontinuances, Hedging Instrument Matured, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative Liability, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_DerivativesHedgeDiscontinuancesHeadingInstrumentTerminatedAmount', window );">Derivatives, Hedge Discontinuances, Heading Instrument Terminated, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other Nonoperating Income (Expense) [Member] | Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="num">$ (7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_DerivativesHedgeDiscontinuancesHeadingInstrumentTerminatedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivatives, Hedge Discontinuances, Heading Instrument Terminated, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_DerivativesHedgeDiscontinuancesHeadingInstrumentTerminatedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivatives, Hedge Discontinuances, Hedging Instrument Matured, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredGainLossOnDiscontinuationOfInterestRateFairValueHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount as of the balance sheet date of the unamortized adjustment to the carrying value of an interest-bearing hedged item made under an effective interest rate fair value hedge that is amortized upon discontinuation of the interest rate fair value hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 35<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121561968&amp;loc=d3e75592-113984<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredGainLossOnDiscontinuationOfInterestRateFairValueHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109998890-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5580258-113959<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558989&amp;loc=d3e80720-113993<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694840575928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_CarryingAmountofLongTermandotherShortTermBorrowings', window );">Carrying Amount of Long-Term and other Short-Term Borrowings</a></td>
<td class="nump">$ 6,731<span></span>
</td>
<td class="nump">$ 6,775<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Estimated fair value</a></td>
<td class="nump">$ 7,177<span></span>
</td>
<td class="nump">$ 7,273<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_CarryingAmountofLongTermandotherShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying Amount of Long-Term and other Short-Term Borrowings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_CarryingAmountofLongTermandotherShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694835801720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Narrative) (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for Repurchase of Common Stock</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 350<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember', window );">Treasury Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury Stock, Shares, Acquired</a></td>
<td class="num">(3.7)<span></span>
</td>
<td class="num">(3.7)<span></span>
</td>
<td class="num">(7.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Treasury shares acquired, average price per share (in usd per share)</a></td>
<td class="nump">$ 54.40<span></span>
</td>
<td class="nump">$ 54.40<span></span>
</td>
<td class="nump">$ 48.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694837530408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period</a></td>
<td class="nump">$ 1,975<span></span>
</td>
<td class="nump">$ 1,002<span></span>
</td>
<td class="nump">$ 1,792<span></span>
</td>
<td class="nump">$ 6,330<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income/(loss), net of tax</a></td>
<td class="nump">5<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="num">(62)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period</a></td>
<td class="nump">1,794<span></span>
</td>
<td class="nump">1,206<span></span>
</td>
<td class="nump">1,794<span></span>
</td>
<td class="nump">1,206<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Foreign Currency Translation Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(92)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income/(loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period</a></td>
<td class="num">(50)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember', window );">Unrealized Gain/(Loss) on Derivatives, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income/(loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember', window );">Accumulated Other Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(104)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive income/(loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period</a></td>
<td class="num">(48)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">AOCI Attributable to Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period</a></td>
<td class="num">(53)<span></span>
</td>
<td class="num">(103)<span></span>
</td>
<td class="num">(104)<span></span>
</td>
<td class="num">(79)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period</a></td>
<td class="num">$ (48)<span></span>
</td>
<td class="num">$ (141)<span></span>
</td>
<td class="num">$ (48)<span></span>
</td>
<td class="num">$ (141)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17B<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL34724394-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694838325048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive (in shares)</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss', window );">shares that would be antidilutive as a result of net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_Sharesthatwouldbeantidilutiveasaresultofnetloss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>shares that would be antidilutive as a result of net loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_Sharesthatwouldbeantidilutiveasaresultofnetloss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694835996456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares&#8211;basic (in shares)</a></td>
<td class="nump">292<span></span>
</td>
<td class="nump">292<span></span>
</td>
<td class="nump">293<span></span>
</td>
<td class="nump">293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Employee stock options, restricted share units, and performance share units (in shares)</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares&#8211;diluted (in shares)</a></td>
<td class="nump">294<span></span>
</td>
<td class="nump">294<span></span>
</td>
<td class="nump">294<span></span>
</td>
<td class="nump">293<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694841315672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Narrative) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Gain (Loss) Related to Litigation Settlement</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 1,085<span></span>
</td>
<td class="nump">$ 5,729<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_ProjectCostsOnInvestmentAndOtherSpending', window );">Project costs on investment and other spending</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_ProjectCostsOnInvestmentAndOtherSpending', window );">Project costs on investment and other spending</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_CordisDivestitureAxis=cah_CordisDivestitureMember', window );">Cordis Divestiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_WriteDownOfAssetsHeldForSale', window );">Write-down of assets held for sale</a></td>
<td class="nump">$ 58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=cah_NewYorkOpioidStewardshipActMember', window );">New York Opioid Stewardship Act [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct', window );">Estimated Liability for New York Opioid Stewardship Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember', window );">Total Opioid Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Gain (Loss) Related to Litigation Settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,020<span></span>
</td>
<td class="nump">5,630<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_SterileSurgicalGownRecallAxis=cah_SterileSurgicalGownRecallMember', window );">Sterile Surgical Gown Recall [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRecallExpense', window );">Inventory Recall Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated Liability for New York Opioid Stewardship Act</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_ProjectCostsOnInvestmentAndOtherSpending">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment spending at the Corporate level. Investment spending generally includes the first year spend for certain projects that require incremental investments in the form of additional operating expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_ProjectCostsOnInvestmentAndOtherSpending</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_WriteDownOfAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Write-down of assets held for sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_WriteDownOfAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRecallExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the amount charged against earnings comprised of the costs to announce and effect a recall of defective merchandise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRecallExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_CordisDivestitureAxis=cah_CordisDivestitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_CordisDivestitureAxis=cah_CordisDivestitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=cah_NewYorkOpioidStewardshipActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=cah_NewYorkOpioidStewardshipActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_OpioidLitigationAxis=cah_TotalOpioidLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_SterileSurgicalGownRecallAxis=cah_SterileSurgicalGownRecallMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_SterileSurgicalGownRecallAxis=cah_SterileSurgicalGownRecallMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694852608888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Revenue by Reportable Segment) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 39,275<span></span>
</td>
<td class="nump">$ 39,157<span></span>
</td>
<td class="nump">$ 119,881<span></span>
</td>
<td class="nump">$ 116,233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">39,278<span></span>
</td>
<td class="nump">39,163<span></span>
</td>
<td class="nump">119,893<span></span>
</td>
<td class="nump">116,245<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">35,104<span></span>
</td>
<td class="nump">35,112<span></span>
</td>
<td class="nump">107,452<span></span>
</td>
<td class="nump">104,254<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">4,174<span></span>
</td>
<td class="nump">4,051<span></span>
</td>
<td class="nump">12,441<span></span>
</td>
<td class="nump">11,991<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=cah_PharmaceuticalDistributionandSpecialtyMember', window );">Pharmaceutical Distribution and Specialty [Member] | Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">34,903<span></span>
</td>
<td class="nump">34,899<span></span>
</td>
<td class="nump">106,859<span></span>
</td>
<td class="nump">103,612<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=cah_NuclearPrecisionHealthServicesMember', window );">Nuclear Precision Health Services [Member] | Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">201<span></span>
</td>
<td class="nump">213<span></span>
</td>
<td class="nump">593<span></span>
</td>
<td class="nump">642<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=cah_MedicaldistributionandproductsMember', window );">Medical distribution and products [Member] | Operating Segments | Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">3,638<span></span>
</td>
<td class="nump">3,539<span></span>
</td>
<td class="nump">10,805<span></span>
</td>
<td class="nump">10,483<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=cah_CardinalHealthAtHomeMember', window );">Cardinal Health At Home [Member] | Operating Segments | Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 536<span></span>
</td>
<td class="nump">$ 512<span></span>
</td>
<td class="nump">$ 1,636<span></span>
</td>
<td class="nump">$ 1,508<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=cah_PharmaceuticalDistributionandSpecialtyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=cah_PharmaceuticalDistributionandSpecialtyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=cah_NuclearPrecisionHealthServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=cah_NuclearPrecisionHealthServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=cah_MedicaldistributionandproductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=cah_MedicaldistributionandproductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=cah_CardinalHealthAtHomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=cah_CardinalHealthAtHomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694845028104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Segment Profit by Reportable Segment) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating earnings</a></td>
<td class="nump">$ 473<span></span>
</td>
<td class="nump">$ 562<span></span>
</td>
<td class="nump">$ 310<span></span>
</td>
<td class="num">$ (4,368)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating earnings</a></td>
<td class="nump">685<span></span>
</td>
<td class="nump">712<span></span>
</td>
<td class="nump">1,966<span></span>
</td>
<td class="nump">1,937<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating earnings</a></td>
<td class="nump">511<span></span>
</td>
<td class="nump">534<span></span>
</td>
<td class="nump">1,326<span></span>
</td>
<td class="nump">1,394<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating earnings</a></td>
<td class="nump">174<span></span>
</td>
<td class="nump">178<span></span>
</td>
<td class="nump">640<span></span>
</td>
<td class="nump">543<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating earnings</a></td>
<td class="num">$ (212)<span></span>
</td>
<td class="num">$ (150)<span></span>
</td>
<td class="num">$ (1,656)<span></span>
</td>
<td class="num">$ (6,305)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694840550072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information Revenue From External Customers By Geographic Areas (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems', window );"><strong>Segment Revenue from External Customers by Geographic Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 39,275<span></span>
</td>
<td class="nump">$ 39,157<span></span>
</td>
<td class="nump">$ 119,881<span></span>
</td>
<td class="nump">$ 116,233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems', window );"><strong>Segment Revenue from External Customers by Geographic Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">38,089<span></span>
</td>
<td class="nump">38,073<span></span>
</td>
<td class="nump">116,425<span></span>
</td>
<td class="nump">113,053<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems', window );"><strong>Segment Revenue from External Customers by Geographic Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">1,189<span></span>
</td>
<td class="nump">1,090<span></span>
</td>
<td class="nump">3,468<span></span>
</td>
<td class="nump">3,192<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems', window );"><strong>Segment Revenue from External Customers by Geographic Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">39,278<span></span>
</td>
<td class="nump">39,163<span></span>
</td>
<td class="nump">119,893<span></span>
</td>
<td class="nump">116,245<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems', window );"><strong>Segment Revenue from External Customers by Geographic Area [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="num">$ (3)<span></span>
</td>
<td class="num">$ (6)<span></span>
</td>
<td class="num">$ (12)<span></span>
</td>
<td class="num">$ (12)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Segment Revenue from External Customers by Geographic Area [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694841723432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Segment Information (Assets by Reportable Segment) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">$ 43,874<span></span>
</td>
<td class="nump">$ 40,766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Total assets held for sale</a></td>
<td class="nump">1,092<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_CordisDivestitureAxis=cah_CordisDivestitureMember', window );">Cordis Divestiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Total assets held for sale</a></td>
<td class="nump">1,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember', window );">Medical | Cordis Divestiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Total assets held for sale</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">23,078<span></span>
</td>
<td class="nump">22,398<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Medical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">15,280<span></span>
</td>
<td class="nump">14,691<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">$ 5,516<span></span>
</td>
<td class="nump">$ 3,677<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_CordisDivestitureAxis=cah_CordisDivestitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_CordisDivestitureAxis=cah_CordisDivestitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_MedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=cah_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694765022424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Tax benefit related to share-based compensation</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_ExercisablePeriodOfPlansInYears', window );">Exercisable period of plans (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Share Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="nump">90,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cah_VestingPeriodinyearsforShares', window );">Vesting Period in years for Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="nump">$ 41,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Units | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Target performance goal (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Units | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Target performance goal (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_ExercisablePeriodOfPlansInYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The instrument's contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_ExercisablePeriodOfPlansInYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cah_VestingPeriodinyearsforShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vesting Period in years for Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cah_VestingPeriodinyearsforShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cah_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694863222168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">$ 84<span></span>
</td>
<td class="nump">$ 68<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Share Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Share Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694841425160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details)<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period (in shares) | shares</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Canceled and forfeited (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period (in shares) | shares</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period (in shares) | shares</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price per Common Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 65.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share) | $ / shares</a></td>
<td class="nump">40.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Canceled and forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period (in usd per share) | $ / shares</a></td>
<td class="nump">67.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 67.80<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694841478088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details) - Stock Options - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value of outstanding options at period end</a></td>
<td class="nump">17,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value of exercisable options at period end</a></td>
<td class="nump">$ 17,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694841357000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)<br> $ / shares in Units, shares in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Share Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $</a></td>
<td class="nump">$ 90,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Share Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at beginning of period (in shares) | shares</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled and forfeited (in shares) | shares</a></td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at end of period (in shares) | shares</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at beginning of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 45.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">53.67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in usd per share) | $ / shares</a></td>
<td class="nump">49.45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Canceled and forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">48.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at end of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 48.96<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $</a></td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140694869182904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details) - Performance Share Units<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Performance Share Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at beginning of period (in shares) | shares</a></td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Canceled and forfeited (in shares) | shares</a></td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at end of period (in shares) | shares</a></td>
<td class="nump">1.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at beginning of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 54.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in usd per share) | $ / shares</a></td>
<td class="nump">55.45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in usd per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Canceled and forfeited (in usd per share) | $ / shares</a></td>
<td class="nump">52.54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at end of period (in usd per share) | $ / shares</a></td>
<td class="nump">$ 60.32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | $</a></td>
<td class="nump">$ 41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>78
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$
MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)I#-ZG7TZSFN4
M?VFK :?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R.AQG0GS/]O:1
MI24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG LR+7E$8D19_(
M+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(R-^-B/>K;YH]
M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M
MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1CVFS(Z=T)LWH
M,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.FJW"$2M"/F(9
M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+
MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T
M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M"T4PH5T L#A#NQHO$%0\9M,.\JT#H:&7_%&M;0QI<&%RX!)E'#ICB,;V'HJ
MXI&]A2*@D YMRBZH'X6CCMV%MKZ(^HW1YVK)7V25^[H,FC+?/<\1DKOVCHJ
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M0E$C^P4#07F%:2T8B[TY^;TZ7N=I/S&OUAM.RGVQ! G EQRG)EB7O58:WLA
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M7G\HLZ?5;W;OL[+,%JNW<QFI);X"J.\?LJQ\_5#]#'CST_7S?P%02P,$%
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MO2Y5._*L@^K4FMA+'*=#(CFLDL2GM2=2- MJ_5,55&B58D^/4M(D7)^W#+9
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MEY$J_\220$+CB6N;+EF>HQ)-[-.OS!9IVD(U.B+ JBA<:[N&Z3>-&F=*OR/
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M#AKI<8V[/GO9@/65PT#N7L3 \-^#ZW\ 4$L#!!0    ( !J#IE+%<E$J> 0
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MQPRW7+(L@.\S@[G8O+"!]MX\_A=02P,$%     @ &H.F4L5&VI#>&   YD4
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MV,#'92N7:$(;6#F";S6B(W(,40V5ANO>P;'W")<PG]?[*XB,4S#W1PLZRX$
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MI73<J3<_#["I%(^"D.ZC0E E[_T(CQ\8O4BX)5'$$F#:2!PMY,>%K\VFCX,
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M.;;%AR4>0]8W5X=^].$X^^T-:,Q*?F'$^0E$_S,<Z=OT(R87_K<[QMO]+Z#
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M#>4#WS8W(8?[ZV@<B-](=YA7/\9"_0=?K&Q?+3;>2!:M+UR^0/WUN<X8/S]
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MA9+@(+@ ?I]9&^HO2*!Y2_+-?P%02P,$%     @ &H.F4C)RJDTN!0  A0P
M !D   !X;"]W;W)K<VAE971S+W-H965T,34N>&ULK5=M;]LV$/XKA%<,">#9
MENRN298$2-(5V]"N1=MU'X9]H*23Q84B%9*RD_[Z/4?)BI(FZ0KLBR61]_;<
M/7>DC[?67?J**(CK6AM_,JE":([F<Y]75$L_LPT9[)36U3+@TZWGOG$DBZA4
MZWFZ6/PXKZ4RD]/CN/;.G1[;-FAEZ)T3OJUKZ6[.2=OMR229[!;>JW45>&%^
M>MS(-7V@\$?SSN%K/E@I5$W&*VN$H_)D<I8<G:]8/@I\4K3UHW?!2#)K+_GC
MU^)DLN" 2%,>V(+$8T,7I#4;0AA7O<W)X)(5Q^\[ZZ\B=F#)I*<+J_]41:A.
M)@<345 I6QW>V^TOU.-YSO9RJWW\%=M.=KF:B+SUP=:],B*HE>F>\KK/PTCA
M8/&(0MHKI#'NSE&,\J4,\O38V:UP+ UK_!*A1FT$IPP7Y4-PV%70"Z>OI'+B
MD]0MB3<D?>L(&0_^>!Y@G$7F>6_HO#.4/F+H4+RQ)E1>_&P**N[JSQ'4$%FZ
MB^P\?=+@&^EF8IE,1;I(DR?L+0>DRVAO^76D+Y7/M66P7OQUEOG@0(Z_G_"Q
M&GRLHH_5-_EX*)E/VSF8B4<*(\Z\)SRD*<3>:R4SI550Y/=W4H5@KHOWE+?.
M*;,6Y](K+SY6)$JKT8.\%F2F@1UM[&%4!-YD?QOVYR'HA!SYT6,_]1T_;O"3
M13\R' E4+J^&THD]9<!<K=&$4']-&](BZ9]I_UR*CS9(W:,[$A?25X*N6H6(
M(NQG(ID>KE9X?O_=09JD/]UYZ_;> H<3RFS(ARY9>\F^2)*#07+WY#4T]5:Z
M0N2@+=<?TNG^(+%*QJ^_M8;$<A$!+?XO0"^0FX?A\,YC8%8/@%E]!<SSY?B5
M[3 =[!<>,JFER0EKN6X+$&&\R:#;T )3V9K"3\6V4BBS+4L@%*5N<VSRI(VB
M&(SDF"6YK7& ^+@C1D2:<0R>[MCL_;$^4Y+3%6Z$9XI%'3B+]J3ACZT*E<B
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MD[]D.JS4 E6%V%#"U']&(2.>FGQI[CQ0FESUL(^/&MGT6C!I'K$QUEZP7Q>
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M8"E:16=F^1)7]NQZO-PH%]ZP[/;N[D60MXY,O1)F!K74W5=<KOQP0V _^8E
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MA^=G<&;PZ*3WZ/+D28&_Z3!5I\<3=3(_.7Y"WNF T*G(._V"O,<<_O=B%5-
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M77!@>V$M[3:!H/_QK?X 4$L#!!0    ( !J#IE(&? O0) ,  #L(   9
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M-Z/JCLINH/6%E&8SL &:_X7Q;U!+ P04    "  :@Z925AB:('4$   1"P
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M,K@PEE-Z80J7C&MX9*+V^]^5S#];U"7<+@7/F<OBANBM+5##HE#:-@8SI8D
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M<'(@0")UM<Y\]:TO<WYLIYX[\L?.]K@ U4EN,>.$L5<P]C[ R"A>4@:))!\
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M "F264^;W6BQL6WA4FAH,NUE3#"$8"; \Y40^G!C%BC^69C^!U!+ P04
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MR\Q\7X"R /-\*27N-S9 ]<4R^ -02P,$%     @ &H.F4C?*-M,Y P  @PL
M !D   !X;"]W;W)K<VAE971S+W-H965T,S,N>&ULM59=;]HP%/TK5M2'5EH;
M'+XK0()^:)-6#8&Z/4Q[,,F%>'5L9ALH_WZV$Q(8)*W:]05LQ_><ZYOCD]O;
M"/FD8@"-GA/&5=^+M5Y>^[X*8TB(NA)+X.;)7,B$:#.5"U\M)9#(!27,#VJU
MEI\0RKU!SZV-Y: G5II1#F.)U"I)B-R.@(E-W\/>;F%"%[&V"_Z@MR0+F()^
M7(ZEF?DY2D03X(H*CB3,^]X07X]PUP:X'=\I;-3>&-FCS(1XLI,O4=^KV8R
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M1S8[JCSSEPTCT^*<O9;&GMJ+QQW0&%0^P+[?2&D.C3Q _>5E_A]02P,$%
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M#Z-],,2 -4G,.@9::7_\.I?&(0EN.E/V!7(YY_,YWW$^'WMPX.)[M*%4@J?
M#Z/KUD;*[56G$RTW-"!1FV]IJ-ZLN B(5+=BW8FV@A(O<0K\#K(LMQ,0%K:&
M@^397 P'?"=]%M*Y -$N"(AXOJ4^/URW8.OEP0-;;V3\H#,<;,F:/E+Y=3L7
MZJZ3HW@LH&'$> @$75VW;N#5%/=CA\3B3T8/4>$:Q*DL./\>W]QYURTKCHCZ
M="EC"*+^]G1$?3]&4G'\DX&V\C%CQ^+U"_HT25XELR 1'7'_+^;)S76KUP(>
M79&=+Q_XX3>:)>3$>$ON1\DO.&2V5@LL=Y'D0>:L(@A8F/Z3IXR(@H/"J7=
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M+#^RAQM2.A1J?0L6B_Q?\%".]7I@D0G)DE)869#0M/@?_R@#41- @Q8!6 K
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M>Z_WC3&O]V.X'O0CA(8FH=:>W0#5_$CM_/@Y4< >GQ8B$1/T =J/V0;5$7-
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MP1W%+Y1118E\#0F!T0AX),M4")JLP3665+X')PNB,&7ZZA?P_+0 )^_>@W>
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M;V<]V(YMMW?8'E')7N-N0U_NX!V::!JIORV6.YGE3FRYL\/R<$'XG)H6?>&
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M0S< '#^%.4E@HAJ8'KCC3*TEF+. !!7Z,[O^P*+OZ)1E>4-O>9L@J\$[+*Z
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MC(#^?<FY>GLQ#K*[^-$_4$L#!!0    ( !J#IE)'YQA3V (  +X'   9
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M)C@FPDS0SY><J\.-6: XH1S\!U!+ P04    "  :@Z92,BH+[4$#  "6#
M&0   'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6S-5UMOVC 8_2M6U(=6VIH;
MMU: Q&U:I55#I=T>ICV8Y(-$=>+,-J7\^]E.""$)*=KZT!>PG7/.=R7^Z&\I
M>^8!@$"O$8GYP B$2&Y-DWL!1)A?TP1B^61%682%W+*UR1,&V->DB)B.977,
M"(>Q,>SKLSD;]NE&D#"&.4-\$T68[<9 Z'9@V,;^X"%<!T(=F,-^@M>P /&4
MS)G<F;F*'T80\Y#&B,%J8(SLVYGM*H)&_ AARPMKI$)94OJL-G?^P+"41T#
M$TH"RZ\7F  A2DGZ\2<3-7*;BEA<[]6_Z.!E,$O,84+)S] 7P<#H&<B'%=X0
M\4"W7R$+J*WT/$JX_D3;#&L9R-MP0:.,+#V(PCC]QJ]9(@H$J5-/<#*"4R:T
M3A#<C.">:Z&5$5KG6FAG!!VZF<:N$S?% @_[C&X14VBIIA8Z^YHM\Q7&JE$6
M@LFGH>2)X2+ ##Z/9:I]-*&1[#^.=04O%[(G_0T!1%?HD0I,T$GL[%6M 2UW
MZ'&7:,9HBYE_A2ZG('!(^!7ZC)X64W1Y<84N4!BC^Y 02>5]4\@HE"^FEWD\
M3CUV3GCLHGL:BX"C6>R#7\.?-O-O&OBFS%Z>0F>?PK'3*'B/V35R[4_(L1R[
MQI_)^72K+IS_LS[[9^M'R7#S?G*UGMO83\MJCXP8P_$:Y#M&J#XIXN9XIX]U
MSZ!?WZ0DNA,0\=\-#K5RAUK:H=8)A]+6Y05S7L&MNO9+]3I:3[UG7X:NVS=?
MBA6M0ISN,61:A?1:QY!9%=+IY9"C8-MYL.W&8!^ "Q9Z0D:I$XR>XE T)+&3
MZW8^1E6[N4/==ZYJJM<NELPJ5?5MR+0*:7=*5:V!N/55[>7!]AJ#G44)H3L
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M%,)Z(HX_3TZ]:DUKV&R?O?_B@J=@-DSCDQ3?>&JRN3?Q(,4M.PCS61Y_PU-
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M;W)K<VAE971S+W-H965T-3<N>&ULO59M;],P$/XKIX@/0RI+FKYL3&VEOH
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MF314][GFDBIM5'8!S<^E-(>.-9#5[J.O4$L#!!0    ( !J#IE*LRRQ#L ,
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MPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE
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M&^IM!'K;9+.$0&]#O8U ;T.]C4!O0[V-0&]#O8U ;T.]C4!O0[V-0&]'O9U
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M              "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
M  @ &H.F4J.W<[@F!0  6A4  !@              ("!#@@  'AL+W=O<FMS
M:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( !J#IE+M@ 9UW08  *H<   8
M              " @6H-  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"
M% ,4    "  :@Z92-LBD"=4#  !.#0  &               @(%]%   >&PO
M=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ &H.F4A3H[]UC!@
MV!H  !@              ("!B!@  'AL+W=O<FMS:&5E=',O<VAE970T+GAM
M;%!+ 0(4 Q0    ( !J#IE*=.$LH@@(  "H'   8              " @2$?
M  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    "  :@Z92V#'K
MIH()  #&/@  &               @('9(0  >&PO=V]R:W-H965T<R]S:&5E
M=#8N>&UL4$L! A0#%     @ &H.F4N<_LM'R!@  9QL  !@
M ("!D2L  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( !J#
MIE(>M<$#K <  (03   8              " @;DR  !X;"]W;W)K<VAE971S
M+W-H965T."YX;6Q02P$"% ,4    "  :@Z92A0R3+@4'  !)$   &
M        @(&;.@  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%
M  @ &H.F4L5R42IX!   $0L  !D              ("!UD$  'AL+W=O<FMS
M:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    "  :@Z92V9K/29H%  "I#@
M&0              @(&%1@  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+
M 0(4 Q0    ( !J#IE+]F/+PG@4  $,/   9              " @59,  !X
M;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ &H.F4L5&VI#>
M&   YD4  !D              ("!*U(  'AL+W=O<FMS:&5E=',O<VAE970Q
M,RYX;6Q02P$"% ,4    "  :@Z926W ^L3,-   Q*0  &0
M@(% :P  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( !J#
MIE(R<JI-+@4  (4,   9              " @:IX  !X;"]W;W)K<VAE971S
M+W-H965T,34N>&UL4$L! A0#%     @ &H.F4OX)6\+1#   @RH  !D
M         ("!#WX  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
M    "  :@Z92RN__7 X$  !Q"0  &0              @($7BP  >&PO=V]R
M:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( !J#IE(Y:2H&40,  )4)
M   9              " @5R/  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL
M4$L! A0#%     @ &H.F4EBN[0^Z"P  9B(  !D              ("!Y)(
M 'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    "  :@Z92.,9U
M<EL&   I%   &0              @('5G@  >&PO=V]R:W-H965T<R]S:&5E
M=#(P+GAM;%!+ 0(4 Q0    ( !J#IE(FQMM$P <  +$3   9
M  " @6>E  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @
M&H.F4D\<WQ(C P  ! <  !D              ("!7JT  'AL+W=O<FMS:&5E
M=',O<VAE970R,BYX;6Q02P$"% ,4    "  :@Z92!GP+T"0#   ["   &0
M            @(&XL   >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4
M Q0    ( !J#IE)6&)H@=00  !$+   9              " @1.T  !X;"]W
M;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ &H.F4A:VJ0<Y!0
M9 P  !D              ("!O[@  'AL+W=O<FMS:&5E=',O<VAE970R-2YX
M;6Q02P$"% ,4    "  :@Z926O^39\H"   ,!@  &0              @($O
MO@  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( !J#IE(@
MY]7J]0(  &,&   9              " @3#!  !X;"]W;W)K<VAE971S+W-H
M965T,C<N>&UL4$L! A0#%     @ &H.F4NO]FU?V @  >@<  !D
M     ("!7,0  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !J#IE(WRC;3.0,  (,+   9              "
M@0S:  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ &H.F
M4AOIM^*Z @  $ @  !D              ("!?-T  'AL+W=O<FMS:&5E=',O
M<VAE970S-"YX;6Q02P$"% ,4    "  :@Z92^P6HL=D#  "%$0  &0
M        @(%MX   >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0
M   ( !J#IE+L)0[*OP0  &05   9              " @7WD  !X;"]W;W)K
M<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ &H.F4C$^BS&I P  ?@T
M !D              ("!<^D  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q0
M2P$"% ,4    "  :@Z92;[74&0T%   &&   &0              @(%3[0
M>&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( !J#IE)/*/IJ
M: (   \&   9              " @9?R  !X;"]W;W)K<VAE971S+W-H965T
M,SDN>&UL4$L! A0#%     @ &H.F4IN]9 KG!@  -R,  !D
M ("!-O4  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    "  :
M@Z920XC 0!$&  #K&P  &0              @(%4_   >&PO=V]R:W-H965T
M<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( !J#IE+16ES%HP0  /(5   9
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M970T-BYX;6Q02P$"% ,4    "  :@Z921^<84]@"  "^!P  &0
M    @('G%P$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    (
M !J#IE+X/S#>+P,  *8)   9              " @?8: 0!X;"]W;W)K<VAE
M971S+W-H965T-#@N>&UL4$L! A0#%     @ &H.F4HAT//)!!   V!   !D
M             ("!7!X! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"
M% ,4    "  :@Z92+^4!:(@$   L%0  &0              @('4(@$ >&PO
M=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( !J#IE+8*I^NE0,
M .4.   9              " @9,G 0!X;"]W;W)K<VAE971S+W-H965T-3$N
M>&UL4$L! A0#%     @ &H.F4@48I&]] P  Y T  !D              ("!
M7RL! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    "  :@Z92
M6T<\NR,#   "#   &0              @($3+P$ >&PO=V]R:W-H965T<R]S
M:&5E=#4S+GAM;%!+ 0(4 Q0    ( !J#IE(=R0OO-P0  *T4   9
M      " @6TR 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%
M  @ &H.F4C(J"^U! P  E@P  !D              ("!VS8! 'AL+W=O<FMS
M:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    "  :@Z922:MJ.%$#  #&"P
M&0              @(%3.@$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+
M 0(4 Q0    ( !J#IE)8K7?B1P,  !@*   9              " @=L] 0!X
M;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ &H.F4JEQ1_P4
M!   QP\  !D              ("!64$! 'AL+W=O<FMS:&5E=',O<VAE970U
M."YX;6Q02P$"% ,4    "  :@Z92K,LL0[ #  !T#   &0
M@(&D10$ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( !J#
MIE( 4E5O. ,   H4   -              "  8M) 0!X;"]S='EL97,N>&UL
M4$L! A0#%     @ &H.F4I>*NQS     $P(   L              ( ![DP!
M %]R96QS+RYR96QS4$L! A0#%     @ &H.F4B4*3'JC!   F2<   \
M         ( !UTT! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( !J#IE)9
M=@'X]0$  #@C   :              "  :=2 0!X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    ( !J#IE(7R,P;VP$  -$B   3
M      "  =14 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !# $, 3!(
' .!6 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>232</ContextCount>
  <ElementCount>331</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>75</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Statements of Earnings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings</Role>
      <ShortName>Condensed Consolidated Statements of Earnings</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Assets held for sale</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/Assetsheldforsale</Role>
      <ShortName>Assets held for sale</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2107103 - Disclosure - Restructuring and Employee Severance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/RestructuringandEmployeeSeverance</Role>
      <ShortName>Restructuring and Employee Severance</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2112104 - Disclosure - Goodwill and Other Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets</Role>
      <ShortName>Goodwill and Other Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2117105 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings</Role>
      <ShortName>Long-Term Obligations and Other Short-Term Borrowings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2121106 - Disclosure - Commitments, Contingent Liabilities and Litigation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation</Role>
      <ShortName>Commitments, Contingent Liabilities and Litigation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2123107 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2125108 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2128109 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2132110 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2136111 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc.</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc</Role>
      <ShortName>Earnings Per Share Attributable to Cardinal Health, Inc.</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2140112 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2147113 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Discontinued Operations and Disposal Groups (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsTables</Role>
      <ShortName>Discontinued Operations and Disposal Groups (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2308302 - Disclosure - Restructuring and Employee Severance (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables</Role>
      <ShortName>Restructuring and Employee Severance (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/RestructuringandEmployeeSeverance</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2313303 - Disclosure - Goodwill and Other Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Other Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2326305 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/FairValueMeasurements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2329306 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/FinancialInstruments</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2333307 - Disclosure - Shareholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareholdersEquityTables</Role>
      <ShortName>Shareholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareholdersEquity</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2337308 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables</Role>
      <ShortName>Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2341309 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/SegmentInformation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2348310 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensation</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Discontinued Operations and Disposal Groups (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails</Role>
      <ShortName>Discontinued Operations and Disposal Groups (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails</Role>
      <ShortName>Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails</Role>
      <ShortName>Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Restructuring and Employee Severance Narative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails</Role>
      <ShortName>Restructuring and Employee Severance Narative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2414406 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2415407 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2416408 - Disclosure - Goodwill and Other Intangible Assets (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails</Role>
      <ShortName>Goodwill and Other Intangible Assets (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails</Role>
      <ShortName>Long-Term Obligations and Other Short-Term Borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2420410 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails</Role>
      <ShortName>Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2422411 - Disclosure - Commitments, Contingent Liabilities and Litigation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails</Role>
      <ShortName>Commitments, Contingent Liabilities and Litigation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2424412 - Disclosure - Income Taxes (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/IncomeTaxes</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2427413 - Disclosure - Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2430414 - Disclosure - Financial Instruments (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails</Role>
      <ShortName>Financial Instruments (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2431415 - Disclosure - Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails</Role>
      <ShortName>Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2434416 - Disclosure - Shareholders' Equity (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails</Role>
      <ShortName>Shareholders' Equity (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareholdersEquityTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2435417 - Disclosure - Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareholdersEquityTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2438418 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails</Role>
      <ShortName>Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2439419 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails</Role>
      <ShortName>Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2442420 - Disclosure - Segment Information (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationNarrativeDetails</Role>
      <ShortName>Segment Information (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/SegmentInformationTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2443421 - Disclosure - Segment Information (Revenue by Reportable Segment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails</Role>
      <ShortName>Segment Information (Revenue by Reportable Segment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/SegmentInformationTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2444422 - Disclosure - Segment Information (Segment Profit by Reportable Segment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails</Role>
      <ShortName>Segment Information (Segment Profit by Reportable Segment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/SegmentInformationTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2445423 - Disclosure - Segment Information Revenue From External Customers By Geographic Areas (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails</Role>
      <ShortName>Segment Information Revenue From External Customers By Geographic Areas (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2446424 - Disclosure - Segment Information (Assets by Reportable Segment) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails</Role>
      <ShortName>Segment Information (Assets by Reportable Segment) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/SegmentInformationTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2449425 - Disclosure - Share-Based Compensation (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails</Role>
      <ShortName>Share-Based Compensation (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2450426 - Disclosure - Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails</Role>
      <ShortName>Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2451427 - Disclosure - Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails</Role>
      <ShortName>Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2452428 - Disclosure - Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails</Role>
      <ShortName>Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2453429 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails</Role>
      <ShortName>Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="cah-20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2454430 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails</Role>
      <ShortName>Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardinal.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="cah-20210331.htm">cah-20210331.htm</File>
    <File>a21q3_10qx033121xexhibit311.htm</File>
    <File>a21q3_10qx033121xexhibit312.htm</File>
    <File>a21q3_10qx033121xexhibit321.htm</File>
    <File>a21q3_10qx033121xexhibit991.htm</File>
    <File>cah-20210331.xsd</File>
    <File>cah-20210331_cal.xml</File>
    <File>cah-20210331_def.xml</File>
    <File>cah-20210331_lab.xml</File>
    <File>cah-20210331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>cah-20210331_g1.jpg</File>
    <File>cah-20210331_g2.jpg</File>
    <File>cah-20210331_g3.jpg</File>
    <File>cah-20210331_g4.jpg</File>
    <File>cah-20210331_g5.jpg</File>
    <File>cah-20210331_g6.jpg</File>
    <File>cah-20210331_g7.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>83
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cah-20210331.htm": {
   "axisCustom": 7,
   "axisStandard": 24,
   "contextCount": 232,
   "dts": {
    "calculationLink": {
     "local": [
      "cah-20210331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cah-20210331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "cah-20210331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cah-20210331_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cah-20210331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "cah-20210331.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 497,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 5
   },
   "keyCustom": 26,
   "keyStandard": 305,
   "memberCustom": 34,
   "memberStandard": 39,
   "nsprefix": "cah",
   "nsuri": "http://www.cardinal.com/20210331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i67ba371541c247eb885ce35370b4c954_D20200701-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.cardinal.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i67ba371541c247eb885ce35370b4c954_D20200701-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i67ba371541c247eb885ce35370b4c954_D20200701-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107103 - Disclosure - Restructuring and Employee Severance",
     "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeverance",
     "shortName": "Restructuring and Employee Severance",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i67ba371541c247eb885ce35370b4c954_D20200701-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i67ba371541c247eb885ce35370b4c954_D20200701-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112104 - Disclosure - Goodwill and Other Intangible Assets",
     "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets",
     "shortName": "Goodwill and Other Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i67ba371541c247eb885ce35370b4c954_D20200701-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i67ba371541c247eb885ce35370b4c954_D20200701-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117105 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings",
     "role": "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings",
     "shortName": "Long-Term Obligations and Other Short-Term Borrowings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i67ba371541c247eb885ce35370b4c954_D20200701-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i67ba371541c247eb885ce35370b4c954_D20200701-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121106 - Disclosure - Commitments, Contingent Liabilities and Litigation",
     "role": "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation",
     "shortName": "Commitments, Contingent Liabilities and Litigation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i67ba371541c247eb885ce35370b4c954_D20200701-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i67ba371541c247eb885ce35370b4c954_D20200701-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123107 - Disclosure - Income Taxes",
     "role": "http://www.cardinal.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i67ba371541c247eb885ce35370b4c954_D20200701-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i67ba371541c247eb885ce35370b4c954_D20200701-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125108 - Disclosure - Fair Value Measurements",
     "role": "http://www.cardinal.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i67ba371541c247eb885ce35370b4c954_D20200701-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128109 - Disclosure - Financial Instruments",
     "role": "http://www.cardinal.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i2cdbb514e27c44e9a0c666769dc64a20_D20190701-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i67ba371541c247eb885ce35370b4c954_D20200701-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132110 - Disclosure - Shareholders' Equity",
     "role": "http://www.cardinal.com/role/ShareholdersEquity",
     "shortName": "Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i67ba371541c247eb885ce35370b4c954_D20200701-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i67ba371541c247eb885ce35370b4c954_D20200701-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136111 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc.",
     "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc",
     "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc.",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i67ba371541c247eb885ce35370b4c954_D20200701-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i67ba371541c247eb885ce35370b4c954_D20200701-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2140112 - Disclosure - Segment Information",
     "role": "http://www.cardinal.com/role/SegmentInformation",
     "shortName": "Segment Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i67ba371541c247eb885ce35370b4c954_D20200701-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Statements of Earnings",
     "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
     "shortName": "Condensed Consolidated Statements of Earnings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GrossProfit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i4a236c9400454873a09fc936aa60bf22_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147113 - Disclosure - Share-Based Compensation",
     "role": "http://www.cardinal.com/role/ShareBasedCompensation",
     "shortName": "Share-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i4a236c9400454873a09fc936aa60bf22_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i67ba371541c247eb885ce35370b4c954_D20200701-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i67ba371541c247eb885ce35370b4c954_D20200701-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i67ba371541c247eb885ce35370b4c954_D20200701-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Discontinued Operations and Disposal Groups (Tables)",
     "role": "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsTables",
     "shortName": "Discontinued Operations and Disposal Groups (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i67ba371541c247eb885ce35370b4c954_D20200701-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i67ba371541c247eb885ce35370b4c954_D20200701-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308302 - Disclosure - Restructuring and Employee Severance (Tables)",
     "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables",
     "shortName": "Restructuring and Employee Severance (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i67ba371541c247eb885ce35370b4c954_D20200701-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i67ba371541c247eb885ce35370b4c954_D20200701-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313303 - Disclosure - Goodwill and Other Intangible Assets (Tables)",
     "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables",
     "shortName": "Goodwill and Other Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i67ba371541c247eb885ce35370b4c954_D20200701-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i67ba371541c247eb885ce35370b4c954_D20200701-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2326305 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.cardinal.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i67ba371541c247eb885ce35370b4c954_D20200701-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i67ba371541c247eb885ce35370b4c954_D20200701-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2329306 - Disclosure - Financial Instruments (Tables)",
     "role": "http://www.cardinal.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i67ba371541c247eb885ce35370b4c954_D20200701-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i67ba371541c247eb885ce35370b4c954_D20200701-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2333307 - Disclosure - Shareholders' Equity (Tables)",
     "role": "http://www.cardinal.com/role/ShareholdersEquityTables",
     "shortName": "Shareholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i67ba371541c247eb885ce35370b4c954_D20200701-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i67ba371541c247eb885ce35370b4c954_D20200701-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2337308 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)",
     "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables",
     "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc. (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i67ba371541c247eb885ce35370b4c954_D20200701-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i67ba371541c247eb885ce35370b4c954_D20200701-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2341309 - Disclosure - Segment Information (Tables)",
     "role": "http://www.cardinal.com/role/SegmentInformationTables",
     "shortName": "Segment Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i67ba371541c247eb885ce35370b4c954_D20200701-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income",
     "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i67ba371541c247eb885ce35370b4c954_D20200701-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2348310 - Disclosure - Share-Based Compensation (Tables)",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationTables",
     "shortName": "Share-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i67ba371541c247eb885ce35370b4c954_D20200701-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "ibe76498d80224b4f96b532177a01467f_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Discontinued Operations and Disposal Groups (Details)",
     "role": "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails",
     "shortName": "Discontinued Operations and Disposal Groups (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i7cdd3ec3331046ec97e3ab5eeb7a43e0_I20210331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409403 - Disclosure - Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)",
     "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails",
     "shortName": "Restructuring and Employee Severance (Activity Related to Restructuring and Employee Severance Costs) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "ib19c0c691fb5445d9011b91ede443228_I20200630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)",
     "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails",
     "shortName": "Restructuring and Employee Severance (Liabilities Associated with Restructuring and Employee Severance Activities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "ib19c0c691fb5445d9011b91ede443228_I20200630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i67ba371541c247eb885ce35370b4c954_D20200701-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Restructuring and Employee Severance Narative (Details)",
     "role": "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails",
     "shortName": "Restructuring and Employee Severance Narative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "ib19c0c691fb5445d9011b91ede443228_I20200630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414406 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)",
     "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
     "shortName": "Goodwill and Other Intangible Assets (Schedule of Goodwill by Reportable Segment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i67ba371541c247eb885ce35370b4c954_D20200701-20210331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "ibe76498d80224b4f96b532177a01467f_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415407 - Disclosure - Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)",
     "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails",
     "shortName": "Goodwill and Other Intangible Assets (Schedule of Intangible Assets) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "ibe76498d80224b4f96b532177a01467f_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "ibe76498d80224b4f96b532177a01467f_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416408 - Disclosure - Goodwill and Other Intangible Assets (Narrative) (Details)",
     "role": "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
     "shortName": "Goodwill and Other Intangible Assets (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "ibe76498d80224b4f96b532177a01467f_I20210331",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "cah:TotalLongTermandShortTermObligations",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419409 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings (Details)",
     "role": "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
     "shortName": "Long-Term Obligations and Other Short-Term Borrowings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "ib19c0c691fb5445d9011b91ede443228_I20200630",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "ibe76498d80224b4f96b532177a01467f_I20210331",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "cah:TotalLongTermandShortTermObligations",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420410 - Disclosure - Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details)",
     "role": "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails",
     "shortName": "Long-Term Obligations and Other Short-Term Borrowings Summary of Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "ibe76498d80224b4f96b532177a01467f_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "ibe76498d80224b4f96b532177a01467f_I20210331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ReceivablesNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "ibe76498d80224b4f96b532177a01467f_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422411 - Disclosure - Commitments, Contingent Liabilities and Litigation (Details)",
     "role": "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
     "shortName": "Commitments, Contingent Liabilities and Litigation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i6be08e009bc84db19fea6af132f4df1c_D20210401-20210630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "cah:ProceedsFromSettlementsOfClassActionLawsuits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424412 - Disclosure - Income Taxes (Narrative) (Details)",
     "role": "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "ib19c0c691fb5445d9011b91ede443228_I20200630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
       "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
       "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
       "span",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427413 - Disclosure - Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details)",
     "role": "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
     "shortName": "Fair Value Measurements (Fair Value of Assets and Liabilities Measured on a Recurring Basis) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i2bde8641630642bf8d5434c1fadce5ef_I20200630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
       "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
       "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
       "span",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430414 - Disclosure - Financial Instruments (Narrative) (Details)",
     "role": "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails",
     "shortName": "Financial Instruments (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i58ec7cecb23b4f45bed4e5c64a8bb562_D20210101-20210331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "ibe76498d80224b4f96b532177a01467f_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "cah:CarryingAmountofLongTermandotherShortTermBorrowings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431415 - Disclosure - Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details)",
     "role": "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails",
     "shortName": "Financial Instruments Summary of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "ibe76498d80224b4f96b532177a01467f_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "cah:CarryingAmountofLongTermandotherShortTermBorrowings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRepurchaseOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434416 - Disclosure - Shareholders' Equity (Narrative) (Details)",
     "role": "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails",
     "shortName": "Shareholders' Equity (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:TreasuryStockAcquiredAverageCostPerShare",
       "span",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i3ca53978778d45b291d32f2884428093_D20210101-20210331",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockAcquiredAverageCostPerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i04980c8bb80847f688361a08698a8057_I20201231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435417 - Disclosure - Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)",
     "role": "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails",
     "shortName": "Shareholders' Equity (Changes in the Accumulated Other Comprehensive Income (Loss)) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i10d07f0a48104550b0a508675603448e_I20200630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438418 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details)",
     "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails",
     "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc. (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439419 - Disclosure - Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)",
     "role": "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails",
     "shortName": "Earnings Per Share Attributable to Cardinal Health, Inc. (Reconciliation of Common Shares Used to Compute Basic and Diluted EPS) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossRelatedToLitigationSettlement",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442420 - Disclosure - Segment Information (Narrative) (Details)",
     "role": "http://www.cardinal.com/role/SegmentInformationNarrativeDetails",
     "shortName": "Segment Information (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "ibbb9380a5af84ba6ae989a20e860a444_D20190701-20200331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:InventoryRecallExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "ibe76498d80224b4f96b532177a01467f_I20210331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443421 - Disclosure - Segment Information (Revenue by Reportable Segment) (Details)",
     "role": "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
     "shortName": "Segment Information (Revenue by Reportable Segment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i13210788c384499eb6bd49c7ac901881_D20210101-20210331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444422 - Disclosure - Segment Information (Segment Profit by Reportable Segment) (Details)",
     "role": "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails",
     "shortName": "Segment Information (Segment Profit by Reportable Segment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "ic430db4eef8d4096927747687050f4ab_D20210101-20210331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OperatingIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445423 - Disclosure - Segment Information Revenue From External Customers By Geographic Areas (Details)",
     "role": "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails",
     "shortName": "Segment Information Revenue From External Customers By Geographic Areas (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i155df096ff374a49874a1b86694a8d78_D20210101-20210331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "ibe76498d80224b4f96b532177a01467f_I20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Assets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446424 - Disclosure - Segment Information (Assets by Reportable Segment) (Details)",
     "role": "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
     "shortName": "Segment Information (Assets by Reportable Segment) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i03c64db735f449b18a2b4bbcb90984f0_I20210331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
       "span",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449425 - Disclosure - Share-Based Compensation (Narrative) (Details)",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
     "shortName": "Share-Based Compensation (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
       "span",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450426 - Disclosure - Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails",
     "shortName": "Share-Based Compensation (Schedule of Total Share-Based Compensation Expense by Type of Award) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i65c8ccf16e4b44c38e667cecd3e50309_D20210101-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "ib19c0c691fb5445d9011b91ede443228_I20200630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451427 - Disclosure - Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details)",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails",
     "shortName": "Share-Based Compensation (Schedule of All Stock Option Transactions Under the Plans) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "ib19c0c691fb5445d9011b91ede443228_I20200630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i5226be778dfe441d9f2c92df26a11158_I20210331",
      "decimals": "5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452428 - Disclosure - Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details)",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
     "shortName": "Share-Based Compensation (Schedule of Additional Data Related to Stock Options) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "cah:AdditionalStockOptionPlanDataTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i5226be778dfe441d9f2c92df26a11158_I20210331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i8a89c112cd7f42b3a5456dc100a7ede7_D20200701-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453429 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
     "shortName": "Share-Based Compensation (Schedule of All Transactions Related to Restricted Share Units Under the Plans) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "ib6304faf17b842ef9c340762418125fc_I20200630",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i9f362429a27e4da98d58d075d240086a_I20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454430 - Disclosure - Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)",
     "role": "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
     "shortName": "Share-Based Compensation (Schedule of All Transactions Related to Performance Share Units Under the Plans) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i9f362429a27e4da98d58d075d240086a_I20200630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i1c2d8220369a4176bd9a77e28f267fbd_I20190630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Shareholders' Equity",
     "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
     "shortName": "Condensed Consolidated Statements of Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i1c2d8220369a4176bd9a77e28f267fbd_I20190630",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i67ba371541c247eb885ce35370b4c954_D20200701-20210331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i67ba371541c247eb885ce35370b4c954_D20200701-20210331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i67ba371541c247eb885ce35370b4c954_D20200701-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "role": "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i67ba371541c247eb885ce35370b4c954_D20200701-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i67ba371541c247eb885ce35370b4c954_D20200701-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Assets held for sale",
     "role": "http://www.cardinal.com/role/Assetsheldforsale",
     "shortName": "Assets held for sale",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cah-20210331.htm",
      "contextRef": "i67ba371541c247eb885ce35370b4c954_D20200701-20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 75,
   "tag": {
    "cah_A2.4Notesdue2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.4% Notes due 2020",
        "label": "2.4% Notes due 2020 [Member]",
        "terseLabel": "2.4% Notes due 2020 [Member]"
       }
      }
     },
     "localname": "A2.4Notesdue2020Member",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_A2.616Notesdue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.616% Notes due 2022",
        "label": "2.616% Notes due 2022 [Member]",
        "terseLabel": "2.616% Notes due 2022 [Member]"
       }
      }
     },
     "localname": "A2.616Notesdue2022Member",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_A3.2Notesdue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.2% Notes due 2022",
        "label": "3.2% Notes due 2022 [Member]",
        "terseLabel": "3.2% Notes due 2022 [Member]"
       }
      }
     },
     "localname": "A3.2Notesdue2022Member",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_A3.41Notesdue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.41% Notes due 2027",
        "label": "3.41% Notes due 2027 [Member]",
        "terseLabel": "3.41% Notes due 2027 [Member]"
       }
      }
     },
     "localname": "A3.41Notesdue2027Member",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_A4.368Notesdue2047Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.368% Notes due 2047",
        "label": "4.368% Notes due 2047 [Member]",
        "terseLabel": "4.368% Notes due 2047 [Member]"
       }
      }
     },
     "localname": "A4.368Notesdue2047Member",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_A4.6Notesdue2043Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.6% Notes due 2043",
        "label": "4.6% Notes due 2043 [Member]",
        "terseLabel": "4.6% Notes due 2043 [Member]"
       }
      }
     },
     "localname": "A4.6Notesdue2043Member",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_A4.9Notesdue2045Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.9% Notes due 2045",
        "label": "4.9% Notes due 2045 [Member]",
        "terseLabel": "4.9% Notes due 2045 [Member]"
       }
      }
     },
     "localname": "A4.9Notesdue2045Member",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_AdditionalStockOptionPlanDataTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A disclosure of additional data related to all stock option activity",
        "label": "Additional Stock Option Plan Data [Table Text Block]",
        "terseLabel": "Schedule of Additional Data Related to Stock Option Activity"
       }
      }
     },
     "localname": "AdditionalStockOptionPlanDataTableTextBlock",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cah_AggregateAnnualAssessment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate Annual Assessment",
        "label": "Aggregate Annual Assessment",
        "terseLabel": "Aggregate Annual Assessment"
       }
      }
     },
     "localname": "AggregateAnnualAssessment",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_AlamedaCountyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alameda County [Member]",
        "label": "Alameda County [Member]",
        "terseLabel": "Alameda County [Member]"
       }
      }
     },
     "localname": "AlamedaCountyMember",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_Amortizationandotheracquisitionrelatedcosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of acquired intangible assets and changes in the fair value of contingent consideration obligations. This also represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Amortization and other acquisition-related costs",
        "terseLabel": "Amortization and other acquisition-related costs"
       }
      }
     },
     "localname": "Amortizationandotheracquisitionrelatedcosts",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_CARESActDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CARES Act",
        "label": "CARES Act [Domain]",
        "terseLabel": "Net Operating Loss Carryback [Domain]"
       }
      }
     },
     "localname": "CARESActDomain",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CVSHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CVS Health [Member]",
        "label": "CVS Health [Member]",
        "terseLabel": "CVS Health"
       }
      }
     },
     "localname": "CVSHealthMember",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CardinalHealthAtHomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cardinal Health At Home [Member]",
        "label": "Cardinal Health At Home [Member]",
        "terseLabel": "Cardinal Health At Home [Member]"
       }
      }
     },
     "localname": "CardinalHealthAtHomeMember",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CareFusionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CareFusion [Member]",
        "label": "CareFusion [Member]",
        "terseLabel": "CareFusion [Member]"
       }
      }
     },
     "localname": "CareFusionMember",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CarryingAmountofLongTermandotherShortTermBorrowings": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying Amount of Long-Term and other Short-Term Borrowings",
        "label": "Carrying Amount of Long-Term and other Short-Term Borrowings",
        "terseLabel": "Carrying Amount of Long-Term and other Short-Term Borrowings"
       }
      }
     },
     "localname": "CarryingAmountofLongTermandotherShortTermBorrowings",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_CashReclassifiedToAssetHeldForSale": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Reclassified to Asset Held for Sale",
        "label": "Cash Reclassified to Asset Held for Sale",
        "terseLabel": "Cash Reclassified to Asset Held for Sale"
       }
      }
     },
     "localname": "CashReclassifiedToAssetHeldForSale",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_ClassActionLawsuitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Action Lawsuits [Member]",
        "label": "Class Action Lawsuits [Member]",
        "terseLabel": "Class Action Lawsuits [Member]"
       }
      }
     },
     "localname": "ClassActionLawsuitsMember",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CommittedReceivablesSalesFacilityProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Committed receivables sales facility program that exists largely to provide liquidity by selling interests in trade receivables.",
        "label": "Committed Receivables Sales Facility Program [Member]",
        "terseLabel": "Committed Receivables Sales Facility Program [Member]"
       }
      }
     },
     "localname": "CommittedReceivablesSalesFacilityProgramMember",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CordisDivestitureAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cordis Divestiture",
        "label": "Cordis Divestiture [Axis]",
        "terseLabel": "Cordis Divestiture [Axis]"
       }
      }
     },
     "localname": "CordisDivestitureAxis",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_CordisDivestitureDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cordis Divestiture [Domain]",
        "label": "Cordis Divestiture [Domain]",
        "terseLabel": "Cordis Divestiture [Domain]"
       }
      }
     },
     "localname": "CordisDivestitureDomain",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_CordisDivestitureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cordis Divestiture",
        "label": "Cordis Divestiture [Member]",
        "terseLabel": "Cordis Divestiture"
       }
      }
     },
     "localname": "CordisDivestitureMember",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_DOJInvestigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DOJ Investigation",
        "label": "DOJ Investigation [Member]",
        "terseLabel": "DOJ Investigation [Member]"
       }
      }
     },
     "localname": "DOJInvestigationMember",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_DerivativesHedgeDiscontinuancesHeadingInstrumentTerminatedAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivatives, Hedge Discontinuances, Heading Instrument Terminated, Amount",
        "label": "Derivatives, Hedge Discontinuances, Heading Instrument Terminated, Amount",
        "terseLabel": "Derivatives, Hedge Discontinuances, Heading Instrument Terminated, Amount"
       }
      }
     },
     "localname": "DerivativesHedgeDiscontinuancesHeadingInstrumentTerminatedAmount",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivatives, Hedge Discontinuances, Hedging Instrument Matured, Amount",
        "label": "Derivatives, Hedge Discontinuances, Hedging Instrument Matured, Amount",
        "terseLabel": "Derivatives, Hedge Discontinuances, Hedging Instrument Matured, Amount"
       }
      }
     },
     "localname": "DerivativesHedgeDiscontinuancesHedgingInstrumentMaturedAmount",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_DisposalGroupIncludingDiscontinuedOperationGoodwillAndOtherIntangiblesNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group Including Discontinued Operation Goodwill and other intangibles, net",
        "label": "Disposal Group Including Discontinued Operation Goodwill and other intangibles, net",
        "terseLabel": "Disposal Group, Including Discontinued Operation, Goodwill and other intangibles, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwillAndOtherIntangiblesNet",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_EstimatedLiabilityForNewYorkOpioidStewardshipAct": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated Liability for New York Opioid Stewardship Act",
        "label": "Estimated Liability for New York Opioid Stewardship Act",
        "terseLabel": "Estimated Liability for New York Opioid Stewardship Act"
       }
      }
     },
     "localname": "EstimatedLiabilityForNewYorkOpioidStewardshipAct",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_ExercisablePeriodOfPlansInYears": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The instrument's contractual term.",
        "label": "Exercisable period of plans, in years",
        "terseLabel": "Exercisable period of plans (in years)"
       }
      }
     },
     "localname": "ExercisablePeriodOfPlansInYears",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cah_FacilityExitAndOtherCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_RestructuringCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility exit and other costs primarily consist of lease termination costs, accelerated depreciation, equipment relocation costs, project consulting fees and costs associated with restructuring our delivery of information technology infrastructure services.",
        "label": "Facility Exit and Other Costs",
        "terseLabel": "Facility Exit and Other Costs"
       }
      }
     },
     "localname": "FacilityExitAndOtherCosts",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_FloatingRateNotesdue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Floating Rate Notes due 2022",
        "label": "Floating Rate Notes due 2022 [Member]",
        "terseLabel": "Floating Rate Notes due 2022 [Member]"
       }
      }
     },
     "localname": "FloatingRateNotesdue2022Member",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_GownRecallAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gown Recall [Axis]",
        "label": "Gown Recall [Axis]",
        "terseLabel": "Gown Recall [Axis]"
       }
      }
     },
     "localname": "GownRecallAxis",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_GownRecallDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Gown Recall [Axis]",
        "label": "Gown Recall [Domain]",
        "terseLabel": "Gown Recall [Domain]"
       }
      }
     },
     "localname": "GownRecallDomain",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_IPRDTrademarksandOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Includes in process investigation of new knowledge useful in developing new product or service or new process or techniques or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for the improvements to existing product or process and rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "IPR&amp;D,TrademarksandOther [Member]",
        "terseLabel": "IPR&amp;D, trademarks and other"
       }
      }
     },
     "localname": "IPRDTrademarksandOtherMember",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_IndemnificationReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indemnification receivable from Patient recovery related to certain pre-acquisition tax exposures and transaction taxes.",
        "label": "Indemnification Receivable",
        "terseLabel": "Indemnification Receivable"
       }
      }
     },
     "localname": "IndemnificationReceivable",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_LawsuitTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lawsuit Type [Axis]",
        "label": "Lawsuit Type [Axis]",
        "terseLabel": "Lawsuit Type [Axis]"
       }
      }
     },
     "localname": "LawsuitTypeAxis",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_LawsuitTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Lawsuit Type [Axis]",
        "label": "Lawsuit Type [Domain]",
        "terseLabel": "Lawsuit Type [Domain]"
       }
      }
     },
     "localname": "LawsuitTypeDomain",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_LongTermObligationsandOtherShortTermBorrowingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Obligations and Other Short-Term Borrowings [Abstract]",
        "label": "Long-Term Obligations and Other Short-Term Borrowings [Abstract]",
        "terseLabel": "Long-Term Obligations and Other Short-Term Borrowings [Abstract]"
       }
      }
     },
     "localname": "LongTermObligationsandOtherShortTermBorrowingsAbstract",
     "nsuri": "http://www.cardinal.com/20210331",
     "xbrltype": "stringItemType"
    },
    "cah_LossContingencyLawsuitsNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Lawsuits, Number",
        "label": "Loss Contingency, Lawsuits, Number",
        "verboseLabel": "Loss Contingency, Lawsuits, Number"
       }
      }
     },
     "localname": "LossContingencyLawsuitsNumber",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cah_MaximumQuarterlyPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Quarterly Payment for pharmaceutical sourcing venture if certain milestones are achieved.",
        "label": "Maximum Quarterly Payment",
        "terseLabel": "Maximum quarterly payment"
       }
      }
     },
     "localname": "MaximumQuarterlyPayment",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_MedicalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical [Member]",
        "label": "Medical Member",
        "terseLabel": "Medical"
       }
      }
     },
     "localname": "MedicalMember",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_MedicaldistributionandproductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical distribution and products [Member]",
        "label": "Medical distribution and products [Member]",
        "terseLabel": "Medical distribution and products [Member]"
       }
      }
     },
     "localname": "MedicaldistributionandproductsMember",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_NarativeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Narative [Abstract]",
        "label": "Narative [Abstract]",
        "terseLabel": "Narative [Abstract]"
       }
      }
     },
     "localname": "NarativeAbstract",
     "nsuri": "http://www.cardinal.com/20210331",
     "xbrltype": "stringItemType"
    },
    "cah_NetOperatingLossCarrybackAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Operating Loss Carryback",
        "label": "Net Operating Loss Carryback [Axis]",
        "terseLabel": "Net Operating Loss Carryback [Axis]"
       }
      }
     },
     "localname": "NetOperatingLossCarrybackAxis",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_NetOperatingLossCarrybackMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Operating Loss Carryback",
        "label": "Net Operating Loss Carryback [Member]",
        "terseLabel": "Net Operating Loss Carryback [Member]"
       }
      }
     },
     "localname": "NetOperatingLossCarrybackMember",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_Netproceedstaxwithholdingsfromsharebasedcompensation": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow/(outflow) associated with the amount received from holders exercising their stock options and paid by the company to satisfy an employee's income tax withholding obligation when shares are withheld from settlement of a share-based award to cover taxes. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.",
        "label": "Net proceeds/(tax withholdings) from share-based compensation",
        "terseLabel": "Net proceeds/(tax withholdings) from share-based compensation"
       }
      }
     },
     "localname": "Netproceedstaxwithholdingsfromsharebasedcompensation",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_NewYorkOpioidStewardshipActMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New York Opioid Stewardship Act",
        "label": "New York Opioid Stewardship Act [Member]",
        "terseLabel": "New York Opioid Stewardship Act [Member]"
       }
      }
     },
     "localname": "NewYorkOpioidStewardshipActMember",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_NotesPayableRepurchased": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Principal Amount of Notes Payable Repurchased during the year",
        "label": "Notes Payable Repurchased",
        "terseLabel": "Notes Payable Repurchased"
       }
      }
     },
     "localname": "NotesPayableRepurchased",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_NuclearPrecisionHealthServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nuclear Precision Health Services [Member]",
        "label": "Nuclear Precision Health Services [Member]",
        "terseLabel": "Nuclear Precision Health Services [Member]"
       }
      }
     },
     "localname": "NuclearPrecisionHealthServicesMember",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_NumberofStateAttorneysGeneralfilinglawsuits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of State Attorneys General filing lawsuits",
        "label": "Number of State Attorneys General filing lawsuits",
        "terseLabel": "Number of State Attorneys General filing lawsuits"
       }
      }
     },
     "localname": "NumberofStateAttorneysGeneralfilinglawsuits",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cah_OpioidLawsuitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opioid Lawsuits [Member]",
        "label": "Opioid Lawsuits [Member]",
        "terseLabel": "Opioid Lawsuits [Member]"
       }
      }
     },
     "localname": "OpioidLawsuitsMember",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_OpioidLawsuitsStateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opioid Lawsuits State and Political Subdivisions [Domain]",
        "label": "Opioid Lawsuits State [Domain]",
        "terseLabel": "Opioid Lawsuits State [Domain]"
       }
      }
     },
     "localname": "OpioidLawsuitsStateDomain",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_OpioidLitigationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opioid Litigation",
        "label": "Opioid Litigation [Axis]",
        "terseLabel": "Opioid Litigation [Axis]"
       }
      }
     },
     "localname": "OpioidLitigationAxis",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_OpioidLitigationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opioid Litigation [Domain]",
        "label": "Opioid Litigation [Domain]",
        "terseLabel": "Opioid Litigation [Domain]"
       }
      }
     },
     "localname": "OpioidLitigationDomain",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_OtherJurisdictionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Jurisdictions [Member]",
        "label": "Other Jurisdictions [Member]",
        "terseLabel": "Other Jurisdictions [Member]"
       }
      }
     },
     "localname": "OtherJurisdictionsMember",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_PatientRecoveryBusinessMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patient Recovery Business [Member]",
        "label": "Patient Recovery Business [Member]",
        "terseLabel": "Patient Recovery Business"
       }
      }
     },
     "localname": "PatientRecoveryBusinessMember",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_PharmaceuticalDistributionandSpecialtyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmaceutical Distribution and Specialty [Member]",
        "label": "Pharmaceutical Distribution and Specialty [Member]",
        "terseLabel": "Pharmaceutical Distribution and Specialty [Member]"
       }
      }
     },
     "localname": "PharmaceuticalDistributionandSpecialtyMember",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_PharmaceuticalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmaceutical [Member]",
        "label": "Pharmaceutical Member",
        "terseLabel": "Pharmaceutical"
       }
      }
     },
     "localname": "PharmaceuticalMember",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_PlaintiffTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plaintiff Type [Axis]",
        "label": "Plaintiff Type [Axis]",
        "terseLabel": "Plaintiff Type [Axis]"
       }
      }
     },
     "localname": "PlaintiffTypeAxis",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_PlaintiffTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Plaintiff Type [Axis]",
        "label": "Plaintiff Type [Domain]",
        "terseLabel": "Plaintiff Type [Domain]"
       }
      }
     },
     "localname": "PlaintiffTypeDomain",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_PrivatePartiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private Parties [Member]",
        "label": "Private Parties [Member]",
        "terseLabel": "Private Parties [Member]"
       }
      }
     },
     "localname": "PrivatePartiesMember",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_ProceedsFromSettlementsOfClassActionLawsuits": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Settlements of Class Action Lawsuits",
        "label": "Proceeds from Settlements of Class Action Lawsuits",
        "terseLabel": "Income from Settlements of Class Action Lawsuits"
       }
      }
     },
     "localname": "ProceedsFromSettlementsOfClassActionLawsuits",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from divestitures and disposal of property and equipment and held for sale assets",
        "label": "Proceeds from divestitures and disposal of property and equipment and held for sale assets",
        "terseLabel": "Proceeds from divestitures and disposal of property and equipment and held for sale assets"
       }
      }
     },
     "localname": "Proceedsfromdivestituresanddisposalofpropertyandequipmentandheldforsaleassets",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales of available-for-sale securities and other investments.",
        "label": "Proceeds from sale of available-for-sale securities and other investments",
        "terseLabel": "Proceeds from investments"
       }
      }
     },
     "localname": "Proceedsfromsaleofavailableforsalesecuritiesandotherinvestments",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_ProductLiabilityLawsuitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Liability Lawsuits [Member]",
        "label": "Product Liability Lawsuits [Member]",
        "terseLabel": "Product Liability Lawsuits"
       }
      }
     },
     "localname": "ProductLiabilityLawsuitsMember",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_ProjectCostsOnInvestmentAndOtherSpending": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment spending at the Corporate level. Investment spending generally includes the first year spend for certain projects that require incremental investments in the form of additional operating expenses.",
        "label": "Project Costs On Investment And Other Spending",
        "terseLabel": "Project costs on investment and other spending"
       }
      }
     },
     "localname": "ProjectCostsOnInvestmentAndOtherSpending",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_Purchaseofavailableforsalesecuritiesandotherinvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from purchases of available-for-sale securities and other investments.",
        "label": "Purchase of available-for-sale securities and other investments",
        "negatedLabel": "Purchase of investments"
       }
      }
     },
     "localname": "Purchaseofavailableforsalesecuritiesandotherinvestments",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Line Items] for Segment Revenue from External Customers by Geographic Area [Table]",
        "label": "Segment Revenue from External Customers by Geographic Area [Line Items]",
        "terseLabel": "Segment Revenue from External Customers by Geographic Area [Line Items]"
       }
      }
     },
     "localname": "SegmentRevenuefromExternalCustomersbyGeographicAreaLineItems",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_SegmentRevenuefromExternalCustomersbyGeographicAreaTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Segment Revenue from External Customers by Geographic Area [Table]",
        "label": "Segment Revenue from External Customers by Geographic Area [Table]",
        "terseLabel": "Segment Revenue from External Customers by Geographic Area [Table]"
       }
      }
     },
     "localname": "SegmentRevenuefromExternalCustomersbyGeographicAreaTable",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_Sharesthatwouldbeantidilutiveasaresultofnetloss": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "shares that would be antidilutive as a result of net loss",
        "label": "shares that would be antidilutive as a result of net loss",
        "terseLabel": "shares that would be antidilutive as a result of net loss"
       }
      }
     },
     "localname": "Sharesthatwouldbeantidilutiveasaresultofnetloss",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cah_ShortTermCreditFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other short-term credit facilities and an unsecured line of credit",
        "label": "Short Term Credit Facilities Member",
        "terseLabel": "Short Term Credit Facilities Member"
       }
      }
     },
     "localname": "ShortTermCreditFacilitiesMember",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_SterileSurgicalGownRecallAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sterile Surgical Gown Recall [Axis] [Axis]",
        "label": "Sterile Surgical Gown Recall [Axis]",
        "terseLabel": "Sterile Surgical Gown Recall [Axis]"
       }
      }
     },
     "localname": "SterileSurgicalGownRecallAxis",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_SterileSurgicalGownRecallDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Sterile Surgical Gown Recall [Axis] [Axis]",
        "label": "Sterile Surgical Gown Recall [Domain]",
        "terseLabel": "Sterile Surgical Gown Recall [Domain]"
       }
      }
     },
     "localname": "SterileSurgicalGownRecallDomain",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_SterileSurgicalGownRecallMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sterile Surgical Gown Recall [Member]",
        "label": "Sterile Surgical Gown Recall [Member]",
        "terseLabel": "Sterile Surgical Gown Recall [Member]"
       }
      }
     },
     "localname": "SterileSurgicalGownRecallMember",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_TaxMatterAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Matter [Axis]",
        "label": "Tax Matter [Axis]",
        "terseLabel": "Tax Matter [Axis]"
       }
      }
     },
     "localname": "TaxMatterAxis",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_TaxMatterDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Tax Matter [Axis]",
        "label": "Tax Matter [Domain]",
        "terseLabel": "Tax Matter [Domain]"
       }
      }
     },
     "localname": "TaxMatterDomain",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_TaxMattersAgreementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Matters Agreement [Axis]",
        "label": "Tax Matters Agreement [Axis]",
        "terseLabel": "Tax Matters Agreement [Axis]"
       }
      }
     },
     "localname": "TaxMattersAgreementAxis",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cah_TaxMattersAgreementDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Tax Matters Agreement [Axis]",
        "label": "Tax Matters Agreement [Domain]",
        "terseLabel": "Tax Matters Agreement [Domain]"
       }
      }
     },
     "localname": "TaxMattersAgreementDomain",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_TotalLongTermandShortTermObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Long-Term and Short-Term Obligations",
        "label": "Total Long-Term and Short-Term Obligations",
        "terseLabel": "Total Long-Term and Short-Term Obligations"
       }
      }
     },
     "localname": "TotalLongTermandShortTermObligations",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cah_TotalOpioidLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Opioid Litigation",
        "label": "Total Opioid Litigation [Member]",
        "terseLabel": "Total Opioid Litigation [Member]"
       }
      }
     },
     "localname": "TotalOpioidLitigationMember",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_TrademarksAndPatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, and the exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Trademarks And Patents Member",
        "terseLabel": "Trademarks, trade names and patents"
       }
      }
     },
     "localname": "TrademarksAndPatentsMember",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cah_VestingPeriodinyearsforShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting Period in years for Shares",
        "label": "Vesting Period in years for Shares",
        "terseLabel": "Vesting Period in years for Shares"
       }
      }
     },
     "localname": "VestingPeriodinyearsforShares",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cah_WriteDownOfAssetsHeldForSale": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Write-down of assets held for sale",
        "label": "Write-down of assets held for sale",
        "negatedTerseLabel": "Write-down of assets held for sale",
        "terseLabel": "Write-down of assets held for sale"
       }
      }
     },
     "localname": "WriteDownOfAssetsHeldForSale",
     "nsuri": "http://www.cardinal.com/20210331",
     "presentation": [
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "UNITED STATES"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r137",
      "r150",
      "r151",
      "r152",
      "r153",
      "r155",
      "r157",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r137",
      "r150",
      "r151",
      "r152",
      "r153",
      "r155",
      "r157",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case Type"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r169",
      "r248",
      "r250",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r261",
      "r264",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r445",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r261",
      "r264",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r445",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r169",
      "r248",
      "r250",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r251",
      "r261",
      "r264",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r445",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r251",
      "r261",
      "r264",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r445",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast [Member]"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r165",
      "r166",
      "r248",
      "r249",
      "r446",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r165",
      "r166",
      "r248",
      "r249",
      "r446",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r219",
      "r262",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r415",
      "r436"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Accounts Payable",
        "terseLabel": "Accounts Payable"
       }
      }
     },
     "localname": "AccountsPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r57",
      "r62",
      "r63",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Foreign Currency Translation Adjustments"
       }
      }
     },
     "localname": "AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r58",
      "r62",
      "r63",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges, including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Net Gain (Loss) from Cash Flow Hedges Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Unrealized Gain/(Loss) on Derivatives, net of tax"
       }
      }
     },
     "localname": "AccumulatedNetGainLossFromCashFlowHedgesIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r35",
      "r60",
      "r61",
      "r62",
      "r430",
      "r453",
      "r454"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r59",
      "r62",
      "r63",
      "r105",
      "r106",
      "r107",
      "r334",
      "r449",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income/(Loss)",
        "verboseLabel": "AOCI Attributable to Parent"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net earnings/(loss) to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r266",
      "r289",
      "r296"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total share-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r94",
      "r182",
      "r189"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potentially dilutive employee stock options, restricted share units and performance share units that were antidilutive (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r59",
      "r62",
      "r63",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r99",
      "r145",
      "r152",
      "r159",
      "r172",
      "r328",
      "r335",
      "r379",
      "r410",
      "r429"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "terseLabel": "Total assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r21",
      "r22",
      "r55",
      "r99",
      "r172",
      "r328",
      "r335",
      "r379"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": {
     "auth_ref": [
      "r0",
      "r1",
      "r11",
      "r13",
      "r17",
      "r198"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Assets",
        "terseLabel": "Total assets held for sale",
        "totalLabel": "Total assets held for sale",
        "verboseLabel": "Total assets held for sale"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails",
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r268",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r350",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "verboseLabel": "Basis of Presentation and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r260",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r260",
      "r263",
      "r320",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r19",
      "r41",
      "r96"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and equivalents at end of period",
        "periodStartLabel": "Cash and equivalents at beginning of period",
        "terseLabel": "Cash and equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r91",
      "r380"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedging [Member]"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": {
     "auth_ref": [
      "r366"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments",
        "terseLabel": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper [Member]"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r215",
      "r216",
      "r217",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments, Contingent Liabilities and Litigation"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Cash dividends declared per common share"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r105",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Common shares, without par value:"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common shares, authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Balance at end of period (in shares)",
        "periodStartLabel": "Balance at beginning of period (in shares)",
        "terseLabel": "Common shares, issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Authorized\u2014755 million shares, Issued\u2014327 million shares at March\u00a031, 2021 and June 30, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r66",
      "r68",
      "r69",
      "r77",
      "r421",
      "r441"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive income attributable to Cardinal Health, Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r66",
      "r68",
      "r76",
      "r326",
      "r339",
      "r420",
      "r440"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Total comprehensive income/(loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r153",
      "r155",
      "r161",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Corporate"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r81",
      "r406"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of products sold",
        "verboseLabel": "Cost of Goods and Services Sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrencySwapMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Swap involving the exchange of principal and interest in one currency for another currency.",
        "label": "Currency Swap [Member]",
        "terseLabel": "Currency Swap [Member]"
       }
      }
     },
     "localname": "CurrencySwapMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Customer relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Long-Term Obligations and Other Short-Term Borrowings"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r28",
      "r29",
      "r30",
      "r411",
      "r412",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r378"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Estimated fair value"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r47",
      "r101",
      "r238",
      "r241",
      "r242",
      "r243",
      "r390",
      "r391",
      "r393",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "auth_ref": [
      "r303"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.",
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "terseLabel": "Estimated range of decrease in unrecognized tax benefits within the next 12 months"
       }
      }
     },
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredGainLossOnDiscontinuationOfInterestRateFairValueHedge": {
     "auth_ref": [
      "r365"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount as of the balance sheet date of the unamortized adjustment to the carrying value of an interest-bearing hedged item made under an effective interest rate fair value hedge that is amortized upon discontinuation of the interest rate fair value hedge.",
        "label": "Deferred Gain (Loss) on Discontinuation of Interest Rate Fair Value Hedge",
        "terseLabel": "Deferred Gain (Loss) on Discontinuation of Interest Rate Fair Value Hedge"
       }
      }
     },
     "localname": "DeferredGainLossOnDiscontinuationOfInterestRateFairValueHedge",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAndOtherLiabilitiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting, and liabilities classified as noncurrent and other.",
        "label": "Deferred Tax and Other Liabilities, Noncurrent",
        "terseLabel": "Deferred income taxes and other liabilities"
       }
      }
     },
     "localname": "DeferredTaxAndOtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r94",
      "r140"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsLiabilitiesAtFairValueNet": {
     "auth_ref": [
      "r340"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair values as of the balance sheet date of the net amount of all assets and liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments.",
        "label": "Derivative Assets (Liabilities), at Fair Value, Net",
        "terseLabel": "Forward contracts"
       }
      }
     },
     "localname": "DerivativeAssetsLiabilitiesAtFairValueNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative, Name [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r351",
      "r352",
      "r356",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r348",
      "r351",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": {
     "auth_ref": [
      "r355",
      "r357"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net",
        "terseLabel": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityNotionalAmount": {
     "auth_ref": [
      "r342",
      "r343",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payments on the derivative liability.",
        "label": "Derivative Liability, Notional Amount",
        "terseLabel": "Derivative Liability, Notional Amount"
       }
      }
     },
     "localname": "DerivativeLiabilityNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r341",
      "r344",
      "r345",
      "r348",
      "r349",
      "r354",
      "r356",
      "r363",
      "r364",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "verboseLabel": "Developed technology and other"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of Revenue [Table Text Block]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "verboseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation": {
     "auth_ref": [
      "r2",
      "r3",
      "r14",
      "r316"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) on gain (loss) not previously recognized resulting from the disposal of a discontinued operation.",
        "label": "Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation",
        "terseLabel": "Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation"
       }
      }
     },
     "localname": "DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities": {
     "auth_ref": [
      "r0",
      "r1",
      "r11",
      "r198"
     ],
     "calculation": {
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Accrued Liabilities",
        "terseLabel": "Disposal Group, Including Discontinued Operation, Accrued Liabilities"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents": {
     "auth_ref": [
      "r0",
      "r1",
      "r11",
      "r198"
     ],
     "calculation": {
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents",
        "terseLabel": "Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Consideration",
        "terseLabel": "Disposal Group, Including Discontinued Operation, Consideration"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses": {
     "auth_ref": [
      "r385"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) in the disposal group, including discontinued operation, recognized in the statement of income as a result of the sale or complete or substantially complete liquidation of an investment in a foreign entity.",
        "label": "Disposal Group, Including Discontinued Operation, Foreign Currency Translation Gains (Losses)",
        "terseLabel": "Disposal Group, Including Discontinued Operation, Foreign Currency Translation Gains (Losses)"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1": {
     "auth_ref": [
      "r0",
      "r1",
      "r11",
      "r198"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Goodwill",
        "terseLabel": "Disposal Group, Including Discontinued Operation, Goodwill"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwill1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets": {
     "auth_ref": [
      "r0",
      "r1",
      "r11",
      "r198"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Intangible Assets",
        "terseLabel": "Disposal Group, Including Discontinued Operation, Intangible Assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1": {
     "auth_ref": [
      "r0",
      "r1",
      "r11",
      "r198"
     ],
     "calculation": {
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as inventory attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Inventory",
        "terseLabel": "Disposal Group, Including Discontinued Operation, Inventory"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationInventory1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets": {
     "auth_ref": [
      "r0",
      "r1",
      "r11",
      "r198"
     ],
     "calculation": {
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Other Assets",
        "terseLabel": "Disposal Group, Including Discontinued Operation, Other Assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r0",
      "r1",
      "r11",
      "r198"
     ],
     "calculation": {
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment",
        "terseLabel": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r18",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations, Disclosure"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/Assetsheldforsale"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r260",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Dividends": {
     "auth_ref": [
      "r244",
      "r425"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.",
        "label": "Dividends",
        "negatedTerseLabel": "Dividends"
       }
      }
     },
     "localname": "Dividends",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Earnings/(loss) per common share attributable to Cardinal Health, Inc.:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r124",
      "r126",
      "r127",
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings Per Share [Text Block]"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthInc"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": {
     "auth_ref": [
      "r380"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.",
        "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
        "terseLabel": "Effect of exchange rates changes on cash and equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r290"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r289"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, Tax Benefit",
        "terseLabel": "Tax benefit related to share-based compensation"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]",
        "terseLabel": "Employee- Related Costs"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options",
        "verboseLabel": "Employee Stock Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r105",
      "r106",
      "r107",
      "r109",
      "r114",
      "r116",
      "r129",
      "r173",
      "r237",
      "r244",
      "r292",
      "r293",
      "r294",
      "r310",
      "r311",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r387",
      "r449",
      "r450",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FacilityClosingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Closing of a facility associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Facility Closing [Member]",
        "terseLabel": "Facility Exit and Other Costs"
       }
      }
     },
     "localname": "FacilityClosingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r369",
      "r370",
      "r371",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring",
        "verboseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r370",
      "r396",
      "r397",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r369",
      "r370",
      "r372",
      "r373",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Disclosures"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueHedgingMember": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.",
        "label": "Fair Value Hedging [Member]",
        "terseLabel": "Fair Value Hedging"
       }
      }
     },
     "localname": "FairValueHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r252",
      "r253",
      "r258",
      "r259",
      "r370",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level\u00a01"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r252",
      "r253",
      "r258",
      "r259",
      "r370",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2",
        "verboseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r370",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r396",
      "r397",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsSummaryofEstimatedFairValueofLongtermObligationsandOtherShorttermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsNonrecurringMember": {
     "auth_ref": [
      "r369",
      "r370",
      "r372",
      "r373",
      "r374",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value.",
        "label": "Fair Value, Nonrecurring [Member]",
        "terseLabel": "Fair Value, Nonrecurring"
       }
      }
     },
     "localname": "FairValueMeasurementsNonrecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r375",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.",
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r188"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r190"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "Estimated annual amortization of intangible assets - Year One"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "Estimated annual amortization of intangible assets - Remainder of Fiscal Year"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r190"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "Estimated annual amortization of intangible assets - Year Four"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r190"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "Estimated annual amortization of intangible assets - Year Three"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r190"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "Estimated annual amortization of intangible assets - Year Two"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r183",
      "r185",
      "r188",
      "r192",
      "r407",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r188",
      "r408"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross Intangible"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r183",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "verboseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r188",
      "r407"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Net Intangible"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "terseLabel": "Weighted- Average Remaining Amortization Period (Years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r252",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign Exchange Contract [Member]"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.",
        "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges",
        "negatedTerseLabel": "Impairments and (gain)/loss on disposal of assets, net"
       }
      }
     },
     "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "auth_ref": [
      "r218"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.",
        "label": "Gain (Loss) Related to Litigation Settlement",
        "negatedLabel": "Gain (Loss) Related to Litigation Settlement",
        "negatedTerseLabel": "Litigation (recoveries)/charges, net"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlement",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r94",
      "r231",
      "r232"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Loss on Extinguishment of Debt",
        "verboseLabel": "Gain (Loss) on Extinguishment of Debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r175",
      "r176",
      "r409"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r177"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Goodwill, Transfers"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Other Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r178"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "negatedTerseLabel": "Foreign currency translation adjustments and other"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r80",
      "r99",
      "r145",
      "r151",
      "r155",
      "r158",
      "r161",
      "r172",
      "r379"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross margin"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r348",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r102",
      "r145",
      "r151",
      "r155",
      "r158",
      "r161"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Earnings/(loss) before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r71",
      "r78",
      "r108",
      "r110",
      "r111",
      "r112",
      "r113",
      "r119",
      "r121",
      "r122",
      "r416",
      "r417",
      "r422",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r71",
      "r78",
      "r108",
      "r110",
      "r111",
      "r112",
      "r113",
      "r119",
      "r121",
      "r122",
      "r123",
      "r422",
      "r437",
      "r439",
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Income (Loss) from Continuing Operations, Per Diluted Share"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r260",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r1",
      "r5",
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r12",
      "r15",
      "r16",
      "r17",
      "r200",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Schedule of Assets and Liabilities Held for Sale [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r301",
      "r307",
      "r308",
      "r312",
      "r314",
      "r317",
      "r318",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r100",
      "r115",
      "r116",
      "r143",
      "r299",
      "r313",
      "r315",
      "r443"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Provision for/(benefit from) income taxes",
        "negatedTerseLabel": "Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReceivable": {
     "auth_ref": [
      "r40",
      "r427"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of income taxes previously overpaid to tax authorities (such as U.S. Federal, state and local tax authorities) representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes. Also called income tax refund receivable.",
        "label": "Income Taxes Receivable",
        "terseLabel": "Income Taxes Receivable"
       }
      }
     },
     "localname": "IncomeTaxReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Increase in accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Increase in inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Change in operating assets and liabilities, net of effects from acquisitions and divestitures:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "negatedTerseLabel": "Other accrued liabilities and operating items, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Receivables",
        "negatedTerseLabel": "Increase in trade receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInReceivables",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r184",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Indefinite-lived Intangible Assets [Line Items]",
        "terseLabel": "Indefinite-lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r191"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Net Intangible"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r184",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "terseLabel": "Gross Intangible, Total other intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r181",
      "r186"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Net Intangible, Total other intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.",
        "label": "Intangible Assets, Net (Including Goodwill)",
        "terseLabel": "Goodwill and other intangibles, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetIncludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r72",
      "r139",
      "r389",
      "r392",
      "r423"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense, net"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest Income (Expense), Nonoperating, Net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest Rate Swap"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
        "label": "Internal Revenue Service (IRS) [Member]",
        "terseLabel": "Internal Revenue Service (IRS) [Member]"
       }
      }
     },
     "localname": "InternalRevenueServiceIRSMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r20",
      "r53"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories, net",
        "verboseLabel": "Inventory, Net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRecallExpense": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the amount charged against earnings comprised of the costs to announce and effect a recall of defective merchandise.",
        "label": "Inventory Recall Expense",
        "terseLabel": "Inventory Recall Expense"
       }
      }
     },
     "localname": "InventoryRecallExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r369"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Other investments"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r38",
      "r99",
      "r172",
      "r379",
      "r414",
      "r433"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Shareholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r46",
      "r99",
      "r172",
      "r329",
      "r335",
      "r336",
      "r379"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": {
     "auth_ref": [
      "r0",
      "r1",
      "r11",
      "r13",
      "r17",
      "r198"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities",
        "terseLabel": "Disposal Group, Including Discontinued Operation, Liabilities",
        "totalLabel": "Total liabilities held for sale"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails",
      "http://www.cardinal.com/role/FairValueMeasurementsFairValueofAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r11",
      "r13",
      "r17",
      "r195",
      "r198"
     ],
     "calculation": {
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent",
        "terseLabel": "Disposal Group, Including Discontinued Operation, Deferred Tax Liabilities"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r44"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationReserve": {
     "auth_ref": [
      "r48",
      "r218"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.",
        "label": "Estimated Litigation Liability",
        "terseLabel": "Estimated Litigation Liability"
       }
      }
     },
     "localname": "LitigationReserve",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Litigation Settlement, Expense"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.",
        "label": "Long-term Debt and Lease Obligation",
        "terseLabel": "Long-term obligations, less current portion",
        "verboseLabel": "Long-term Debt and Lease Obligation"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as current.",
        "label": "Long-term Debt and Lease Obligation, Current",
        "terseLabel": "Current portion of long-term obligations and other short-term borrowings",
        "verboseLabel": "Long-term Debt and Lease Obligation, Current"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r47",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsSummaryofDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongtermPurchaseCommitmentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Long-term Purchase Commitment, Period",
        "terseLabel": "Long-term Purchase Commitment, Period"
       }
      }
     },
     "localname": "LongtermPurchaseCommitmentPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r218",
      "r219",
      "r220",
      "r222",
      "r223",
      "r224",
      "r225",
      "r227",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r218",
      "r219",
      "r220",
      "r222",
      "r223",
      "r224",
      "r225",
      "r227",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r218"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Loss Contingency Accrual"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r218",
      "r219",
      "r220",
      "r222",
      "r223",
      "r224",
      "r225",
      "r227",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.",
        "label": "Loss Contingency, New Claims Filed, Number",
        "terseLabel": "Loss Contingency, New Claims Filed, Number"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyNumberOfPlaintiffs": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Number of Plaintiffs",
        "terseLabel": "Loss Contingency, Number of Plaintiffs"
       }
      }
     },
     "localname": "LossContingencyNumberOfPlaintiffs",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r52",
      "r99",
      "r172",
      "r379",
      "r413",
      "r432"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r91",
      "r92",
      "r95"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r17",
      "r64",
      "r67",
      "r74",
      "r95",
      "r99",
      "r108",
      "r110",
      "r111",
      "r112",
      "r113",
      "r115",
      "r116",
      "r120",
      "r145",
      "r151",
      "r155",
      "r158",
      "r161",
      "r172",
      "r379",
      "r418",
      "r438"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net earnings/(loss) attributable to Cardinal Health, Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r64",
      "r67",
      "r115",
      "r116",
      "r331",
      "r338"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Less: Net earnings attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Financial Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Non-US [Member]"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r105",
      "r106",
      "r107",
      "r244",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument [Member]"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OpenTaxYear": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax year that remains open to examination under enacted tax laws, in CCYY format.",
        "label": "Open Tax Year",
        "terseLabel": "Open Tax Year"
       }
      }
     },
     "localname": "OpenTaxYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "gYearListItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r145",
      "r151",
      "r155",
      "r158",
      "r161"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Total operating earnings",
        "totalLabel": "Operating earnings/(loss)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r153",
      "r155",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r23",
      "r24",
      "r25",
      "r45"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities",
        "verboseLabel": "Other Accrued Liabilities, Current"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in other comprehensive income.",
        "label": "Other Comprehensive Income Location [Axis]",
        "terseLabel": "Other Comprehensive Income Location [Axis]"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in other comprehensive income.",
        "label": "Other Comprehensive Income Location [Domain]",
        "terseLabel": "Other Comprehensive Income Location [Domain]"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r62",
      "r70",
      "r381",
      "r383",
      "r387"
     ],
     "calculation": {
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "verboseLabel": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).",
        "label": "Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax",
        "terseLabel": "Net unrealized gain/(loss) on derivative instruments, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustments and other"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r358"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r65",
      "r68",
      "r70",
      "r75",
      "r237",
      "r381",
      "r386",
      "r387",
      "r419",
      "r439"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Total other comprehensive income/(loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income/(loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r65",
      "r68",
      "r326",
      "r327",
      "r333"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r58",
      "r60",
      "r368"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).",
        "label": "Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other (income)/expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).",
        "label": "Other Nonoperating Income (Expense) [Member]",
        "terseLabel": "Other Nonoperating Income (Expense) [Member]"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForProceedsFromHedgeFinancingActivities": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash outflow or inflow for a financial contract that meets the hedge criteria as either cash flow hedge, fair value hedge or hedge of net investment in foreign operations.",
        "label": "Payments for (Proceeds from) Hedge, Financing Activities",
        "negatedTerseLabel": "Payments for (Proceeds from) Hedge, Financing Activities"
       }
      }
     },
     "localname": "PaymentsForProceedsFromHedgeFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Payments for Repurchase of Common Stock",
        "terseLabel": "Payments for Repurchase of Common Stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r89",
      "r204"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "negatedLabel": "Payments and other adjustments"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividendsCommonStock": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.",
        "label": "Payments of Ordinary Dividends, Common Stock",
        "negatedLabel": "Dividends on common shares"
       }
      }
     },
     "localname": "PaymentsOfDividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Acquisition of subsidiaries, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Additions to property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Share Units",
        "verboseLabel": "Performance Share Unit"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Preferred shares, without par value:"
       }
      }
     },
     "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred shares, authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred shares, issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Authorized\u2014500 thousand shares, Issued\u2014none"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfShortTermDebt": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from (Repayments of) Short-term Debt",
        "terseLabel": "Net change in short-term borrowings"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r17",
      "r64",
      "r67",
      "r90",
      "r99",
      "r108",
      "r115",
      "r116",
      "r145",
      "r151",
      "r155",
      "r158",
      "r161",
      "r172",
      "r326",
      "r330",
      "r332",
      "r338",
      "r339",
      "r379",
      "r424"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net earnings/(loss)",
        "totalLabel": "Net earnings/(loss)",
        "verboseLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r26",
      "r27",
      "r196",
      "r435"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r79",
      "r174"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Provision for bad debts"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r33",
      "r39",
      "r434",
      "r455"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]",
        "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Loss [Rollforward]"
       }
      }
     },
     "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r62",
      "r63",
      "r70",
      "r381",
      "r385",
      "r387"
     ],
     "calculation": {
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "negatedTerseLabel": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Loss [Table]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock": {
     "auth_ref": [
      "r152",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets.",
        "label": "Reconciliation of Assets from Segment to Consolidated [Table Text Block]",
        "terseLabel": "Assets by Reportable Segment"
       }
      }
     },
     "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": {
     "auth_ref": [
      "r151",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]",
        "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r151",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Segment Profit by Reportable Segment"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable": {
     "auth_ref": [
      "r150",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.",
        "label": "Reconciliation of Revenue from Segments to Consolidated [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedTerseLabel": "Reduction of long-term obligations"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Share Units",
        "verboseLabel": "Restricted Share Unit"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring and Employee Severance"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeverance"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r94",
      "r203",
      "r208",
      "r212"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      },
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring and employee severance",
        "totalLabel": "Total restructuring and employee severance"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringChargesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Charges [Abstract]",
        "terseLabel": "Restructuring Charges [Abstract]"
       }
      }
     },
     "localname": "RestructuringChargesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCosts": {
     "auth_ref": [
      "r94"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Costs",
        "terseLabel": "Additions",
        "verboseLabel": "Restructuring Costs"
       }
      }
     },
     "localname": "RestructuringCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringPlanAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by individual restructuring plan.",
        "label": "Restructuring Plan [Axis]",
        "terseLabel": "Restructuring Plan [Axis]"
       }
      }
     },
     "localname": "RestructuringPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the individual restructuring plans.",
        "label": "Restructuring Plan [Domain]",
        "terseLabel": "Restructuring Plan [Domain]"
       }
      }
     },
     "localname": "RestructuringPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r204",
      "r209"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Restructuring Reserve [Roll Forward]",
        "terseLabel": "Restructuring Reserve [Roll Forward]"
       }
      }
     },
     "localname": "RestructuringReserveRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r34",
      "r244",
      "r295",
      "r431",
      "r452",
      "r454"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r105",
      "r106",
      "r107",
      "r109",
      "r114",
      "r116",
      "r173",
      "r292",
      "r293",
      "r294",
      "r310",
      "r311",
      "r449",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "terseLabel": "Revenue from External Customers by Geographic Areas [Table Text Block]"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r73",
      "r99",
      "r136",
      "r137",
      "r150",
      "r156",
      "r157",
      "r164",
      "r165",
      "r169",
      "r172",
      "r379",
      "r424"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenue",
        "verboseLabel": "Total revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/SegmentInformationRevenueFromExternalCustomersByGeographicAreasDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility [Member]"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/LongTermObligationsandOtherShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r62",
      "r386",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Changes in the Balance of Accumulated Other Comprehensive Loss by Component and in Total"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.",
        "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Estimated Fair Value of Long-term Obligations and Other Short-term Borrowings Compared to the Respective Carrying Amount"
       }
      }
     },
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Schedule of Total Share-based Compensation Expense by Type of Award"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "auth_ref": [
      "r1",
      "r5",
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r12",
      "r15",
      "r16",
      "r17",
      "r200",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations"
       }
      }
     },
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/DiscontinuedOperationsandDisposalGroupsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r369",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r183",
      "r187",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails",
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r183",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r179",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r179",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Goodwill by Reportable Segment"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r191",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units.",
        "label": "Schedule of Nonvested Performance-based Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Transactions Related to Performance Share Units Under the Plans"
       }
      }
     },
     "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r206",
      "r207",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r206",
      "r207",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Summary of Restructuring and Employee Severance"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "auth_ref": [
      "r204",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Schedule of Activity Related to Liabilities Associated with Restructuring and Employee Severance"
       }
      }
     },
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r145",
      "r148",
      "r154",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r268",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of Transactions Related to Restricted Share Units Under the Plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r271",
      "r283",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Transactions Under the Plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r49",
      "r97",
      "r130",
      "r131",
      "r234",
      "r235",
      "r236",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "terseLabel": "Reconciliation of Common Shares Used to Compute Basic and Diluted Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r132",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r150",
      "r151",
      "r152",
      "r153",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r161",
      "r169",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r132",
      "r134",
      "r135",
      "r145",
      "r149",
      "r155",
      "r159",
      "r160",
      "r161",
      "r162",
      "r164",
      "r168",
      "r169",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]",
        "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Distribution, selling, general and administrative expenses",
        "verboseLabel": "Selling, General and Administrative Expense"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r94",
      "r203",
      "r208",
      "r212"
     ],
     "calculation": {
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_RestructuringCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs",
        "verboseLabel": "Employee-related costs"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceActivityRelatedtoRestructuringandEmployeeSeveranceCostsDetails",
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceNarativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Canceled and forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Canceled and forfeited (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Nonvested at end of period (in shares)",
        "periodStartLabel": "Nonvested at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Restricted Share Units",
        "verboseLabel": "Performance Share Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Nonvested at end of period (in usd per share)",
        "periodStartLabel": "Nonvested at beginning of period (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value per Share",
        "verboseLabel": "Weighted-Average Grant Date Fair Value per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable at end of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable at end of period (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedTerseLabel": "Canceled and forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Canceled and forfeited (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r291"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of outstanding options at period end"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r273",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at end of period (in shares)",
        "periodStartLabel": "Outstanding at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at end of period (in usd per share)",
        "periodStartLabel": "Outstanding at beginning of period (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price per Common Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r265",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoRestrictedShareUnitsUnderthePlansDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofTotalShareBasedCompensationExpensebyTypeofAwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Target performance goal (as a percent)",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllTransactionsRelatedtoPerformanceShareUnitsUnderthePlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r291"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of exercisable options at period end"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAdditionalDataRelatedtoStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r4",
      "r132",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r150",
      "r151",
      "r152",
      "r153",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r161",
      "r169",
      "r179",
      "r199",
      "r205",
      "r213",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]",
        "verboseLabel": "Operating and Reportable Segment"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/GoodwillandOtherIntangibleAssetsScheduleofGoodwillbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationAssetsbyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationNarrativeDetails",
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails",
      "http://www.cardinal.com/role/SegmentInformationSegmentProfitbyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r51",
      "r105",
      "r106",
      "r107",
      "r109",
      "r114",
      "r116",
      "r129",
      "r173",
      "r237",
      "r244",
      "r292",
      "r293",
      "r294",
      "r310",
      "r311",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r387",
      "r449",
      "r450",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "verboseLabel": "Statement of Stockholders' Equity"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r105",
      "r106",
      "r107",
      "r129",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r31",
      "r32",
      "r237",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r31",
      "r32",
      "r237",
      "r244",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareBasedCompensationScheduleofAllStockOptionTransactionsUnderthePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r31",
      "r32",
      "r244",
      "r267",
      "r284"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r32",
      "r36",
      "r37",
      "r99",
      "r171",
      "r172",
      "r379"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Cardinal Health, Inc. shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r99",
      "r105",
      "r106",
      "r107",
      "r109",
      "r114",
      "r172",
      "r173",
      "r244",
      "r292",
      "r293",
      "r294",
      "r310",
      "r311",
      "r324",
      "r325",
      "r337",
      "r379",
      "r381",
      "r382",
      "r387",
      "r450",
      "r451"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityChangesintheAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r98",
      "r244",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Shareholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityOtherShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of increase (decrease) in shares of stock classified as other.",
        "label": "Stockholders' Equity, Other Shares",
        "terseLabel": "Stockholders' Equity, Other Shares"
       }
      }
     },
     "localname": "StockholdersEquityOtherShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SubsegmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business subsegments.",
        "label": "Subsegments [Axis]",
        "terseLabel": "Subsegments [Axis]"
       }
      }
     },
     "localname": "SubsegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsegmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Subsegments [Domain]",
        "terseLabel": "Subsegments [Domain]"
       }
      }
     },
     "localname": "SubsegmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/SegmentInformationRevenuebyReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r388",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r388",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r388",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CommitmentsContingentLiabilitiesandLitigationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Tax Credit Carryforward [Line Items]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "TaxCreditCarryforwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.",
        "label": "Tax Credit Carryforward [Table]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "TaxCreditCarryforwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.",
        "label": "Treasury Stock Acquired, Average Cost Per Share",
        "terseLabel": "Treasury shares acquired, average price per share (in usd per share)"
       }
      }
     },
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r50",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock",
        "verboseLabel": "Treasury Shares"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r50",
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "negatedPeriodEndLabel": "Treasury, balance at end of period (in shares)",
        "negatedPeriodStartLabel": "Treasury, balance at beginning of period (in shares)",
        "terseLabel": "Common shares in treasury"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r32",
      "r237",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "negatedLabel": "Treasury shares acquired (in shares)",
        "negatedTerseLabel": "Treasury Stock, Shares, Acquired"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity",
      "http://www.cardinal.com/role/ShareholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r50",
      "r245",
      "r246"
     ],
     "calculation": {
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Common shares in treasury, at cost: 36 million shares and 34 million shares at March\u00a031, 2021 and June 30, 2020, respectively",
        "negatedPeriodEndLabel": "Treasury, balance at end of period",
        "negatedPeriodStartLabel": "Treasury, balance at beginning of period"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r237",
      "r244",
      "r245"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Treasury Stock, Value, Acquired, Cost Method"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/RestructuringandEmployeeSeveranceLiabilitiesAssociatedwithRestructuringandEmployeeSeveranceActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r298",
      "r305"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r302"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Unrecognized tax benefits, interest and penalties accrued"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r306"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r123"
     ],
     "calculation": {
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Employee stock options, restricted share units, and performance share units (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]",
        "terseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r118",
      "r123"
     ],
     "calculation": {
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted-average common shares\u2013diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r117",
      "r123"
     ],
     "calculation": {
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted-average common shares\u2013basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings",
      "http://www.cardinal.com/role/EarningsPerShareAttributabletoCardinalHealthIncReconciliationofCommonSharesUsedtoComputeBasicandDilutedEPSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Weighted-average number of common shares outstanding:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.cardinal.com/role/CondensedConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8475-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=2122178"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2510-110228"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "http://asc.fasb.org/topic&trid=2175745"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5333-128473"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5504-128473"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=117331979&loc=d3e41228-113958"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(i)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998890-113959"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998896-113959"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624181-113959"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41641-113959"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41678-113959"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121561968&loc=d3e75592-113984"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121558989&loc=d3e80720-113993"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r466": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r467": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r468": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r469": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r471": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868656-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>84
<FILENAME>0000721371-21-000041-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000721371-21-000041-xbrl.zip
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M@MD6V08TS&MM1=N?2@+FBL2F$,4<W&%*I3>TJ@M>M]&$+:]5@;;=&>OE[8[
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M8RW )0OE)*VPBZRL])K,A$H!GX-;FQ'K#XGUT?U7B"4*)"?PC&RZUF&6!WV
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MW+.]\B:V_]-/.VMYNYMWX&LY,"-&M\'O[;QST,MG;#R@)B;3(4X2F(J>.$;
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MX=[@V/[3J[\._AU,JW>RBB%5X81V!F$>N6-2:,VB-=ISKPPH25KC9+>$LG?
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M_? CSL?/3;Y#43B0A&O:G8!VMZ]H5UM&A0S-(#50K&6DJ;T&.(<@&;;$*4>
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M4F(ZW7<=VFFY6;MK7)6W/8+*O='+)'FF?H9W,E51I= E8%SFTPWW&E*Z^&5
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MQIT"[2"L)0RP""T!])E9O]K!=,%'>[_;LK!'>,O*W,1E);^T)EF_S3N[(-;
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MNY8$)W5%I,ZIS/1QK9&SQ$_32A/E"\:".O!QX%N!*581GV83\>![#)HTC8,
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MVHUC?/S]G<ECX^,;']_X^,;'W^+CXZC.[+_.2N267I\=/3#0E#  &2^]':,
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MP/=6@>,'EP_"#JQ(+#%I(7A(FE3BX Q/C,B/ZQ,-:274_A '\RU[.A4N=KV
M?ZYB>,T.D8"3A^QTI[[GB2DM[]X!(N T_#BBWD)J.?_T'!SE)H+!J)W&N\__
M_>G]9?>Z;6G;XB&8<OE=27MO]JV5"! F$J?]JML9M8=JAUI($F!)8"9K!B_!
M ^%^MPR^8(-JL5WX@C^?AR)2'[J#AY="M?',T#;;2U11HV7=+QS8GG1E:JU
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MMDQ6T-?MNI;ZHBSC/:<W<Q)<403@7SEV8S;F&.(Z:DI?5,,51]R;'7M+'<.
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M1*HK%Q]#([Y'EB;J)P=6E_I_N:Y+TA5=^3O):;VVF7K413<866?S5VQ+I:>
MCN(,&FU(WGA83KQ<L>]/;4F35IPVA?I9):E9X!.QET0PT'J4:2WPJ3]B!TBO
M6YV_Q[/;I?*/>5LCW%6Y_\@-VA(U/9C_C9"8A0T/U)("]0$L35DRH<:V#30
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M;FI+4:(F U0,.:%/,@J<VUL1<$^#K(>81M,:R/K?R-C G*<E>$EQD.Q^*0$
MY1*S][65^]'55>8)AKDF:B=4BP@OIL KVCG<TDFSW5N@H")22ZZS=)BI6#[A
MN)C&;N(SIF>I.C9;B>_I$"P"+-Q#H:4_8F<!=!*BA +)2K=;!6LT(+:60"44
MI42)BI?+C"^KV7VMA-D$?C"=OO<@^9R8CPD4FM3U_:6N=Z\'TJGH-=VI4#Y%
M<1H[&OZ4SGBKV#EKJ5;!N<B_8*Q/]/FO4MXK:%\3<381YZ?*\9>DS"GQT\!
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M91? ?V IQ_D9+NGL@EC5(Y".I+E5H%;7HD(9 I2!WY;V5,2<%@#'8(S? <G
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M:20(VY;DQ[JCKYF-,8"058G:-T0]1:(:%9*[,9UVIWH[Z[KLC>D$8SK!U%S
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MT0^65K=S^8_*[+^IBI1%47)!WYRE"*W?Q+WUU5_:WLYKZF6H6>T E^;,%E-
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M,>V*] =SQX'IA\:@5;;K42CLX>F&@WZ^Y7#D#^P+_^I8#PJOV2J?Z_G "^K
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M&%^>G20;G9G [9G[VY/&_?IU[;?^X$LU>T&/K'(_V)/^L,S)??50WHR4(AM
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MJVJECZEXSL9%X864XJPJU?#X9^PMKK2[Z*8_FI/-M ?.GRRRG6;9-J1\_0'
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MRW+H7O?[IGC>,^_MX&NN;?'>KTW$IV7PZ:)A#"0RDXRD7F-%5GFR1R605EG
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MIKE*%72<B"KN]BZFU(?"OG5FS&MT%B\?I1\?$!_0T@<\G<R \]6!JW55SNW
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M!^]=Y1(#!&*OG=-8<Y6DUDP"&&IIM-58W$(*RR5!O2'R8*;Y7_(B"FR0LL$
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MQ)@<9@0USIN#DY/8"OG^OQ''GP1+,]Y\3_F$'%IS\Z8,Y=2(K$U% F4KM;3
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MT4=P)5TO[S>6SQ?=_F _#DZZ15*7E-2I\T@E0X@C$AF>\[*4B,@%C!$/2KM
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ML9"<028D#(!(/3*PQRA:1:SWE%&.MW:5*6A8T/ )H.$RM<@%4890XI4E7'H
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MG+(2;J1>M]WHGL8L0IWC<4ND9NS_=I^Z="L[8 ]9&VGY26YZ>>Z#.&A$V^O
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M.K)O8*]FMZI*1LH;5>W3[#851%L*T2X52.*42TDU08XFG_VY"6DCJG["GL<
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M#N"[_ *J</J KRMS8(A?J/$"V'MST/AW-^O^=53P%5123.20RKUZ_N[W!AA
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M03SGAC$=.&-&.JQ35,ZE!7J?/83K%D@ ;$?G115;X"^.\B79,.S@#UC4_C"
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MXC1T8XK;>9'BYB<I;@5L,K+9BC9,^F8\]EJ7'N9Q(ITUMO%XV39LK"1RQ4K
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ML1L.=G0@A/FYMG0#Y@V8-V#^;,'<YQ$YG,24<L.#RHQ@E.2YQH1G>6C _/'
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M5-;3.O4=%Q7EU@ V6Q/JF&N)$,84(Z"]6,(%4\:#34(L&/E"8.W%S61$=S%
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M+$*6A5A87VP/'9F@@C$MO7&6>^(URU0P03IL<&P5EVCAVT"QIH4'T,+IB>'
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MMSL2\6T70>E9N-_1.NG6CF?$7Q#2A/@+HUU*6+@L$^:+[//JN51O5TIMF%W
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M%UIC[N0B9/@\P(%X!7AAN9%<.T9P9G)I*> ,QNM#QNYP[^@/"Z!%#:Z*FDM
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M?&:M@][GUN29__S9,>>N=WC6A/=_Z!VW_^P<G;V#9]ZSYL&?W=;-<:=UUNK
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MH%G.0A0[[J&DA$-N43[8(-!OH=9B39,_#4U62KN>P5K:=ELT^4!TTYQ&!Z[
M&F.N ];>&>-QD$SD-J?Y9M&C-25]'_?/*]&\.3K1(,LP+V,39T6!DBSP29D;
MQ(SS-# 70D[61;?2J+%I!',5V/8;\3A'4P'/+XIXV[#@)%F_HJZ$;PS"!B&]
MUTN7:6[B94DMT">GGJRRTOQZBUBB92Y+X=GU>GD[ITDLVANC0:"(2U@@F*AW
MSHAFUB2@#\MH$#HA$#U'33M1TJ$%,W\WJTCV?"WELSH-MPO$W%5L8Z%-R"2_
M/F'4Y$VCL1EU75</BQ8S@W@MX1K&^G(P8G>T6!3$QE85:#I^64MBOFQ?M2!?
MX>">G\GSLMA.',ZOQJ<P?B-R]67A(Q$6Q3]7"A!G%]>+ H2TQ#"I8],&KEU0
M06:98%XP@YT3]DE-J]^_5<!32P$?KYOM=R?!^9P)1I",_)X;RI'$7*&<*$<S
M+:AFH"%G?'^)^W#2&N"7C<3&73KUGT_VBZ=^=")U3GT.\EZ&B48\]Q9)3PCR
M#H,2F DBL@Q._0Z?\:_+@+"L$9A"$:),1)\?SOVQ#-[G47UY\ZF(_BFVO5K5
MIF@#E>*0RLJJHXO!Y4(A.#TI;C6I>Y.J^"1MY47!SVX)E=6@J*5L,5FU>T6R
MYN:^3[@BW5[IFNRE(J:12U[&2FVPS;WN_XZCQ3U5U;H5P+_(Z2)+36O[>IFJ
M<\6]^)8]3@54X<!B =?D!X59OYAWB ^':2:3DD+S3O'Y.D?I.,KN7$,_5T7H
M?N_J;E#L<I-X<K<LW\7J(A^!>!Y@96?4$ZV=4X;PS.?:<RJ!17BK@C72/H65
M/=H.0%Z>B<M)6IY8%0JKP8>I;F#3YKSJNY_;D/!11(^LYC$;D6ED>$Q0M3:*
M$)8@*W-N3>X,]G[O)5>/8X:RF'"0*( NJ.2Y,%KFWFF<9\P&!W/9+*VQ)IZG
M))[V>R >C!4&J=,(9Q%GUB!CC$8>A$_K !>D5/<G&A3$\SWMZH91+)S @N64
M.RX5QA(+&$R(S#*'G\*N7I/A \CPZ*IYUCSQ& >"'46@FU#$LZ"1))E&.=;:
M<&(Y=_G>R_O\A%.SXX8^&4US&WNQ<9'S+'/:>$9RS33<!).Y\!26])IV'D8[
M-_:$<":$I!X8GF2("\J0=$HA[ICU/A/!,^!_3&P(8=LPH*^99;5V7<S%F)J)
MS3R&6E;4@>5R)V@]A=*29-/XNU@B>C0Z+Z7+PLHW%>I3I=YDI-]5<6"22UC<
MH-?%IK8&_;*\</\4+M3/?#MN8B8A5T( =L'%8"I#G+J 9$X)TLQPIW3&O:0;
M%31X2FVA/N$U3MB0>!B8(BLL1IQ+@DP@#KE G9-Y3KWA>R]OP]\]>/@MTMS&
MS4J?4'JK:>H>FFJU7YT01W-!A4<D$Q+D,4&145PA31T7)L\5B:$-A-]#0YO2
MP5-*8C4=W$L']L0 B]!6<:1SG@.VA("4R3(DO""."1V,8$ 'JYH7+\&2;Q.K
M=L&M^QI(=G#>M8U?@%K0P=1N^NLS]O!6'*RWS)&5UB6#:J>?6PU+IAE2E?8^
M16O?:I#WBT(.CI;+6$^^;.P5J6,NNG^:5#R7*IS2?$9S#69\M#,7QM+D!B[[
M;9W'7Q=U"5+CK5D;NK*=FTT=OHJ!O4Z2\NV<I\U;MZU93W^QK5M1JN&NQ@*C
MA1Y^HZI3X%8K@;A@'0^C2$1.$RT$_15&9U ^!I.TA]0Z)LUCXK\KI@>?7O;\
M1%^XO_? EB>1]CPUO*J:T LJ^:5(2?_U'U7=*G73FOYV,Z- EBMN,N64#!2X
M$3.:\<PX^']*-<%ZFR+)S&%:*<K5&ES.L.75[2S<T<0X\'/S*7O=NFF>2&5
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MM,QY(S3=>TEJP'O>@%<7&WD0X%%#A5"Y)]HXGF=4"T:H,(X $.;!9C7@/0_
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MI^5ASG@&_NEN^.NK)O ,#!P<&X&BRHAX)C RF7/("">H8!J427*7/7MG3K8
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M0CC13FKX8%-3B'[T-_9'40:<\28X\KCA'P&08."_+N-)1WH"'C69(6#*(#X
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MH8B'\-K[1&3DCG//=)12^>@#BP(S;$K8Z\G!?J(=E&/"1*8TC(:EB&<=-6<
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MAED*VWX 158ZPCPA.NLB>AVU RB*+#*'LV;>-!2OX,UL\6:BL"UIFK#6$;G
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MJ(5-M2S)[0L5)WCF2/_P8*4/S@G"(U6>\V@L]E)*)4WPDEN*BR.P($A_Z0C
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M*ONPFB#54YMW:L8"6=':Q@4]R84!MV>H/ L]_5GT)3*)Y;B+L51%'JS10>B
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M!ZHC]^)Q![Y5'= >#_:[/;CK<+MH\,\B:/.*EX';I>E]\)G7!9XN G6GHQI
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M,H!?2@E6*'!.P#\%O=L\:P<J!8?_^UAGZWLM=(?G(&W#D#M177'#%%P4\A$
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MR_&7\?+J/:RZRRUG3_Z+TLN^1ZN"UHB&H+ZFT#95AB>3)#"F+5^UK-#6@+3
MLS)2<_ZTRM237V55NY=Y]6JQF,5Q@??[>/FIZY+P'S;4NYKPAE#"9N+<T$@-
M2K.8'5>2RLRM-9F;[#V5BDMIV-,:61-IWU[&]UY8U!Y=5OPSF'^!NSL>M(>T
M4Z6^VI>.W1 L<2Q2@G^8HP@L4=OD!KH+N/[-G.^]X^;A[V>3R4^S^>^H@B,A
MG?7"&0)9)R*ME&C6QTQ <T5Y0/O-0_.U/\8U_"5[=4UYW.VY'A--NGX_AC=R
M5%#F<8% 2P=[M.F)Y:4;08J::1DC;5-9M0W,B56B+V,=M.$@<3>(PC_Z!!8C
M;;)QK-Q\@U-$1BZ)*V-ST)@%'DL34]<D9?(QE#.F_W!1-V@ _F"8\3UP(^5P
M5[/,$I\DQ64:35Q QH(+B5O0EK'40@5V 3HO1:@B]@:M!K;N3R+:H 'A)&O*
M9,LDB4T!%QIL$0!C8$]T'!R^P _Q$Z3+";S-#YZ^.O57?M3JJ[R^FO 0<O L
M$,Z5*9.? G(!B:28D=UHHJ=-/H$#, Z5>]7<3&K%RW-)?-HCP%6<W0EOC541
M3P# [QZT(E[;2'AI-"*!BRC]P,[(26>PM5*'IP[D'K2T&,J"/[<A@IN ?A=@
M+3-Y=B([3:Y.51XWQ[94)6%0+8E1*JX5)X$"*U-O-?&VC"/5T3B=@_&IS=3;
M8;7CB528TRC'(;)O,<5O,\:V'ARC6':\9.CHTCS#230U<^G[$D)D*7IE:!.5
MV(%G>+.^$F.;(_PJB+M!>.<G'TM$]NHUFCJXT#4H%Z(33!/T7E#A6?3$<NZ(
ME@%-?9X<^"8#>K:B.1<-Z"_JG;O L!?EO_KK,0 -[V V7S'$/<K>96W<A7!K
M<J912YFI-* =]9Y'CMZ,$)H;\?1=R.;;!KC/8(+;;$,DR90QI$Y8$H+F)%K#
M$IYQX,0P0;O6]QG7@3.0&D1P@NA0BM2M+$T9T;LP@:: 2R[S%/\0,<H:^M A
M4'F(O!N<9 ]OL=D(/;L2'X_$@1%$BI!)L '1:2%L8#2'S9S;2L&9ASC.D/L^
MDJZ<LK<^4W_\.EZN>[->:R.^MJ2 NS)I62(H*X@70A)G6$FB@"@TZY"TM_,%
M9\1K/4$VN'\X)- C3 P1'"?9)$ND#XK89-&60E*]R*!3FQW_I<9C>VT"C7AY
MEO'8TJ9\%0D02FBO&"6(6!-I8L*MSJ']+PRUSG$I6)-#92N:EQ![/8CZ?3;&
M412TO@POH&X\PRZP6L9;=^!Z!M'6XYA[2A=ZB'U K3#19"><)3R6-H=@'%FU
M\W3HW@>7(L^F?0I9:VTX)+K:5!D.D78#)=@UD?M-^9=%RF7=!L P92@1O-3+
M*"6)%:5UFC,H#UQWY$TTH@NX<S]0JA/4P-Y]"N-:U3N@;'G<=(-YFM.G/LT'
MZE$/CDZP+:V+II7E1DI#4N* SEXN'7E!$A#*LVQ91LSGIDE/G%S/19$.H6:8
M.X)U?SG_:![.S;"6P^\$GGQDA3N PV!O#O9.1@D7I%I5Y!AI0U*@;*9:*X:V
MQNB0%=05]]%U=!T?/(#H.U31!2LH<T91FJ5D*0>C$GX6V0@K@F/L20+Z%M$]
M]?RU'3/+ZY\,5^_A\VR^+"_^<!V8./[6K.KK!Z#T>'%L$"]]MDXH9JGV,KOL
MJ7":9YFEDM0F^B3Q!R'I=]JN7W 79>-*N8P;!HFFI)"($$A(,A.6'.7!YN!3
MDV8TCY#T-236#[R?XZQ!!IIQ75'AJ22-!V(UMP22 15I]@R:A%RW8!D^(M^/
MZTUCH*]X&]RIK2&-A 7OK!3$0<F HH">=;"&  !S')QNU"]O#>!TW![-Q@YV
M#Q)E V_@=I)A_.?E> [IA^L@"LS'LS02>,068X8D6JYP.07BN$5;-B4\8TL6
MG-8M:=X&ZGRH[RWR!N&&-;;]??]+<_21#H$[(]#W *:(3 I_)U"%N>,AE1S(
MZ)K,3^\.\7Q4I3(=#0J!;O<SQKWF&L^X"(KAD><20<]7$YND$,(X&G63(ICM
M1\/A"SFJJ[KV+JKDR^CM$H5T-)1V.1)W<N>9U4SY-G']E]%0OZY=U)R@!J?L
M741[#>DZ>FTS9,VB(IK9C'N#4<0[$XFC/DK(P)AJ<L#NP#-4-D)=A:@AW.>2
M9G#7/_%R@<)9+&Z<T>OFF8&R*(RVR*@M4](R&@=*:*(A 74J6-6FS'HOJM/?
M$O6@?5.5JHF_Q29R$Y>X#@)W =/RQN<!FM-<[%1DZU%*8U]1-^<_!Y4-M^6*
M(:X&N1BTL^QJ#I%-247\RS9'1WO>G[B&&8KV0R1<.8_UW2<_O_ 1+I?CZ"<W
MI2$Y:@01#/%6.E+N'4A0Z$V %,F!C$J*#<:WIK!N>_;P-F$/4<\JRJEBD*S@
M^072/2#@P%M!+5$VAI(O6VJY4D17"-  U8$ZUX6P!P]]J4P=+YE!.G(+0;FG
MC)'DBM&@F2.VZ SU((QAUAH5.E#UK#IRUS20ZDANH [:72"=3P?M@PCHT''Y
M&.D-U$&;XMYMF:#$6 5$QJB)94$02G$+\CI1R8_Z2I]5!^W:?!XBM($Z: LI
M3=:&$H9;/Y&4!N*B]X2)C N/P43CC^'Q.770/DCL'3IH'R*S83IH=[]EW_R;
M(7(>=KUST$2'3@O?R&X029C,7-0F<"D#"SZRK+-DP:+.6'U =L.NU_>=R78C
M.'B#6IHV7_+]U2_^_\SFKR=^<6] GK1>TM(NPT"9DFZC(RZY1$3)Q0[44VN;
MA*Z. =M_:-W>=_[X]29F?7MGXC5U +H,,2G=\95!X>!Z2"I5Y5(YJ4.3E)!#
M@9YBIFEC77L\#ZXA=RW*G&^-_">07]O^+*'E7^X&O;6EN,)1XE70!%TZ'Y/D
MFBO3]L*A"\SA)H0.K%T-V7HN-Q@'R/0Z7@<<(-,RDLLZ(CTD$KQ/)&7F*="8
M:)O[X@-QGMZ)KZ\QAVU]O9AK$ Y_ NX=V'N3X+I ;GEI<@3F4\VR;*@+A^E=
M-2*?B0XJH[D5T1#!HR62HZ*XF")JBQ?1<2ZX:)(K\FQT[\E!E,];]0[AKW(\
MY>=W[W_X;>X37/CY/Q9K_^\F0."4<HZ*2*31JU]XP:4)9SPE&EGB/#_A73_U
MCF=G__<G:-9 NBWZ\NV6P9UE"I'9S!!C2*O6\%F4(6N4@';6)".]I4UVEB[@
M&@K@[_.2_QB8E2YF1JRC&2T?T,0;A7!#ID$&E7AH<A_^%+#AOYGJNO*H<V%-
M+H;]6%[%>'EQN2HB?W4QFR_'_W>5*#@R1CIFO"&!!4ID L2.2$F*)?;NT:Q.
M0VO/#JA_+'VJP5<#NV\/XE]A.9+"&B]I0+<+55\&6X9<XY<@'' E@&;NA]Z(
M$=8?2W,.Y:%!,<4>=.^A"+ TM;BGU=<E(&Q$711>"T. ,UUJ0#2Q2@1BA;!:
M.Y^C<P.KSSZ\?RR]JL9<@R*,NV#1G@5<!XJT2")X[@D7J?0KSN@_F80JP5/(
M&8]LEYI4\'6'.%00N+DR-6)EVX9UBH#OGD4]\M5]XBA%4R:7<30,D_$D<(V+
MQ%^#4#(#;Q+L/0#CZ0.]=;6D^\[6BZUAC:RM?G\7N"V#NP?B/4U@MQG_W?6L
M&GG/0.=LS)+RJ$AT!F&K,GG-\D#0^?5)!^]DFY%?ST+7G@CD/E=5.X2S!BKV
M^G*QG%W ?-7+#N6X^#3^O+B),D;J7(@,W5J>RV294BML0R*XJ1OAI7-*-FFZ
MM0?3L[+N^_,Y:T-&Y3J"NS#TJVEZYY>ENF5=W<!8-II9A $.+5$=B:?H<6C.
M!94NTA2>2J+;_X;S)+RB5!OL"3_ %YC,/D/Z#>*GZ6PR^WCU?OSQTRT\HYBA
MC 4$A6:?9.B#!*]1*6.Y]+("_0_68E]X M=YJDH+4G9&EP;-R/W5S_N.ZCGX
M%0/DV^Y?UF;;/I5H  ,V9"%YRM9)8:, R208D?.3Z;6/WC; S9X0RFGE!1'.
MHQI+'4A@UA"6A0]X,JGL8& SL]K-WFTF)?7.:<D5[L%)XE=4HBV<TI))R5P(
M3-@VF]SILENK<[^SR]0ALFUP(W= SXY-092):![/7X,6&%NY!A*]@BR)D4%$
M1FE@L<GPN1Z8SU"3AF*P:?.5)R-K)H-0*7N2F<;/!"@B->B0<CS_N$DZ\38W
M+R\T*MY'H1JQ\ES2H \)?CB?/(],$:""X>:<*'&E-#=(2FGF)EO9)"G_O*+B
M!VE)CZCX(6P]@PAE%[A_1L5;\=\S5'D,><] YV0*AGL7"(35C+@<B*,R$$9S
M4C&II'PX6UVK&!4?4M4.X:RBBBWFR]'KV70QFXS3M?58+(O5ZI/*6@:>2.0E
M[S8)14($293.)F@EC.G4*!O?<$^#\+\VM6<WA#,]]2K)O&+&U'9$-YK9!=,!
M)]B1^G"*XZD647MY[R'EYOO >LPZR! U,F2C"$0:2,25JK9 K=;9^B1DEZ[R
MSY#Y'8?%D,0?(MS*A+_'#>VZZ0G/(@8\88AF'%?%M2.^U&Q(+P,P+:*573)F
M.S%\^]8SWMZ/DVS%E,1;$#>7)5U@U-[$[[U_^'W[2 8V.>PAOA8?ZPV<)$+*
M#-42E%%$HE[BG@&:1!-<D,'BGE)M0V[.XIX]N"Z)ATAMD*YW- :7@'/BI-#H
M7W"#NXN0)+(8/9XQ5O.-IBPOJ>M=D\VUCC ?LRO;]$M[&M+Y-,([B(!.C=,.
ME]Y C?!BPFV(1MPZLG!$HJE&@C&.4,FSCL5H2_*Y$7IP([S:?!XBM($:X5FE
MN.8N$U.2C21/94Z&8T2!BY(R)E0^JJ'A<VJ$=Y#8.S3".T1FPS3">S.;?OP-
MYA=OPV3\\3J-<)T\\N'3;+XL?_?];#Z?_3Z>?CPFZ>; %U1(N>FSI(V$&RHR
MU9"8#MK+J'0 Y0)XJCVU@&;/Z/C5M:3IZ!F:1[UF<,HZS->4PGE#N5+2,QD9
MLN8DS6C^1AU9LOY XOI.VSSL;<=GN!WWGL$)[)+K9GP.3@696/"26AFD#HF#
M%G[U__1 !NLDO/T 8?GSM,QU+_?L;VZ3"526U$?&B-202[%NQN/>:L)4M*!=
M#D$TF2>V T^O].W9TD_6LD6!WLKRGIQ'W-"4'/6$,5^F.(=,?,B"F&0EFCU!
M<=4ID;O#NX;/1ZI!\H/4[=H2;9#D5E;Y-K^>0QHO?_)Q/!DOKW[Q7\<7EW??
MT&O_&?]F>36*EBH#PJ+M$BQB-8FXF#GQ4<ALF,JN3<O/0T"^;+5I3DME'^'7
MV1(6[_Q5.2;?P^?+>?SD%Y!&U"FTG',F5)=+8*<4\2D8$FBT&BU>GWV79MD[
M'O^R.:XEMQ:3-%$6BS*9$19OIS]^7:*678X7G\J:W^8B@U$"8,DY1YB1I39!
M*^*4B83G2)GRGDO=I-CK260O6R?:$-"@6\.K&&>7T^5:=Z^'>RY?3=.OLVF\
M_H^18]&@_9T)MR")I,(3JZ@D+GMC0?DB@A8ZT@';>6A);1(J1G:W+_LF="UH
MCIXK$B3G1%H\K'RTB<BL0\FV5C*W28I_C&6HC.06[/<5[7/)-GZXCE7T%#P
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M>*32>1U)HJ79OM&,..\BX48)PZP,&;ITCW@QE3Y ><A2)F(UX,?/A",V&$O
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M=2?/_*>8?,FH@<DZ7585<JEE,F #<FE*C#FV*=5ZOIG_QUNG9R&,\%R U]R
MXA3 8*%[L X=5-I$[]NTWGUMP#_H&3AQ _X^6M022#TX(B+2%4QVJX!5Q8$J
MOH"S-M<TL>."(S.^"7#@%2TS^9/02S=.$>?NXNM/_W-SN?SZ]VOR!6Y6[O-[
M,O_S3[_A]>8=_XX;'V975W34ZW^Z"$&*HH("YHHFAUD+"$;79O,E"&,HAHMJ
M4A;YH&V^N.,Q82UJ!3IHN]MW-YO.@59I+RN:W_+:+"< A88"9)#62PJ&&)L6
MXJSO#L_HI(R@JN.?J@/T[*R,T%_I(Y:+OU^O'<X+'5BP*4J0MECR,*NQS3(
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M%2-\8$EP]0:J4W/_E%D35F>L<M1GY&:*,-C2PUX:V3?58?<\/6<_VBRRF4S
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M9^T."_,_+C U\"T>1I#2$-236CC0*.44-)7KCE1^F.PB37G&AD0$CU669<'
M8\J-,W1"5<1#7/Z^-,7;Z.DDHDZ$4AZ[!5_EB&?*7^( [Q3Z6V8(4OW-9DD
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M\/VT2?8N?RO35V<UZO0/PVS._D$R[Y5P@.6/4/%IM 19$+RE4A<I^M!:=7(
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MSCO8A@B+44+,2HFOF^-CE'+Q2JC+YCM[GP?B'])A(>AE^C<#T(.\AA$"'=^
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M"=@SP/_"[P\\=9:B/-[*A@U1WE[5#GKTM:?G,U^B//J4U4N_1.X7Q9'<D0#
MY1S83O"&@1I%*[:,ZTNF7Y,8&M@AN *M9#7NMG'YY<+C/\QWE;=\4DD_E2ME
M+O#0\ I5KJ'P?^[4)MC*WJG  1[K8@=@=/5V#E P-DJ/P&R]&9+!RFW<CQTE
M4(\C'\ J^IOTMN-0Z-9VN'SRN.4@Q,MU*-C1_1^CK!J#/J6VX37U>S\FFRY*
M<+6QNV'4,XZPN<5V$0&F%(QZ##>5V61[-O(YK:8-%NT\%1QWX6)UV+VT&9WY
M)+G:E$NB<7K*.PU2UR%6U$XF3HFP!78P?-&=G<CW)JUF*;N^XZL-A0I!IU;Z
MX.OJ ;;.Q0LU#0_U!3/&;W\:%]\(+4]]$LF'?0'>&0M7X.[H6;)XU.HK9E?+
M+RS*?>#@,O( KOD8SE<$8FLPM@KVD]Q&"V(;!PATQYBQ\G^528 =2(J\'Z+B
MUY.;+"M9W>N&\=YM:6V-YRWGS=Y+1-H!_: UE#MP+'R]+$,;(\?*9N\)-*V&
M>*A@1:=SH\68WKW!QS1<8KIOV&J5DN$-HS942(AJLQ!WX<%M*T?YKB'>CS6\
M8(\AJ&[(^[BJSI5%"979Q:A&T59JJP>MY+'*2J,F[?32)?K1F+C>VQ\Q6O00
M/811K_*CXAVWD53W!G$Z9PM*K=0404-'LG<%>JG5TT(32E8:E6= 5,<=G[C7
M;FB_;8%=*S^K!/+M2G4!5ZES8C*C\T&U4S;]X-[,^SC_,L$?'T-76N=@H.IY
M8D5FJ]-VT#&SU?T!3O*7S@W^G+TQSOTK?\(KOUZYK[I>U3IO<(0Q41_Y4$2,
M=0_*^=LYP.554"?TP4W'T#F3!+8*>NO45L6.N'CS\+E^J1,$_[%;]N:V(5RI
M2DXS[H=3/5HEG =WI-K*O>KNA0T=VVSI)>FUQ^-(I5-XBJ5ZC#[)(V6RI;-E
M8!D?'/UM-'_\Y\^OT]W$16%+3<23,[UF[^2O[8F _1U.@CW!4T\BIMRGZ>>@
M!+[,/ 2FWF+H8DZ"'VI@[[]57##7IZ:U[%J^\TR-:0E1I(#PL+WQVD(+5_U-
MKAB6/U"8A!U#G\#=0U)=4!,U9),6Q'U8>4T[,@:N2#,]CPXY,P#712LKB)_[
M/]JYTJZFLBP:$84H0@$B"QEB*9-" BA&1<C31B9I%D*I8)A4AH"(Z:IB")J\
MAR!&IJ)1(0)"U&"!,@<C,D@ $4HI5(:"A,B0($)9"22EQJ?O)7;H3]7?^@?4
MA_,#]KW[W+7W7N<>UB?#@$V<)*, YYC<$X9WKE?:ME)9\\_< Y&]=,H8-/L
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ME<R9)!/RABS2R:$R?8.E"T/GMPITZ$Q1OXJ>O_'64=%7$K1$'2?S@"J_1SQ
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MDOLGO?V])+.\MV%?6DG!IA@QX::ET]Q:T,=0&N:VR(??8;V!?7P8Z?5LH_#
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M7@IQRR,,D^/,"V\KJW:_^NL.6&R#Z6P#L.T8VE+#F)0647B5EDK=_+X+)WW
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MI).0:ZG/]M(7I^'B$P-NG6EG^UZKGI[V4 0B_*A75&S.O:#- A5D EJ&ERV
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M.C72UOPJOF*8CB]'EV>Y#A:1&[W8%&G8=L]DROH4G#7K09*'!SN]M(=DYWG
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MC4O \UG(19UD4F(MU.'5=A)A)$HF3'\T=LEBZ@#^? ;>,/)2\K!&?SI65EB
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MED"&5[WD(&RGX;V6+<P;1=X1-+A&&)(FO_Q>5[L6]RQ@1Y:$3<@W^119("[
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MG2T985?"25^\Y6PQK(SE3XXA_A]4C@B2^D4YBG,\6^1-Q*('*/51$[P$K[^
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MA7SIXGFSXN*.'<LS<B<EE -U_4_Y:CF_\COW/6$F6:ZW8UIUB%XC;6Y?D[*
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M$7JAD]CX?T!O_O^__J^\!-;'_AM02P,$%     @ &H.F4ND0$X+@7   CG
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MXJ"S ;"69Q<Y!83\^A8G0(T479U&:UH)_9<EG%1JL<?FM[.?N$WYKNR#+SE
M6G'_I+<A=;=VC%^H4^D_%E3T5;80LK@AF9J>@ZFI;\$F3N[E #$S;?37.CD=
ME<&E<0-XFX"P2.]MZ4G7+%?Z=0Z,V8IG7Y 6:XB(O0-$ND3*,"5-Z&^1B8(Q
MGB1)0A]8KS_)"Q>7^-"'V<IPV@PZ4<9)>R/KZ:.S^W6^#G)YJX>Z^;<::FS?
MQ@$ TB!IM)_2SA9AW6L4]*;Y=DF/-547AJ-LD;3?_4[VCJ-_U]H1VT$9PRGZ
MF)2^FZN?%'GYFS2_QA:RX  [">QN#D _H4]A29&&0Q!W?K">-NE2$&_,.,!%
M'*S!WQJP%?O4">\-&<7W)<['65F$2(;><*DM;(P]HLN5.V?CHA=U(:G_)B:P
M29HP!%:M=9G=6&XE\Y"]T0#<=7I@L);]8 JW==1'1KI;5###Y+K+'>XNI6!G
MLH2Y#GXGK#5UW320ECD=$-^H]K1#R28D3<+WQ#FG_&UWGCE.G)"([HR08P;!
M1 [ E^T#5@^W+\>@%3#43'(M[WPT/H":XK@+;U^!/SSD<7]7[T5'?Z74_O%E
M$T&5[(G;"=.9_E9;;2;!EDCR!7!4=Z9OR1'JHF<BI?<0;#FFGQ9/X3<U>6I[
MF2C K(MBL\^(OS-[GYR@FG%LY>CG=YJV)WLD=SR)EE+B_BTSA>Y:OH5&KSY(
MB:!B.LD"\%AGOX7"T'(,WL:WV%+XX93+TM>K!50(ZX9#IG^QMN3&P,(];-%"
MF,'0#Z^GQ]#RBJ#E0U!=OF$*-6)9[$M/P<C;A$*I\'+'7OL7O]Q;SFS])3\X
MW(Z#K'!;V6\Q2#%1YW0%F!C$5D?\"9I_/N30*2=:6>2"%M?^9(.O])+)(8DY
MGMRO*-50$W>D]_DV-_YGV $BA"6NGS]%S^  E9C3'."CO@_ ^D":^T&=3R!3
MJRE0T-H2+^W4=,[B N.:"UX!ODB-O*P5B6K+)F@-ZK]5B@J]-W;XXD!S1''C
M2]L>T_GX()569@)K^_"O5PQ7I"+(' !R2(/5EY?LIOO&,MD"))J&PRLH^\US
MVPCI6U.Z8M8>)=Z?EU1LZ?)))G'G#.3#[R>V\^>V<[U6LE#E'D&<BD?7Y3 E
MU^B.B&//82);H ^IN&UP?!G3,M'$)/,Q3#K]YN5@7O>*O.Z20)[.P1#Q]]Z!
M[@I1Q\)4RBX>]NP]Q-"@A<VL-1-'&=;U-%07,<55'+(BANV)ZV=TL%5K!R[F
M'MAKKSA]^.P5L>;]<V0ED!J/@ZX2EQ)H$?1W\6S!-&2]$[#7&+9=ZVN>"'^[
MD>LV/WE[9_B";[3G\]&E(X/OA$RL5;VWO#TS,GG! VZ8MNX 1ZS90DG(=:_A
MA1D,K(U:<HF@]L4219=K4:),@X^/!]5C_4_V_RY73C5,U<07:$D.!\4"C0.H
M!UY*-T$[@@0-C&%&3O5@ML(R'7*AM04^6];KY"HR(Q3>U_9>[X1GD[-"WII&
M64N]AW_0[[(>F<N$CQ^#O6EZ,\M1C2;39EXDNE'\;XJ4XQ@.]].O]&N+=I+J
M*W^^H?VF#E,!3/D'#&>F$>L.F?H8K"$M&D#R,[64=O"F$QCS&R//-!E22T^=
MJUQ1B-+:[I>^5"&W_[[]H7?NR9+<KH$(C",($&6'WX<\LB:8P7\Z(]AB9:X2
M3CXS%(*1,[]?1(K_;>]SZ4VX^)QWO6D0_DZ70<V)@YC0VP52%[8 J&]]5G 6
M--].V-$$6<<W@D]Q/YPN:)SLUZX]Y_&Z!H@UOW*T8Z9%"=\<=*!,Q('^E'6_
M1I=[@GG\,P?P(FX:A7VQKVP1^-PR$?ZZVT3>^YZ'6T;H7:MD:V7;3;[0 %LD
M#G:9(=VB0.?3QO*I.>VD;9/A1"?(,\[ C.]7^XV8Y &?2WWG:^I29WO$VQL#
M\X-LYC/L\#,(5GP&6]#F(F#+.28O[>PPO1B^-;.5*49U9NR9ZA,)#W"4?O'H
MTH;L63^+-95HU:MCS8E[HAM_4B_<!(_)%2TI,$R_@4(7X>5R9CCD0;SUT]Z)
MTAGFNJ,F[6B68V*Q<]V=@\TOE+9\24^<@#!I>!&:26L=P03VG;'3:#=6S)>Y
M7_0#^4]JHK#?/>73>XF]^]ZJ*.5E,3N1'=1 AHYB>,"6T[-P+:1"KX?),P_2
M8I':^KV#V$;8\M'@EZ\?J[Y$_K8'^8Q'R-ES-9^:78\E91SP"/! FD,0V6?Y
M-OB"M.C! +^E3 O6.N-NG=6L"+>V:^AQ3CEA63K>X/=.J*K'S>.E:#=6GXO1
M,X,;JZ:[P+ZT3<-31NVX,=MF8_Y$4F)D4ILQ)?E*>8AP"@<(]FBL*DMKJ).<
MKPU55*5AXICR3\^'/^A@*U?VUXQ;BH0\]W'PYMD2=3!J9;_0XPQ^C>)-Y$S2
MR"\JFBF.HK]@);/5"!\IT$DTO".UL)#03]@]^-OW/:\NJ4)^,4<H]G'N@F5C
MU-<OV)=-YR]M+\ESWC3T>WYQG>&!MV&5(9#P$9NF* _73YN4XQQAE^<64\XN
M1S=.J?Y:*(TL^#(6$-RS]?/4X_,KXA-Z>35<#-),P%@/W0'V+/3:F&\'QW!3
M'"!^L?'@D8^Z!F39<V.6Q7="B=6-5<\?\*?=R0NOD& +63*N+&!>I"V:S)#'
MVNS2#@_5HE!PD'/?Y@7CO(HZZ/N:I766W(OU@JTFW46]W44\D5,PAF$ M@BQ
MA0@#(!2 NXVA%H+RYEKA??9PRE.F'DVQEGJ$KRK_^,>:-T*V%"VL<U#**W7#
MS :%-KYY)2U^SV_F"DS% ="? \#Z3J L\QJ-G*#6Q'K$M"O'P;)EI.GV5N[9
M-K^@RXE6$==2V8=/6UG9;[NP^\SX 70%"!W$C9,ZP?IYID12,U&AR8AI]=$@
M($%NMO--R+2?T1$OY8BM.:Z#2K5IBY\R/G;6T9IOX[2[2WH_])YCI>/2,9!7
M'U-B@$INZ1O!_=G>L;!;.WL'L9,HLQII:T?;=1^,N#+F4G-6[O?O&AT_.>>R
MYQTZ=UY==^=-NK!#"37L ^QXFOB?.MA7D2QG$C=AII[A=9%2=X.51=)?-0SK
M[++*%)"= $7F;WO6S+";MM]F2\T1H2NDYM'?E-$9^A3KN<$1!?(+T-/,MG4L
MI+=QF>&1-='[MH #!%YC7%Q4L 1/K)[@_U6$X-@(*[%)B3U)AGQ0'6E1:(%K
M]8.F.&]:$,,5^G!?AD)^56EG>+G.8M+FHH15=&-JUC29CTRM0/IE7PP&PE(V
MLWNED=YFB8[+TV*5-IJH%<7%=B6S^1>,8U-+M1V$9?.6N0P$2>X)^+IXKV 3
M_[WHUV"QSSN$XJ&:*=!=L#4 8<"7,UFU]0%T,OT:SJ=SXN6OT.7.?3\&$@'F
M<20+W\$68[*7;AH9.@A&4\0;C1@J,!:IW90F:1=,@NE%*',*%Q];&)?D]KQ+
MQ;6\ML"Q/7U_77:(R\CVV;4MKS#[$?"P0>(X%2")H-J?@&X0%]] $70G6F0%
MV:W0VZF^BRSYY;:SU8"?]L_R"=?)PT%?L?BZ\<.ELKB7/#$_T?V//,/!5G,)
M*/>+1BQ^3Y%WU,]@LY&!Q?P8.\WORR]$>B,1Q& N@"U',+-8RBB.W<WW@ ,\
MK=WXC8)W+2_&T]HZ$$V!'FE@"Z$9YK#3C,,@@1?FMGC0'EH76FXR/FI;M%"_
MFV*LJ[Y5HZ;]WK=ZDU0IV?CE$)Y-NRT!$$.4 :ES?>,XMI G38*ZMHC((9X0
MV'(:Y&):#H7<S>D<=FIZ<+%D;,E=K.: Z<GG+Y(BWJOU)@G?DKN@NW\&I%;E
MJ<,@0Q-L>:LHR7J*H1:C>6L#$G#<7R'_1XJW>#O3%88>#09Z7Y:5U2GPB+HH
M_6P JU9\A6MW4)FL%/D)!Q )YV]NVIP[/=_"%NJ_=G_76Z,@[]=73NA_%;<(
M2C0*,8NTLYT.X(=M.[-MGL%=K6.AY7[;GIY;^FVR==[RJL!FJ1: FG?CUP'T
M!_1B ^-TN/Q,$5-!"T+1\Z&TQ9GG3#78;7J"[WO/U-FL,J] [WC[_O&#0]=Z
M(MKCT!/;WT?,E<1H[ZGQ-\,B%*K%')P-Q([9LMM9ISC @4^E:X;[^E7%#M\Z
M<T"H9#>P6OAX<]IM<U0M'$O5"6@V&HM]7R WEQY<]#[$4]/FB<U3KY[.MJRK
M\DJI,4+L*^!%#*R%74*Z ]\DW@\N8HB#+0<(F\)+N^1<BZ8-A_3?V_R.3YQV
M'.(ETV,+ZG>^"_,.WGQB6QSOY@/H!S=0"]F53 ^(T8P1N[;:3U""5:R'_=PB
M:>.^QNX.]J5@N'9B,_H&P([ 4!^Q#5B/0>H;#'0U(!ZD/LNU;I8G\C#WP"X!
M8J^:+EU.U:^INZ^CX_KCDEK'UX&^-^D'5J;XGR?K!5+$:_I&*6P!$-GZI?!
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M96-P&@ZZG!GY?&1FT6$M]]K)]P'1+Z^$GGP7W<<3[#3(M:Z"@-DZ!\@R,>
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MZ=?QMQN=\]]=_@#=&VJ\%S?_X%I5V8[GPJ:/GQ;OXV\%W4FP,8*K]@P<,W*
M[(F4(+EC4NIS2,_O2@A9(86)47@45WQMJ6Z?6^[^V97)0S>11CVW,W_N0@'W
MZLG$]6$Z(@RC"MEO$6)&2<1L;A(G#"CN'+SVR';Z0ZE:?*S_A8%CV0G;L;["
M;WH[HL8[R\,$=WWA_8(5\IU'Q1.A:\M,<;UIW)*)-V.O%UK"%"OL8]RZ<,,S
M-00E>EV.=ZB'G+-5HB8O2.65D%J&9+*[WE[2^P/H?'V']QR@KIXIY4"W8=UL
MTF$:P1J,0S_DENH::&>9H["5F=;AB.<%=\];<(F_OJ,B__/25[HJO10'V6-@
MS;5%)+\\K^'(QW@[5FFMGW_?4=JNJC'7[ WUY.&*86&)HX=VIM?XG>HK!R)%
M+,/#EI"U>*59=T'J(PR7&^LIZ(.[C<K_5I]96)?FX>TU+#-6WO,D)&J2=Y;B
MI6VS\S:?X]U@5PUD"4351D?]N0HZ14X(QDO",M-D,2]S/>G^\PML&=J'-(6L
M#X6;?9S.UGD]R]4\ND/;[1?/@T.[3Y:T Y$-_X7;_>^V_]<TIB*BZ7<\ALBL
M'!$$&>UR:PFG"9\I+\*8TMST/[>T+C U6;42=#IM/J%)&.YI,>89-M_Z$1]9
M=CA/LG)06SG"Q+'<%:>QV*)F>^'4U[,C#PZ$D,9UX?T-=$E6"4A]@H.P*?Q4
M</$65,T6YP"2H_C3 [5)CW0905W840^IU'S)C/6<ZC;9MKXM8ULK)^X(\*0]
MP7CB1KYW(136)BT>_2)MR8UZYCR3^V.CPLQ[GHE#>L[G+?/'Q[YT9A[ND\W0
MM$^TE=\MFOBM"_C(WXZ!CF!C_[2B11R2!TFXG(&PK19CO$LY'-TNU]?*BF@W
M5Z7IWE9.-#NK$V#;_S//S/S(=K4+SMYA]V8V,QIGE,(<I4I_G6(+Q-.&6T%A
MT V#AAW:$;UQ4#<17;-(WF)J?=V/Q+2$*%'/!JG.V*K6Z..VL54/VU2OK/0>
M-6[Z$>/6_01] UF4GTS-)D,G^V -7%= "K$2NV0$&=121O.G[?(*O?F3=1J=
M"_7W'DNDTUR%U1J,3I3//MCZ%:=UX_7XS]8G%Z?)_!@WI+OL1[$%'IJKLY%.
M\P+=O(2:)K;IROL,R^1)T!ZF^:\L5-O)C2>-I).4#'-<CQY0M>D_PMU:]N#N
MGJLBR,7;L8O<#$>\#Y)&;<(0!3J.&XNG!]&0EQ*.#<;$-BW=VTV2C?VY=D=M
M<89\\4N!UF]4&@>6%.B;N544A7/7K<;90BGEAQ X?6W+$(ALFF=+1-.2V%OT
M!^(((_KJF0RO)LJ;-).0[%Y/[_&!1!8%F5F#_8Y<1UY,9VQU"L>RA;@9UN%)
MT^CV%,]3D5;K(<L2[TO34.-W#R<=3YT[ZZ9YH.QG<Q9%96?VZ;,!O4E$V+"'
MGI/)%A5'*V9.B9"9>K;,,XHFX!:PU:)HW8(.>CU O;C. ;S'64\>N&X?GU48
M'3^P#<W<Y@@%(-6"_>-RT6+DGZ\\/H4YC9</KN7IU==<DEYVC/JD3MS'^.[_
M6ZL(F+\37Q*U#P?OE,1MP5PAC\HWDZN7%ZL1+[\P";#-M&[\C<)\.*Q3FB@4
MT,L!+J3R)SI[NXH8[U??NR?QTL^.Y/0 #>UV]A]UT(*!CF*W($\<., E+_8V
MIM;@E2ML95COO$M82T"Q[6S+#?:I#K/DC OKOMH!64&[5>-TVC4OF0-I+2 4
M2E[ZI-N&&K6>)L1BFOUDFC<>BDP')"LJT,2]U\:2 ZTNZ$V\\P:5R0$Z#V_K
M?+J4;2VB+JGUF%\8Z:Y&Y^"VF0HBXNG2 ,'\VUCV?1+<TZ8KDW*-=7!B:5DG
M8%=7?.S7DU94TY-E&4?*RKBU-@GP.+@@5R82WN*J-181[J.!%Z3I-I-OY4E#
M(9^SIGL>\8UA1;SNC%:?D]?=<S$TP>*.UH'"L P+3Z79<8PUXB0BGVTYP#B.
MW@.O(9(XC>X .U^?>:0R=9QT;=+@<RU:<J&N7IHF7ZZ<<9TP&BA\WJ2P[&>G
MFEO6?J JNA^9H)\('2>/H]E"!HP]>'WX.D,.KXCH\IYS$ =(4QL,B<# 1_19
M)F_K?#4OB0<TO8R5G[]@6*SS(3#5BWLV#=Z??^KU( ?P0]*L,5E=,B&K_G+H
M8N[<=93V^V*OWE[L8*9+%U-Q-G@3 =DM?%?&#JAF3OOU/'4KJ7BT0P/2)C^Z
M8<3<%H+$[!&+A$R#NXDP-8(>N\M<P>[4M&Z+X9WSX3XFW[:_>I5XK0HTY+\?
M@U5K_'P47]5VHWLV3$J(HOP774\D0D%$IK0>53>:K4[H1U?'QUPKMVX9HXP@
MO;>HS;B.^*Q/7V_\5>/GGU\;!YT, O9.?I:,L6T0;]"V?W[Y#A=(G24GRN75
M(]TE@Y5-V )W4?W?T$ZUFDM#ZDD5EA#I8-WUGZ:V9I^+K^WRNY0@UAL7OLKP
M<CQ8N3-9*X=5SK1GG"3T@Y ];K2'WL;* *G1H *;]SM%U-3!DP,(ADR06_T.
M:D4ZO=/U<U+>/G[N<*(XNLY2Q3S,<F^QR0DAQC);>!:)0B:K'/0FB3-E660R
M-6_%&9V"O,GN3O?*D;ES8".K1B*I-'ASYHO8@JB9]^J:6U4KOQS1RQ+4>,CN
MIH@B4?A*'N< ;"%!A/KV+=72*:-]4P%M@S%P?%N>($UX9#R\V"WG0X1GE>UX
M_,OK7U0#5#O<$A4F<7UWJ.AJ?7M+0/*_8YPT*?!R3X\J2:Z6N,F+]X5.L86#
M&7OQP4C8]['')L4A5#)Q*J>9%8JTOD;:YM#L"KPM_;"C&O$XUC0@S?U.U?UC
M[@D.3W@ 5-4WTE;63;(_,1K1I<NC25:L,@*WMQPK+2YDO*?'UR1 8M0R()SD
M=Y6^(G/$(PO0E1>+W[_U@[%#-<+@I7[5,R7[V$(!#'.P1=.<>P%3@UG2> R7
MVG^L)<I83/4<,54NL@@)J@]VFCA?NA=KNE-EU'.'ZAZ3Q)0"\0/\G_3/RK2A
M;AMK=)#B\A3@XJE[_FX#>+LG3CYC^+#TDMX7YP]F6BF<?K%9JO. *G<>UHFV
M#&NBF))A5 Q3?(8>$4_/8CVMP4KX***)[6?'=EI,F9D+/R#58+?UJTCF>CE<
M5L8_&GVW3;%9D66)#V!X@2V!(-)\1K!T)]B>X8)WAXAI_LP]M+3CM6^@\OKX
M55^;Y8NI$5N73YPOJ+<O\.S.LA!8_N7NGNH;3$>D550KH0=$FHTB7@,.HU':
M7/6;FN"NZSKUL;@V8[O:]A.-06.'.[_V!(LE^S<FR7-#Z(_NW-^[M6:)8\%L
MH67&;@(B0>L#VM"P!K&=+ )_F._"2"M79K8YO#;/\MOU0*#A3>X'W9JC:YK;
MQ51%G:\$Q"HE9QS8R+TIM./I7P;I(9E*1$,G*=%DZ$0GG#7% ;AA:Q>H/I$@
M#L_-M$[N@](2/G-%> 1+&&M37J4/MJET&&NYBW]>V<3'I82V^F0I"=C_UPXN
MVC!3Y@?]\1#9'815 SK!1%?90:=AIR9H&HZPS-48WXXM[E-(R- ;G4F][L%?
MF616.H\:(;7D";.BD.TW-*XK'YY)G8R=\?5N$G6!*3B(E*#\/IO,*GB/KSQ_
M4_3K;CN>2/-%7P>0"@F$"(+4U.%^Q[*X?6S5;WZA)R"57JH_??(4K2.$4NO^
M^@K"<'S/+&[LX4,XK[N+0KGAP[0=W^H: N%+-TV[J&BFU.L>.K))H@,?L(7L
M(6&Z 82*/F5%X\G^C-YL:KSB[$63Q1^L$S]2"'A<_N7D=JN'>!3J2Z! U[J8
MDD0GUJ-5<)R?[H_4!JX%T^JGWMV-1L,<H#T[-^9UA$_:;.&@8<8AU4L[5%Z"
MU0F4][RTEYK*6MVK >LG9<XB=*X%_&T0UU0/Q:44C"(@_/#DR+CWQP(->GC3
MRST\\OC/+[//XL'PM[;SC"Y]K@U9!,=^L&J9,@C 2K"23049EV"4!=&FBI;]
M0#M'SJQWVF'@)_5E]MC<EY?<X39366?H%;^%QJT641_Z8#-GMKT'%<W8)Z+%
M 8[=F$6H'%,.1#CR43B8 [CQWR:O+@6[(LJ.OQ3LUF[DY@">7(7@0MKYQRB>
M 039,?".OL59QGZF 3PQI0NK-:X0WAL;QA>$7S<-G#Y"NOCZ<^[DI(E#GM;S
MD1:?#%N)LHBG639<8=7B_,-$R#$ UB0M#A>#+7*-W(P;WIAJ_N@FPW"5+E?-
M3U_[&]5HBL,AM369SI/2U\7"8E_=FLZ6!N[(]P+I[\*6/DU3;B$M!?*)_5#K
M&5:$%OK"_J H7_\QZ^CZI1]O*U/[E?3:$ZZIN+PY\W'^CN\O^9G"G 1MI)#>
MXZ+C76VD!9M,SML4E-U,=I9?"DC/Z[377!HV_\H]2J8ND&6],6)DZAU*95J[
M#G>+7%C<E9 E\S;[*F@RM<%/_Y[G1YU9VR/\7D_/BCUG?Q=:Q%!_!*P;@R.Z
M[$YA"FO71ZV>/^T"NVY1M(BDYA(A@0,\?U]X(YZI@+1R#2R#%X&:%D2&%([Q
M I%J2-+VL6H(8DP%I%J6"+W$:H=$#G"1&,<VI*&2KZP:]C=IAB<.UM5.51I6
M1VS2R>=5/NPG?[0Q+<^J(IXMC+!57L8@TM! V48CAA3A';J:P72$9Z<?A'O&
M']ATW6]U\%'BN-7'<6Z#H?:&<V4")V)VSK[HEI_M@W5RF.4:# G$&DP;>B/]
M^YDLQKZ)\(@V)*@WL!VJ\)2V3:GKMQQ-JG?(=BXCU)-S\H%B_G/-Y[?//!1_
M$WQ \0=2=X@HCDXAF#*/L^JT,=1'R*5GT*.\!&&F)4WV'%/S.F_A;,J;CMY$
M)V''\@#'K]A]FN>*;%Q4,WW\Y*//(DU"BRVJ#\<R!, 6[&_TR-X!^E%STRI%
M^9J<ML#PH+G0SR'EEU<^FCU*#MQ9M?--6V?RE&.4_\[4D4._BI@*Q\=<&Q#O
M[5A)IKI0ZA'TM-?P]MY0D :GORL_)Z(7:GZ![.7<G\>^J/!]N--%YO@PDA8Z
M!X@W-"Y\W2-)D)/96?9X^@A>^;F=?/"W;T708]0)5CR&.H,:=W9&<I'MA8:P
M:%AS>-'D&5YSL#%XYZ&IZ]=@DL[/*\_N*RR9_GZ9;?DZ\?(A@>SMM]Q-29ME
M$&.BD%RW()3K"HZ73=G(84H8L07/,*07.(!TDPKL8)5D3\OZ20[4&/4[U+&Y
M<]],JA??8.KT%].^O6E[+VX]:(7M(T(NI>%^?WYC$3#B>^J6(=9@.%8YXXRJ
MM,5TTD/=@7F0\:T?;#E'IF:2MV"\^N"=&&1)'Q!6Z6-*.K2\QG;]*E";3VV2
M7@#%XHBD<P8%H?23=I+9%>_%WYKW5CE_N9T3>,DE>O$$J@RD(@0(<L:E$>LX
MP)+"S/*( _TK*X,RA>O@ , (JVY%Q%#KEEN@7,W%J6OW&IR[I;T*T]:JM#^9
M&-^1F(-P\:Y*.?2M2/Z;3!V@^J-WQL(]Z0_@T-SD.DRH&"$;>W67V43%M9XA
M_L^_NVYT_9%*2&R<,-3B202HHG*0GL<3@SQY$>ZO<*@C[+7=^XZXRF _]]Q'
ML>W2:/]D.[-;#+-%<:?.D<RYS-#>MU8'0*:4N<$;9,%:C%NIGZSL<CXD^G#-
MU7[_EHHGI,J^%Q;**@/?=W#36Q-W/-[T7SQ0F4B*7J&K.HL9[HA;F@1]O!@T
M>6\X=P ^_4..M\;FOGK30&$J>P?"*_Q/^7U-PQDIB."7$)_+/Y9AJ*4@Y.<9
MQP$NWR-L3T.Y?B>*!I@K^N1VT</&G8]D=#O4).2B#'7U6+(Z7P7G='NVKVBM
MSC5JT;<A\0HG])$AK!9:,1RD^T<&]1RBK:7XFYZ*F)HX=,*FK*9G=% [R3U)
MKF:/Y)$<-SWJX9N*H@?,7:J0*S>QTM@"L6&(#4C[BZN:H)=?P'& 5B0U,1+R
M@>7/BJL9F*4OK#XMC-<R&=WFVO(,;$$0LYI,346Z),\##A"[0 YKN]Z()%(0
M:1,J6QFS:6.$-GK>.'EHG=7T.S+ $L CU(,'$6I1B"QM>X&YA!,E=&$@I,*F
M]B'K@"<&_<E3*NQF=N\O]E"83B>E>OW7XOB<7]^]X&2JIQ1B2PLBWZEWB1",
M&74[P,K%3$6"K0WL-OB6[S2X1(8MR;5,#J#>N3&\R,:.E=?-+S6L+>];J:SY
MV<T"+0&"*A/1IM$'\-@9E-@"6; 1A2"$'BTO!Q*EG'6Q;Y*AC'Z9L'XV86C7
MYF@U#%X^&]17Y9#<>.G8_GO%G@PWMI F8KX=[/F'%!J9(I#,,P0;T,P(4N'.
MS1L5.8%/<:1X3&UWBT> Z7:-Y"_C.=<WSTZ>_)J]^8A: CK _@#Z$<+"=&$E
M(Z8IFBX'"S.06F\[AT19A0,(65M75B)!R&1OP2*=RR^2>"RN"QQE3Z!&ZZ^[
M7C9]MZ?!_[B18CY;"/F4YSB"5(_PIV%AFAY;SHV])0T^:1RSAKN$3*#'L&7X
M]N:UNC2P1_E'*^G;/*_<_Q6<EB.R%BG)!74M(=J>YSR2XHX_=RSQ",!'92%6
M(%*N=3]B12C%-HF]A0P?:AIED>AF1^?6,%<8[J GA9Y"_.X^7AVV?VQ_&JQ=
MSY1?@[K80EDS((K]B2QJKH=C:L)M4TE>Y8N-%Y^-W)]NBI+=_$+[6X;E=EN)
M#+>7*6V/KTA=?2ZQ:IP(,&N015W!EMK788O1C#.Z2\,,+_;01E<7-M&8, <M
MS97[[8[&WNN\)!/T+MATP.5#);,R>T>E^YVR%@6SS'8*9-D''R%3ZYL0O1SU
M[H_QZY@18Y,1L/4EXK])&+'A\*O^-0[@%?D"P<HTHA':$Q-\^?H7\_FG-\VW
MLAHQU"0B-(Z#3O;=0H0C"O;&P%;@E.UY[R D"&@.(! V#M81NDK,V.;#]+=-
M?60PAUUB]W*B;X*T UDQ'6QY?8.\I,EP^].BZ.*LZI#EFT2I6H$AO&5$@7/O
M1Q]Q@1CUZ?TZ\W'.WHIJ@CO9*_L#,THZ$+*&??X8]2$ 5D,SM^@@;3QMS,&%
MU0#Z+(^17>!9&NG\BXQNM,2/$T?3%SX=*=V6*G?]6?;UY".5@K)9)[=_*KF
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M.E'OH[HR/S?D[N!N1Z)+&FE#U&DE)<[TT-/Q\+@^ES?#>+N0XHJR7"''GH"
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MY'T'6&[:,U">U<K- X)3HG8*@EHH&=5!W.[J$'GY F34$UWX>'IP*:#0\ N
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M..@"NUN1$P*CF &W0-0:K#IT%_L9LM['HTC6A/&!T?ZXIY%;)WO&2,J3Q'T
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MYX+&Z9286V9SWP+\LQ];KGW;X:6@I2FFM6B$)UFC:7?0M6A8+I8GWH#8=ML
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MOS"0KA2I+6<M1*"KG_WLY8W;7]544U\2H2CJ8C(7]5QSYI9_W>*DQ][X]ZU
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M=>*XS8=<X</SD8=UHM^WEWY[2:(1,<)HV@,"<W\O9"*-E/5**D *U-C)6$Z
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M.U*5QZCL]:F.KZ$>IC]CQ0B4@!*9QS]#W;N;LPXO.Q><;]]2G*XGVS"J?MM
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MVJAC%6Q+;B(?H&-G5M!D-]?6'<UW^("DJS.S=_1Y9(Q>@_0WC(4%74?=V.$
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M3L0,A"7YB(F>Z@ZT%"S8CO(Q&RAK>YFK5MI&-0%9R=;O.9TF2_9ZRWRT\LK
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M'NNDY*:9ANHF!\HM/2LW_?CKSXSJWA,MWT1'KO19F+@FO7%-WD*<D'/H(R@
MH[>O%9L@%>)B!L^^N*\:7?@H^&[/%N),Q!E(/1%=A 'WI#'&V '$[C&R"D<
M4&!9<-.CQ2UM >NY"<I[G"KCP8UNT>'8I[YKSJ$'Y2ZX/#D6U8[4./" C88D
M>,>A87@YP)HC*2ZX]9M*)S;;RIQ_^';U8A]KGX.U;=TL63S.K0<2&]?X8+6+
MWBZNW:..K]8_,**68I.>N(?SC(O R\#T2 /J(DG#!?^0")S0CZ5/=?O(^W@/
MV(@SQ4E9'8?*#QMK5^G71'6;=OAWU(9%1[@Z&*RF'[J2._0*35M9EU]% \>)
M8,QY8D-L5@"X87X33?>\3Y=N;CP61F[,'IW90BPN414)V,8_-_#K]V/0L5A8
M82!YP=WXD_CP3O'QU"8WOT\#I0J4S,5PJ[EV9HY1V;^GA!8]NI$W2<!IF$RN
M<Y3[J[YCX=7$I),4\<<F.S"1"[E9D CS9$K44[.BQ]C9&O$6RGSPN_%N@=?Y
MH\KA9\0/J=4<)8T0P3T8ACG,JJ[#(;K)$0*>9[&%8,@PYWC3UBE9?93:6UXY
M)-IK-=M*DSY4LRTN*#3B6]2R(S&Z8?*0T; <Q95<NV]@O',7WN9#]#>.VT-0
MX5C#QQ_."56N31/J.?&Q*BW?Y.S,,#HZ)0C.+?@[;D/C6. 4$M12X,A4LRZ
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MZ>?";]8BW4U&#$^,F8#72I5/)HV/S^\O9$V^J(GLJRA_]H3'X<4#D:__A>Q
M]S;HS+;'"X,;3^+N'@=UF5&]T+Z70$RK=N["O5^[3EJ2UEX?.6!'>7_J3OY3
M?EFKVU&^3G!%7>76_2!?@(M0>PO13Z:D.;0Y1F?S]8P*I5828E9;KVJ5W@V#
MU%IE^I:(T<H/EO"V<#OJ9 86<:3%(/&B-F[3;X:1(=ZE!H1[U(+ ^JS/O<O7
M6YY:>'\[<DDGTL/N<<6_*X4:=P^C*DA-"HQVM@KT=F/6$YI -^LD6@E%W4 5
M!P8ND.6]/,^?UX[L/!AXQ_*YK7*!H^+S9%H50QR08=T%BIG4-2:SKJ?,8LP=
MH_\;*PPFS;K>U!R(,>Y:D^.>H>4>APAD6@X*.!Q,IC6A):)'P;WK'-G%Q?6<
MZ$,V:F#JKZ_R;:H/=YA?+\HSMC5=VAB1?:@NHWFG'R>M9HOK%FD6:B2\)0-'
MUN%NRY$VAL1LZ=A=4)>Y$ODV,:@V1-^?N?QT 2EUSJO#Z\Q/)[F1TL^6B^9%
M\M,*KE;[$S&%-N=?JJ':9#W>8IL'.?(3+%YN&CHD@/L/+!X-TRV>IRP$ 8&#
M&1P823PU&^2-O'T^^[]W>_=>[\O1=-Y1C6/)6OTZ:PEP(NJXJ>@KN3,* ^16
MA=0.Y^=QYO2IWCEW'W2_UVCNK^8&^?'*4\,__YP^T5#H21=-']$P>7+?_$ 2
MS^]FN3\%P# D 3.5)!N\$]@KU!/?$;J(D_":F\\*Q>Z,N]^31'6(T6_VK'0J
M"_;7S"T[YWKFZA>$9D(U.X@PCVY861-AHT?9)P@31!G]7SC1FC'O;QNS1Z>,
M+Q<=J#9Q9]4[%)8YG+W$$R=<LW96[A[BAH#<GVZV-K'[(PJF3I3%14(N@#PR
MQ<'1&/Y]%K=BE.2H.1V6XK4%C,^WY?<<G=R422^>3G';8Z]Y\XZCT%>8B^MP
MY*98.K"]9T$/QRGRY3H5ZN#3N%LPHL,Z/J7#LBJAT>VCM'5G0(;J%\?%TT/F
M0U\K_^7%R/+\FI.#X9@C TM327AZ% PQ+M!>=!?U9ME>IG;RHD-SX<I)8#3'
M)*#AY<?R#.?C8?,['V<>.RKP[D;?_;/W]IZY2(XX)5042FH56O.DYZ:/ L0^
M<O-F#\.ROWYUKY].2EVG6LB+5=V8I7W>]X/N'=>Z.,0;]MD9(61*@2-; 8S2
M1I/#(0W\!3#K89Q;[Z2@44)=7)%'ZL#0Y[?J@XKY\3.NYI;/=N057A#2%(5L
MT;3FO]CL<MC2]] X2;I#7+<WDH95UFXWI01%O_"^+Q9<J;IPXY[%WZGO59Q=
MN]GGR(,D4'.T"\F/W^NGM<E +;P6.C.AYW>5,''QBOV'VQ+PBG5J?[&%^/U!
MZ'M1-Y5BS+K!+=?#-:.W:2HYV2HZ[/'QO,L>JA),^\>/"W-H!9Y>% >I>L0=
M9?[$2)^";=5\MSJ,3KZ):CJ]6C1F+YYV^U=>9)3NK6PY_?#60SHIIW@TRY(Z
MT\&[,*^.AZ.K!JER7-K!Z*I5JI05)C3H^N1X7'6OKW2FB]%0RV2^6<GRWLK;
MDHZ!Z:DJSVFV:J@GUSS>DZ7)M&>H^K1>[+02&MQ[BRSUW+3N5M2LEPON^5>E
M*W='U%YV.&MAU5*BHU\2]<<2 P(CNN34.["T(HX*G%'^&6X%^O(6@@<:) HT
MCRJ&0MI@<I6W3XC'I(VRN%^0)BN5$?8\8"-V\, 18[5S<^J'/ (#(QZ@XEVQ
M95N(9@^.RC?X(E7</'2(\^@,<7 >S;1IK G^F_$"?J4;(L48YD=?N<]J&@\O
M5[]AENT*&[]X>R?R?4T%90L1@ )U5];LV-&$L7D#[CWTI5P4-BX9"URZ8^IR
M'-(WR;98_O!V1ZCIZ_?'W]4$W4ZR2"[[R,,@BA"#1V?6%]?::M"\!$O0>*#N
MX;"*%R7.N5^^)&]B;G/-L[\C]XMQ_-4+9B+3T^S'[?LX)+B'QZO!E8'E2(P3
M0];342]&!^HRRO2:)^K63 TSB$#IUU.SRGR\JPW'6I+V3(SPB]6LZ"R=\-=N
MI\K#B9DD HY$4<Z.!G!1J \EOUK]-+35PB<WQ61T![%OP8X_HJ-(<&?@T4PD
MM;PFW[%]^N#A ?,NH6^[Y.AD  -#'6FM%0:= Z"\#1H:ZC1Z^?':$QREUWVB
MV=(XC/C(=U_U_1OI&;N]_2L$W0,N4'555&Z@,CO<Z&2^..QI9NOMYED?0\>Q
M->W.3]&6W_I.>7D?376ZE#=[R][^DEX<0N:PPM>Z89<H",D/>[B]>2FE"=C7
M;O:-.&!RUM]N(6ZU#'8[<?\=_C?^8<!+Y_)2F+R%#]K7M78:$;OMMQ#^F)O8
M>@:9\87)MYAZ7Z'G._< A0UWXG(G<U;)Y\2PA=84CW>%'N_Y_6(-E.-.Y9SA
MFPVN&T'.+$(2 ]M[LM 'LF(3.=GU.V0)1 \T/M'*N?\\;JKWU.RW!HS&E6RO
M8(-+^ZN-^/#/TE\-'[B=]Q=[6$!NPYPC>Q<2I;/EX.CNZ]A= =YE53.;.;&0
M>KQ#6H<AG6')*"DLKP_;"' <5M<,?6T;[Z.@A]!D^H;!Y;8,IS,%32M% 6ZY
M6>( BA:4SL$\ ,>=G9XW4<5!JIWSH>:#Y4=^WH]-#2F/@?$HL)?A?N&1:V9B
M0K^]["F>_Z(A],6!HVJT8.UV% Z#W>RWDAN.NR=M]();8F>%!+626+1PUH9:
M+K/?'!(3 F9/D2!Q3&Z/C2@L?6U!.^ OMO$(^>>WT,A*A8._'#^\^B5,2/M$
MIGU%PNCB!K)A-R^!)&YRP)126E+E!,<#)ZU-C ZZ2KI,O%"8?[Z3.,T)A=DB
MK; DK1<W6P0)DP!B[SQZ_,$DQW*!G.1>)L^T_R=MJ5W2L]2 =<#AB*](FLK3
M;V\>(+>AG <<[:/*$FES:)&OI$;?5_PVEF,<U$*MC*/ZN>X74Y,_N;6Q10*R
MA844W+]2+6<U+TPMI_639[TAB>/<1'08-HG$BP['45:7YPW3"7KCK!#*U:]%
M>7/39H_$.[ZN"[2X[1[Z+22DWEYK"(GDPN"&A+,L1C"(:X=I=9('E91!%NG
M$,(?M&;H&6Q>",MXWL1^[+2[_0R/4NB5RLR,5R_/302Q0N#/JL,3KZ!ICTBM
M"LG$<"0("X^^7OHN\^[KGW(>^CWV]?%T(>J93>E&%,:XFVG.3O>]OQ=[I^;?
M'T9#)X-YJ("GX<PF?9WA IO@R>$!I9A!1W+/ I.OZ#AD:=3Q^S8^C"8%I=+A
M+G"I(CUFO^)0_5+T\V1(8A70Z27-"+&T0'OV7F@8O8.#!M:[RBS AT]#.S7'
M\+J/'Y/\31G-E5(#([+[I,[\80\E"GZ5JB_@3]!GGX%-/DB\LIZ! JY2N['@
M'H4D2#RAE:YPJP,ED)N.]]Y"B,B7HF9TO,,\11,*G5/:[BZ_2@Q4]]OX3:]?
M1P&^AJ"6'AEPSYU^"DG&&?LVC%O%T\/\HJF\JQ9W#\Q:CP\PG4(L]^CEN2CG
MO>0].Z[=+6J+^#,*B7G_C[V+!/SV1K(*..P ^K&M06^[3Y T>'K"%2#?;F(H
M"3=[AON5R!7\,"@X6B3XQ3F#_W9WR>&N\*.Z3&P?<<:;18<G;^\A-Y$;X&"3
MDFP4.YB#F382X%V/I)7>W4>GE%KR0J.C L,T][_].6?:X0[8+=&+)P@?'*>O
M626PC8G=D]168I>X$"3BSS[,T1KO, >@@5!+E'3<%N)LYXMCY(:F:_L36GZ(
M%7O]/$@Y^*]87,>,EZD!=MET$\F114/"Z^Q+<3J02 % 9%V!C7$@3*CJ N0,
M&V'O>U\^-(W*ORWO7;Q5=*55^KQLGI^Y(,/KFE/N72C/(O] $\^?ND>P[9>)
M_M2<+81"AQAP%Q*KA@.3/G8MP:.K*$N\*K-#.8A(__Y:(:9O+OJ18(ZGW^F;
M[PB19_8=/SR24E>#IBT19S187W-9"Z Q#-HQW$R"B#<>.V8E3IL-M20AD7 Q
MAW>':BIXQ+I^'KZ0]NYE2XGEYS]YO!=#$[XLVGA[%$.PU&P8Y*@XP-.G[],'
MU]ZR@Z!^57[0@8X3"?U&?,YQ.)-ZR/9GB4@@'Z/QK8%K:>&\@/!/68.A9S4D
M+V+W>?)%]':E]Y"S_\/10NM S=A^&-;CBAS D <SW[SJNKAN_>OR]V/"7.G>
M%4&:P.Q<S>2/B\6QFD.NONJ>C8I",.P#)["@+I4C$\KZ"$?Q :C0CVI)X\@0
MG4 ?]E&7:-R#.+L%5$ISZ,MKDQ_?YA_T>S6QZ;"$T3@1-NDIT+MK;.!=.@_J
M@RE!GJ._753$;BR,-K58X"P6%N&M'AS9*I8G4-2-%,6K=$RL^Z<Y!!>N>^</
MK/G:X5Z<_XS9'=(CF'\LQR1]?ZYA*;7M# ]G !\!2J)##$$]'$>V@GX^1GOY
M"R005WUV@O'IZOC<MZDV^0K>/1"S\!-B4_V5(:A3-1A*!?>2&/?A_-&YN>L4
MYZ\$@9#-UNNKCE7#.<Z[3JZ?<GP?I\L2UW5VFRZ:96"KR/4HCHP0JP\,VP8=
M:(S84C6 N1D2"D0MZ-SZ76I^A*E2ICY1Y>/X^7/(E7KE<\^]EO>/S8Z^R]NC
MO-]1*VJ!!(23.))1K/?;'F__B1<?Q=QD58%HU5RZOD+/]<=Y !M>9K?NNG2$
MG0Q9?W#TI9379R<]-8J#D?H9.S9-0E@]\1 .-%7")D5 O:264&C\^C\Q1*0X
M@%7Y/)Q@W3!8N<L"]+FKWZXW!BV]W3C:8\O1--,=Q">PST)#V_=H)%W#7^*6
MD6EY6, .(_6=+"KC./F\PX$YN["KP8F;*<^G690WJA=EZ8Q3TKLS,'7QJ-3#
MGV\U/3Z2 <=U4%V!,4A#@MJ;C 3V+N@C%>D'1M5R+IW)ZO8HLMG]XN/NO,GY
MQ8#\4IOX=Y$9)VQ[_5H:P]PRF74S4:Q#<$O]YQ=Z6KF/#-C/&;). T%)'+XH
M^3H!& 1&;IQM";E_LBW?Z8>>_E+JM_&H*(VW2F^_2%<?VC&&T#PLX4"'*F[
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M$L'O0%$OX2#3MY[)PT$G1"TPU,6=)C#R9IL2#\[K,F2<H_?>6=PL._U#)W@
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M/<//I=2-D007?"#\-=]?)0U"$J>X*<_7M<^50^/ LS\Y$:]L]O[#0WJ**O6
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M>[G_7$/U0,69MUG,]76.>3M>OQ/1D+$_L*4.^.=#(D*NE(T"Q&SQ+!;:EBY
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MO/7Q>=_7AK>5]36&>]Z5(Z:4'*6*Z#8&_!$T>&(I"]Y#7R9P+G=,^3!D&Y(
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M I98_4*( +'Q(ZN,<:<+"7D($), ^):_R98.+"PM -6 WY_XA&;".+?/@C]
MT,;S*AG14TWG.0D(/ 9H@TF7WT?G [R7-H87 *66'=C8D3[V"996&1A)=6UY
MJ84]-% 2/:SWYIP3\C+X96)"'''BM7><W]<=R@L M!W)53";9!N#TRE@(TTY
MZ0FLR=WHC#MRP80-?-4QC9YG4TD_?:=D',87#)=UB@)VK'LNE&Y0C(+C%GF
MK,T]!-$8%,B3 -X$VK]!E9$,;!7@EW"+@_I4EXRL"OOYF&-OG3T=IOUIX:)*
MSQ\B8X8KRV&#+")70:^+ AY#CS?R)4:19$V_SGBIDI2R'Y'\OE7L=8+= ',
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M&FP0Y -BYDUB5BYL&FQ'K2"-S=3KX0)&V*] 0^NPB!\AH2U]#],H<X_6U-K
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MZA@2PCZR<@(</<4QL&Z]->GS;LGD6I7H_-6M@JCMPPVY84Z(Q@@?D)Q'@OC
MG_EH2\!0Y@//K'&CUA-L2FM .K/Z0V1$'%KB0('18$SE>3B;LW\B>-2<&?U"
M?>R616M#0SM>XD!5U=#MTD-#1Y);4KW??MRRZQH'JYO0@-QTM<$D(VA7'N?.
M!\X9IF)+N](Y.J1>*G1<&O2"J#%;$JT5YK+(,OX68<GR)>X94X)7,GP=OY39
MR0:5A!77>]ZME'D&TI^#T'X95=(8'U"UQI!&:&5D9O1S[@9XF;Y![O(SUF!R
M?DF"1Y4 3)C./2$B$APC%BF0>C9QH'\;[C.JZE(K>Q,J =%:ABC,RR7M))KR
M7I%,YG&J5J&<_6-6&$5BU(O]H8495A]9R7X_#WW3OG2@+[+XTXG]*7<%E$3C
MB3O0R7Z(E5,Q<0^\FW,$S? C5LXL&78T[#)U>I"H#KTE7!X]L)#28AD98&XX
MT_*R4^.8D5Q-LFP<R6%!&O7P!!J8N] HV\CUX!7S@5"*"%B_C^I/'@MVA359
MEHWOQ3Y7[#DR9FO>%GY6JNY@C+.&MMRXH[I6O*-*P/A6)]0U]68@_?HHGJO0
MP2Z!"SE_?<=69'U@Z7'=H"*+L^_.3.7*J/P\86*KS_RU3 L"RTV7BGI#?F;Z
MW3/X.O*N%GD2@]U*]<?!YJ+3X$(!Y#!-6[A#@UQ?.[C#1UFX>HO:&PQ0RIFQ
M6]54MWII#>JH#I4QY=V%!_SDE)QCG9OC'-K)SG ''Q"!N<;PGTV#^W H>AYD
M@:VOAKFVT-UF6FRM;E"MAJQS*%'[?LJM ':\]5'M9B_-7;OWGZ<_I_1(H%ZP
M9:.I'2M(/ COX9SP0B8PD*O+V ,?WF.K:'1-Z8Y'\-9S;.-F_-/1-L4WU67.
M5FFZ*T>[E&SLW/,<UR[[=7RQED<=X65M23!G%#89#O<UH,GMAO9)09BRPN1%
MO)F384*EAMR-XOA'K&OGPGZHX6FVBNG>5B6M,_H?8]9HGEU++2D_+/KUSWX+
MG<8\VH+VA N9'.OO*.*O)^$7RJ85!_N\DQF3HHFG4G]:WF36D)DROXSE-Z>T
MU88\K.U9#OX5?=?WH$6L6+W0>3M]10&8QC)$I"_ /*AZ6B>%B(HBU(1J^!1N
MI ?$6D5?79HG"??E?TBU/#R3F+0[Y =#H>7:Q"GYC83/S"7US:^^D4=L$6F(
METX-P,!;JE)1AO40V3KTVT7%FWM4^@)+L*6L+FLH.[OCS9B/=^M]98$0EH.V
M4=D!P?BSAA^N<2:3 &X:K(!ZI9=+*H4?0&7VO%(LO1#9#!= $70290,?:$Q+
M$']DEBIE=TC.>=O;S) #<OZC@F3=RQ?*#[;4H$1'!H5(G:$F0UA?P?L/,Q:$
M,SGKB9=[N/I!F)LDG=9\;2^5)-/EDEL,@N'C_M"OL?C-M_*M[CGLK#W1<-@$
M^3:4BO3C(!?R<"9[\%W?;YG1,K8?%)&*-[V7XA667_Q-;-F]1_YX4V:QMES6
MYLJPL;P+.0#W#_M<0_I(EB!9D#Y3H<.8>&R92[,^S@T.F'(1(@,$<"JUF (:
M/-;GFK_I>&$]C1G]$N#QSD]54%SEAZA/] 3*1>N%L16HO1(L7+ARF8A:60?2
MT:\VCR@[<#>^6[I$Z7S%1+HYY\>0ZK;N49D)6NH5F4H20.JD N 9EX3;7!W>
M@UH90E2]QOKX*[F7TZ2_71AM6-HA4' ^1E7;[Z5DB=Z5E#SA*_T"4 (3;1:$
M_D)Q]CWLR=$GFJ*?[J'8&H6H%A[N+:Y%$4DL8!3%3"V.HO*%T!'V1Z25NG"_
MZUOERKW&T+89$+\(:U8U\X$46F5N-U<1;1GG.1>_TP!D*R'.QEF]U60TD ^$
ME _I#V@EGO;3=LX08UR7;?_>(O8P,NS&V*^SJ)._0"Y<]4YZF@!8O\D:!;)Z
M8U/LJ+_;@R:L4D6@69H:T7W05"M2>S46Y^5K4I#^;M^F3?T;;7>']M:D?#K^
M.IQ<)<.5LT3431#QO1 %$8]#<\T(%9O&U=V#;=Q)A1Z"#:KL;J;APBVC(O/H
M-&9ZI'78HHG&I866<>HDI7KND4P7!=Y.YLK.3Y&9;2P\?8BY@6-*&C6GB=5N
M(F[^[+T_KNG*>]-,J\&B73D*BJP:^>*5>M]/Q67^NE7ZJ](,7\,CG[F&S^;>
M=U6NYL[D7M_A^_V(0TEQP7Z)WKL=H7I[0TY/[W'QHMH!BJ[_=4/I$S%XX#=6
MAJO&"J,^F=Q3,9,6;_A#WT +:WJDH":E:$\]@"CU#6ER]H%M@JQ67N(J&<EH
ML\%THV51 5M'@RZT<I44V';]*'MUB:%![F.WC"XORI[XIIRGSMH\]G0H8N?G
M1@.KIDI"#Z[+3?BMT'KZ)5PDZBQ)++VRD)WTIWV&X]AH2Q*;RG7[7+/[)=>0
MA59LC6VLVI>;2BO[E?=?8QILD7N>NOM^X8XW=A*=LGXB/T6_>G!EI]F6Z*Q?
M2"_X9NUK#%>!RF9#AHV&UU<34GYOP![[_#OR:=Q13E#L&--<SGEMY@6]J/S
MV#MO[877K@G'_@76.Z")DF6MCJYQ )7G#566&A"%4S=,Y-H5$99LAXAGIM:]
M3C'RQ76\.-Y<JGC*\V3JUE-VXQ>;+&\7M,?(#*+S0.@PVD=ELM/@_*FT6#X@
MB W"21'(3;62?<W+2:83!A"5'?UNN]0M35=5B4\O.<=70J[4]C5?Q(E1Z6_(
MT"'#-*QZ-OLBO)<3"LN<8-T9VC+:<:!L@.2]$@^&!UMNC?_6M599Y>*%.K.5
M2QPBZ2,HC*7G4*'0O7 N9RO1)*W1>C=,@9;J+;#-F'4CXY_PX4Y194K-]/3[
M(ZYGLX).^3T27#^VV\UF!Y;^&@,=3!O68A]'2P6I5H,T@"D;:N29-Y+EB5J%
ML.WQ'F33W%*Y5UYU!'&P(2(K/*2CNCOJ#H#,-=2>:!:2E3F$SKL)T@L0LRI>
M-2(-UEN1A,!Z^S&Z>X+^EU)B *LPP?!0! F3X2J5]>3;=,8V.2&ITW)Z-TNC
M'SME*%U8!$NI:21MH@B/2O&>]N J!S1091%U@CD;7S)@1A$^]_YI^O>4C;V_
M5HJMCEX2OY6Q=;.K69MUU%WO@K8P9Z(+YQ)1$C;D' #KO:GT/+1U&H$L;6H&
MK/<0K7K-TE*4L[T(8Y03'U(V\EX0)EW=_ 53A 0KHK!H-&"DPA=A2\RT2MV>
M@+K5Z.XX0_#,1R(V@O'.3Z375_]7I\;(:U7+II-;C*D3NQ[)/*+2;V @+S(<
M.92,&*#(BU8!L1%"7F-K=@)C\=KE?<K'H.::G1^K_"I/T$U+Y7^6U <TO-PJ
M@3V@RXI I.50'B4R3,!-#[5*8F^,6I$,/M>:?)]4[^'NRWKDZQ4D(NDIG8$-
MK'H>6ON$&OC\?^2A5Q%X\P3:4EU?JK.8O8;0V"[,7(VOK<P3'O>_K/281K&_
MA+4L3&OM:K$+04GJ5K!>':3?PT+?L",:LW_"YP9*2B0%F1H[/@R!52!##6D?
M8]]\/?V3F%8^'H!/S^6LT&[EK_^%@=S1UH_&M>(#[,TLS,(E=!8>D07A V;2
M%O.(/'9!AHG56JBZX!/*P9)%>),GQE?B5+O6&N$<>FPT,"PL6PIV8,W_X48)
M1.+EK-!+#<L:@F^@R<?/O9KT"P/*XY7BV4I;]BJ^,)7KBLF6F'NT",PN@8QE
MKMH'5K+W0,T&R)M=C29I =PZY;*P#"T==^(#4L0MH0;!9^X?KLK&:U6,)TIL
M-W%XIW3/_J?>"7MNV@A*QZ:IHWV(N%$ !T6(_=@ /C#6^A=,4XD/183LM,\3
M#&3$DZ\/I#\L?3DN>:_Y^>%],9MN^UWY=@0V1\0=T>J1S55V:B9#[MTP#H=6
ML.OY#"YI'6HT$/VNLKLL)+X+6QY=S70@D=IR\_;Q@:*6Q6R=^564!J(EZ#Y:
M4^W@ ?0\S*M$-A(#(!RS%7Q%Q+!2"U]\/\_5"54^D,W,#GN]OJ^-':?>ML8P
M:[/<5SO![;E4NZU/8B3^.X?#Y5M2&3O<7+-.G0<**(:\J@IF0 .M)*)Y40&^
MZ)%VN(^D,K_LOC8FRS._K_"RUH9E 1M,+ECBP3S*L4<FR&6&S'J46(E6\%[_
M0#"PM^?@;XPT47+ C'>64.XB$I3CEJ7B=?R.15.?*<O1])IJ51W]0OUJ(]N"
M][I6A0OP8A&)/_S4G,F@=Z^;/V$DZ-AGO7E+D3,YN4+G;?:I,4?MP-.G=MS;
M7O.8<@WKYZQRL!=%^T^4=;0@CA73B9'0)/F F4OL0:UZ:Q+Q<4764>Z >,K:
M49B*2-/0J(DB_+4:>2KN&'R-[5APC?U>.^.$YO:H'=*WHP,%EQ/H(%=)!Q&?
MX1PD7N['GB5?PU308KFNT[?,NY8N2QL>G5Q:V6W,R_TH-Q$B\6G2R7K@2&N,
M<U1$8HWC(]BD\6I"BI7;R\:3!=_<C2?/>0P95EI&$6[79!@MO'SI:!U+E</2
M"\@ELPN-' FP_@)()_NS]\)::-HEI,];ZR"?!J:@VKS*5]%2YEFW=;O+1()2
M/(YJ?>(\O;UCLO,:CH*K7.3>!YL7.9O1QAMY4/A(1H^%X2I3$7$LPQ(O,3E/
MJZ(TOO5C%2\Q.JX/$C_^D-/)F"BX8K=I4M/T2.O73Z[F]M,1[1?ZJ5PE443\
M![F<BRU)Y!77*)*VC/ML+K=6]#VFZC73XC[4*=C.L3TM(,('3#, G]NZ*PAL
MQI$DM:\F<-4<68;LVGZ25* Y3J$[1>M=&:MS\F'&=_=M,C?U0FY\J%DP;Y2T
MZ7UE_U17]?X]>8$-%"8?X"B2.LEEHESY*$1\EG. J *[/0W$R1(=IBABW_,T
M6<7DT^G?KSY=S7J8\_#UI?.B]ZT[8I[M6=CO=W)-7!+ NTAE85H$T*!J*87:
MP7H;*T-,;'=#HR[2U7HDD^/E_;H4;/IL^V7AY_L-DV=)1YN) AQ=M(3Q@3!#
M-;#> $M_1%['/<HY"&=PFC%25D&1073I<Y&?.Q\WE+XY%L.L ];2ATJ#L3_?
MYF7R@;.3M%6A 5;"@B\?V(HV?;&/P!$;*A_HZ;3!A(X0K_)>D+8C];0WV.8'
M9'C;E1L0]00KK*# !_[&]7]I98Z5'?A222MLG*F;<GRH[%OH]ZDQC\ 3XKVF
MXLG#8VPYZ'="(C68/(IIS!.I&CA]N??Q0/']8GR2?V3\Y.;( K?QZONR-\;?
M:9WO1L."Z8K*@/HZ=C\?&+'Y3/V5_Q?E'(S"*A=M=6(S4'+32RYWN4$-PPH/
M$_H<8$?H1Y>,  '3Y#1[O%G,>3=Q6O#"=L%(J['C2DN&$?[;[P&\8-B)<Q+I
M(&M8"TZ0^JBB:'.);R()O"E_]Z[?RK7@N^[FBH=76/=UEM*.>YFJWU^ON[5>
M*_W$GT>5L#Z>*Y]0EX.[84951"9Q,J$+W-#U&?"Y&3/0S.!)ZE=OC_LIYR;W
M[R.<3>O,/A66V+)X9_IG/CL,,D^@^KO V]*XBM5L$=Y#H4JRF";O@1E9WCOP
M@H]IUONP M[=,YL:-::NA"#]'ZY+S8:(%5J*6%6QO5$M(TD?$5V4H_Q%TB8-
M3&Z$-1D\VRF?UF,#(=P+T7ZEYZY>*!G($GM<^78W0=.H:2Q_W_.O 7KJI@(<
M-.SL22-@:=5".E1,F\8S-5GSC2?DH-<+Z:V%P1;/GCRQG+ULD!BF<,G'9*.!
M\HZFY_HI:X)EV"=Y[['^,O!6E]B*:O*("3NCAW@F.$!FI"*3T7G0*8JWZU"1
MW.A.\3WO0G:V210?W%"X_0(\Q'%&FC&55*8+"O%_'C)'(T-@&:9A<2W1MP8V
MI^]*?0&]:G&UBPA];0^-K.@L7')4HVUJ/3-3(S$9;-!Y[<WP+]3 &].8KIR-
M*%!)X*9=! A+B'@$R-F!].;08G,-RS\8>#.Q^_M#3N[\Z:QXU2I9ZHIQU=WU
MTT:.-79:B<=*/(#5*D1,@'.<>!9^!5&FAA8".*Y$F_X:-Y8E&P^_>D%P\F%M
MJ;C<-QFL=LGGKQ!\0'I;P-F?Q?Y2I)][5=NT<W@ I0T58HMM&]HC[XY@ST.X
MA!E!1RJTG/!;MS^%^&QQ@8W/<%"/\_6)^D*^RO-[M"9IZW_]*".>83BKM.;)
M#A"EIYS\=^:^#BH;IC6L-:\W#56G3!79!:%D)HT,[5\<Z3L!=Z+V3^<5H"4A
M&2MG=0&MS4/)UAC"4K.U0'^X?9]T3UD9]>CFVD?ZG])72MJT?$L-?J]]<7MX
M-\471AL?$=0+#9.\:]@ S# >45OD8!%53K-X$=B )J*8Z />ATI'<CO'?&QH
M@3I_H;HS^\>OV;0:KB;'BJ@ B;;(*!-)D$=CM/DA5EHJHS2YQ8+WT$YG4+G+
M9 .%')=@]'A[D;V-=H#2R&?1CY@J\,\^L'H >XJ7BPVAH:P"2D'O?HTEE$/F
M:H%0<G05)RJ\LPC!C5H/J(Q<8(=6U[PC(1=:9-""IUZ+=C<-7V!#-"^O8\>P
M(U3H+@%WN(</E).Z9Z.SF3M[]WY=B<HF37 J?_A,JZIVABL>%IU-N(8:)I8,
MQ8/U\C5HER2$<K?X(HX+5ULMSA=L0+OVZRH!Z;E>T@[X8>OQ"#[P_.<2^]IR
ME?^M0G]V'1K6&#[0Z$%JQ)4%+)Q$NVI+'KJ@U.\+C#:0H8U.UF7BQE"D\O(K
M:1U!QC CQ/%(\OSFD642^ $7U6.#T3Z!0I8>,H)">>*?%X)*P89?8VQ<_&P#
M",6 #4:Y(VNM^]B+Y:QE/C"PLJ'V-Z&U'H3-IQ$ET850SF%2&Q8:I(UBH5[K
MC>2CZ/WB$%E#'42.9M0127(8&V,2NLPC;\]^]IC[K2BPPF =1<2VH>34A!W-
M2[<60D5WCTY&5+V;E"W(; IW8VT =S/F;,8$EZK+[&#K3]J;AY'55]=?[(:W
M97-E7S7C*G!,WV>HQ#9\X)3AF((W+,EZ1COH;.(S5/[ /(?F4[E?3O..@UY8
MAEAL2]/*S6^*!_V%S3WF[BH*0#H+*$(+;8' A0L<4V(PI),$!OKB6JG*).R<
MUZV$)IGD'/;#;A.S@1J68;9@5]?'M O:E/>A2[L[C&.2LJVET;LJ4!E'P'H5
M,S0GM3%<TU9V OLK^:47ZO=&5'63]I_6(\2AJ-IZ=LM$V95/T8_"6BY:>$S\
M.BSZM; 5G6.>9)B(*:4ML.@NUW&5:RET, 57]M<MI818DOXW:\QHU<T"SZQ@
MPW+YF/<B/H?&S ^L.U#L_IX*ZSAPY2*FJA:^<?S.T:##BV,4=G]_K07Q5 W4
M\]DT]"]G8=,Q?;4F^HY4LRN3,WL/'[-/VIS]Y6ST]*\UCP8N=VS .[WKJ=AU
M*&OHRJ)TT\GV'PY'BHR?RMUVV1AG@[D'0OCN^*?P(N<H,@)"1Z^X6#K ^:P\
MO QA[>\$+O&;FM.GY NJ/S+T!N?S[.?/"CZF]%O,6(L1I6!;CAE7OY<D3A2!
MHYX1/!JN*AYQ>!IHL5_#]\/+FC0T\-S3)]IV;[Z7V59<_-_+E_\_.8H#I@V;
M</ QLJ09+1$<Y@.CF.'WER:BDYD:'KE5< 0SE.J#*0 N]WLT42&8NEKEPJVF
M<C+28"*.YUV(^-)X;2C=<<7)HUF#8LSW">S/'WS@QT$L@P7^#B.O1(#+FX'H
M"CLBVGK))/.!5Y?Y0 ?:E+W;BI)9%$<&WH,S$WQ@_(X >T")9<BU-D1>]_$!
M@T7D"^4I'SA#'A5%U+P9I[CH_.M.')4K^6:4X5H:F_P[BA2*>(5/]*WW?PU<
MW:/H:B/\9RA](O"!*0?NQJ&=@WQ@F':.LS]DA&/?^78C>'GV]24:]!G\C=[Z
M"Q_@ \&/9 X\J:$A:C)( 89+1FG49;!Q+Q_HS^<#*,'C%<?LV92T!,*!V-4[
MX$^T?ZM <5-:E \<24/0^LU^#_Q*TD4+">,1JC@*_&A51(:.>'&)'.=/5_@
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MMY%NC!PUD#+R<\P)WN>7V32IPC(CW[SLK5[HELH.#K]KE8&;:?,\?FOX2+O
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M6;%\/@GZU9QKK[99_TQ2J3WO =L&]@=9:),;P#"\\1Y_BU*SVZ"*D55IT?6
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MSD9N'IP+SH,=^(!V82.&;>@)SETOCO^7O4*H.Y'\<\]WW.]Q<&[3AZX:DZD
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MRUBA73ZE_4"+K=SGG!(T5)4@'22I"S5WG"(?4%M]\$\L'X"HZ=)=>$JYHGQ
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M,MU-!L)'!/A5(+FK=LXEK;I0JS1DSMG]\CN&0O-?&VYESR>N>7_DNH?BX-&
M8@(#:%*DDR>*.;$D!C-EM(0D.MOSL3^]['%T25+07+#[ ZQQUJ?.;Y.9VX_O
MX52:[?O\.B@H<"GW?YOI4)3833:%40$B?5@!O%E^?A07HXZ+9J 5&UT#&]O,
MNV_2]8;Y-F7VP7-%>RW.?*\Z>QS/B'YP5NUIH#+BI[+E)U0>&CR*@2M(F1;I
MHT]X Z@M(R*8F8"6) C\REVD94E.A8$3>Z[_>N;W*3YKU(?UO:SMQ^NIJ[N>
M I>JC$^NHI 5)081CYQ[TB$U&KB/-J$%C>-=G$3@32@D5OK0L6PG59<=(<;>
MF=%+R>[OG>14Q_4@"#<',.OP43"$\'#1'&8&P4#R.Q8R+Q:8\- ;\7^"6NW6
MJ1WN&\$M;;V-#\<]+\<^"OFZ^S)%-8OKU7%V]9Z^,[P6U!A#IJ()RHG:(6Z\
MV :7RF'V8%,!K5.#=X_4@<A>FL(]C66$?]UNXO-ZZ4RFBZV?\QHC!X5M.1UR
M7_?_V_X9BKNT$HC4]QGW$5T2$@7&_TAV"G6SK5IU'[ZJ/.>"3#-./[@K*;!F
MJ-7"K;9L X]MH4"WU%?X,.:WZK-C !F_0UHA4Y0<D=[^09M0Z0IU:? ALB@W
M=+O[*"=>:KC&NK[\/E-PWJ<HS&/J=*EO?LK,QE]'852\N*8>)':P#62Z\ <;
MVCF2 13'4RMT_^?^%,Z9.]GXR]NQ&;>YZ$(QT/R],W' PK7$W+-#=:O<_ M+
MSL)8I4R%RF5/4+K;UQ&YL%Y/$-UM (MSL27L0]"=I]#J#[@KD[XSN9^*ONDW
M:^VMVR.LWQJSW:3"J0_"RM1LP(0\Q\IEA!Y^Y=AN &&TU!JLOOMT:LR'QUZ+
MMZ(./S.-]II28NW<W&;\WM!9\8'^H8NI'J@RQY6DQ32A.Y 379P=Q>*]LOY2
M.Q<&T6FG:4JW2*#P/NV#9\Q(\79:O^H 5;6\8MO_-6'_ZPN?#)?F$I3&8Z:C
M0$\D2ZXG5+F]B"65J+& >TK&12I]MV-FZ0:D#TPC9LSH *K>O).]6K)>>L]-
M!4SE%I&QT2LG;G'>/D,-&56'MR6N#WEH>9%NM89W%9877OVHAE&^E&/+:A%=
M%9;S1X7N2B@/(2.]^D?LP?M&WEIQW:\^]1[RR%=2*Z_?7/K^%U&HV(T&+Z+H
MZ'%:%U!#Z\*,IQX=E5P$8:2I2>V@-:!26J,?,LIP9.\&__2MBU5HOR.F^]]I
M?Q^]Y/I*HPZ=@%A$0F9$OA3$])(;% 4MX@T0DRLKIN =P%G!IG+<W5W@QQG]
M9_Q&_3[+V%W',E=U6@4<[IW+3O/?M.9<<3<F"ZV//PM'9 ;2CA?'2M8\AXYP
MEA%*7=,G'$3Q(\_BLY-/(PW.C1;QIL)IS],8HC!W\MH2?>?<;%?UL^&'&WME
MO;3Z"(G6W@G1&N@+*.[T-[2!XL2AJ!S!]#)B XZ$28EM0&Z<TPBU$HY_&<UW
M-64=']G1=\[#<N;ES&]_F@94[.:2)]@K"PPG)*K"<H&*6&T.M<I]$WZM<$^I
MW0BY6V9;,]R(5(=28DVI3?6U(>8GFVH=F29,LX%MG*U^.Q%2K?_#L2^EW?V+
M"*V-YO!(*:'R0M:6M[? [Z($H7D.WB+BPH.R$^&S?M2A1[<M."^;/OPS4VUO
M-]+^BT("..6H.EW!EFE,)AINR5A@;->FC0O3SO3L[,]5$DN>"CTZ;-IZ]9*3
M]^3F(*;ZZRNF-_?/GKETYN\S]M<<9"J_P*^=Z/4 YR;:@)@UO:>X:PH)J'].
M&)^P+GI\:O/Q"6]-,*SP38[91Z-\$]N]1HM7E*:3+471@P 6FX*N(Q0*=>&(
M91&TH"N#O-=8]:X'?96=/+TI)6R$_[[3:=4VYBHU198U)VM,OH>(OI-D*F7B
M2TR>&*,GZX;1=)/8Y2MMS!X?"OFWF[V+SST?$F+9<J4MM6OOQ.OG-_L-MDQN
MNKV_1Q1V(4?:(BSDP90!*4J2ECFBX$0-E]Z3A BS.0EY[3I1([IHQ6>-22=,
M_,%#E>OMZ8G:55\WQQ0I^2L]5'R3.]UW(67?F@2)_L(S1H4$ 76PU4W:!]MM
MYS -MIF-[+Q0U?:AD3%<='<"4RLW(D8G:,\($.%])8OCJE373W^)2AI]20;W
M8\>)H@SH;**0)*J75KN9E^-">.8,-JH\(QXI%Q7\$./)O>?"&G'U5M&S"9-.
M]G1VYPR^0KWLZ779N#3_[]L3)9]AD&%%N5M)TPG&.%V92C;HW 73R*.0[UJ0
MV6N+_.-"#4H39R^+)YT*^_FXL;7 XO0F!^/PWW*4I;J4(C2G"5-/[ 58LS*E
MB\($49RT%*\/IS\RI]6W;)S^()+-VC%"CLIWT@^ZG4BU]]0X_=MDW7S9QXZ9
M:QXP&9//E>:WQHF=96]'V=JT2.\,BLP1'S4R(Z3U3/KN'*^87/?NR\#?]YI$
M%[2H>^3O6QH?4.Q)?$^5/)M.6D:$&\<N(_YYM/@31:R*J'UG%5-=-FZUXZ)I
M]LT+=(2)25[CMVY4O7/O#/R"<R<(X^LX?^.="T4'4NF9/+3 \GQ\C]!MM'>(
M+XN )9OAF[K$4LRMMY/B]F $1V:VC'C]$J4"\(?=8&98WA?\&*[PUB''!67\
M26EFN]OGK44RFT%:#%H5%^$S'(9A;[(,RIIC^S7)Q]7M>YA#C?%D'G^/A+:B
MKJU8%\$WXCPE(X'SY+$A$5P8:=-E<-05G&S7SBUA)=;6)EWH\.;FX8(9]!W\
M&^:-C NUVJXRT&2-+1$MA^8\1H&^Z F8CPI@SJZP3GH;[PJ:<ZD= K]9#,QD
M+&U1$[ABOU')7K!!YR<UP/_D'P8ZKYFFYU:WB^BJS_8C"!F^_[)Z=L3&6K!@
M/=/0DK(EZZB%E=_6L_$F\NHXH[SAI:UR0M= :3$ZDBDO&PXU@@4_MG6=HPA8
M1=B,*T5G+@&9UHOK"C_3U QY7O& VIY5ZPREOL9-N>G3'R?WOU5^Z2%]!+*)
MCBA%W)6N3G?M <$/@>W^NBSFP2$^;WU7+%9#/L_4M_/ITS3$!<3J]B"A(K]?
M^$(L4TGCTB96C])=VS<%$MZ4$&_,2_Z4/HYQ:SM]\*I^0Y-X9R%S9XJ>A*Z7
M$Z:0>A$3]$ZQ$P7&T"3W9SF>TM1%FA0]YPC0GY._Y62CQ-L,G981P^E++4S(
MF 3?OT7D D__,8D93*(C%U86S'=.^ZB.SV561])8_J/D\*C&I(D,QKUHTWSW
MTR4[?FVJ;5&45W??(TUU6_$D> L/OBIC)F#J&*DT3F;1E./UT=ZKLL=/<"/?
M121PGJPUP)Y+T+W8,H[<X5%AAB YQ*T:\.I _+2%S,SNE.-WPN.;"&PXT24:
MF='<)(PN3K-'/>JFS=C]]XVY:E&+%@@#;-&^L'S:E-XBFA#P&@/NIXW1I@/X
M3"XZ V- BX81D%7>2\Z5.<$@M1M0*XY%>ZMHT,\^FG"0#.Z.7BU0O93@FOMV
M=>U2TW]S7_(*7C]#-28(R&+T5[8<83VARPO\Z'9*F,1SE!GH IK/;".&JO(=
MOV:WS?(OF6;%J=G++?:Z7D/65%"R"8JX!)D:K*+2BL_0&DC=I'$+O*&HN++B
M%:<*V7WIG.^!6#,=BL;Q%WOFJ'O7Y ?]U;#+X]F&ZSO@<KB# 7VQZH1!6CTC
M;QX=8[E.D8[2AN]7Z/>.X/Q%YP#X92FFZ(G7D</$MPD7SSH]S?3;>UHI[[A&
M90EB:2I+P@9G)=I,$>T]<*H9B!%CKKU0$,SVTG)&2E6EA:W(>&Q<V);)7$$7
M_=0_T4<:\HZ=W5?^PG+C7GG?^^LR=Y??QRNOF#IQ'@#RZ/,^JPD]:- O&<DU
MJZ!M:'6M9.,=A.3.M4[Z@67#ERO\>.*#K51:T5X3_L(GAKVV8KAR@4_1JI\*
MVB!:L'(&[@GXGB31HG%M)9I#HI-##X0[APDFWO?Q8<+$FJ(3Z#_NQ-@\.6BH
M-_QTQ_U@C6^J-6G&9[:=N/M:S/OWF;#\'K^,.(>";!0%=G 33X1"Q!KG8-VR
MHY##O.'N3NPJFN5=R:^^MY=+]J&V3 6_]L]E+&2\51<.-8]*']*BD9 52J+Y
M771X"#BWP/KN!1E/KT-WP@+7&N!&1[&5+Q\\WDB[;AZ""UT:GGQ3;1L[OS$@
M?JNPX= C_K</-Y'O7EA^1$(6BA(MW6YR_3*B T#TB#<%11HZ095"9G?P%2+H
MX]T><?<0S=G8_.X1\JOXN#!L9'!$?N"J%U8W]9VZ\4'29P#G,1NFRM%D+5D/
MJL;F%I@^(N8JWK@<PLQBKR=LBRJY&Q0ZMW2KA1D;5CX^?F"35@_J[V]N!3$:
M\KT?UW@@FRLHS%Q+F8J#<,6VC^Q"Z4D.X*C]Q6[0N26LDBF1B3I7*^]M6V"0
MH[W/[*M&,D4F!ME7+B6L?5^8:+0OB3P>)VJ3MA ,9>-+ -\2GAD+<+9++YYL
M@#-;Z&:KMF+!4E=QLNOA'?:[2O)N_=[VHV"_S69-AOW+1R9[$E?5(13'A_^5
MY ; <HN^'\8+0\)+3(U/#XD5QTW.NQ/'0\E!]@O^ X+%NPE%@UZ\XQ6W3"Z'
M^QS6\VG#MW"::9Q9'P.<JY>P^@Y,1,:*+&/##EP735G\ +05]Q0YY>\^E?%2
MU>'ZWJ1WBI]O:7\SIU,FBJ>)Z? +5Q#@PKA^13;R(B"=SQN1V"IFMZ_&D7;5
ME4S&"^SL2W)S9#&#BJU-?YV19X5J12EOM?R[:<7M$R?N)C<5]_:CZ,&'\M@(
M(!R+./Y!$BC$B"Y3-Z8_YEVF)C$&^9O" Z^S6$^^?,OK]*M5;TD]K#C^(^"C
M=!DAT9J6*0^!&!$6+)9HJXCN0':@'U.4+-PTE9_,0\I%:LY%]+3K@?.5;NHL
M3-N'NN2BN<OB QK>RMU_NP_4I%OPEQ%@, JR0EX'.'=0<O$GS#M<KD*4Z4.5
MW.PJ;WJI$K6^:":8M=? ^QGF6>#VL3]JQ^KM[P0[;,PGXCK<QQ_6N&OABGV%
MY9T+ZW",P,">J:K[05,GUAY]JK0E95/3]4-K CEG1J3_HCXP*YMLX8Y\C@*M
MG&Y G\>FT6H#))HCV-2F$E*NFUPUCG1LF& 3]>*O=YO'CH=XUNVHN6E?8..B
M=?+B< )"G)4%$>E7 8G!SD>X (8+N8>B0W@=G"NEI5#"0052JF,LOHV1L9Z7
M%'F^?=0JTOI,;D3FG>/V;ODTXR ?;[$30 \AJ.)]X-@']L-IM@6B4KMN0IY=
M5 "L;T4W/%IR;PL35_;;A=V<UW#J.)9FL!#_/-6M#9$<]R<AP6ME.S@\],Z8
M["VJ_F?*/$$)_SM15"!]$I^\?Z$K6(T2FQQ['V>YJZE)?+E@+N1L='9V1JPA
M&W]N0*?HBL<J4K2(7 \#CKFH&#HH_D/B([T)YT[YDD^7V$<#I\+=C3\\(,&"
M[:[/?[2%==;V;VF;>!6;:-*'O8AU3-HW=:QK1@'A<"VYY4]"!.0L4TZ%?XXS
MB.E:2">#AVU9J9R$SBI+$18JYQW<]N[S1M.?\.3>@AR\1LSSUID?:W]>M#OZ
M4MH3JH.G0>1K\X/WU>G @?^F$?A;-F0SFM;NA)N &UPB%S,^RJLJONX6FR0<
M%+C]SFOSW'UP_SH7+-]U\$Q2@'&X@IS-H.<4\YQ4@Z(N?0J$8: H<BY:CK =
MZ&3(NN'68R=<C84Y4000)BT7A[T9FK>2,3\EOA+A$\4_!86N5P2S1G(D:18!
M =!]"=KX(S"9$\<"= ^)K1#368@CA"2CNUZ8=V:?4 Y)]F#*>5X^OSG_SOO3
M7M/?7M(=ULA6_>>VO[/ Z5>28W"L+"$TEYT&P^I"*^JA;,S."Q1/R\A/+(Y4
M?PE&%S[UW+;=B'%)5--_\NRL>A]5WSM=&D%9*ZU G\9"42A6' <ET%\Y 2?6
MEVD!64XGPL3Z8GT!>@(3.\1BOO[>.B/>T3_Q,Z;PR@[NU7>*CZ'R'O2:9<39
MA>O%H19"_\I'.->.4@50),[.O )W_R\CM0B$7-J>W-5/4TI77SND@ \0K_N"
MT:)QGJ";_._"/Q<+57$$GIV BD2?*]B]6WJ[U?A9R&W*@H B@LELYOR[[THO
MLARSUI("M\\DCYLNDB!+LD23PG.6:,V*X@;1$8 \8=A.LKV^09A;U%SUP8<3
MN0C%_]6H!HXS8YW>K&_='*?UIB QXY.\ZHWP6N L9HPJ4Z:"P#1 E,2*/0%Z
M>"&/DN+8W7P"PV41W@:K77M1T/BLUD-!\*C?^GE61!;V)G[J4%=:G(<!(-&J
MI(>JP5VU6*P5C+/MO'H^7^>!V&ONQ2W)U;,Y%ZS[/_82*U[]_B8%P;;*ZYE\
M&W2[P,OIYRT<47!$O'$9T75 $@7I"U-E.FB1N<2"E*&)(XM=Q2@XNH;AY(L1
M(L#AK4_]-)--B[DS0<7N-&3_VUHE*I^VFJ  T+T)5@#]CV5$3%6 ""5M=7,"
MB_<T0N-1.O6/H\DJ@L;9MA>R[MK-\4411]37'KNB9N\P1?,D*$NTH:H$L44/
M:"Z:@0K+\('"-?\\GG-)R%WLPZHR'H]'7Z$Z')(W>[O#<F-VD$G*-?2.SLE@
M.&#8L5&9WMUI'X9M#@JL74; B,Z-DW@0X<P>9X_!\D;&^/9#G(2N_U4:)RUS
MWRL5A_4*6G"O1$L(22D,(T@9HZ0H5>R/#QZ66>./M@NKR/S'O-]].+,=E<G^
M;NV996Z""I\+W06&'[G-C0T:B,<GF[XQ7AZUA>\-^J&@K;%4?ABW39&;T&DK
MYPUWK#Q T\9TR'V]Q*%F9Z%OB]RGMA=&I/JQD!DOQS='%?SDU()<T+" ,5NQ
M=88RA5T,&EB/YL(Z(:U/>!JF8&=DO6)S$?I>K#SJS.2LER@G4;_U@^>]L3&[
MPN\8!A,R^2G@3F.@K3ZY-,Y]H#Y!HEV-2G=A9/W0_UW19W!62OY!6^^>73;Q
M$%7[Q\6*T$T9WRL_>'UDZ/R\.:]XCB/WRMV.T%-J+$UKWR#K<5\+%4XW"-'9
MK0?%EZ.FK*!&'MDR)IB:M1AB[>=5_F>'R@;\;CV64N"[F\^Z ][1J!>22)#5
M3[Z>PC4SG@[TX/>IH4&F;/U+W[K?59FQS J)970W"CS 9ME.L_E>580W*TZ<
M,"/RA1\S+&RC9A$,):<&9!N_3.FW@+F+Y/''0RQ+2\_(\NT?NAQS^*\'MPPQ
M_F)5V\I@>>[#9+EVHALDM*9RP5=QP)=EA(Z[T9=V-4 99X9$0DZ.!RV[EB[7
MFXX>,5T=I%J<8*L5\O&UX)A=A>6U^ZCC_R+65GTC2G2]98>EXA73 =MAX,>J
MT #Q9L+KE;8K-1OE$K/Q<7"I!X+^%$Y(Y _O_K!.=;QJ';7TIY>O2M]IZJX3
M RT=&XVWZ_E-U.9C_ F3Z'I%R0XR'Q!JBGR7$3>F9>LID$^K;5S9?[K5AB?7
M\PTC&7=G$FL3G\OF%YD5U7!.+J2AN7*@&I$#4*44L;YG4ZTXX-;'7U,'O VE
MS:YQU-]>]5XL]$ A5_Y 08UR&366CIZ8Y1)HTE2ACRAZM I_"A1W6R *]<O3
M6=\ZCZ$)+)Z>G6FR0?>UCY>0[2N68K0S%!59+ZJ6E"K3^,QJ?=%;E1P9O[ 1
M5\H/G\6,8H5QR8"#0;UC0;/*\X+:1U&%38T YP&[#B5QIO!#A'(BN&;38&!>
M6RXQ#W8)!#IW2PM%"S6"4HN$7X8QH=BEUK WH<W,#=6D:5TZQ0"W( H0(E>H
MRRB/WZXVNHB19][_XOX;=;"_^\6!P>#;.J+?Y ?F+[]=Q-A=Z,!_.*S836N@
MY"TB(6NLP(A=X]QQK  S/LLEYO 7T)'DC,_-C4*SQZ=<CM.Y!W<N'<R<SIU_
M$FJR]OYVUSWMS2L:$@Q(?;#"& @#RXCUI\'2DG:CY]#.I"?,:NN<T]^\?^OK
MVU1_,/?3EH(@ V/7W?NZ50NB8?8>80N9("7:Y:)]D,,#&1.H+Y?H/ASJE"'!
MCRV['T6. '4!1-/ 5%?7>B_KH5=6.?PW@_O>\-]XVYD[B981@B'Q=J K2L:
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M)^QW<_]C@^#_?_V_>2V/_P=02P,$%     @ &H.F4K;L;/U,4P  &60  !,
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M-[UH[^CLZNYYW?MF8'!H>&1T;)S*F)K^/#,[-__E*WOIQ\]?G-_0\LH?O80
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M&CP(6; <6Y$*;VEZMYT=K+XF-URGH<XV][[_ 2VAZ*B5ZJI6K"I/&S']'7P
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MNX5Q[F:PS8!,+P'KTMK %"_;%+9X)\&(E?UX"J7^A>.@7?;$Z7%P[^,WHQ9
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M?>YK@5-4H'QSA-*:+OW<Y\;>L.0PPTD;[J.QG%%9F)HYIO3T<2B-+=SMJS"
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M14\[6ONB]N5^QY?2$VZ1/^[FV%Z6;RL]U11KCN580OYT6C)I#=Z;ZTH8)#>
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MP1.9-_R=?05N;P07__$YV)OIW/G8,5%H\F,(=5O!+(325S<?T;VWV8%\7'%
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ML0"QH';1-<C13Q$!S]%4?<+((?"$1R]?P_[M)XLN>D/=O)]AUD1UM+/*XC/
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M^%]P2/C_V__!MF"V[S\ 4$L#!!0    ( !J#IE).AGWCS>L  $7;"0 4
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MJ+E]^(VTVUKF3]Y&7H?# -W@GC<]AX-L9"(XC5:/#LEG8',X33$8?%.=J[@
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M.-S7ST+;=%KY)<ME>KNJF9\_W6A#LEA6[]:O-%U5==4)1E"$5 !$XP1 %%-
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MVTXQS5SWYFB=VXHRWAMAM[K,8IXGC!:-.\7.J\OH\ ^YTHPG[*2KSNB8[Z]
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M=\.E#E>K=*<VKM[((KU=F5,:U\6?I+A-5[>M"S;54S[(<H&D"E@<2[TRB1A
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M8WNYKBKN?ZJ+YWC799FG;%U6.UO:;_J@Z2Q;E5JB97VVH_:4^DQPCQ:\X\W
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M,5 <<<%1P'UB=8QV %GFQI(;=>K&1"U!'4J$7S@[YX,H$V(^,CL^A]M(7G6
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M)%4.A>^PC'JQ5!,3[U H'O+S8$_NVWH@3Q_U(Q_EK@GOY[3X>^7Z($@4(RH
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MK]WS1T_C(TT;0BKNTU5J\L.K>JE-R9]T&^C8S$JU3636AE+_?]U9S$R.S,T
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MTER\K<Y<OEL59;ZNZT^:6/#-'5U]K#LH?,A6C[(HI:C+M"^"4*@D"AA0T&<
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MW7/=^H V:(*;DP#39K7UP>8@E:W70WH6-=BDQKU;/:S+XKU\E,N@";9QK/R
MFUJPBFM^BU4,F#"53I&,(!(D]J53+YR.L>;&9I5L__+[ /E_#!R+&70 :D=*
M \$T,@7M,FM-DI<1],JK1/6",3IGG<=DT"(&'<--6\'@O-X'Y0LL;NE[3IGG
MDA;RC:S_^V[U;F6.06>Y9J9%H +("6- A(DY.""D9HM0  H1YLSW58)4C\..
MG8-:?0_3'WG<R&QRT].=M*YGFKO0MJ.2R\&;ZKQS ]@/&TE_--B]L\"NQPEH
M"TR&/0_=->#$IZ,M=#\\*VUSTX7F1UU?19L[[U/*MCLNU%@ZXN/JL]GNRDV[
M^Y7XD*WRS3]?T2(M;DPA_ 41,&;(]P'QE3 -Z2&@*A% "AQ1''!)W!KW#2;9
MW$R;UI&81HW*TKSRMJI4+D5;F9X6T,5S2B-*S'%8P!BF !(J <4P! *9;@1Q
ME,"0N/6S?Y%9G:;E?=L@.SV5WF^5^*X-80>;4D<3>,IIFM!@OF!^^IO.0V$Y
MBJ%]L7 O8Y8/A>E)(WZP =SW -\697IO3.;-T$^_9/D'^?6_LOSO'Q_2+!5?
M2EEEF=ZE#]>\7. D2FA"$)"F?!F,( ;Z5Q)P7Z^^,5$ACZSR//L,/K=5=BN_
MMU6@RA[7*GA&!Z]6PFMIX6DU[+>0G&?G_&[>F)B/3*[S@]M^DVY,V"?:EQL:
M?J>-N+[X=>R].3]RLNVVOLJV=]AZ/V.HL-$UYV:SKOA$GRJC$/HH#OPD!#Z/
M3+H;B;7%+SF0""L8Q(*KT&DC[>R(<ULMV@$CVHCJ/=2R7AHUV@>[;^3H @A?
M)GJT$=C[= ;( 4)()\ 9-XRT/^@+AY).8' ^G'3JQMEV'OJ<+9>:,LU-"XA"
M&OO$!R*1,8!)' +F\QB$DHF$$2CCQ.EPT[3BSXT(/VL!\Y0;2Z+2TOO+*G4M
MVS#Q"Q!%R/?#" .6Q#Z  =8O  D5$%PJJ(T*K%CH%J2:[RLP323KD\RU\7AO
MTGV^F[? ;E6=[\R.O$2_8(LA<SRF>FSA_6; \1ITAJR:_2+3^ITU(&IK\#^M
M"]&1V7F!5D3'I!C*9:L&;0JQK&Y?TX>TI$O3G4.BF/BQ.<T=$P4@0C$@+(&F
M<4%,((N30-!!MOU/23#3'(":F[0SEZ^K<WK;Z&T5\L\V>GAI*>_[])9WF**^
M'M]%B+^HZU>#OQ6]Z:U2(=^*HP_<:\4=P''=PY.CO["?> Z5\P[CV2>X;W:\
MSU:WYM3G1[9,;RMJ+O3;4@VT/1'Z*LOS[*L>L=BF&2>8P%@D"A!LVK90/P(X
M0@)(Q:0(6!2'W*J4<W\1YN;!&2U =1J\I4?UY=4?9:5*?<%.&>>D\ NF[/P^
MR/@3,3(KSGX.[#='QI^+B;9(1IL3I[V2R^#LV#'I^>#)]DTN4[R]>W+AD_KV
M%6#ES@6H&ELA1C%!D01^Q+%>>B)M>(<!!B1B-$(Q"J%PZA)T.,3<EA8C8?M8
M7Y\V84> M#./+X-G9,)W1*9'V?]3R@];Y/]@E(E+^I_2\K" _\DK+\R#;8XW
M-@=&2,0CR@0"H532G##4AB:,0A!%+(I"$:H@[)?4^FR8N7WGAT7;>V8K/@?3
M[CN_'**1O_4C)>U'/&]S%(51,@"?C_0RZ7Q'M3V9FW?\ZIZ%@3;>[!=Y6T7Y
M-A79HL3G'$/@R\#T"I(4$,084*'R8S^ C+CU CPQSMPH8!>ZV<CI6.#G!)QV
M'#  2".3P"$^(Y# &1@&+=%S8JAI:_)TZWM0A.?,Y3U+$"QI47Q457NR]^E*
MOC/QX06*50RY1"!!TD39M2% 51B ,(P55#A@D$*G4@/'1ID;"51"5MMW1DSO
M-R.H5TGJ6CK@**9V7' Q4B,S01^0W(_\=X$PZ-'^HP-->X2_2]>#H_J=%_=C
M@)N\RN]_JAY:'P+@_UBGN=DY+,H_R_(N$PN!$Q'Y3((HU$!")24@E C 0YSX
M$3;1YZ#'MIO-V#/=<-N(7G\(5YNC-AOYF^+NM0IN]&$U(79L,AB^TY#+()@Z
MLXT+2$.2C]6XDW*1"Q+[U.1T;S^FNA9_6Q=UH9*;S!2/7_%T*3_(<E.-L-"_
M-]U:/N798RJD>/7TET**=ZNMZ73-R_2QVHS=[@U$,8L8HQ!P"6, @Q@#'!*D
M/1X4(1I23H+(Q=090\BY64HM';TR\_*-EB:MP),T7YE0],\_+*NV>/H"\VMN
MVBT]-#J;W*M=3@+=*OP'-Z8<Y86P8]:7GN:1F7AOAK<*FA2&3?'6INVA_G/5
M2NM3:VY_,+IZZ>K'=E+$5M]1RD2-.2%#LOXH<DZZ2HR)]/ZJ,NI8O9/5FI%_
MT=#4Y;+6>J!MV[#BD\S-B5A>)=@M$I9()"@%W"2KP1@)@&-A.MPJ)0AE@9!.
M[;<=QY_;VE%)YOV0KKRBRI+]T3D/S0E].S8?$=.1B?HY%YN/U=N)O^M[6%0]
MI;P:_$J'01/1^H W<#::DPA3IZ3UP>=(7EJOQ[BQ7)&7B_>:+F\W'1!EM6FM
MW7X:AS(&84@@@#P0@ 9Z'A".? XAAB*T"@@>?_S<.&HGH3%M+(]$GD"NFX N
MQV-D?MF#8K"M_F[%.[A!W]CB!?VO?4XX\>1)/OENK39?])FKW+-);W(JY#W-
M_VXJ=WRB96L'*D84<JEBX%/* 22Q ,SW*2!0Q23RH1"*V6:,GAYF;A_P3M(K
MKS0_>]755?[;0RVX?=)A![K='_=PF(T>=]L(Z6DIO49,YVY*'4#99V . ]A$
M698W=]++T]L[D^S?1+N\\B[/UK=W7BYO4^-P5-R9*8_6;Z)1S?C,MU2;P%EN
M0B*EY*4GO_'ENNJ-LBYD?3W3_U[)HJA>WBNO>+IGV=+<DU4IG$*:OHSFWT7Y
MM-07F+=;_Z7UJ*6\I<M:0N\VIZNR=L_-1;?9H\Q75?J6EL;\)ONZJH^OF7_4
M7XGYD_SVL,S2TC2"JHM+5OKD6CXM.C?BJ?I?=<]2<W^J+=+B0?)4I?6 2_KU
MIV$R2L^_'AU9HQTW3Y89>EZ!=O:GQ=7NR\4U_ E]T&]=(=8R]&&TR?Y2B":,
M8H"D\ &$/ 8$"03B0/F<1@F',;%=*HX/,;=E0@OYSUXEIJ?E](R@CKTT.^ \
MOS9<#M+(Z\*H^-@O"9?C--%R< 2O85BO&X$.QCMQXV1LURUXF^G.7'E)K.Z&
M?CO2L@$%/@H1CP!+8 A@C"&@ @H ?2%HS)$F/.D>ESLZUMQXKPD::5F'Z)31
M!;)+^.UBZ*8)M;FCUC.BUHG'\-&SX\.]0*2L4^_C4;'N6WHXU*:/^>;DC3:K
MMR=M6J=P%BBDA(41 Y&"B;:7< (P\B' 2E&>!"I&H?5A3)L!Y\8BE<S>[J"9
M<3]:Q\I:DCNXD#; 6WC= \,YMO_]4D@ZN.4#(SJ5@WXYLF[NJ0-,78ZJS6.F
M<UD=E'KFO+K<U\_ ^RP?L^6C.97?;I_\U+@8.$D$]9$$,M+6'13:K64^Y4#%
M%)- B( A*X_6:K2YT?-6V+T^Z4^.+IP=U':&WF  CDS(%V#G;.Q983*DN=<]
MX*0&GY7N^R:?W4T]JSGR.RG62_E1_9IEXFNZ7-9]!&)?4BGC!"C, P!5$@,<
M^C$(XP1'2HB8V=EZ9\:9&X=LA.O7QN$4F'9<,0!$([/$1D(3\[9&RKW:6S<.
M@Y9E.S'4M/73NO4]*'1VYO(+ T>?)9?I8_7:(DB10J$$,&8^@"%'@#"B/3\<
MHSB42<@#WBM@M!MC;M__+N0A"V\G9L_X4 M+Q[A0/X0FBP?9@=,_#'2H_BCA
MG]8P+Q/V.=3S9+CGR*7N89[7UY_??KGFY9OLGJ:K!8TP%G["]+<=ZT4^\!G
M/*8@$"H4DH4)1E;E#PX?/;?OVF1Q[S*S34Z9]YKF^1.CYDQ?+;/##L\>CN?C
M,_W1&?F;K@0SJ>J7HV ?6^F/QD11E"TJPP1)CNO;$0[9NV&RP,=Q0=LACA-7
M]#,ZS'?XK/WRJZ</5;?YCVKWZZ<Z'Y.I2/IA"!+H0VV0A 306"(@A*)A$DD5
M!<K%%K$?>FY45I/73D:OEKM7M2:'"; S8,:!=60.[(FHLWGC#LZ05H_#Z),:
M0^ZH[-M(/9[0,UBR9H7\QUJO/V]-7E@3"?2Y+W&(*.!QI !4/-165,A +",D
M8H6HMJZ<0B7'1ID;"^V$]"HI'0,E1X&T#)-<"L_809(]9$:(H'9",&A\Y.A
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M;34N=G7<1(-G-,&$4 6HL F$(K$E&"D$/,M5IJE 7'AU5+H@9V[<^$S-:K?
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M&RM6=CG^<?5&;8KO1H7OJKS=%*71ZDT=T5*5<WFEC(:V@NZ"$4Z1UAS$&<<
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M..4I,&L.9%P19 ^&&0,)4B1G5%">.P6^7I0PMP]_IV33+2PR:D963_=M@/-
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M1.^7931 &Q\VF"85Z7)!PWUOG*:$[XE1_2M6#AE/-^*>:(S&/K <>7"\F3H
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M+<_G=EO/8QT;[&NCNS?JFUJ59G5KI=VK#W8$;;"W]8]1EB5<2 1@0A* $DT
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M<[FG'W$<^2&_/]J,FH_Z3;%\-+^M')KRX^.VW+*J7M\B18J+3&5 DDP )(D
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MB?H -T[>J),&+Y1*ZH/.Y>Q2KZ?XEZ=XN]H6VZ=WQ;+9P%ID.M,*TA1P%6.
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MDC0&*436D8P%(%CF &E!<YV0W#.[[*R4N;' ,R4CJZ57/81N1-TX8#!.(U.
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M:'S0X\%3*=.>#5ZT\N1@\/*5_N[Z:W-A4;XY,$R539>C& N9,I#SW+C=.8:
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M3WM/(>%)@C6&0&A+"KDA!8HS!E2J4,QU@D7L52OR6,#<&.%H.B\:-3V;>9S
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M>N)SS'%]'],W4&E3?#<K^.]-4]RV9[;=U]PVPA92JR3-"0%(X]C\1Q- >*P
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M@<3693?3>T)LC B%6(@\8<*M+GM+&U,;/QX."<LFOI:-S7XD=0E-+F0&M8*
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M\Z*^2[BG!Q<;OO]BK?B?:G'0J*:]5S_*S]_5XIOZA['DJ9AQPK7(20)RH2!
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M[J![D;N/#)7!((!;\I:55;4!(S=@D1NOB(MBFO2GV$++N! [*1:>Q.'^BND
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M2(RT-H/-P'G4GD?Z6YLJGOU)[:1BXU@L;<D::ZFS#@[%;N5,VI21\""!69E
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MD)ED 67-I-BE0>#VIX\7&AVOK2=4?X#H>D@*N<_&95Z44=%J7Z>HIIHGF90
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M&&_J%6HY.(R.8D+TSEI!4>%I:EM_V6L8*S\'SKV!Q=\!D&H:84I_Y-NON+Q
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MO%J=/'Z1"@M2&DU>=2Z5JZV.K*ZL;2Q&BBZ5R:+-;7O@@CM) XWN()Y$X1T
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MQNRCD*7)P1[1YMUV;JX8->AK*^>E?OWM8CGY4AFJ;UR:ZDQ@7-Y7Y.WA$I:
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M&KI[R5D/R;413;(&4B9O1MF:-Q2* P_.!+HI#(^##9T^XG6PR="_TZC]^??
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M-)8[^ZI']X>P#/>VA4ANHL,,,><(*A@.W@@#6&+2CH?,PBYS@_?XY+A/<R.
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M9SV0:\Q<UW&8Z"$ &<XR_"?6AA3,KW['>?B$US[L;_-)PFK(RL:0A925C=(
MDW60CE.5P"'4\;"5,"YYQGB3/M/3;_6L1XQUDD)N@:J_SKF[2,$7@=R#DE+4
M<?44/W+N0)64C+'T#W(XX\/V8E+136 ^SJG<"W/GD[Q^M#9H:S;R20%AM#EH
MX<$K6<B51T/.LR=?.GFAA>6AI'$"K>'V^&*2W5T<S)&P=P[WY'.BN=[];M*I
MY?.F* [!9P2E=>49X FDS)@X<G2Z2;_I:;?Y8A+S9W$XVR'P',[GL=G9)X55
M?!:<_@]TXK+Z%PY"'59L=7&Y:)^2-SUZMT?M^L6\$'1Q>KO!YPLXS+L&"(6B
M &X005A&"O520E 1P3N#I%FMI.TR;SID4'H.SP_G<$!;8.[E/5@\*9IL,:!2
M"AP*BM(EUF:J0AX(UQD#9T;+)AP+)]K?F9*JG>=Q;(&YL^T9R7E%A!@N?PC+
ML$F[+V=W"WT:]HOL_O'3](H<*(P^^D3(:4M*N@ *+=9^4U=;G!2II.3$4A$Y
M_\U#]43G9'!&\Y@S<$EG7LE8(#K:L>6,;)5/(J<V'M_?/%1[HK<=#]4^&.@@
M&/J>E$:Z6*)3$3C:0B*4'")S2'+$4 2WCN>_IYLW0<*3/%3[J*4#3!TNN"?X
M%:P.UD2LI]MG4%86" 8E^"B2]E&3_]?9:])Y\%#MA:U3\%#MH^@.P/XX>8Q@
M3GO$# :M!R4D.?]%U.%Q1J(+A@G\>[KY*<&R,^W//IKK (('1[._W/ G"-JO
MR*:F<&TD.3(%,14%DB0H8Q2:Y-M5<N27E\:Z<HRW<&( = #Y=M-3HHN1*VU
M*F9!U<94'T( H:*)2@8A\05.V>FO>.Q :)YLRLX^..G@P R8H/UYNIQ/IHM)
M^F>XO,(+SSCW/$K21Q25K3%#D#Z!#$8J8;(5MO>&_^]W=*9%7<,<F#YPTLN!
MB<\+(CXBB#M/!-\+@E]H+0I#%@"%IZM>, TQ! .QU $O61I24[,3TV1+9UIJ
M->"1&1\I+^#,//X*^!YKN$?__,ULNLKV7H7+CSC_(BY\,*0SPKNQ@LR*$09<
M$1DPNY*X3]*Z=E46I]WKF99$]7'*6F/K!1R_QU^U'Q,162BFB@Z&1%3JL$GG
M&#B1:B$GJ5I*Q85NEY8][5[/M."IC^/7&EMG6SUQ>7F74?*F8N ..7[]A14Y
M_NDX.(];TJE8.0<47!_U%U9[2]<*'="HZ;Z)=-]XH3)DD[E0CB7OF]"]O)3Z
M"QVBLRDRP%CYY)2U$((L8#4O-8M:?&Z3BOB[_F)/]+:KO]@' QWX;-\_QNH4
M@[2L,DO7>$_F M%2O&=<B"QEP8)N\F3X(NLO]D+"D_47^ZBE TPU>6G5)J1B
MD$.RDJ0IE8!H$H(++ F;D\IAG":D,Z^_V M;IZB_V$?1'8#]Z2E22 8@,!XA
MQ:1K:7@![WP ;2B.5\+3I=2DHO6O-@=L+]#L-0=L'PUV ,<GBDJ2M#YZ"TF(
MRC0C(T11 G#EF=4)4RQ-#.A?:0K8,3 <1G,O90Q33MD7K,QW4GERG@I=2S(;
ML#%P:4JB7??%//KB"H*.<5]/#(">[.[0A1[K_N<?9_/-/ZI_CE^@$$9X+L!K
M;D!QI2 4E*"U0:4-A;J^2=K[M-OLW%$9&,2G*ATZ'E$O^;Q=I)A12DZ&3I7*
MIN4+.%L;>I1U7/# C&^2Q!NW *_G>J(N3]%>..G@P!RLA[?_<S59?OMY2D'2
MU<IM>+?\C/./G\-T\[1V([V[/,HQ2E%45!OF8JNK)ZP]6%&B,$8%F<:A>!IT
MFV=?=W3,T>H847^-\W;-A:RMTE[6 ;V6''6G(SCM!<A(8:/D3#+65P'LOCL\
M4S?P!# __8D\ '/G0SYZL'B^9X:\T)%%FY,$:8LE7[JZ!B@C!-0A>.,$*WV-
M>-AS@V?J4;ZD WD$XE[TY?C/E?YNY(+">&TER277HO],QLKE1*&M]]HP4I[H
MK*]PSPV>J0/ZDD[B$8A[ 6..GA7/AMKQCH1"D<446\ K2Q+RUH-GTD!F5HCB
MLO:JK\D4^^_Q3"OE7]*Q/ YW?X63>=^G9T9'QXT#C*9VE'(&GAM&QPF-XSJ4
M,A(K]TGCR/X*Z%_2J3P&<^?.%[J[<.YU**Q\_1_(K/P8)O-59]Y=10>+5A6A
M@0+OU4#>4GE".*S>;X5+3H8S"S8/DL.97KEGDXIMALD7'8[N+KX+PU-T0130
MI'!0)I(I-&0*B[)2"69887VQ[ ^X^1>?X6UW>CJT!'M!^2^7'7Y>?-9@<2@]
MF!J>*-0*G+(,L+*(6I\8/[>WTSTE\.+SRR_ '+0$]8MV";[/%SXON(@LJE@,
M).=E?6KSX+,V8#Q/)6BA8N+G90WVE,"+SW&_ &O0$M0OVAK<F7RT@]22ERPR
MA&2$ L5R@N"5@R*=M2(8F12>ERG89_MG&N'_I>Q ,SB_:".P1VBED1FCC80L
M"LDL4U05@XN0O6'9%43)SLP$#)PE..?\_0LP (V@/&CNOQ.*'?*5RFS^)4PW
M9>D]<.SLOJ91278.%%TG+#L8"JNUD][HU;47(2K"O0SUXDN5:;O)D).7PK)C
M4Y$F(=D-;TE^/%J()I/QL%($[HMF;:9$_<VRLR]ZV['L[(.!#ES'[RDWK$!K
M)?KUJ AE&"V>*PV\3G=@R8F0PM\L.RV0\"3+SCYJZ0!3APON"0*#HHP)CGD0
MJ!@H:R+X'!D8F3TWR28AFT"SQ69Z8MG9"UNG8-G91]$=@/V^P[?84&.0PQM3
M9@JDH;^HVK\<=="UB,B'7&3 TL07>&0]G;]C-P?*;'BM=0"^ 8I[C,GH2YT3
M3"$[*$%1KXLN$;*8T,PI;51?15J_O#0ZDV/\A!,#H!?(Q^=W'+=:DOH:-)E^
M>E\S0 LR JE"YA->H(Y6T7:A)%\E84G\TG%(F!DKCKM@FD2^37;3N:T?&))#
MT7$/AH_S)KHZK*9;>!MR$BLN\CJ. SG%WL5!SEXJK11*?6;=; >3*O17_3/@
MP>H347^5$W?=XDX> RO:U@F(Y/B2SPJ!:P&Z."V8=]GP,ZO"^RO3*NP%]/%H
M%?; W%^N</9"1<FQ" I%!1T;59BN+YZUBR\5X:3-R;=S'T^PP3.]^%[2@3P"
M<;U$;:=H<F=2YXB90S$!026C(7I/$77@C!?.HE#ZO$[B7YA6H<^3> 3B_@K-
MVP_;VZ60"E$HLE44-ZOD/03R)2 [+:U61LK0;JKG:?;XXBM ^S^6Q^'NKW R
M[_OTP41R%JK3(&J5:ZD/* DK55H,TD7!)&\R4Z>O./*<RS+[/Y7'8.YO6H6M
MY;7:""]R*N!<C*!"J<^3Y'#D8H/04:)-YWIL!Z=5Z,\3/IMD;#-,_E6RM<_7
MF?O(D;D<0!9-4LL\0$@VD<E67CO,&L^- _!O8H43G)\.;<%>4/[+Y8=WZ#@1
M*7+A,E2J'5!1:PC>(K@BT6MCC#SO!/+?Q HOP!RT!/5?*$>]@S$U7%DN&5A6
M66K(M$) LJU&:'3%9EORF7GX?Q,KO#AKT!+4+]H:[-6)[KA+CC$$[G+5O7?@
M@E.KUX6 /@L\-^K3OXD57I8=: ;G%VT$]@BM7%),%V.@>%5[$KR$B"Z"<)(K
MGPP)],R>M/\F5GA)!J 1E#O)_K<;TZ>8#='F#"4S30Z12^ B"^!5(%T&32'2
M>4U*/=/;>IB,?!\XZ>#.//%TV&)+0%G'WO-@0:&@L((E 3PXZ6PQCOLF)(0=
MSAON[Q[L_&@=CZ@.SMO!RKG;\+26!+]PRJ+WY)^CK -CI2?77$1/5D>P: 63
M&/MZD=JRB9W.BGFA9V4T- QV$A[EP-K\B_J7VKSW__P?_S]02P$"% ,4
M"  :@Z923@%8/ 4(   Q)P  'P              @ $     83(Q<3-?,3!Q
M># S,S$R,7AE>&AI8FET,S$Q+FAT;5!+ 0(4 Q0    ( !J#IE(I*\5W# @
M *@G   ?              "  4((  !A,C%Q,U\Q,'%X,#,S,3(Q>&5X:&EB
M:70S,3(N:'1M4$L! A0#%     @ &H.F4D>"4U3V!   7!<  !\
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M &-A:"TR,#(Q,#,S,2YX<V102P$"% ,4    "  :@Z92:GAV:"(>   Z/ $
M%               @ &MIP( 8V%H+3(P,C$P,S,Q7V-A;"YX;6Q02P$"% ,4
M    "  :@Z921T&5R?1R  !W) 4 %               @ $!Q@( 8V%H+3(P
M,C$P,S,Q7V1E9BYX;6Q02P$"% ,4    "  :@Z92)O!7S,-)  !N6   $P
M            @ $G.0, 8V%H+3(P,C$P,S,Q7V<Q+FIP9U!+ 0(4 Q0    (
M !J#IE)[DTT"C&D  #I]   3              "  1N# P!C86@M,C R,3 S
M,S%?9S(N:G!G4$L! A0#%     @ &H.F4ND0$X+@7   CG   !,
M     ( !V.P# &-A:"TR,#(Q,#,S,5]G,RYJ<&=02P$"% ,4    "  :@Z92
M,;K$C$A.  #F7P  $P              @ 'I200 8V%H+3(P,C$P,S,Q7V<T
M+FIP9U!+ 0(4 Q0    ( !J#IE+7UG>0KG8  'R'   3              "
M 6*8! !C86@M,C R,3 S,S%?9S4N:G!G4$L! A0#%     @ &H.F4D74LMZ7
M7   <FT  !,              ( !00\% &-A:"TR,#(Q,#,S,5]G-BYJ<&=0
M2P$"% ,4    "  :@Z92MNQL_4Q3   99   $P              @ $); 4
M8V%H+3(P,C$P,S,Q7V<W+FIP9U!+ 0(4 Q0    ( !J#IE).AGWCS>L  $7;
M"0 4              "  8:_!0!C86@M,C R,3 S,S%?;&%B+GAM;%!+ 0(4
M Q0    ( !J#IE*<ZU"GPIP  *I>!P 4              "  86K!@!C86@M
F,C R,3 S,S%?<')E+GAM;%!+!08     $0 1 '\$  !Y2 <    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
